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The addition of O-linked β-N-acetylglucosamine (O-GlcNAc) to intracellular serine and 
threonine residues is a ubiquitous post-translational modification (PTM) found in all higher 
eukaryotes. Like other PTMs, it is finely regulated in response to stimuli and dysregulated in 
multiple diseases. However, unlike other PTMs, methods to detect and profile the dynamics 
of O-GlcNAc glycosylation are still in their infancy. Herein, we discuss the background, 
development, and application of new chemical tools that have allowed for some of the first 
systems-level investigations of O-GlcNAcylation in different cells, organ systems, and 
disease states. We also significantly advance established techniques for the detection and 
monitoring of O-GlcNAc on proteins of interest. Using these new techniques, we first 
uncover a novel O-GlcNAcylation site on Cdk5 and show that this site can dynamically 
regulate Cdk5 activity in the context of neurodegenerative disease. Next, we apply novel 
chemical, mass spectrometric, and computational tools to, for the first time, uncover cellular 
networks engaged by O-GlcNAcylation in vivo. Finally, we undertake the systematic 
optimization of mass spectrometry based O-GlcNAcomics and use these new insights to 
significantly advance our understanding of O-GlcNAcylation dynamics in metabolic 
diseases of the liver. Overall, the techniques developed and data generated herein are closing 
the methodological and intellectual gaps between the study of O-GlcNAc glycosylation and 
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The dynamic post-translational modification (PTM) O-linked β-N-acetyl glucosamine 
glycosylation (O-GlcNAcylation) is present on thousands of intracellular proteins. Similar to 
phosphorylation, O-GlcNAcylation is inducible and plays a myriad of functional roles in 
physiological and pathological processes. However, unlike phosphorylation, which is controlled 
by hundreds if not thousands of kinases and phosphatases, there are only two enzymes known to 
be responsible for O-GlcNAc cycling in higher eukaryotes, O-GlcNAc transferase (OGT) and O-
GlcNAcase (OGA). This, along with the unique challenges of detecting this modification on 
proteins of interest, has provided a major challenge to understanding the functional roles of O-
GlcNAc in biology. For instance, O-GlcNAc has long been hypothesized to serve as a metabolic 
sensor, yet a precise mechanism for how this occurs, and its implications, has yet to be firmly 
established. Accordingly, altered O-GlcNAcylation has been observed in metabolic diseases 
including type 2 diabetes mellitus (T2DM) and Alzheimer’s (AD). Given the prevalence and 
alarming rise of these conditions, an explosion of research into the role of O-GlcNAc in these 
conditions has already begun. Here, we review the current understanding of the role of O-GlcNAc 
in metabolism and neuronal function. First, we discuss the role of O-GlcNAc in regulating glucose 
homeostasis and in responding to metabolic stimuli, with a particular focus on its role in the liver. 
Then, we explore the regulatory roles for O-GlcNAc in neurons and its role in neurodegenerative 
disease. Overall, it is becoming increasingly clear that, like phosphorylation, O-GlcNAcylation 





 O-GlcNAcylation of serine or 
threonine residues is a dynamic, inducible 
PTM of intracellular proteins that 
regulates multiple physiological functions including insulin signaling,1 transcription,2 mitosis,3 
metabolism,4 and neuronal homeostasis.5 Unlike other forms of N- and O-glycosylation, which are 
often made up of extensive, intricately branching polymers, O-GlcNAcylation is never elaborated 
beyond the single GlcNAc monomer. To date, O-GlcNAcylation has been observed in all 
metazoans and over 1,000 O-GlcNAcylated proteins have been described in higher mammals and 
plants.6,7 
Despite this incredible substrate diversity, there are only two enzymes known to be 
responsible for addition and removal of O-GlcNAc in mammals, OGT and OGA, respectively 
(Fig. 1.1).6 Notably, OGT knockout (KO) is embryonically lethal in mice and is necessary for 
survival in dividing mammalian cells.8,9 OGA KO is also perinatal lethal, although in rare cases 
mice survive to adulthood with profound metabolic abnormalities.10-12 Given the widespread, 
critical, and specific regulatory nature of this modification, the fact that only two enzymes are 
responsible for its cycling suggests exquisite mechanisms for controlling the activity and targeting 
of these enzymes. Accordingly, dysregulation of O-GlcNAc cycling has been linked to numerous 
human diseases such as diabetes,13 cancer,14 and neurodegeneration.15 
 The OGT gene is located on the X-chromosome (Xq13.1 in humans) and is expressed as 
three distinct isoforms generated by alternative splicing: nucleocytoplasmic (ncOGT), 
mitochondrial (mOGT), and short (sOGT).8,16 8,9 The three OGT isoforms are each composed of a 
conserved C-terminal catalytic domain and differ by the number of N-terminal tetratricopeptide 
 







(TPR) repeats. OGA is encoded by MGEA5 on chromosome 10 (10q23.1-23.4 in humans) and has 
two isoforms: full-length OGA (fOGA) and short (sOGA), which are predominantly localized to 
the cytosol and nucleus, respectively.17-19 fOGA and sOGA differ by the presence or absence of a 
C-terminal histone acetyltransferase domain.20 Crystal structures of both human OGT 21,22 and 
OGA 23-25 have been recently described, and insights into structure-function relationships have 
been reviewed elsewhere.6,20,26-28 
Understanding the specifics of O-GlcNAc cycling on different substrates is key to 
understanding the overall functions of O-GlcNAc on a cellular and organismal scale. Moreover, it 
may lead to novel therapeutic interventions in human disease.13,15 In higher mammals, O-
GlcNAcylation and its cycling enzymes are most highly expressed in the pancreas and brain.6,15 
OGT activity was also shown to be 10-fold higher in the brain compared to other tissues,29 and 
there have been thousands of O-GlcNAc sites identified on proteins intimately involved with 
neuronal function.30-35 Importantly, there is also a strong association between aberrant O-
GlcNAcylation and AD and other neurodegenerative diseases.15 Thus, given the immense costs 
and rapidly increasing prevalence of AD, along with absence of disease-modifying treatments, 
understanding the function and regulation of O-GlcNAcylation in the brain is perhaps one of the 
most pressing issues in modern biomedical research.36,37 
Within the brain, OGT and OGA expression exhibits temporal and spatial variability across 
substructures, with the highest levels occurring within the cortex, hippocampus, and 
cerebellum.29,38-40 At the cellular level, OGT and OGA, along with O-GlcNAc, are highly enriched 
in the nuclear and synaptosomal fractions of neurons.39,41,42 Interestingly, while O-GlcNAcylation 
and OGT are also enriched in the postsynaptic density (PSD), OGA is excluded.43 Furthermore, 




inhibitory neurons as well as astrocytes, oligodendrocytes, and microglia.40,44 Overall, the 
aforementioned observations have led to intense investigation of the role of O-GlcNAc in neuronal 
function, the results of which have recently been well-summarized previously.12,45  
In some of the same studies, reporting aberrant O-GlcNAcylation in AD, alterations in O-
GlcNAcylation were also found at earlier time points, including in individuals with mild cognitive 
impairment and T2DM.46,47 O-GlcNAcylation has also been found to be elevated across multiple 
organ systems in T2DM, including peripheral fat tissue, muscle, liver, pancreas, and kidneys.48-50 
It has long been hypothesized that O-GlcNAc serves as a sensor for extracellular glucose 
concentrations and can direct intracellular response accordingly.51 Importantly, elevated O-
GlcNAcylation in response to hyperglycemia has been mechanistically linked to kidney, cardiac, 
and pancreatic complications of T2DM.46,52-54 In the liver, increased O-GlcNAcylation has also 
been demonstrated to play a major role in maintaining organismal glucose homeostasis.50 
Moreover, T2DM has a strong epidemiological link with AD and other dementias,55-58 and the 
changes in O-GlcNAcylation and associated dysfunction across organ systems seen with T2DM 
may potentially set the stage for the development of brain pathology.15 Altogether, it is becoming 
increasingly clear that O-GlcNAcylation is intimately associated with cellular and organismal 
homeostasis and is likely a major player in the pathophysiology of metabolic and 
neurodegenerative diseases. 
In spite of the wealth of information that has already been gathered on O-GlcNAcylation, 
many studies up to this point have almost exclusively taken a reductionist approach, trying to 
understand the role of O-GlcNAcylation on the function of a single protein2 or exploring how 
modulating global O-GlcNAc levels affects a limited number of selected proteins or flux through 




recognize, discriminate, and act upon specific protein substrates in response to specific stimuli is 
critical to our understanding of the functions of O-GlcNAcylation in neurons, a task which has 
been largely ignored. For example, OGT has been shown to preferentially glycosylate 
neurofilament proteins in response to glucose deprivation; a preference arising from an increased 
affinity to p38 mitogen-activated protein kinase (MAPK).59 Moreover, the observation that OGT 
interacts and participates in a functional complex with trafficking kinesin proteins (TRAKs) 
1/260,61 led to the discovery that O-GlcNAcylation regulates mitochondrial motility in response to 
glucose availability in neurons.62 In fact, it has been proposed that the interactions of OGT/OGA 
with various binding proteins, scaffolds, and lipids allow them to act specifically on coordinated 
groups of proteins to differentially respond to stimuli, known as the adaptor protein hypothesis.27,63 
Taken with the multitude of examples of a regulatory role for O-GlcNAcylation/OGT in 
multiprotein complexes, well-outlined in a recent review,26 these data suggest that identifying and 
characterizing the dynamics of OGT/OGA interacting partners may provide critical insight into 
the functions of O-GlcNAc in neurons. 
 Herein, we will review the previous literature on the role of O-GlcNAcylation in 
metabolism and neuronal function, with a particular focus on the role of O-GlcNAcylation in 
maintaining glucose homeostasis in the liver and its role in neuronal signaling and neuroprotection. 
In the liver, we will outline the role of O-GlcNAcylation in insulin resistance, gluconeogenesis, 
and lipid metabolism. In neurons, we will discuss modulation of neuronal signaling, synaptic 
plasticity and cognition, neuroprotection, and neurodegenerative diseases as potential overarching 
functions of O-GlcNAc. Overall, the continued elucidation of the functional roles of O-GlcNAc in 





1.3. The Role of O-GlcNAc in Metabolic 
Homeostasis. 
 O-GlcNAc appears at the center of multiple 
metabolic signaling pathways as uridine 
disphospho-N-acetylglucosamine (UDP-GlcNAc), 
the end-product of the hexosamine biosynthesis 
pathway (HBP) serves as the high-energy donor 
substrate for OGT. The HBP (Fig. 1.2) integrates 
signals from amino acid, nucleotide, and fatty acid 
metabolism through multiple intermediates 
throughout the pathway. However, this pathway is 
primarily sensitive to extra- and intracellular glucose 
concentrations.64 Interestingly, OGT has been 
shown to respond to changes in the levels of UDP-
GlcNAc with changes in turnover rate and substrate 
specificity.65 Taken together, it appears that O-GlcNAcylation is in a prime position to sense 
changes in glucose levels, and it has been postulated that the changes in O-GlcNAcylation also 
seen under varying levels of glucose represent the first steps towards restoring cellular 
homeostasis.51 For example, modulating the levels of UDP-GlcNAc in a cell through inhibition of 
GFAT, the rate limiting step in the HBP, can prevent insulin resistance in the context of 
hyperglycemia.66 Moreover, overexpression of GFAT can also directly lead to the development of 
insulin resistance in mice.67 In both diabetic rats and multiple cells/tissues of humans with 
confirmed T2DM, there is an increase in O-GlcNAcylation concordant with insulin 
 
Fig. 1.2. The Hexosamine Biosynthesis 
Pathway.  
HK: Hexokinase; GPI: Glucose-6-
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resistance.49,53,68 Specifically, in the pancreas of rats and mice, elevated O-GlcNAcylation leads to 
a decrease of glucose-mediated secretion of insulin, which is a well-established feature of 
T2DM.53,69 O-GlcNAcylation has also been directly implicated in insulin resistance in multiple 
cell types through its modification of multiple proteins in the insulin singling pathway, including 
the insulin receptor (IR) β subunit, IR substrate 1, 3-phosphoinositide-dependent protein kinase-1, 
protein kinase B, and  phosphoinositide 3-kinase.1 
 O-GlcNAcylation has also been observed to impact lipid metabolism on multiple levels.70 
In adipocytes and skeletal myocytes, increased O-GlcNAcylation has also been shown to lead to 
insulin resistance.66,71,72 However, in adipocytes, there has been some controversy with later 
studies showing that increased O-GlcNAcylation does not promote insulin resistance,73 nor does 
reduction of OGT prevent insulin resistance.74 Clearly, there is a complicated relationship between 
cell and tissue type, O-GlcNAc, and insulin signaling. On the organismal level, increased O-
GlcNAcylation in ArgP neurons of the hypothalamus can suppress the browning of white fat, 
which on its own (or through other mechanisms) ultimately leads to increased insulin resistance 
and susceptibility to diet-induced obesity.75 Moreover, blocking O-GlcNAcylation in adipocytes 
has been shown to reduce the production of signaling molecules that induce hyperphagia in the 
context of high-fat diet and promote intrinsic lipolysis.76,77 Taken together, the direct relationship 
between extracellular glucose concentrations and O-GlcNAcylation of intracellular proteins can 
have wide range and deleterious consequences in T2DM.  
 Finally, O-GlcNAcylation has also been shown to play a major role in mitochondrial 
energy metabolism of both lipids and carbohydrates. In fact, multiple mitochondrial proteins, 
including many proteins in the electron transport chain and enzymes in the tricarboxylic acid cycle, 




diabetes and heart failure, with increased O-GlcNAcylation leading to decreases in electron 
transport, ATP generation, and contractility.78-80 Systemic manipulation of global O-
GlcNAcylation through OGA hemizygosity also regulates organismal energy metabolism through 
changes in mitochondrial function.11,81 Specifically, elevated O-GlcNAcylation as a result of either 
genetic or chemical means led to a marked shift toward carbohydrate-dependent metabolism. 
However, interestingly, OGA hemizygous mice exhibited weight gain, increased fat accumulation, 
and insulin resistance11 while thiamet G (TMG), a potent OGA inhibitor,82 treated did not.81 It is 
possible that these conflicting results are due to different compensatory mechanisms, such as an 
increase in OGA expression in the TMG treated mice,81,83 but future research into the roles of O-
GlcNAc in regulating cellular and organismal metabolism will be important for resolving these 
and other long standing questions in the field. In summary, O-GlcNAcylation plays multiple roles 
throughout different signaling pathways and organ systems to regulate metabolism, and its 
dysregulation can have dramatic consequences for both the initial pathogenesis and prolonged 
disease progression in T2DM and other metabolic diseases. 
 
1.4. O-GlcNAcylation in the Liver Controls Systemic Energy Homeostasis. 
 Having outlined the role of O-GlcNAc in metabolism, the following section will discuss 
its roles specifically in the liver. The liver is a central player in carbohydrate, lipid, and amino acid 
metabolism, storing, releasing, and interconverting carbohydrates and lipids to respond to systemic 
nutrient availability. Dysregulation of liver carbohydrate and lipid metabolism is also a key feature 
in metabolic diseases such as T2DM, metabolic syndrome, and nonalcoholic fatty liver disease 
(NAFLD) and nonalcoholic steatohepatitis. Under normal circumstances, the liver takes up 




to maintain blood sugar in the fasted state. As this glycogen reserve is exhausted, i.e. with 
prolonged fasting, the liver will produce glucose from other sources, such as those derived from 
lipid metabolism or amino acids. Similarly, when there is a prolonged excess of carbohydrate and 
amino acid levels, the liver converts these molecules into fatty acids and triglycerides, which are 
then exported to and stored in adipose tissue throughout the body. The liver typically undertakes 
these functions in response to hormonal signals from the pancreas (and to a lesser extent, other 
organs). Briefly, in response to rising glucose levels, the pancreas excretes insulin which promotes 
uptake of glucose and glycogen and fatty acid synthesis by the liver (conversely inhibiting 
gluconeogenesis). Conversely, in response to falling glucose levels, the pancreas produces 
glucagon, which stimulates gluconeogenesis and glycogenolysis. Thus, the liver is the major organ 
responsible for maintaining systemic glucose homeostasis.  
 As mentioned in the previous sections, altered O-GlcNAcylation plays a central role in 
regulating insulin signaling, and this is no different in the liver.1 However, as the liver is the major 
site of gluconeogenesis for the organism, insulin resistance in the liver can be particularly 
problematic due to the continued synthesis and export of glucose in the fed state (a major cause of 
diabetic hyperglycemia).84 Therefore, understanding the molecular underpinnings of insulin-
resistant gluconeogenesis in the liver would undoubtedly have important implications for 
therapeutic intervention in T2DM. Given the role of O-GlcNAcylation in insulin resistance 
generally, it is perhaps not surprising then that it also plays a major role in regulating hepatic 
gluconeogenesis. For instance, increased O-GlcNAcylation of cyclic AMP-responsive element-
binding protein (CREB)-regulated transcription coactivator 2 (CRTC2) in response to 
hyperglycemia results in its nuclear localization, enhanced promoter binding at gluconeogenic 




GlcNAcylated at two protein kinase A (PKA) phosphorylation sites, sites that are known to 
sequester CRTC2 in the cytoplasm by engaging 14-3-3 proteins.86 Thus, in addition to its role in 
stimulating aberrant gluconeogenesis, CRTC2 O-GlcNAcylation also highlights an important 
general function of O-GlcNAc in blocking phosphorylation (as they often share the same residues).  
In addition to CRTC2, a master regulator of gluconeogenic gene expression, peroxisome 
proliferator activated receptor gamma coactivator 1 alpha (PGC-1α) is also O-GlcNAcylated in 
response to hyperglycemia.87 Here, O-GlcNAcylation facilitates the binding of ubiquitin carboxyl-
terminal hydrolase BAP1 (BAP1), which stabilizes PGC-1α through its potent deubiquitinase 
activity. The modification of PGC-1α is also interesting in that it is mediated through host cell 
factor 1 (HCFC1), which targets OGT to O-GlcNAcylate PGC-1α.87 This is perhaps one of the 
most striking examples of the adaptor protein hypothesis (discussed in more detail in Chapters 4, 
5, and 7). In addition to the aforementioned examples, there are also numerous others showing that 
increased O-GlcNAcylation of transcription factors, e.g. forkhead box protein O1 (FOXO1) whose 
O-GlcNAcylation is dependent on the PGC-1α-OGT interaction,88 receptors, e.g. IR-β,1 and 
proteins across multiple signaling cascades paradoxically lead to increased liver gluconeogenesis 
in hyperglycemic conditions.50 Finally, at the organismal level, multiple studies have shown that 
decreasing liver O-GlcNAcylation through OGT knockdown87 or OGA overexpression85 can lead 
to increased insulin sensitivity and an improved metabolic profile in diabetic mice. Interestingly, 
hepatic OGT KO also decreases glucagon sensitivity, preventing autophagy and the subsequent 
production of glucose and ketone bodies in response to starvation.89 Altogether, the O-
GlcNAcylation of hepatic proteins is a critical PTM for regulating the homeostatic functions of 




 In addition to its role in hepatic gluconeogenesis, O-GlcNAcylation events have also been 
demonstrated to regulate hepatic lipid metabolism. For example, multiple lipogenic transcription 
factors are also O-GlcNAcylated in the liver, including two central regulators of lipogenesis 
enzyme expression carbohydrate responsive element binding protein (ChREBP) and liver x 
receptor α (LXR-α).50 Like with CRTC2, ChREBP O-GlcNAcylation facilitates its nuclear 
localization and subsequent expression of lipogenic genes.90 LXR-α O-GlcNAcylation also 
increases its promoter activity and subsequent expression of sterol regulatory element-binding 
protein 1c (SREBP1c).91 SREBP1c directly promotes fatty acid synthase (FAS) expression and de 
novo lipogenesis.92 Interestingly, this positive regulation of lipogenesis by O-GlcNAcylation may 
represent a resolution to a long standing paradox in T2DM, metabolic syndrome, and NAFLD, 
namely, that the increased insulin resistance seen in these diseases should result in decreased 
lipogenesis (however, in all cases, lipogenesis in the liver is elevated which is, at the very least, 
partially responsible for the fatty liver pathology seen in these diseases).93 Despite marked insulin 
resistance, lipogenesis proceeds unhindered in the liver due to the hyperglycemia-induced 
upregulation of O-GlcNAcylation on lipogenic transcription factors, receptors, and other signaling 
proteins.50 This hypothesis also bears out at organismal level where OGT overexpression 
(presumably leading to markedly upregulated O-GlcNAcylation of proteins promoting 
lipogenesis) results in increased circulating lipids in mice.1 
 Overall, the regulation of hepatic metabolism and systemic energy homeostasis depends 
intimately on O-GlcNAc. In many cases, O-GlcNAc serves as a nutrient sensor to fine tune hepatic 
responses to extracellular glucose and lipids. However, in metabolic disease, aberrantly increased 
O-GlcNAcylation can lead to a host of deleterious effects likely including the paradoxical 




investigations into the role of O-GlcNAc in these and other disorders, including elucidating the 
full landscape of O-GlcNAcylated proteins and how it changes in response to disease state, are 
thus likely to reveal new avenues for therapeutic intervention. 
 
1.5. Roles for O-GlcNAc in Neuronal Function and Neurodegeneration. 
To date, thousands of O-GlcNAc-modified proteins have been identified in the mammalian 
brain,33-35 and O-GlcNAc has been shown to regulate many important neuronal functions, such as 
activity-dependent gene expression, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor (AMPAR) trafficking, calcium signaling, and metabolism.94 Notably, the modification 
may also contribute to higher-order brain functions. For instance, manipulating global O-
GlcNAcylation levels profoundly alters synaptic plasticity, as well as learning and memory in 
vivo.5,40,42,43,95-97 Moreover, O-GlcNAc regulates the function of numerous proteins critical for 
learning and memory, including AMPAR subunit 2,40 protein kinase A,95 and cAMP response 
CREB.2 Remarkably, mutation of only a single O-GlcNAcylation site on CREB increased its 
transcriptional activity and accelerated long-term memory consolidation in mice.2  
In addition to its physiological roles in the brain, aberrant O-GlcNAcylation and 
OGT/OGA expression have been linked to several neurodegenerative disorders such as 
Alzheimer’s, Huntington’s, and Parkinson’s disease.5,12,15,98 For instance, global levels of O-
GlcNAcylation and neuronal OGT are significantly decreased in AD brains.5,99,100 Moreover, 
conditional genetic deletion of OGT in excitatory neurons of the mouse forebrain recapitulates 
many of the pathological and behavioral hallmarks of AD, including progressive neuronal loss, 
increased production of hyperphosphorylated microtubule-associated protein tau (tau) and 




Globally increasing O-GlcNAcylation has also been demonstrated to limit cognitive decline and 
neuronal pathology in mouse models of neurodegeneration.15,83,101-103 Overall, it is becoming 
increasingly clear that O-GlcNAcylation plays a pivotal role in neuronal health and function, and 
modulating O-GlcNAc signaling may represent a promising neuroprotective strategy for 
neurodegenerative diseases.12,15  
 
1.5.1. Modulation of Neuronal Signaling. 
 Given that a major function of neurons is to integrate, respond to, and relay extracellular 
signals, it is perhaps not surprising that many studies have uncovered a functional role for O-
GlcNAcylation in this area. The regulation of protein phosphorylation, the canonical mode of 
signal transduction in neurons,104-106 by O-GlcNAc is a common theme, especially in regards to 
interplay at the site and protein level.6,107,108 In fact, a major function of O-GlcNAcylation in 
neuronal signaling may simply be to oppose phosphorylation. For instance, Hart and coworkers 
have long advanced the idea that O-GlcNAcylation and phosphorylation exist in a yin-yang 
relationship,6,107-109 and there are numerous examples of direct yin-yang relationships between 
phosphorylation and O-GlcNAcylation in regulating the function, binding, and activity of 
individual proteins.99,110-115 Moreover, inhibition or activation of multiple kinases and 
phosphatases were shown to, in general, reciprocally modulate global O-GlcNAcylation (i.e. 
treatments that generally increased global phosphorylation reduced, and treatments decreasing 
phosphorylation increased, O-GlcNAcylation) in cultured mouse cerebellar neurons, with the most 
significant effects seen in the cytoskeletal associated fraction.116 However, proteome-wide 
analyses of O-GlcNAcylation and phosphorylation have revealed a more complicated picture. In 




GlcNAc sites were either within 10 amino acids of or themselves a known phosphorylation site.33 
In another study which isolated both O-GlcNAcylated and phosphorylated proteins from murine 
synaptosomes, O-GlcNAcylation and phosphorylation sites were not correlated (outside of both 
being more common in disordered regions), and less than 7% of all O-GlcNAc sites were also 
phosphorylation sites.34 In an in vitro, peptide glycosylation assay, OGT also did not recognize the 
proline-directed kinase motif, PX(S/T)P, which makes up ~40% of all known phosphorylation 
sites.117 However, the same study described a well-defined “interplay motif,” 
(pS/pT)P(V/A/T)(gS/gT), where O-GlcNAcylation is strongly inhibited by phosphorylation. 
Overall, while the above data suggest that while direct competition for the same or close by 
serine/threonine residues is likely a minor phenomenon on the scale of the phosphoproteome, there 
is clearly a certain subset of O-GlcNAcylation/phosphorylation events that exist in a yin-yang 
relationship. 
At the protein level, virtually all O-GlcNAcylated proteins are known to also be 
phosphorylated, and the subset of O-GlcNAcylated proteins are enriched for kinases as a class.33-
35 Globally increasing O-GlcNAcylation also increases the phosphorylation of synapsin 
extracellular signal-regulated kinase (ERK) 1/2 in hippocampal slices.42 Thus, O-GlcNAc may be 
playing a more active role in regulating functional aspects of neuronal kinases and signaling 
cascades. To date, many kinases heavily implicated in learning and memory, such as calcium-
calmodulin dependent kinase (CaMK) II,46 CaMKIV,113 and PKA95 have been shown to be 
functionally regulated by O-GlcNAcylation. We have also found that O-GlcNAcylation and 
phosphorylation occur simultaneously in distinct locations on CREB, and interestingly, 
phosphorylated CREB is preferentially O-GlcNAcylated in response to neuronal activity.2 Taken 




the activity of multiple kinases and their substrates in ways other than directly opposing 
phosphorylation.  
Next, we discuss examples of how O-GlcNAcylation regulates, and is regulated by, 
calcium signaling, a major subset of the neuronal signally machinery and absolutely required for 
long-term potentiation (LTP) and memory formation.118-120 In neurons, calcium levels are 
mediated by the flux of calcium into the cell primarily through voltage-operated channels (VOCs), 
and the release of calcium from intracellular stores mediated by receptor-operated channels 
(ROCs) and store-operated channels (SOCs). Major targets of calcium signaling include the 
CaMKs, a family of serine/threonine kinases expressed throughout the brain and are involved in 
neuronal excitability and plasticity.121 This class of kinases is activated by increases in the 
cytosolic concentration of calcium, resulting in phosphorylation of their substrates and activation 
of downstream signaling events. Increasing evidence suggests an intimate relationship between 
CaMK-mediated calcium signaling and O-GlcNAcylation.  
In neuroblastoma cells, potassium chloride-induced depolarization across the membrane 
results in an increase in the activity of OGT, leading to an increase in O-GlcNAcylation of protein 
substrates.122 Interestingly, this effect could be prevented by inhibition of voltage-operated calcium 
channels, indicating that these effects on O-GlcNAcylation were mediated by calcium signaling 
pathways.122 Furthermore, inhibition of CaMKs also abolished the previously observed increase 
in O-GlcNAcylation indicating that CaMKs are involved in regulating the activity of OGT.122 Of 
the CaMKs, CaMKIV activity was found to upregulate phosphorylation of OGT upon 
depolarization of cells, resulting in an increase in OGT activity.  While CaMKIV may regulate 
OGT activity, evidence indicating a role for OGT in regulating the activity of CaMKIV has also 




phosphorylation and activation 113. Importantly, O-GlcNAcylation of CaMKIV also impeded 
activation of downstream signaling events such as activation of CREB, highlighting OGT as a 
regulator of CaMKIV-mediated calcium signaling pathways.  
Similar interplay between calcium signaling and O-GlcNAcylation may also exist along a 
CaMKII-mediated axis. In 2013, it was demonstrated that diabetic hyperglycemia induced O-
GlcNAcylation of CaMKII in the heart and brain, resulting in chronic activation of CaMKII-
dependent pathways. In cardiomyocytes, these effects contributed to dysfunctional spontaneous 
release of calcium from intracellular stores, contributing to arrhythmias. Importantly, these effects 
were rescued by inhibition of O-GlcNAcylation, suggesting a regulatory role for O-GlcNAc in 
CaMKII-mediated calcium signaling.46 More recently, it was demonstrated that CaMKII 
phosphorylates OGT and that this modification has some influence on substrate-specificity of 
OGT.89 While performed in liver cells, this study highlights the role of calcium-signaling as a 
means through which O-GlcNAcylation levels are regulated and CaMKII-mediated activation of 
OGT may be important in excitable cells, similar to that observed of CaMKIV-mediated activation. 
Together, the above studies highlight a delicate interplay which is present in calcium-mediated 
and OGT-mediated signaling pathways and suggest there may exist feed-back mechanisms; 
however, future studies will be needed to probe CaMKII-OGT and CaMKIV-OGT regulatory axes 
in order to further explore these mechanisms.  
A role for O-GlcNAcylation in regulating store-operated calcium signaling was highlighted 
by early studies demonstrating that increases in hexosamine biosynthesis pathway flux and 
increases in O-GlcNAc levels by treatment with extracellular glucosamine dampened store-
operated calcium entry (SOCE) in excitable cells, such as cardiomyocytes.123 Furthermore, the 




to dampen SOCE and that concomitant inhibition of the hexosamine biosynthesis pathway by 
azaserine (a potent inhibitor of GFAT) restored SOCE.123 
Recent studies aimed at identifying mechanisms through which O-GlcNAcylation may be 
mediating these effects have focused on the ER-membrane protein and calcium sensor stromal 
interaction molecule 1 (STIM1). Upon depletion of calcium stores in the ER, STIM1 adopts an 
extended, active conformation.124-127 Active STIM1 oligomerizes and translocates to pre-existing 
endoplasmic reticulum (ER)-plasma membrane junctions,128,129 leading to recruitment of ORAI1 
and activation of SOCE.127,130 These STIM1-ORAI1 complexes mediate calcium-selective influx 
of ions into the cell. Importantly, the O-GlcNAcylation of STIM1 was found to inhibit STIM1 
mediated SOCE. O-GlcNAcylation may play a protective role in calcium signaling based on the 
findings that acute increases in O-GlcNAc levels prevent Ca overload induced by the calcium 
paradox characteristic of ischemia and reperfusion injuries 131. 
 
1.5.2. Synaptic Plasticity and Cognition. 
         Having highlighted some examples of how O-GlcNAcylation may be involved in 
regulating neuronal signaling cascades, we next turn to the discussion of O-GlcNAc’s roles in 
higher-order neuronal functions. We start on the synaptic level with the emerging role of O-
GlcNAcylation in regulating AMPAR trafficking. We then move to the role of O-GlcNAcylation 
in LTP and long-term depression (LTD) of excitatory synapses, beyond its role in regulating 
AMPAR trafficking, the likely cellular correlates of memory formation and maintenance. Finally, 
we review the first evidence that site specific O-GlcNAcylation can influence memory formation 





         AMPAR are ligand-gated (glutamate) cation channels responsible for the majority of 
excitatory neurotransmission in the mammalian brain.132 Moreover, they are intimately connected 
to learning and memory as their dynamic insertion into and removal from the postsynaptic 
membrane (trafficking) is thought to be the major means by which neurons potentiate or depress 
individual synapses.132,133 Thus, the interesting observation by Vosseller and coworkers that 
inhibiting OGA/OGT enhanced/inhibited LTP (discussed further below),42 strongly suggested that 
global modulation of O-GlcNAc levels likely has a strong effect on AMPAR trafficking. Shortly 
after the aforementioned observation, Din et al. hypothesized that O-GlcNAc may oppose known, 
functionally relevant phosphorylation events on AMPAR subunits GluA1 and GluA2 to maintain 
LTD and LTP respectively.134 Thereafter, Kanno et al. reported that treatment with the OGT 
inhibitor alloxan resulted in the increased insertion of both GluA1 and GluA2 into the plasma 
membrane.135 Another study reported that GluA2, but not GluA1, was O-GlcNAc modified, and 
that this modification was independent of S880 phosphorylation by PKC, a well-established 
mediator of AMPAR internalization.40 Finally, culturing embryonic cortical neurons harvested 
from floxed-OGT mice9 allowed Huganir and colleagues to assess the role of O-GlcNAcylation 
on AMPAR trafficking during synapse formation and development.43 Interestingly, they found 
that conditional KO (cKO) of OGT, via transduction with Cre recombinase, decreased the synaptic 
expression of the GluA2 and GluA3, but not the GluA1 AMPAR subunits.43 
Overall, these results clearly suggest a role for O-GlcNAc in the regulation of AMPAR 
trafficking, perhaps through the direct modification of GluA2, but we have yet to develop a 
mechanistic understanding of how this might occur. It will be interesting to see whether more 
sensitive techniques will be able to identify, map, and quantify the dynamics of individual AMPAR 




AMPAR O-GlcNAcylation in regulating trafficking by revealing how O-GlcNAcylation changes 
at individual sites in response to physiologically relevant stimuli and allowing for the investigation 
of the effects of expressing glycosylation-deficient AMPAR subunits. Alternatively, it is also 
possible that O-GlcNAcylation of AMPARs themselves is not responsible for the differences 
observed in AMPAR trafficking after global changes in O-GlcNAcylation. In fact, several large-
scale proteomics studies of O-GlcNAcylated proteins isolated from mouse and human brains 
revealed multiple PDZ-domain-containing scaffold proteins, SH3 and multiple ankyrin repeat 
domains (SHANK) 1/2/3, multiple members of the membrane-associated guanylate kinases 
(MAGUKs), and synaptic Ras GTPase activating protein (SynGAP) 1, are O-GlcNAcylated.30,33-
35,136 PDZ-domain containing scaffolding proteins are known to regulate trafficking and clustering 
of AMPAR and play a pivotal role in organizing the postsynaptic density and its signaling 
machinery (also necessary for AMPAR trafficking).137  
Thus, perhaps it is not altered AMPAR O-GlcNAcylation itself that is mediating the 
differences in trafficking outlined above, but rather altered synaptic organization (and hence 
AMPAR trafficking and clustering132,137) caused by gross perturbations in the O-GlcNAcylation 
state of many organizational and scaffolding proteins. This might at least partially explain the 
somewhat conflicting result that decreased O-GlcNAcylation can both increase135 and decrease43 
AMPAR insertion into the postsynaptic membrane; if the above hypothesis is correct, small 
differences in the time course/length of inhibitor treatment, age of the neurons, etc… are likely to 
lead to large changes in synapse organization (that subsequently effect AMPAR trafficking).132,138 
Finally, regardless of whether AMPAR O-GlcNAcylation or changes in the O-GlcNAcylation of 
scaffolding proteins (certainly not mutually exclusive) are responsible for modulating AMPAR 




role of O-GlcNAcylation (either globally or site-specifically) on regulating AMPAR subunits 
(both individually and in concert) given the diverse roles of each subunit in different contexts.132,139  
Closely related to AMPAR trafficking is LTP and LTD of excitatory synapses. In fact, 
many of the studies outlined above showed differences in LTP/LTD when O-GlcNAcylation levels 
were globally altered. As previously mentioned, Tallent et al. found that OGA inhibition increased 
LTP while the opposite was true with OGT inhibition.42 However, Taylor et al. found that OGA 
inhibition rather caused severe LTD, and Kanno et al. found that OGT inhibition caused increased 
LTP, both in acute rat hippocampal slices.40,135 Moreover, in an extensive characterization of OGA 
hemizygous mice, shown to have increased levels of O-GlcNAcylation in the brain, Suh and 
colleagues found that both LTP and LTD were attenuated in response to relevant stimuli in acute 
hippocampus slices.140 Here, the authors suggest that these impairments may be due to the 
markedly altered phosphorylation dynamics of AMPAR subunit GluA1 at sites critical for LTP 
and LTD.140 Interpreting these studies in relationship to one another is difficult given the in 
vivo42,140 versus in vitro40,135 modulation of O-GlcNAc levels and the use of different 
chemical40,42,135 and genetic140 tools. The result of this is a fairly significant difference in the time 
between enzyme inhibition and treatment, which is likely to engage differentially engage known 
compensatory mechanisms.51,81,83 Moreover, the studies almost uniformly used different protocols 
to alter O-GlcNAcylation, assess LTP and LTD, and investigate mechanisms, further highlighting 
the need for more systematic studies on the role of O-GlcNAcylation in regulating synaptic 
plasticity. Last, an alternative explanation for the aforementioned conflicting results might be 
timescale/treatment dependent, differential reorganization of the global synaptic machinery 





Another major aspect of LTP/LTD beyond AMPAR insertion in the postsynaptic 
membrane is modulation of glutamate release from the presynaptic neuron.141-143 Interestingly, 
multiple O-GlcNAc sites have been identified on presynaptic proteins involved in regulating 
presynaptic vesicle trafficking, recycling, and release, e.g. bassoon, piccolo, and synapsin, in 
multiple large scale O-GlcNAc proteomics experiments.30-35 Both Tallent et al. and Taylor et al. 
addressed potential presynaptic mechanisms, although they again reached different conclusions. 
Taylor et al. assessed whether glucosamine treatment (demonstrated to significantly increase 
global O-GlcNAcylation) changed the paired-pulse ratio, an indirect measure of presynaptic 
vesicle release, in hippocampal slices and found no effect.40 On the other hand, Tallent et al. 
described a decrease in paired-pulse facilitation, increased short-term potentiation, and a marked 
increase in synapsin phosphorylation at multiple sites after OGA inhibition.42 Synapsin, which 
generally serves to tether presynaptic, neurotransmitter containing vesicles to the neuronal 
cytoskeleton thereby preventing migration to and fusion with the presynaptic membrane (hence 
inhibiting neurotransmitter release), is dynamically regulated by phosphorylation in response to 
neuronal activity.42,144 For example, phosphorylation at serine 9 blocks the association between 
synapsin and synaptic vesicles while phosphorylation at serine 603 induces a conformational 
change which decreases synapsin’s affinity for both actin and synaptic vesicles, essentially 
“freeing” synaptic vesicles for neurotransmitter release.144 An eloquent followup study by 
Vosseller and colleagues showed furthermore that O-GlcNAcylation of synapsin I itself, at the 
single site, Thr87, can directly disrupt the binding between synapsin and synaptic vesicles and 
decrease the amount of synapsin I localized to synapses.145 Taken together, these studies indicate 
that O-GlcNAc is playing a key role in regulating synapsin phosphorylation and function to 




Finally, another way that O-GlcNAcylation could be involved in regulating LTP and LTD 
could be in modulating neuronal membrane potential (and thus controlling neuronal activity). An 
eloquent study by Yang and coworkers found that the activity of AgRP neurons in the 
hypothalamus was drastically reduced by OGT KO.75 Two more recent studies by Huganir and 
colleagues arrived at similar conclusions for α-CaMKII positive neruons in the paraventricular 
nucleus of the hypothalamus and embryonic excitatory cortical neurons (although the defects here 
were attributed to impaired development of synaptic spines).43,96 Yang and colleagues 
hypothesized that the loss of O-GlcNAcylation on potassium voltage-gated channel subfamily 
KQT member 3 (KCNQ3) may contribute to the decreased neuronal activity observed in OGT KO 
neurons,75 presumably by changing the baseline excitability and responsiveness to synaptic input 
of these neurons.146 Interestingly, a subsequent study also showed that increased O-GlcNAcylation 
also decreases spontaneous activity in excitatory neurons in hippocampal slices.147 In summary, it 
is clear that changes in global O-GlcNAcylation can have marked effects on neuronal excitability 
and firing rate, perhaps by regulating the conductance of voltage gated potassium channels (or 
through other, as of yet unexplored, mechanisms), which would have drastic effects on LTP/LTP 
on the individual neuron, circuit, and organismal level.146,148,149 
Although the evidence for the regulation of molecular and electrophysiological events by 
O-GlcNAc is being increasingly explored, there are relatively few studies investigating the role of 
O-GlcNAc in regulating neurobehavioral phenomenon.2,5,40,95,96,140 First, hippocampal 
overexpression of glycosylation-deficient S40A CREB (versus wild-type CREB) significantly 
enhanced long-term memory consolidation in a cued auditory fear conditioning paradigm.2 This 
study represents the potential, critical importance of individual O-GlcNAcylation events in 




studies have focused on the behavioral consequences globally altering O-GlcNAcylation in 
neurons. Two groups studied the effects of OGT KO on memory acquisition and recall, 
overcoming the embryonic lethality of OGT KO by crossing floxed-OGT mice with mice 
expressing Cre recombinase, either constitutively5 or inducibly96, under the α-CaMKII promoter 
(which is not active until postnatal day 14-21). Interestingly, these studies both found very 
different behavioral phenotypes, hyperphagia96 and increased anxiety and impaired contextual and 
cued fear leaning (discussed further in the neurodegeneration section below).5 Similarly, Xie et al. 
showed that decreasing O-GlcNAcylation pharmacologically also impaired both contextual and 
cued fear conditioning in mice.95 On the other hand, increased O-GlcNAcylation, due to OGA 
hemizygosity, also impaired spatial learning and memory in mice as assessed by the Barnes 
circular maze test and contextual fear conditioning.140 However, increasing O-GlcNAcylation 
through pharmacological inhibition of OGA did not affect the performance of rats in a contextual 
fear learning task, although they did demonstrate profound defects in novel object recognition and 
novel object preference tasks.40  
These comparable disruptions in learning and memory observed with decreasing and 
increasing O-GlcNAcylation suggest that dynamic O-GlcNAc cycling, rather than the presence or 
absence of the modification, on certain proteins is critical for neuronal function and cognition. Yet, 
outside of the study of glycosylation-deficient CREB mentioned above,2 almost nothing is known 
about which specific O-GlcNAcylation events are most important for regulating behavioral 
phenomena or how they might act to do so. In summary, although we have only begun to explore 
the role of O-GlcNAc in regulating behavioral phenomena such as memory, appetite, and 






When challenged by chemical, biological or thermal stress, O-GlcNAcylation of proteins 
is increased on a rapid and global scale across diverse cell types, suggesting that O-GlcNAcylation 
is involved in sensing and responding to a variety of stresses.150 In neurons, O-GlcNAcylation has 
been hypothesized to serve neuroprotective functions by mediating responses to cell stress via 
mechanisms including: stabilization of protein integrity, regulation of protein degradation, 
inhibition of protein aggregation, and damping the effects of oxidative stress.12,15 
            Protein degradation by proteasomes is a main mechanism through which misfolded 
proteins are eliminated and concentrations of proteins are controlled.151 Several studies have 
identified OGT as playing a central role in proteasomal regulation through its O-GlcNAcylation 
of the 19S regulatory particle of 26S proteasomes, thus inhibiting proteolysis by through inhibition 
of proteasomal ATPase activity.152,153 In addition to regulating proteolytic activity of the 
proteasome, O-GlcNAcylation is also involved in regulating the susceptibility of proteins to 
degradation. For instance, O-GlcNAcylation of transcription factor Sp1 (SP1) appears to directly 
oppose its proteasomal degradation.154 Moreover, loss of O-GlcNAc results in increased 
ubiquitination and subsequent degradation of nuclear pore protein p62.155 O-GlcNAcylation has 
also been implicated in protein folding and in cellular responses to unfolded proteins. Studies have 
demonstrated that the unfolded protein response activates the hexosamine biosynthesis pathway, 
resulting in an increase of cellular O-GlcNAc levels.156 A physiological role for this OGT-ER 
stress axis was also demonstrated in studies with mice lacking OGT in pancreatic β cells, which 
produce insulin.157 These mice presented with massive β cell failure resulting from increased ER 
stress, ultimately leading to apoptosis triggered by accumulation of unfolded proteins. These 




Another important neuroprotective function of O-GlcNAcylation includes inhibition of 
protein aggregation. Several aggregation prone proteins, such as tau and amyloid-precursor protein 
(APP), are abundant in neurons and the brain and heavily implicated in the pathogenesis of 
neurodegenerative disease. The microtubule-binding protein tau is an intrinsically disordered 
protein which is prone to aberrant oligomerization and fibril formation, a process characteristic of 
neurodegenerative diseases such as AD (discussed below).  While long known to have the capacity 
to be extensively modified by OGT,158 it was not until recently that O-GlcNAcylation of tau was 
found to inhibit fibril formation.102 O-GlcNAcylation also inhibits the aggregation of another 
protein prone to forming fibrils, α-synuclein.159 Furthermore, this protective role of O-
GlcNAcylation is not unique to fibril-forming proteins; O-GlcNAcylation suppresses the 
aggregation of proteins which have been partially destabilized by thermal or chemical stress.102,160 
Recent studies of the polycomb protein polyhomeotic have also demonstrated that O-
GlcNAcylation is essential to prevent aggregation of the native protein under physiological 
conditions.161 These studies emphasize the expanding role of O-GlcNAcylation as a general 
protective mechanism against protein aggregation. 
Finally, OGT may also impart protective functions by regulating cell response to oxidative 
stress and the generation of reactive oxygen species (ROS). Recent studies have demonstrated that 
global increases in O-GlcNAcylation result in decreased ROS production in cells,81,162 and, 
similarly, that ROS increases O-GlcNAcylation in cells.163 Interestingly, in response to oxidative 
stress, FAS appears to associate with and inhibit OGA, and FAS overexpression increased ROS-
induced O-GlcNAcylation.163 This also appears to be beneficial in the context of ischemic stroke, 
where (1) O-GlcNAcylation is upregulated in response to ischemia, and furthermore (2) that TMG 




Multiple proteins involved in protecting against oxidative stress, e.g. NF-E2–related factor 2, 
nuclear factor erythroid 2-related factor, and FOXO1, are also known to be positively regulated by 
O-GlcNAcylation.166 Thus, in addition to its direct roles in protein stability and homeostasis, O-
GlcNAc can also regulate broad cellular responses to ROS, which may have important 
implications for disease of the nervous system such as ischemic stroke and amyotrophic lateral 
sclerosis.15,167 
 
1.5.4. Neurodegenerative Diseases. 
     Focusing on neurodegeneration in the context of metabolic abnormalities is critically 
relevant given that T2DM is strongly associated with both AD and all-cause dementia.57,168-171 
Specifically, persistent hyperglycemia eventually leads to brain insulin resistance and decreased 
glucose metabolism, also the earliest known pathological feature of AD.15,48,100,172 In fact, 
decreased cerebral glucose metabolism precedes mild cognitive impairment and 
neurodegeneration sometimes by many years, and further decreases correlate extremely well with 
further cognitive decline.173-176 Because of the intimate link between glucose metabolism and O-
GlcNAc,6,15 a decrease in brain glucose metabolism is likely to lead to a concomitant decrease in 
O-GlcNAc levels. Thus, it is perhaps not surprising that there have been multiple reports of 
decreased O-GlcNAcylation in the brains of AD patients.99,100,177 We also recently reported that 
neuronal OGT expression was decreased in tissue samples from Braak Stage V/VI AD patients.5 
Interestingly, there have also been several reports of increased O-GlcNAcylation in AD brains,178-
180 although they all use the CTD110.6 antibody (which does not specifically recognize O-GlcNAc 
in the presence of other N- or O-linked glycans),181,182 and a recent study identified both increases 




specific O-GlcNAcylation events in AD is likely to be more complex than a universal upregulation 
or downregulation. Thus, it will be extremely important for future studies to explore the 
mechanistic underpinnings of individual or function specific O-GlcNAcylation events in a 
systematic and standardized manner, especially given the current differences in detection 
techniques, post mortem delay, etc.99,183  
However, there have been multiple studies that have shown detrimental effects of 
modulating global levels of O-GlcNAcylation on cellular, electrophysiological, and behavioral 
phenomenon relevant to AD (see also Section 1.5.2). Moreover, a protective effect of increased 
O-GlcNAcylation in mouse models of AD and other neurodegenerative diseases has been 
consistently demonstrated. The topic has been reviewed extensively elsewhere;15,184-187 however, 
we note briefly here that OGA inhibition reduces the formation of both amyloid β (Aβ) 
plaques101,103 and tangles of hyperphosphorylated tau101,102, the two pathological hallmarks of 
AD.15 Importantly, OGA inhibition also reduces overall neurodegeneration and attenuates the 
behavioral defects in these mouse models.101-103 To understand whether decreased O-
GlcNAcylation has a consistent phenotype, we recently generated a conditional KO of OGT in 
αCaMKII positive neurons, which, as mentioned previously, develop normally as OGT is 
expressed through postnatal day 14-21.5 Consistent with a neuroprotective role of O-
GlcNAcylation in the brain, these mice exhibited profound neurodegeneration and features of AD 
starting at 2 months of age. Specifically, we noted massive neuronal loss in the cortex and 
hippocampus, increased tau phosphorylation and amyloidogenic Aβ peptide levels, gliosis, the 
formation of plaques and aggregates, and significant memory defects.5 Notably, the mouse 
recapitulates virtually all of the features of AD, including both of the pathological hallmarks, 




models).188 Taken with the previous studies showing a neuroprotective effect of OGA inhibition, 
this study provides further, convincing evidence that O-GlcNAcylation may be protective in AD 
and that the decreased O-GlcNAcylation and OGT expression seen in human patients may be an 
important pathogenic mechanism. 
As alluded to previously, Huagnir and coworkers also characterized a similar, conditional 
OGT KO mouse, but found a strikingly different phenotype, hyperphagia and extreme weight 
gain.96 Moreover, they did not observe significant neuronal loss, although the time point examined 
was not specified.5,96 Notably, their model employed the tamoxifen-inducible expression of Cre 
recombinase under the αCaMKII promoter, where ours was constitutively expressed, in floxed-
OGT mice.5,96 Notably, this results in a different time course of OGT KO; in their case OGT was 
universally deleted in αCaMKII neurons at ~6 weeks of age versus OGT deletion happening 
stochastically starting at ~2-3 weeks of age. Perhaps this difference in the time course is important 
for the phenotype, but it is difficult to say without definitive information about neuronal health in 
the tamoxifen-inducible conditional KO mouse over time (for instance, we also did not see 
significant neuronal loss at 1 month of age). Finally, differences in the spatial/cell-type distribution 
of Cre/loxP recombination due to the use of different αCaMKII-Cre founder lines may explain 
why we did not observe a hyperphagia phenotype (i.e. OGT may not have been deleted in the same 
subset of hypothalamic neurons regulating satiety in our mouse, although we did not assess this 
specifically); another possibility is that the hyperphagia phenotype was masked by the marked 
neurodegeneration.5,189 It would be interesting to further characterize both mice to see whether and 
when the tamoxifen-inducible conditional OGT KO exhibits a neurodegenerative phenotype or 
other pathological changes associated with AD. If neurodegeneration is in fact absent, it would be 




difference. Regardless, future studies should aim to build a comprehensive understanding of how 
disruptions in O-GlcNAcylation play a role in neurodegenerative diseases. Moreover, as previous 
studies have mostly focused on the role of O-GlcNAcylation in regulating individual cellular 
pathologies, e.g. tau or α-synuclein aggregation, looking at the coordinated results of disrupted O-
GlcNAcylation across multiple proteins, pathologies, and/or functions given the multifaceted and 
enigmatic nature of neurodegenerative disease. It would also be interesting to see whether there 
are certain, key O-GlcNAcylation events that can, on their own, attenuate or worsen 
neurodegeneration, as is the case for S40 CREB O-GlcNAcylation in fear memory.2 
 
1.6. Conclusion and Outlook. 
It is becoming increasing clear that O-GlcNAcylation is on par with phosphorylation for 
regulating the cellular response to metabolic, chemical, or electrical signals. UDP-GlcNAc, the 
high-energy donor substrate for OGT is synthesized from glucose through the HBP and is thus 
ideally suited to respond to changes in extracellular glucose concentrations. Accordingly, 
increased O-GlcNAcylation mobilizes metabolic machinery across the cell to attenuate glucose 
influx and, in the liver, stimulate lipogenesis. However, in the context of metabolic diseases like 
T2DM, sustained increases in O-GlcNAcylation can lead to the paradoxical elevation of 
gluconeogenesis, lipogenesis, and systemic insulin resistance as well as pancreatic β cell death. 
Understanding the physiological and pathological roles of O-GlcNAc is thus key to our 
understanding of metabolism and systemic energy homeostasis in general. 
In the brain, O-GlcNAc has also been shown to regulate a wide range of functions. Like in 
metabolism, it regulates key transcriptional responses to extracellular signals and directly 




neuronal communication and survival. O-GlcNAcylation may also serve to regulate protein-
protein interaction necessary for the assembly of synaptic signaling machinery as well as modify 
the properties of receptors and ion channels. Interplay with phosphorylation and regulation of 
calcium signaling are also major themes (as they are in the liver). O-GlcNAcylation also seems to 
be playing a major role in diseases of the nervous system. Especially in neurodegenerative diseases 
such as Parkinson’s and AD, aberrant O-GlcNAcylation has been linked to disease pathogenesis 
and progression through its multiple neuroprotective properties and ability to prevent aggregation 
of pathologic proteins like α-synuclein and tau. This emerging theme of O-GlcNAcylation serving 
as a central regulator of neuronal function, homeostasis, and disease is ripe for further exploration. 
Finally, although we have made significant strides in understanding the function of O-
GlcNAc on multiple neuronal proteins individually, the chemical, genetic, and biotinformatic tools 
and model systems to study the neuron- or brain-wide functions of O-GlcNAcylation in an 
unbiased manner have only arisen in the last few years. Specifically, detecting and mapping O-
GlcNAcylation events and sites, respectively, has been limited by the poor immunogenicity and 
chemical lability of O-GlcNAc, complicating the use of traditional biochemical techniques.183 As 
a result, the kinds of systems-wide analyses of O-GlcNAcylation dynamics necessary for making 
unbiased functional hypotheses have been severely lacking. For example, to our knowledge, there 
have only been two attempts to quantify changes in O-GlcNAcylation after treatment with relevant 
stimuli or across different neuronal states (both discussed further in Chapter 4). First, building on 
our well-established chemoenzymatic labeling technique,136,190 we developed a quantitative 
isotopic and chemoenzymatic tagging (QUIC-Tag) mass spectrometry (MS) method to explore the 
dynamics of O-GlcNAcylation in culture neurons and rat brains.32 Ten years later, Wang et al. 




and coworkers,191 to profile differences in O-GlcNAcylation in AD brains versus age-matched 
controls.35 Although both of these studies represent a significant advance in our ability to profile 
dynamic O-GlcNAcylation events, they do not provide the amount of data necessary to truly 
provide an unbiased insight into the numerous, global functions of O-GlcNAcylation and lag far 
behind techniques for other PTMs, such as phosphorylation.192,193 Thus, there is a critical need for 
improved chemical and MS techniques to explore the proteome-wide differences in O-
GlcNAcylation in response to stimuli or across disease states. The development and application of 
such advanced tools would revolutionize the study of O-GlcNAcylation and shed new light on the 
intimate links between metabolism and neuronal function, cognition, and multiple devastating 
diseases including AD and T2DM.  
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 The addition of O-GlcNAc to serine/threonine residues of proteins is a ubiquitous PTM 
found in all multicellular organisms. Like phosphorylation, O-GlcNAcylation is inducible and 
regulates a myriad of physiological and pathological processes. However, understanding the 
diverse functions of O-GlcNAcylation is often challenging due to the difficulty of detecting and 
quantifying the modification. Thus, robust methods to study O-GlcNAcylation are essential to 
elucidate its key roles in the regulation of individual proteins, complex cellular processes, and 
disease. In this chapter, we describe a set of chemoenzymatic labeling methods to (1) detect O-
GlcNAcylation on proteins of interest, (2) monitor changes in both the total levels of O-
GlcNAcylation and its stoichiometry on proteins of interest, and (3) enable mapping of O-GlcNAc 
to specific serine/threonine residues within proteins to facilitate functional studies. First, we 
outline a procedure for the expression and purification of a multi-use mutant galactosyltransferase 
enzyme (Y289L GalT). We then describe the use of Y289L GalT to modify O-GlcNAc residues 
with a functional handle, N-azidoacetylgalactosamine (GalNAz). Finally, we discuss several 
applications of the copper-catalyzed azide-alkyne cycloaddition “click” reaction to attach various 
alkyne-containing chemical probes to GalNAz and demonstrate how this functionalization of O-
GlcNAc-modified proteins can be used to realize (1) - (3) above. Overall, these methods, which 
utilize commercially available reagents and standard protein analytical tools, will serve to advance 






O-GlcNAcylation is a dynamic, inducible PTM found on thousands of intracellular 
proteins.1 Only two are enzymes responsible for O-GlcNAc cycling in metazoans: OGT, which 
catalyzes the addition of O-GlcNAc, and OGA, which catalyzes its removal.1 The O-GlcNAc 
modification plays a key role in many important cellular functions, including transcription,2 
nutrient sensing,3 metabolism,4 mitochondrial dynamics,5 and autophagy.6 Furthermore, 
dysregulation of O-GlcNAcylation has been strongly implicated in a number of human diseases 
such as diabetes,7 cancer,8 and neurodegenerative disorders.9,10 However, the regulatory nature of 
the modification (e.g. dynamic, low cellular abundance) and its unique chemical characteristics 
(e.g. low immunogenicity of the neutral sugar, chemically labile) represent a central challenge in 
its detection and study. These features have necessitated the development of customized methods 
to visualize and quantify this PTM.11  
 One of the first techniques developed to detect O-GlcNAcylation used bovine milk 
galactosyltransferase to transfer [3H]-galactose to terminal GlcNAc residues on proteins.12 Along 
with metabolic labeling using [3H]-glucosamine,13 this method facilitated early studies of O-
GlcNAcylated proteins. Another common detection method took advantage of the specificity of 
wheat-germ agglutinin (WGA) lectin, which binds to all terminal GlcNAc sugars as well as sialic 
acid.14 Several antibodies have also been produced using various O-GlcNAcylated proteins and 
peptide fragments, including the C-terminal domain of RNA polymerase II (CTD110.6)15 and the 
pore complex-lamina fraction from rat liver nuclear envelopes (RL-2).16,17 A comprehensive list 
of O-GlcNAc-specific antibodies has been recently described in detail elsewhere.18 However, the 
relatively poor immunogenicity of the neutral O-GlcNAc sugar has limited the availability of 




metabolic oligosaccharide engineering (MOE) has emerged as a powerful method to label cellular 
glycans, including O-GlcNAc.19,20 Here, a non-natural, peracetylated sugar such as N-
azidoacetylglucosamine21 is incubated with live cells and incorporated into O-GlcNAcylated 
proteins by the cell’s native biosynthetic machinery. The bioorthogonal azide group can then be 
used for downstream detection and enrichment. 
Although many of these detection methods have been widely adopted, they have some key 
limitations. Labeling of proteins with bovine milk galactosyltransferase requires handling of 
expensive, radioactive materials and often necessitates exposure times of days to months.22 While 
antibodies offer a convenient and faster means of detection, they exhibit a preference for specific 
sequence or structural motifs and thus only detect a subset of the O-GlcNAcylated proteins.18 
Moreover, like tritium-based methods, both antibody- and lectin-based techniques are often not 
sensitive enough to detect O-GlcNAc modifications in cases of low abundance or where sample is 
limiting. Additionally, the lack of specificity of some detection reagents like the CTD110.6 
antibody can lead to misinterpreted results. For example, the increase in O-GlcNAc levels 
observed upon nutrient deprivation by Western blotting with CTD110.6 was later found to be due 
to an increase in truncated N-glycans.23,24 O-GlcNAc detection using antibodies and lectins has 
also resulted in conflicting reports on the levels of total protein O-GlcNAcylation in similar 
systems. For example, an increase in O-GlcNAcylation in Alzheimer’s disease brain tissue was 
observed by immunoblotting with the CTD110.6 antibody,25 whereas the opposite finding was 
observed using the RL-2 antibody.26 MOE methods also suffer from specificity issues, with reports 
of N-azidoacetylglucosamine incorporation into cell-surface N- and O-linked glycans27 that have 
prompted efforts to develop more selective probes.28,29 Furthermore, the addition of relatively high 




artifically change physiological levels of O-GlcNAcylation in cells. Finally, MOE cannot achieve 
complete labeling due to competition with natural sugars, which limits its detection sensitivity and 
hinders the quantification of O-GlcNAc stoichiometry. Nevertheless, all of these methods can be 
effectively used for O-GlcNAc detection and remain key tools in the study of O-GlcNAcylation.  
Given the above limitations, methods that are (1) highly sensitive and specific, (2) unbiased 
towards certain subsets of proteins, (3) able to easily and accurately assess changes in O-
GlcNAcylation levels, and (4) compatible with traditional techniques for protein analysis are 
paramount to expanding our understanding of O-GlcNAcylation dynamics and function.  Herein, 
we describe a chemoenzymatic labeling approach that utilizes engineered bovine β-1,4-
galactosyltransferase 1 (Y289L GalT) to tag O-GlcNAcylated proteins with an GalNAz group 
(Fig. 2.1a). When combined with peptide:N-glycosidase F (PNGase F) treatment to remove 
GlcNAc-containing N-linked glycans,30 this method allows for the specific, unbiased, and global 
labeling of O-GlcNAcylated proteins. The appended azide handle can subsequently be reacted 
with a wide variety of alkyne-modified chemical probes, facilitating multiple downstream 
analyses. Here, we describe four distinct workflows that take advantage of the copper-catalyzed 




carboxytetramethylrhodamine (TAMRA), high-molecular-weight poly(ethylene glycol) (PEG), or 
cleavable Dde-biotin probes to O-GlcNAcylated proteins (Fig. 2.1a).  
Biotinylation or TAMRA-labeling enables rapid, sensitive detection of O-GlcNAcylated 
proteins by Western/streptavidin blotting or direct in-gel fluorescence.4,31 Importantly, these 
approaches allow for unbiased protein detection (Fig. 2.1b) and a significant enhancement in 
detection sensitivity (>380-fold relative to tritium labeling in the case of α-crystallin) compared to 
traditional methods (Fig. 2.1c).22,31 Thus, detection of novel O-GlcNAcylated proteins is more 
 
















TMG − − − − ++++
GalT − − + +
Chemoenzymatic 























readily possible, such as CREB2 and PFK1.4 The biotin and TAMRA tags also allow for the 
selective enrichment of O-GlcNAcylated proteins by using streptavidin or anti-TAMRA antibody 
affinity chromatography. Such an enrichment step can greatly improve the detection of O-
GlcNAcylated peptides by MS as the presence of unmodified peptides often suppresses the 
ionization of their O-GlcNAcylated counterparts.32 To improve further the efficiency of 
enrichment and detection, we developed a chemically cleavable Dde-biotin probe (Fig. 2.1a).33 
This probe allows for the mild, quantitative elution of O-GlcNAcylated proteins from streptavidin 
beads and produces a positively charged amine upon cleavage to enhance ionization/MS-based 
detection.  
Biotin or defined PEG mass tags can be used to monitor O-GlcNAcylation dynamics and 
stoichiometry by quantitative Western blotting. The ability to study changes in O-GlcNAcylation 
in response to cellular stimuli or across disease states is critical to understanding the specific 
Fig. 2.1. Chemoenzymatic Labeling Strategies for the Study of O-GlcNAcylated Proteins.  
(a) Incubation of O-GlcNAcylated proteins with Y289L GalT and UDP-GalNAz installs a 
chemical handle that can be further functionalized with alkyne-containing biotin, TAMRA, PEG, 
or Dde-biotin probes using CuAAC. The Dde-biotin probe is cleaved by hydrazine to provide a 
positively charged amine at the site indicated (dotted line). (b) Attachment of either an alkynyl 
biotin or alkynyl TAMRA probe allows for the assessment of total O-GlcNAcylation dynamics in 
response to cellular stimuli. HEK 293T cells were treated for 6 hours with 50 μM of the OGA 
inhibitor thiamet-G (TMG) or vehicle and subjected to the workflow in Sections 2.4 and 2.5. 
Total O-GlcNAcylation levels were visualized by blotting with AlexaFluor 680-conjugated 
streptavidin. Robust, unbiased labeling of proteins is observed by chemoenzymatic labeling. Note 
the marked difference in the number and molecular weight of O-GlcNAcylated proteins detected 
as compared to the anti-O-GlcNAc antibodies RL-2 and CTD110.6. (c) Attempts to detect O-
GlcNAcylated α-crystallin by various methods show the sensitivity advantage afforded by 
functionalization with biotin-PEG4-alkyne. In all cases, 0.75 μg of bovine lens α-crystallin was 
resolved on SDS-PAGE (after chemoenzymatic labeling, as described in Section 2.4, or tritium 
labeling, as described in (Khidekel et al., 2003)) and detected as indicated. (d) Labeling proteins 
with alkynyl PEG (2-kDa) allows for the observation of multiple O-GlcNAcylation states (mono-, 
di-O-GlcNAcylated, etc.) and their corresponding stoichiometries. Mouse primary cortical 
neurons were treated with 60 mM KCl for 2 hours and subjected to the workflow in Sections 2.4 




functions of the O-GlcNAc modification. Chemoenzymatic labeling with biotin enables the rapid, 
global assessment of O-GlcNAcylation and has the advantage of detecting many more proteins 
than antibody-based methods (Fig. 2.1b). Thus, it can be readily used to monitor changes in O-
GlcNAcylation on either specific proteins or the total O-GlcNAcylated protein population in 
response to cellular stimuli. On the other hand, labeling with PEG tags of defined molecular mass 
provides the powerful ability to reveal O-GlcNAcylation states (i.e. mono-, di-O-GlcNAcylated, 
etc.) and quantify in vivo O-GlcNAcylation stoichiometries on proteins of interest (Fig. 2.1d). 
Such information cannot be readily obtained using other methods. When combined with site-
directed mutagenesis, the PEG tagging approach can also determine O-GlcNAc occupancy levels 
and cycling at specific serine/threonine sites in a protein.2,4,34 Quantitative comparisons of O-
GlcNAcylation states and their stoichiometries following cellular stimulation or during disease 
progression are important for identifying the most physiologically relevant O-GlcNAcylation 
events.  
We begin this chapter with an updated method for the purification of Y289L GalT (Section 
2.3). We next describe how to use this enzyme to label O-GlcNAcylated proteins efficiently with 
GalNAz in a complex cellular lysate (Section 2.4). After attaching this azide handle, we outline a 
general method to install a variety of functional tags through CuAAC and detail how the four 
representative chemical probes can be used to detect, quantify, and measure the dynamics of O-
GlcNAcylation both on individual proteins and on the total O-GlcNAcylated proteome (Sections 
2.5, 2.6, and 2.7). Lastly, we briefly discuss methods to localize the O-GlcNAc modification to 





2.3. Expression and Purification of Y289L GalT. 
 The first step of the chemoenzymatic approach is the selective labeling of O-GlcNAcylated 
proteins with GalNAz. This is achieved using Y289L GalT, which is robustly expressed in E. coli, 
purified from inclusion bodies, and refolded to obtain active enzyme.35 The procedure below is a 
streamlined protocol for making large quantities of Y289L GalT. The enzyme can be stored for up 
to 1 year as the active protein or for several years in the unfolded form or cell pellet. We also 
describe procedures to test the purity and activity of the enzyme prior to its use. These checks are 
necessary before proceeding with the remaining techniques in this chapter.  
 
2.3.1. Equipment. 
1. 37°C incubator with shaker 
2. UV-Vis spectrophotometer  
3. Refrigerated centrifuge 
4. Sonicator (Vibra-Cell VCX 130; Sonics & Materials) 
5. Centricon Plus-70 Centrifugal Filter, 10-kDa nominal molecular weight limit (NMWL) 
(UFC700308, EMD Millipore)  
6. Spectra/Por 4 Standard RC Dialysis Tubing, 12-14-kDa molecular weight cut-off 
(132706, Spectrum Labs) 
7. Standard equipment for sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and Coomassie staining 





a. Other MS methods such as liquid chromatography (LC)-electrospray ionization 
MS (Khidekel et al., 2003) also work well. 
 
2.3.2. Materials. 
1. Y289L GalT expressing plasmid (Ramakrishnan & Qasba, 2002) 
2. 2-Nitro-5-(Sulfothio)-Benzoate (NTSB) (Thannhauser, Konishi, & Scheraga, 1984) 
a. To prepare 10 mL of NTSB, dissolve 0.1 g of 5,5’-dithiobis(2-nitrobenzoic acid) 
in 10 mL of 1 M Na2SO3 at 37°C. Adjust the pH to 7.5 with NaOH and bubble air 
through the solution until the color changes from deep orange-red to pale yellow 
(~1-2 hours). 
b. Make fresh or store at -20°C immediately after production. 
3. Electro- or chemically competent BL21(DE3) E. coli  
4. Luria-Bertani agar (LA) plates containing 100 μg/mL of ampicillin 
5. Luria-Bertani (LB) broth containing 100 μg/mL of ampicillin 
6. 100 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) in H2O 
7. Phosphate-buffered saline (PBS) pH 7.4 (10 mM Na2HPO4, 1.8 mM KH2PO4, 137 mM 
NaCl, 2.7 mM KCl), 1 mM ethylenediaminetetraacetic acid (EDTA) 
8. 25% (w/v) Sucrose, 0.1% Triton-X100, and 1 mM EDTA in PBS pH 7.4 
9. 5 M Guanidine hydrochloride in H2O* 
10. 5 M Guanidine hydrochloride and 0.3 M sodium sulfite in H2O* 
11. Refolding buffer: 50 mM tris(hydroxymethyl)aminomethane HCl (Tris) pH 8, 5 mM 




12. Dialysis buffer: 50 mM Tris pH 8, 5 mM EDTA, 4 mM cysteamine, and 2 mM 
cystamine*  
13. 100 pmol/μL of Click-iT O-GlcNAc Peptide LC/MS Standard (Click-iT peptide) 
(C33374, Invitrogen) 
14. 100 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.9 
15. 10 mM uridine 5’-diphospho-2-acetonyl-2-deoxy-α-D-galactose (UDP-ketogal) 
(Khidekel et al., 2003) or 10 mM uridine 5’-diphospho-2-azidoacetylamino-2-deoxy-α-
D-galactose (UDP-GalNAz)36 in H2O  
a. Store at -80°C and thaw on ice just before use. 
16. 100 mM MnCl2 
17. C18 ZipTips (ZTC18M096, EMD Millipore) 
18. MS grade acetonitrile (ACN)  
19. MS grade H2O 
20. 1% trifluoroacetic acid (TFA) in H2O 
21. Super-DHB (sDHB) MALDI matrix (50862, Sigma-Aldrich) 
* Make fresh on the day of use. 
 
2.3.3. Procedure. 
1. Transform 50 μL of electro- or chemically competent BL21(DE3) E. coli with 1 μL of 
Y289L GalT expressing plasmid (10 ng/μL), plate onto LA plates containing 100 μg/mL 
of ampicillin, and incubate overnight at 37°C. 
2. Pick two colonies, add individually to 100 mL of LB containing 100 μg/mL of ampicillin, 




3. Distribute the two 100-mL flasks equally between six 1-L volumes of LB containing 100 
μg/mL of ampicillin.  
4. Incubate with shaking (250 RPM) at 37°C until the optical density at 600 nm reaches 0.7. 
5. Add IPTG to a final concentration of 1 mM to induce protein production. 
6. Incubate with shaking (250 RPM) for another 4 hours at 37°C. 
7. Harvest the cells by centrifugation at 8000 x g for 10 minutes. 
a. The bacterial pellets can be frozen at -80ºC for at least 2 years. 
8. Resuspend bacteria from 1 L of culture medium in 10 mL of PBS containing 1 mM 
EDTA and sonicate thoroughly (10-15 x 30 seconds, with 10-second rest) at 40% 
amplitude on ice.   
a. From now on, the volumes correspond to the purification of Y289L GalT from 1 
L of bacterial culture; we generally purify Y289L GalT from 1-2 L of bacterial 
culture at a time and save the remaining pellets for future purification. 
Alternatively, the purification can be performed up to step 2.3.19 below and 
frozen at -80°C for at least 2 years. 
b. Unless otherwise noted, all steps from this point onward should be performed on 
ice or at 4°C, and all reagents should be ice cold. 
9. Dilute the bacterial lysate to 80 mL with PBS containing 1 mM EDTA and centrifuge at 
14,000 x g for 30 minutes. 
10. Discard the supernatant and resuspend the pellet in 25% (w/v) sucrose in PBS containing 
1 mM EDTA and 0.1% Triton X-100. 




a. It is important to ensure that the pellet is completely resuspended with each wash 
step to ensure efficient purification of Y289L GalT. With repeated washes, the 
color of the pellet should change from yellow to ivory white.  
b. If necessary, the pellet can be stored overnight at 4°C at any point. 
12. After the last centrifugation, resuspend the pellet in 50 mL of PBS containing 1 mM 
EDTA and centrifuge for 30 minutes at 14,000 x g.  
13. Discard the supernatant, and repeat this step once more to remove any residual detergent. 
14. Discard the supernatant, and resuspend the pellet in 20 mL of 5 M guanidine 
hydrochloride with 0.3 M sodium sulfite at room temperature. 
15. Add 2 mL of S-sulfonating agent, NTSB, and stir the reaction vigorously until it has 
turned pale yellow in color. 
a. When NTSB (pale yellow) is added to the mixture, the solution should turn red-
orange. The reaction is complete when the solution has turned back to pale 
yellow, which usually takes approximately 45 minutes. 
16. Add 180 mL of ice-cold H2O to precipitate the protein and centrifuge at 10,000 x g for 10 
minutes. 
17. Discard the supernatant, resuspend the pellet in 10 mL of H2O, and centrifuge the sample 
at 10,000 x g for 10 minutes. 
18. Repeat two more times to remove any remaining sulfonating agent. 
19. Resuspend the pellet in 5 M guanidine hydrochloride to a protein concentration of 1 




a. We typically use absorbance at 280 nm on a NanoDrop® 2000 UV-Vis 
Spectrophotometer (ThermoFisher Scientific) to determine the protein 
concentration.  
b. If desired, the unfolded, sulfonated protein can be frozen and stored at -80°C for 
at least 2 years. 
20. Dilute the protein solution 10-fold over the course of 15 minutes in refolding buffer. 
a. Add the refolding buffer in 10 portions over the course of 15 minutes while 
mixing the solution (by hand or with an orbital shaker).   
b. Some protein will precipitate as the refolding buffer is added.  
21. Leave the protein undisturbed to refold at 4°C for 48 hours.   
22. Centrifuge the solution at > 7,000 x g for 10 min to pellet any precipitate, and dialyze the 
supernatant 3 x 12 hours with 4 L of dialysis buffer. 
a. Some protein will precipitate during the dialysis process. 
b. Dialyzation using a stirred cell (e.g. UFSC05001, MilliporeSigma) or centrifugal 
concentrator is also possible, and we have observed no loss of activity using these 
methods. However, it is important in either case that the dialysis is closely 
monitored to avoid over-concentration and precipitation of the enzyme. 
23. After dialysis, remove the precipitated protein by centrifugation at > 7,000 x g for 15 
minutes. 
24. Concentrate the Y289L GalT to 1 mg/mL (determined as previously described) using 
Centricon Plus-70 10-kDa NMWL Centrifugal Filter Units and store at 4°C. 




b. Protein can be stored for at least 1 year at 4°C; use the assay described below to 
ensure activity of older protein stocks before use. 
25. Check the quality of the Y289L GalT by performing SDS-PAGE followed by staining 
with Coomassie blue (Fig. 2.2a). 
26. Check that the purified Y289L GalT labels an O-GlcNAcylated peptide using UDP-
ketogal or UDP-GalNAz. Set up a dilution series of enzyme as follows: 
a. Add 0.75 μL of 100 mM MnCl2; 1.5 μL of 100 mM HEPES (pH 7.9); 0, 0.375, or 
0.75 μL of 2 mg/mL Y289L GalT; 0.75 μL of 10 mM UDP-ketogal or UDP-
GalNAz; and 1.5 μL of 100 pmol/μL Click-iT peptide to 10.5, 10.125, or 9.75 μL 
of H2O (pipetting up and down after each condition to mix). The final reaction 
conditions are outlined in Table 2.1. 
b. Incubate the above reactions at 4°C for 16 hours. 
Table 2.1. Reaction Conditions for Testing Y289L GalT Activity. 
Reaction Componentsa Volume (μL) Final Concentration 
H2O 10.5, 10.125, or 9.75  
100 mM MnCl2 0.75 5 mM 
100 mM HEPES pH 7.9 1.5 10 mM 
2 mg/mL Y289L GalT 0, 0.375, or 0.75 0, 0.05, or 0.1 mg/mL 
10 mM UDP-ketogal or UDP-
GalNAz 
0.75 500 μM  
100 pmol/μL Click-iT Peptide 1.5 10 pmol/μL 
Final Volume 15  
a Flick tubes to mix and spin down briefly after each addition. 
 
27. After incubating for 16 hours, quench the reaction by adding 1.5 μL of 1% TFA and 
purify the peptides using ZipTips per the manufacturer’s instructions. 




29. After MALDI-TOF analysis, look for the complete conversion of the unlabeled peptide to 
the labeled peptide to confirm quantitative labeling (Fig. 2.2b). 
a. With UDP-ketogal, look for the labeled and unlabeled peptides at an m/z of 
1320.5 and 1118.5 Da, respectively, in positive ionization mode. Often times their 
sodium adducts are also seen at 1342.5 and 1140.5 Da. If UDP-GalNAz is used, 
the labeled peptide will be observable at 1362.5 Da. A peak at [M-28], 
corresponding to the loss of N2, is also usually observed. Note that using reflector 
mode detection may complicate analysis when using UDP-GalNAz.38  
 
 
Fig. 2.2. GalT Characterization.  
(a) Coomassie stained gel of purified Y289L GalT. (b) Representative MALDI-TOF spectra of 
the peptide labeling reaction with 0 mg/mL (left) or 0.1 mg/mL (right) Y289L GalT. The blue 
arrows indicate the unlabeled peptide (1118.23) and its sodium adduct (1140.23). The red arrows 


















































We usually obtain 5-10 mL of active Y289L GalT at a concentration of 2 mg/mL from the 
purification procedure described above. It is important to note that some protein will continue to 
precipitate over the first few days to weeks of storage. Although the precipitation of protein is 
usually not enough to significantly affect the concentration, it is important to re-check both the 
protein concentration and activity periodically to ensure consistent labeling in subsequent 
procedures. Overall, if stored properly at 4°C, the Y289L GalT should retain almost 100% of its 
activity for more than 1 year.  
 
2.4. Labeling of O-GlcNAcylated Proteins with GalNAz. 
 The Y289L GalT (hereafter referred to as “GalT”) produced in Section 2.3 can be used to 
label O-GlcNAcylated proteins with UDP-ketogal or UDP-GalNAz. Here, we focus on the use of 
UDP-GalNAz to add an azide handle to O-GlcNAcylated proteins in cell lysates for further 




2. Vortex mixer 
3. End-over-end rotator 
4. Spectrophotometer  






1. 20 mM TMG stock in DMSO 
2. 50x cOmplete EDTA-free Protease Inhibitor Cocktail (11873580001, Sigma Aldrich) 
stock in H2O 
3. Lysate containing protein(s) of interest 
a. We generally use the following lysis buffer for most applications: 2% SDS, 100 
mM Tris pH 8, 1x protease inhibitor cocktail, and 50 μM TMG. 
b. Other non-denaturing methods of lysis are also compatible with this protocol; 
however, it is important that OGA inhibitors, such as TMG,39 be included at all 
steps until the protein is completely denatured to prevent the potential loss of 
protein O-GlcNAcylation. 
c. Purified protein obtained by recombinant expression or immunoprecipitated from 
cell lysate can also be used. In this case, reduce and alkylate the protein, and start 
at step 8 below.  
4. Dithiothreitol (DTT) 
5. Iodoacetamide (IAA) 
6. IGEPAL CA-630 (I8896-50ML, Sigma-Aldrich) 
7. Milli-Q (or equivalent) purified H2O 
8. PNGase F (glycerol-free) (P0705S, New England Biolabs) 
9. BCA Protein Assay Kit (23225, ThermoFisher Scientific) 
10. Methanol  
11. Chloroform 




13. 2.5x GalT labeling buffer: 50 mM HEPES pH 7.9, 125 mM NaCl, 5% IGEPAL CA-630* 
14. 100 mM MnCl2 in H2O* 
15. 500 μM UDP-GalNAz in 10 mM HEPES pH 7.9*  
a. Store at -80°C and thaw on ice just before use. 
16. 2 mg/mL GalT* 
a. Keep on ice. 
* These materials are also commercially available as part of the Click-iT O-GlcNAc Enzymatic 
Labeling System (C33368, ThermoFisher Scientific). 
 
2.4.3. Procedure. 
1. Lyse the cells in boiling lysis buffer, boil for 5 minutes, and sonicate the lysate 3 x 10 
seconds to sheer DNA.  
2. Centrifuge the sample for 5 minutes at 21,130 x g and transfer the supernatant to clean 
1.5-mL microcentrifuge tubes. 
3. Measure the protein concentration of the sample using the BCA assay and dilute the 
sample to 1-2 mg/mL prior to reduction and alkylation. 
4. Add 25 mM (final concentration) of DTT, boil for 5 minutes, and allow the sample to 
return to room temperature.  
5. Add 80 mM (final concentration) of IAA and incubate with end-over-end rotation at 
room temperature in the dark for 60 minutes. 
a. Reduction and alkylation of the protein lysate is very important for preventing 




side reactions produce nonspecific background and artificially increase the O-
GlcNAcylation stoichiometry.  
6. Dilute cell lysate containing 150 μg of protein with H2O to a total volume of 200 μL. 
a. This amount is a good starting point for detecting specific O-GlcNAcylated 
proteins of interest from cell lysates; however, the reaction can be easily scaled 
depending on the application. 
7. Precipitate the protein to remove it from endogenous UDP-sugars in the cell lysate: 
a. Add 600 μL of methanol and vortex the sample. 
b. Add 200 μL of chloroform and vortex. 
c. Add 450 μL of H2O, vortex, and centrifuge at 21,130 x g for 5 minutes to separate 
the aqueous and organic phases. 
i. The protein will be a thin solid layer at the aqueous-organic interface. 
d. Remove the top, aqueous layer carefully without disturbing the pellet. 
e. Add 450 μL of methanol and invert gently to produce a single organic layer. 
f. Remove all solvent and resuspend the pellet gently in another 450 μL of 
methanol. 
8. Remove all solvent and resuspend the protein in 40 μL of 1% SDS, 20 mM HEPES pH 
7.9 by boiling. 
a. Usually the protein will redissolve completely after ~1-2 minutes; however, care 
should be taken to ensure that the sample has completely redissolved as the 
protein pellet is often difficult to observe. The samples can be boiled or sonicated 




9. After the protein has redissolved, add (in order) 49 μL of H2O, 80 μL of 2.5x GalT 
labeling buffer, and 11 μL of 100 mM MnCl2. 
10. Vortex the sample to mix and transfer to ice before adding 10 μL of 500 μM UDP-
GalNAz and 10 μL of 1 mg/mL GalT or H2O. The final reaction components are outlined 
in Table 2.2. 
a. Adding H2O in place of GalT or UDP-GalNaz is a suitable and important negative 
control for all of the workflows presented hereafter. 
b. If total O-GlcNAcylation levels or the O-GlcNAcylation level of a 
transmembrane protein is being measured, it is important to remove N-glycans as 
they may contain terminal GlcNAc residues that can be labeled by GalT. To 
achieve this for the reaction described above, add only 46 μL of H2O and 3 μL of 
500 U/μL PNGase F after adding GalT. 
i. Ovalbumin can serve as a useful positive control for PNGase F 
treatment.30 
 
Table 2.2. Reaction Conditions for GalNAz Labeling. 
Reaction Components Volume (μL) Final Concentration 
Protein mixture (3.75 mg/mL in 1% SDS, 
20 mM HEPES pH 7.9) 
40 0.75 mg/mL 
H2Oa 49  
2.5x GalT Labeling bufferb 80 1x 
100 mM MnCl2 11 5.5 mM 
500 μM UDP-GalNAz 10 25 μM 
2 mg/mL GalTc  10 0.1 mg/mL 
Final Volume 200  
a
 If using PNGase F, add only 46 μL, and add 3 μL PNGase F (500 U/μL) after GalT.  
b Vortex gently to mix after this step. 





11. Rotate the reaction end-over-end at 4°C for 1 hour.  
a. The reaction can also be left to proceed overnight if desired.  
12. Precipitate the proteins using the methanol/chloroform/H2O method as described above. 
a. If necessary, at this point, the pellets can be stored in methanol at -80°C for up to 
1 year. 
 
2.5. CuAAC “Click” Reaction with Small Molecule Alkyne Probes.  
 After labeling protein(s) with GalNAz, they are ready to be further functionalized with 
chemical probes and analyzed. In this section, we provide a workflow using CuAAC to append a 
biotin, TAMRA, or chemically cleavable biotin probe to GalNAz-labeled proteins. However, this 
general method can be used with a wide variety of alkyne-containing molecules with minimal 
modifications. Labeling of O-GlcNAcylated proteins with biotin or TAMRA provides a robust and 
sensitive method for quantifying the total levels of O-GlcNAcylation by streptavidin/Western 
blotting or direct in-gel fluorescence (Section 2.5.4). Moreover, biotin-labeled proteins of interest 
can be captured using streptavidin resin to determine the fraction of labeled proteins and 
approximate their O-GlcNAcylation stoichiometry (Section 2.7.3.1). TAMRA labeling followed 
by immunoprecipitation using an anti-TAMRA antibody can also be used for these same purposes 
(Section 2.7.3.2). Finally, labeling with Dde-biotin-alkyne provides a convenient method for the 
efficient capture and release of O-GlcNAcylated proteins under mild conditions; this may be 








2. Vortex mixer 
3. End-over-end rotator 
4. Standard equipment for SDS-PAGE and Western blotting 
 
2.5.2. Materials. 
1. GalNAz-labeled protein pellet (step 3.3.14) 
2. 1% SDS, 20 mM HEPES pH 7.9 
3. 50 mM CuSO4-5H2O in H2O* 
4. 100 mM Tris(2-carboxyethyl)phosphine (TCEP) in H2O* 
a. Prepare fresh immediately before use and protect from light. 
5. Milli-Q (or equivalent) purified H2O   
6. Methanol  
7. Chloroform 
8. 10 X PBS pH 7.4 (100 mM Na2HPO4, 18 mM KH2PO4, 1.37 M NaCl, 27 mM KCl)* 
9. Alkyne-functionalized chemical probe 
a. 5 mM Biotin-PEG4-alkyne in DMSO (TA105-25, Click Chemistry Tools) or  
b. 5 mM Dde-biotin-alkyne in DMSO (1137-10, Click Chemistry Tools) 
c. 5 mM TAMRA alkyne in DMSO (TA108-5, Click Chemistry Tools) 
10. 10 mM 2-(4-((Bis((1-(tert-butyl)-1H-1,2,3-triazol-4-yl)methyl)amino)methyl)-1H-1,2,3-




11. SDS-PAGE loading buffer: 2% SDS, 50 mM Tris pH 6.8, 100 mM DTT, 0.1% (w/v) 
bromophenol blue, and 10% glycerol 
* As an alternative, commercial kits are also available as the Click-iT Biotin or TAMRA Protein 
Analysis Detection Kits (C33372 and C33370, ThermoFisher Scientific). Furthermore, the Click-
iT Protein Buffer Kit (C10276, ThermoFisher Scientific) provides all necessary components 
except for the alkyne probe for reaction customization. 
 
2.5.3. Procedure. 
1. Redissolve the protein pellet with 37.5 μL of 1% SDS, 20 mM HEPES pH 7.9 as 
described above. 
2. After the protein is completely dissolved, add (in order) 87 μL of H2O, 15 μL of 10x 
PBS, 3 μL of the 5 mM alkyne probe (if using other probes/volumes, adjust the volume 
of H2O accordingly), 1.5 μL of 10 mM BTTAA, and 3 μL of 50 mM CuSO4 with vortex 
mixing after each addition. Finally, add 3 μL of 100 mM TCEP and vortex to mix; the 
solution should change to a yellow-blue-green color before rapidly (less than 1 minute) 
retuning to clear. The final reaction conditions are outlined in Table 2.3.  
a. For multiple conditions, it is also possible to make a ‘master mix’ of the 
components as follows: (1) mix CuSO4 and BTTAA together by gentle vortexing, 
(2) dilute the CuSO4-BTTAA with H2O, and (3) add the alkyne probe and vortex 
briefly. This master mix can then be added to multiple samples before vortex 





Table 2.3. Reaction Conditions for CuAAC with Small Molecule Alkyne Probes. 
Reaction Componentsa  Volume (μL) Final Concentration 
Protein mixture (4 mg/mL in 1% SDS,  
20 mM HEPES pH 7.9) 
37.5 1 mg/mL 
H2O 87  
10x PBS 15 1x 
5 mM alkyne probe 3 100 μM 
50 mM CuSO4 3 1 mM 
10 mM BTTAA 1.5 100 μM 
100 mM TCEP 3 2 mM 
Final Volume 150  
a Vortex briefly to mix after each addition. 
 
3. Incubate the solution with end-over-end rotation for 1 hour at room temperature. 
4. Precipitate the protein as previously described and wash three times with 1 mL of 
methanol to remove any unreacted alkyne probe. 
5. Redissolve the pellet in 40 μL of 20 mM HEPES pH 7.9 containing 1% SDS. 
a. At this point, the redissolved, functionalized proteins can be frozen and stored for 
later analysis or subjected directly to SDS-PAGE (see Section 2.5.4 below). 
Labeled proteins can also be enriched (Section 2.7) for further analysis and 
quantification. 
 
2.5.4. Quantifying Total O-GlcNAcylation Levels. 
After labeling O-GlcNAcylated proteins from a cellular lysate with biotin or TAMRA, the 
total levels of protein O-GlcNAcylation can be quantified. Typically, we resolve the labeled 




GalT) by SDS-PAGE, transfer the gel to a PVDF membrane, and blot with an anti-TAMRA 
antibody (A6397, ThermoFisher Scientific) or streptavidin-conjugated dye (S32358, 
ThermoFisher Scientific or 32230, LI-COR Biosciences). The total levels of O-GlcNAcylation can 
then be assessed using densitometry. Alternatively, TAMRA-labeled proteins can be resolved by 
SDS-PAGE and subjected to direct in-gel fluorescence analysis. These approaches are particularly 
useful for monitoring changes in protein O-GlcNAcylation in response to cellular stimuli (Fig. 
2.1b). Moreover, the captured O-GlcNAcylated proteins can be excised from the gel, subjected to 
proteolytic digestion, and identified by MS analysis.31 Together, these probes provide a robust, 
unbiased method for comparing total O-GlcNAcylation levels under various conditions and may 
avoid previously reported issues with O-GlcNAc antibodies. 
 
2.6. CuAAC “Click” Reaction with PEG Alkyne. 
 Using a similar procedure to that described in Section 2.5, it is also possible to add an 
alkyne-functionalized PEG tag of defined molecular mass (e.g. 2-kDa or 5-kDa) to O-
GlcNAcylated proteins. The PEG-labeled lysates can be resolved by SDS-PAGE and 
immunoblotted for specific proteins of interest (Fig. 2.1d). This provides a rapid, convenient way 
to monitor the O-GlcNAcylation state and stoichiometry across different conditions with minimal 
manipulation after labeling. Tagging O-GlcNAcylated proteins with alkynyl PEG is our method 
of choice for most applications, including: (a) monitoring O-GlcNAcylation in different tissues or 
in response to various treatments,2,4 (b) confirming sites of O-GlcNAcylation,2 and (c) detecting 







2. Vortex mixer 
3. End-over-end rotator 
4. 37°C incubator 
5. Standard equipment for SDS-PAGE and Western blotting 
 
2.6.2. Materials. 
1. GalNAz labeled protein pellet (step 2.4.3.14) 
2. 1% SDS, 50 mM Tris pH 8 
3. Milli-Q (or equivalent) purified H2O   
4. Methanol  
5. Chloroform 
6. 50 mM CuSO4 in H2O 
7. 100 mM TCEP in H2O 
a. Prepare fresh immediately before use and protect from light. 
8. 10 mM PEG alkyne in 200 mM Na2HPO4 pH 8 
a. We typically use 2-kDa or 5-kDa mPEG alkyne (PLS-2035 or PLS-2034, 
Creative PEGWorks). 
b. Prepare fresh immediately before use. 
c. For proteins with a very high molecular weight (MW), it may be possible to use a 
higher MW PEG.43 Polymers up to 30-kDa are available from Creative 




temperatures are necessary for efficient labeling with larger PEG molecules. The 
precipitation of proteins labeled with 10-kDa or higher PEG molecules can also 
be problematic.  
d. Inspect the quality of any PEG compound prior to use by MALDI-TOF MS. 
High-quality PEG will present a narrow set of peaks centered on the reported 
MW. 
9. 500 mM BTTAA in DMSO  
10. SDS-PAGE loading buffer: 2% SDS, 50 mM Tris (pH 6.8), 100 mM DTT, 0.1% (w/v) 
bromophenol blue, and 10% glycerol 
 
2.6.3. Procedure. 
1. Redissolve the protein pellet in 50 μL of 1% SDS, 50 mM Tris pH 8 as described 
previously. 
2. Add 46 μL of H2O and vortex briefly. 
3. Pre-mix BTTAA, CuSO4, and PEG stock solutions: 
a. Add 0.5 μL of 500 mM BTTAA to 5 μL of 50 mM CuSO4, mix, and incubate for 
1-2 minutes. 
b. Add 100 μL of 10 mM PEG alkyne to the CuSO4-BTTAA mixture and incubate 
for 1 minute. 
4. Add (in order) 100 μL of the BTTAA-CuSO4-PEG solution and 4 μL of 100 mM TCEP 





a. The solution should turn bright yellow after vortex mixing, but will turn back to 
clear over the next 1-2 minutes. 
 
Table 2.4. Reaction Conditions for CuAAC with PEG Alkyne. 
Reaction Componentsa Volume (μL) Final Concentration 
Protein mixture (3 mg/mL in 1% SDS, 
50 mM Tris pH 8) 
50 0.75 mg/mL 
H2O 46  
PEG-CuSO4-BTTAA mixtureb 
   0.5 μL 500 mM THPTA 
   5 μL 50 mM CuSO4 






100 mM TCEP 4 2 mM 
Final Volume 200  
a Vortex briefly to mix after each addition. 
b Prepared according to instructions in text. 
 
5. Incubate the reaction at 95°C for 1-2 minutes. 
a. Alternatively, the reaction can be left to rotate end-over-end at 37°C in the dark 
for 24 hours. If using 5-kDa PEG for 24 hour labeling at 37°C, sometimes 
incubating for an additional 24 hours (48 hours total) may improve labeling 
efficiency. Furthermore, for the potential use of higher MW PEG, we have found 
that many proteins are stable for at least 60 hours under these conditions. 
b. See also the recent protocol published by Pratt and colleagues.44 
6. Precipitate the protein as previously described and wash three times with 1 mL of 
methanol to remove unreacted PEG. 
7. Redissolve the protein in the desired volume of loading buffer for SDS-PAGE and 




2.6.4. Quantification of Protein O-GlcNAcylation Stoichiometry. 
The lysates are resolved by SDS-PAGE and analyzed by Western blotting using antibodies 
against the protein(s) of interest.  For standard cell lysates, we typically use 50 to 100 μg of total 
protein for analysis, depending on the abundance of the protein. For other applications, such as 
detecting O-GlcNAcylation of purified or overexpressed proteins, the amount needed depends on 
the O-GlcNAcylation stoichiometry and resolution capacity of the gel. Successful PEG labeling 
will reveal a mass-shifted band corresponding to the MW of the PEG tag for each O-GlcNAc group 
on the protein. The relative abundance of each O-GlcNAcylated form and the total O-
GlcNAcylation stoichiometry can be obtained by quantifying the ratio of the signals for the mass 
shifted band(s) to the total, protein-specific band.2,34 See Fig. 2.1d for typical results using an 
antibody against CREB (4820, Cell Signaling Technologies). In general, we have found that CREB 
serves as an excellent positive control that is expressed in many mammalian cell lines with an O-
GlcNAcylation stoichiometry of approximately 20-30%. Although other well-characterized O-
GlcNAcylated proteins can be used, we recommend against using highly O-GlcNAcylated proteins 
as a positive control because they often show a mass shift even when the labeling is incomplete. It 
is important that the labeling be complete for an accurate assessment of O-GlcNAcylation 
stoichiometry. Notably, this method can also be used to study the interplay between O-
GlcNAcylation and other PTMs such as phosphorylation using phosphorylation state-specific 
antibodies.2 Finally, in all of the above cases, it is important to employ a quantitative Western 
blotting system, such as the Odyssey Imaging System (LI-COR Biosciences). Overall, this method 
provides the only direct way to measure O-GlcNAcylation stoichiometries without the use of 
laborious MS methods. Moreover, this approach utilizes standard techniques for protein analysis 




2.7. Biotin/TAMRA Immunoprecipitation. 
 This section describes our workflow for streptavidin capture or TAMRA 
immunoprecipitation of O-GlcNAcylated protein(s) from a complex cell lysate. Upon release, the 
O-GlcNAcylated protein(s) can be subjected to detection and quantification (Section 2.7.4) or MS 
analysis (Section 2.8). These methods are most useful for initial detection of O-GlcNAcylation on 





2. Vortex mixer 
3. End-over-end rotator 
4. Magnetic separator  
5. Standard equipment for SDS-PAGE and Western blotting 
 
2.7.2. Materials. 
1. Biotin or TAMRA-labeled proteins (step 2.5.3.5) 
2. Neutralization buffer: 6% IGEPAL CA-630, 100 mM Na2HPO4 pH 8, 150 mM NaCl 
3. Dilution buffer: 100 mM Na2HPO4 pH 8, 150 mM NaCl 
4. Streptavidin magnetic beads or High Capacity NeutrAvidin Agarose (Pierce, for biotin 
IP) 
5. Protein A/G magnetic beads (Pierce, for TAMRA IP) 




a. Alternatively, a TAMRA monoclonal antibody (MA1-041, ThermoFisher) can 
also be used. 
7. TAMRA wash buffer: 1% IGEPAL CA-630, 100 mM Na2HPO4 pH 8, 150 mM NaCl  
8. Biotin low salt wash buffer: 100 mM Na2HPO4 pH 7.5, 150 mM NaCl, 1% Triton X-100, 
0.5% sodium deoxycholate, 0.1% SDS 
a. While cleavage of the Dde-biotin-alkyne in buffers containing SDS has been 
previously reported,45 we have found that it is stable in up to 1% SDS at room 
temperature.33 
9. Biotin high salt wash buffer: 100 mM Na2HPO4 pH 7.5, 500 mM NaCl, 0.2% Triton X-
100 
10. Biotin elution buffer: 50 mM Tris pH 6.8, 2.5% SDS, 100 mM DTT, 10% glycerol, and 2 
mM biotin (add 0.1% (w/v) bromophenol blue if to be used directly for Western blotting) 
11. TAMRA wash buffer: 50 mM Tris pH 7.4, 150 mM NaCl, 1% Triton X-100 
12. TAMRA elution buffer: 2% SDS, 50 mM Tris pH 6.8, 100 mM DTT, and 10% glycerol 
(add 0.1% (w/v) bromophenol blue if to be used directly for Western blotting) 
13. PBS pH 7.4 (10 mM Na2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl) 
14. 2% (w/v) hydrazine monohydrate in H2O 
a. Make this solution fresh immediately before use. 
15. Acetone  





1. Save 1/10 (4 μL) of the biotin or TAMRA-labeled protein solution as input to confirm 
effective enrichment or to quantify the O-GlcNAcylation stoichiometry of labeled 
proteins. 
2. To avoid denaturing proteins on the affinity resins, neutralize the SDS in the protein 
sample with an equivalent volume of neutralization buffer. 
3. Dilute the sample to 500 μL with dilution buffer. 
4. Wash the beads twice with 1 mL of wash buffer. Typically, we use the following 
amounts of beads for the applications discussed: 
a. 40 μL of streptavidin magnetic beads (Section 2.7.3.1) 
b. 50 μL of Protein A/G magnetic beads (Section 2.7.3.2) 
c. 25 μL of high capacity NeutrAvidin agarose (Section 2.7.3.3) 
5. Add the diluted protein solution to the washed beads. 
 
2.7.3.1. Non-Cleavable Biotin. 
1. Rotate end-over-end for 2 hours at room temperature. 
2. After the precipitation is complete, remove the flowthrough, resuspend the beads in 1 mL 
of biotin low salt wash buffer, and rotate end-over-end for 5 minutes at room temperature 
a. A portion of the flowthrough can be retained and analyzed to ensure complete 
precipitation by the affinity resin. 
3. Remove the wash buffer and repeat four more times with 1 mL of low salt wash buffer 





a. In applications where there tends to be high background (e.g. protein 
overexpression), the wash conditions can be made more stringent by replacing the 
low salt wash buffer with 100 mM Na2HPO4 pH 7.5, 150 mM NaCl, 1-3% SDS. 
However, this may elute some biotinylated proteins as well. 
4. After the last wash, centrifuge the beads briefly (5-10 seconds) at 500 x g and remove 
any residual wash buffer. 
5. Resuspend the beads with 30 μL of biotin elution buffer and boil for 15 minutes with 
occasional vortex mixing. 
6. Centrifuge the tube briefly and transfer the elution buffer to a new tube. 
a. The eluent can be safely stored indefinitely at -80°C. 
b. For endogenous proteins, we typically resolve the entire eluent in a single gel 
lane. However, for overexpressed proteins, it is usually sufficient to run as little as 
1/10 of the eluent. 
 
2.7.3.2. TAMRA. 
1. Add 10 μL of TRITC polyclonal antibody to the mixture. 
2. Rotate end-over-end overnight at 4°C. 
3. Remove the flow-through and wash the beads by rotating end-over-end for 5 minutes at 
4°C with 1 mL of TAMRA wash buffer. 
4. Remove the wash buffer and repeat four additional times. 
5. After the final wash, elute TAMRA-labeled proteins by boiling with 30 μL of TAMRA 




a. These conditions are used to quantitatively release TAMRA-labeled proteins, but 
they will also elute the antibody, which can interfere with Western blot 
quantification. We suggest the use of a conformation-specific secondary antibody 
for detection during Western blotting (e.g. 3678S, Cell Signaling Technology). 
b. Alternatively, 100 mM glycine pH 2.5 can be used to elute the protein in cases 
where co-elution of TAMRA antibody is problematic and/or stoichiometric 
elution is not required. 
 
2.7.3.3. Cleavable Dde-Biotin. 
1. Rotate end-over-end for 2 hours at room temperature. 
2. Transfer the beads to a spin filter and wash the beads as described for the non-cleavable 
biotin. 
3. Wash the beads twice more with 0.5 mL of PBS. 
4. Resuspend the beads with 50 μL of 2% (w/v) hydrazine monohydrate and incubate with 
end-over-rotation for 1 hour at room temperature. 
5. Collect the eluent via centrifugation at 2,000 x g for 30 seconds. 
6. Resuspend the beads in 50 μL of PBS and incubate with end-over-end rotation for 5 
minutes at room temperature. 
7. Collect this wash by centrifugation as before and combine with the eluent. 
8. Precipitate the eluted proteins by the addition of 4 volumes (400 μL) of -20°C acetone 




a. Do not use the methanol/chloroform/H2O method here as it is extremely difficult 
to form a pellet with low quantities of protein. The precipitated proteins can be 
stored for up to 6 months in acetone at -80°C. 
9. Centrifuge the precipitated proteins at 21,130 x g for 10 minutes at 4°C, remove the 
acetone, and dry the pellet as before. 
10. For analysis by SDS-PAGE, resuspend the pellet in 40 μL of SDS-PAGE loading buffer.  
a. For direct analysis by MS, redissolve the proteins in a buffer compatible with an 
in-solution digestion method, such as 8 M urea, 50 mM Tris pH 8. 
 
2.7.4. Detection and Quantification of Enriched O-GlcNAcylated Proteins. 
Western blotting of the eluted solution can provide putative evidence for O-GlcNAcylation 
of specific proteins. It is important to run a negative control simultaneously in which GalT has 
been omitted from the GalNAz labeling step (as described earlier) to corroborate these results. 
Approximate O-GlcNAcylation stoichiometries can be determined following biotin labeling by 
resolving the eluted sample (step 2.7.3.1.6) by SDS-PAGE along with a portion of the retained 
input sample (step 2.7.3.1) and calculating the fraction of eluted O-GlcNAcylated protein to the 
total protein signal.4 Furthermore, the method can be used to monitor changes in the O-
GlcNAcylation levels of individual proteins across different physiological conditions. Although 
this method cannot reveal the presence of multiple O-GlcNAcylation sites, it does have some 
advantages over labeling proteins with PEG alkyne. Specifically, (1) enrichment allows for the 
detection of low O-GlcNAcylation stoichiometries, (2) O-GlcNAcylation of high MW proteins 
can be readily measured without relying on a mass shift, and (3) some antibodies may not 




GlcNAcylated, MS-based methods can be used as further, more definitive verification and to 
identify the exact site(s) of O-GlcNAcylation. 
 
2.8. O-GlcNAc Site Identification. 
The identification of specific serine/threonine residues that are modified by O-GlcNAc is 
often critical to interrogate its functional relevance. Accordingly, several techniques have been 
developed for this purpose. Originally, O-GlcNAcylated peptides were labeled with [3H]-galactose 
and sequenced by Edman degradation.30 However, with the rise of powerful MS-based methods 
for peptide/protein sequencing, many techniques have been developed to map O-GlcNAc sites on 
proteins;32,33,46-49 a thorough review of current methods for O-GlcNAc site mapping can be found 
elsewhere.18 Here we describe a general approach for O-GlcNAc site mapping and its enhancement 
using chemoenzymatic labeling. Unlike MS analysis of immunoprecipitated protein alone, 
chemoenzymatic labeling has the specific advantages of providing 1) an effective method for 
enrichment of O-GlcNAcylated peptides/proteins to greatly improve the detection sensitivity, 2) a 
positively charged amine left by the cleavable biotin tag to facilitate O-GlcNAc site mapping, and 
3) a unique ion fragment signature upon MS/MS analysis for conclusive identification of the O-
GlcNAc modification. Once modification sites are discovered, the tools outlined in the previous 
sections can be used to investigate how O-GlcNAcylation at individual sites changes in response 
to stimuli.  
 
2.8.1. Mapping of O-GlcNAc Sites Using MS. 
To map the O-GlcNAc sites on a protein of interest, a tagged form of the protein can be 




to the cells to enhance the overall levels of O-GlcNAcylation. The protein of interest is then 
immunoprecipitated, subjected to SDS-PAGE, and excised from the gel.  After reduction, 
alkylation, and proteolytic digestion in gel, the extracted peptides are analyzed by MS.50 The use 
of electron-transfer dissociation tandem MS (ETD-MS/MS) has become a powerful technique for 
mapping O-GlcNAc sites due to its ability to fragment peptides without breaking the glycosidic 
linkage between serine/threonine residues and GlcNAc.18 Indeed, we and others have used this 
workflow to successfully map O-GlcNAc sites on multiple occasions.2,4,5,51  
Recently, we used a similar workflow in conjunction with a cleavable Dde-biotin-alkyne 
probe to identify two known and four novel O-GlcNAcylation sites on OGT.33 The Dde-biotin 
moiety allows for efficient capture and release of O-GlcNAcylated peptides and generates a 
positively charged amine functionality on the glycopeptide to improve its ionization efficiency 
(Fig. 2.1a). We believe that this new probe has significant potential to facilitate the identification 
of O-GlcNAc sites. In this case, overexpressed, immunoprecipitated protein could be subjected to 
the workflow described in Section 2.7.3 using Dde-biotin-alkyne as the azide-reactive probe. The 
eluted O-GlcNAcylated protein is then purified by SDS-PAGE and processed as outlined above. 
Alternatively, the eluent can be processed directly by in-solution digestion or with filter-aided 
sample preparation.52  
Labeled O-GlcNAcylated peptides can be easily identified using higher-energy collisional 
dissociation (HCD) MS/MS fragmentation by the presence of up to three fragmented linker ions 
at 300.1, 318.1, and 503.2 m/z. These fragment ions correspond to cleavage of the glycosidic bond 
between GlcNAc and GalNAz and its water adduct (300.1 and 318.1 m/z, respectively) and 
cleavage between GlcNAc and the serine/threonine residue (503.2 m/z). For subsequent ETD-




(ThermoFisher Scientific), but any instrument capable of performing ETD-MS/MS would be 
sufficient. Regardless, it is important to account for the variable addition of the mass tag 
(502.202341 Daltons) to serine and threonine residues in the analysis.33 In summary, we believe 
that the procedure outlined may aid in the detection of low-abundance or otherwise hard to identify 
O-GlcNAc sites. 
 
2.9. Integrated Workflow for Discovery and Biological Assessment of Novel O-GlcNAcylated 
Proteins. 
 Together, chemoenzymatic tagging methods provide a powerful approach for the detection 
and analysis of novel O-GlcNAcylated proteins. In our lab, we follow an integrated workflow 
when assessing the importance of a putatively modified protein. First, we use biotin or TAMRA 
labeling followed by immunoprecipitation and Western blot detection (Sections 2.5 and 2.7.3.1 or 
2.7.3.2) to provide direct evidence of protein O-GlcNAcylation. Importantly, we perform a 
negative control experiment without adding GalT to ensure that the observed signal is specific for 
the O-GlcNAcylated structure. Next, we map the modification site(s) by either direct MS analysis 
of a FLAG-tagged, immunoprecipitated protein of interest (Section 2.8.1) or labeling and 
enrichment with the Dde-biotin-alkyne probe prior to MS analysis (Sections 2.5 and 2.7.3.3). If 
the protein has multiple sites, expression of alanine mutants lacking specific O-GlcNAcylation 
sites in cells, followed by analysis of their stoichiometries using PEG or biotin labeling, can 
sometimes be used to determine the major sites (Sections 2.7 and 2.8). Moreover, these mutants 
can be expressed in the presence of TMG or other stimuli to uncover which sites are dynamic or 
rapidly cycled. Finally, cells with the endogenous protein or overexpressed mutants can be 




mediated depolarization followed by PEG labeling to measure changes in the levels of each O-
GlcNAcylation state in response to biological stimuli. Again, we have found CREB to be an 
excellent positive control for the strategies outlined in this section. As an example, the increase in 
O-GlcNAcylation of CREB stimulated by TMG treatment can be seen in Fig. 2.3 Using PEG 
labeling, mono-O-GlcNAcylation of CREB was also found to increase in neurons after KCl-
induced depolarization (Fig. 2.1d). Ultimately, the collective results of this integrated workflow 
will provide strong evidence for novel O-GlcNAcylation events and guide subsequent functional 
studies. 
 
2.10. Conclusions and Future Directions. 
The O-GlcNAcylation of intracellular proteins is emerging as a major regulator of key 
cellular processes in both health and disease. Effective methods to characterize the presence and 
dynamics of this PTM will greatly propel studies of its functional significance. Traditional 
methods such as tritium labeling and the use of certain O-GlcNAc-specific antibodies suffer from 
a lack of sensitivity and specificity. Moreover, using such methods to detect changes in O-
GlcNAcylation levels and stoichiometry reliably in a complex lysate can be very difficult or in 
some cases impossible. Although the rapid proliferation of MS-based techniques has alleviated 
some of these concerns, MS-based approaches require specialized expertise and access to 
expensive instrumentation. Thus, highly accessible, cost-effective approaches that can be readily 
performed in most laboratories on a routine basis remain vital to elucidate the physiological 




The protocols above provide a practical 
platform that is easy to implement in many 
research settings. GalT labeling and the CuAAC 
reaction provide an efficient means to install a  
variety of functional tags for diverse downstream 
applications. The commercial availability of the 
reagents and the simplicity of the experimental 
approach should facilitate adoption of this 
methodology by non-specialists. In the future, 
further development of these techniques in 
conjunction with MS will pave the way for more 
quantitative, high-throughput methods to study O-
GlcNAcylation dynamics on individual proteins as well as on a global scale. Combining the 
techniques with established methods such as stable isotope labeling by amino acids in cell culture 
(SILAC),53 isobaric tag for relative and absolute quantitation (iTRAQ),54 or tandem mass tags 
(TMT)55 should allow for direct comparison of the O-GlcNAcome across diverse physiological 
conditions. Together, we hope that these advances will illuminate the broad importance of O-
GlcNAcylation and lead to new discoveries at the frontiers of biology and human health. 
 
2.11. References. 
1 Hart, G. W., Slawson, C., Ramirez-Correa, G. & Lagerlof, O. Cross talk between O-
GlcNAcylation and phosphorylation: Roles in signaling, transcription, and chronic 
 
Fig. 2.3. Monitoring O-GlcNAc 
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The prevalence of AD and other dementias has reached epidemic proportions. However, 
to date, not a single disease modifying therapeutic intervention has been developed. Furthermore, 
besides postmortem analysis of brain tissue, there are no consensus methods for AD diagnosis, 
especially in the early stages of the disease when preventing further cognitive decline is of utmost 
importance to patients and their families. It is highly likely that a more comprehensive 
understanding of the molecular underpinnings of AD will do much to remedy this unfortunate 
situation. Therefore, the studies in this chapter aim to address this lack of understanding through 
the investigation of two intracellular events that have emerged as potential, major drivers of AD 
pathogenesis: dysregulated cyclin-dependent kinase 5 (Cdk5) activity and aberrant modification 
of intracellular proteins by O-GlcNAc. Cdk5 is known to play a role in regulating, among others, 
two central intracellular events in AD: hyperphosphorylation of tau and amyloidogenic processing 
of APP. O-GlcNAc, on the other hand, is a dynamic, inducible PTM of proteins thought to regulate 
key cellular signaling pathways in response to a wide variety of stimuli such as stress, nutrient 
availability, and neuronal activity. Here, we report that Cdk5 activity is increased in the absence 
of OGT and dynamically regulated by O-GlcNAcylation. Moreover, we map specific O-GlcNAc 
sites on Cdk5 and show that blocking O-GlcNAcylation at two potential sites in Neuro-2a (N2A) 
cells is sufficient for increasing Cdk5 activity. Finally, we also develop a lentiviral knockdown 
(KD) and replacement strategy to facilitate the further study of Cdk5 O-GlcNAcylation in neurons 
and in vivo. Altogether, the data presented herein suggests a previously unappreciated link between 






 In a progressively aging population, the prevalence of AD and other dementias has reached 
epidemic proportions. AD, which is characterized by the accumulation of senile plaques and 
neurofibrillary tangles (NFTs), striking neuronal loss, and a profound disruption of episodic 
memory, has an associated healthcare cost upwards of $172 billion per year in the United States 
alone.1-3 Nevertheless, the pathogenesis of this devastating disease is poorly understood, and we 
lack both definitive diagnostic methods, beyond postmortem analysis of brain tissue, and any 
disease modifying treatment.4,5 Thus, efforts to better understand the molecular underpinnings of 
AD are desperately needed. Here, we explore two promising paths toward unraveling the cellular 
mechanisms that underlie AD: understanding the role of (1) dysregulated Cdk5 activity and (2) 
aberrant modification of intracellular proteins by O-GlcNAc. 
 Cdk5 is a proline-directed serine/threonine kinase notable for its apparent lack of 
involvement in the cell cycle and its high activity in the brain.6 Unlike other cyclin-dependent 
kinases, its activity does not depend on cyclins, but rather on two unique activator proteins, p35 
and p39, and their calpain-mediated cleavage products, p25 and p29, respectively.7 Cdk5 has been 
implicated in a huge variety of neuronal processes starting in early development (reviewed 
extensively by Tsai and colleagues6). For instance, KO of p35, the major of the two Cdk5 activator 
proteins, in mice results in severe cortical lamination defects due to the failure of newly generated 
neurons to correctly migrate past older neurons.8 KO of Cdk5 itself is perinatally lethal with major 
disruptions to multiple nervous system structures.9 Accordingly, during development, Cdk5 has 
been found to localize to the leading edge of migrating neurons as well as axonal growth cones 
where it seems to be playing a key role in regulating actin and other cytoskeletal dynamics.10,11 




regulating dendritic spine development, again through the phosphorylation of substrates involved 
with actin dynamics such as Wiskott-Aldrich syndrome protein (WASP) family verprolin 
homologous protein 1 (WAVE1)12 and serine/threonine-protein kinase PAK 1.13  
As expected given the major role of actin dynamics in learning and memory,14 inducible 
(to avoid the severe developmental phenotype) p35 KO mice show profound defects in learning 
and memory.15-17 Consistent with this phenotype, Cdk5 is also known to modify multiple proteins 
directly involved in synaptic plasticity, LTP, and LTD in addition to regulating actin and 
cytoskeletal dynamics.18 For instance, Cdk5 regulates both presynaptic vesicle release through its 
phosphorylation of multiple proteins, e.g. syntaxin-binding protein 1,19,20 and the presence and 
function of receptors at the PSD, e.g. N-methyl-D-aspartate receptor (NMDAR) subunits 2A 
(NR2A)21,22 and 2B (NR2B).23 Interestingly, blocking the interaction between Cdk5 and NR2B 
actually improves synaptic transmission and memory formation in vivo, suggesting that Cdk5 
activity also plays an inhibitory role in learning and memory.24 Indeed, it has been suggested that 
Cdk5 activity is maintained in a fine balance where activity is necessary to promote memory 
formation but also inhibit prolonged neuronal activation which can lead to excitotoxicity and 
neuronal death, a key feature of many neurodegenerative diseases.6  
Furthermore, one of the earliest identified substrates of Cdk5 was tau, which also suggests 
a role for Cdk5 in AD pathogenesis given that hyperphosphorylated tau is a major component of 
NFTs.25,26 In addition, APP, the precursor to Aβ peptides, is also phosphorylated by Cdk5, and this 
phosphorylation is known to promote the formation of Aβ peptide species that have a higher 
propensity to form plaques.27,28 Numerous subsequent studies have implicated dysregulated Cdk5 
activity as a major driver of tau pathology,29-32 neurodegeneration,22,33,34 memory impairment,22,35-




Cdk5 is sufficient to drive neurodegeneration and the accumulation of NFTs in mice.44,45 Cdk5 
overactivity also occurs in the context of ischemic stroke, and Cdk5 inhibitors as an adjuvant 
therapy for improving stroke outcomes are in active development.46-49 Overall, Cdk5 overactivity 
seems to be driving the deleterious phenotypes across multiple neurological disorders. Thus, in 
AD specifically, we believe the following general conclusions are warranted: (a) increases in Cdk5 
activity precipitate a host of neurodegenerative events, along with profound synaptic 
dysfunction,6,24,50,51 and (b) pharmacological or other inhibition of Cdk5 has beneficial effects in 
models of neurodegeneration.32,52-54 However, despite the strong body of literature implicating 
Cdk5 in AD and other neurodegenerative diseases, relatively little is known about how or why 
Cdk5 activity might increase in the context of AD. Here, we propose that this pathological increase 
in activity may be partially or wholly mediated by loss of O-GlcNAcylation on Cdk5.  
 O-GlcNAcylation is a dynamic, inducible PTM of intracellular proteins at serine and 
threonine residues. Interestingly, a decrease in the overall levels of neuronal O-GlcNAcylation has 
been strongly implicated in AD.55-57 Moreover, as discussed in Chapter 1, O-GlcNAcylation has 
been shown to stabilize tau against aggregation and plays a host of neuroprotective roles. Recently, 
our lab created a forebrain-specific, conditional OGT KO (OGT cKO) mouse which exhibited a 
striking phenotype characterized by extensive neurodegeneration, formation of NFTs, and 
increases in the amyloidogenic 42-mer Aβ peptide.58 Consistent with the profound 
neurodegeneration, these mice also showed defects in both cued and contextual freezing assays as 
well as increased anxiety. Interestingly, the deficits in cued freezing were apparent at only 2 
months of age, before any detectable loss of neuronal thickness Moreover, we showed a marked 
decrease in OGT expression levels in the brains of AD patients, consistent with an overall decrease 




protein expression was markedly downregulated in neurons, yet genes involved in cell cycle arrest, 
another major function of Cdk5 in neurons,6,58 were upregulated. Together, this suggests a 
reduction in Cdk5 expression or protein stability that may be a compensatory response to increased 
Cdk5 activity. Herein, we first confirm that Cdk5 activity is increased in the context of OGT KO. 
Subsequently, we demonstrate that Cdk5 is O-GlcNAcylated in neurons and furthermore that this 
modification is dynamic suggesting a regulatory versus structural role. Finally, we show that 
mutation of potential O-GlcNAc sites on Cdk5 in N2A cells is sufficient to increase its activity. 
Along with (1) the wealth of prior data demonstrating that increased Cdk5 activity is deleterious 
in neurons, and (2) the observation by multiple labs that O-GlcNAcylation is decreased globally 
in AD, these findings suggest that decreased O-GlcNAcylation of Cdk5 may at least in part 
contribute to AD pathogenesis.  
 
3.3. OGT KO Increases Cdk5 Activity and p25/35 Binding. 
 To follow up on the possible causative link between Cdk5-specific defects and 
neurodegeneration in our OGT cKO mouse, we first set out to confirm whether neuronal Cdk5 
activity was increased in the context of OGT KO. To simulate OGT KO in controlled neuronal 
culture conditions, we harvested embryonic cortical neurons from floxed-OGT mice and used a 
lentiviral system to deliver Cre recombinase (Cre). This system proved extremely robust and 
yielded approximately 97% KO of OGT (Fig. 1a). With an efficient method for generating OGT 
KO neurons in hand, we then prepared 6 neuronal cultures from floxed-OGT mice and treated 




these neurons were lysed, Cdk5 was immunoprecipitated (IPed), and Cdk5 activity was assayed 
using ADP-Glo (Promega, Madison, WI). Excitingly, we found Cdk5 IPed from OGT KO neurons 
exhibited significantly higher activity (Fig. 3.1b). To see whether this increased activity was a 
direct result of increased p35 binding, we also interrogated the amount of p35 co-IPed with Cdk5 
by quantitative Western blotting (WB). Consistent with the increase in Cdk5 activity, we also 
found a concomitant increase in Cdk5-p35 binding (Fig. 3.1c-d). Interestingly, we also found that 
OGT IPs with Cdk5 confirming a direct interaction between the two proteins and suggesting that 
 
Fig. 3.1. OGT KO Increases Cdk5 Activity and Affinity for p35.  
(a) Lentiviral transduction of floxed-OGT neurons with Cre results in efficient knockout of OGT 
versus an mCherry control. (b) Cdk5 activity is increased in primary mouse cortical neurons 
lacking OGT. Cdk5 from floxed-OGT neurons transduced with Cre or an mCherry control was 
IPed and activity was assessed using the ADP-Glo system. (c) Cdk5 co-IPs more p35 in floxed-
OGT neurons transduced with Cre versus an mCherry control; p35 expression does not differ 
significantly between the two conditions. (d) Graph of the data in (c) with n=3 technical replicates 
from each of n=22 biological replicates. (e) OGT co-IPs with Cdk5 in mouse primary cortical 
neurons. Error bars are ± s.e.m., *p < 0.05, ***p < 5e-5 by unpaired Student’s t-test. 
WB: OGT
WB: α-tubulin





















































Cdk5 may be a substrate of OGT (Fig. 3e). In summary, these results confirm for the first time 
that globally decreased O-GlcNAcylation leads directly to an increase in Cdk5 activity in neurons, 
which may have important implications for AD and other neurodegenerative diseases.  
 
3.4. Cdk5 is Dynamically O-GlcNAcylated in Neurons. 
 Having determined that the absence of OGT interacts with and increases Cdk5 activity, we 
next sought to investigate whether this was through direct modification of Cdk5 or some other 
mechanism. To our knowledge, Cdk5 O-GlcNAcylation has not been previously observed in large 
mouse or human O-GlcNAcomics data sets.61-63 Thus, we used our well-established 
chemoenzymatic labeling technique (Chapter 2) to assess whether Cdk5 is O-GlcNAcylated in 
neurons. Briefly, O-GlcNAcylated proteins in neuronal lysate were labeled with an azido-
containing nucleotide sugar analog (UDP-GalNAz) using Y289L GalT. Alkynyl biotin was then 
selectively added to O-GlcNAcylated proteins using CuAAC, and the O-GlcNAcylated proteins 
were captured using streptavidin resin.64,65 The captured proteins were then subjected to SDS-
PAGE and interrogated by WB with an anti-Cdk5 antibody. Using the above workflow, we found 
that Cdk5 is indeed O-GlcNAcylated in primary mouse cortical neurons. To see if this modification 
dynamically cycles in response to relevant physiological stimuli, we also compared Cdk5 O-
GlcNAcylation levels between silenced and KCl depolarized neurons. Here, we noted a striking 
increase in Cdk5 O-GlcNAcylation after KCl-mediated depolarization (Fig. 3.2a-b), strongly 




With direct evidence of Cdk5 O-GlcNAcylation, we next moved forward with using MS to map 
the O-GlcNAc sites on Cdk5. To prepare O-GlcNAcylated Cdk5 for site mapping experiments, 
we expressed FLAG-tagged Cdk5 in N2A cells. These cells were also co-transfected with OGT 
and treated with TMG and KCl to maximally increase Cdk5 O-GlcNAcylation stoichiometry and 
thus our chances of identifying O-GlcNAcylated peptides. Cdk5 was then purified from cell lysates 
over FLAG immunoaffinity gel (Sigma-Aldrich, St. Louis, MO). A portion of the FLAG eluent 
was also subjected to WGA affinity chromatography to further enriched O-GlcNAcylated from 
unmodified Cdk5. Both FLAG and WGA eluent were then gel purified, digested, and submitted 
for LC-MS/MS analysis. Excitingly, from the FLAG eluent, we were able to map O-GlcNAc to 
T245/T246/S247 in two separate trials using collision-induced dissociation (CID)/ETD and HCD 
fragmentation, respectively (see Chapters 2 and 4 for in depth discussion on O-GlcNAc site 
mapping). During the course of these experiments, Ke and co-workers also identified this and an 
 
Fig. 3.2. Neuronal Depolarization Dynamically Induces Cdk5 O-GlcNAcylation.  
(a) Primary mouse cortical neurons were lysed after treatment with 60 mM KCl or vehicle for 2 
hours, and O-GlcNAcylated proteins were isolated using the chemoenzymatic labeling strategy 
described in the text. Immunoblotting with a Cdk5 antibody revealed increased signal in the elution 
for KCl simulated neurons. (b) Data were quantified as described in Section 3.8.4; each condition 












































additional site of Cdk5 at S46/S47.66 Taken together, these studies provide the first evidence that 
Cdk5 is dynamically O-GlcNAcylated in neurons, potentially at multiple sites.  
 
3.5. Mutation of Potential Cdk5 O-GlcNAcylation Sites Increases Cdk5 Activity in N2A 
Cells.  
 To help understand the potential effects of O-GlcNAcylation at each of the aforementioned 
sites, we used GLYCAM Web67 to build a structural model of O-GlcNAcylated Cdk5. First, 
SWISS-MODEL68 was 
used to build an optimized 
homology model of the 
mouse Cdk5/p25 complex 
from human Cdk5/p25 
(PDB file 1H4L).69 This 
model was then submitted 
to GLYCAM Web where 
an O-GlcNAc residue was 
modeled onto each known 
site (Fig. 3.3a). 
Interestingly, the model 
clearly shows that O-
GlcNAcylation at S46 has 
the potential to disrupt 
binding of p25/p35 and 
 
Fig. 3.3. O-GlcNAcylation of Cdk5 May Inhibit Its Activity 
through Inhibition of p25/35 Binding.  
(a) Predicted crystal structure of O-GlcNAcylated Cdk5 at all 
known sites. (b) Magnified image of the environment sounding O-
GlcNAcylated S46, highlighting that O-GlcNAcylation at S46 is 
likely to disrupt the interaction between Cdk5 (white) and p25 (red). 
(c) S46A/S47A Cdk5 has higher activity in N2A cells. Exogenous, 
FLAG-tagged WT and S46A/S47A Cdk5 were FLAG IPed from 
N2A cells, and the activity of each was quantified using the AD-Glo 
system. Each condition is the average of 3 technical replicates from 
each of 3 biological replicates. Error bars are ± s.e.m., *p < 0.05 by 


























therefore inhibit Cdk5 activity (Fig. 3.3b). The role of T245/T246/S247 O-GlcNAcylation is less 
obvious, although it may affect substrate binding given its relative proximity to residues predicted 
to be involved in this function.70 To test whether O-GlcNAcylation at S46/S47 might affect Cdk5 
activity as suggested by the computational model, we used site-directed mutagenesis (SDM) to 
mutate both S46 and S47 to alanine and expressed either wild-type (WT) or S46A/S47A FLAG-
tagged Cdk5 in N2A cells. The Cdk5 constructs were subsequently purified by FLAG IP and 
assayed for kinase activity as described above. Notably, the S46A/S47A mutant had significantly 
higher activity compared to WT Cdk5 (Fig. 3.3c). Thus, in summary, O-GlcNAcylation at S46/S47 
likely inhibits the interaction between Cdk5 and its activator proteins and is thus a key mechanism 
for attenuating Cdk5 function in neurons. In the context of AD, reduced O-GlcNAcylation59 may 
result in decreased Cdk5 O-GlcNAcylation at S46/S47 and explain the increased Cdk5 activity 
observed in this devastating disease41  
 
3.6. Development of a Lentiviral Mediated Cdk5 KD and Replacement Strategy for Studying 
Cdk5 O-GlcNAcylation in Neurons and In Vivo. 
Having confirmed that Cdk5 is O-GlcNAcylated at multiple sites and that the modification at 
S46/S47 is likely involved in regulating Cdk5 activity, we next turned to the development of new 
tools for interrogating the role of Cdk5 O-GlcNAcylation in neurons and in vivo. As transfection 
efficiencies in primary cortical neurons are known to be relatively low compared to other cell 
types,71 we sought to develop a lentiviral delivery system to express mutant Cdk5 in neurons. To 
avoid any deleterious consequences of Cdk5 overexpression, we aimed to simultaneously KD 
endogenous Cdk5 and replace it with our mutants at a similar level of expression. Notably, 




DNA in vivo.72 The simultaneous 
delivery of short harpin (sh)RNA and 
shRNA resistant proteins of interest has 
proven to be a powerful method for 
targeted gene KD and replacement.73 
Therefore, we created four lentiviruses 
to deliver shRNA resistant, myc-FLAG-
tagged Cdk5 mutants using SDM, 
S46A/S47A (46AA), 
T245A/T246A/S247A (T245AAA), an 
all known sites to alanine mutant (QM), 
and WT. These viruses were then used to 
transduce neurons that had also been co-
transduced with Cdk5 shRNA. Notably, 
our Cdk5 vectors also delivered GFP for 
efficiency visualization of viral 
transduction. After 7 DIV, neurons were 
visualized with confocal microscopy 
(Fig. 3.4a), lysed, and subjected to WB 
with FLAG antibody. Excitingly, we 
were able to detect expression of all 4 constructs (Fig. 3.4b) at roughly the same level as 
endogenous Cdk5 (Fig. 3.4c). In future experiments, we hope to use this lentiviral KD and 
replacement system to confirm whether O-GlcNAc-deficient Cdk5 has increased activity in the 
 
Fig. 3.4. Lentiviral Transduction of Neurons with 
shRNA-Resistant Cdk5 Allows for the 
Replacement of Endogenous Cdk5 with 
Glycosylation-Deficient Mutants.  
(a) Fluorescence confocal microscopy confirms 
efficiency lentiviral transduction as determined by 
GFP expression. (b) All 4 shRNA-resistant Cdk5 
constructs express at relatively equal levels in 
neurons even after co-transduction with Cdk5 
shRNA. (c) WB showing the absence of Cdk5 after 
transduction with Cdk5 shRNA (KD efficiency 
>99%) but no effect after transduction with a 
scrambled shRNA control. Notably shRNA-resistant 






















mammalian nervous system. Importantly, these studies may provide a unifying theory for 
decreased O-GlcNAcylation, increased Cdk5 activity, and the development of AD pathology.  
 
3.7. Conclusion. 
In this chapter, we have shown for the first time that Cdk5, an important kinase in both neuronal 
health and disease, activity is regulated by O-GlcNAcylation. The aforementioned studies strongly 
suggest that increased Cdk5 activity seen in the context of OGT KO is due to the absence of O-
GlcNAcylation. This increase in activity may be responsible, at least in part, for the 
neurodegenerative phenotype observed in our OGT cKO mice and would be consistent with the 
well-established neurodegenerative effects of aberrant Cdk5 activity.6 Moreover, combined with 
the fact that there are lower levels of both OGT and overall O-GlcNAcylation in AD, loss of Cdk5 
O-GlcNAcylation may be an important contributor to AD pathogenesis in humans as well (Fig. 
3.5). Future studies will be directed towards confirming whether loss of Cdk5 O-GlcNAcylation 
at S46/S47, specifically, contributes to increased Cdk5 activity and neurodegeneration in vivo. O-
GlcNAc mimetic74 Cdk5 constructs could also be used to replace endogenous Cdk5 with our 
lentiviral KD and replacement system to determine whether mimicking an increase in Cdk5 O-
GlcNAcylation can attenuate the severe neurodegenerative phenotype in OGT cKO mice. In 
summary, the studies herein are beginning to (1) forge a critical new link between two cellular 
mediators of neurodegeneration previously thought to be unrelated, increased Cdk5 activity and 
decreased O-GlcNAc levels, and (2) suggest Cdk5 as a major agent through which disruptions in 





3.8. Experimental Methods. 
 
3.8.1. Reagents and Chemicals. 
 All chemicals were purchased from Sigma-Aldrich (St. Louis, MO), and all cell culture 
materials were purchased from ThermoFisher Scientific (Waltham, MA) unless otherwise noted. 
All primers were purchased from Integrated DNA Technologies (Coralville, IA), and all molecular 
biology supplies were purchased from New England Biolabs (NEB, Ipswich, MA) unless 
otherwise indicated. 
 
Fig. 3.5. Proposed Mechanism for the Role of Decreased Cdk5 O-GlcNAcylation in AD 
Pathogenesis.  
Decreased O-GlcNAc on Cdk5 S46 may lead to an increased association of Cdk5 with activator 
proteins p25/35 and/or p29/39, resulting in higher activity. This, in turn, results in the increased 
phosphorylation of pathogenic proteins such as tau and APP which eventually leads to the 
formation of NFTs and Aβ plaques, respectively. Increases in phoshpo-tau and APP may have even 
more drastic effects in the context of decreased O-GlcNAcylation seen in AD, as O-GlcNAcylation 
is known to both oppose phosphorylation and stabilize proteins against aggregation. Adapted with 






3.8.2. Neuron and Cell Culture. 
Primary mouse cortical neurons were harvested as previously described,36 plated on poly-
d-lysine coated plates, and cultured in Neurobasal medium with 1% penicillin-streptomycin (P/S), 
2mM GlutaMAX Supplement, and GS-21 (MTI-GlobalStem, Gaithersburg, MD). Every 2-4 days, 
half of the media was changed for fresh culture media as outlined above. Neurons were allowed to 
grow for 7 days before transduction with lentivirus. Otherwise, they were cultured for the lengths 
indicated in the text. For KCl stimulation experiments, neuronal activity was first silenced by 24 
hours treatment with 10 μM tetrodotoxin (Tocris Biosciences, Bristol UK) and 100 μM D-AP5 
(Tocris Biosciences). Neurons were then treated with KCl (60 mM) or vehicle for 2 hours and 
subsequently lysed with either RIPA buffer (for IP experiments) or 2% SDS in HEPES pH 7.9 (for 
chemoenzymatic labeling experiments), containing Roche cOmplete protease inhibitor cocktail, 
0.1 mM TMG, and 0.25 U/μL benzonase nuclease (Santa Cruz Biotechnology, Dallas, TX). In all 
cases, the protein concentration was measured using BCA assay (ThermoFisher).  
N2A and HEK 293T cells were maintained in Dulbecco's Modified Eagle Medium with 
100 U/mL P/S, and 10% FBS. Cells were split 1:8 every 2-3 days as necessary. N2A cell lysis was 
performed as described above for neurons. 
 
3.8.3. Co-Immunoprecipitation.  
 Neuronal or N2A lysate, prepared as described above, was diluted to 0.5 mg/ml with Tris-
buffered saline (TBS) buffer,75 0.1 mM TMG, and Roche cOmplete protease inhibitor cocktail. 30 
μg of protein was saved as input. The remaining lysate was incubated with anti-FLAG magnetic 
beads (Sigma-Aldrich) or pre-incubated (1 hour) Cdk5 antibody (sc-173, Santa Cruz 




overnight or for 1 hour at room temperature with end-over-end rotation. The following day, beads 
were washed 3 times with 0.1% Triton-X-100 in TBS and eluted by boiling in 2% SDS in Tris, pH 
8. For samples undergoing subsequent WGA affinity chromatography, elution was performed with 
150 μg/mL 3xFLAG Peptide (Sigma-Aldrich) in TBS. Inputs and eluents were run on SDS-PAGE 
and subjected to WB as described below. 
 
3.8.4. Wheat Germ Agglutinin Affinity Chromatography. 
 Cdk5 eluted from the FLAG resin was immediately incubated with WGA agarose (Vector 
Laboratories, Burlingame, CA) overnight with end-over-end rotation at 4 °C. The following day, 
the beads were washed 5 times with 0.1% Triton-X 100 in TBS and eluted with 0.5 M GlcNAc in 
0.1% Triton-X 100 in TBS. The elution was then concentrated by vacuum centrifugation and 
subjected to SDS-PAGE. 
 
3.8.5. Western Blotting. 
Primary antibodies were all used at 1:1000 dilution, and secondary antibodies at 1:10000 unless 
otherwise specified. Samples were diluted with 4x SDS-PAGE buffer (200 mM Tris-HCl pH 6.8, 
400 mM DTT, 8% SDS, 0.4% bromophenol blue, 40% glycerol), resolved on a NuPAGE 4-12% 
Bis-Tris protein gel (ThermoFisher Scientific), and transferred to Immobilion-FL PVDF 
membrane (MilliporeSigma, Burlington, MA). Blots were blocked for 1 h at RT with LiCor 
Odyssey Blocking Buffer (927-50003, LI-COR Biosciences, Lincoln NE) before probing 
overnight at 4 °C with the following antibodies diluted in blocking buffer: Cdk5 (DC-17, Santa 
Cruz Biotechnology), FLAG (1:5000, F3165, Sigma-Aldrich), p35 (2860S, Cell Signaling 




T9026, 1:3000). Blots were rinsed three times with TBST and then probed with the appropriate 
secondary antibodies in blocking buffer: anti-mouse AlexaFluor 680 conjugate (A21057, 
ThermoFisher), anti-rabbit AlexaFluor 680 (A21109, ThermoFisher), anti-rabbit AlexaFluor 790 
(A11369, ThermoFisher), or anti-mouse IgG DyLight 800 (A11357, ThermoFisher). Blots were 
washed 3 x 5 min with TBST and then imaged using an Odyssey Infrared Imaging System (LI-
COR Biosciences). Images were processed using ImageStudio v5.2 (LI-COR Biosciences). To 
calculate O-GlcNAcylation stoichiometry, the ratios of eluents to inputs, weighted by proportion 
of the total protein in each lane, were used as previously described.76 
 
3.8.6. Cdk5 Activity Assay. 
 Cdk5 activity was measured using ADP-Glo (Promega). Briefly, Cdk5 was IPed as 
described above, however, before elution from the FLAG beads, Cdk5 activity towards a well-
characterized peptide substrate (sc-3066, Santa Cruz Biotechnology) was measured. Each kinase 
activity assay was performed in 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.1 mg BSA with the 
addition of 0.75 μL ultrapure ATP (ADP-Glo) and 0.1 mM Cdk5 substrate peptide (75 μL final 
volume). As a control, the Cdk5 substrate peptide was omitted or roscovitine (Cell Signaling 
Technologies), a potent Cdk5 inhibitor, was added. The kinase reaction was left to proceed for 45 
min at room temperature with end-over-end rotation. The supernatant was then removed and the 
amount of ADP assayed with ADP-Glo according to the manufacture’s protocol. Final 
luminescence values were normalized to the level of Cdk5 in each kinase reaction (after elution 





3.8.7. Chemoenzymatic Labeling. 
 O-GlcNAcylated proteins from neuronal lysates were labeled as previously described.76 
Briefly, lysate containing 150 μg of protein was diluted to 200 μL in water and proteins were 
precipitated by the addition of 3 volumes of methanol, 1 volume of chloroform, and 2.25 volumes 
of water followed by centrifugation at 21,130 x g for 5 minutes to reveal a disc-like protein pellet 
at the aqueous-organic interface. The aqueous layer was removed and the pellet washed three times 
with 2.25 volumes of methanol. Protein pellets were then resolubilized with 40 µL dissolution 
buffer (20 mM HEPES, 1% SDS, pH 7.9). Water (49 µL), 5.5 mM MnCl (11 μL), and 80 µL 2.5x 
GalT labeling buffer (50 mM HEPES, 125 mM NaCl, 5% IGEPAL CA-630, pH 7.9) were added 
and the solution was vortexed gently before adding 10 µL Y289L GalT (1 mg/mL), and 10 µL of 
UDP-GalNAz (0.5 mM in 10 mM HEPES, pH 7.9). The reaction was then left to rotate end-over-
end at 4 °C overnight. Control experiments were carried out in parallel in the absence of UDP-
GalNAz. The following day, proteins were precipitated as before and resolubilized in dissolution 
buffer (1% SDS in TBS pH 7.6). The following were added (in order) to the redissolved protein: 
100 µL H2O, 2.5 µL BTTAA (10 mM, Click Chemistry Tools), 5 µL CuSO4 (50 mM), and 5 µL 
of biotin-PEG4-alkyne (5 mM, Click Chemistry Tools). The solutions were mixed by gentle 
vortexing and 4 µL of TCEP was added. The reaction was allowed to react for 1 hour with end-
over-end rotation in the dark before being precipitated as before. Proteins were resolubilized in 
dissolution buffer as described, and 10% of the reaction volume was taken as input. The remaining 
volume was then incubated with streptavidin magnetic beads (ThermoFisher) for 1.5 hours in the 
dark. Beads were then washed 5 times with 0.5 ml of low salt buffer (100 mM Na2HPO4, 150 mM 
NaCl, 0.1% SDS, 1% Triton X-100, 0.5% sodium deoxycholate) and 5 times with 1 ml of high salt 




by boiling the resin in 50 mM Tris-HCl pH 6.8, 2.5% SDS, 100 mM DTT, 10% glycerol, and 2 
mM biotin for 15 min with occasional vortexing. 
 
3.8.8. In-Gel Digestion of Cdk5 for O-GlcNAc Site Mapping. 
 After SDS-PAGE, the gel was stained and visualized using Imperial protein staining 
reagent (ThermoFisher Scientific) and destained in doubly deionized H2O (ddH2O). The band 
corresponding to FLAG-tagged Cdk5 was then excised and stored at -80 °C until in-gel digestion 
as previously described.77 Briefly, the gel piece was cut into 1 mm squares, reduced with 10 mM 
DTT for 1 h at 37 ºC, and alkylated with 50 mM iodoacetamide for 45 min at room temperature 
protected from light. The slices were dried and incubated with 20 ng/uL Pierce Trypsin, or Pierce 
Chymotrypsin, protease (ThermoFisher Scientific) solution in 100 mM NH4HCO3 (pH 8.0) 
overnight at 37 ºC. The peptides were recovered using sequential washes with 100 mM NH4HCO3, 
1:1 v/v 100 mM NH4HCO3/CH3CN, and 5% formic acid. The recovered peptides were dried and 
desalted with a C18 ZipTip pipette tip (MilliporeSigma). The desalted peptides were resuspended 
in 25 μL of 0.2% formic acid for LC-MS/MS analysis. 
 
3.8.9. LC-MS/MS Analysis. 
 Cdk5 samples were analyzed on a nanoflow LC system, EASY-nLC 1000 (ThermoFisher 
Scientific), coupled to either a Q-Exactive or LTQ Velos (ThermoFisher Scientific) equipped 





3.8.9.1. LTQ Velos Analysis (CID/ETD). 
 Cdk5 peptides (2 μL and 5 μL) were loaded onto a 360x100 μm precolumn (2cm Monitor 
C18, Waters Milford, MA) prior to separation on a 360x75μm column/tip (9cm BEH 1.7 μm) at 
1μL/min at 600 bar constant pressure for 15 μL. The column was heated to 60 °C. The peptides 
were separated with a 145-min gradient at a flow rate of 250 nL/min. Solvent A consisted of 
99.9% water and 0.1% formic acid, and Solvent B consisted of 80% acetonitrile, 19.9% water, 
and 0.1% formic acid. The gradient was as follows: 0-30% Solvent B (120 min), 30-90% B (2 
min), and 90% B (13 min). Full spectra were acquired over m/z 350-1500 in the Orbitrap (60 K 
resolution at 200 m/z); automatic gain control (AGC) was set to accumulate 50,000 ions, with a 
maximum injection time of 50 ms. Data-dependent MS2 analysis was performed using a top 5 
approach with alternating CID and ETD fragmentation.   
 
3.8.9.2. Q-Exactive Analysis (HCD). 
 Cdk5 peptides (2 μL) were loaded onto a 360x100 μm precolumn prior (2cm Monitor 
C18, Waters) to separation on a 360x75μm column/tip (9cm BEH 1.7 μm, Waters) at 1μL/min at 
600 bar constant pressure for 15 μL. The column was heated to 60 °C. The peptides were 
separated with a 77-min gradient at a flow rate of 250 nL/min. Solvent A consisted of 99.9% 
water and 0.1% formic acid, and Solvent B consisted of 80% acetonitrile, 19.9% water, and 0.1% 
formic acid. The gradient was as follows: 2% Solvent B (10 min), 2-35% B (60 min), 35-95% B 
(2 min), and 95% B (5 min). Full spectra were acquired over m/z 350-1500 in the Orbitrap (70 K 
resolution at 200 m/z); automatic gain control (AGC) was set to accumulate 1,000,000 ions, with 




previously78 using a top 12 approach with HCD fragmentation at 35 K resolution, a max 
injection time of 60 ms, and an intensity threshold of 100,000 ions. 
 
3.8.10. LC-MS/MS Data Analysis. 
 The data was converted to MGF files for Mascot searching using Proteome Discoverer. 
ETD and CID spectra were extracted to separate MGF files for searching. The data was then 
searched against a custom database with the expected sequence of interest and a mouse slice of the 
UniProt database downloaded in April 2015 with fixed modifications of carbamidomethyl (C) and 
variable mods of O-GlcNAc (ST), and oxidation (M). Enzyme specificity was Trypsin with 2 
missed cleavages and semichymotrypsin with 4 missed cleavages. Mass tolerances were 25 ppm 
and 0.8 Da for precursor and fragments ions, respectively. CID data and ETD data were searched 
with instrument parameters of ESI-trap or ETD-Trap, respectively. For HCD, mass tolerances were 
25 ppm and 50 mmu for precursor and fragment ions, respectively. Data was then loaded into 
Scaffold (Proteome Software, Portland OR) and filtered for a 1% false discovery rate at the peptide 
level. 
 
3.8.11. Lentiviral Plasmid Construction. 
 Cdk5 shRNA lentiviral plasmid (pLKO.1) was purchased from Sigma-Aldrich 
(TRCN0000278085). Cdk5-Myc-FLAG in pCMV6 (MR204021) was purchased from Origene 
(Rockville, MD). Mutations conferring shRNA resistance (1325-
CCCTGAGATTGTGAAGTCATTC-1346 to CCCTGAaATTGTGAAGagtTTt) and all serine to 
alanine mutations were produced using the Q5 Site-Directed Mutagenesis Kit (NEB) according to 




shRNA resistant mutant or WT Cdk5 was then linearized by using the Q5 Hot Start High-Fidelity 
2x master mix and the pEF-ENTRA A73 entry vector was linearized by digestion with BamHI-HF 
and XbaI. Linear DNA was then gel purified using the Zymoclean gel DNA recovery kit (Zymo 
Research, Irvine, CA) and assembled with the NEBuilder HiFi DNA assembly kit according to the 
manufacturer’s protocol. The Cdk5 entry vectors were then recombined with the pLENTI CMV 
GFP73 destination vector using the Gateway LR Clonase II Enzyme mix (ThermoFisher) as 
described by the manufacturer. The final lentivectors were then amplified in Stable Competent E. 
coli (New England Biolabs), purified using ZymoPURE II Plasmid Kit (Zymo Research, Irvine, 
CA), sequenced (Laragen, Culver City, CA), and resolved by 1% agarose gel electrophoresis to 
ensure plasmid fidelity.  
 
3.8.12. Lentivirus Production. 
 HEK 293T cells were transfected with the lentiviral plasmids produced above, as well as 
lentiviral packaging plasmids (ViraPower Lentiviral Packaging Mix, ThermoFisher), using 
Lipofectamine 3000 (ThermoFisher) at 90% confluency according to manufacturer’s instructions. 
The virus was harvested by collecting media every 24 hours for 3 days. Lentiviral particles were 
concentrated approximately 50 fold at 4 °C using 15-mL 100 kDa MWCO Amicon concentrator 
tubes (MilliporeSigma), flash frozen immediately, and stored at -80 °C until use. Lentiviral titer 
was estimated by traducing neurons with a dilution series of lentivirus and estimating transfection 
efficiency by GFP fluorescence confocal microscopy or determining Cdk5 expression levels 
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The dynamic PTM, O-GlcNAcylation, is present on thousands of intracellular proteins. 
Like phosphorylation, O-GlcNAcylation is inducible and plays important functional roles in both 
physiology and disease. Recent advances in MS and bioconjugation methods are now enabling the 
mapping of O-GlcNAcylation events to individual sites in proteins. However, our understanding 
of which glycosylation events are necessary for regulating protein function and controlling specific 
processes, phenotypes, or diseases remains in its infancy. Given the sheer number of O-GlcNAc 
sites, methods are greatly needed to identify promising sites and prioritize them for time- and 
resource-intensive functional studies. Revealing sites that are dynamically altered by different 
stimuli or disease states will likely go a long way in this regard. Here, we describe advanced 
methods for identifying O-GlcNAc sites on individual proteins and across the proteome, and for 
determining their stoichiometry in vivo. We also highlight emerging technologies for quantitative, 
site-specific MS-based O-GlcNAc proteomics (O-GlcNAcomics), which allow proteome-wide 
tracking of O-GlcNAcylation dynamics at individual sites. These cutting-edge technologies are 
beginning to bridge the gap between the high-throughput cataloging of O-GlcNAcylated proteins 
and the relatively low-throughput study of individual proteins. By uncovering the O-
GlcNAcylation events that change in specific physiological and disease contexts, these new 
approaches are providing key insights into the regulatory functions of O-GlcNAc. 
 
4.2. Introduction. 
Over the past decade, growing interest in O-GlcNAcylation has led to the discovery of 




physiology and pathology. 
However, the huge diversity of 
functions and substrates has 
created a major challenge for 
the field – namely, the 
prioritization of O-
GlcNAcylation events for 
follow-up studies. Given the 
sheer number of O-GlcNAc 
modification sites, methods are 
greatly needed to identify promising sites and prioritize them for time- and resource-intensive 
functional studies. To address this challenge, it will be critical to move from a static picture of 
whether a protein is O-GlcNAcylated to a more dynamic view and identify context-specific 
changes in O-GlcNAcylation, such as sites that are induced by specific stimuli or altered during 
development or disease progression. Identifying these key sites and developing methods to 
selectively modulate their glycosylation status may also prove critical for therapeutic intervention 
in neurodegenerative disease, as globally altering O-GlcNAcylation levels could have deleterious, 
compensatory, or potentially unforeseen off-target effects.1-5 
 The importance of monitoring the dynamics of O-GlcNAcylation at specific sites is further 
underscored by the observation that OGT and OGA exhibit exquisite selectivity for particular 
 
Fig. 4.1. Selected Functions of O-GlcNAc.  
An explosion of studies has identified many new functions for 
O-GlcNAcylation. Yet, a central challenge remains in 
distinguishing the most functionally important sites in a given 






substrates, depending on the cellular context.5-9 For instance, early quantitative proteomics studies 
by our laboratory showed that robust stimulation of excitatory neurons in vivo induces O-
GlcNAcylation on only a subset of OGT substrates, while pharmacological inhibition of OGA 
affects almost an entirely different subset.6 This suggests that OGT can discriminate among its 
various substrates in response to specific cellular signals. OGT can also exhibit exquisite 
selectivity for different sites within the same protein. For example, neuronal depolarization induces 
CREB glycosylation at only a single site, Ser40, while other glycosylation sites in CREB remain 
unchanged.10 Thus, different sites within 
the same protein can show distinct 
temporal dynamics, which may enable 
O-GlcNAc to regulate various aspects of 
a protein’s function. Finally, several 
studies have observed that changes in O-
GlcNAcylation at the protein level often 
do not correlate with changes at 
individual sites. This is exemplified by 
the transcriptional repressor methyl CpG 
binding protein 2 (MeCP2), whose loss 
of function underlies Rett syndrome.11 
Although the O-GlcNAcylation level on 
the total MeCP2 population decreases 
upon neuronal depolarization, the O-
GlcNAcylation level on the Ser80-
 
Fig. 4.2. O-GlcNAcylation Undergoes Complex 
Regulation and Site-Specific Dynamics in the 
Brain.  
(a) Inhibition of OGA increases O-GlcNAcylation on 
a subset of OGT substrates (in red), whereas excitatory 
neuronal stimulation with kainic acid increases O-
GlcNAcylation on a different subset (in blue). (b) 
Neuronal stimulation increases O-GlcNAcylation of 
CREB at S40, while the other two sites remain 
unchanged. (c) Overall O-GlcNAcylation of MeCP2 
decreases upon neuronal depolarization; however, for 






phosphorylated subpopulation of MeCP2 significantly increases.12 These examples clearly 
demonstrate that O-GlcNAcylation undergoes complex regulation and site-specific dynamics in 
neurons (Fig. 4.2a-c). 
Herein, we will highlight state-of-the art technologies for identifying O-GlcNAc sites and 
tracking their context-specific dynamics. We will first focus on methods for mapping glycosylation 
sites within proteins and for quantifying site occupancy or stoichiometry. We will then describe 
emerging technologies for quantitative, MS-based O-GlcNAcomics and discuss how such 
approaches are providing new, systems-level insights into the site-specific dynamics of O-GlcNAc 
in response to different cellular or disease states. Our intention is to provide an overview of these 
technologies with an emphasis on their potential impact on the field of neurobiology. Overall, the 
development and implementation of quantitative O-GlcNAcomics methods should greatly 
accelerate the prioritization of O-GlcNAcylation sites for further study and are a critical next step 
toward advancing our understanding of the functions of O-GlcNAc in health and disease.  
 
4.3. O-GlcNAc Site Identification on Individual Proteins.  
The identification of O-GlcNAc sites is often crucial for elucidating the function of the 
modification in the context of specific proteins. However, this task can be challenging as there is 
no known consensus sequence for OGT, and the O-GlcNAc modification occurs 
substoichiometrically on many proteins. Moreover, the O-GlcNAc moiety is frequently found 
within a stretch of serine or threonine residues and is readily lost upon CID MS due to the lability 
of the O-glycosidic linkage.13,14 As a result, O-GlcNAcylation sites are often ambiguous, difficult 
to localize to a single serine or threonine residue, or require confirmation with time-consuming 




In response to these challenges, Hart and coworkers developed the BEMAD (β-elimination 
followed by Michael addition with dithiothreitol) approach,17 which chemically converts O-
GlcNAcylated serine and threonine residues to thiol-containing derivatives that are stable during 
CID. As other O-linked modifications such as phosphorylation are also derivatized in the process, 
this technique is not well suited for the selective mapping of O-GlcNAc sites unless it is combined 
with some form of enrichment for O-GlcNAcylated peptides.15,18,19 Our laboratory has developed 
a chemoenzymatic labeling strategy that accomplishes this task.16,20-23 The approach allows for 
selective, quantitative labeling of O-GlcNAcylated peptides or proteins with an unnatural azido- 
or ketone-containing galactose sugar GalNAz22 or 2-acetonyl-2-deoxy-α-D-galactose20 using an 
engineered β-1,4-galactosyltransferase (Y289L GalT).24 The azide or ketone functionality enables 
the attachment of different reporter groups (e.g. biotin, fluorescent dyes) using bioorthogonal 
chemistry.16,20,22,23 Thus, following labeling with biotin, O-GlcNAcylated proteins can be captured 
using streptavidin resin and then simultaneously derivatized and eluted using BEMAD (Fig. 4.3a). 
This dual chemoenzymatic labeling/BEMAD strategy has proven effective for mapping O-
GlcNAcylation sites on individual proteins15,18,19,25,26 and has been applied on a proteome-wide 
level,18,26-28  albeit with less success in site identification compared to the methods discussed 
below. Using this approach, several residues near the active site of CaMKIV, an important kinase 
whose signaling functions have been linked to learning, memory, and neurodegeneration,19,29-31 
were identified.19 Site-directed mutagenesis studies demonstrated that O-GlcNAcylation of these 




BEMAD has some limitations (such as being prone to false positives and causing peptide 
degradation27,33), it remains a useful method for mapping O-GlcNAc sites and is amenable to 
traditional MS workflows.  
With advances in MS instrumentation, the direct mapping of O-GlcNAc sites, without 
chemical conversion of the labile O-GlcNAc moiety, has also become possible in some cases. ETD 
enables the observation of O-GlcNAcylated serine and threonine fragment ions in MS/MS spectra 
without O-glycosidic bond cleavage,6,34 thereby localizing the exact modification site. Typically, 
O-GlcNAcylated proteins of interest are overexpressed, immunoprecipitated, and analyzed 
directly by LC-MS/MS following in-gel digestion.10,16 We and others have successfully employed 
this approach to identify crucial, regulatory O-GlcNAcylation sites on neuronal proteins involved 
in learning and memory, signal transduction, and metabolism, including CREB and the 
mitochondrial motor-adaptor protein Milton.10,35 Given the limitations of the BEMAD approach 
 
Fig. 4.3. Strategies for Mapping O-GlcNAc Sites.  
(a) Chemoenzymatic labeling/BEMAD strategy. O-GlcNAcylated peptides are 
chemoenzymatically labeled with a biotin moiety, enriched by streptavidin capture, and then 
eluted using BEMAD prior to LC-MS/MS analysis. (b) Cleavable biotin-Dde-alkyne strategy. 
O-GlcNAcylated peptides are chemoenzymatically labeled with a biotin-Dde-alkyne derivative 
and enriched by streptavidin capture. Quantitative release of O-GlcNAcylated peptides is then 
achieved using hydroxylamine or hydrazine, which imparts an additional positive charge on the 




discussed above, the use of ETD-MS/MS to map exact O-GlcNAc sites is generally preferred if 
appropriate instrumentation is available.  
Difficult-to-detect or low-abundance O-GlcNAc sites on proteins require techniques for 
the highly efficient enrichment and release of O-GlcNAcylated peptides. While labeling O-
GlcNAcylated peptides with a biotin tag provides an effective enrichment strategy,6,18 the strength 
of the biotin-streptavidin interaction can hinder efficient release of the peptides from the resin. To 
overcome this problem, we recently developed a biotin tag containing a chemically cleavable 1-
(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl (Dde) functionality to selectively capture O-
GlcNAcylated peptides after chemoenzymatic labeling.36 The O-GlcNAcylated peptides are then 
quantitatively released from streptavidin resin using hydrazine or hydroxylamine (Fig. 4.3b).16 
Importantly, this cleavage event leaves O-GlcNAcylated peptides with an additional positive 
charge that significantly improves their ETD fragmentation efficiency. Ultimately, this approach 
greatly increases the likelihood of successful identification and sequencing of O-GlcNAcylated 
peptides.16,36-39 It is worth noting that an additional advantage of the biotin-Dde tag is that produces 
three signature ions upon fragmentation by HCD, which result from cleavage of the glycosidic 
bond between GlcNAc and GalNAz (300.1 m/z), the water adduct of the previous fragment (318.1 
m/z), and cleavage between GlcNAc and the serine/threonine residue (503.2 m/z).16 These 
signature ions enable unambiguous assignment of the modification at the peptide level, and the 
increased ETD fragmentation efficiency (due to the additional positive charge) increases the 
likelihood that an O-GlcNAcylation event can be definitively localized to a single residue. In fact, 
using this strategy, we identified four new O-GlcNAc sites on OGT that were previously 
undetectable by other methods, all of which were on tryptic peptides spanning multiple sites of O-




applicable for discovering low-abundance sites or sites that were previously ambiguous due to the 
lability of O-GlcNAc or poor glycopeptide ionization/fragmentation. Thus, the development of 
new chemoenzymatic labeling tags coupled with cutting-edge MS technologies has significantly 
reduced the barriers to the unambiguous assignment of O-GlcNAc sites, and in the future, the 
complete mapping of sites on nearly any protein of interest should become increasingly routine.  
 
4.4. O-GlcNAc Site Mapping Across the Proteome. 
The identification of O-GlcNAc sites across the proteome requires effective methods for 
the enrichment of O-GlcNAcylated proteins or peptides from complex biological samples. One 
powerful, widely used approach involves the chemoenzymatic tagging strategy described above. 
In early studies, we applied this strategy to enrich O-GlcNAcylated proteins from the mammalian 
brain and identified 34 O-GlcNAcylated peptides corresponding to 25 proteins. These proteins had 
a wide range of important neuronal functions, including the regulation of gene expression, 
neurotransmission, and synaptic plasticity.18 Similar to the biotin-Dde tag described above, the 
biotin tag in this case also provided a unique fragmentation pattern upon MS/MS analysis that 
enabled us to conclusively identify the modification. This approach was subsequently improved 
through the development of a photocleavable biotin tag (biotin-PC)40 and the chemically cleavable 
biotin-Dde tag described above (Fig. 4.3b).36 Using the biotin-PC tag, Hart and colleagues 
identified 458 O-GlcNAc sites on 195 proteins in the brains of WT and 3xTg (a common mouse 
model of AD41) mice.42 Impressively, 168 of the identified O-GlcNAcylated proteins had not been 
previously described and included multiple proteins involved in synaptic plasticity and neuronal 
signaling, cytoskeletal organization, and neuronal gene expression.42 More recently, the 




map O-GlcNAc sites across the proteome. In a direct side-by-side comparison, the biotin-Dde tag 
outperformed the biotin-PC tag, enabling the identification of 414 unique O-GlcNAcylated 
peptides from human embryonic kidney 293T cells, as compared to the 227 unique O-
GlcNAcylated peptides identified using the biotin-PC tag (unpublished). Building further on this 
approach, we have designed a next-generation, chemically cleavable tag that has greater thermal 
stability compared to biotin-Dde and has enabled the mapping of over 1,300 O-GlcNAc sites 
across ~600 proteins in 293T cells (manuscript in preparation).  
An alternative to chemoenzymatic labeling strategies involves the use of lectin weak 
affinity chromatography with wheat germ agglutinin to enrich O-GlcNAcylated peptides. Using 
this approach combined with high-pH reversed-phase fractionation and ETD-MS/MS, Burlingame 
and coworkers identified 1,750 unique sites of O-GlcNAcylation from fractionated mouse 
synaptosomes, the most sites described thus far in a single experiment.43 This study also 
interrogated the phosphoproteome on these same samples given the precedent for a high degree of 
crosstalk between these two modifications.5,44 Interestingly, all but one of the extensively O-
GlcNAcylated proteins were extensively phosphorylated. Moreover, protein kinases as a class 
were found to be more extensively O-GlcNAcylated in synaptosomes, suggesting an intriguing 
potential for crosstalk at the level of enzyme activity. However, at the site level, the number of O-
GlcNAc sites that were also phosphorylation sites did not exceed what would be expected by 
chance, and there was no propensity for O-GlcNAc and phosphorylation sites to cluster in primary 
sequence or three-dimensional space. 
Collectively, studies of the O-GlcNAcylated proteome have provided critical insights into 
the physiological functions of O-GlcNAc in the brain. For instance, these analyses have revealed 




modification in synaptic communication and function.45 Moreover, the unbiased identification of 
O-GlcNAc sites has facilitated follow-up studies to understand the function of O-GlcNAc in the 
context of specific proteins, as demonstrated by a recent study by Pratt and coworkers on the 
effects of site-specific O-GlcNAcylation on α-synuclein aggregation.46,47 However, despite the 
power of O-GlcNAcomic approaches, these technologies provide only a static snapshot of the O-
GlcNAcome, without regard for the stoichiometry or dynamics of specific sites. As described 
below, knowledge of the site occupancy and inducibility of specific sites can provide insights into 
the importance of specific glycosylation events and the cellular contexts in which they function.  
 
4.5. Methods for Measuring Dynamic O-GlcNAc Stoichiometry.  
Determining the stoichiometry of glycosylation on a protein, or at a specific site, is critical 
for assessing whether that glycosylation event is likely important. The modification is more likely 
to be functionally relevant and to operate in a regulatory capacity if a significant population of the 
protein is modified and the modification is dynamically cycled. Glycosylation stoichiometries can 
be challenging to quantify and thus are known for only a small fraction of the O-GlcNAcome. To 
quantify O-GlcNAc stoichiometries, large amounts of purified protein (e.g. for high-pH anion-
exchange chromatography with pulsed amperometric detection)48-50 or synthetic O-GlcNAcylated 
peptide standards encompassing the sites of interest are typically required. In order to overcome 
these challenges, we have developed two methods to detect and quantify the O-GlcNAc-modified 




strategy described above, in combination with immunoblotting to detect the protein of interest. 
The amount of a captured (i.e. O-GlcNAcylated) protein is quantified relative to the total amount 
of that protein to give an approximate measure of stoichiometry.16,21,51 The second approach allows 
for direct visualization and quantification of the O-GlcNAc-modified subpopulation via 
chemoenzymatic labeling of the proteins with resolvable PEG tags (Fig. 4.4a). Specifically, O-
GlcNAcylated proteins from cell lysates are labeled with a keto-galactose or azido-galactose sugar 
as described above and then reacted with an aminooxy-, alkyne-, or dibenzocyclooctyne-
functionalized PEG tag of defined molecular mass (typically 2-kDa or 5-kDa). Importantly, the 
PEG tag shifts the molecular weight of the glycosylated species and allows them to be resolved 
from the non-glycosylated species by SDS-PAGE.12,16,23,52 After immunoblotting to detect the 
 
Fig. 4.4. Chemoenzymatic Labeling with PEG Tags to Determine O-GlcNAcylation 
Stoichiometry.  
(a) A PEG tag of defined mass (2-kDa or 5-kDa) is installed on O-GlcNAcylated proteins in cell 
lysates using Y289L GalT and copper (I)-catalyzed azide-alkyne cycloaddition (CuAAC) 
chemistry. (b) Neurons expressing either WT or S40A CREB fused to a FLAG tag were 
depolarized with KCl for the times indicated before lysis and chemoenzymatic labeling with 
PEG. Labeled proteins were then subjected to SDS-PAGE and Western blotting for CREB or 
FLAG. Note the presence of two major CREB glycoforms, mono- and di-glycosylated, and the 




protein(s) of interest, simple inspection of the mass-shifted bands can rapidly establish whether a 
protein is singly, doubly, or multiply glycosylated. Moreover, in vivo glycosylation 
stoichiometries can be readily calculated by quantifying the relative intensities of each band. One 
caveat with chemoenzymatic labeling, however, is that GalT can also label complex glycans that 
contain a terminal GlcNAc sugar. For known membrane proteins, complex N-linked glycans can 
be removed using Peptide:N-glycosidase F.16 In addition, it is possible that chemoenzymatic 
labeling may differ in efficiency for different sites, although the use of excess reagents ensures 
highly efficient labeling, and both of these methods have been consistently demonstrated to 
provide accurate measurements of the O-GlcNAcylation stoichiometry on a range of peptide and 
protein substrates.12,16,23,36,53  
When used in combination with site-directed mutagenesis, this approach allows for rapid 
interrogation of O-GlcNAc stoichiometry at specific sites and across multiple conditions. For 
instance, we found that approximately 30% of CREB was mono-glycosylated in resting neurons. 
Upon KCl-mediated depolarization, glycosylation was induced specifically at a single site, Ser40 
(Fig. 4.4b).10,12 Strikingly, mutation of Ser40 to alanine resulted in increased CREB-dependent 
gene transcription, and significantly accelerated long-term memory formation in mice.10 Overall, 
this powerful method enables the measurement of O-GlcNAcylation stoichiometries on 
endogenous proteins of interest without the need for protein purification, advanced 
instrumentation, or expensive radiolabels.  
 
4.5. Quantitative O-GlcNAcomics. 
Systems-level approaches to quantify site-specific changes in O-GlcNAcylation across the 




functionally important in a specific cellular or disease context. We will describe here three 
promising technologies for quantitative site-specific O-GlcNAcomics: QUIC-Tag, quantitative 
CEPC, and quantitative IsoTaG.  
  The QUIC-Tag method, developed in 2007, was the first quantitative O-GlcNAcomics 
approach.6 This approach combines chemoenzymatic biotin tagging for O-GlcNAcylated peptide 
enrichment with stable isotope dimethyl labeling for quantitative proteomics (Fig. 4a). Using 
QUIC-Tag, we observed changes in O-GlcNAcylation at specific sites following stimulation of 
rats with kainic acid, a kainate-type glutamate receptor agonist that produces widespread excitatory 
stimulation of the brain.6 These studies provided the first evidence that O-GlcNAcylation is 
 
Fig. 4.5. Strategies for Quantitative O-GlcNAcomics.  
(a) QUIC-Tag strategy. O-GlcNAcylated proteins are chemoenzymatically labeled with biotin, 
digested, captured, and subjected to isotopic dimethyl labeling before LC-MS/MS analysis. (b) 
Quantitative CEPC. O-GlcNAcylated proteins are digested, TMT labeled, and fractionated 
before chemoenzymatic labeling with a biotin-PC tag. The labeled peptides are then enriched, 
eluted from the beads by UV cleavage, and subjected to LC-MS/MS analysis. (c) Quantitative 
IsoTaG. Metabolically labeled O-GlcNAzylated proteins are functionalized with an acid-
cleavable biotin linker containing an isotopic label (IsoTaG Probe) using CuAAC. Labeled 
proteins are then enriched, digested, eluted from the beads, and analyzed by LC-MS/MS. 
Importantly, glycopeptides can then be readily identified by their unique isotopic signature in 
MS1. In all cases, the relative O-GlcNAcylation levels on peptides derived from two or more 
samples can be calculated from the ratio between light and heavy isotopically-labeled peptides 




dynamically modulated in vivo by neuronal activity. Moreover, we found that different subsets of 
O-GlcNAc sites respond to different neuronal stimuli, with kainic acid affecting a distinct set of 
sites compared to the OGA inhibitor O-(2-acetamido-2deoxy-D-glucopyranosylidene)amino-N-
phenylcarbamate (PUGNAc). Overall, our findings highlight key differences in the occupancy and 
temporal dynamics of specific sites in response to different stimuli and demonstrate the complex 
regulation of O-GlcNAcylation in neurons. With recent advances in MS instrumentation and the 
new chemoenzymatic tags described above, this strategy can now be adapted to enable more 
comprehensive, quantitative comparisons across many different functional states. 
The quantitative CEPC strategy relies on isotopic labeling (e.g. SILAC) or isobaric labeling 
(e.g. TMTs) of peptides derived from cell lysates, followed by chemoenzymatic labeling using 
Y289L GalT and biotin-PC to enrich O-GlcNAcylated peptides (Fig. 4b).54 Recently, Liu and 
coworkers exploited this technique to quantify site-specific differences in O-GlcNAcylation 
between AD and non-diseased brain tissue.52 After TMT labeling followed by chemoenzymatic 
labeling, enrichment, and photochemical cleavage, they determined 623 ratios at the O-
GlcNAcylated peptide level and mapped 1,094 sites. Twenty-four of these sites showed significant 
differences in O-GlcNAcylation between AD and control tissues that were not due to changes in 
protein expression. Most of the sites were found on proteins involved in pre- and post-synaptic 
organization and structure, such as synaptopodin, ankyrin-3, integrin beta-4, and neurofascin.52 
Overall, these quantitative O-GlcNAcomics studies show that dysregulated O-GlcNAcylation 
occurs on multiple, select neuronal proteins during the development of sporadic AD and identify 





Finally, Pitteri and colleagues have recently reported combining the isotope-targeted 
glycoproteomics (IsoTaG)55,56 strategy with label-free quantification to profile changes in O-
GlcNAcylation (Figure 4C).57 This approach relies on metabolic incorporation of N-
azidoacetylglucosamine (GlcNAz) into O-GlcNAcylated proteins.58 Briefly, cells are incubated 
with peracetylated GalNAz, which is converted to uridine diphosphate (UDP)-GlcNAz by the 
UDP-galactose 4-epimerase pathway.59 As OGT tolerates UDP-GlcNAz as a substrate, O-
GlcNAcylated proteins can be labeled with GlcNAz and then conjugated to an acid-cleavable 
biotin-alkyne linker containing an isotopic label (IsoTaG Probe) using CuAAC. It is important to 
note, however, that other GlcNAc- and N-acetylgalactosamine-containing complex glycans will 
also be metabolically labeled,56,58 and the incorporation of GlcNAz is substoichiometric, reducing 
the labeling efficiency compared to chemoenzymatic strategies. The labeled glycoproteins are 
enriched by streptavidin capture, proteolytically digested, and the resulting glycopeptides are 
released by cleavage of the linker and analyzed by LC-MS/MS. Importantly, the cleaved IsoTaG 
Probe imparts a readily detectable isotope pattern to the glycopeptides, which allows them to be 
definitively identified and targeted in subsequent LC-MS/MS runs.56,57 Using this strategy, Woo 
et al. mapped 851 O-GlcNAc sites in primary human T cells across 77 MS runs.57 They also 
quantified changes in O-GlcNAcylation in response to T cell activation using label-free 
quantification and identified differences in the levels of 518 O-linked glycopeptides, 
corresponding to 227 proteins, between resting and activated T cells. One caveat with such 
comparisons is that the non-natural GlcNAz sugar may or may not be incorporated into proteins 
with the same relative ratios as the endogenous O-GlcNAc modification, and thus the differences 
in O-GlcNAcylation at specific sites may not reflect physiological conditions. Nonetheless, diverse 




CREB, nuclear pore complex protein Nup98, transcription factor jun-B, and protein phosphatase 
1 regulatory subunit 12A. Given the interesting parallels between T cell and neuronal activation,60 
these results may also have important implications for neurons and shed light on common 
pathways and mechanisms shared by both cell types. 
 
4.6. Conclusions and Future Directions.  
Significant advances in O-GlcNAc detection, site mapping, and quantitative MS-based O-
GlcNAcomics are uncovering key regulatory roles for O-GlcNAcylation in multiple aspects of 
cellular (patho)physiology. As these advanced methods develop and become widely available, the 
number of important discoveries will only continue to grow. We have focused here on the 
emergence of new MS-based O-GlcNAcomics technologies for profiling and monitoring the 
dynamics of O-GlcNAc at thousands of sites simultaneously. These technologies have the potential 
to revolutionize our understanding of the modification by providing unprecedented insight into the 
specificity and kinetics of glycosylation at particular sites, by facilitating the much-needed 
prioritization of O-GlcNAcylation sites for functional studies, and by revealing those sites that are 
important in specific physiological and disease contexts (Fig. 4.6).  
Chemoenzymatic 
labeling strategies are 
particularly well-suited for 
quantitative, site-specific O-
GlcNAcomics because they 
provide highly specific, 
nearly quantitative labeling 
 
 
Fig. 4.6. Emerging Quantitative MS Technologies Can Help 






and enrichment of low-abundance O-GlcNAcylated proteins or peptides. Bringing other advanced 
techniques for PTM profiling and quantitative proteomics to bear on the O-GlcNAc field would 
also open up even more exciting experimental possibilities. Moreover, with additional 
improvements in the design of new chemical tags and MS analysis workflows specially tuned for 
glycopeptides, we may soon find that the long-standing challenge of quantitative “shotgun O-
GlcNAcomics” has become a thing of the past.  
The continued development of quantitative, site-specific O-GlcNAcomics methods will 
also help to overcome key gaps in our understanding of O-GlcNAcylation. For instance, the ability 
to compare O-GlcNAcylation levels across different cell populations or regions of a tissue of 
interest should provide new insights into cell-specific roles for the modification and how aberrant 
O-GlcNAcylation at the cellular level may give rise to macroscopic, tissue-level pathology. 
Quantitative O-GlcNAcomics should also enable specific O-GlcNAcylation events to be 
monitored with unprecedented temporal resolution. As such, they could be used to track dynamic 
O-GlcNAc cycling at specific sites under a limitless set of important physiological and disease-
relevant conditions. For example, while global changes in O-GlcNAcylation and expression of 
OGT/OGA are observed during development, aging,61-64 and disease progression,65-68 the site-
specific changes in O-GlcNAcylation associated with these processes are largely uncharacterized. 
In the future, the integration of quantitative O-GlcNAcomics data with other state-of-the-
art “-omics” techniques (e.g. interactomics, phosphoproteomics, transcriptomics, proteomics) will 
also help uncover important correlations across biological systems and crosstalk between O-
GlcNAcylation and other signaling networks. We expect that such multimodal approaches will 
prove particularly powerful for addressing questions such as how O-GlcNAcylation regulates 




regulatory roles for O-GlcNAc, these efforts may shed light on long-standing questions regarding 
the complex regulation of OGT and OGA. Together, we believe that multimodal, systems-level 
approaches, coupled with rapidly emerging technologies for quantitative O-GlcNAcomics, will 
usher in a new era in our understanding of the functional roles played by O-GlcNAc. 
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 The PTM of proteins by O-GlcNAc is essential and widespread across both the proteome 
and lifespan of all multicellular organisms. However, nearly all functional studies have focused on 
the modification of individual proteins, overlooking the possibly thousands of other simultaneous 
O-GlcNAcylation events that may work in tandem to coordinate cellular activities. Here, we 
present networking of O-GlcNAc transferase interactors and substrates (NOTISE), a novel 
systems-level approach to rapidly and comprehensively monitor O-GlcNAcylation events across 
the proteome in a given biological context. Our method integrates affinity purification mass 
spectrometry and site-specific chemoproteomics with network generation and unsupervised 
partitioning to organize potential upstream regulators and downstream targets of O-GlcNAcylation 
into functional clusters. Using a newly generated mouse model, we apply NOTISE to identify both 
conserved and tissue-specific activities of O-GlcNAcylation in the adult brain and liver. This 
holistic, networking approach provides a broadly applicable framework to delineate the roles of 
multifunctional PTMs across diverse tissue-types and biological states. 
 
5.2. Introduction. 
 PTMs allow cells to rapidly and dynamically modulate protein function in response to 
biological stimuli. O-GlcNAcylation is the reversible addition of the monosaccharide β-N-acetyl-
D-glucosamine to intracellular Ser and Thr residues. Unlike other classes of PTMs, this 
modification is catalyzed by a single O-GlcNAc transferase (OGT) and hydrolase (OGA) pair.1 
Nevertheless, O-GlcNAcylation occurs over thousands of proteins and is thought to function as a 
major integrating signal for the physiological status of the cell. The O-GlcNAc moiety incorporates 




UDP-GlcNAc.2 Cycling of the modification rapidly responds to many stimuli such as stress,3 
nutrient availability,4 and extracellular signaling.5 Accordingly, O-GlcNAcylation regulates many 
essential functions, including transcription,5 translation,6 metabolism,7 protein homeostasis,8 and 
signal transduction.9,10 Altered O-GlcNAc levels have been implicated in multiple diseases 
including cardiovascular disease,11 diabetes,12 cancer,13 and neurodegeneration.14  
 Recent methodological advances have improved the identification of O-GlcNAcylated 
proteins and peptides.15 However, the vast majority of O-GlcNAcylation events remain 
functionally uncharacterized, and nearly all previous functional studies have focused only on 
individual modifications. Although critical advances, these studies do not encompass the full 
breadth of the role changes in O-GlcNAcylation plays in these contexts. For example, in cancer 
cells, changes in O-GlcNAcylation in response to nutrient and oxygen availability coordinate 
diverse responses from metabolic reprograming16 to cytoskeletal reorganization,17 ultimately 
significantly influencing tumor aggressiveness and metastatic potential. Moreover, in neurons, 
dynamic O-GlcNAcylation of proteins from the synapse to the nucleus occurs differentially in 
response to multiple stimuli.5,18,19 In both of these cases, O-GlcNAcylation also cycles on multiple 
time scales to immediately regulate protein localization and stability as well as influence long-
term genetic reprogramming through modulation of transcription factor recruitment and the 
epigenome. Interestingly, on the organismal level, O-GlcNAc has also been shown to respond 
differently to the same stimuli in different tissues9,20 and even different cell types of the same 
tissue.21  Thus, O-GlcNAcylation provides a unique challenge to understand how a single 
enzymatic pair can dynamically coordinate such broad cellular responses to intra- and extracellular 




To address this challenge, new systems-level methodologies are needed to provide a more 
holistic analysis of the many simultaneous O-GlcNAc events occurring in a given biological 
context. Furthermore, the sheer breadth of activity of O-GlcNAcylation highlights the difficulty in 
selecting or prioritizing individual sites for intensive, low throughput functional analyses. An 
integrated, bottom-up assembly of PTM sites and possible regulatory factors from a single 
biological condition would provide a thorough and contextualized view of PTM activity. This 
comprehensive approach may in turn inform on critical functions or sites for further investigation. 
In addition, the application of a standardized workflow to more completely identify and 
characterize PTM function across tissues and contexts could provide the first insights into cell-, 
tissue-, and stimulus-specific functions and regulatory networks of O-GlcNAc cycling enzymes. 
However, methods to generate, integrate, and deconvolute these data have not yet been developed. 
A key hurdle to overcome for a systems-level interrogation of PTM function is the 
simultaneous discovery of coordinating or regulatory factors that are active in a given context. To 
discriminate between different stimuli, pleiotropic enzymes rely on a number of regulatory 
mechanisms to control and direct their activity. For example, intensive efforts have been made to 
define the mechanisms underlying the selectivity of OGT for its stimuli or tissue specific targets 
in a universe of thousands of potential modification sites. Emerging evidence suggests that OGT 
activity is controlled, at least in part, by adaptor proteins that target OGT to its cellular substrates.2 
This phenomenon is similar to A-kinase-anchoring proteins (AKAPs), which bind to the regulatory 
subunit of PKA to selectively direct its cellular activity.22 Therefore, OGT interactors may provide 
the organizational basis for O-GlcNAcylation across the proteome that can be exploited not only 





Here, we describe networking of O-GlcNAc transferase interactors and substrates 
(NOTISE), a new approach to conduct comprehensive, systems-level analyses of PTM activity. 
Our method first ascertains potential upstream organizational determinants and downstream 
outcomes of OGT activity by identifying both OGT interacting proteins (Fig. 5.1a) and O-
GlcNAcylated substrates (Fig. 5.1b). These elements are combined to produce a functional 
protein-protein interaction network that is then partitioned into process-specific subnetworks by 
unsupervised clustering (Fig. 5.1c). Together, this workflow produces a holistic, proteome-wide 
snapshot of the interactions and substrates of OGT for a given biological state. It also provides a 
physical framework for downstream functional interrogation. The approach can be applied to cells, 
tissues, or in vivo by utilizing a novel mouse model generated by CRISPR/Cas9 genome editing. 
Using NOTISE, we elucidate functional O-GlcNAc networks from the healthy adult brain and 
liver, revealing novel roles of O-GlcNAcylation in histone modification, mRNA processing, actin 
dynamics, and cytoskeletal organization. In total, these global analyses reveal for the first time 
both conserved and tissue-specific activities of O-GlcNAcylation in vivo. 
 
5.3. Identification of OGT-Interacting Proteins. 
To profile OGT interactors, we performed tandem affinity purification mass spectrometry 
(TAP-MS) using a dual FLAG- and HA-tagged OGT construct (OGT-FH; Fig. 5.1a). A stable 




tetracycline-responsive element (TRE) promoter to ensure uniform, controllable levels of the dual-
tagged OGT (Fig. 5.2). The appended FLAG and HA tags were then used to sequentially 
immunoprecipitate OGT and its associated proteins (Fig. 5.3a). Notably, our method confirms the 
stable interaction between OGT and retinoblastoma-binding protein 5 (RBBP5), nuclear pore 
glycoprotein p62 (NUP62), WD repeat-containing protein 5 (WDR5), and HCFC1 (Fig. 5.3b). 
Using TAP-MS combined with stable isotopic labeling with amino acids in cell culture (SILAC), 
we then compared OGT interacting proteins between HEK-293T cells treated with doxycycline 
 
 
Fig. 5.1. The NOTISE Workflow.  
(a) Tandem affinity purification of OGT interactors by sequential FLAG and HA 
immunoprecipitation. (b) Chemoenzymatic labeling and purification of O-GlcNAcylated 
peptides for chemoproteomic site identification. (c) Combination of interactor and substrate 





(DOX) to untreated cells. This approach allowed us to construct the first statistically validated 
OGT interactome over background, identifying 519 high-confidence OGT interactors. Notably, 
many of the identified OGT interactors (Fig. 5.3c) represent significant advances in the O-GlcNAc 
literature, including HCFC1,23,24 BAP1,25 and ten-eleven-translocation 2 (TET2).26 In addition, 
our studies identified 455 OGT interactors not found in protein-protein interaction (PPI) databases 
BioGRID27 and IntAct28 including DNA damage-binding protein 1 (DDB1), mitotic checkpoint 
protein BUB3 (BUB3), and serine/threonine-protein kinase WNK1 (WNK1), which play critical 
roles in DNA damage repair,29 mitotic spindle assembly,30 and ion homeostasis,31 respectively. 
Our analysis was also extremely robust with 0 single-trial-interactors identified (Fig. 5.3d). 
Overall, these new findings demonstrate the importance of robust, targeted interactomic 
approaches for the comprehensive identification of OGT interacting partners needed for systems-






Fig. 5.2. Tunable Expression of OGTFH in HEK-293T-iOGTFH Cell Line.  
(a) Cells were treated with different concentrations of doxycycline overnight, lysed, and 
immunoblotted for OGT levels. (b) Quantification of OGT expression in A (n = 3, mean ± 
S.E.M.). 
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5.4. Proteome-Wide Site Mapping of Protein O-GlcNAcylation. 
To examine the output of OGT activity, we expanded on our previous chemoenzymatic 
approach to identify and map sites of protein O-GlcNAcylation across the proteome.32,33 This 
method employs a mutant galactosyltransferase (Y289L GalT) to append the non-natural 
monosaccharide GalNAz onto O-GlcNAc-modified proteins as a handle for downstream 
functionalization and enrichment. Importantly, this approach has advantages over other existing 
methods using non-natural sugars, such as metabolic labeling.34 Specifically, due to its higher 
specificity towards O-GlcNAcylated substrates, quantitative labeling, and lack of need for 
exogenous sugars, it provides enhanced detection sensitivity in a native context. To improve the 
 
 
Fig. 5.3. OGT Interactor and Substrate Identification.  
(a) Silver stain of cell lysates before and after tandem immunoprecipitation protocol. Arrow 
indicates OGTFH. DOX = doxycycline. (b) Validation of identified OGT interactors by 
immunoblotting. (c) Graph of p-values for limma-moderated t-test of SILAC ratios vs p-values 
for inverted beta-binomial test of spectral counts. True OGT interactors (p < 0.05 in either 
tests) are shown in blue. Filled red points represent known OGT interactors from the protein-
protein interaction databases BioGRID and IntAct. (d) Reproducibility of identified OGT 
interactors across three independent experiments. (e) Chemical structure of biotin-Dmpt-
alkyne 1 and cleavage product upon NH2OH treatment. (f) Pie chart of localization 
probabilities for localized sites as calculated by ptmRS. (g) Breakdown of localized sites from 
each fragmentation method (note, all HCD sites were considered unlocalized). (h) Frequency 





compatibility of our well-documented chemoenzymatic labeling techniques with downstream 
analysis by MS,32,35 we developed a new chemically cleavable linker for facile capture-and-release 
of modified targets. The novel linker, biotin-Dmpt-alkyne 1 (Fig. 5.3e), is based on the N,N’-
dimethylpyrimidinetrione (Dmpt) group, which exhibits higher chemical and thermal stability than 
the Dde scaffold used in our previous generation linker (Fig. 5.4). Importantly, the Dmpt group is 
stable under conditions used for trypsin-mediated protein digestion and can be quantitatively 
removed by treatment with dilute solutions of alpha nucleophiles like hydroxylamine, providing a 
versatile tag for targeted enrichment workflows. Once cleaved, the Dmpt group also leaves behind 
 
 
Fig. 5.4. Thermostability of the Second-Generation Dmpt-Based Linker.  
(a) Alkyne-Dde-biotin or alkyne-Dmpt-biotin 1 was reacted with azido-Cy3 and immobilized 
onto high-capacity Neutravidin resin. (b) After overnight incubation in phosphate-buffered 
saline, the dye conjugated to the Dde linker showed leaching into the buffer at higher 
temperatures necessary for tryptic digestion. (c) Both linkers showed efficient release of the 












a relatively small additional mass tag that contains primary amine, which can aid in peptide 
fragmentation through ETD by increasing the peptide charge density.36 Tagged peptides also 
produce signature ions of 300.1 m/z during HCD,32,37 allowing for the rapid identification of O-
GlcNAcylated peptides during MS analysis. 
We applied our state-of-the-art chemoenzymatic labeling and enrichment approach with 
the new biotin-Dmpt-alkyne linker to profile OGT substrates in the transduced HEK-293T cell 
line described previously. In this new workflow, we also take advantage of the unique signature 
ions produced by our biotin-Dmpt-alkyne tag to develop a novel MS method for identification, 
sequencing, and site mapping of O-GlcNAcylated peptides. Specifically, we employ both HCD 
product ion triggered electron-transfer dissociation ETD and EThcD using the 300.1 m/z fragment 
ions from the tag as the trigger. This approach significantly improves overall instrument cycle time 
while maximizing O-GlcNAcylated peptide identifications. Duplicate samples were then 
processed through the labeling and enrichment process, and each were analyzed by both HCD-
triggered ETD and HCD-triggered EThcD. Finally, to map and quantify O-GlcNAc sites, we 
developed a novel bioinformatics workflow to rapidly identify non-redundant, localized “sites” 
versus unlocalized “regions” and calculate the total number of O-GlcNAc sites present in our 
dataset with maximum parsimony (Fig. 5.5). Unlike standard methods for counting PTM sites, this 
approach eliminates the counting of duplicate peptides/sites from missed cleavages or different 
charge states and provides a parsimonious enumeration of O-GlcNAcylation events at the site, 
rather than the modified peptide, level. Moreover, this general analysis is immediately applicable 




and ubiquitination. Together, these validation experiments yielded 1,764 unique O-GlcNAcylated 
sites across 646 proteins with a false discovery rate of 1%. Our methods were also able to produce 
highly efficient peptide fragmentation without loss of the glycan, allowing us to localize the O-
GlcNAc modification to a single Ser/Thr residue for 63% of the sites (Fig. 5.3f). For example, 
strikingly, we found 67 localized sites (74 total) on HCFC1, including 47 that were not previously 









we found that that HCD identified the highest number of O-GlcNAcylated peptides followed by 
EThcD and ETD (all HCD identification were considered unlocalized due to essentially universal 
neutral loss of the glycan) (Fig. 5.3g). Finally, logo generation (Fig. 5.3h) and enrichment analysis 
(Fig. 5.3i) of sites using WebLogo,39 revealed an overall lack of consensus sequence for OGT with 
a slight preference for  proline, valine, and alanine in the -3  through  -1 and +2 positions. O-
GlcNAc sites were also more likely to be in the vicinity of multiple additional S/T residues. 
 
5.5. Functional Networking of OGT Interactors and Substrates. 
With comprehensive lists of interactors and substrates derived from the same biological 
source, we sought to integrate this information to better understand how substrates and interactors 
coordinate to affect cellular function. We obtained known PPIs either between two OGT 
interactors or between an OGT interactor and substrate as annotated in at least one of the PPI 
databases BioGRID or IntAct. An O-GlcNAc functional network with undirected edges defined 
Fig. 5.5. Cont. Sites and Regions Workflow. O-GlcNAc sites are counted until all sites in every 
PSM are explained with max parsimony. O-GlcNAc sites are only localized if the localization 
probability (ptmRS) is greater than what would be expected by chance alone. In the example above, 
there are two proteins, denoted by the red and blue circles, each with two PSMs. In PSM 1 (1 O-
GlcNAc), there is only one site with a localization probability of 1. Thus, 1 site is counted at 
position T3 in the first protein. In PSM 2 (1 O-GlcNAc), there are s sites all with localization 
probabilities less than 0.5. The localization probability is summed over all sites until it is greater 
than 0.5 in aggregate resulting in a single site region in (1, 2, 3, … s). However, this site is not 
counted in the total number of sites as PSM 1 would better explain this single site region. In PSM 3 
(2 O-GlcNAcs), there are s sites, two of which combined have a localization probability greater 
than 1.333. Thus, 2 sites are counted at S1 and T5 in the red protein. Finally, in PSM 4 (3 O-
GlcNAcs), there are s sites, of which no three have a combined localization probability of greater 
than 2.25. Again, the localization probabilities of sites 1 through s are then summed until the 
localization probability in aggregate exceeds 2.25 resulting in a 3 site region in (1, 3, 4, 5, … s).  
However sites S1 and T5 can already be explained by PSM 3 so they are removed from the region 
giving a single site region in (3, 4, … s). In cases where multiple amino acids have the same 
localization probability (e.g. in HCD spectra where the localization probability was set to equal on 





by these PPIs was then visualized with Cytoscape.40 To better identify the individual functional 
cellular networks engaged by O-GlcNAcylation, we employed the community clustering 
algorithm GLay.41,42 This program scores edge betweenness for node groups to extract local 
communities from a larger network. Importantly, this approach is inherently blind to protein 
identity, providing a functionally unbiased approach to network partitioning. Excitingly, Gene 
Ontology (GO)43 biological process (BP) term analysis followed by GO term grouping in 
ClueGO44 of the resulting communities (Fig. 5.6a) revealed five subnetworks enriched for distinct 
cellular functions: 1. (Regulation of) Transcription and Translation, 2. Chromatin Organization 
and Remodeling, 3. Nuclear and Organelle Transport, Cytoskeleton Organization, 4. RNA/DNA 
Synthesis and Metabolism, and 5. Translation and mRNA Splicing.  Hierarchical clustering of all 
significant GO terms from the entire dataset also supported the functional segregation of clusters 
in biological process (Fig. 5.6b), molecular function (Fig. 5.7a), and cellular component (Fig. 
5.7b) space, highlighting the power of GLay clustering to reveal and partition networks of 
functionally and spatially related proteins for further analysis. Interestingly, the interactors 
underlie a much more diverse set of biological functions, and the combined networking approach 
reveals functional and component information that would have been missed by analysis of 
interactors and substrates alone (e.g. in Cluster 3). Finally, the clusters were also highly enriched 
for distinct pathways (Figs. 5.7c-e), again revealing new pathways that would not have been 
discovered in the absence of our combined functional networking approach (e.g. in Clusters 3 and 
4. 
In addition to broad functional roles, the resulting network clusters directly offer protein 




O-GlcNAcylation. First, to find potentially undiscovered OGT adaptor proteins in our network, 
we developed a program to rank OGT interactors, rewarding them with 1 point for their connection 
to substrates and penalizing them 0.5 points for their connection to interactors (to avoid co-
selecting members of large protein complexes), to find the most well-connected single proteins 
(Fig. 5.6c). Interestingly, protein dpy-30 homolog (DPY30) and Set1/Ash2 histone 
methyltransferase complex subunit ASH2 (ASH2L), core components of the Set1/mixed lineage 
 
 





leukemia (MLL) complexes and known molecular scaffolds,45-47 were our top two hits. Many of 
the other top hits are also known molecular scaffolds or adaptors, including histone-arginine 
methyltransferase CARM1 (CARM1) which has previously been suggested to function as an OGT 
adaptor protein.48 Overall, the unique structural insight into the PPI networks associated with OGT 
provided by NOTISE is a key first step towards understanding how OGT might associate with 
molecular adaptors to facilitate its different regulatory roles in different contexts.  
In addition to single proteins, NOTISE also reconstructed multiple, well-characterized 
multi-protein complexes with statistical enrichment of 82 complexes across all clusters (Fig. 5.7f). 
Cluster 2, Chromatin Organization and Remodeling, was itself enriched for 44 complexes and 
almost completely reassembled four OGT-containing complexes: the SET1 histone 
methyltransferase complex,49,50 the polycomb repressive deubiquitinase (PR-DUB) complex,51 the 
nonspecific lethal (NSL) histone acetyltransferase complex,52,53 and the MLL complex (Fig. 5.6d). 
Recent results from other groups have confirmed the regulatory roles of OGT/O-GlcNAcylation 
in SET1-mediated histone methylation,49 NSL-mediated histone acetylation,52 and MLL stability54 
that are implicated by our network analysis. O-GlcNAcylation is also known to coordinate 
Fig. 5.6. Cont. NOTISE in 293T Cells.  
(a) O-GlcNAc functional communities revealed by PPI networking and GLay clustering of OGT 
interactors and substrates. Grey fill indicates OGT interactors and black outline represents OGT 
substrates. Larger red nodes are interactors with an adaptor rank score > 10 (see also (c)). Edges 
opacity and thickness is varies for in-cluster (greater) vs out-of-cluster (less) connections. (b) 
Hierarchical clustering of all significant biological process GO terms in our dataset. Terms are 
color-coded based on the cluster in which their p value was lowest. (c) Proteins that had an adaptor 
rank score of 10 or higher in our network (shown in red in a). (d) A closer view of Cluster 2 
highlighting the almost completely reassembly of the NSL, SET1/COMPASS, PR-DUB, and MLL 
complexes. (e) All proteins annotated with “splicing” in the Uniprot Knowledgebase (almost 
exclusively from Cluster 5) are shown with core components of the spliceosome and other RNA 
processing functions indicated. The red box highlights OGT interactors/substrates previously 
implicated in detained intron removal. PTMs from position 306 to 345 on SF1 are shown, including 






transcriptional repression by the PR-DUB complex in Drosophila, and our results imply that this 
regulatory activity is conserved in mammalian cells.55  
To better understand the functional implications of the proteins and sites present in our 
network, we also integrated data from the Uniprot56 and PhosphositePlus databases into our 
 
 
Fig. 5.7. Hierarchical Clustering of 293T Functional Communities.  
Hierarchical clustering of Molecular Function (a) and Cellular Component (b) GO terms; KEGG 
(c), Reactome (d), and Wiki (e) Pathways; and CORUM complexes (f) reveals distinct roles for 





previously constructed Cytoscape network. This allows for the live interrogation and 
contextualization of a vast knowledge base of protein structure and function, including the ability 
to rapidly find O-GlcNAc sites in various PPI domains (Fig. 5.8a) or overlapping with other known 
PTMs (Fig. 5.8b). Strikingly, we found that roughly 65% of O-GlcNAc sites identified in the 
canonical SwissProt sequences were within 10 amino acids of a phosphorylation site in addition 
to hundreds within 10 amino acids of acetylation, methylation, and ubiquitination sites, indicating 
the interplay between O-GlcNAc and other PTMs is perhaps much more extensive than previously 
realized. As an example of a specific function, we focused on the previously uncharacterized role 
for O-GlcNAcylation in RNA splicing. Excitingly, during the preparation of this manuscript, 
Walker and coworkers identified a novel role for O-GlcNAcylation in regulating global splicing 
of detained introns.57 Here, we find that OGT interacts with and modifies many components of the 
 
 
Fig. 5.8. UniProt and PhosphoSitePlus Integrated Cytoscape Networks Allows for Rapid 
Integration of Site and Protein Features.  
(a) Top domains and regions in which O-GlcNAc sites are found. (b) The number of O-GlcNAc 
sites that are within 10 amino acids or overlapping with annotated PTMs in the PhosphoSitePlus 
databased. PTMVar: PostTranslational Modifications (phosphorylation, ubiquitination, acetylation, 
methylation and succinylation) that overlap with genetic variants associated with diseases and 
genetic polymorphisms. In both cases, data was searched against the Swiss-Prot database to 
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spliceosome,58 including many splicing factors that were differentially phosphorylated in response 
to OGT inhibition (Fig. 5.6e). Given our data, it is also tempting to speculate that OGT may 
modulate detained intron splicing through its interaction with or modification of protein arginine 
N-methyltransferase 5 (PRMT5) and various associated splicing factors, e.g. the highly-connected 
protein serine/arginine-rich splicing factor 5 (SRSF5), known to enhance removal of detained 
introns (red box).59-61 It is also possible that O-GlcNAcylation of core spliceosome components 
regulate detained intron removal by changing their activities or molecular associations. For 
example, we found multiple O-GlcNAcylation sites on splicing factor 1 (SF1) that occur in a nexus 
of diverse PTMs (strongly suggesting a role for O-GlcNAcylation in regulating initial spliceosome 
assembly and function).62 Altogether, the discovery of both established and possible new activities 
of O-GlcNAcylation through network analysis highlights the uniquely powerful capacity of 
NOTISE to generate new hypotheses regarding O-GlcNAc function and to provide a molecular 
foundation for future investigations via the underlying OGT interactors and substrates not possible 
with other high-throughput methods. 
 
5.6. NOTISE-Driven, Selective Disruption of Protein O-GlcNAcylation.  
We next aimed to determine if NOTISE could provide molecular insights into the OGT-
adapter hypothesis and reveal specific regulatory proteins that could be targeted to disrupt O-
GlcNAcylation events. We focused on the PR-DUB complex in Cluster 2 given (1) its extensive 
molecular characterization,51 (2) a role of OGT/O-GlcNAcylation in regulating complex activity 
has not yet been described in mammals, and (3) and the presence of forkhead box protein K1 
(FOXK1) near the top of our adapter rank list. Interestingly, we found that siRNA-mediated 




OGT-protein interactions in the SET1/COMPASS complex (Fig. 5.9a). To understand whether 
specifically disengaging OGT from FOXK1 can modulate its activity towards interacting 
substrates, we interrogated site-specific substrate O-GlcNAcylation in CRISPR/Cas9-generated 
BAP1 KO versus WT 293T cells. Specifically, we developed a novel quantitative O-GlcNAcomics 
workflow using TMT-synchronous precursor selection (SPS)-MS3 for site level quantification of 
O-GlcNAcylation (Fig. 5.10), the first of its kind. Because TMT labeling also modifies the primary 
amine installed on the O-GlcNAc residue after purification with our biotin-Dmpt-alkyne linker, 
we were able to take advantage of three new diagnostic ions at 732.4, 547.3, and 529.3 m/z (Fig. 
 
 
Fig. 5.9. NOTISE Driven Disruption of Protein O-GlcNAcylation.  
(a) Validation of OGT decoupling from PR-DUB complex but not the SET1 complex by specific 
targeting of BAP1 by siRNA knockdown after OGT immunoprecipitation. (b) Venn diagram of 
localized sites identified by ETD and EThD with our novel quantitative MS workflow over n=3 
biological samples. (c) Breakdown of all sites identified by each fragmentation method. (d) 
Significantly changing sites in the 293T PPI network. Interactions between BAP1/FOXK1 and 
other proteins are shown as black edges (with those between proteins with significantly changing 
sites shown thicker). Node boarders are colored based on the average log2 fold change of all O-





5.11) in HCD fragmentation as triggers for both ETD/EThcD and SPS-MS3. Notably, this new 
TMT-SPS-MS3 protocol also saved significant cycle time over standard SPS-MS3 fragmentation 
of all precursor ions. We combined top speed (5 sec) and top 10 data-dependent runs (Fig. 5.12) 
over three biological replicates to identify 1,087 sites (76 percent localized) across 365 unique 
proteins (Appendix 5.1). Importantly, our method allowed us to obtain quantitative information 
 
 
Fig. 5.10. Quantitative O-GlcNAcomics Workflow.  
Precursor ions are fragmented by HCD to reveal tag specific fragment ions at 732.4, 547.3, and 
529.3 m/z. If any of these ions are present in the top 30 most intense fragments, precursors are 
further subjected to SPS-HCD-MS3, ETD, and EThcD. Note ETD and EThcD spectra are acquired 
in the Ion Trap with all MS2 and MS3 HCD spectra acquired in the Orbitrap for optimal acquisition 





for all of these sites. We were also able to track the relative site occupancy on 935 sites across 290 
proteins after normalizing for changes in protein expression (6,485 proteins quantified in total), 
the most protein-expression-corrected sites ever described. Interestingly, in this experiment, where 
every precursor was fragmented by both ETD and EThcD in the same run, we found that there was 
a large, non-overlapping set of localized sites only identified by 
either fragmentation method (Fig. 5.9b), with EThcD having 
only a slight advantage in the number of identified sites (Fig. 
5.9c). 
To identify significantly changing sites, fold-change was 
then averaged across the top speed and top 10 runs, and 
significant differences were determined by limma-moderated t-
test (p < 0.05). In total, there were 86 significantly changing 
sites/regions across 45 proteins, of which 27 were present in our 
previously generated PPI network (Fig. 5.9d). Interestingly, 
 
 
Fig. 5.11. TMT-Labeled Biotin-Dmpt-Alkyne Fragments.  
HCD spectra of ANKRD17 O-GlcNAcylated at T2001. Note the three fragments from the full tag 
oxonium ion (732.3720), the tag after loss of GlcNAc (529.2930) and the water adduct of the later 




Fig. 5.12. Comparison of Sites 
Identified in Top N vs Top 
Speed Trials. Overlap between 
sites identified in the top 10 
(n=2) versus the top speed (5 






although FOXK1 O-GlcANcylation remained unchanged, we found a striking decrease on in 
S1031 O-GlcNAcylation on the BAP1 interactor putative polycomb group protein ASXL3 
(ASXL3). In our network, BAP1 is the only interactor with ASXL3 in the PR-DUB protein 
complex, suggesting that BAP1 may be serving as an adaptor protein between OGT and ASXL3. 
However, unfortunately, we did not quantify ASXL3 protein expression, so we are not able to rule 
out confounding changes in ASXL3 expression. Surprisingly, we also found an increase in S1820 
O-GlcNAcylation on BAP1 interactor ankyrin repeat domain-containing protein 17 (ANKRD17) 
and both an increase and decrease on BAP1/FOXK1 interactor HCFC1 (in both of these cases we 
were able to quantify protein expression).  
Throughout the network, we also found both increases and decreases in relative site 
occupancy on proteins that were relatively close to BAP1/FOXK1, including another example of 
both up and downregulated O-GlcNAcylation on nuclear pore complex protein Nup153 
(NUP153). This suggests that BAP1 may not only be targeting OGT to various proteins, but also 
blocking access to certain sites potentially through interaction with either OGT or the target 
protein, a potentially unrecognized nuance of the adapter protein hypothesis (Fig. 5.9e). Overall, 
these studies represent the first successful attempt to modulate the O-GlcNAcylation on specific 
proteins at specific sites through disruption OGT-protein interactions. Moreover, our powerful 
new MS workflow is the first to quantify site-specific changes in O-GlcNAcylation on the same 
peptide (e.g. sites 1238-43 on HCFC1). Taken together, these studies provide the first tools to site-
specifically modulate and monitor O-GlcNAcylation, and, as new technologies emerge to 
specifically inhibit protein-protein interactions, lay the ground work for future targeting of specific 






5.7. Defining Conserved and Tissue-Specific O-
GlcNAc Regulatory Networks In Vivo. 
We next aimed to expand our method to the 
study of O-GlcNAcylation networks in vivo. To 
achieve this goal, we first generated a novel mouse 
model using CRISPR/Cas9 technology in which 
FLAG and HA tags were inserted at the C-terminus 
of the endogenous OGT gene (OGT-FH, Fig. 5.13, 
Fig. 5.14a). To ensure that the dual tags did not affect protein expression levels, we used Western 
blotting to confirm equivalent expression levels of tagged and untagged OGT in the major organs 
of both OGT-FH and WT adult mice (Fig. 5.14b). Moreover, the tagged OGT mouse line exhibited 
no obvious phenotypes through development to adulthood, and inheritance of the tagged OGT 
gene followed a normal Mendelian distribution (chi-square test, P > 0.5, Fig. 5.15).  
Using our OGT-FH mouse model, OGT interacting partners were immunoprecipitated 
from the brains and livers of two-month-old animals by adapting our previously described 
workflow. Briefly, after tandem affinity purification, digested peptides of OGT interactors from 
each organ and control organs from age-matched C57BL/6J mice were subjected to reductive 
amination with isotopically defined formaldehyde in lieu of SILAC labeling prior to mixing and 
downstream mass spectrometric analysis (Fig. S12). Using the same analysis pipeline as for 293T 
cells, we found 993 and 643 high-confidence interactors (Appendices 5.2 and 5.3) and 2,219 and 
1,150 O-GlcNAc sites (Appendices 5.4 and 5.5) across 810 and 492 proteins in the brain and liver, 
respectively. In total, we found 2,785 unique O-GlcNAc sites (62% localized) across both datasets, 
 
Fig. 5.13. OGT-FH Mouse Genotyping. 
Facile genotyping of the OGTFH mouse 
line was achieved by genomic 
amplification of the C-terminal region of 
OGT followed by digestion with BamHI, 
which cleaves genomic DNA amplicons 








significantly updating our understanding of the O-GlcNAcome and by far the most ever described. 
Interestingly, although the overlap between substrates was relatively consistent with that of the 
overall proteome,63 the overlap between interactors was much more distinct (Fig. 5.14c), 
suggesting that the tissue specific roles of OGT may be driven by differences in OGT-protein 
interactions. As with 293T cells, we also built Uniprot/PhosphoSitePlus integrated Cytoscape files 
and enumerated the most common domains found in both the interactors and substrates (Fig. 
5.14d). Interestingly, the PDZ domain, a well-known mediator of PPIs, was near the top of those 
domains found in brain interactors as well as those found in both brain and liver substrates. PDZ 
 
 
Fig. 5.14. In Vivo NOTISE Reveals both Tissue-Specific and Conserved Functions for O-
GlcNAc in the Mouse Brain and Liver.  
(a) CRISPR/Cas9-mediated genome editing for expressing tagged OGT in vivo. (b) Western blot 
profiling of OGT expression between various organs of wild-type and OGTFH mice. (c) Overlap 
between all substrates, interactors, and the full proteomes in the brain and liver. (d) The top 
domains identified in substrates in the liver and brain. (e) Site-level overlap between the brain and 
the liver. (f) Number of O-GlcNAcylation sites within 10 amino acids of other PTM sites as 
annotated in the PhosphoSitePlus database. (g) Hierarchical clustering of individual functional 
communities in the liver shows relatively distinct partitioning of functions into individual clusters. 
Terms are color-coded based on the cluster in which their p value was lowest. (h) Hierarchical 
clustering of individual functional communities in the brain as in (g). (i) Hierarchical clustering of 
all biological process GO terms in the combined brain and liver dataset. Note the distinct clusters 
for liver-specific, brain-specific, and shared function (indicated left). Terms are color coded as in 






domains are essential for organizing synaptic architecture,64 
and our data suggest that OGT interactions/O-
GlcNAcylation may be playing an important role in 
regulating these domains. Thus, it is tempting to speculate 
that the well-established effects of modulating O-
GlcNAcylation on LTP and LTD may also be mediated in 
part through altering the assembly and organization of the 
pre-/postsynaptic signaling.10,65 We also calculated the site-
level overlap between the brain and liver (Fig. 5.14e) and 
again identified numerous sites within 10 amino acids of 
other PTMs, including those known to have a regulatory or 
disease modifying role (Fig. 5.14f). 
We then employed our PPI networking strategy and GLay clustering to construct brain and 
liver networks. Again, we found that individual clusters had relatively distinct functions for both 
the liver (Fig. 5.14g) and brain (Fig. 5.14h). We also performed hierarchical clustering on all 
biological process GO terms and found clear evidence of both conserved and brain-/liver-specific 
functions that were relatively separate by cluster in each organ (Fig. 5.14i). As with 293T cells, 
we also found distinct differences in molecular function, cellular component, complex, pathway, 
and human phenotype space (Fig. 5.16). Notably, this is the first systems-level evidence that O-
GlcNAcylation has tissue-specific functions. Overall, NOTISE revealed eight functional 
communities in the brain and seven in the liver (Fig. 5.17a), enriched for a variety of processes 
from nervous system development to metabolism. Key processes that were shared between the 
tissues were chromatin organization, RNA processing, and cytoskeletal organization/dynamics. 
 
 
Fig. 5.15. Chi-square Analysis 
of OGTFH Gene Heritability. 
Offspring numbers for (a) XFHY x 
XWTXFH or (b) XWTY x XWTXFH 
crossings are presented as Punnett 
squares with chi-square (χ2), 





Interestingly, these processes are also shared with 293T cells, suggesting that they may represent 
more of a core, conserved subset of OGT functions. Finally, there was only 26% overlap between 
 
Fig. 5.16. Hierarchical Clustering of Brain and Liver Gene Ontologies, Pathways, and Protein 





the proteins in both networks, further suggesting that differences in the roles of OGT between the 
tissues goes beyond the differences in their proteomes.  
As in 293T cells, we also used our adaptor rank program to find candidate OGT adaptor 
proteins (Fig. 5.17b). Here, RNA binding protein fox-1 homolog 1 (Rbfox1), a multifunctional 
proteins with molecular adaptor activity involved in alternative splicing, autism, and epilepsy was 
our top hit in the brain.66 In the liver, 14-3-3 protein eta (Ywhah), a known adaptor protein and 
potential O-GlcNAc “reader” protein,67 was far and away the top hit, further suggesting an 
important role for the interplay between phosphorylation and O-GlcNAcylation in the mammalian 
liver. Other proteins in these lists have known molecular adaptor activity and are involved in the 
assembly of the post synaptic density, e.g. disks large homolog 1 (Dlg1),68 and nuclear import, e.g. 
importin subunit alpha-5 (Kpna1).69 
Interestingly, actin dynamics appeared to be a common and, to our knowledge, as yet 
unrecognized function of OGT/O-GlcNAc in the liver and brain. Closer examination of the B5. 
Actin Cytoskeleton Organization and B4. Nervous System Development, Cell Signaling functional 
communities revealed multiple actin binding proteins and effectors including the complete Arp2/3 
and WAVE regulatory complexes (WRC). A closer look at these complexes and associated 
proteins (Fig. 6c) revealed potential regulatory O-GlcNAcylation sites on neural Wiskott-Aldrich 
syndrome protein (Wasl), several members of the WAVE regulatory complex, and protein enabled 
homolog (Enah). For example, Wasl O-GlcNAcylation is positioned to close to the basic (B) and 
GTPase protein binding (GBD) domains, which could potentially disrupt auto-inhibition or 
Fig. 5.16. Cont. Hierarchical Clustering of Brain and Liver Gene Ontologies, Pathways, and 
Protein Databases.  
Hierarchical clustering of Molecular Function (a) and Cellular Component (b) GO terms; KEGG 
(c), Reactome (d), and Wiki (e) Pathways, CORUM complexes (f), and Human Phenotype 






effector binding.70 The closely related protein and member of the WRC, Wiskott-Aldrich 
syndrome protein family member 1 (Wasf1) was also O-GlcNAcylated in the same region. 
 
 
Fig. 5.17. NOTISE Enables Mechanistic Insights into the Tissue-Specific and Conserved 





Although the Wasf1 inhibition is based on its interactions with other proteins in the WRC,71 it is 
also possible that Wasf1 O-GlcANcylation or O-GlcNAcylation of other proteins in this complex 
could disrupt complex association and (de)activation or effector binding.72,73 Specifically, we 
mapped two O-GlcNAc sites to the C-terminal domain of cytoplasmic FMR1-interacting protein 
2 (Cyfip2), a key region for its interaction with Nck-associated protein 1 (Nckap1), and synaptic 
functional regulator FMR1 (Fmr1), a key RNA binding protein known to associated with upwards  
of 4% of neuronal mRNAs.71,74,75 We also found extensive O-GlcNAcylation on known actin 
scaffolding proteins, actin-binding LIM proteins 1-3 (Ablim1-3), and adducin proteins (Add1-3), 
which play important roles in maintaining the cellular cortex as well as in spine development and 
maintenance and neurite outgrowth.76-78 On Enah, we found multiple O-GlcNAc sites in close 
Fig. 5.17. Cont. NOTISE Enables Mechanistic Insights into the Tissue-Specific and Conserved 
Functions of OGT in the Liver and Brain. (a) O-GlcNAc functional communities revealed by PPI 
networking and GLay clustering of OGT interactors and substrates in the liver and brain. Cluster 
name colors represent those displayed in Figs 5g, 5h, and 5i. Filled nodes (teal for the brain and grey 
for the liver) indicate OGT interactors while a black outline represents OGT substrates. Larger pink 
nodes are interactors with an adaptor rank score > 10 (see also b). Venn diagram represents the 
overlap of all proteins in each network. (b) Proteins with an adaptor rank score >10 in the brain and 
liver. (c) NOTISE provides extensive mechanistic insight into the potential roles of OGT in actin 
dynamics. Interactions between proteins (lighter) and complexes (darker) are indicated by grey lines. 
WH1: WASP homology 1 domain; B: basic domain; GBD: GTPase protein binding; EVH2: 
Ena/Vasp homology domain 1/2; VCA: Verprolin, cofilin, acidic domain; SH3: SRC Homology 3 
Domain; WW: WWP repeating motif. (d) All primary interactors of Abi2 identified by NOTISE. (e) 
Subset of proteins involved in presynaptic vesicle exocytosis (from clusters B9 and B4). Note every 
member of the liprin-α family of proteins is present. (f) Chemoenzymatic labeling, streptavidin 
capture, and liprin-α1 immunoblotting identifies dynamic O-GlcNAcylation in response to KCl-
mediated depolarization and TMG treatment in mouse primary cortical neurons. (g) Quantification 
of the data in f over n=5 or n=4 trials for KCl and TMG treatment, respectively. *p < 0.05 by paired 
Student’s t-test and Holm-Bonferroni correction. (h) Liprin-α1 co-immunoprecipitates with OGT in 
OGT-FH mouse primary cortical neurons under both resting and stimulated conditions. (i) 
Interrogation of the brain network reveals multiple proteins (and their interrelationships) involved 
with learning, memory, and LTP. (j) Multiple pathways, functions, and memberships in multiprotein 
complexes can be rapidly mapped on to the networks provide unique insights into network 
structure/function, as shown here for the liver network. Note also the blue actin binding cluster also 






proximity to important regulatory phosphorylation sites, including that of PKA at S255,79 and in 
the proline-rich domain, a known mediator of PPIs important for actin dynamics.80,81 Finally, Abi2 
also looks well positioned as a key intermediary between OGT and multiple proteins involved in 
actin dynamics, synaptic spine formation, and neuronal signaling (Fig. 5.17d).  
In addition to the potentially novel role of OGT in regulating actin dynamics, we were also 
intrigued by the many proteins involved in synaptic vesicle exocytosis. Global changes in O-
GlcNAcylation have long been known to affect synaptic vesicle exocytosis,82 and indeed previous 
experiments have identified numerous presynaptic proteins that are O-GlcNAcylated.83 However, 
a clear mechanism for how O-GlcNAcylation is involved in this process has yet to be uncovered. 
Here we find every member of the liprin-α family of proteins is O-GlcNAcylated and tightly linked 
with multiple other proteins that regulate presynaptic function (a subset from clusters B9 and B4 
is shown in Fig. 5.17e).84 We sought to confirm whether the most well-studied member of the 
liprin-α family, liprin-α1 (Ppfia1) was dynamically O-GlcNAcylated in response to neuronal 
activity (suggesting a regulatory role for this modification). Indeed, using our well-established 
chemoenzymatic labeling assay,33 we found this modification to be dynamic to both KCl-mediated 
depolarization and TMG treatment of cortical neurons, indicating that this site dynamically cycles 
in response to stimuli (Figs. 5.17f and 5.17g). Interestingly, we also mapped the site to between 
amino acids 1233 and 1240, the C-terminal PDZ binding domain and an area where O-
GlcNAcylation would likely block key binding events with glutamate receptor-interacting protein 
1.85 Combined with the abundance of PDZ domains identified in OGT interactors and substrates 
(Fig. 5.14d), it is again tempting to speculate that O-GlcNAcylation may play an important role in 




we validate that Ppfia1 is indeed in OGT interactor in primary mouse cortical neurons, an 
experiment enabled by the generation of our novel tagged OGT mouse line (Fig. 5.17h). 
Taken together, the two examples above only begin to scratch the surface of the powerful 
ability of NOTISE to reveal and outline hypotheses for the role of OGT in organ and cell-specific 
functions. In fact, NOTISE, along with our Uniprot/PhosphoSitePlus integrated tables, allows for 
rapid identification the key protein players, and their interrelationships, behind functions, 
pathways, etc. in isolation (e.g. learning, memory, and LTP in the brain, Fig. 5.17i) or altogether 
(e.g. in the liver network, Fig. 5.17j) regulated by OGT substrates and interactors. These data will 




We have developed a new systems-level approach to annotate the multiple functions of O-
GlcNAc regulation in a given biological system by networking of O-GlcNAc transferase 
interactors and substrates (NOTISE). In contrast to current state-of-the-art approaches, the 
NOTISE method provides several new insights into the functional coordination of O-
GlcNAcylation. First, our method integrates both possible upstream regulators and downstream 
effectors of OGT activity, providing a simultaneous, integrated analysis of protein O-
GlcNAcylation across the proteome. The development of robust biological model systems, 
chemical tools, and enrichment and detection methods to, for the first time, obtain these 
comprehensive datasets provides a systematic process to integrate biological context-specific 




vivo biospecimens, which is not currently possible from existing datasets collected from disparate 
sample types or biological contexts.  
By organizing these datasets into networks and partitioning the data into district functional 
communities, NOTISE not only rapidly provides functional information, but also lays the 
groundwork for in-depth followup studies by revealing the PPI networks and modification sites 
that are most likely to be involved. As an initial proof-of-principle, our unbiased method 
recapitulated numerous instances of O-GlcNAc regulation that have previously been demonstrated 
in the literature including histone modification,49,52 intracellular transport,86 transcription and 
translation,6,87 synaptic vesicle exocytosis,65,82 and carbohydrate metabolism,7 validating that our 
approach readily uncovers critical pathways of O-GlcNAc activity. Moreover, by utilizing the 
molecular-level data provided by approach, NOTISE also provided a systematic and unbiased 
approach for untangling the molecular mechanisms behind these functions, something that has 
long eluded researchers in the field given the complexity of OGT regulation. It is our hope that the 
vast array of new functions, substrates and their sites, interactors, and their molecular relationships 
provided herein will spur numerous productive investigations throughout the biological sciences.  
Additionally, our results provide key insights into the adaptor protein hypothesis, showing 
the potential for interacting proteins to both facilitate and block O-GlcNAcylation on their 
interacting partners. The novel quantitative MS methods developed herein are also the first to 
demonstrate and quantify site-specific changes in O-GlcNAcylation on the same peptide and 
increase the scope of protein-expression-corrected, site-specific O-GlcNAc quantification by a 
factor of five. These powerful, new quantitative O-GlcNAcomics techniques have finally enabled 
the long-standing goal of interrogating truly site-specific O-GlcNAcylation dynamics in response 




comparison of conserved and tissue-specific of O-GlcNAc functions between the adult brain and 
liver. 
 In total, NOTISE provides a strong foundation for new studies to interrogate the activity 
of PTMs both in vitro and in vivo. As numerous other enrichment methods for other PTMs have 
been developed, our method could rapidly be generalized to other proteoform states. Although the 
current approach relies upon existing PPI databases, the advent of new, global interactome 
datasets, especially in the mouse, will undoubtedly improve both node connectivity within our 
network and resulting functional annotation. By applying the tools and methods developed herein, 
we envision that global analyses of upstream PTM regulators and downstream effectors could be 
rapidly generated for diverse biological contexts across individual tissues, developmental stages, 
and disease progression. Therefore, we believe that our approach towards the global functional 
annotation of PTMs will accelerate our current understanding of protein regulation and broaden 
our interrogation of coordinated PTM activities across the proteome well beyond the scope of 
current studies. 
 
5.9. Experimental Methods. 
 
5.9.1. Cell Culture Conditions. 
The parental HEK-293T was obtained from American Type Culture Collection (Manassas, 
VA). All cell culture reagents were purchased from ThermoFisher Scientific (Waltham, MA) 
unless otherwise indicated. All cell lines were cultured in DMEM supplemented with high glucose, 
GlutaMAX, 10% fetal bovine serum (PBS), and 1x penicillin–streptomycin (P/S) (complete 




SILAC medium. SILAC medium was produced using SILAC DMEM Flex media supplemented 
with high glucose, GlutaMAX, 10% dialyzed FBS, 1x P/S and either 0.80 mM L-lysine and 0.40 
mM L-arginine (MilliporeSigma, St. Louis, MO; light; K0, R0) or 0.80 mM [U-13C6,15N2] L-lysine 
and 0.40 mM [U-13C6] L-arginine (Cambridge Isotope Laboratories, Tewksbury, MA; heavy; K8, 
R6).  
 
5.9.2. Lentiviral Plasmid Construction. 
Primers were purchased from Integrated DNA Technologies (Coralville, IA). All 
molecular biology supplies were purchased from New England Biolabs (Ipswich, MA) unless 
otherwise indicated. The OGT lentiviral vector was produced by first producing OGT with C-
terminal FLAG and HA tags in the pCMV6 backbone (Origene, Rockville, MD) using the 
NEBuilder HiFi DNA assembly and Q5 site-directed mutagenesis kits according to the 
manufacturer’s protocols. Both the tagged form of OGT (OGTFH) and pTRIPZ vector were 
linearized by amplification using the Q5 Hot Start High-Fidelity 2x master mix. Fragments were 
gel purified using the Zymoclean gel DNA recovery kit (Zymo Research, Irvine, CA) and 
assembled with the NEBuilder HiFi DNA assembly kit according to the manufacturer’s protocol. 
The ligated plasmid was transformed into Stable Competent E. Coli (New England Biolabs), and 
colonies were picked and sequenced (Laragen, Culver City, CA) to ensure proper incorporation 
and no recombination. Bacterial cultures were stored as glycerol stocks (50%) at -80 °C, and 
maxiprep cultures (100 mL) of the plasmid-expressing bacteria were grown and purified by 
ZymoPure plasmid kits (Zymo Research). Each purification of pTRIPZ-OGTFH was resolved by 





5.9.3. Cell Line Generation. 
Transfection and cell culture reagents were purchased from ThermoFisher Scientific unless 
otherwise indicated. The lentiviral packaging plasmids pMD2.G and psPAX2 (Didier Trono; 
12259, 12260) were obtained from Addgene (Cambridge, MA). Four 15-cm culture plates 
containing HEK-293T cells at 80% confluency were transfected with 8 μg pTRIPZ-OGTFH, 6 μg 
psPAX2, and 2 μg pMD2.G using Lipofectamine 3000 at a 2:1 lipid/DNA ratio according to the 
manufacturer’s protocol in OptiMEM. The medium was replaced at 6 h post-transfection with 
complete DMEM containing only 2% FBS. Medium was harvested at 48 h and 72 h post-
transfection, and lentiviral particles were concentrated using 15-mL 100 kDa MWCO Amicon 
concentrator tubes (MilliporeSigma). Lentiviral concentrate was used immediately. To a six-well 
plate containing HEK-293T cells at 80% confluency in complete DMEM containing 8 μg/mL 
hexadimethrine bromide (MilliporeSigma), 0-50 μL lentiviral concentrate was added. Medium 
was replaced with complete DMEM after 24 h. After 48 h, cells were passaged 1:4 into new six-
well plates with complete DMEM containing 2 μg/mL puromycin. After selection for two weeks, 
cells treated with the least amount of lentiviral supernatant that survived were then split for clonal 
dilution. After 2-3 weeks, single clones were isolated and expanded. Clones were then tested for 
induction of OGTFH expression by incubating with complete DMEM containing 0.1 μg/mL 
doxycycline hyclate (MilliporeSigma) for 24 h followed by Western blotting. A single clone for 
the HEK-293T-iOGTFH cell line was chosen and used for subsequent experiments. 
 
5.9.4. Mouse Line Generation and Genotyping. 
All mouse procedures were performed in accordance to protocols approved and guidelines 




Jackson Laboratory (Bar Harbor, ME) or Charles River (Wilmington, MA). The OGTFH mouse 
model was generated and maintained with a C57BL/6 mice background. sgRNA candidates were 
designed using the CRISPR design (www.genome-engineering.org) and CHOPCHOP programs 
(chopchop.cbu.uib.no). Genomic DNA isolated from the tail tip of a wild-type C57BL/6J mouse 
using the DNEasy Blood and Tissue Kit (Qiagen, Hilden, Germany). The genomic C-terminal 
region of OGT was amplified using the Q5 Hot Start High Fidelity 2x master mix (New England 
Biolabs). The pCAG-EGxxFP plasmid (Addgene, Masahito Ikawa; 50716) was cut with BamHI 
and SalI, and the construct was assembled using the NEBuilder HiFi Assembly kit. sgRNA 
candidates were cloned into the pX330 plasmid (Addgene, Feng Zhang; 42230) according to the 
published protocol. The two plasmids were then transfected into HEK-293T cells at 80% 
confluency in a six-well plate using Lipofectamine 3000 at a 2:1 lipid/DNA ratio according to the 
manufacturer’s protocol. After 48 h, cells were observed using an LSM 710 confocal microscope 
(Carl Zeiss AG, Oberkochen, Germany) for GFP+ cells, indicating active sgRNA. The most active 
sgRNA found within 20 bp of the OGT stop codon was chosen for in vivo genomic editing (5’-
CCTGAATAAAGACTGCGCAC-3’).  
The sgRNA was amplified from the pX330 plasmid and then transcribed and purified using 
the MEGAshortscript T7 transcription and clean-up kits (ThermoFisher Scientific), respectively. 
For homology-directed recombination, a single stranded oligodeoxynucleotide (ssODN) was 
synthesized as an Ultrimer oligonucleotide by Integrated DNA Technology containing an MluI cut 
site, FLAG tag, BamHI cut site, HA tag, and OGT stop codon flanked on either side by 60 
nucleotides homologous to the genomic region surrounding the insertion site. The protospacer 





Zygotes from C57BL/6N mice from Charles River were produced, collected, cultured, and 
implanted as previously described.88 Microinjection of embryos was performed using an inverted 
microscope (Carl Zeiss AG) equipped with a micromanipulator (Leica Microsystems, Wetzlar, 
Germany), CellTram (Eppendorf, Hamburg, Germany), and FemtoJet (Eppendorf). Injections 
were carried out as previously described.89 Solutions containing 2.5 ng/μL sgRNA, 10 ng/μL 
ssODN, and 5 ng/μL Cas9 mRNA (System Biosciences, Palo Alto, CA) in 10 mM Tris-HCl pH 
8.0, 0.1 mM EDTA were used for injection into the pronucleus of fertilized mouse zygotes. 
Following injection, the zygotes were cultured to the two-cell stage and implanted into 
pseudopregnant foster mothers at 0.5 days post coitum (up to 30 two-cell embryos per recipient). 
Approximately 19.5 days after implantation, the pups were delivered, and 3 weeks after birth the 
pups were tailed and separated by gender. Offspring were genotyped by restriction enzyme 
digestion using BamHI after purification of the genomic DNA from tail tips using the DNEasy 
Blood and Tissue kit and amplification of the genomic C-terminal region of OGT. A single 
heterozygous female was obtained containing the correct on-target inserted sequence. The line was 
then backcrossed for at least three generations with the C57BL/6J strain prior to experiments. 
Subsequent homozygous mice obtained from this founder exhibited no abnormalities in growth, 
behavior, or breeding and were indistinguishable from wild-type and heterozygous mice. 
 
5.9.5. siRNA Knockdown. 
The BAP1 RNA knockdown was performed with a set of 3 unique 27mer siRNA duplexes 
targeting BAP1 (Origene, SR305435) using siTrans 1.0 (Origene). Briefly, cells in six-well plates 
at 70% confluency were transfected with 20 nmol siRNA mixture according to the manufacturer’s 




above. Knockdown was validated by Western blotting. Co-immunoprecipitation experiments were 
carried out as described below for TAP-MS sample preparation. 
 
5.9.6. CRISPR/Cas9-Mediated KO of BAP1. 
BAP1 CRISPR/Cas9 KO Plasmid (h) (sc-400232 ), BAP1 HDR Plasmid (h) (sc- 400232-
HDR), and Control CRISPR/Cas9 Plasmid (sc-418922) were purchased from Santa Cruz 
Biotechnology and prepared per the manufacturer’s instructions. 293T cells at ~60-70% 
confluency (maintained as described above) in a 12-well tissue culture plate before were then 
transfected with 1 ug of BAP1 KO/HDR or control plasmid using Lipofectamine 3000 
(ThermoFisher Scientific) at a 2:1 lipid/DNA ratio according to the manufacturer’s protocol in 
OptiMEM. Once confluent, the cells were split 1:1 into media containing 10 μg/mL puromycin 
(ThermoFisher Scientific) or normal media for the control. Cells were then selected for 2 weeks 
replacing the media or splitting as necessary. BAP1 KO was confirmed by Western blotting (Fig. 
5.18) before splitting the KO and WT cells into three 10 cm plates which were grown to 
confluency, lysed as described below, and subjected to chemoenzymatic labeling and enrichment 
as described below. 100 μg of lysate from each condition was also saved for quantitative 
proteomics. 
 
5.9.7. Cell Lysate Preparation. 
To prepare HEK-293T cell lysate 
for immunoprecipitation or Western 
blotting, two 15-cm plates of heavy-labeled 
HEK-293T-iOGTFH cells at 60% 
 
Fig. 5.18. BAP1 KO in 293T Cells.  
Transfection of BAP1-targeting gRNA, Cas9, and a 
homology directed repair template conferring 
puromycin resistance shows efficient KO after 2 
weeks of puromycin selection compared to 
transfection with off-target control gRNA. 
WB: BAP1
WB: α-tubulin




confluency were treated with freshly made 0.04 μg/mL doxycycline hyclate for 24 h. As a control, 
light-labeled HEK-293T-iOGTFH cells were left untreated. The cells were collected with a scraper 
and homogenized on ice in 10 mL of 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% NP-40, 1x 
cOmplete EDTA-free protease inhibitor cocktail (Roche, Basel, Switzerland) using 30-40 strokes 
with a 20-mL Potter-Elvehjem tissue grinder (Wheaton, Millville, NJ) followed by centrifugation 
at 15,000 g for 10 min at 4 ºC. The protein concentration of the clarified supernatant was measured 
using the Pierce BCA Protein Assay Kit (ThermoFisher Scientific).  
 To prepare HEK-293T cell lysate for chemoenzymatic labeling, two 15-cm plates of HEK-
293T-iOGTFH cells at 60% confluency were lysed in 5 mL of 1% SDS, 50 mM Tris-HCl pH 7.4, 
150 mM NaCl, 1x cOmplete EDTA-free protease inhibitor cocktail, 10 μM Thiamet-G 
(MilliporeSigma) and probe sonicated to shear DNA. The protein concentration was measured as 
described above. 
 
5.9.8. Affinity Purification from 293T Cells. 
For each replicate, approximately 15 mg cell lysate from heavy- and light-labeled cells were 
subjected to immunoprecipitation with 200 μL settled volume of ANTI-FLAG M2 Affinity 
Agarose Gel (MilliporeSigma) overnight at 4 ºC. The beads were washed 3 x 5 min in wash buffer 
(50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% NP-40) and eluted with 150 μg/mL 3xFLAG 
peptide (MilliporeSigma) in wash buffer, followed by immunoprecipitation with 100 μL settled 
volume of anti-HA agarose beads (ThermoFisher Scientific) for 6 h at 4 ºC. The beads were washed 
with wash buffer and eluted with 3 M NaSCN. The eluates were acetone precipitated, re-dissolved 
in 1x SDS loading buffer (50 mM Tris-Cl pH 6.8, 100 mM dithiothreitol (DTT), 2% SDS, 0.1% 




The eluates from heavy- and light-labeled samples were mixed immediately before loading 
onto a NuPAGE 4-12% Bis-Tris protein gel (ThermoFisher Scientific). The gel was stained and 
visualized using Imperial protein staining reagent (ThermoFisher Scientific) and destained in 
doubly deionized H2O (ddH2O). The gel lane was cut into 30-40 gel slices. Each gel piece was 
reduced with 10 mM DTT (MilliporeSigma) for 1 h at 37 ºC and then alkylated with 50 mM 
iodoacetamide (MilliporeSigma) for 45 min at room temperature protected from light. The slices 
were dried and incubated with 20 ng/uL Pierce trypsin protease (ThermoFisher Scientific) solution 
in 100 mM NH4HCO3 (pH 8.0) with 1 mM CaCl2 overnight at 37 ºC. The peptides were recovered 
using sequential washes with 100 mM NH4HCO3, 1:1 v/v 100 mM NH4HCO3/CH3CN, and 5% 
formic acid. The recovered peptides were dried and desalted with a C18 ZipTip pipette tip 
(MilliporeSigma). The desalted peptides were resuspended in 0.2% formic acid for LC-MS/MS 
analysis. 
 
5.9.9. Affinity Purification from Brain and Liver Tissue. 
To prepare brain and liver tissue lysate, 2-month old OGTFH and WT mouse forebrains 
and livers were freshly dissected and rinsed with ice cold phosphate-buffered saline. One 
hemisphere or lobe was used per experiment. Lysate from each of OGT-FH and WT organs was 
harvested and homogenized on ice in 10 mL of 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% NP-
40, 1x cOmplete EDTA-free protease inhibitor cocktail using 30-40 strokes with a Potter-Elvehjem 
homogenizer followed by centrifugation at 15,000 g for 10 min at 4 ºC. Lysates from each mouse 
(15 mg) were subjected to immunoprecipitation using the same procedure outlined above followed 




The eluates were loaded onto 0.5 mL 10 kDa MWCO Amicon Ultra centrifugal filters 
(MilliporeSigma) and buffer exchanged into 100 mM TEAB pH 8.5 (MilliporeSigma). The 
samples were then reduced with 10 mM DTT for 1 h at 37 ºC and alkylated with 50 mM 
iodoacetamide for 45 min at room temperature protected from light. The proteins were digested 
with 50 ng/μL trypsin in 100 mM TEAB at 37 ºC overnight. The resulting peptides were recovered 
by washing the centrifugal filter with 100 mM TEAB three times for a final volume of 100 uL. To 
each peptide mixture, 4 uL of 4% v/v CH2O (WT) or CD2O (OGTFH) was added followed by 4 
uL of 0.6 M NaBH3CN. Samples were rotated end-over-end for 1 h at RT and then quenched with 
16 uL of 1% v/v NH3 followed by 8 uL formic acid. The differentially labeled samples from OGT-
FH and WT mice were mixed and desalted by an Agilent 1100 Series HPLC system with a 
MicroTrap Cartridge (Michrom, 1x8 mm internal dimension, 5.0 μL bed volume, 20μg capacity, 
1-1000 μL sample volume). Solvent A consisted of 99.8% H2O and 0.2% formic acid and solvent 
B consisted of 99.8% ACN, and 0.2% formic acid. The gradient was as follows: 0% Solvent B (10 
min), 0-85% Solvent B (2 min), 85% Solvent B (5 min), 85-90% B (1 min), 90% B (5 min), 90-
100% B (1 min), and 100% B (6 min). Eluted peptide fractions were collected in 1 mL fractions, 
lyophilized, and resuspended in 0.2% formic acid for LC-MS/MS analysis.  
 
5.9.10. Chemical Synthesis of Biotin-Dmpt-Alkyne 1. 
Unless otherwise indicated, all chemical reagents were obtained from MilliporeSigma and 
used as provided. Reactions were performed in flame-dried glassware under Ar using freshly dried 
solvents passaged through an activated alumina column under Ar. Preparative HPLC was 
conducted using a 1260 Infinity II LC system (Agilent) with a custom Zorbax Eclipse XDB-C18 




Formic acid over 70-85 min with a flow rate of 6 mL/min. 1H and 13C NMR experiments were 
recorded on a Bruker 400 spectrometer at the Caltech NMR facility. Spectra are reported in parts 
per million (δ) relative to CDCl3 (7.26 ppm). Data are reported as chemical shift (ppm), 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet, b = broad), 
coupling constant (Hz), and integration. Mass spectra were obtained using a Waters LCT Premier 




1,3-dimethylpyrimidine-2,4,6-trione (Biotin-Dmpt-OH, 2).  
 Biotin-PEG4-CO2H (BroadPharm, 400 mg, 0.814 mmol) and N,N’-dimethylbarbituric acid 
(164.8 mg, 1.3 eq) were suspended in 10 mL of dry DCM under Ar and cooled to 0 °C. Separately, 
EDC·HCl (202.7 mg, 1.3 eq), DMAP (9.9 mg, 0.1 eq), and TEA (170.1 μL, 1.5 eq) were dissolved 
in 5 mL of dry DCM. The coupling solution was added to the suspension dropwise. The reaction 
was allowed to warm to RT and stirred overnight. The solution was then concentrated to a yellow 
oil and redissolved in a minimal volume of 5% aq. MeCN. The product was then purified by 
preparative HPLC. Fractions were combined, concentrated, and lyophilized to afford the product 
as a light yellow powder (468.9 mg, 92% yield). 1H NMR (500 MHz, CDCl3): δ 7.33 (bs, 0.2H, 
OH), 6.73 (bt, J = 5.4 Hz, 0.8H, OH), 6.28 (s, 1H, NH), 5.43 (s, 1H, NH), 4.51 (t, J = 6.5 Hz, 1H, 
biotin-CH), 4.32 (dd, J = 7.6, 4.5 Hz, 1H, biotin-CH), 3.86 (t, J = 6.3 Hz, 2H, OCH2), 3.68-3.59 
(m, 12H, OCH2), 3.55 (t, J = 5.1 Hz, 2H, CH2), 3.48-3.27 (m, 10H, OCH2, CH3), 3.15 (dt, J = 12.0, 
6.0 Hz, 1H, biotin-CH), 2.91 (dd, J = 12.7, 4.9 Hz, 1H, biotin-CH), 2.73 (d, J = 12.7 Hz, 1H, 




7.5 Hz, 2H, biotin-CH2). 13C NMR (100 MHz, CDCl3): 196.88, 173.41, 169.85, 164.02, 150.45, 
96.02, 77.36, 70.68, 70.57, 70.53, 70.34, 70.22, 70.08, 66.91, 61.91, 60.33, 55.55, 40.68, 39.29, 




propargyl)aminopropylidene)-1,3-dimethylpyrimidine-2,4,6-trione (Biotin-Dmpt-Alkyne, 1).  
 Compound 2 (50.0 mg, 0.079 mmol) was suspended in 2 mL of neat propargylamine and 
stirred at 50 °C for 4 h. The reaction was then concentrated, and the residue was diluted in DCM. 
The solution was extracted with H2O, and the aqueous layer was back-extracted twice with DCM. 
The organic layers were combined, dried with MgSO4, and concentrated. The residue was 
redissolved in a minimal volume of 5% aq. MeCN and then purified by preparative HPLC. 
Fractions were combined, concentrated, and lyophilized to afford the product as a light yellow 
powder (14.8 mg, 28% yield). 1H NMR (400 MHz, CDCl3): δ 12.87 (bt, J = 5.5 Hz, 1H, NH), 6.64 
(bt, J = 5.6 Hz, 1H, NH), 6.20 (s, 1H, NH), 5.28 (s, 1H, NH), 4.50 (ddt, J = 7.5, 5.0, 1.2 Hz, 1H, 
biotin-CH), 4.45 (dd, J = 5.5, 2.6 Hz, 2H, NCH2), 4.31 (ddd, J = 7.8, 4.6, 1.4 Hz, 1H, biotin-CH), 
3.86 (t, J = 5.5 Hz, 2H, OCH2), 3.67-3.53 (m, 14H, OCH2), 3.51-3.40 (m, 4H, OCH2), 3.33 (s, 3H, 
NCH3), 3.29 (s, 3H, NCH3), 3.14 (td, J = 7.4, 4.6 Hz, 1H, biotin-CH), 2.90 (dd, J = 12.8, 4.9 Hz, 
1H, biotin-CH), 2.74 (d, J = 12.8 Hz, 1H, biotin-CH), 2.41 (t, J = 2.6 Hz, 1H, CCH), 2.22 (td, J = 
7.3, 2.2 Hz, 2H, biotin-CH2), 1.78-1.58 (m, 4H, biotin-CH2), 1.44 (q, J = 7.6 Hz, 2H, biotin-CH2). 
13C NMR (100 MHz, CDCl3): δ 175.65, 173.30, 166.84, 163.79, 162.63, 151.35, 90.31, 77.86, 




36.02, 33.97, 31.14, 28.25, 28.22, 28.14, 27.91, 25.67. ESI-HRMS (m/z): [M+H]+ calc’d for 
C30H47N-6O9S+: 667.3120, found: 667.3133. 
 
5.9.13. Chemoenzymatic Labeling and Enrichment for O-GlcNAcomics. 
HEK-293T-iOGTFH cell lysate, brain, liver, or WT/BAP1 KO 293T cell lysate (5 mg) was 
diluted with 1% SDS, 20 mM HEPES pH 7.6 to 2.5 mg/mL. Samples were reduced using 20 mM 
DTT pH 7.6 for 45 min at 60 °C, cooled to room temperature, and alkylated with 80 mM 
iodoacetamide for 45 min at RT protected from light. Protein was then precipitated by the addition 
of 3 volumes of methanol, 1 volume of chloroform, and 2.25 volumes of water. The precipitated 
protein was pelleted by centrifugation at 7,068 x g for 35 min at 4 °C. Solvents were removed and 
the pellet washed twice with 3 volumes of methanol before redissolving at 5 mg/mL with 1 mL of 
1% SDS, 20 mM HEPES pH 7.9 at 95 °C for 5 min. Samples were then diluted with 2 mL of 2.5x 
GalT labeling buffer (50 mM HEPES pH 7.9, 125 mM NaCl, 5% IGEPAL CA-630), 1.2 mL of 
ddH2O, and 275 μL of 100 mM MnCl2. The mixture was chilled on ice for 5 min, and then 250 μL 
of 0.1 mM UDP-GalNAz, 250 μL of 2 mg/mL Y289L GalT, 50 μL of 500 kU/mL PNGase F (New 
England Biolabs, 5 U/μg of protein), and 62.5 μL of Lambda Protein Phosphatase (New England 
Biolabs, 5 U/μg of protein) were added with gentle mixing after each addition. Sample was rotated 
end-over-end overnight at 4 °C. The following day, samples were then precipitated by the 
methanol/chloroform/water method described above. The protein pellet was redissolved at 5 
mg/mL in 1 mL of 1% SDS, 20 mM HEPES pH 7.6 at 95 °C for 5 min. The solution was diluted 
with 2.85 mL of ddH2O and 0.15 mL of 200 mM HEPES pH 7.6. In a separate tube, a 5x CuAAC 
mix was prepared by sequential addition of 885 μL of ddH2O, 10 μL of 5 μL of 100 mM BTTAA 




and 50 mM 1 in DMSO. The 5x mix was then added directly to the protein sample and mixed 
gently before adding 100 μL of 100 mM TCEP (freshly prepared). The CuAAC reaction was 
allowed to proceed with end-over-end for 1 h at RT before the proteins were precipitated as 
described above. The protein was resuspended in 5 ml of 50 mM HEPES pH 7.6, 10 mM EDTA 
pH 8 to chelate residual Cu2+. Then, 200 μg Pierce trypsin protease (1:25 w/w) was added, and the 
sample was rotated end-over-end for 20 hours at 37 °C. Two 15-mL 10 kDa MWCO Amicon 
concentrator tubes were rinsed with 2 x 5 mL of 50% MeOH and 2 x 5 mL of ddH2O by 
centrifugation at 4,000 x g for 5 min. Tryptic solutions were then centrifuged in the rinsed 
concentrator tubes at 4,000 x g for 20 min. The remaining residue was rinsed 2 x 2.5 mL of H2O 
by centrifugation, and the flowthrough fractions were combined. The sample was diluted two-fold 
with PBS. In a separate tube, 500 μL of a 50% slurry of high capacity Neutravidin agarose 
(ThermoFisher Scientific) was washed twice with 0.5 mL of PBS. The washed agarose resin was 
then added to the sample and rotated end-over-end for 1 h at RT. The resin was pelleted by 
centrifugation at 500 x g for 5 min and then transferred to a 900 μL spin filter (ThermoFisher 
Scientific) pre-rinsed twice with 50% MeOH and 50% ddH2O. Beads were washed 5 min each 
with the following solutions: 5 x 0.5 mL of PBS, 5 x 0.5 mL of 1 M NaCl in PBS, and 5 x 0.5 mL 
of PBS. Captured peptides were eluted in twice with 0.75 mL of 2% v/v NH2OH with end-over-
end rotation for 1.5 h at 37 °C. Elution fractions were combined and concentrated to dryness with 
vacuum centrifugation before desalting as described for affinity purified peptides. For each pair of 
quantitative samples, dried peptides were resuspended in 50 μL of 100 mM TEAB pH 8.5 and 
labeled using two tags from the TMT10plex Isobaric Labeling Kit (ThermoFisher Scientific) per 
the manufacturer’s instructions. Labeled peptides were then combined, desalted and dried as 




5.9.14. Preparation of Peptides for Quantitative Proteomics Experiments. 
 100 μg of WT or BAP1 KO lysate (n=3 for each), prepared as described above, was 
precipitated using the methanol/chloroform/water method as described above except the samples 
were centrifuged at 21,130 x g for 5 min to pellet proteins. 100 ul of 100 mM TEAB pH 8.5 was 
then added to the pellets before adding 3 μg of Pierce MS Grade Trypsin Protease (ThermoFisher 
Scientific) (1:33 w/w enzyme:protein). The samples were then left to digest for 20 hours at 37 °C. 
The following day, peptides were labeled with the TMTsixplex Isobaric Labeling Kit 
(ThermoFisher Scientific) per the manufacturer’s instructions. After labeling, peptides from all 
groups were combined and dried in a vacuum centrifuge. Peptides were then resuspended in 100 
μL of 10 mM ammonium hydroxide and subjected to offline high pH reversed phase fractionation90 
using an Agilent Extend-C18; 5 μm, 2.1x150 mm on an Agilent 1100 HPLC (Santa Clara, CA) 
operating at 0.2 mL/min. Buffer A consisted of 10 mM ammonium hydroxide in water and buffer 
B consisted of 10 mM ammonium hydroxide in 90% acetonitrile. The combined 600 μg of peptides 
were injected onto the column and separated per the following gradient: 1% Solvent B (4 min), 1-
30% B (50 min), 30-60% B (4 min), 60-70% B (2 min), and 70-90% B (5 min). 64 1 min fractions 
were collected into 96 deep-well plates, concatenated to 16, and dried by vacuum centrifugation. 
Each fraction was resuspended in 10 uL of 0.2% formic acid by bath sonication for MS analysis. 
 
5.9.15. LC-MS/MS Analysis. 
 
5.9.15.1. Affinity Purification from HEK293T Cells. 
Affinity purified, in-gel digested samples from HEK293T cells were subjected to LC-




a LTQ Orbitrap Elite mass spectrometer (ThermoFisher Scientific). For the EASY-nLC II system, 
solvent A consisted of 97.8% H2O, 2% ACN, and 0.2% formic acid and solvent B consisted of 
19.8% H2O, 80% ACN, and 0.2% formic acid. Samples were directly loaded onto a 16-cm 
analytical HPLC column (50 µm ID) packed in-house with ReproSil-Pur C18AQ 3 µm resin (120 
Å pore size, Dr. Maisch, Ammerbuch, Germany). The column was heated to 60 °C. The peptides 
were separated with a 60-min gradient at a flow rate of 220 nL/min. The gradient was as follows: 
2-30% Solvent B (60 min), 30-100% B (1 min), and 100% B (9 min). Eluted peptides were then 
ionized using a Nanospray Flex ion source (ThermoFisher Scientific) and introduced into the mass 
spectrometer. The LTQ Orbitrap Elite was operated in a data-dependent mode, automatically 
alternating between a full-scan (m/z 400-1600, 120K resolution) in the Orbitrap and subsequent 
MS/MS scans of the 20 most abundant peaks in the linear ion trap (Top20 method).  
 
5.9.15.2. Affinity Purification from Brain and Liver Tissue. 
Affinity purified samples from brain tissue were subjected to LC-MS/MS analysis on a 
nanoflow LC system, EASY-nLC 1200, (ThermoFisher Scientific) coupled to a Q Exactive HF 
Orbitrap mass spectrometer (ThermoFisher Scientific) equipped with a Nanospray Flex ion source. 
Samples were directly loaded onto a PicoFrit column (New Objective, Woburn, MA) packed in 
house with ReproSil-Pur C18AQ 1.9 µm resin (120 Å pore size, Dr. Maisch, Ammerbuch, 
Germany). The 20 cm x 50 µm ID column was heated to 60 °C. The peptides were separated with 
a 120-min gradient at a flow rate of 220 nL/min. The gradient was as follows: 2-6% Solvent B (7.5 
min), 6-25% B (82.5 min), and 25-40% B (30 min) and to 100% B (9 min). Solvent A and B were 
the same as described above. The Q Exactive HF Orbitrap was operated in data dependent mode. 




injection time of 15 ms. Mass range was set to 300-1650 m/z. For data dependent MS2 scans the 
loop count was 12, target value was set at 1 × 105, and intensity threshold was kept at 1 × 105. 
Isolation width was set at 1.2 m/z and a fixed first mass of 100 was used. Normalized collision 
energy was set at 28%. Peptide match was set to off, and isotope exclusion was on.  
 
5.9.15.3. O-GlcNAcomics Samples. 
Chemoenzymatic labeled and enriched digested samples were analyzed on a nanoflow LC 
system, EASY-nLC 1000 (ThermoFisher Scientific), coupled to an Orbitrap Fusion Tribrid mass 
spectrometer (ThermoFisher Scientific) equipped with a Nanospray Flex ion source. Sample 
loading and LC separation was identical to the QE Orbitrap LC method mentioned above. Full 
spectra were acquired over m/z 350-1800 in the Orbitrap (120 K resolution at 200 m/z); automatic 
gain control (AGC) was set to accumulate 50,000 ions, with a maximum injection time of 50 ms. 
Data-dependent MS2 analysis was performed using a top-speed approach (cycle time of 5 s) with 
multiple fragmentation methods (see below). Dynamic exclusion set to exclude features after 1 
time for 15 seconds with exclude isotopes turned on. The normalized collision energy was 
optimized at 28% for high collision dissociation (HCD) fragmentation. The intensity threshold for 
fragmentation was set to 25,000. HCD fragmentation spectra were collected in the Orbitrap 
operating at 30K resolution at 200 m/z. ETD/EThcD fragmentation was then performed for 
precursor ions that whose HCD spectra contained a fragment of mass 300.1303 m/z (15 ppm 
tolerance, within the top 30 ions). AGC was set to 50,000 with a maximum injection time set at 
500 ms for the Orbitrap operating at 30K resolution. ETD reaction time was charge-dependent and 





5.9.15.4. Quantitative O-GlcNAcomics Samples. 
 Quantitative O-GlcNAcomics samples were analyzed on a nanoflow LC system, EASY-
nLC 1000 (ThermoFisher Scientific), coupled to an Orbitrap Fusion Tribrid mass spectrometer 
(ThermoFisher Scientific) equipped with a Nanospray Flex ion source. ~4 μg of peptides per 
sample were loaded onto an Aurora 25cm x 75µm ID, 1.6µm C18 reversed phase column (Ion 
Opticks, Parkville, Victoria, Australia) and separated over 135 min at a flow rate of 350 nL/min 
with the following gradient: 2–6% Solvent B (7.5 min), 6-25% B (82.5 min), 25-40% B (30 min), 
40-100% B (1 min), and 100% B (14 min). MS1 spectra were acquired at 120,000 resolution with 
a scan range from 350-1800 m/z; AGC was set to accumulate 50,000 ions, with a maximum 
injection time of 50 ms. Data-dependent MS2 analysis, either top speed (5 s) or top 10 was then 
performed in which features were filtered for monoisotopic peaks with a charge state of 3-8 and a 
minimum intensity of 25,000, with dynamic exclusion set to exclude features after 1 time for 15 
seconds with a 10 ppm mass tolerance and exclude isotopes turned on. HCD fragmentation was 
performed with normalized collision energy of 28 after quadrupole isolation of features using an 
isolation window of 1.6 m/z, an AGC target of 1e5, and a maximum injection time of 100 ms. MS2 
scans were then acquired at 30K resolution in Centroid mode with the scan range set to automatic. 
Detection of at least fragment of 732.3726, 547.3037, or 529.2931 m/z in the top 30 ions triggered 
three additional scans: (1) SPS-MS3 in the Orbitrap on the top 5 SPS precursors, an isolation 
window of 1.3 m/z, 65% normalized collision energy, a resolution of 50,000, an ACG target of 
50,000, an automatic scan range, and a maximum injection time of 250 ms. Precursor selection 
range, ion exclusion and isobaric tag loss exclusion were all employed. (2) ETD-MS2 in the Ion 
Trap with an isolation window of 1.6 m/z, calibrated charge-dependent ETD parameters, rapid scan 




100 ms. (3) EThcD-MS2 was performed as described for (2) except with 20% supplemental 
activation energy. 
 
5.9.15.5. BAP1 KO Protein Expression. 
Liquid chromatography-mass spectrometry (LC-MS) analysis of native peptide fractions 
was carried out on an EASY-nLC 1000 (Thermo Fisher Scientific, San Jose, CA) coupled to an 
Orbitrap Eclipse Tribrid mass spectrometer (Thermo Fisher Scientific, San Jose, CA). 3 μL of each 
resuspended fraction was loaded onto a monolithic column (Capillary EX-Nano MonoCap C18 
HighResolution 2000, 0.1 x 2000 mm, Merck, Darmstadt Germany) fitted with a silica coated 
PicoTip emitter (New Objective FS360-20-10-D) and separated over 180 min at a flow rate of 500 
nL/min with the following gradient: 2–6% Solvent B (10 min), 6-40% B (140 min), 40-98% B (1 
min), and 98% B (29 min). MS1 spectra were acquired in the Orbitrap at 120K resolution with a 
scan range from 400-1500 m/z, an AGC target of 4e5 and the maximum injection time set 
automatically. Features were filtered for monoisotopic peaks with a charge state of 2-5 and a 
minimum intensity of 5,000, with dynamic exclusion set to exclude features after 1 time for 60 
seconds with a 10 ppm mass tolerance. Data-dependent MS2 analysis was performed using a top-
speed approach (cycle time of 5 s). CID fragmentation was performed with normalized collision 
energy of 35% and an activation time of 10 ms with an activation Q of 0.25 after quadrupole 
isolation of features using an isolation window of 0.7 m/z. Scans were acquired in the Ion Trap 
using automatic scan range, a maximum injection time of 250 ms, and rapid scan mode. HCD-
SPS-MS3 scans were also performed in Orbitrap on the top 10 SPS precursors, an isolation 




150,000, a scan range of 100-500 m/z, and a maximum injection time of 118 ms. Precursor 
selection range, ion exclusion, and isobaric tag loss exclusion were all employed. 
 
5.9.16. MS Data Analysis.  
All raw files were searched using Proteome Discoverer 2.4.0.305 (ThermoFisher 
Scientific) with the Byonic (Protein Metrics, Cupertino, CA) search node v3.7.4. Search parameter 
files are provided in. Peak lists were searched against the species-specific complete UniProtKB 
databases and the UniprotKB/Swiss-Prot databases (Mus musculus, retrieved January 21, 2020; 
Homo sapiens, retrieved January 25, 2020) supplemented with database of frequently observed 
contaminants (245 sequences). The Swiss-Prot only searches were used to match O-GlcNAc sites 
with known PTMs in the PhosphoSitePlus database and for the BAP1 KO quantitative O-
GlcNAcomics and proteomics experiment (to facilitate matching of O-GlcNAcylation peptides to 
their parent protein expression). For all searches the following parameters were set: MS1 tolerance 
of 5 ppm, MS2 tolerance of 10 ppm or 0.5 Da for Orbitrap and Ion Trap spectra, respectively, 
minimum peptide length of 6 amino acids, a maximum of three missed cleavages, 
carbamidomethylation of cysteine residues was set as a fixed modification, acetylation of the 
protein N-terminus and oxidation of methionine (common2) were set as a variable modifications, 
and the tagged O-GlcNAc was set as a variable modification (common 2), dimethylation or TMT 
labeling of lysines and peptide N-termini were set to fixed modification where appropriate, and 
phosphorylation was set as a variable modification for the protein expression samples. Data was 
filtered to a 1% false discovery rate on PSMs using the Percolator or target decoy algorithm in 




HCD spectra, equal localization probabilities were assigned to every serine/threonine due to 
neutral loss of the glycan.  
 
5.9.17. Data Analysis. 
 
5.9.17.1. General and Statistics. 
All data analysis was performed using the Python language (Python Software Foundation. 
Python Language Reference, version 3.7.3. Available at http://www.python.org) with all 
Anaconda packages installed (Anaconda Software Distribution, version 4.8.3. Available at 
https://anaconda.com). Information from the Uniprot Knowledgebase56 and PhosphoSitePlus38 
database used for the integrated Cytoscape tables was retrieved on April 22, 2020 and April 28, 
2020, respectively. For the limma moderated t-test91 (package, limma v3.42.2) and inverted beta 
binomial tests92 (package, ibb v13.06) the R language (R Development Core Team, version 3.6.1. 
Available at https://www.R-project.org) was employed using the rpy2 (Laurent Gautier, v2.9.4) 
python package. Multiple hypothesis testing correction was performed with either the Benjamini-
Hochberg method (interactomics and O-GlcNAcomics) or Holm- Bonferroni method (Western 
blotting). A p-value of less than 0.05 was considered significant. Code for all analyses and figures 
is in Appendix 5.6. 
 
5.9.17.2. Bioinformatics Analysis of OGT Interactome and O-GlcNAcome. 
The input for the network analysis included OGT interactors from TAP-MS and OGT 
substrates from chemoenzymatic labeling and proteomics generated in this project, and known 




BioGRID (Homo sapiens-specific dataset, downloaded February 25, 2020) and (2) IntAct (human-
human PPIs, downloaded February 25, 2020 and filtered for only multivalidated interactions). An 
in-house script was used to filter for interactions between an OGT interactor and other interactors 
or substrates to generate the edges of the O-GlcNAc network. Edges from individual OGT 
interactor baits with more than thirty connections to other protein prey within were removed to 
avoid biasing during community clustering. Examples of these proteins include ribosomal proteins, 
heterogeneous nuclear ribonucleoproteins (hnRNPs), and heat shock proteins (HSPs). In most 
cases, the eliminated edges coincided with interactions from proteins highly represented within the 
CRAPome, implying a high rate of non-specific interactions. However, edges generated in the 
reverse direction (e.g. from an interactor/substrate bait to a ribosomal protein prey) were retained. 
The nodes and edges were then used to build a network of OGT interactome and O-GlcNAcome, 
which was visualized and analyzed using Cytoscape version 3.7.2. To partition the network, we 
used the Community cluster (GLay) algorithm42 in the Cytoscape plug-in clusterMaker293 (v1.3.1) 
which is a community clustering algorithm that implements the Girvan-Newman fast greedy 
algorithm.41  
The protein names from the whole network or from each cluster were submitted for 
statistical overrepresentation testing using g:Profiler.94 Only terms with a p-value of less than 0.01 
with the g:SCS significance threshold were used and electronic GO annotations were excluded. 
To group GO terms and appropriately name clusters the Cytoscape plugin ClueGO44 v2.5.6 was 
used. For each cluster, the proteins were submitted to ClueGO analysis with the GO Biological 
Processes (Downloaded February 17, 2020) without electronic annotation. GO term Fusion was 




specificity was set to medium with all dependent parameters left as default; GO Term grouping 
was employed. 
 
5.9.18. Neuron Culture, Stimulation, and Lysis. 
Primary mouse cortical neurons were prepared as previously described,5 plated on poly-d-
lysine (PDL) coated plates, and cultured in Neurobasal medium (ThermoFisher) with 1% 
penicillin-streptomycin (P/S, ThermoFisher), 2mM GlutaMAX Supplement (ThermoFisher), and 
B-27 Plus (ThermoFisher). Half of the media was changed every 2-4 days. After 20 DIV, neuronal 
activity was silenced using tetrodotoxin (TTX, 10 μM, Tocris Biosciences) and D-AP5 (100 μM, 
Tocris Biosciences), and a subset was also treated with Thiamet-G (TMG, 50 μM, Sigma Aldrich). 
The following day, silenced neurons were depolarized with KCl (60 mM) or vehicle for 2 hours 
and subsequently lysed with 2% SDS in HEPES pH 7.9, containing Roche cOmplete protease 
inhibitor cocktail (Sigma Aldrich) and TMG (0.1 mM), and protein concentration was measured 
using BCA assay (ThermoFisher). For the immunoprecipitation experiments, silenced and 
depolarized neurons were prepared as described and lysed with 1% Triton in TBS containing 
Roche cOmplete protease inhibitor cocktail (Sigma Aldrich), TMG (0.1 mM), and 0.25 U/μL 
benzonase nuclease (Santa Cruz Biotechnology). 
 
5.9.19. Chemoenzymatic Labeling of Neuronal Lysates. 
O-GlcNAcylated proteins from cell lysates (150 μg) were labeled as previously 
described.95 Briefly, proteins were precipitated by the methanol/chloroform/water method 
described above. Protein pellets were then resolubilized with 40 µL dissolution buffer (20 mM 




2.5x GalT labeling buffer (50 mM HEPES, 125 mM NaCl, 5% IGEPAL CA-630, pH 7.9) were 
added and the solution was vortexed gently before adding 10 µL Y289L GalT (1 mg/mL), and 10 
µL of UDP-GalNAz (0.5 mM in 10 mM HEPES, pH 7.9). The reaction was then left to rotate end-
over-end at 4 °C overnight. Control experiments were carried out in parallel in the absence of 
UDP-GalNAz. The following day, IAA was added (12.5 mM final concentration) to alkylate free 
cysteine residues, and the solution was left to rotate end-over-end in the dark at room temperature 
for 1 hour. Proteins were then precipitated as before and resolubilized by boiling in 199.6 μL of 
dissolution buffer (1% SDS in TBS pH 7.6). After allowing the redissolved proteins to cool to 
room temperature, 0.4 μL of 50 mM WS DBCO Biotin (Click Chemistry Tools) was added. The 
solution was allowed to react for 1 hour with end-over-end rotation in the dark before being 
precipitated as before. Proteins were again resolubilized by boiling in dissolution buffer and 10% 
of the reaction volume was taken as input. The remaining aliquot was then incubated with 
streptavidin magnetic beads (ThermoFisher) for 1.5 hours in the dark. Beads were then washed 5 
times with 0.5 ml of low salt buffer (100 mM Na2HPO4, 150 mM NaCl, 0.1% SDS, 1% Triton X-
100, 0.5% sodium deoxycholate) and 5 times with 1 ml of high salt buffer (100 mM Na2HPO4, 
500 mM NaCl, 0.2% Triton X-100). Biotinylated proteins were eluted by boiling the resin in 50 
mM Tris-HCl pH 6.8, 2.5% SDS, 100 mM DTT, 10% glycerol, and 2 mM biotin for 15 min with 
occasional vortexing. 
 
5.9.20. Western Blotting. 
Primary antibodies were obtained from Cell Signaling Technology (Danvers, MA), and 
secondary antibodies were obtained from ThermoFisher Scientific unless otherwise specified. 




otherwise specified. Cell lysates were diluted with 4x SDS-PAGE buffer (200 mM Tris-HCl pH 
6.8, 400 mM DTT, 8% SDS, 0.4% bromophenol blue, 40% glycerol), resolved on a NuPAGE 4-
12% Bis-Tris protein gel (ThermoFisher Scientific), and transferred to Immobilion-FL PVDF 
membrane (MilliporeSigma). Blots were blocked for 1 h at RT with LiCor Odyssey Blocking 
Buffer (LiCor, Lincoln NE, 927-50003) before probing overnight at 4 °C with the following 
antibodies diluted in blocking buffer: Rb anti-OGT (Proteintech, Rosemont, IL; 11576-2-AP), Rb 
anti-HA (C29F4), Ms anti-Nup62 (BD Biosciences, Franklin Lakes, NJ; 610498), Rb anti-HCFC1 
(Bethyl Laboratories, A301-399A-M), Rb anti-SET1A (61702S), Rb anti-RBBP5 (61702S), Rb 
anti-BAP1 (Bethyl Laboratories, Montgomery, TX; A302-243A-M), Rb anti-WDR5 (13105S), Rb 
anti-FoxK1 (Bethyl Laboratories, A301-728A-M), Rb anti-FoxK2 (12008S), Rb anti-liprin-α1 
(Proteintech, 14175-1-AP), Ms C-4 anti-BAP1 Antibody (Santa Cruz Biotechnology, sc-28383), 
or Ms anti-α-tubulin (Sigma Aldrich, T9026, 1:3000). Blots were rinsed three times with TBST 
and then probed with the appropriate secondary antibodies in blocking buffer: Gt anti-Ms 
AlexaFluor 680 conjugate (A21057), Gt anti-Rb AlexaFluor 680 (A21109), Gt anti-Rb AlexaFluor 
790 (A11369), or Gt anti-Ms IgG DyLight 800 (ThermoFisher, A11357). Blots were washed 3 x 
5 min with TBST and then imaged using an Odyssey Infrared Imaging System (LI-COR 
Biosciences, Lincoln, NE). Images were processed using ImageStudio v5.2 (LI-COR 
Biosciences). To calculate O-GlcNAcylation stoichiometry, the ratios of eluents to inputs, 
weighted by proportion of the total protein in each lane, were used as previously described.33 
 
5.9.21. Co-Immunoprecipitation. 
Neurons harvested from OGT-FH mice were grown and either silenced or KCl stimulated 




was diluted to 1 mL with TBS buffer, TMG (0.1 mM), and Roche cOmplete protease inhibitor 
cocktail (Sigma Aldrich). 15 μg of protein was saved as input. The remaining lysate was incubated 
with anti-FLAG magnetic beads (Sigma Aldrich) at 4°C overnight with end-over-end rotation. The 
following day, beads were washed with 3 times with 0.1% Triton-X-100 in TBS pH 7.9 and eluted 
by boiling in 2% SDS in Tris, pH 8. Inputs and eluents were run on SDS-PAGE and Western 
blotted for HA and liprin-α1.  
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Appendix 5.1. All Sites and Regions Quantified in WT and BAP1 KO 293T Cells. 
 Whether each site was identified in the top speed, top 10, or both runs is indicated by the 
“Experiment” column. logFC Protein: log2 fold change in protein expression. logFC_Corrected, 
and P-Val_Corrected are the log2 fold change, p-value (after correction for multiple comparisons 
using the Benjamini-Hochberg method). If protein expression could not be quantified, these values 














A3KN83 SBNO1 1 130 Site Both 0.2634 0.25765 0.16 0.103378705 0.7400405 
A3KN83 SBNO1 1 135 Site Both 0.4848 0.10288 0.16 0.324841051 0.31261988 
A3KN83 SBNO1 1 138 Site Both 0.4848 0.10288 0.16 0.324841051 0.31261988 
A3KN83 SBNO1 1 112 Site Both 0.2777 0.23985 0.16 0.117695545 0.70759286 
A3KN83 SBNO1 1 113 Site Both 0.0213 0.95725 0.16 -0.13871259 0.65957296 
A3KN83 SBNO1 1 126 Site Both 0.4043 0.08851 0.16 0.244318929 0.3509044 
A3KN83 SBNO1 1 127 Site Both 0.3775 0.11222 0.16 0.217494756 0.41239846 
A5YKK6 CNOT1 1 
(1 of 
5,7,11,14,21) 
Region TopSpeed 0.4282 0.30747 -0.01 0.438155494 0.3509044 
A5YKK6 CNOT1 1 1037 Site Both 0.3432 0.15566 -0.01 0.353235846 0.17220996 
A5YKK6 CNOT1 1 1038 Site Both 0.2865 0.2284 -0.01 0.296521412 0.2501051 
A5YKK6 CNOT1 1 1041 Site Both 0.3642 0.13435 -0.01 0.374216885 0.15033071 
A5YKK6 CNOT1 1 1042 Site Both 0.3642 0.13435 -0.01 0.374216885 0.15033071 
A5YKK6 CNOT1 1 1043 Site Both 0.4498 0.05551 -0.01 0.459794992 0.05793284 
A5YKK6 CNOT1 1 1044 Site Both 0.4288 0.06881 -0.01 0.438813953 0.07316613 
A5YKK6 CNOT1 1 1046 Site Both 0.2912 0.22228 -0.01 0.301209739 0.24428434 











Region Both -0.043 0.92396  -0.04263184 0.92511993 
A8CG34 POM121C 1 599 Site Both 0.1142 0.714  0.114194512 0.70759286 
A8CG34 POM121C 1 583 Site Both 0.0808 0.79813  0.080833764 0.80312346 
A8CG34 POM121C 1 663 Site Both -0.227 0.48597  -0.22722047 0.51842158 
A8CG34 POM121C 1 665 Site Both -0.176 0.62736  -0.17640576 0.64364752 
A8CG34 POM121C 1 603 Site Both 0.1142 0.714  0.114194512 0.70759286 
O00151 PDLIM1 1 128 Site Both -0.277 0.25669 -0.23 -0.04729067 0.90986391 




Region TopN 0.2251 0.67242 0.02 0.205058211 0.70759286 
O00268 TAF4 1 409 Site Both -0.089 0.83321 0.02 -0.10870175 0.7935387 




Region TopSpeed -0.316 0.30656 -0.06 -0.25551919 0.48282553 




Region Both -0.018 0.97709 -0.06 0.041900376 0.92511993 
O00512 BCL9 1 1035 Site TopSpeed 0.1881 0.73332 -0.06 0.248062426 0.65348486 
O00584 RNASET2 1 103 Site Both 0.1655 0.76807 -0.07 0.235548823 0.66993821 
O14497 ARID1A 1 (1 of 263,264) Region Both 0.0202 0.96144 0.13 -0.10979539 0.73706765 
O14497 ARID1A 1 265 Site Both 0.0134 0.97926 0.13 -0.1165729 0.71796103 
O14497 ARID1A 1 238 Site Both -0.012 0.97926 0.13 -0.14242844 0.66085936 
O14497 ARID1A 1 241 Site Both -0.012 0.97926 0.13 -0.14242844 0.66085936 
O14497 ARID1A 1 249 Site Both -0.012 0.97926 0.13 -0.14242844 0.66085936 
O14497 ARID1A 1 255 Site Both 0.0134 0.97926 0.13 -0.1165729 0.71796103 
O14686 KMT2D 1 2402 Site Both 0.3552 0.13477 0.31 0.045183147 0.90986391 
O14686 KMT2D 1 2405 Site Both 0.3552 0.13477 0.31 0.045183147 0.90986391 
O14964 HGS 1 (1 of 299,300) Region Both -0.125 0.70431 -0.23 0.10540641 0.74875917 
O14964 HGS 1 297 Site Both -0.164 0.58701 -0.23 0.065983656 0.86597032 
O14964 HGS 1 306 Site Both -0.378 0.11674 -0.23 -0.14817061 0.6241827 
O14964 HGS 1 309 Site Both -0.311 0.18108 -0.23 -0.08091512 0.80292165 
O14964 HGS 1 310 Site Both -0.283 0.22228 -0.23 -0.05345055 0.88767054 
O14964 HGS 1 314 Site Both -0.259 0.25945 -0.23 -0.02861969 0.92831607 
O14964 HGS 1 315 Site Both -0.239 0.30656 -0.23 -0.00872719 0.97975 


















Region Both -0.018 0.97709 -0.04 0.022394637 0.95760145 
O14974 PPP1R12A 1 (1 of 659,660) Region Both 0.058 0.86036 -0.04 0.097965707 0.75083287 
O14974 PPP1R12A 1 644 Site Both -0.079 0.80699 -0.04 -0.03869652 0.91823676 
O14974 PPP1R12A 1 590 Site Both -0.115 0.76699 -0.04 -0.07537674 0.86597032 
O14974 PPP1R12A 1 592 Site Both -0.115 0.76699 -0.04 -0.07537674 0.86597032 
O14974 PPP1R12A 1 658 Site Both 0.0423 0.89837 -0.04 0.08233485 0.79704572 
O14974 PPP1R12A 1 565 Site Both -0.018 0.97709 -0.04 0.022394637 0.95760145 
O14974 PPP1R12A 1 631 Site Both -0.011 0.97926 -0.04 0.028822912 0.92831607 
O14974 PPP1R12A 1 637 Site Both -0.01 0.97938 -0.04 0.029781363 0.92831607 
O15014 ZNF609 1 1196 Site Both -0.002 0.99326 0.32 -0.32177089 0.20896022 
O15027 SEC16A 1 (1 of 2158,2159) Region Both -0.286 0.24557 0.04 -0.32570797 0.22504717 
O15372 EIF3H 1 8 Site Both -0.289 0.34289 -0.02 -0.2692201 0.43520501 
O15372 EIF3H 1 10 Site Both -0.289 0.34289 -0.02 -0.2692201 0.43520501 




Region TopSpeed -0.035 0.96144  -0.03472066 0.95269929 




Region Both 0.4431 0.13039  0.443106148 0.1578518 
O43166 SIPA1L1 1 1408 Site TopSpeed 0.1129 0.73082 0.09 0.022949152 0.94300057 
O43312 MTSS1 1 491 Site Both -0.419 0.08291  -0.41940964 0.10146861 
O43318 MAP3K7 1 (1 of 382,383) Region TopSpeed -0.414 0.1724 0.02 -0.43442926 0.18280589 
O43318 MAP3K7 1 378 Site TopSpeed -0.544 0.06693 0.02 -0.56356598 0.06661396 
O43395 PRPF3 1 176 Site TopSpeed -0.477 0.24557 0.11 -0.58707126 0.1911075 




Region TopN -1.456 0.00077  -1.45612394 0.00124114 





Region TopN 0.0592 0.92655 0.19 -0.13080781 0.83311173 
O43432 EIF4G3 1 258 Site Both 0.2944 0.20869 0.19 0.10435455 0.73706765 
O43432 EIF4G3 1 251 Site Both 0.2138 0.37511 0.19 0.02378505 0.94022854 
O43432 EIF4G3 1 253 Site Both 0.2445 0.29634 0.19 0.054547432 0.88667585 
O43524 FOXO3 1 418 Site Both 0.0324 0.92718 0.41 -0.37757893 0.1324731 






Region TopSpeed 0.2086 0.45523 -0.14 0.348625466 0.20309052 
O43823 AKAP8 1 216 Site TopSpeed 0.1493 0.69788 0.08 0.069334225 0.88425848 




Region TopSpeed 0.0832 0.8847 -0.03 0.113173737 0.86428932 













Region TopSpeed 0.1556 0.77943 0.1 0.055617497 0.92831607 
O60675 MAFK 1 153 Site TopSpeed 0.459 0.12517 0.06 0.399029019 0.20309052 
O60675 MAFK 1 156 Site TopSpeed 0.459 0.12517 0.06 0.399029019 0.20309052 
O60675 MAFK 1 133 Site Both 0.5112 0.08291 0.06 0.45124976 0.15033071 
O60675 MAFK 1 134 Site Both 0.5112 0.08291 0.06 0.45124976 0.15033071 
O75170 PPP6R2 1 899 Site Both 0.408 0.08851 0.29 0.118040261 0.70710977 
O75170 PPP6R2 1 887 Site Both 0.3971 0.09827 0.29 0.107101138 0.73229249 
O75170 PPP6R2 1 903 Site Both 0.3595 0.12714 0.29 0.069518523 0.84513314 





Region TopN -0.042 0.94684 0.13 -0.17243844 0.75674684 
O75179 ANKRD17 1 (1 of 1563,1566) Region TopSpeed -0.486 0.24051 0.13 -0.61591879 0.17220996 
O75179 ANKRD17 1 1825 Site Both 0.2962 0.23195 0.13 0.166236225 0.60078955 
O75179 ANKRD17 1 1826 Site Both 0.4651 0.05551 0.13 0.335086668 0.19486577 
O75179 ANKRD17 1 1830 Site Both 0.2962 0.23195 0.13 0.166236225 0.60078955 
O75179 ANKRD17 1 1831 Site Both 0.3515 0.13469 0.13 0.221486479 0.41007524 
O75179 ANKRD17 1 2001 Site Both 0.1085 0.75105 0.13 -0.02145716 0.95269929 
O75179 ANKRD17 1 1820 Site Both 0.6201 0.01176 0.13 0.490145419 0.04891006 
O75376 NCOR1 1 1487 Site Both 0.0297 0.93293 0.24 -0.21027994 0.4557783 
O75533 SF3B1 1 296 Site Both 0.2968 0.53663 0.02 0.276810206 0.60078955 
O75533 SF3B1 1 299 Site Both 0.2968 0.53663 0.02 0.276810206 0.60078955 
O75947 ATP5PD 1 37 Site Both 0.124 0.84412 -0.29 0.414010355 0.41163169 
O75947 ATP5PD 1 39 Site Both 0.1495 0.78918 -0.29 0.439547796 0.3509044 
O94832 MYO1D 1 240 Site TopSpeed 0.028 0.97573 0.09 -0.06202952 0.92511993 







Region TopSpeed 0.0528 0.93131 0.29 -0.23716402 0.6680228 
O95382 MAP3K6 1 1285 Site Both 0.4081 0.16314  0.40814701 0.19131351 
O95382 MAP3K6 1 1286 Site Both 0.3534 0.22767  0.353387251 0.2609852 
O95487 SEC24B 1 347 Site Both -0.294 0.23195 -0.28 -0.01429667 0.97305303 
O95487 SEC24B 1 310 Site Both -0.33 0.16065 -0.28 -0.05023136 0.89825847 
O95487 SEC24B 1 311 Site Both -0.27 0.24051 -0.28 0.01012769 0.97877402 
O95487 SEC24B 1 344 Site Both -0.294 0.23195 -0.28 -0.01429667 0.97305303 
O95487 SEC24B 1 315 Site Both -0.32 0.17273 -0.28 -0.04043916 0.91559759 
O95628 CNOT4 1 331 Site TopSpeed -0.095 0.86659 -0.02 -0.07466505 0.91381441 
O95628 CNOT4 1 333 Site TopSpeed -0.092 0.87183 -0.02 -0.07168632 0.91559759 












Region Both -0.309 0.28953 -0.07 -0.239164 0.49091587 
O95677 EYA4 1 112 Site Both -0.188 0.58701 -0.07 -0.11787429 0.76034174 
O95677 EYA4 1 123 Site Both -0.164 0.65436 -0.07 -0.09354478 0.82382993 
O95789 ZMYM6 1 615 Site Both 0.0612 0.85398 0.04 0.021220457 0.94931495 
O95817 BAG3 1 (1 of 144,145) Region TopSpeed -0.408 0.22729 -0.14 -0.26845961 0.5100738 
P02545 LMNA 1 (1 of 612,613) Region Both -0.013 0.97926 0.25 -0.26313788 0.43085957 
P02545 LMNA 1 615 Site Both -0.013 0.97926 0.25 -0.26313788 0.43085957 
P04792 HSPB1 1 184 Site TopSpeed -0.243 0.438 -0.34 0.096926157 0.81537205 
P05062 ALDOB 1 (1 of 160,161) Region TopSpeed 0.0946 0.86659  0.094611325 0.88875793 
P05387 RPLP2 1 
(1 of 
64,74,79,86) 
Region TopSpeed -0.132 0.81511 -0.21 0.077552052 0.91044412 
P06576 ATP5F1B 1 405 Site TopSpeed 0.1949 0.73082 0.03 0.164894815 0.76722608 
P06748 NPM1 1 75 Site Both 0.2405 0.3163 -0.06 0.300458111 0.24051635 
P07197 NEFM 1 50 Site Both 0.474 0.11047 0.49 -0.01601658 0.97340685 
P07197 NEFM 1 47 Site Both 0.5646 0.05342 0.49 0.074639285 0.86792234 
P07339 CTSD 1 265 Site TopSpeed -0.482 0.24375 0.21 -0.69151582 0.12260258 
P07711 CTSL 1 218 Site Both -0.048 0.88252 0.03 -0.07773968 0.81593663 
P07711 CTSL 1 223 Site Both -0.048 0.88252 0.03 -0.07773968 0.81593663 
P07902 GALT 1 377 Site TopSpeed -0.574 0.1724 -0.04 -0.5336392 0.23658316 
P08651 NFIC 1 473 Site Both 0.3759 0.11275 0.29 0.085863376 0.79074906 
P08651 NFIC 1 462 Site Both 0.541 0.02605 0.29 0.250985064 0.35679661 
P08670 VIM 1 32 Site Both -0.211 0.38826 -0.31 0.099417475 0.74875917 
P08670 VIM 1 33 Site Both -0.055 0.86134 -0.31 0.25488492 0.32418494 
P08670 VIM 1 34 Site Both -0.455 0.0523 -0.31 -0.14516197 0.62861844 
P08670 VIM 1 35 Site Both -0.096 0.76383 -0.31 0.213784417 0.43727997 
P08670 VIM 1 7 Site Both -0.595 0.04462 -0.31 -0.2848734 0.39591243 
P08670 VIM 1 20 Site Both -0.016 0.97703 -0.31 0.294353503 0.2609852 
P08670 VIM 1 22 Site Both -0.164 0.62052 -0.31 0.145503903 0.6902866 
P09012 SNRPA 1 131 Site Both 0.0701 0.86086 -0.14 0.210118398 0.56656261 
P09012 SNRPA 1 148 Site Both 0.3165 0.29634 -0.14 0.456524016 0.16094902 
P0C7T5 ATXN1L 1 22 Site Both 0.1728 0.51124  0.172754828 0.54933658 
P0C7T5 ATXN1L 1 23 Site Both 0.1728 0.51124  0.172754828 0.54933658 





Region Both -0.14 0.63582  -0.13976111 0.65781223 
P0CJ78 ZNF865 1 93 Site Both -0.232 0.34289  -0.23183599 0.39591243 
P10071 GLI3 1 
(1 of 78,79)&(1 
of 77,78) 
Region Both -0.325 0.317  -0.32527636 0.36895199 








Region TopSpeed -0.071 0.90456 -0.14 0.068888477 0.91878967 
P10253 GAA 1 884 Site TopN -0.235 0.65436 -0.14 -0.09521978 0.88772423 
P11940 PABPC1 1 635 Site Both -0.151 0.60645 -0.06 -0.09133626 0.78573066 
P11940 PABPC1 1 485 Site TopSpeed 0.4164 0.08291 -0.06 0.476393117 0.05035599 
P11940 PABPC1 1 486 Site TopSpeed 0.2714 0.24051 -0.06 0.331426813 0.18623291 
P11940 PABPC1 1 631 Site Both -0.151 0.60645 -0.06 -0.09133626 0.78573066 
P12270 TPR 1 (1 of 1661,1662) Region Both -0.74 0.01205 0.08 -0.81963063 0.00616466 
P12270 TPR 1 1672 Site Both -0.74 0.01205 0.08 -0.81963063 0.00616466 
P12270 TPR 1 1666 Site Both -0.74 0.01205 0.08 -0.81963063 0.00616466 
P12270 TPR 1 1676 Site Both -0.74 0.01205 0.08 -0.81963063 0.00616466 
P14859 POU2F1 1 267 Site TopSpeed -0.158 0.66876 -0.31 0.152329916 0.69740433 
P14859 POU2F1 1 255 Site TopSpeed -0.158 0.66876 -0.31 0.152329916 0.69740433 
P15336 ATF2 1 
(1 of 
283,290,294) 
Region TopSpeed 0.1863 0.73332 -0.19 0.376329078 0.43514761 
P15822 HIVEP1 1 1633 Site TopSpeed 0.1222 0.75105  0.122195485 0.75067469 
P15822 HIVEP1 1 741 Site TopSpeed -0.32 0.49818  -0.32031838 0.52828118 
P15822 HIVEP1 1 2325 Site Both 0.3961 0.17803  0.396129358 0.20309052 
P15822 HIVEP1 1 698 Site TopSpeed -0.135 0.73332  -0.13477281 0.73658347 
P15822 HIVEP1 1 699 Site TopSpeed -0.135 0.73332  -0.13477281 0.73658347 
P15880 RPS2 1 293 Site Both 0.3265 0.1687 -0.33 0.656521619 0.00616466 






Region TopSpeed 0.0906 0.87206 0.15 -0.05941887 0.92511993 
P18583 SON 1 1097 Site Both 0.1479 0.65395 0.15 -0.00214061 0.99576765 
P18583 SON 1 265 Site TopSpeed 0.274 0.37335 0.15 0.124046451 0.75179055 
P18583 SON 1 244 Site Both 0.3198 0.1857 0.15 0.169759363 0.58282978 
P18583 SON 1 252 Site Both 0.3237 0.18108 0.15 0.173655092 0.57129172 
P18583 SON 1 253 Site Both 0.2983 0.21998 0.15 0.148345204 0.6375374 






Region TopSpeed 0.2082 0.53065 -0.01 0.218158639 0.54109863 
P19419 ELK1 1 270 Site TopSpeed 0.1711 0.637 0.22 -0.04894678 0.91692242 
P20719 HOXA5 1 72 Site TopN -0.21 0.70431  -0.21018123 0.70495902 
P22681 CBL 1 601 Site Both 0.1765 0.50486 -0.14 0.316484714 0.20309052 
P23246 SFPQ 1 660 Site Both 0.1303 0.67048 -0.07 0.20030839 0.48282553 
P23246 SFPQ 1 652 Site Both 0.0907 0.78143 -0.07 0.1606535 0.60786377 
P23769 GATA2 1 196 Site Both 0.6792 0.02182  0.679198462 0.0242215 
P25054 APC 1 2715 Site TopSpeed -0.282 0.56324 -0.17 -0.11217118 0.86428932 
P27540 ARNT 1 642 Site Both 0.3162 0.17833 0.21 0.106233867 0.73357459 




P27816 MAP4 1 793 Site Both -0.108 0.73332 -0.08 -0.02847438 0.92993035 
P27816 MAP4 1 811 Site TopSpeed 0.2008 0.72438 -0.08 0.280756324 0.60078955 
P27816 MAP4 1 797 Site Both -0.074 0.83802 -0.08 0.00574355 0.98629216 
P31629 HIVEP2 1 
(1 of 
442,443,444) 
Region TopSpeed 1.4092 0.00099  1.409219662 0.00143963 
P31629 HIVEP2 1 1057 Site TopSpeed 0.041 0.95052  0.040968591 0.94241548 
P31629 HIVEP2 1 1936 Site Both 0.0524 0.87183  0.05242962 0.89452881 
P31629 HIVEP2 1 406 Site Both 0.0563 0.86271  0.056327818 0.88667585 
P31629 HIVEP2 1 1274 Site TopSpeed 0.1252 0.83276  0.125194601 0.84495868 
P31629 HIVEP2 1 251 Site Both 0.259 0.39149  0.259026179 0.43727997 
P31629 HIVEP2 1 1981 Site TopSpeed 0.802 0.05597  0.802021943 0.06716852 
P31942 HNRNPH3 1 (1 of 14,17) Region TopN -0.382 0.37903 0.12 -0.50233338 0.2609852 




Region TopSpeed -0.364 0.22246  -0.36444125 0.2560924 
P35527 KRT9 1 85 Site TopSpeed 0.4855 0.24051 -0.18 0.665469038 0.14452898 








Region Both 0.0335 0.92718 -0.1 0.133458847 0.67158708 
P35658 NUP214 1 (1 of 1271,1272) Region Both -0.093 0.7694 -0.1 0.007249102 0.98261543 
P35658 NUP214 1 (1 of 1291,1292) Region Both -0.126 0.67751 -0.1 -0.02589688 0.93373979 




Region Both -0.048 0.88358 -0.1 0.051519989 0.89825847 




Region Both 0.0435 0.89829 -0.1 0.14348877 0.63995712 




Region TopSpeed -0.208 0.40508 -0.1 -0.108489 0.73182451 
P35658 NUP214 1 (1 of 1278,1279) Region Both -0.093 0.7694 -0.1 0.007249102 0.98261543 
P35658 NUP214 1 (1 of 439,440) Region Both -0.482 0.04462 -0.1 -0.38164613 0.1432696 
P35658 NUP214 1 1283 Site Both -0.091 0.7717 -0.1 0.008850902 0.97975 
P35658 NUP214 1 1925 Site Both 0.102 0.75105 -0.1 0.202038684 0.48282553 
P35658 NUP214 1 1553 Site Both 0.1641 0.54766 -0.1 0.264068719 0.30809545 
P35658 NUP214 1 1301 Site Both 0.0986 0.86134 -0.1 0.198565282 0.71678949 
P35658 NUP214 1 1304 Site Both 0.0986 0.86134 -0.1 0.198565282 0.71678949 
P35658 NUP214 1 1305 Site Both 0.0986 0.86134 -0.1 0.198565282 0.71678949 
P35658 NUP214 1 1572 Site Both 0.0443 0.89829 -0.1 0.144346574 0.64266867 
P35658 NUP214 1 430 Site Both -0.482 0.04462 -0.1 -0.38164613 0.1432696 
P35658 NUP214 1 1202 Site Both -0.025 0.95198 -0.1 0.074717547 0.85736486 
P35658 NUP214 1 437 Site Both -0.482 0.04462 -0.1 -0.38164613 0.1432696 
P35658 NUP214 1 962 Site TopSpeed 0.7689 0.06881 -0.1 0.868897753 0.04333656 




P35658 NUP214 1 580 Site Both 0.0489 0.87853 -0.1 0.148873789 0.62022567 
P35658 NUP214 1 966 Site TopSpeed -0.12 0.83909 -0.1 -0.02047024 0.97812544 
P35658 NUP214 1 1354 Site Both -0.338 0.14727 -0.1 -0.2378977 0.36383611 
P35658 NUP214 1 1355 Site Both -0.299 0.20372 -0.1 -0.19923821 0.46976784 
P35658 NUP214 1 1356 Site Both -0.299 0.20372 -0.1 -0.19923821 0.46976784 
P35658 NUP214 1 1358 Site Both 0.0707 0.84721 -0.1 0.170719945 0.60078955 
P35658 NUP214 1 1359 Site Both -0.008 0.98301 -0.1 0.09230139 0.80184027 
P35658 NUP214 1 1360 Site Both -0.171 0.53798 -0.1 -0.07101564 0.84808137 
P35658 NUP214 1 596 Site Both 0.0172 0.96948 -0.1 0.117186691 0.70759286 
P35658 NUP214 1 605 Site Both -0.067 0.84852 -0.1 0.033060094 0.92831607 
P35658 NUP214 1 610 Site Both 0.0327 0.93078 -0.1 0.132741218 0.69207847 
P35658 NUP214 1 613 Site Both 0.1233 0.69055 -0.1 0.223273715 0.40685096 
P35658 NUP214 1 614 Site Both 0.0896 0.77943 -0.1 0.189609236 0.50795571 
P35658 NUP214 1 616 Site Both 0.0038 0.98673 -0.1 0.10377368 0.74560734 
P35658 NUP214 1 1134 Site Both 0.0952 0.76133 -0.1 0.195229106 0.47797702 
P35658 NUP214 1 496 Site Both -0.184 0.48832 -0.1 -0.08368789 0.79704572 
P35658 NUP214 1 1905 Site Both 0.102 0.75105 -0.1 0.202038684 0.48282553 
P35658 NUP214 1 501 Site Both -0.109 0.73332 -0.1 -0.00913283 0.97975 
P35658 NUP214 1 503 Site Both -0.176 0.52077 -0.1 -0.07571411 0.8319825 
P35658 NUP214 1 1146 Site Both -0.18 0.51124 -0.1 -0.08021673 0.81537205 
P35658 NUP214 1 1275 Site Both -0.093 0.7694 -0.1 0.007249102 0.98261543 
P35658 NUP214 1 509 Site Both -0.22 0.37357 -0.1 -0.120074 0.70495902 




Region TopN 0.6932 0.10489 0.05 0.643243005 0.15352465 




Region TopSpeed -0.504 0.22708 -0.39 -0.11414456 0.86428932 
P41235 HNF4A 1 
(1 of 
166,167,170) 
Region TopN 0.2915 0.54815  0.291460632 0.58728077 
P42167 TMPO 1 264 Site Both -0.351 0.14727 -0.14 -0.21084197 0.45686225 
P42167 TMPO 1 265 Site Both -0.47 0.06485 -0.14 -0.329539 0.22202586 
P42857 NSG1 1 
(1 of 
130,137,138) 
Region TopSpeed      









Region Both 0.0427 0.89829  0.042717156 0.91129339 
P48382 RFX5 1 433 Site Both -0.434 0.06946 0.09 -0.5238683 0.03105627 
P48382 RFX5 1 442 Site Both -0.441 0.06827 0.09 -0.53074098 0.03028951 
P48382 RFX5 1 439 Site Both -0.45 0.06179 0.09 -0.5396056 0.02674372 
P48431 SOX2 1 246 Site Both -0.709 0.0054 -0.72 0.01124884 0.97877402 




P48634 PRRC2A 1 1796 Site Both 0.0916 0.77465 0.09 0.001641614 0.99576765 
P48634 PRRC2A 1 1790 Site Both 0.0601 0.85824 0.09 -0.02990007 0.92831607 
P48634 PRRC2A 1 1788 Site Both 0.0601 0.85824 0.09 -0.02990007 0.92831607 
P49321 NASP 1 690 Site Both -0.297 0.3167 0.04 -0.33717117 0.29696117 
P49321 NASP 1 677 Site Both -0.297 0.3167 0.04 -0.33717117 0.29696117 
P49321 NASP 1 678 Site Both -0.244 0.45057 0.04 -0.28385408 0.4009486 
P49336 CDK8 1 420 Site Both 0.194 0.44512  0.194045694 0.48576359 
P49336 CDK8 1 419 Site Both 0.3019 0.1975  0.301947988 0.22504717 
P49336 CDK8 1 411 Site Both 0.0728 0.83276  0.072841649 0.84495868 
P49336 CDK8 1 410 Site Both 0.2427 0.30747  0.242736362 0.35793478 
P49750 YLPM1 1 751 Site TopSpeed -0.186 0.73332 -0.03 -0.15611039 0.7882435 
P49790 NUP153 1 (1 of 197,199) Region TopSpeed 0.2346 0.65473 0.06 0.174635259 0.75179055 






Region Both 0.0674 0.83909 0.06 0.007418259 0.98261543 
P49790 NUP153 1 
(1 of 
776,778,780) 
Region Both 0.0881 0.82977 0.06 0.0281486 0.94241548 
P49790 NUP153 1 (1 of 1178,1179) Region Both 0.2486 0.31176 0.06 0.188610023 0.52599901 
P49790 NUP153 1 (1 of 1114,1115) Region Both -0.696 0.01956 0.06 -0.75641094 0.0125797 
P49790 NUP153 1 897 Site Both -0.085 0.88252 0.06 -0.14459536 0.80312346 
P49790 NUP153 1 515 Site Both 0.4832 0.05597 0.06 0.423159773 0.12136128 
P49790 NUP153 1 771 Site Both 0.0426 0.92396 0.06 -0.01744124 0.9722008 
P49790 NUP153 1 1031 Site Both 0.0602 0.85694 0.06 0.00017259 0.99908938 
P49790 NUP153 1 520 Site Both 0.3104 0.22708 0.06 0.250442561 0.39293271 
P49790 NUP153 1 1159 Site TopSpeed 0.1647 0.7694 0.06 0.104655886 0.87523489 
P49790 NUP153 1 519 Site Both 0.5734 0.01865 0.06 0.51342951 0.04036339 
P49790 NUP153 1 908 Site Both -0.131 0.73332 0.06 -0.19073954 0.60786377 
P49790 NUP153 1 909 Site Both -0.079 0.84852 0.06 -0.13858992 0.71678949 
P49790 NUP153 1 783 Site Both 0.0783 0.84852 0.06 0.018291545 0.97001968 
P49790 NUP153 1 534 Site Both 0.4046 0.11222 0.06 0.344556137 0.19530979 
P49790 NUP153 1 535 Site Both 0.5024 0.03892 0.06 0.442364767 0.08451531 
P49790 NUP153 1 1177 Site Both 0.2841 0.24051 0.06 0.224072364 0.42146519 
P49790 NUP153 1 921 Site Both -0.085 0.83549 0.06 -0.14490984 0.70710977 
P49790 NUP153 1 1180 Site Both 0.2841 0.24051 0.06 0.224072364 0.42146519 
P49790 NUP153 1 543 Site Both 0.135 0.65532 0.06 0.074964041 0.83417348 
P49790 NUP153 1 544 Site Both 0.135 0.65532 0.06 0.074964041 0.83417348 
P49790 NUP153 1 548 Site Both 0.0868 0.78918 0.06 0.02683305 0.93373979 
P49790 NUP153 1 550 Site Both 0.1729 0.51992 0.06 0.112854704 0.71678949 
P49790 NUP153 1 937 Site Both -0.039 0.90979 0.06 -0.09922357 0.75179055 
P49790 NUP153 1 947 Site Both 0.1483 0.59754 0.06 0.088342466 0.78573066 
P49790 NUP153 1 1078 Site TopSpeed -0.223 0.49818 0.06 -0.28337146 0.39253732 




P49790 NUP153 1 624 Site Both -0.177 0.51686 0.06 -0.23742102 0.38360195 
P49790 NUP153 1 115 Site Both 0.6077 0.1456 0.06 0.547679511 0.22202586 
P49790 NUP153 1 761 Site Both -0.094 0.81444 0.06 -0.15440366 0.69221229 
P49790 NUP153 1 630 Site Both -0.122 0.70725 0.06 -0.18192196 0.54824901 
P49790 NUP153 1 759 Site Both -0.094 0.81444 0.06 -0.15440366 0.69221229 
P49790 NUP153 1 632 Site Both 0.0543 0.86659 0.06 -0.00569009 0.9862528 
P49790 NUP153 1 633 Site Both -0.025 0.94416 0.06 -0.08521236 0.79441218 
P49790 NUP153 1 893 Site Both 0.1233 0.83402 0.06 0.063330156 0.92400636 
P49792 RANBP2 1 (1 of 1953,1954) Region TopSpeed 0.1637 0.76942 -0.06 0.223658076 0.69130082 






Region TopN -0.101 0.86086 -0.06 -0.04055195 0.94241548 
P49792 RANBP2 1 1894 Site Both -0.267 0.25172 -0.06 -0.20704984 0.45276858 
P49792 RANBP2 1 1399 Site Both -0.101 0.75713 -0.06 -0.04064314 0.91692242 
P49848 TAF6 1 (1 of 595,598) Region Both -0.018 0.97703 0.13 -0.14837728 0.70101954 
P49848 TAF6 1 481 Site TopSpeed 0.335 0.4663 0.13 0.204965358 0.70759286 
P49848 TAF6 1 594 Site Both -0.018 0.97703 0.13 -0.14837728 0.70101954 
P49848 TAF6 1 587 Site Both -0.053 0.89829 0.13 -0.18344512 0.62321657 




Region TopSpeed -0.41 0.08291 -0.01 -0.39962593 0.11121166 
P50454 SERPINH1 1 122 Site TopSpeed 0.1561 0.77943 0.1 0.056078791 0.92831607 
P51003 PAPOLA 1 706 Site TopN -0.052 0.89886 0.14 -0.19206099 0.60078955 
P51003 PAPOLA 1 709 Site TopN -0.052 0.89886 0.14 -0.19206099 0.60078955 







Region Both 0.0061 0.98301 0.08 -0.07387311 0.84621405 





Region Both 0.4815 0.24375 0.08 0.40152833 0.39591243 




Region TopSpeed -0.319 0.49928 0.08 -0.3988956 0.4009486 




Region Both 0.3732 0.12517 0.08 0.293242219 0.25550595 





Region Both -0.174 0.63582 0.08 -0.25367277 0.4590033 
P51610 HCFC1 1 (1 of 695,698) Region TopSpeed 0.7684 0.03462 0.08 0.688397988 0.06815382 
P51610 HCFC1 1 1153 Site Both 0.2709 0.24543 0.08 0.190887637 0.49565552 
P51610 HCFC1 1 771 Site Both 0.2159 0.37335 0.08 0.135945211 0.66085936 




P51610 HCFC1 1 518 Site Both 0.8747 0.00036 0.08 0.794678273 0.00138288 
P51610 HCFC1 1 775 Site Both 0.5331 0.04016 0.08 0.453052993 0.10340696 
P51610 HCFC1 1 779 Site Both 0.5099 0.05342 0.08 0.42991359 0.1277745 
P51610 HCFC1 1 658 Site Both 0.3732 0.12517 0.08 0.293242219 0.25550595 
P51610 HCFC1 1 787 Site Both 0.5436 0.03624 0.08 0.463628064 0.09202231 
P51610 HCFC1 1 788 Site Both 0.3688 0.12517 0.08 0.288799917 0.25580836 
P51610 HCFC1 1 405 Site Both -0.076 0.85398 0.08 -0.15567815 0.69098468 
P51610 HCFC1 1 660 Site TopN -0.236 0.65395 0.08 -0.31611791 0.53711129 
P51610 HCFC1 1 797 Site Both 0.1278 0.67468 0.08 0.047815737 0.90677977 
P51610 HCFC1 1 800 Site Both 0.0998 0.74963 0.08 0.019823147 0.95206316 
P51610 HCFC1 1 801 Site Both 0.1028 0.73531 0.08 0.022837842 0.94241548 
P51610 HCFC1 1 419 Site Both -0.083 0.84025 0.08 -0.16286141 0.67158708 
P51610 HCFC1 1 806 Site Both -0.007 0.98301 0.08 -0.08673132 0.79409661 
P51610 HCFC1 1 808 Site Both 0.1346 0.64952 0.08 0.054605187 0.88697434 
P51610 HCFC1 1 685 Site Both 0.241 0.3332 0.08 0.160953818 0.60434096 
P51610 HCFC1 1 562 Site Both -0.139 0.63582 0.08 -0.21916793 0.41618591 
P51610 HCFC1 1 563 Site Both -0.126 0.67542 0.08 -0.20591 0.45311328 
P51610 HCFC1 1 566 Site Both -0.1 0.75105 0.08 -0.17992526 0.52819421 
P51610 HCFC1 1 569 Site Both -0.122 0.69245 0.08 -0.20206357 0.46477752 
P51610 HCFC1 1 446 Site Both 0.4815 0.24375 0.08 0.40152833 0.39591243 
P51610 HCFC1 1 703 Site TopSpeed 0.7697 0.03441 0.08 0.689658664 0.06767492 
P51610 HCFC1 1 574 Site Both -0.093 0.76984 0.08 -0.17254106 0.56143055 
P51610 HCFC1 1 575 Site Both -0.131 0.65608 0.08 -0.2113882 0.43520501 
P51610 HCFC1 1 579 Site Both 0.5449 0.01893 0.08 0.464923365 0.05085475 
P51610 HCFC1 1 586 Site Both 0.2894 0.21736 0.08 0.209424944 0.43520501 
P51610 HCFC1 1 587 Site Both 0.1436 0.61976 0.08 0.06356562 0.86428932 
P51610 HCFC1 1 588 Site Both 0.1839 0.51124 0.08 0.103892731 0.75067469 
P51610 HCFC1 1 848 Site TopSpeed 0.0671 0.87961 0.08 -0.01288798 0.97975 
P51610 HCFC1 1 1234 Site Both 0.4319 0.12517 0.08 0.351901957 0.23715992 
P51610 HCFC1 1 726 Site Both -0.037 0.91819 0.08 -0.11728657 0.71631465 
P51610 HCFC1 1 1239 Site Both -0.635 0.00841 0.08 -0.71453363 0.00381407 
P51610 HCFC1 1 1238 Site Both -0.515 0.0296 0.08 -0.59533246 0.0125797 
P51610 HCFC1 1 858 Site Both 1.003 0.00078 0.08 0.922995735 0.00248528 
P51610 HCFC1 1 1243 Site Both -0.598 0.01937 0.08 -0.6784639 0.00886704 
P51610 HCFC1 1 861 Site Both 0.98 0.00099 0.08 0.899963929 0.00315997 
P51610 HCFC1 1 1246 Site Both 0.2755 0.35377 0.08 0.195460153 0.60078955 
P51610 HCFC1 1 607 Site Both -0.671 0.11674 0.08 -0.75124756 0.09202231 
P51610 HCFC1 1 480 Site Both 0.1185 0.76383 0.08 0.038521447 0.92831607 
P51610 HCFC1 1 870 Site TopSpeed 0.2606 0.25987 0.08 0.18061222 0.52815702 
P51610 HCFC1 1 490 Site Both 0.2632 0.26438 0.08 0.183249811 0.52819421 
P51610 HCFC1 1 619 Site Both 0.3695 0.1272 0.08 0.289464076 0.26010785 
P51610 HCFC1 1 620 Site Both 0.5312 0.0278 0.08 0.451180812 0.07461082 




P51610 HCFC1 1 495 Site Both -0.175 0.5556 0.08 -0.2548633 0.37870029 
P51610 HCFC1 1 623 Site Both 0.5038 0.03624 0.08 0.423762568 0.09810077 
P51610 HCFC1 1 496 Site Both -0.137 0.65436 0.08 -0.21722021 0.4378204 
P51610 HCFC1 1 498 Site Both -0.157 0.59356 0.08 -0.23676741 0.39591243 
P51610 HCFC1 1 625 Site Both 0.5055 0.03624 0.08 0.425513215 0.09810077 
P51610 HCFC1 1 1150 Site Both 0.2297 0.34289 0.08 0.14973261 0.6241827 
P52594 AGFG1 1 362 Site Both 0.0496 0.90456 -0.11 0.159553644 0.6806514 
P52594 AGFG1 1 367 Site Both 0.0403 0.92718 -0.11 0.150349468 0.70052671 
P52594 AGFG1 1 359 Site Both 0.0624 0.87352 -0.11 0.172409555 0.65348486 





Region TopSpeed -1.053 0.01277 0.01 -1.06334025 0.0125797 






Region Both -0.193 0.73332 0.01 -0.20264149 0.71329871 
P54253 ATXN1 1 22 Site Both -0.411 0.10095  -0.41134357 0.12136128 






Region TopSpeed -0.158 0.77669 -0.02 -0.13795793 0.81593663 









Region Both -0.281 0.33282 0.02 -0.30120122 0.34894985 
P55198 MLLT6 1 412 Site Both 0.067 0.85694  0.067015024 0.87022092 
P55198 MLLT6 1 413 Site Both 0.1993 0.48128  0.199276697 0.51295544 
P55198 MLLT6 1 414 Site Both 0.1416 0.67242  0.14160748 0.6902866 





Region TopSpeed -0.759 0.02553 -0.02 -0.73857424 0.03549576 
P57740 NUP107 1 (1 of 64,66) Region TopSpeed -0.377 0.38874 0.15 -0.52672942 0.24428434 
P78312 FAM193A 1 (1 of 707,708) Region Both 0.374 0.12132  0.374017556 0.14474479 
P78312 FAM193A 1 709 Site Both 0.3519 0.13469  0.351885388 0.16525791 
P78337 PITX1 1 195 Site Both 0.6962 0.10288  0.696245482 0.12136128 
P78337 PITX1 1 188 Site Both 0.6962 0.10288  0.696245482 0.12136128 
P78344 EIF4G2 1 
(1 of 
506,508,514) 
Region TopSpeed -0.016 0.98301 -0.09 0.073868264 0.914156 
P78347 GTF2I 1 202 Site TopSpeed -0.12 0.76383 0.08 -0.20002076 0.60078955 
P80192 MAP3K9 1 118 Site TopSpeed -1.008 0.0162  -1.00801526 0.01783221 
P82979 SARNP 1 115 Site TopN -0.131 0.73332 0.04 -0.17053373 0.66085936 










Region Both 0.0721 0.8305 -0.04 0.112092343 0.71917436 
P85037 FOXK1 1 
(1 of 
530,531,534) 
Region Both -0.013 0.97926 -0.04 0.026859541 0.93373979 
P85037 FOXK1 1 549 Site Both -0.081 0.80863 -0.04 -0.04102832 0.91674426 
P85037 FOXK1 1 679 Site Both -0.132 0.66876 -0.04 -0.09240613 0.78573066 
P85037 FOXK1 1 681 Site Both -0.123 0.70131 -0.04 -0.08304899 0.80455849 
P85037 FOXK1 1 562 Site Both -0.081 0.80863 -0.04 -0.04102832 0.91674426 
P85037 FOXK1 1 691 Site Both -0.07 0.83321 -0.04 -0.03011871 0.92831607 
P85037 FOXK1 1 695 Site Both 0.1169 0.70725 -0.04 0.156931817 0.60078955 
P98082 DAB2 1 
(1 of 
471,473,477) 
Region Both -0.389 0.18539 0.02 -0.40920172 0.19131351 
P98082 DAB2 1 464 Site Both -0.283 0.33696 0.02 -0.3032347 0.3509044 
Q02078 MEF2A 1 280 Site Both -0.002 0.99326  -0.00165042 0.99576765 
Q02078 MEF2A 1 281 Site Both -0.013 0.97884  -0.01340033 0.97305303 




Region TopSpeed 0.1105 0.85197 0.07 0.040470518 0.94241548 
Q02880 TOP2B 1 
(1 of 
788,799,813) 
Region TopSpeed -0.509 0.22228 0.17 -0.67905884 0.1324731 
Q02880 TOP2B 1 1466 Site TopN -2.287 ####### 0.17 -2.45715473 2.45E-07 
Q04637 EIF4G1 1 61 Site Both -0.325 0.26722 0.01 -0.33466987 0.30324723 
Q04721 NOTCH2 1 1297 Site Both -0.475 0.04462 -0.23 -0.24547612 0.35176469 
Q04724 TLE1 1 
(1 of 
296,297,298) 
Region Both 0.3565 0.13039 0.65 -0.29346717 0.24697571 
Q04724 TLE1 1 290 Site Both 0.335 0.15676 0.65 -0.31496169 0.20843731 
Q04724 TLE1 1 284 Site Both 0.2881 0.22708 0.65 -0.36193576 0.16010262 
Q04724 TLE1 1 286 Site Both 0.2881 0.22708 0.65 -0.36193576 0.16010262 
Q04725 TLE2 1 334 Site Both 0.273 0.23985  0.27303963 0.28033045 
Q04726 TLE3 1 289 Site Both -0.014 0.97865 0.34 -0.35430995 0.17519547 
Q04726 TLE3 1 293 Site Both 0.0534 0.87183 0.34 -0.28661534 0.28012236 
Q04726 TLE3 1 294 Site Both 0.0317 0.93078 0.34 -0.30826805 0.23658316 
Q04726 TLE3 1 295 Site Both 0.0055 0.98301 0.34 -0.3345212 0.1911075 
Q04726 TLE3 1 328 Site TopSpeed 0.3043 0.29634 0.34 -0.03573367 0.92831607 
Q04726 TLE3 1 296 Site Both 0.0055 0.98301 0.34 -0.3345212 0.1911075 
Q04726 TLE3 1 332 Site TopSpeed 0.3043 0.29634 0.34 -0.03573367 0.92831607 
Q04726 TLE3 1 333 Site TopSpeed 0.3043 0.29634 0.34 -0.03573367 0.92831607 
Q04726 TLE3 1 286 Site Both 0.0283 0.93512 0.34 -0.31168198 0.22599199 




Region Both 0.3727 0.11817 0.06 0.312729424 0.20838287 
Q04727 TLE4 1 321 Site Both -0.282 0.25706 0.06 -0.3419141 0.20309052 
Q04727 TLE4 1 330 Site Both 0.3719 0.11925 0.06 0.311906841 0.20843731 




Q04727 TLE4 1 318 Site Both -0.282 0.25706 0.06 -0.3419141 0.20309052 
Q04743 EMX2 1 25 Site Both 0.6476 0.02553  0.647576092 0.02945771 
Q04743 EMX2 1 20 Site Both 0.6476 0.02553  0.647576092 0.02945771 







Region TopSpeed 0.1397 0.80863 0.13 0.009707716 0.9862528 
Q06546 GABPA 1 264 Site Both 0.2288 0.52697 0.16 0.068835888 0.89452881 
Q06546 GABPA 1 278 Site Both 0.2153 0.5556 0.16 0.055276238 0.914156 
Q07912 TNK2 1 817 Site Both 0.2249 0.35734  0.224890877 0.40655976 
Q07912 TNK2 1 818 Site Both 0.1937 0.4663  0.193706048 0.49907317 
Q07912 TNK2 1 823 Site Both 0.3403 0.14159  0.340301007 0.17354814 




Region Both 0.3688 0.12425 -0.04 0.408797496 0.10429034 
Q0D2I5 IFFO1 1 183 Site Both 0.5817 0.04711  0.581658753 0.05209999 
Q0D2I5 IFFO1 1 173 Site Both 0.5997 0.04016  0.599662231 0.04461592 
Q0D2I5 IFFO1 1 175 Site Both 0.5994 0.04016  0.599414009 0.04461592 







Region TopN -1E-03 0.99808 0.23 -0.23096878 0.67805155 








Region TopSpeed -0.103 0.86075 0.23 -0.33260834 0.50549352 
Q12830 BPTF 1 2081 Site TopSpeed -0.131 0.73657 0.23 -0.36134063 0.25763321 
Q12830 BPTF 1 2093 Site Both -0.241 0.30217 0.23 -0.47132736 0.04862263 
Q12830 BPTF 1 2094 Site Both -0.322 0.16929 0.23 -0.55169354 0.01961629 
Q12830 BPTF 1 1709 Site Both 0.1569 0.58701 0.23 -0.07313964 0.84490759 
Q12830 BPTF 1 1712 Site Both 0.098 0.77465 0.23 -0.1319771 0.70101954 
Q12830 BPTF 1 1749 Site Both 0.1344 0.64584 0.23 -0.09560922 0.75915012 
Q12830 BPTF 1 1750 Site Both 0.1415 0.63582 0.23 -0.08851561 0.79074906 
Q12830 BPTF 1 1719 Site Both 0.098 0.77465 0.23 -0.1319771 0.70101954 
Q12830 BPTF 1 1752 Site Both 0.1153 0.71246 0.23 -0.11467676 0.70759286 
Q12830 BPTF 1 1753 Site Both 0.0825 0.7987 0.23 -0.14752854 0.63222257 
Q12830 BPTF 1 1754 Site Both 0.0308 0.93078 0.23 -0.19921989 0.48356887 
Q12830 BPTF 1 1755 Site Both 0.1055 0.73332 0.23 -0.12448369 0.69740433 
Q12830 BPTF 1 2230 Site TopSpeed 0.1124 0.77152 0.23 -0.11758757 0.76034174 
Q12830 BPTF 1 2237 Site TopSpeed 0.1124 0.77152 0.23 -0.11758757 0.76034174 











Region TopSpeed -0.43 0.30656 -0.14 -0.289946 0.58728077 
Q12948 FOXC1 1 
(1 of 
329,330,335) 
Region Both -0.574 0.01536 -0.2 -0.37363455 0.14474479 
Q12948 FOXC1 1 (1 of 487,506) Region TopSpeed 0.4962 0.23195 -0.2 0.696246463 0.12136128 
Q12948 FOXC1 1 339 Site Both -0.574 0.01536 -0.2 -0.37363455 0.14474479 
Q12948 FOXC1 1 340 Site Both -0.574 0.01536 -0.2 -0.37363455 0.14474479 
Q13188 STK3 1 (1 of 329,330) Region TopSpeed -1.455 0.00077 -0.11 -1.34545449 0.0023022 
Q13188 STK3 1 333 Site TopSpeed -1.347 0.0014 -0.11 -1.23726976 0.00441517 




Region TopSpeed -0.04 0.92796 -0.01 -0.03000793 0.94022854 
Q13310 PABPC4 1 (1 of 643,644) Region Both -0.058 0.86075 -0.07 0.0122177 0.9764823 
Q13492 PICALM 1 297 Site Both -0.377 0.38874 -0.2 -0.17673113 0.75024933 







Region TopSpeed 0.2384 0.46631 0.13 0.108356034 0.7935387 
Q14119 VEZF1 1 110 Site Both 0.3102 0.19579  0.310173439 0.22504717 
Q14119 VEZF1 1 117 Site Both 0.2598 0.28478  0.259826876 0.34122004 
Q14119 VEZF1 1 118 Site Both 0.2598 0.28478  0.259826876 0.34122004 
Q14119 VEZF1 1 111 Site Both 0.2505 0.30747  0.250510396 0.35793478 





Region TopSpeed 0.0799 0.8926 -0.07 0.149872023 0.79526178 




Region TopN -0.047 0.94008 -0.07 0.023360684 0.97340685 




Region TopSpeed -0.005 0.98673 -0.07 0.065277072 0.89043821 
Q14157 UBAP2L 1 453 Site Both -0.111 0.73038 -0.07 -0.04129292 0.914156 
Q14157 UBAP2L 1 454 Site Both -0.901 0.02821 -0.07 -0.83100091 0.04891006 
Q14157 UBAP2L 1 783 Site TopN -0.466 0.25945 -0.07 -0.39571021 0.40541964 
Q14157 UBAP2L 1 439 Site Both -0.953 0.01761 -0.07 -0.88286676 0.03189479 
Q14157 UBAP2L 1 444 Site Both -0.165 0.53663 -0.07 -0.09534715 0.7587687 
Q14157 UBAP2L 1 445 Site Both -0.938 0.01956 -0.07 -0.86839374 0.03735066 
Q14157 UBAP2L 1 446 Site Both -0.147 0.60052 -0.07 -0.07656378 0.81593663 
Q14247 CTTN 1 344 Site TopN 0.0346 0.96144 0.03 0.004593925 0.99576765 
Q14444 CAPRIN1 1 (1 of 478,479) Region Both -0.323 0.40787 -0.05 -0.27296242 0.55702358 
Q14444 CAPRIN1 1 497 Site Both -0.323 0.40787 -0.05 -0.27296242 0.55702358 










Region TopSpeed 0.0708 0.84614 0.14 -0.06915149 0.86428932 
Q14684 RRP1B 1 736 Site TopSpeed 0.2675 0.59117 0.09 0.177464549 0.74875917 
Q14684 RRP1B 1 731 Site TopSpeed 0.1014 0.86086 0.09 0.011404101 0.98322904 
Q14684 RRP1B 1 735 Site TopSpeed 0.2675 0.59117 0.09 0.177464549 0.74875917 







Region Both 0.0146 0.97926 0.16 -0.14535495 0.70754983 
Q14686 NCOA6 1 1641 Site Both -0.042 0.90087 0.16 -0.20192891 0.47797702 
Q14686 NCOA6 1 1107 Site TopSpeed 0.5935 0.15848 0.16 0.433475824 0.35176469 
Q14686 NCOA6 1 1933 Site Both 0.2269 0.38695 0.16 0.06692767 0.86428932 
Q14686 NCOA6 1 1649 Site Both -0.033 0.92795 0.16 -0.19321073 0.49907317 
Q14966 ZNF638 1 789 Site Both -0.005 0.98673 0.1 -0.10542768 0.7935387 





Region Both 0.3852 0.18604 -0.1 0.485151346 0.12136128 
Q14980 NUMA1 1 1844 Site TopSpeed -0.342 0.14074 -0.1 -0.24219947 0.35176469 





Region TopSpeed 0.2495 0.63227 0.33 -0.08050699 0.90986391 
Q15061 WDR43 1 390 Site TopSpeed 0.0357 0.96038 -0.05 0.085674292 0.90457041 




Region TopSpeed 0.2766 0.57065 0 0.276649165 0.60078955 
Q15418 RPS6KA1 1 734 Site TopSpeed 0.3029 0.52697 0.19 0.112863293 0.86428932 
Q15637 SF1 1 328 Site Both 0.0594 0.86086 0.01 0.04941044 0.90473946 
Q15637 SF1 1 331 Site Both 0.088 0.78918 0.01 0.077975206 0.83189333 
Q15637 SF1 1 333 Site Both 0.0123 0.97926 0.01 0.002251456 0.99576765 
Q15637 SF1 1 337 Site Both 0.0978 0.75877 0.01 0.087787714 0.7898207 
Q15637 SF1 1 338 Site Both 0.0054 0.98301 0.01 -0.00463028 0.98815648 
Q15637 SF1 1 342 Site Both -0.075 0.81814 0.01 -0.08514038 0.79704572 
Q15637 SF1 1 315 Site Both 0.1932 0.44818 0.01 0.183198879 0.51842158 
Q15652 JMJD1C 1 1457 Site Both -0.298 0.20372 -0.1 -0.19766751 0.46976784 
Q15652 JMJD1C 1 650 Site TopSpeed -1.498 0.00059 -0.1 -1.39831188 0.00147127 
Q15652 JMJD1C 1 1453 Site Both -0.292 0.21005 -0.1 -0.19160086 0.48891404 





Region TopSpeed 0.497 0.23195 0.31 0.186981288 0.73658347 
Q15723 ELF2 1 378 Site Both 0.2465 0.30448 0.03 0.216484188 0.43085957 




Q15723 ELF2 1 374 Site Both 0.2899 0.21821 0.03 0.259881991 0.31836649 
Q15723 ELF2 1 375 Site Both 0.2752 0.23985 0.03 0.245194097 0.3509044 
Q15750 TAB1 1 (1 of 399,400) Region Both -0.061 0.87667 -0.03 -0.03127127 0.93471134 
Q15750 TAB1 1 395 Site Both -0.072 0.86075 -0.03 -0.04154887 0.92511993 
Q15750 TAB1 1 396 Site Both -0.072 0.86075 -0.03 -0.04154887 0.92511993 
Q15942 ZYX 1 170 Site Both -0.099 0.76383 0.22 -0.31880081 0.22504717 
Q15942 ZYX 1 169 Site Both -0.099 0.76383 0.22 -0.31880081 0.22504717 
Q15942 ZYX 1 258 Site Both 0.0285 0.93452 0.22 -0.19151173 0.49566768 
Q16186 ADRM1 1 225 Site Both -0.268 0.31873 -0.28 0.012099766 0.97877402 
Q16186 ADRM1 1 213 Site Both -0.528 0.02433 -0.28 -0.24806466 0.3467146 
Q16186 ADRM1 1 217 Site Both -0.235 0.32056 -0.28 0.045423283 0.90986391 
Q16186 ADRM1 1 219 Site Both -0.271 0.25385 -0.28 0.009461637 0.97975 
Q16186 ADRM1 1 221 Site Both -0.291 0.23987 -0.28 -0.011301 0.97877402 
Q16186 ADRM1 1 222 Site Both -0.185 0.50057 -0.28 0.095410027 0.76863976 





Region TopSpeed 0.17 0.76319 -0.12 0.289971045 0.58728077 
Q2KHR2 RFX7 1 342 Site Both 0.1635 0.54815  0.163453229 0.58728077 







Region TopSpeed 0.2013 0.54815 -0.05 0.251299495 0.45686225 
Q2KHR3 QSER1 1 290 Site Both -0.429 0.16065 -0.05 -0.37853671 0.2501051 
Q2KHR3 QSER1 1 105 Site Both 0.0694 0.83511 -0.05 0.119353487 0.70495902 
Q2KHR3 QSER1 1 558 Site Both -0.095 0.81411 -0.05 -0.04543834 0.92229001 
Q2KHR3 QSER1 1 1270 Site TopSpeed 0.2013 0.54815 -0.05 0.251299495 0.45686225 
Q2KHR3 QSER1 1 282 Site Both -0.429 0.16065 -0.05 -0.37853671 0.2501051 
Q2KHR3 QSER1 1 284 Site Both -0.429 0.16065 -0.05 -0.37853671 0.2501051 
Q2KHR3 QSER1 1 285 Site Both -0.429 0.16065 -0.05 -0.37853671 0.2501051 
Q2M2I8 AAK1 1 360 Site TopSpeed -0.175 0.63582 -0.21 0.034998897 0.92993035 
Q2M2I8 AAK1 1 359 Site TopSpeed -0.175 0.63582 -0.21 0.034998897 0.92993035 
Q2Q1W2 TRIM71 1 163 Site TopSpeed 0.1488 0.78918  0.148784548 0.79694509 
Q2TAL8 QRICH1 1 364 Site TopSpeed 0.2439 0.30048 0.16 0.083921264 0.79609599 
Q495X7 TRIM60 1 465 Site TopSpeed 0.1679 0.76383  0.167890106 0.76207249 
Q4KMP7 TBC1D10B 1 51 Site Both 0.0068 0.98301 -0.05 0.05684767 0.88132546 
Q4KMP7 TBC1D10B 1 43 Site Both 0.0068 0.98301 -0.05 0.05684767 0.88132546 
Q4KMP7 TBC1D10B 1 46 Site Both 0.0068 0.98301 -0.05 0.05684767 0.88132546 
Q4VCS5 AMOT 1 
(1 of 
182,185,186) 
Region TopN -0.163 0.76996 0.36 -0.52260377 0.24840102 
Q4VCS5 AMOT 1 195 Site Both 0.4556 0.05342 0.36 0.095550495 0.7592459 
Q4VCS5 AMOT 1 196 Site Both 0.4136 0.08262 0.36 0.053646884 0.88767054 
Q4VCS5 AMOT 1 774 Site Both 0.6213 0.01516 0.36 0.261314361 0.35629934 




Q4VCS5 AMOT 1 780 Site Both 0.4024 0.08938 0.36 0.042400415 0.91220682 
Q4VCS5 AMOT 1 274 Site Both 0.5964 0.01486 0.36 0.236427738 0.39128449 
Q52LR7 EPC2 1 750 Site Both 0.1384 0.73082  0.138400527 0.72107369 





Region Both 0.3228 0.29634 0.31 0.01279594 0.97975 
Q5H9F3 BCORL1 1 133 Site Both -0.178 0.51686 0.31 -0.4875276 0.04862263 
Q5H9F3 BCORL1 1 127 Site Both -0.123 0.68431 0.31 -0.43278712 0.07751725 
Q5HYC2 KIAA2026 1 1452 Site Both 0.0878 0.78632  0.087775176 0.79409661 
Q5HYW2 NHSL2 1 350 Site Both 0.2113 0.40866  0.211293614 0.45686225 
Q5JSZ5 PRRC2B 1 (1 of 1984,1990) Region Both -0.122 0.73332 -0.06 -0.06159262 0.88667585 
Q5JSZ5 PRRC2B 1 1793 Site Both -0.194 0.43956 -0.06 -0.13436017 0.66352405 
Q5JSZ5 PRRC2B 1 1796 Site Both -0.212 0.38951 -0.06 -0.15212105 0.61468324 
Q5JSZ5 PRRC2B 1 1801 Site Both -0.181 0.49928 -0.06 -0.12141756 0.70101954 
Q5JSZ5 PRRC2B 1 1808 Site Both -0.169 0.52811 -0.06 -0.10917434 0.72451182 
Q5JSZ5 PRRC2B 1 1982 Site Both -0.122 0.73332 -0.06 -0.06159262 0.88667585 




Region Both -0.189 0.59117 -0.08 -0.10919225 0.79074906 
Q5SW79 CEP170 1 1165 Site TopN -0.397 0.35377 -0.04 -0.35679226 0.46658124 
Q5SW79 CEP170 1 1331 Site Both 0.2536 0.29634 -0.04 0.293566484 0.25763321 
Q5SW79 CEP170 1 1339 Site Both 0.1937 0.4579 -0.04 0.233670095 0.38842528 
Q5SW79 CEP170 1 1342 Site Both 0.212 0.38941 -0.04 0.252042736 0.34100654 
Q5SW79 CEP170 1 1343 Site Both 0.2239 0.35377 -0.04 0.263914465 0.3122305 
Q5T0B9 ZNF362 1 (1 of 217,220) Region TopSpeed   0.08   



















Region Both 0.3051 0.20318 0.08 0.225136019 0.40541964 
Q5T0B9 ZNF362 1 (1 of 114,116) Region Both 0.2145 0.39149 0.08 0.134514909 0.67158708 
Q5T0B9 ZNF362 1 408 Site TopSpeed 0.6753 0.00462 0.08 0.595330914 0.01331913 
Q5T0B9 ZNF362 1 113 Site Both 0.2145 0.39149 0.08 0.134514909 0.67158708 
Q5T0B9 ZNF362 1 138 Site Both 0.4046 0.09528 0.08 0.324578479 0.20309052 




Q5T6F2 UBAP2 1 (1 of 789,790) Region TopSpeed -0.198 0.73082 -0.02 -0.17753928 0.74875917 






Region Both -0.511 0.22228 -0.02 -0.49123341 0.28012236 
Q5T6F2 UBAP2 1 1006 Site Both 0.0851 0.81444 -0.02 0.105138382 0.76243442 
Q5T8P6 RBM26 1 691 Site TopSpeed -0.008 0.98301 0.08 -0.08788229 0.84495868 
Q5T8P6 RBM26 1 692 Site TopSpeed -0.008 0.98301 0.08 -0.08788229 0.84495868 




Region TopSpeed 0.1596 0.77465 0.08 0.079589268 0.90986391 
Q5VT52 RPRD2 1 417 Site Both 0.2186 0.38512 0.08 0.138568457 0.66528784 
Q5VT52 RPRD2 1 422 Site Both 0.2404 0.32626 0.08 0.160422834 0.60078955 
Q5VT52 RPRD2 1 424 Site Both 0.1164 0.73394 0.08 0.036407995 0.92657403 
Q5VT52 RPRD2 1 396 Site Both 0.1359 0.73082 0.08 0.055891788 0.90986391 
Q5VT52 RPRD2 1 399 Site Both 0.1359 0.73082 0.08 0.055891788 0.90986391 
Q5VT52 RPRD2 1 593 Site Both -0.032 0.93078 0.08 -0.11234665 0.72645216 
Q5VT52 RPRD2 1 596 Site Both -0.151 0.60052 0.08 -0.23104754 0.39591243 
Q5VT52 RPRD2 1 597 Site Both -0.103 0.74963 0.08 -0.18284874 0.53246758 
Q5VT52 RPRD2 1 404 Site Both -0.036 0.93284 0.08 -0.11591152 0.76243442 
Q5VT52 RPRD2 1 407 Site Both -0.036 0.93284 0.08 -0.11591152 0.76243442 
Q5VT52 RPRD2 1 602 Site Both -0.003 0.98679 0.08 -0.08342374 0.8081101 
Q5VT52 RPRD2 1 603 Site Both 0.004 0.98673 0.08 -0.07602774 0.83417348 
Q5VT52 RPRD2 1 604 Site Both -0.032 0.93078 0.08 -0.11234665 0.72645216 
Q5VT52 RPRD2 1 414 Site Both 0.1112 0.75105 0.08 0.031195672 0.92993035 
Q5VT52 RPRD2 1 415 Site Both 0.0678 0.85197 0.08 -0.01218549 0.97846125 
Q5VWN6 TASOR2 1 1097 Site Both -0.325 0.20701 0.27 -0.59517233 0.02357941 
Q5VWN6 TASOR2 1 1098 Site Both -0.325 0.20701 0.27 -0.59517233 0.02357941 
Q5VWN6 TASOR2 1 1099 Site Both -0.274 0.2807 0.27 -0.54438843 0.03735066 
Q5VWN6 TASOR2 1 1593 Site TopSpeed -0.011 0.98301 0.27 -0.28111704 0.60078955 
Q5VWN6 TASOR2 1 1595 Site TopSpeed -0.011 0.98301 0.27 -0.28111704 0.60078955 
Q5VWN6 TASOR2 1 1150 Site Both 0.2715 0.24375 0.27 0.001529204 0.99576765 
Q5XG87 TENT4A 1 769 Site TopSpeed 0.4079 0.33696  0.407925417 0.39128449 





Region Both 0.2788 0.56699 0.04 0.238770451 0.6680228 
Q6AI39 BICRAL 1 590 Site TopSpeed -0.171 0.76133  -0.17127397 0.7587687 
Q6MZP7 LIN54 1 106 Site Both -0.268 0.40384 -0.38 0.11152646 0.7935387 
Q6MZP7 LIN54 1 235 Site Both -0.335 0.24557 -0.38 0.0454572 0.92229001 
Q6MZP7 LIN54 1 238 Site Both -0.335 0.24557 -0.38 0.0454572 0.92229001 
Q6MZP7 LIN54 1 243 Site Both -0.335 0.24557 -0.38 0.0454572 0.92229001 









Region Both -0.113 0.77943 -0.06 -0.05272944 0.91559759 






Region TopSpeed 0.0607 0.92396 -0.06 0.120715705 0.85339519 
Q6P4R8 NFRKB 1 1156 Site Both 0.5752 0.01536 0.26 0.315203657 0.21242528 
Q6P4R8 NFRKB 1 1030 Site Both -0.108 0.7819 0.26 -0.36757368 0.24697571 
Q6P4R8 NFRKB 1 841 Site TopN -0.195 0.73082 0.26 -0.4552252 0.32647628 
Q6P4R8 NFRKB 1 1291 Site Both 0.0816 0.79813 0.26 -0.17841293 0.53711129 
Q6P4R8 NFRKB 1 750 Site Both 0.109 0.77943 0.26 -0.15095742 0.70101954 
Q6P4R8 NFRKB 1 1141 Site Both 0.4387 0.0892 0.26 0.178715654 0.58384107 
Q6P4R8 NFRKB 1 1174 Site Both 0.1838 0.59754 0.26 -0.07621936 0.86597032 
Q6P4R8 NFRKB 1 1051 Site TopSpeed 0.3691 0.39948 0.26 0.10911518 0.86597032 
Q6P4R8 NFRKB 1 863 Site TopN -0.522 0.21204 0.26 -0.78227365 0.07461082 
Q6PJT7 ZC3H14 1 (1 of 734,735) Region TopSpeed 0.4856 0.24051 0.15 0.33562007 0.49907317 
Q6PJT7 ZC3H14 1 360 Site TopSpeed -0.008 0.98301 0.15 -0.15807985 0.68490254 
Q6PJT7 ZC3H14 1 370 Site Both 0.2756 0.24051 0.15 0.125626215 0.69526006 
Q6PJT7 ZC3H14 1 365 Site TopSpeed 0.1493 0.70431 0.15 -0.00068618 0.9980702 
Q6PJT7 ZC3H14 1 374 Site Both 0.3142 0.19504 0.15 0.164151668 0.59767111 
Q6UN15 FIP1L1 1 253 Site Both -0.053 0.87051 0.22 -0.27291121 0.29540703 
Q6UN15 FIP1L1 1 205 Site Both 0.0272 0.93687 0.22 -0.19278331 0.49521567 
Q6UN15 FIP1L1 1 206 Site Both -0.083 0.81019 0.22 -0.302619 0.25580836 
Q6UN15 FIP1L1 1 207 Site Both -0.03 0.93452 0.22 -0.25037488 0.38169817 





Region TopSpeed -0.034 0.94008 0.31 -0.34352819 0.29975916 
Q6VMQ6 ATF7IP 1 
(1 of 
994,995,996) 
Region Both 0.3748 0.11664 0.31 0.064792775 0.86388013 
Q6VMQ6 ATF7IP 1 992 Site Both 0.2009 0.43056 0.31 -0.10910307 0.72881104 
Q6VMQ6 ATF7IP 1 988 Site Both 0.3705 0.14583 0.31 0.060524105 0.88578642 
Q6W2J9 BCOR 1 453 Site TopSpeed 0.5666 0.178 0.54 0.026614377 0.97001968 
Q6W2J9 BCOR 1 366 Site TopSpeed 0.3234 0.49198 0.54 -0.21658578 0.70052671 
Q6Y7W6 GIGYF2 1 678 Site Both 0.142 0.637 0.02 0.122002635 0.70495902 
Q6ZNB6 NFXL1 1 41 Site TopSpeed 0.1318 0.81619 -0.08 0.211833489 0.70495902 
Q6ZNB6 NFXL1 1 228 Site TopSpeed -1.348 0.0014 -0.08 -1.26814054 0.00360272 
Q6ZNB6 NFXL1 1 230 Site TopSpeed -1.348 0.0014 -0.08 -1.26814054 0.00360272 
Q6ZQY2 LRRC74B 1 294 Site TopN 0.2277 0.66876  0.227721626 0.68490254 
Q6ZRI6 C15orf39 1 635 Site Both 0.3232 0.18108 0.75 -0.4267629 0.09810077 




Region TopSpeed 0.1551 0.77943 0.13 0.025058424 0.9722008 




Q6ZU65 UBN2 1 1011 Site Both 0.2732 0.24051 0.11 0.163174049 0.58728077 
Q6ZU65 UBN2 1 1007 Site Both 0.4331 0.06881 0.11 0.323101849 0.20197226 
Q6ZW76 ANKS3 1 329 Site TopN 0.1085 0.85398  0.108496341 0.86597032 
Q6ZW76 ANKS3 1 333 Site TopN 0.1085 0.85398  0.108496341 0.86597032 
Q70E73 RAPH1 1 (1 of 805,807) Region Both -0.056 0.86134 -0.03 -0.02557883 0.93373979 
Q70E73 RAPH1 1 793 Site Both -0.056 0.86134 -0.03 -0.02557883 0.93373979 
Q7KZ85 SUPT6H 1 1526 Site Both -0.221 0.37192 0.12 -0.34080978 0.18417863 
Q7LBC6 KDM3B 1 (1 of 425,426) Region TopSpeed 0.1781 0.51124 0.14 0.038103145 0.92229001 
Q7LBC6 KDM3B 1 1284 Site TopSpeed 0.5537 0.18604 0.14 0.413742791 0.38169817 
Q7LBC6 KDM3B 1 428 Site TopSpeed 0.1781 0.51124 0.14 0.038103145 0.92229001 
Q7LBC6 KDM3B 1 429 Site TopSpeed 0.1781 0.51124 0.14 0.038103145 0.92229001 
Q7Z3K3 POGZ 1 
(1 of 
361,362,363) 
Region Both -0.118 0.84328 0.05 -0.16792283 0.76207249 




Region TopN -0.741 0.08254 0.05 -0.79103418 0.07186233 






Region Both -0.056 0.86086 0.05 -0.1062941 0.73229249 





Region Both -0.127 0.66876 0.05 -0.17703816 0.53670439 
Q7Z3K3 POGZ 1 434 Site Both -0.206 0.40049 0.05 -0.25575525 0.32395753 
Q7Z3K3 POGZ 1 310 Site TopSpeed 0.2674 0.59117 0.05 0.217382335 0.70052671 
Q7Z417 NUFIP2 1 (1 of 374,376) Region Both -0.371 0.13469 -0.17 -0.20053647 0.49565552 







Region Both -0.371 0.13469 -0.17 -0.20053647 0.49565552 







Region TopN -0.403 0.34289 -0.17 -0.23267705 0.67324247 
Q7Z417 NUFIP2 1 380 Site Both -0.371 0.13469 -0.17 -0.20053647 0.49565552 
Q7Z417 NUFIP2 1 396 Site Both -0.371 0.13469 -0.17 -0.20053647 0.49565552 
Q7Z434 MAVS 1 
(1 of 
300,301,307) 
Region TopSpeed -0.212 0.53065 -0.02 -0.19190006 0.60978896 
Q7Z434 MAVS 1 354 Site TopSpeed 0.0708 0.86086 -0.02 0.090798301 0.83417348 
Q7Z434 MAVS 1 366 Site Both -0.103 0.79071 -0.02 -0.08282834 0.85736486 
Q7Z460 CLASP1 1 578 Site Both -0.884 0.00235 -0.07 -0.81430515 0.00616466 
Q7Z589 EMSY 1 (1 of 504,506) Region Both -0.357 0.42251  -0.3569155 0.46658124 
Q7Z589 EMSY 1 1120 Site Both -0.239 0.30656  -0.23943881 0.35679661 




Q7Z589 EMSY 1 236 Site TopSpeed 0.0299 0.93131  0.029862092 0.92831607 
Q7Z589 EMSY 1 557 Site Both -0.078 0.84967  -0.07797854 0.86428932 
Q7Z589 EMSY 1 534 Site Both 0.1462 0.70431  0.146202259 0.70495902 
Q7Z589 EMSY 1 535 Site Both 0.1462 0.70431  0.146202259 0.70495902 
Q7Z589 EMSY 1 502 Site Both -0.357 0.42251  -0.3569155 0.46658124 
Q7Z589 EMSY 1 541 Site Both 0.1462 0.70431  0.146202259 0.70495902 
Q7Z6E9 RBBP6 1 98 Site Both -0.141 0.73082 0.03 -0.17056606 0.6680228 
Q7Z6E9 RBBP6 1 99 Site Both -0.141 0.73082 0.03 -0.17056606 0.6680228 
Q7Z6E9 RBBP6 1 92 Site Both -0.011 0.98301 0.03 -0.04079606 0.92831607 
Q7Z6J0 SH3RF1 1 520 Site Both -0.331 0.16909 0.18 -0.51110069 0.03740923 
Q7Z6J0 SH3RF1 1 505 Site Both -0.014 0.97926 0.18 -0.19356928 0.60078955 
Q7Z6J0 SH3RF1 1 524 Site Both -0.486 0.04016 0.18 -0.66604472 0.00616466 
Q7Z6J0 SH3RF1 1 519 Site Both -0.902 0.00059 0.18 -1.08181964 4.41E-05 





Region TopSpeed 0.1153 0.84725 0.05 0.065260979 0.92229001 
Q7Z6Z7 HUWE1 1 2922 Site Both -0.364 0.13469 0.05 -0.41436267 0.11121166 
Q7Z6Z7 HUWE1 1 2923 Site Both -0.299 0.22128 0.05 -0.34910488 0.18417863 
Q7Z6Z7 HUWE1 1 2926 Site Both -0.308 0.20879 0.05 -0.35771159 0.17421552 
Q7Z6Z7 HUWE1 1 2927 Site Both -0.301 0.22067 0.05 -0.35143401 0.18417863 
Q7Z739 YTHDF3 1 (1 of 218,219) Region Both 0.0077 0.98301 0.02 -0.01228336 0.9772446 
Q7Z739 YTHDF3 1 229 Site Both 0.0265 0.94045 0.02 0.006549465 0.98322904 
Q7Z739 YTHDF3 1 230 Site Both -0.086 0.78918 0.02 -0.10582048 0.73706765 
Q7Z739 YTHDF3 1 201 Site Both 0.1645 0.53987 0.02 0.144467134 0.62887819 
Q7Z739 YTHDF3 1 205 Site Both 0.2045 0.40698 0.02 0.184501355 0.51191244 
Q7Z739 YTHDF3 1 213 Site Both 0.0372 0.91819 0.02 0.017150554 0.96482269 
Q7Z739 YTHDF3 1 215 Site Both 0.0739 0.82577 0.02 0.053877895 0.89043821 
Q7Z7K6 CENPV 1 98 Site TopN 0.1384 0.81019 0.32 -0.18164787 0.74475012 




Region Both -0.292 0.31873 0.19 -0.48153162 0.12183743 





Region TopN 0.1555 0.77943 -0.03 0.185533945 0.73706765 








Region Both 0.2597 0.39149 -0.16 0.419742063 0.1821957 
Q86XN7 PROSER1 1 609 Site TopSpeed 0.0923 0.81489 -0.26 0.352287383 0.2560924 
Q86XN7 PROSER1 1 612 Site TopSpeed 0.0923 0.81489 -0.26 0.352287383 0.2560924 
Q86YP4 GATAD2A 1 581 Site TopSpeed 0.124 0.83321 0.34 -0.21599559 0.70101954 




Q86YP4 GATAD2A 1 330 Site Both -0.061 0.85694 0.34 -0.40135119 0.12136128 
Q86YP4 GATAD2A 1 333 Site Both -0.077 0.81489 0.34 -0.41655141 0.10496422 
Q86YP4 GATAD2A 1 625 Site Both 0.3122 0.19504 0.34 -0.02775749 0.93096088 
Q86YP4 GATAD2A 1 210 Site Both -0.37 0.20372 0.34 -0.70957332 0.01539257 
Q86YP4 GATAD2A 1 340 Site Both -0.077 0.81489 0.34 -0.41655141 0.10496422 
Q86YP4 GATAD2A 1 217 Site Both -0.37 0.20372 0.34 -0.70957332 0.01539257 
Q86Z02 HIPK1 1 
(1 of 
947,948,950) 
Region TopSpeed 0.0853 0.88252  0.085306253 0.90473946 








Region Both 0.1411 0.72438  0.141139318 0.71533959 
Q8IVW6 ARID3B 1 (1 of 556,557) Region Both -0.664 0.00462 -0.51 -0.15441615 0.60078955 
Q8IVW6 ARID3B 1 408 Site TopSpeed -0.341 0.14894 -0.51 0.168626857 0.57766052 
Q8IVW6 ARID3B 1 560 Site Both -0.664 0.00462 -0.51 -0.15441615 0.60078955 
Q8IVW6 ARID3B 1 395 Site Both -0.384 0.19579 -0.51 0.126193744 0.74875917 
Q8IVW6 ARID3B 1 558 Site Both -0.664 0.00462 -0.51 -0.15441615 0.60078955 
Q8IWB9 TEX2 1 (1 of 181,184) Region Both -0.545 0.06263 -0.36 -0.18456821 0.62022567 
Q8IWB9 TEX2 1 (1 of 178,179) Region Both -0.572 0.05158 -0.36 -0.21184813 0.56131209 
Q8IWB9 TEX2 1 180 Site Both -0.572 0.05158 -0.36 -0.21184813 0.56131209 
Q8IWB9 TEX2 1 175 Site Both -0.545 0.06263 -0.36 -0.18456821 0.62022567 




Region Both 0.3624 0.1272 0.21 0.152406249 0.61326319 
Q8IWI9 MGA 1 1561 Site Both 0.3109 0.20372 0.21 0.100915223 0.75674684 
Q8IWI9 MGA 1 1557 Site Both 0.3138 0.20146 0.21 0.103780668 0.74875917 
Q8IWI9 MGA 1 1911 Site Both 0.2567 0.27988 0.21 0.046687697 0.90986391 
Q8IWP9 CCDC28A 1 
(1 of 
271,272,274) 
Region TopSpeed 0.5646 0.17833  0.564613462 0.203931 
Q8IWX8 CHERP 1 (1 of 373,374) Region Both 0.2029 0.51124 0.03 0.172925688 0.62172767 
Q8IWX8 CHERP 1 379 Site Both 0.1596 0.637 0.03 0.129616574 0.71678949 
Q8IWY8 ZSCAN29 1 (1 of 483,495) Region Both 0.1007 0.86086  0.100747737 0.88132546 
Q8IWZ3 ANKHD1 2 
(2 of 
58,59,64,66) 
Region TopSpeed -1.008 0.0162 0.05 -1.05766805 0.0125797 
Q8IWZ3 ANKHD1 1 1813 Site TopSpeed 0.9498 0.02427 0.05 0.899809573 0.03735066 
Q8IWZ8 SUGP1 1 118 Site Both -0.387 0.18539 -0.1 -0.28730897 0.38360195 
Q8IWZ8 SUGP1 1 108 Site Both -0.454 0.12565 -0.1 -0.3540138 0.25904595 
Q8IWZ8 SUGP1 1 102 Site Both -0.395 0.17707 -0.1 -0.29516795 0.36539083 
Q8IWZ8 SUGP1 1 103 Site Both -0.395 0.17707 -0.1 -0.29516795 0.36539083 
Q8IX15 HOMEZ 1 291 Site TopSpeed -0.135 0.81444 -0.07 -0.06526393 0.92229001 
Q8IZ21 PHACTR4 1 202 Site Both 0.556 0.07405 -0.09 0.64600931 0.04036339 
Q8IZ21 PHACTR4 1 203 Site Both 0.556 0.07405 -0.09 0.64600931 0.04036339 
Q8IZ21 PHACTR4 1 205 Site Both 0.556 0.07405 -0.09 0.64600931 0.04036339 




Q8IZ21 PHACTR4 1 215 Site Both 0.7063 0.02433 -0.09 0.796309128 0.0125797 
Q8N122 RPTOR 1 696 Site Both -0.084 0.83909 -0.04 -0.04354863 0.92511993 
Q8N122 RPTOR 1 700 Site Both -0.077 0.85197 -0.04 -0.03710292 0.92831607 
Q8N122 RPTOR 1 704 Site Both -0.093 0.81489 -0.04 -0.05348012 0.91044412 
Q8N1E2 LYG1 1 (1 of 119,120) Region TopN -0.65 0.12517  -0.65003497 0.15033071 
Q8N1E2 LYG1 1 115 Site TopN -0.65 0.12517  -0.65003497 0.15033071 
Q8N1G0 ZNF687 1 (1 of 377,379) Region Both -0.12 0.75883 0.07 -0.18984563 0.60594301 
Q8N1G0 ZNF687 1 380 Site Both -0.107 0.77943 0.07 -0.17748224 0.6375374 
Q8N1I0 DOCK4 1 1787 Site TopSpeed -0.154 0.78143 0.05 -0.20373377 0.71058792 
Q8N3V7 SYNPO 1 (1 of 411,412) Region Both 1.2305 #######  1.230542408 1.02E-06 
Q8N3V7 SYNPO 1 409 Site Both 1.7164 #######  1.716373871 1.99E-08 
Q8N3V7 SYNPO 1 410 Site Both 1.2305 #######  1.230542408 1.02E-06 
Q8N3V7 SYNPO 1 415 Site Both 1.4271 #######  1.427074636 1.55E-07 
Q8N3X1 FNBP4 1 797 Site Both -0.2 0.55175 0 -0.20012548 0.58903014 








1 122 Site Both -0.444 0.35734  -0.44411612 0.40655976 
Q8ND82 ZNF280C 1 (1 of 213,214) Region TopN -0.176 0.75105 0.09 -0.26605587 0.62022567 
Q8ND83 SLAIN1 1 
(1 of 
414,417,418)&(
1 of 414,422) 
Region Both 0.0192 0.96548 -0.67 0.689191669 0.00631517 
Q8ND83 SLAIN1 1 293 Site TopSpeed -1.362 0.0014 -0.67 -0.69189237 0.12260258 
Q8ND83 SLAIN1 1 292 Site TopSpeed -1.362 0.0014 -0.67 -0.69189237 0.12260258 
Q8ND83 SLAIN1 1 413 Site Both 0.004 0.98673 -0.67 0.674033899 0.00659634 
Q8ND83 SLAIN1 1 421 Site Both -0.029 0.93512 -0.67 0.641114332 0.00923662 




Region TopSpeed -0.113 0.84852 0.26 -0.37313015 0.43727997 
Q8NDV7 TNRC6A 1 1688 Site Both -0.156 0.67751 0.26 -0.41586578 0.18877354 
Q8NDV7 TNRC6A 1 1666 Site TopSpeed 0.1385 0.81019 0.26 -0.12151321 0.85168276 
Q8NDV7 TNRC6A 1 1686 Site Both -0.156 0.67751 0.26 -0.41586578 0.18877354 
Q8NDV7 TNRC6A 1 1687 Site Both -0.009 0.98301 0.26 -0.26873259 0.41618591 
Q8NDX5 PHC3 1 283 Site TopSpeed -0.761 0.0722  -0.76142538 0.08564855 
Q8NEM8 AGBL3 1 729 Site Both 0.3302 0.15892  0.330197635 0.18877354 
Q8NEM8 AGBL3 1 726 Site Both 0.3302 0.15892  0.330197635 0.18877354 
Q8NEZ4 KMT2C 1 2230 Site Both -0.338 0.26828  -0.33836706 0.32395753 
Q8NFC6 BOD1L1 1 1540 Site TopSpeed 0.0803 0.89207 -0.03 0.110334756 0.86597032 
Q8NFH5 NUP35 1 298 Site Both -0.215 0.52697 -0.13 -0.0849761 0.85664364 
Q8NFM7 IL17RD 1 (1 of 304,311) Region TopN -0.097 0.86418  -0.09695052 0.88697434 
Q8TDD1 DDX54 1 240 Site TopN 0.1583 0.77645 -0.06 0.2183245 0.69996477 
Q8TEQ6 GEMIN5 1 627 Site Both 0.3574 0.13319 -0.01 0.367394713 0.15033071 








Region Both -0.447 0.1303 -0.27 -0.17742491 0.64062732 
Q8WUH6 TMEM263 1 
(1 of 
70,73,74,77) 
Region TopSpeed 0.6305 0.13435 -0.18 0.810539362 0.0635335 
Q8WV99 ZFAND2B 1 150 Site TopN -0.422 0.3167  -0.42228931 0.36821502 
Q8WVE6 TMEM171 1 266 Site Both -0.191 0.73332  -0.19064179 0.73150788 
Q8WVJ2 NUDCD2 1 
(1 of 
137,142,146) 
Region TopSpeed 0.0235 0.97884 -0.04 0.063505196 0.92400636 
Q8WWI1 LMO7 1 1584 Site Both 0.1696 0.54815 0.25 -0.08042586 0.81593663 






Region Both -0.316 0.20869 -0.03 -0.28580882 0.29995112 
Q8WWM7 ATXN2L 1 678 Site Both -0.496 0.03892 -0.03 -0.46611055 0.06087099 
Q8WWM7 ATXN2L 1 680 Site Both -0.307 0.20426 -0.03 -0.27688651 0.29696117 
Q8WWM7 ATXN2L 1 681 Site Both -0.038 0.91749 -0.03 -0.00765123 0.98261543 
Q8WWM7 ATXN2L 1 683 Site Both -0.038 0.91749 -0.03 -0.00765123 0.98261543 
Q8WWM7 ATXN2L 1 684 Site Both -0.523 0.02553 -0.03 -0.49269722 0.04036339 
Q8WWM7 ATXN2L 1 268 Site Both 0.035 0.93512 -0.03 0.065023074 0.89452881 




Region Both 0.1923 0.73332 0.08 0.112302813 0.86428932 
Q8WXI9 GATAD2B 1 584 Site Both -0.202 0.55729 0.08 -0.2815964 0.40347809 
Q8WXI9 GATAD2B 1 525 Site TopSpeed -0.187 0.73332 0.08 -0.26656219 0.62022567 




Region TopSpeed -0.138 0.81179 -0.24 0.102410425 0.88132546 
Q8WYP5 AHCTF1 1 1165 Site Both -0.219 0.51041 0.1 -0.3188713 0.32418494 
Q92538 GBF1 1 (1 of 1788,1789) Region TopSpeed -1.212 0.00453 -0.25 -0.96244856 0.0242215 




Region TopN -0.3 0.53065 -0.25 -0.05018958 0.92993035 
Q92540 SMG7 1 624 Site Both -0.15 0.63756 0.02 -0.1696132 0.60078955 
Q92540 SMG7 1 627 Site Both -0.246 0.33679 0.02 -0.26620012 0.3467146 
Q92615 LARP4B 1 581 Site Both 0.3239 0.17345 0.34 -0.01608623 0.9659325 
Q92733 PRCC 1 (1 of 227,228) Region Both 0.2852 0.5556 0.06 0.225243099 0.6902866 
Q92733 PRCC 1 226 Site Both 0.2852 0.5556 0.06 0.225243099 0.6902866 
Q92750 TAF4B 1 187 Site Both 0.3753 0.20372 0.17 0.205281029 0.58552609 
Q92750 TAF4B 1 190 Site Both 0.3717 0.20372 0.17 0.201680501 0.58749894 
Q92750 TAF4B 1 46 Site Both -0.013 0.97926 0.17 -0.18303889 0.62321657 
Q92750 TAF4B 1 383 Site TopSpeed 0.7117 0.09528 0.17 0.541703339 0.22504717 
Q92841 DDX17 1 64 Site Both 0.1649 0.54424 0.04 0.124877069 0.69221229 
Q92841 DDX17 1 55 Site Both 0.1464 0.61124 0.04 0.106368309 0.73658347 
Q92945 KHSRP 1 144 Site Both -0.141 0.62736 -0.04 -0.1008171 0.74671998 
Q92945 KHSRP 1 191 Site TopSpeed 0.1304 0.73332 -0.04 0.17039893 0.65957296 




Q93052 LPP 1 11 Site Both -0.364 0.21821 -0.37 0.005512601 0.98815648 
Q93052 LPP 1 12 Site Both -0.364 0.21821 -0.37 0.005512601 0.98815648 
Q96BD5 PHF21A 1 124 Site Both -0.369 0.13039 -0.57 0.201189116 0.48356887 
Q96BD5 PHF21A 1 125 Site Both -0.065 0.8473 -0.57 0.505027119 0.03735066 




Region TopSpeed 0.1629 0.76984 0.18 -0.01706091 0.97975 
Q96DF8 ESS2 1 437 Site TopN 0.6142 0.14074 0.18 0.434194905 0.35176469 





Region TopSpeed -0.187 0.73332 -0.04 -0.14737055 0.797687 






Region TopSpeed -0.238 0.65016 0.14 -0.3778663 0.43296161 




Region TopN -0.076 0.89829 -0.03 -0.04642662 0.93373979 




Region Both 0.3186 0.49928 0.04 0.278627309 0.60078955 
Q96KM6 ZNF512B 1 225 Site TopSpeed -0.103 0.79045 0.04 -0.14273154 0.70759286 




Region TopSpeed 0.0642 0.91819 -0.02 0.084161002 0.90658075 




Region Both 0.1039 0.73889 -0.02 0.123905064 0.70019113 
Q96KR1 ZFR 1 195 Site Both -0.361 0.13469 -0.02 -0.34137046 0.18918449 
Q96KR1 ZFR 1 135 Site Both -0.724 0.00462 -0.02 -0.70395354 0.00659634 
Q96KR1 ZFR 1 136 Site Both -0.724 0.00462 -0.02 -0.70395354 0.00659634 
Q96KR1 ZFR 1 423 Site Both 0.1641 0.55244 -0.02 0.184063713 0.52599901 
Q96KR1 ZFR 1 202 Site Both -0.361 0.13469 -0.02 -0.34137046 0.18918449 
Q96KR1 ZFR 1 142 Site Both -0.429 0.08291 -0.02 -0.40882187 0.12136128 
Q96KR1 ZFR 1 144 Site Both -0.674 0.01058 -0.02 -0.65408057 0.0125797 
Q96KR1 ZFR 1 434 Site Both 0.2034 0.41228 -0.02 0.223448352 0.40347809 
Q96KR1 ZFR 1 532 Site Both 0.146 0.60707 -0.02 0.165985849 0.58079224 
Q96KR1 ZFR 1 533 Site Both 0.146 0.60707 -0.02 0.165985849 0.58079224 
Q96KR1 ZFR 1 149 Site TopSpeed -0.31 0.28579 -0.02 -0.2895806 0.37837942 
Q96L91 EP400 1 2689 Site Both 0.0686 0.85763 0.05 0.018637286 0.96545905 
Q96L91 EP400 1 2691 Site Both 0.0964 0.75883 0.05 0.046355546 0.90863054 
Q96L91 EP400 1 2696 Site Both -0.123 0.71306 0.05 -0.17306941 0.58728077 
Q96L91 EP400 1 2699 Site Both 0.1395 0.63582 0.05 0.089500677 0.78573066 
Q96L91 EP400 1 2700 Site Both -0.039 0.90979 0.05 -0.08877451 0.78573066 
Q96L91 EP400 1 2604 Site Both 0.1073 0.73332 0.05 0.057283773 0.88132546 
Q96L91 EP400 1 1488 Site TopSpeed 0.1129 0.72438 0.05 0.062866405 0.86428932 




Q96L91 EP400 1 1495 Site TopSpeed 0.1129 0.72438 0.05 0.062866405 0.86428932 
Q96L91 EP400 1 2712 Site TopSpeed 0.6656 0.11948 0.05 0.615629535 0.17220996 
Q96L91 EP400 1 2686 Site Both 0.2017 0.46113 0.05 0.1516742 0.63995712 






Region Both -0.237 0.51124 -0.15 -0.08717574 0.86428932 
Q96MY1 NOL4L 1 375 Site Both 0.6373 0.00701  0.637264826 0.00722461 
Q96N67 DOCK7 1 14 Site TopSpeed 0.1175 0.84355 -0.22 0.337544275 0.49566768 




Region Both 0.3678 0.20701 0.41 -0.04220113 0.92511993 
Q96PK6 RBM14 1 
(1 of 
225,231,236) 
Region TopSpeed 0.228 0.49818 -0.06 0.287951697 0.39348757 
Q96PK6 RBM14 1 256 Site Both 0.0486 0.882 -0.06 0.108605532 0.72881104 
Q96PK6 RBM14 1 244 Site Both -0.155 0.56699 -0.06 -0.09525019 0.7587687 
Q96PK6 RBM14 1 278 Site Both -0.113 0.73036 -0.06 -0.05299425 0.89061809 
Q96PK6 RBM14 1 280 Site Both -0.219 0.36761 -0.06 -0.15908225 0.60078955 
Q96PK6 RBM14 1 254 Site Both 0.0062 0.98301 -0.06 0.066224198 0.86428932 






Region TopSpeed 0.0367 0.95813  0.036700316 0.95080035 




Region TopSpeed -0.082 0.88826  -0.08179017 0.90986391 
Q96RK0 CIC 1 132 Site Both 0.3845 0.18664  0.384520227 0.21589723 
Q96RK0 CIC 1 127 Site Both 0.3845 0.18664  0.384520227 0.21589723 
Q96RN5 MED15 1 405 Site Both 0.4712 0.07856 0.18 0.291203614 0.32115861 
Q96RT1 ERBIN 1 1070 Site Both -0.785 0.0296 0.17 -0.95473365 0.00901228 





Region Both 0.1921 0.57065 0.2 -0.00788737 0.98322904 




Region TopN 0.1356 0.81444 0.2 -0.06437736 0.92257958 





Region TopSpeed 0.3175 0.50076 0.2 0.117472573 0.85936701 
Q96T58 SPEN 1 2529 Site Both 0.0193 0.96144 0.2 -0.18071218 0.52819421 
Q96T58 SPEN 1 2530 Site Both -0.034 0.92396 0.2 -0.23445534 0.37449508 
Q96T58 SPEN 1 2531 Site Both -0.166 0.55309 0.2 -0.36572514 0.15933894 
Q96T58 SPEN 1 2522 Site Both 0.3509 0.14159 0.2 0.150939178 0.6241827 
Q96T58 SPEN 1 2619 Site Both -0.05 0.87459 0.2 -0.25017446 0.34187785 
Q96T58 SPEN 1 2525 Site Both 0.0386 0.91151 0.2 -0.16139323 0.59767111 




Q99550 MPHOSPH9 1 (1 of 511,513) Region TopN 0.1133 0.84852 0.35 -0.23667043 0.6680228 
Q99550 MPHOSPH9 1 
(1 of 
977,980,984) 
Region TopSpeed 0.7768 0.06671 0.35 0.42680919 0.36102741 







Region TopN -0.564 0.17833 -0.15 -0.41408615 0.38169817 
Q99700 ATXN2 1 666 Site TopN 0.0004 0.99876 -0.15 0.150418062 0.79441218 
Q99856 ARID3A 1 408 Site Both 0.0871 0.83321 0.1 -0.01287465 0.97877402 
Q9BQC3 DPH2 1 470 Site Both 0.0419 0.89954 -0.07 0.111901942 0.71678949 
Q9BR26 OCSTAMP 1 (1 of 385,386) Region TopN -0.012 0.98301  -0.01165269 0.98322904 







Region Both -0.163 0.55025 0 -0.16266714 0.58749894 




Region TopSpeed -0.006 0.98673 0.08 -0.08638122 0.90425011 
Q9BXB4 OSBPL11 1 (1 of 742,743) Region Both 0.2938 0.31873 -0.24 0.533820284 0.08457958 
Q9BYJ9 YTHDF1 1 196 Site Both -0.395 0.09528 -0.76 0.364688756 0.15020879 
Q9BYJ9 YTHDF1 1 198 Site Both -0.35 0.13469 -0.76 0.410334164 0.10146861 





Region TopSpeed 0.05 0.93452  0.049997574 0.92993035 
Q9BYP7 WNK3 1 1312 Site TopSpeed 0.0521 0.87144  0.052110399 0.89160973 
Q9BYP7 WNK3 1 709 Site TopSpeed -0.153 0.78246  -0.15269994 0.7935387 
Q9BZA8 PCDH11Y 1 713 Site TopSpeed 1.0267 0.01536  1.026719098 0.01539257 





Region Both 0.4911 0.04052  0.491135077 0.0457197 
Q9C0C7 AMBRA1 1 441 Site TopSpeed 0.9159 0.02893 0.03 0.885876261 0.04036339 
Q9C0F0 ASXL3 1 1031 Site Both -2.864 #######  -2.86433827 6.29E-12 
Q9H0E9 BRD8 1 284 Site Both -0.123 0.75105 0.13 -0.25271561 0.4557783 




Region TopSpeed -0.018 0.97938 0.18 -0.19797461 0.71777261 




Region Both -0.015 0.97703 0.34 -0.35518895 0.17220996 
















Region TopSpeed -0.448 0.28298 -0.11 -0.33797649 0.49565552 
Q9H4A3 WNK1 1 1849 Site TopN -0.132 0.73332 0.04 -0.17175119 0.65896254 
Q9H4A3 WNK1 1 1950 Site TopSpeed 0.0258 0.95813 0.04 -0.01422783 0.97812544 
Q9H4A3 WNK1 1 1951 Site TopSpeed 0.0166 0.97884 0.04 -0.02336926 0.95631267 




Region TopN 0.0543 0.93078  0.054286837 0.92831607 
Q9H7P9 PLEKHG2 1 1314 Site TopSpeed 0.1918 0.73332  0.19179229 0.72881104 
Q9H7S9 ZNF703 1 
(1 of 
180,181,182) 
Region Both -0.27 0.24706 0.04 -0.31022131 0.22202586 
Q9H7S9 ZNF703 1 259 Site Both -0.055 0.87202 0.04 -0.09483631 0.78573066 
Q9H7S9 ZNF703 1 170 Site Both -0.335 0.16027 0.04 -0.37524996 0.14474479 
Q9H7S9 ZNF703 1 172 Site Both -0.332 0.17291 0.04 -0.37195079 0.15457126 
Q9H7S9 ZNF703 1 173 Site Both -0.315 0.19579 0.04 -0.35521922 0.17220996 
Q9H7S9 ZNF703 1 174 Site Both -0.31 0.20146 0.04 -0.3495109 0.17519547 
Q9H7S9 ZNF703 1 177 Site Both -0.294 0.21821 0.04 -0.3336451 0.1911075 
Q9H7S9 ZNF703 1 179 Site Both -0.292 0.22228 0.04 -0.33151834 0.19418349 
Q9H7S9 ZNF703 1 184 Site Both -0.32 0.18108 0.04 -0.360492 0.16199967 
Q9H7S9 ZNF703 1 252 Site Both -0.044 0.90087 0.04 -0.08394283 0.81537205 
Q9H8Y8 GORASP2 1 424 Site Both -0.239 0.34227 -0.12 -0.11920483 0.71533959 
Q9H8Y8 GORASP2 1 367 Site TopSpeed -0.735 0.08291 -0.12 -0.61498228 0.17220996 
Q9HAP2 MLXIP 1 602 Site Both 0.2237 0.34572 0.24 -0.01634719 0.96482269 
Q9HAP2 MLXIP 1 603 Site Both 0.2823 0.22708 0.24 0.042291806 0.91220682 
Q9HAP2 MLXIP 1 607 Site Both 0.2887 0.22228 0.24 0.048708485 0.90457041 
Q9HAU0 PLEKHA5 1 382 Site Both 0.0491 0.91175 -0.3 0.349137192 0.29539138 
Q9HBD1 RC3H2 1 897 Site TopSpeed 0.3388 0.45828  0.338807689 0.49565552 
Q9HBD1 RC3H2 1 482 Site TopSpeed 0.3227 0.25945  0.322659319 0.31349934 
Q9HBD1 RC3H2 1 483 Site TopSpeed 0.3227 0.25945  0.322659319 0.31349934 
Q9HBD1 RC3H2 1 770 Site TopSpeed 0.7884 0.06223  0.788399354 0.07282391 
Q9HBD1 RC3H2 1 478 Site TopSpeed 0.3313 0.24557  0.331258543 0.29696117 
Q9HBD1 RC3H2 1 909 Site Both 0.7207 0.00192  0.720722212 0.00280956 
Q9HBD1 RC3H2 1 468 Site TopSpeed 0.1949 0.56699  0.194862986 0.60078955 
Q9HBD1 RC3H2 1 756 Site Both 0.6184 0.00841  0.618439323 0.00886704 
Q9HBD1 RC3H2 1 470 Site TopSpeed 0.3313 0.24557  0.331258543 0.29696117 
Q9HBD1 RC3H2 1 471 Site TopSpeed 0.3313 0.24557  0.331258543 0.29696117 
Q9HBD1 RC3H2 1 574 Site TopSpeed 0.4483 0.12714  0.448290194 0.15189114 
Q9HBM6 TAF9B 1 152 Site Both 0.4077 0.1724  0.407696117 0.20019143 
Q9HCJ0 TNRC6C 1 (1 of 547,548) Region TopSpeed -0.054 0.93078  -0.05383715 0.92831607 
Q9HCJ0 TNRC6C 1 542 Site TopSpeed -0.054 0.93078  -0.05383715 0.92831607 
Q9HCK8 CHD8 1 2522 Site Both 0.2608 0.26124 0.31 -0.04917738 0.90255635 




Q9HCM7 FBRSL1 1 
(1 of 
989,1004,1010) 
Region TopSpeed 0.1436 0.79945  0.143573522 0.8045802 
Q9HDC9 APMAP 1 162 Site Both 0.1479 0.70288 -0.06 0.207894594 0.57422616 




Region TopN 0.1971 0.73082 0.12 0.077082688 0.91044412 
Q9NQC3 RTN4 1 160 Site Both 0.0134 0.97926 -0.31 0.323417741 0.3370957 
Q9NQX3 GPHN 1 260 Site Both -0.292 0.3576 0.02 -0.3122891 0.3695296 





Region TopSpeed -0.11 0.85197 0.12 -0.23028352 0.67932235 




Region Both 0.8121 0.05348 0.23 0.582149109 0.1936142 
Q9NR12 PDLIM7 1 89 Site TopSpeed 0.081 0.84852 0.23 -0.14897549 0.70754983 
Q9NR12 PDLIM7 1 196 Site Both 0.5758 0.17156 0.23 0.345773946 0.48516346 
Q9NRA8 EIF4ENIF1 1 
(1 of 
768,769,772) 
Region TopSpeed -0.53 0.20577 0.09 -0.61972505 0.17056868 
Q9NSI2 FAM207A 1 39 Site TopSpeed 0.0139 0.98301 -0.17 0.183887797 0.73910336 
Q9NTZ6 RBM12 1 111 Site Both -0.397 0.12961 0 -0.39684991 0.15457126 




Region TopN -0.373 0.20403 -0.07 -0.30318887 0.35483335 
Q9NXV6 CDKN2AIP 1 323 Site TopSpeed 0.1738 0.63587 -0.19 0.363770158 0.25195289 
Q9NYJ8 TAB2 1 456 Site Both -0.083 0.84102 -0.13 0.04698471 0.92229001 
Q9NYV4 CDK12 1 592 Site TopSpeed 0.4582 0.12091 0.07 0.388215829 0.20838287 
Q9NYV4 CDK12 1 593 Site TopSpeed 0.4582 0.12091 0.07 0.388215829 0.20838287 
Q9P2B4 CTTNBP2NL 1 
(1 of 
637,638,639) 
Region TopSpeed -0.62 0.00841 -0.27 -0.34976538 0.16525791 




Region TopSpeed 0.0192 0.96548 0.02 -0.00082661 0.99778642 
Q9P2N6 KANSL3 1 860 Site Both 0.4076 0.16314  0.407564126 0.19131351 
Q9P2P6 STARD9 1 3937 Site TopSpeed 0.7181 0.09169  0.718109757 0.11065661 
Q9P2R6 RERE 1 1237 Site Both 0.3901 0.11047 -0.05 0.440059034 0.08031377 
Q9P2R6 RERE 1 1238 Site Both 0.1835 0.49928 -0.05 0.233497741 0.39293271 





Region Both -0.119 0.73332 0.02 -0.13857632 0.69130082 
Q9UHD9 UBQLN2 1 112 Site Both -0.261 0.33696 0.02 -0.28134191 0.3509044 
Q9UHD9 UBQLN2 1 113 Site Both -0.261 0.33696 0.02 -0.28134191 0.3509044 
Q9UHD9 UBQLN2 1 123 Site Both -0.028 0.94675 0.02 -0.04755437 0.914156 
Q9UHD9 UBQLN2 1 121 Site Both -0.261 0.33696 0.02 -0.28134191 0.3509044 
Q9UHR5 SAP30BP 1 231 Site Both 0.1836 0.48429 0.09 0.093578674 0.76243442 
Q9UHR5 SAP30BP 1 232 Site Both 0.3428 0.14074 0.09 0.25275918 0.33206844 
Q9UHR5 SAP30BP 1 233 Site Both 0.3043 0.19504 0.09 0.214292899 0.42146519 




Q9UHR5 SAP30BP 1 245 Site Both 0.1551 0.58145 0.09 0.065085095 0.86428932 
Q9UHY1 NRBP1 1 
(1 of 
532,534,535) 
Region Both 0.1602 0.56379 -0.13 0.290229661 0.25580836 
Q9UHY1 NRBP1 1 528 Site Both 0.1602 0.56379 -0.13 0.290229661 0.25580836 
Q9UHY1 NRBP1 1 150 Site TopN 0.177 0.75105 -0.13 0.306968665 0.557488 





Region TopN -0.494 0.09528  -0.49381305 0.1161024 




Region TopSpeed -0.352 0.43444 0.13 -0.48179117 0.29539138 
Q9UKD1 GMEB2 1 404 Site Both 0.0855 0.78918 -0.15 0.235471978 0.38431317 
Q9UKD1 GMEB2 1 407 Site Both 0.1053 0.73487 -0.15 0.255265804 0.33838036 




Region Both -0.162 0.66876 0.1 -0.26245561 0.44935957 
Q9UKY1 ZHX1 1 232 Site Both 0.3744 0.11948 0.1 0.274367565 0.28724519 
Q9UKY1 ZHX1 1 227 Site Both 0.3428 0.14074 0.1 0.242758611 0.35176469 
Q9UKY1 ZHX1 1 228 Site Both 0.3428 0.14074 0.1 0.242758611 0.35176469 




Region TopSpeed 0.2733 0.24098 0.07 0.203289073 0.46104916 
Q9ULH7 MRTFB 1 (1 of 209,211) Region Both -0.26 0.38973 -0.08 -0.17986893 0.62887819 
Q9ULH7 MRTFB 1 207 Site Both -0.26 0.38973 -0.08 -0.17986893 0.62887819 
Q9ULH7 MRTFB 1 223 Site Both -0.26 0.38973 -0.08 -0.17986893 0.62887819 
Q9ULM3 YEATS2 1 723 Site TopSpeed -0.345 0.44512 0.09 -0.43523607 0.35176469 
Q9ULM3 YEATS2 1 389 Site Both -0.285 0.23985 0.09 -0.37521841 0.15189114 
Q9ULM3 YEATS2 1 935 Site Both -0.147 0.79071 0.09 -0.23746513 0.6680228 






Region TopN 0.5634 0.17833 0.6 -0.03656186 0.95080035 







Region Both 0.1777 0.51796 -0.12 0.297654624 0.25195289 
Q9ULU4 ZMYND8 1 (1 of 756,760) Region Both -0.283 0.23195 -0.12 -0.1633565 0.59767111 
Q9ULU4 ZMYND8 1 746 Site Both -0.255 0.2807 -0.12 -0.13489632 0.6680228 
Q9ULU4 ZMYND8 1 750 Site Both -0.255 0.2807 -0.12 -0.13489632 0.6680228 
Q9ULU4 ZMYND8 1 751 Site Both -0.255 0.2807 -0.12 -0.13489632 0.6680228 
Q9UMR5 PPT2 1 208 Site Both 0.1329 0.81489  0.132873669 0.82909303 




Region Both -0.131 0.66876 0.04 -0.17109962 0.57766052 








Region Both 0.46 0.12517  0.459988189 0.15033071 
Q9UPN6 SCAF8 1 (1 of 617,619) Region TopSpeed 0.0686 0.86418 0.11 -0.04137163 0.92657403 
Q9UPN6 SCAF8 2 
(2 of 
533,534,536) 
Region TopN -0.333 0.47087 0.11 -0.44269654 0.3467146 
Q9UPN6 SCAF8 1 615 Site TopSpeed 0.0686 0.86418 0.11 -0.04137163 0.92657403 
Q9UPX8 SHANK2 1 1288 Site Both 0.3376 0.26828  0.337636644 0.32395753 
Q9UQ35 SRRM2 1 
(1 of 
111,119,121) 
Region TopSpeed 0.2591 0.6078 0.12 0.1391044 0.81537205 
Q9UQ35 SRRM2 1 2236 Site TopSpeed -0.065 0.91749 0.12 -0.18478065 0.73706765 
Q9Y253 POLH 1 457 Site TopSpeed -0.199 0.56379  -0.19900761 0.60078955 
Q9Y2K5 R3HDM2 1 345 Site Both 0.5629 0.01536 0.23 0.332876857 0.18417863 
Q9Y2X9 ZNF281 1 (1 of 883,884) Region Both -0.025 0.94526 -0.38 0.355179049 0.16525791 
Q9Y2X9 ZNF281 1 872 Site Both -0.025 0.94526 -0.38 0.355179049 0.16525791 
Q9Y2X9 ZNF281 1 876 Site Both -0.031 0.93078 -0.38 0.348953899 0.17220996 
Q9Y2X9 ZNF281 1 879 Site Both -0.043 0.89886 -0.38 0.336828854 0.19033394 
Q9Y2X9 ZNF281 1 891 Site Both -0.752 0.00224 -0.38 -0.37190448 0.16010262 
Q9Y2X9 ZNF281 1 61 Site Both -0.202 0.43985 -0.38 0.177786386 0.55949039 
Q9Y3S1 WNK2 1 (1 of 1605,1606) Region Both 0.384 0.10547 0.6 -0.21604236 0.41618591 
Q9Y3S1 WNK2 1 1608 Site Both 0.384 0.10547 0.6 -0.21604236 0.41618591 
Q9Y3S1 WNK2 1 1611 Site Both 0.384 0.10547 0.6 -0.21604236 0.41618591 
Q9Y467 SALL2 1 531 Site TopSpeed 0.0414 0.90087 0.34 -0.29862717 0.24051635 
Q9Y467 SALL2 1 253 Site TopSpeed -0.133 0.81489 0.34 -0.47280904 0.30392115 
Q9Y467 SALL2 1 527 Site TopSpeed 0.0414 0.90087 0.34 -0.29862717 0.24051635 




Region Both 0.1314 0.73332 0.09 0.041428367 0.92511993 
Q9Y4B4 RAD54L2 1 1074 Site Both 0.1314 0.73332 0.09 0.041428367 0.92511993 
Q9Y4B4 RAD54L2 1 1075 Site Both 0.1314 0.73332 0.09 0.041428367 0.92511993 
Q9Y4B4 RAD54L2 1 1012 Site TopN 0.0095 0.98301 0.09 -0.08047481 0.90986391 
Q9Y4B4 RAD54L2 1 983 Site Both 0.1503 0.58701 0.09 0.060330907 0.86597032 
Q9Y4L1 HYOU1 1 933 Site Both 0.1176 0.71306 0 0.117638878 0.70759286 
Q9Y4L1 HYOU1 1 935 Site Both 0.1371 0.64275 0 0.137123605 0.6622578 







Region Both 0.1318 0.65532  0.131763777 0.67158708 
Q9Y4X4 KLF12 1 
(1 of 
97,98,99,102) 
Region Both -0.047 0.89829  -0.0470728 0.91044412 
Q9Y4X4 KLF12 1 106 Site Both -0.037 0.92396  -0.0369753 0.92511993 




Region TopSpeed -0.319 0.29634 -0.09 -0.22919452 0.53880758 
Q9Y520 PRRC2C 1 2176 Site Both -0.449 0.12517 -0.09 -0.35945674 0.2501051 




Q9Y520 PRRC2C 1 2192 Site Both -0.292 0.2284 -0.09 -0.20212004 0.4850436 
Q9Y520 PRRC2C 1 2196 Site Both -0.306 0.20372 -0.09 -0.21645872 0.43514761 
Q9Y520 PRRC2C 1 2200 Site Both -0.281 0.22708 -0.09 -0.19096522 0.4936985 
Q9Y520 PRRC2C 1 2203 Site Both -0.236 0.32929 -0.09 -0.14563296 0.6375374 
Q9Y520 PRRC2C 1 2211 Site Both -0.368 0.22228 -0.09 -0.27778642 0.42146519 
Q9Y520 PRRC2C 1 2221 Site Both -0.368 0.22228 -0.09 -0.27778642 0.42146519 
Q9Y520 PRRC2C 1 2229 Site Both -0.502 0.03655 -0.09 -0.41167691 0.11000914 
Q9Y520 PRRC2C 1 2682 Site Both -0.235 0.36991 -0.09 -0.14453134 0.6680228 
Q9Y520 PRRC2C 1 2233 Site Both -0.248 0.32521 -0.09 -0.15755908 0.62172767 
Q9Y520 PRRC2C 1 2238 Site Both -0.495 0.05342 -0.09 -0.40467838 0.14474479 
Q9Y520 PRRC2C 1 2243 Site Both -0.391 0.11948 -0.09 -0.30148241 0.25550595 
Q9Y520 PRRC2C 1 2245 Site Both -0.481 0.05342 -0.09 -0.3905221 0.14474479 
Q9Y520 PRRC2C 1 2165 Site Both -0.449 0.12517 -0.09 -0.35945674 0.2501051 
Q9Y520 PRRC2C 1 2681 Site Both -0.11 0.73082 -0.09 -0.02021436 0.95199371 
Q9Y520 PRRC2C 1 2170 Site Both -0.493 0.09528 -0.09 -0.4032777 0.19409839 
Q9Y520 PRRC2C 1 2685 Site Both -0.364 0.13469 -0.09 -0.2736026 0.31033822 
Q9Y520 PRRC2C 1 2175 Site Both -0.47 0.11275 -0.09 -0.37968846 0.22202586 




Region Both 0.9322 0.00027 0.36 0.57217617 0.02084017 
Q9Y618 NCOR2 1 (1 of 1214,1215) Region TopSpeed -0.618 0.13822 0.35 -0.96844092 0.02372115 
Q9Y618 NCOR2 1 1561 Site Both 0.1984 0.43956 0.35 -0.15161698 0.62022567 
Q9Y618 NCOR2 1 1562 Site Both 0.2061 0.43956 0.35 -0.14386954 0.66085936 
Q9Y618 NCOR2 1 1517 Site TopSpeed 0.5638 0.17833 0.35 0.213831608 0.70101954 
Q9Y618 NCOR2 1 1558 Site Both 0.0218 0.95724 0.35 -0.32816019 0.20309052 
Q9Y692 GMEB1 1 453 Site TopN -0.105 0.85824 0.19 -0.29499915 0.58079224 
Q9Y6X8 ZHX2 1 265 Site Both 0.1176 0.76383 0.33 -0.21238036 0.56028578 
Q9Y6Y8 SEC23IP 1 136 Site Both 0.1408 0.64435 -0.16 0.300842898 0.25195289 
Q9Y6Y8 SEC23IP 1 118 Site Both 0.1408 0.64435 -0.16 0.300842898 0.25195289 
Q9Y6Y8 SEC23IP 1 134 Site Both 0.1408 0.64435 -0.16 0.300842898 0.25195289 
Q9Y6Y8 SEC23IP 1 126 Site Both 0.1998 0.44511 -0.16 0.359800566 0.16525791 
 
Appendix 5.2. All Significant OGT Interactors Identified in the Mouse Brain. 
 Table of all proteins with a value of less than 0.05 in either the limma moderated t-test 
(limmapVal) or inverted beta binomial test (ibbpVal) after correcting for multiple comparisons 
using the Benjamini-Hochberg method. FC: log2 fold change, B: limma B statistic. 
 




Q8VDD5 MYH9 1.88 0.2044 -4.565 -11.47 0.00015 
P14873 MAP1B 3.5133 0.0081 0.7929 -7.912 0.00033 
Q8CGY8 OGT 6.64 0.0008 1.9925 -29.69 1.98E-07 
Q3UHF7 HIVEP2 5.2267 0.0119 0.4132 -1E+05 8.67E-11 
O88737 BSN 3.0533 0.0321 -1.011 -1E+05 9.07E-11 
Q68FD5 CLTC 2.2667 0.0587 -2.022 -5.704 0.00131 
Q61879 MYH10 2.42 0.2396 -4.911 -4 0.00131 
Q61191 HCFC1 6.0567 0.0244 -0.531 -1E+05 9.21E-11 
P20357 MAP2 4.1733 0.0161 0.0779 -14.07 2.83E-05 
P60710 ACTB 3.5667 0.1735 -4.291 -3.003 0.01344 
E9Q557 DSP 0.8267 0.4732 -6.663 -3.271 0.04052 
A3KGU9 SPTAN1 2.6233 0.031 -0.905 -8.757 0.0001 
Q03172 HIVEP1 1.5433 0.076 -2.633 -1E+05 2.54E-08 
Q8R0Y6 ALDH1L1 1.5933 0.0947 -3.088 -13 0.03379 
D3YZ62 MYO5A 3.19 0.0613 -2.129 -1E+05 4.71E-10 
Q61768 KIF5B 6.0567 0.0025 1.5961 -1E+05 1.48E-09 
Q9QYX7 PCLO 1.61 0.2276 -4.812 -1E+05 1.48E-09 
A2ARP8 MAP1A 3.2933 0.0134 0.2967 -1E+05 1.32E-09 
Q6PD31 TRAK1 6.4133 0.0017 1.7484 -1E+05 1.29E-09 
Q6P9N8 TRAK2 4.43 0.03 -0.849 -1E+05 3.99E-09 
E9Q6J5 BOD1L 3.51 0.018 -0.08 -1E+05 1.08E-08 
B1ASP2 JAK1 1.47 0.2304 -4.835 -6.654 0.00208 
P63017 HSPA8 4.6833 0.0323 -1.06 -16.04 2.92E-05 
Q62261 SPTBN1 2.6933 0.0137 0.2592 -19.76 1.51E-05 
P33175 KIF5A 5.0433 0.0613 -2.137 -1E+05 4.62E-09 
A2A884 HIVEP3 0.9933 0.2498 -5.327 -1E+05 1.08E-08 
P46735 MYO1B 0.82 0.474 -6.667 -1E+05 8.55E-05 
Q02257 JUP 1.3467 0.2143 -4.668 -4 0.02055 
Q7TSJ2 MAP6 4.11 0.0314 -0.942 -1E+05 6.22E-09 
F7DCH5 CLASP2 4.0333 0.0046 1.2463 -1E+05 8.34E-09 
Q9JMH9 MYO18A 2.2633 0.0789 -2.73 -7.41 0.00062 
E9Q175 MYO6 3.1667 0.0278 -0.746 -1E+05 7.18E-07 
Q7TMY8 HUWE1 1.1433 0.3251 -5.896 -1E+05 5.15E-06 
Q8CAQ8 IMMT 2.7567 0.033 -1.096 -1E+05 8.78E-07 
Q8K010 OPLAH 1.8733 0.1255 -3.61 -1E+05 0.00023 
A0A0R4J049 PRMT5 3.21 0.167 -4.22 -3.797 0.01993 
Q8BTI8 SRRM2 2.34 0.2195 -4.718 -1E+05 4.02E-07 
Q61781 KRT14 1.9267 0.3864 -6.201 -8.25 0.00372 
Q6PIC6 ATP1A3 4.1233 0.0275 -0.717 -39.33 4.65E-06 
Q8BG87 TET3 3.7367 0.0507 -1.78 -1E+05 4.05E-07 
A0A571BDG0 SRCIN1 3.7633 0.0632 -2.219 -1E+05 3.08E-08 




Q9DBR7 PPP1R12A 3.9533 0.0436 -1.554 -1E+05 5.82E-08 
Q8C9B9 DIDO1 1.8467 0.0974 -3.138 -1E+05 2.71E-07 
Q9QXS6 DBN1 3.56 0.0744 -2.584 -7.72 0.0008 
P62702 RPS4X 1.6433 0.4172 -6.325 -3.9 0.02058 
P13020 GSN 3.3 0.076 -2.635 -5.25 0.00806 
Q9WTI7 MYO1C 0.5567 0.4967 -6.722 -96349 0.0067 
Q6NZL0 SOGA3 1.6933 0.1784 -4.336 -3.552 0.01528 
P27659 RPL3 3.05 0.2473 -5.078 -1E+05 1.49E-05 
Q9D8E6 RPL4 3.4867 0.0581 -2.003 -14.34 0.00067 
P20029 HSPA5 3.01 0.0317 -0.983 -1E+05 5.63E-05 
Q5SVJ0 CAMK2B 5.71 0.0593 -2.075 -1E+05 2.54E-08 
P38647 HSPA9 2.52 0.1398 -3.858 -1E+05 4.09E-06 
Q7TMM9 TUBB2A 5.46 0.0099 0.6025 -11.78 0.00013 
P83741 WNK1 3.1167 0.1351 -3.767 -1E+05 1.27E-07 
P28665 MUG1 0.44 0.7573 -7.133 -25 0.01074 
P10126 EEF1A1 3.0133 0.1181 -3.501 -14.93 0.00043 
Q7TPH6 MYCBP2 2.1167 0.1255 -3.61 -1E+05 2.04E-07 
P12970 RPL7A 3.0367 0.0757 -2.623 -8.511 0.00105 
Q9DBG3 AP2B1 2.9733 0.0186 -0.165 -9.509 0.00081 
Q6ZPE2 SBF1 2.8133 0.0322 -1.037 -40.88 7.36E-06 
P97351 RPS3A 2.1033 0.3423 -6 -4.082 0.01362 
P62908 RPS3 2.4867 0.0836 -2.867 -7.2 0.00177 
P28738 KIF5C 3.0433 0.1432 -3.902 -1E+05 1.62E-07 
A0A0A0MQF6 GAPDH 5.23 0.0637 -2.245 -11.92 0.00028 
P14148 RPL7 3.1067 0.1523 -4.038 -10 0.00205 
P46460 NSF 4.61 0.0351 -1.216 -1E+05 1.27E-07 
P61979 HNRNPK 3.3167 0.0561 -1.934 -18.63 0.00021 
A0A0A0MQA5 TUBA4A 4.26 0.0246 -0.559 -8.921 0.00056 
P16330 CNP 3.2767 0.0589 -2.042 -5.228 0.00546 
P25444 RPS2 2.5467 0.2473 -5.105 -10.25 0.00076 
A2AQ25 SKT 3.26 0.0162 0.0652 -1E+05 3.71E-07 
Q3U7K7 TRIM21 0.3767 0.4457 -6.56 -13 0.03379 
Q80VC9 CAMSAP3 1.9867 0.0412 -1.451 -1E+05 6.14E-07 
Q9CWW7 CXXC1 5.3867 0.0336 -1.129 -1E+05 7.89E-07 
Q99NF7 PPM1B 3.0633 0.0321 -1.016 -9.091 0.0067 
Q8BGD9 EIF4B 2.6967 0.1021 -3.218 -32.03 0.00016 
P15105 GLUL 3.4567 0.0314 -0.946 -12.58 0.00064 
P17426 AP2A1 2.65 0.0246 -0.561 -34.66 1.75E-05 
Q03265 ATP5F1A 3.2 0.058 -1.994 -18.11 0.00044 
Q4JK59 TET2 1.2533 0.2102 -4.638 -99548 0.00043 




Q80WJ7 MTDH 0.7733 0.4449 -6.448 -5.806 0.01694 
P47738 ALDH2 1.5067 0.1374 -3.806 -97206 0.00276 
Q91YI0 ASL 0.8533 0.22 -4.731 -5.252 0.01496 
A0A1D5RM83 IQSEC1 3.0967 0.0185 -0.152 -1E+05 9.94E-07 
P17427 AP2A2 2.0267 0.131 -3.694 -1E+05 4.87E-05 
P47911 RPL6 2.4533 0.2473 -5.062 -4.87 0.01408 
A2RSY1 KANSL3 3.39 0.0071 0.918 -1E+05 1.35E-05 
Q00623 APOA1 0.3967 0.6866 -7.057 -3 0.04448 
Q5XJF6 RPL10A 3.1433 0.1335 -3.729 -10.16 0.00235 
P29341 PABPC1 2.4667 0.1314 -3.7 -1E+05 6.30E-06 
Q9JHJ0 TMOD3 2.1867 0.2219 -4.753 -99261 0.0006 
P70398 USP9X 2.4533 0.1081 -3.334 -1E+05 8.05E-07 
Q8CFE4 SCYL2 1.0267 0.2473 -5.069 -4.786 0.01363 
Q9ESK9 RB1CC1 1.5167 0.4449 -6.499 -1E+05 1.04E-06 
P11499 HSP90AB1 2.2933 0.1682 -4.239 -10.67 0.00127 
P62270 RPS18 1.89 0.2473 -5.086 -5.846 0.005 
Q62167 DDX3X 3.8467 0.0618 -2.158 -1E+05 2.13E-05 
F7BQW7 SYNJ1 2.5067 0.208 -4.604 -1E+05 1.99E-06 
Q9Z1R2 BAG6 2.4567 0.0137 0.2553 -1E+05 3.40E-06 
Q99J09 WDR77 2.0367 0.1808 -4.376 -11.33 0.00096 
Q61656 DDX5 2.9533 0.0183 -0.127 -1E+05 4.09E-06 
Q8BFR5 TUFM 4.0467 0.0697 -2.449 -1E+05 9.85E-06 
Q3UHD9 AGAP2 2.9567 0.0979 -3.15 -1E+05 1.22E-06 
P63318 PRKCG 5.5367 0.0779 -2.695 -1E+05 6.14E-07 
P63038 HSPD1 2.69 0.0473 -1.675 -1E+05 5.63E-05 
P58252 EEF2 1.26 0.1108 -3.373 -98641 0.00083 
P68372 TUBB4B 5.53 0.0035 1.4109 -12 0.00586 
Q8VDM4 PSMD2 0.6367 0.4732 -6.664 -98310 0.00137 
Q80U49 CEP170B 1.51 0.2473 -5.065 -1E+05 1.31E-06 
Q3U1J4 DDB1 1.81 0.2671 -5.506 -1E+05 0.0002 
S4R2K9 ANK3 1.4867 0.3879 -6.209 -1E+05 5.20E-06 
E9QAQ5 GSK3B 5.6533 0.0214 -0.363 -1E+05 4.09E-06 
P68254 YWHAQ 4.67 0.0747 -2.602 -1E+05 3.36E-06 
P51881 SLC25A5 4.2 0.1179 -3.491 -8.5 0.00521 
Q9CZM2 RPL15 2.41 0.0561 -1.929 -1E+05 7.73E-05 
Q91X20 ASH2L 4.3933 0.0503 -1.766 -1E+05 6.30E-06 
Q6A0A9 FAM120A 1.96 0.0783 -2.708 -1E+05 9.18E-06 
O08553 DPYSL2 5.3333 0.0275 -0.724 -1E+05 1.16E-06 
Q8VDJ3 HDLBP 0.8833 0.2597 -5.441 -95353 0.01528 
P62281 RPS11 3.1433 0.2483 -5.312 -4 0.02779 




A0A0G2JGS4 CAMK2D 4.4167 0.0453 -1.611 -1E+05 3.71E-06 
P05213 TUBA1B 5.19 0.0079 0.8262 -98956 0.00074 
P62754 RPS6 2.2967 0.0306 -0.885 -24 0.00062 
E9QM73 WNK2 3.95 0.062 -2.166 -1E+05 5.88E-06 
A0A0R4J2B6 RBBP5 4.9267 0.0071 0.9274 -1E+05 7.18E-06 
P11798 CAMK2A 6.61 0.0008 1.9855 -1E+05 5.55E-06 
Q91VR2 ATP5F1C 2.8233 0.0317 -0.986 -6.223 0.00853 
P62301 RPS13 2.2667 0.1472 -3.967 -4.6 0.01324 
P62918 RPL8 3.69 0.2473 -5.182 -17.03 0.00213 
Q8K2B3 SDHA 2.4567 0.1358 -3.78 -1E+05 5.52E-05 
P62983 RPS27A 2.9167 0.0909 -3.011 -7.626 0.00183 
Q91VR5 DDX1 2.1533 0.0617 -2.151 -1E+05 0.00016 
Q9EPU0 UPF1 1.6933 0.2152 -4.678 -1E+05 2.83E-05 
P51410 RPL9 0.98 0.2094 -4.619 -9 0.02346 
P63328 PPP3CA 5.99 0.0173 -0.015 -1E+05 3.16E-07 
Q8CJG0 AGO2 1.9933 0.0257 -0.619 -1E+05 0.00011 
A8DUK4 HBB-BS 2.33 0.2597 -5.44 -94143 0.0412 
Q8CGF6 WDR47 2.2433 0.1808 -4.373 -1E+05 3.52E-06 
Q68FG2 SPTBN2 1.8033 0.2508 -5.333 -1E+05 2.74E-05 
D3YUP1 CARM1 4.4233 0.042 -1.495 -1E+05 7.73E-06 
Q8BGH2 SAMM50 0.8867 0.598 -6.925 -99261 0.0006 
Q99PU7 BAP1 3.0967 0.1895 -4.45 -1E+05 1.49E-05 
D3YXZ3 KLC2 3.7867 0.0236 -0.484 -1E+05 4.09E-06 
Q3UQ44 IQGAP2 -0.177 0.779 -7.153 -99548 0.00062 
P62717 RPL18A 2.7833 0.0347 -1.195 -8.591 0.00448 
P17751 TPI1 3.45 0.018 -0.074 -10.14 0.00361 
H3BJU7 ARHGEF2 3.1867 0.008 0.8175 -1E+05 3.32E-06 
Q9Z0H8 CLIP2 2.15 0.1086 -3.345 -1E+05 5.88E-06 
Q9JJ28 FLII 2.8467 0.0344 -1.166 -1E+05 5.11E-05 
P0C090 RC3H2 3.4667 0.0589 -2.045 -1E+05 1.62E-05 
Q8BG51 RHOT1 4.6033 0.0602 -2.099 -1E+05 1.56E-06 
Q91V55 RPS5 2.2233 0.2832 -5.616 -15 0.02345 
Q925I1 ATAD3 2.2733 0.2212 -4.744 -1E+05 2.09E-05 
P62242 RPS8 3.52 0.0535 -1.855 -5.333 0.01735 
Q06890 CLU 1.74 0.0589 -2.049 -4.43 0.03411 
E9PZ43 MAP4 4.36 0.0172 0.0005 -1E+05 6.35E-06 
G5E829 ATP2B1 2.8367 0.2473 -5.012 -1E+05 5.34E-06 
P47963 RPL13 3.6133 0.0637 -2.262 -22 0.00103 
Q6ZWN5 RPS9 3.4467 0.0356 -1.241 -1E+05 6.19E-05 
Q9CR57 RPL14 3.0033 0.1523 -4.044 -4.47 0.02105 
P62830 RPL23 3.26 0.0744 -2.588 -9.107 0.00494 




Q9EQQ9 OGA 2.9 0.2473 -5.008 -1E+05 5.43E-06 
P60469 PPFIA3 1.96 0.1318 -3.708 -1E+05 4.38E-06 
Q8R326 PSPC1 3.3933 0.0302 -0.864 -1E+05 8.55E-05 
P46096 SYT1 1.0567 0.1383 -3.817 -2.6 0.02949 
P17182 ENO1 1.5733 0.1441 -3.919 -1E+05 8.12E-05 
Q9JHU4 DYNC1H1 2.1867 0.1528 -4.066 -1E+05 6.30E-06 
Q8K3E5 AHI1 2.0533 0.2597 -5.432 -1E+05 1.56E-05 
Q811P8 ARHGAP32 3.12 0.1335 -3.737 -1E+05 1.19E-05 
P47857 PFKM 3.55 0.0228 -0.441 -1E+05 5.88E-06 
Q61805 LBP 1.5933 0.0427 -1.524 -3 0.04448 
P84091 AP2M1 3.15 0.0845 -2.885 -22 0.00012 
Q8VEK3 HNRNPU 3.0333 0.0136 0.2772 -36 0.00013 
Q8BH59 SLC25A12 2.89 0.2473 -5.174 -1E+05 3.71E-06 
A2ADM8 ZFP831 2.3467 0.4449 -6.433 -1E+05 1.39E-05 
O08788 DCTN1 2.7267 0.2057 -4.58 -1E+05 1.28E-05 
P46660 INA 4 0.0706 -2.486 -1E+05 4.42E-06 
S4R2F3 ANK2 2.23 0.237 -4.893 -1E+05 1.32E-05 
P35980 RPL18 2.9933 0.1138 -3.426 -5.5 0.00741 
P42669 PURA 3.68 0.0998 -3.185 -13.06 0.00039 
Q9CPR4 RPL17 2.8467 0.2276 -4.817 -5.5 0.02691 
Q3UKW2 CALM1 5.3133 0.0161 0.0766 -11.94 0.00126 
A2AJI0 MAP7D1 3.17 0.0501 -1.755 -1E+05 1.49E-05 
Q9R1L5 MAST1 1.1667 0.1467 -3.955 -1E+05 1.62E-05 
Q9D0E1 HNRNPM 1.7833 0.2975 -5.721 -1E+05 2.88E-05 
Q571I4 PRAG1 5.3 0.1131 -3.412 -1E+05 1.49E-05 
Q8BPN8 DMXL2 0.2033 0.9349 -7.242 -1E+05 1.20E-05 
P61965 WDR5 5.2633 0.0501 -1.757 -1E+05 2.84E-05 
A2AUK5 EPB41L1 2.0833 0.0649 -2.32 -1E+05 1.23E-05 
Q3U2G2 HSPA4 0.4533 0.8595 -7.209 -1E+05 8.64E-05 
Q6ZQ08 CNOT1 1.8033 0.3352 -5.958 -98957 0.00061 
E9QPE7 MYH11 1.3867 0.1369 -3.799 -1E+05 4.03E-05 
E9PWM3 ARMCX4 2.6467 0.3708 -6.135 -1E+05 2.92E-05 
Q3UVC0 KSR2 2.97 0.2328 -4.859 -1E+05 1.30E-05 
O35668 HAP1 1.52 0.2473 -5.166 -1E+05 1.15E-05 
A0A0R4J227 MARK2 3.3067 0.0185 -0.153 -1E+05 1.52E-05 
P62259 YWHAE 4.66 0.2019 -4.543 -25 0.00058 
Q9JME5 AP3B2 2.0767 0.0885 -2.968 -43 4.06E-05 
P99027 RPLP2 2.3333 0.0397 -1.4 -4 0.02957 
A0A2I3BQP6 CAMK2G 5.1833 0.004 1.3283 -1E+05 3.36E-05 




P62911 RPL32 2.6967 0.2473 -5.031 -8.063 0.00874 
P62960 YBX1 0.6133 0.4831 -6.691 -95871 0.00938 
Q9WUM4 CORO1C 2.77 0.0316 -0.96 -7.236 0.0026 
Q80XP9 WNK3 3.76 0.2473 -5.045 -1E+05 2.92E-05 
P59759 MRTFB 2.0633 0.0829 -2.851 -1E+05 2.09E-05 
P62245 RPS15A 3.0433 0.0644 -2.289 -5.441 0.01408 
P47754 CAPZA2 3.4667 0.0632 -2.205 -6 0.01004 
B1AQW2 MAPT 2.8733 0.3364 -5.966 -1E+05 2.20E-05 
Q5SQX6 CYFIP2 1.9533 0.2349 -4.876 -1E+05 1.19E-05 
Q99LF4 RTCB 1.6733 0.1384 -3.82 -98956 0.00064 
D3Z4U5 JAKMIP1 2.84 0.0079 0.8296 -1E+05 2.04E-05 
Q8CDG3 VCPIP1 0.4633 0.5464 -6.837 -1E+05 1.22E-05 
P61514 RPL37A 2.3933 0.2473 -5.004 -3.794 0.0498 
E9Q3L2 PI4KA 1.83 0.2358 -4.883 -1E+05 1.49E-05 
P08226 APOE 1.4733 0.0647 -2.299 -25 0.00673 
Q6PIE5 ATP1A2 0.7833 0.5635 -6.868 -1E+05 2.37E-05 
Q91W50 CSDE1 1.67 0.091 -3.021 -1E+05 0.00013 
O35295 PURB 1.4767 0.5407 -6.822 -4.18 0.02063 
Q99K48 NONO 3.7567 0.0818 -2.82 -1E+05 0.00017 
E9Q1S3 SEC23A 1.7267 0.3886 -6.215 -1E+05 7.44E-05 
Q6P9K8 CASKIN1 5.0167 0.1608 -4.154 -1E+05 7.73E-05 
Q76MZ3 PPP2R1A 3.39 0.0807 -2.779 -1E+05 1.39E-05 
Q6ZWV3 RPL10 4.0433 0.2548 -5.39 -98310 0.00124 
Q62073 MAP3K7 2.17 0.0317 -0.974 -1E+05 2.67E-05 
Q6DFV3 ARHGAP21 4.85 0.0704 -2.475 -1E+05 3.15E-05 
Q8CBB6 HIST1H2BQ 1.6767 0.1614 -4.163 -98956 0.00077 
Q68FF6 GIT1 0.82 0.4506 -6.587 -1E+05 1.17E-05 
Q99JY9 ACTR3 2.35 0.074 -2.568 -99827 0.00029 
P28660 NCKAP1 3.5867 0.1393 -3.837 -1E+05 1.51E-05 
Q9QXS1 PLEC 0.6433 0.2975 -5.723 -1E+05 2.68E-05 
Q9EPN1 NBEA 1.19 0.4449 -6.541 -1E+05 1.75E-05 
P62889 RPL30 3.2633 0.1287 -3.662 -99827 0.00046 
Q80TV8 CLASP1 2.29 0.0772 -2.667 -1E+05 1.75E-05 
Q8QZT1 ACAT1 2.2 0.1021 -3.225 -1E+05 0.00025 
P43006 SLC1A2 5.64 0.0278 -0.743 -1E+05 1.97E-05 
Q9DB20 ATP5PO 1.0967 0.2541 -5.38 -8 0.02998 
Q9JLM8 DCLK1 3.69 0.0538 -1.873 -1E+05 6.33E-06 
O55143 ATP2A2 -0.467 0.6978 -7.07 -1E+05 6.26E-05 
P62852 RPS25 1.3267 0.3333 -5.941 -3.333 0.02695 
P03995 GFAP 2.98 0.2323 -4.854 -1E+05 2.27E-05 
P48453 PPP3CB 5.1067 0.0715 -2.51 -1E+05 1.15E-05 




P19253 RPL13A 2.48 0.1349 -3.763 -1E+05 0.0001 
Q8BFQ4 WDR82 3.0933 0.0807 -2.777 -1E+05 2.10E-05 
P41105 RPL28 2.39 0.3238 -5.888 -42.99 0.00168 
F8VPU2 FARP1 2.1267 0.1444 -3.924 -1E+05 4.68E-05 
A2A690 TANC2 1.03 0.3218 -5.877 -1E+05 2.59E-05 
Q01853 VCP -0.01 1 -7.257 -95352 0.01528 
Q9JKK7 TMOD2 3.25 0.0872 -2.943 -5.6 0.00926 
G3X928 SEC23IP 4.7167 0.2253 -4.793 -11 0.04484 
P47757 CAPZB 2.8567 0.0138 0.2454 -1E+05 1.75E-05 
H7BX08 CAMSAP2 2.3967 0.0647 -2.311 -1E+05 2.46E-05 
A0A1B0GSX0 LDHA 2.1033 0.0185 -0.151 -96349 0.0067 
Q9ES97 RTN3 1.86 0.1138 -3.427 -1E+05 3.55E-05 
A1BN54 ACTN1 2.7567 0.0581 -2.005 -1E+05 6.71E-05 
P18872 GNAO1 3.1233 0.0816 -2.809 -1E+05 1.34E-05 
P61255 RPL26 3.0133 0.0632 -2.226 -4.739 0.02345 
Q8K0U4 HSPA12A 2.3867 0.1681 -4.236 -1E+05 2.37E-05 
P48962 SLC25A4 4.28 0.058 -1.992 -11.33 0.00144 
Q9EQZ6 RAPGEF4 0.35 0.5409 -6.823 -1E+05 4.99E-05 
B7ZNF6 CTNND2 0.5533 0.3013 -5.744 -1E+05 5.94E-05 
P18760 CFL1 3.1733 0.0275 -0.709 -1E+05 9.19E-05 
A2A5Y4 KANSL1 1.67 0.2102 -4.638 -1E+05 0.00017 
O70161 PIP5K1C 3.1933 0.0102 0.5623 -1E+05 2.68E-05 
P61358 RPL27 2.67 0.2226 -4.763 -10 0.00291 
Q920I9 WDR7 4.6233 0.1468 -3.958 -1E+05 2.83E-05 
P42932 CCT8 2.6267 0.2219 -4.751 -1E+05 7.10E-05 
A0A338P769 5-Sep 2.21 0.2829 -5.611 -1E+05 1.56E-05 
P70333 HNRNPH2 3.2833 0.1452 -3.939 -1E+05 6.07E-05 
P63101 YWHAZ 4.5567 0.0968 -3.126 -20 0.00139 
Q9DBN5 LONP2 6.64 0.0008 1.9925 1 0.50437 
Q3UHL1 CAMKV 3.8967 0.1119 -3.39 -1E+05 2.74E-05 
O35129 PHB2 2.6933 0.2597 -5.439 -10 0.00309 
A0A2R8VHH2 SYNGAP1 2.2833 0.0356 -1.245 -1E+05 6.43E-05 
P59598 ASXL1 4.9367 0.1335 -3.741 -1E+05 0.00013 
P56399 USP5 2.0733 0.2473 -5.189 -99827 0.00042 
D3YZU1 SHANK1 -0.677 0.7568 -7.132 -1E+05 6.88E-05 
P09405 NCL 2.2367 0.2473 -5.111 -5.089 0.04269 
Q571K4 TAB3 2.3267 0.1142 -3.436 -1E+05 0.00027 
Q5DTN8 JAKMIP3 1.5 0.0647 -2.31 -1E+05 6.74E-05 
Q5PRE5 PROSER1 2.8 0.0189 -0.199 -98310 0.00117 




Q9QYC0 ADD1 3.63 0.247 -4.961 -1E+05 3.87E-05 
Q9CVB6 ARPC2 2.7 0.131 -3.693 -7.274 0.00689 
Q8BP67 RPL24 3.4167 0.0316 -0.966 -3 0.08524 
Q9CRB9 CHCHD3 1.2433 0.5411 -6.825 -99828 0.00043 
P80315 CCT4 1.5067 0.2403 -4.921 -98958 0.00064 
O09167 RPL21 2.0267 0.1895 -4.449 -98312 0.00105 
Q91VA7 IDH3B 3.2933 0.1803 -4.366 -26 0.00043 
P62267 RPS23 3.3433 0.0589 -2.049 -9 0.02345 
Q80TE7 LRRC7 1.4633 0.4367 -6.397 -1E+05 3.04E-05 
Q8R570 SNAP47 3.46 0.2473 -5.117 -1E+05 7.10E-05 
Q8VEM8 SLC25A3 2.9167 0.0855 -2.907 -1E+05 6.43E-05 
Q9ERU9 RANBP2 0.61 0.4269 -6.36 -1E+05 0.00058 
Q5SRY7 FBXW11 1.55 0.4422 -6.413 -1E+05 9.19E-05 
P80318 CCT3 1.2367 0.4826 -6.689 -1E+05 0.0001 
P56480 ATP5F1B 1.5267 0.2473 -5.268 -97595 0.00205 
A0A498WGS3 MBP 6.2433 0.0117 0.4338 -1E+05 7.36E-06 
Q8CC35 SYNPO 1.38 0.3093 -5.793 -1E+05 0.00019 
A0A0A0MQ79 PRRC2C 1.0033 0.3071 -5.781 -46.99 0.00154 
Q5RJI5 BRSK1 2.6867 0.3701 -6.128 -1E+05 0.00016 
Q80XN0 BDH1 4.3567 0.0983 -3.162 -98641 0.00081 
Q8VDN2 ATP1A1 2.5533 0.1803 -4.362 -1E+05 7.10E-05 
Q6A065 CEP170 2.0067 0.5069 -6.75 -1E+05 8.78E-05 
E9Q1G8 7-Sep 4.4867 0.1181 -3.499 -1E+05 3.87E-05 
P17225 PTBP1 -0.453 0.7332 -7.111 -95873 0.00938 
P68404 PRKCB 2.1367 0.22 -4.728 -1E+05 8.55E-05 
P48722 HSPA4L 2.4267 0.4251 -6.352 -1E+05 0.00012 
Q80YA9 CNKSR2 2.4033 0.0322 -1.035 -1E+05 6.43E-05 
P14094 ATP1B1 2.14 0.2053 -4.574 -7 0.00637 
P12382 PFKL 3.47 0.0706 -2.488 -1E+05 8.64E-05 
Q569Z6 THRAP3 -1.3 0.6868 -7.058 -17 0.02102 
Q922B2 DARS 1.34 0.2721 -5.538 -96795 0.00416 
P80317 CCT6A 1.7167 0.2967 -5.709 -98312 0.00107 
D3YXK0 JAKMIP2 1.7633 0.2044 -4.561 -1E+05 6.71E-05 
P17156 HSPA2 1.3733 0.284 -5.624 -1E+05 7.90E-05 
P84099 RPL19 2.5233 0.2079 -4.601 -98956 0.00076 
P67778 PHB 0.7767 0.4449 -6.445 -4.75 0.017 
P80314 CCT2 2.01 0.0717 -2.523 -98641 0.001 
P80316 CCT5 2.1733 0.4449 -6.436 -98957 0.00068 
A0A0J9YUN4 DNM1 1.8133 0.0747 -2.601 -1E+05 2.74E-05 
Q9WU78 PDCD6IP 3.42 0.2529 -5.366 -1E+05 0.00016 




Q9Z2C4 MTMR1 3.2533 0.1144 -3.442 -1E+05 3.83E-05 
E9Q455 TPM1 0.9867 0.3879 -6.208 -99548 0.00043 
Q0KL02 TRIO 0.7367 0.3725 -6.143 -1E+05 9.82E-05 
Q63810 PPP3R1 4.4367 0.1526 -4.055 -1E+05 4.18E-05 
Q9Z1W9 STK39 3.4167 0.1692 -4.251 -1E+05 6.88E-05 
Q9ES28 ARHGEF7 2.3667 0.1549 -4.1 -1E+05 0.00026 
Q9WUA3 PFKP 2.8167 0.2473 -5.099 -1E+05 0.00016 
Q9R1R2 TRIM3 4.02 0.1739 -4.296 -1E+05 0.00012 
Q8BH44 CORO2B 3.5933 0.1052 -3.279 -13.37 0.00141 
Q80U63 MFN2 1.2267 0.4449 -6.541 -1E+05 0.00023 
Q7TQH0 ATXN2L 0.6967 0.3344 -5.951 -1E+05 8.55E-05 
Q80SW1 AHCYL1 2.81 0.0637 -2.258 -1E+05 6.60E-05 
P20152 VIM 3.0167 0.2993 -5.733 -98957 0.00068 
P63037 DNAJA1 4.5 0.0089 0.7087 -99258 0.00081 
P62900 RPL31 2.82 0.0637 -2.257 -98956 0.00076 
P35486 PDHA1 4.7133 0.0862 -2.924 -1E+05 6.19E-05 
O70305 ATXN2 3.41 0.2767 -5.579 -1E+05 0.00019 
Q8BG05 HNRNPA3 0.65 0.7847 -7.158 -99259 0.00064 
P29788 VTN 0.6233 0.4337 -6.387 -94785 0.02345 
P60335 PCBP1 5.69 0.0345 -1.18 -1E+05 0.00011 
Q3UHK6 TENM4 0.8633 0.4601 -6.62 -1E+05 0.00019 
Q8BJH1 ZC2HC1A 3.4667 0.0704 -2.466 -1E+05 0.0001 
P61161 ACTR2 3.6267 0.0671 -2.377 -21 0.00105 
D3YWN7 MAP7 2.03 0.0776 -2.681 -1E+05 0.00023 
H7BX95 SRSF1 2.8067 0.0981 -3.156 -1E+05 0.00033 
Q3TES0 IQSEC3 1.6433 0.339 -5.978 -1E+05 0.00027 
Q8BUV3 GPHN 2.59 0.0704 -2.474 -1E+05 0.00015 
Q8BGR3 CAMK4 2.1333 0.2493 -5.323 -1E+05 0.00015 
P61164 ACTR1A 2.9767 0.2473 -4.981 -1E+05 0.0001 
P62849 RPS24 3.8133 0.042 -1.49 -96792 0.00393 
Q80ZX0 SEC24B 3.38 0.2473 -5.235 -1E+05 0.0002 
E9Q7C9 KLC1 2.8933 0.3425 -6.008 -1E+05 0.0001 
A0A087WPK3 LRRFIP1 1.54 0.167 -4.222 -1E+05 0.00017 
P06837 GAP43 4.75 0.0783 -2.714 -39 0.00201 
P63085 MAPK1 3.2533 0.2578 -5.417 -1E+05 5.73E-05 
Q9D6M3 SLC25A22 4.8067 0.0101 0.5766 -1E+05 0.00015 
P59764 DOCK4 1.26 0.2546 -5.384 -1E+05 0.00017 
Q8CIE6 COPA -1.077 0.2768 -5.581 -94144 0.0412 
Q3UMP4 SERBP1 4.4267 0.2473 -5.302 -27 0.00549 
A2AHJ7 DGKZ 0.95 0.4095 -6.292 -1E+05 0.00019 




Q9QY01 ULK2 1.3933 0.2473 -5.089 -1E+05 0.00019 
P11983 TCP1 3.0267 0.3278 -5.912 -98641 0.00083 
Q9QVP9 PTK2B 2.83 0.3423 -6.003 -1E+05 0.00017 
Q8C3Q5 SHISA7 1.9567 0.3706 -6.131 -1E+05 0.00012 
E9Q6E0 MAPK8IP3 3.1133 0.3664 -6.107 -1E+05 0.0002 
E9Q828 ATP2B4 1.8467 0.2634 -5.47 -1E+05 0.00019 
Q9CQA3 SDHB 5.49 0.0829 -2.849 -1E+05 0.00023 
A0A0R4J0B4 CMAS 2.55 0.4124 -6.303 -96795 0.00416 
P62141 PPP1CB 3.0033 0.3194 -5.858 -98310 0.00117 
P83882 RPL36A 2.6733 0.2508 -5.342 -21 0.01035 
P47753 CAPZA1 2.71 0.3743 -6.152 -95351 0.01408 
Q7TMK9 SYNCRIP 1.69 0.066 -2.348 -97597 0.00208 
Q9WUM5 SUCLG1 0.12 0.9749 -7.252 -97962 0.00142 
Q6NS52 DGKB 2.11 0.1608 -4.156 -1E+05 0.00018 
Q3UHU5 MTCL1 0.44 0.4282 -6.366 -1E+05 0.00019 
P68510 YWHAH 3.0567 0.2226 -4.767 -1E+05 0.0003 
B2RXT3 OGDHL 3.8867 0.211 -4.646 -1E+05 7.33E-05 
P14115 RPL27A 3.7767 0.0322 -1.046 -12 0.00932 
Q8BG95 PPP1R12B 5.2333 0.1255 -3.608 -99827 0.00029 
O70325 GPX4 2.6 0.1824 -4.392 -1E+05 7.33E-05 
A2ATK9 FAM171A1 2.2767 0.0925 -3.049 -1E+05 0.00019 
P10639 TXN 3.91 0.1981 -4.517 -96795 0.00393 
P48318 GAD1 1.71 0.2851 -5.636 -1E+05 0.00033 
Q8VHJ5 MARK1 3.6267 0.1142 -3.437 -1E+05 0.0001 
Q3TUQ7 PRKAA1 1.7467 0.4478 -6.573 -98641 0.00081 
Q8CCJ9 PHF20L1 6.64 0.0008 1.9925 1 0.50437 
A0A0N4SW73 RAB11FIP5 1.9267 0.21 -4.629 -99548 0.00049 
P28656 NAP1L1 4.2967 0.1335 -3.741 -97962 0.00154 
E9PU87 SIK3 0.65 0.2699 -5.524 -1E+05 0.00014 
A0A1B0GS91 SVIL 6.64 0.0008 1.9925 1 0.50437 
Q6PB44 PTPN23 0.5133 0.3726 -6.145 -1E+05 0.00012 
D6REV1 ASXL2 2.68 0.1397 -3.851 -96350 0.00643 
Q99KJ8 DCTN2 6.0967 0.0213 -0.351 -1E+05 0.00023 
O55142 RPL35A 3.1667 0.3106 -5.806 -25 0.00673 
A0A0G2JEG8 AMPH 2.8467 0.0105 0.5351 -1E+05 0.00023 
Q3UNH4 GPRIN1 0.28 0.7197 -7.096 -35 0.00324 
F8WJE3 KANSL2 2.0633 0.2742 -5.56 -97966 0.00147 
P43277 H1-3 2.3733 0.2749 -5.565 -6.982 0.01276 




Q6R891 PPP1R9B 1.1533 0.1452 -3.936 -99827 0.00053 
A0A1Y7VNZ6 MARK3 3.3 0.2621 -5.459 -1E+05 0.00023 
Q60598 CTTN 1.8333 0.1448 -3.93 -1E+05 0.00017 
Q7TPV2 DZIP3 1.2567 0.2887 -5.665 -1E+05 0.0001 
Q2M3X8 PHACTR1 0.24 0.6947 -7.066 -33 0.0031 
A0A494BB75 WDR26 2.7933 0.3932 -6.23 -97206 0.00276 
Q6ZPQ6 PITPNM2 4.7333 0.2226 -4.76 -1E+05 0.00011 
Q60865 CAPRIN1 2.9433 0.3106 -5.807 -97598 0.00208 
Q61937 NPM1 2.1933 0.4449 -6.462 -27 0.00582 
Q9JI90 RNF14 1.2567 0.2637 -5.481 -1E+05 0.00021 
P99024 TUBB5 5.98 0.0314 -0.927 -37 0.00239 
P60202 PLP1 5.5933 0.0379 -1.342 -6 0.01344 
Q9Z2X1 HNRNPF 2.9033 0.2473 -5.235 -95351 0.01408 
Q8K0T0 RTN1 1.4533 0.4454 -6.55 -99259 0.00053 
Q61171 PRDX2 1.9567 0.1537 -4.081 -11 0.01347 
G3UW85 ERH 4.7467 0.22 -4.734 -94144 0.0412 
Q5DTY9 KCTD16 3.3667 0.2276 -4.811 -1E+05 0.0002 
Q3U741 DDX17 3.9333 0.1796 -4.349 -99550 0.00049 
Q9Z2I9 SUCLA2 2.1333 0.1179 -3.494 -98641 0.001 
B1AZP2 DLGAP4 2.4033 0.4435 -6.419 -1E+05 0.00033 
O08919 NUMBL 3.1833 0.2975 -5.721 -99827 0.0003 
P63011 RAB3A 1.57 0.4251 -6.352 -1E+05 0.00011 
Q3UHB8 CCDC177 5.31 0.1121 -3.395 -99548 0.00051 
Q5SSL4 ABR 0.3167 0.6723 -7.029 -1E+05 0.00033 
Q6PCP5 MFF 5.4867 0.0833 -2.859 -98957 0.00068 
Q60749 KHDRBS1 2.1767 0.4478 -6.573 -99548 0.00059 
Q8CCF0 PRPF31 1.3 0.3423 -6.004 -97595 0.00243 
Q6ZWV7 RPL35 2.8633 0.339 -5.981 -7 0.03868 
S4R1C4 ATP2B2 5.27 0.1184 -3.508 -99549 0.00049 
Q6PAJ1 BCR 4.28 0.2699 -5.525 -99548 0.00068 
Q80U23 SNPH 5.67 0.0632 -2.226 -99259 0.00053 
Q8C1B7 SEPTIN11 5.7333 0.058 -1.985 -99827 0.00053 
G5E8J2 ANK1 2.9667 0.0589 -2.036 -99827 0.00029 
P28740 KIF2A 1.9833 0.3952 -6.238 -1E+05 0.00013 
A0A0A6YWI6 DCLK2 4.1 0.1656 -4.204 -99259 0.00057 
E9Q456 TPM1 1.5367 0.0263 -0.65 1 0.50437 
Q9D2G2 DLST 1.6933 0.464 -6.635 -97206 0.00276 
O88196 TTC3 3.31 0.0642 -2.278 -1E+05 0.0002 
Q3UMT1 PPP1R12C 1.18 0.273 -5.543 -99827 0.00056 




P23242 GJA1 1.8267 0.0341 -1.149 -4.019 0.09383 
Q60960 KPNA1 3.3133 0.2529 -5.359 -99259 0.00053 
O70503 HSD17B12 5.9567 0.0322 -1.036 1 0.50437 
Q91V61 SFXN3 1.8467 0.5299 -6.801 -99548 0.00043 
Q9ERD7 TUBB3 3.66 0.0055 1.1221 -1E+05 3.21E-05 
Q812A2 SRGAP3 1.6767 0.2473 -5.087 -99548 0.00044 
Q8BFU3 RNF214 4.9767 0.1689 -4.246 -98313 0.00107 
A0A338P6K9 QSER1 6.64 0.0008 1.9925 -98642 0.00137 
O54950 PRKAG1 5.9767 0.0314 -0.943 -9 0.06498 
A0A494B9F0 NEDD4L 1.09 0.3882 -6.213 -99827 0.0003 
P21126 UBL4A 6.1133 0.0199 -0.265 -97962 0.00142 
Q9JM52 MINK1 0.7267 0.6623 -7.017 -99258 0.00062 
Q80YN3 BCAS1 2.3167 0.0322 -1.042 -1E+05 0.00027 
Q6ZQ58 LARP1 -2.487 0.3423 -5.997 -25 0.00878 
P84078 ARF1 2.14 0.0457 -1.624 -96350 0.00643 
Q8C2Q7 HNRNPH1 6.64 0.0008 1.9925 1 0.50437 
G3X972 SEC24C 1.9067 0.5118 -6.762 -96353 0.0067 
Q8K4G5 ABLIM1 2.5167 0.1431 -3.899 -98642 0.00079 
Q8CI32 BAG5 4.2533 0.1337 -3.748 -98641 0.00083 
P61982 YWHAG 3.5133 0.2473 -5.052 -98310 0.00147 
Q61548 SNAP91 -0.563 0.8535 -7.206 -99259 0.00057 
Q3UG20 KMT2E 4.06 0.3132 -5.821 -25 0.00741 
E9PZP8 HERC1 2.2167 0.3482 -6.033 -1E+05 0.00027 
Q9R111 GDA 0.28 0.6863 -7.056 -98958 0.00064 
Q9D1R9 RPL34 2.9633 0.1337 -3.749 -4.333 0.02826 
Q9EQF5 DPYS 6.64 0.0008 1.9925 1 0.50437 
E9Q9Y4 TET1 1.4367 0.22 -4.736 -98956 0.00064 
Q9JIS5 SV2A 1.1633 0.4454 -6.551 -29 0.00657 
Q9Z0E0 NCDN -0.927 0.2575 -5.412 -98641 0.00119 
P63330 PPP2CA 2.4967 0.2361 -4.887 -1E+05 0.00016 
P27671 RASGRF1 3.3333 0.2637 -5.476 -99260 0.00079 
Q9R0Q6 ARPC1A 2.79 0.2412 -4.927 -99827 0.00033 
Q9CT10 RANBP3 -1.18 0.7068 -7.082 -1E+05 0.00023 
Q8CF89 TAB1 3.3633 0.3365 -5.968 -1E+05 0.00025 
P08553 NEFM 2.25 0.2322 -4.851 -1E+05 0.0001 
O08539 BIN1 2.99 0.3327 -5.935 -99260 0.00052 
Q99L90 MCRS1 2.7867 0.3498 -6.04 -97965 0.00165 
Q5SNZ0 CCDC88A 2.5133 0.407 -6.281 -31 0.0048 
Q9D415 DLGAP1 0.19 0.53 -6.802 -98956 0.00081 




Q9CR62 SLC25A11 2.43 0.2153 -4.68 -98642 0.00079 
Q6ZPJ3 UBE2O 5.3467 0.1058 -3.289 -1E+05 0.00023 
A2AG50 MAP7D2 0.7433 0.4457 -6.555 -99827 0.00033 
O54781 SRPK2 2.0767 0.0644 -2.285 -98956 0.00076 
P08551 NEFL 6.3633 0.0057 1.0885 -99259 0.00053 
Q8K310 MATR3 0.4933 0.4963 -6.72 -99548 0.00043 
A0A0N4SVL0 EIF4G3 6.64 0.0008 1.9925 -97966 0.00147 
Q8VBU5 PDE4B 4.6733 0.1189 -3.516 -1E+05 0.00023 
Q62318 TRIM28 2.83 0.1803 -4.36 -99548 0.00044 
B1AXZ5 ELAVL2 0.6167 0.8031 -7.173 -99259 0.00053 
E9Q3M9 2010300C02RIK 3.47 0.2473 -5.115 -99259 0.00057 
E9Q4K0 ABLIM2 4.2133 0.1395 -3.843 -99828 0.00029 
P07901 HSP90AA1 0.63 0.7791 -7.154 -98641 0.00083 
Q5U4C1 GPRASP1 1.6167 0.2831 -5.614 -99827 0.00056 
Q61584 FXR1 0.8033 0.4251 -6.349 -95351 0.01408 
Q14BB9 MAP6D1 6.14 0.0183 -0.125 -98310 0.00137 
Q6P1F6 PPP2R2A 2.9667 0.3238 -5.888 -98310 0.0012 
Q14CH0 FAM171B 4.9233 0.1803 -4.366 -99259 0.00057 
Q62425 NDUFA4 4.5567 0.0822 -2.829 -12 0.00885 
A2A9M4 DOCK7 3.7567 0.2573 -5.41 -98312 0.00208 
Q64332 SYN2 0.68 0.7231 -7.1 -98310 0.00137 
P59999 ARPC4 2.7367 0.0766 -2.654 -98312 0.00105 
A2AWI7 SH3GLB2 2.7633 0.1537 -4.079 -98313 0.00117 
Q8JZU2 SLC25A1 6.06 0.0244 -0.537 -95871 0.01096 
P70392 RASGRF2 6.64 0.0008 1.9925 -97962 0.0034 
P99029 PRDX5 4.08 0.0213 -0.348 -97962 0.00193 
Q8CBY8 DCTN4 1.88 0.2637 -5.474 -98641 0.00094 
Q8BIZ1 ANKS1B 1.1267 0.3423 -6.006 -99261 0.00057 
P23927 CRYAB 2.5 0.3314 -5.929 -9.823 0.01312 
Q8C2Q3 RBM14 2.6233 0.3781 -6.169 -13 0.03379 
B2RQC6 CAD 0.83 0.2602 -5.446 -25 0.01074 
Q9DD20 METTL7B 6.64 0.0008 1.9925 1 0.50437 
P47708 RPH3A 3.6933 0.2276 -4.818 -98312 0.00154 
P97765 WBP2 4.2433 0.0345 -1.172 -1E+05 0.00016 
Q9QYJ3 DNAJB1 5.2767 0.1123 -3.4 -99259 0.00049 
Q8R5H1 USP15 0.4533 0.4449 -6.521 -97962 0.00154 
P97457 MYLPF 6.64 0.0008 1.9925 1 0.50437 
Q9R0P5 DSTN 4.19 0.1523 -4.043 -98310 0.00107 
Q9D1H7 GET4 0.9833 0.3731 -6.147 -97962 0.00208 




Q6GT24 PRDX6 0.38 0.7981 -7.169 -96793 0.00416 
Q8BX10 PGAM5 3.7467 0.22 -4.734 -98956 0.00064 
Q8R2R9 AP3M2 4.65 0.0949 -3.095 -98641 0.00119 
P54823 DDX6 2.0367 0.2403 -4.918 -97598 0.00208 
Q6PHQ9 PABPC4 3.3033 0.2597 -5.442 -19 0.01427 
Q61151 PPP2R5E 2.1467 0.0362 -1.27 -98641 0.00079 
Q9WTX5 SKP1 3.1267 0.0417 -1.469 -97962 0.00165 
Q8C7M3 TRIM9 3.6267 0.2336 -4.867 -99259 0.00052 
P55937 GOLGA3 6.64 0.0008 1.9925 1 0.50437 
P62196 PSMC5 6.64 0.0008 1.9925 -96349 0.00586 
Q9CQV8 YWHAB 4.18 0.1824 -4.391 -97962 0.00154 
Q8CI94 PYGB 2.12 0.0197 -0.251 -98310 0.00137 
Q8C0T5 SIPA1L1 3.32 0.2843 -5.627 -97598 0.00208 
E9Q804 ANKRD17 0.8167 0.3037 -5.763 -97595 0.00193 
Q99PU8 DHX30 3.8233 0.208 -4.606 -98641 0.00081 
P58871 TNKS1BP1 2.57 0.3969 -6.244 -13 0.03379 
D3Z2H9 TPM3-RS7 1.26 0.2637 -5.485 -11 0.04484 
A2AGT5 CKAP5 2.7967 0.2473 -5.009 -97962 0.00154 
G5E924 HNRNPL 2.57 0.3932 -6.231 -95873 0.00938 
Q8VIJ6 SFPQ 3.79 0.2155 -4.683 -95871 0.01096 
Q8C3F2 FAM120C 3.1767 0.2845 -5.632 -97598 0.00243 
A0A0G2JFT8 RUFY3 3.04 0.018 -0.089 -98957 0.00068 
P68040 RACK1 3.29 0.2865 -5.647 -95352 0.01528 
Q99KB8 HAGH 2.0167 0.1391 -3.83 -96792 0.00454 
A0A0B4J1E7 KPNA4 6.64 0.0008 1.9925 1 0.50437 
Q6URW6 MYH14 2.9167 0.0789 -2.734 -99258 0.00077 
E9QKR0 GNB2 2.16 0.2473 -5.232 -98958 0.00064 
P63168 DYNLL1 5.3133 0.0909 -3.017 -98957 0.00061 
P62814 ATP6V1B2 -0.477 0.4506 -6.586 -97963 0.00154 
Q61097 KSR1 5.0833 0.1494 -3.994 -97962 0.00208 
Q5DTT2 PSD 6.64 0.0008 1.9925 -97596 0.00261 
Q9QXZ0 MACF1 0.9567 0.407 -6.28 -98641 0.00178 
Q8BHJ5 TBL1XR1 1.1733 0.0378 -1.328 -97962 0.00147 
E9QMC2 GRM5 0.7967 0.4974 -6.724 -97208 0.00504 
Q8R4U7 LUZP1 1.35 0.3882 -6.212 -97962 0.00154 
P63089 PTN 1.56 0.0314 -0.941 -97598 0.00208 
Q6A4J8 USP7 2.1367 0.4528 -6.595 -97966 0.00147 
D3YTQ9 RPS15 2.0867 0.4752 -6.671 -97962 0.00165 
Q8K0S0 PHYHIP 6.64 0.0008 1.9925 -98642 0.00094 




Q8BXK8 AGAP1 0.4767 0.4506 -6.586 -98310 0.00147 
D6RI62 ASXL2 5.36 0.1034 -3.25 -97962 0.00193 
A0A0A6YWM5 RAB3GAP2 4.3133 0.1303 -3.681 -97962 0.00195 
Q8C0M9 ASRGL1 5.3933 0.0979 -3.151 -97206 0.00276 
Q8R5H6 WASF1 -0.16 0.8494 -7.203 -97962 0.00154 
Q5F4T0 TRPM3 3.1833 0.2975 -5.721 -23 0.01255 
P50516 ATP6V1A 5.06 0.1525 -4.051 -97965 0.00165 
Q7TPW1 NEXN -0.243 0.6601 -7.013 -98642 0.00147 
H3BIV5 AKAP5 1.1433 0.2556 -5.397 -98310 0.00107 
D3YZC9 SF1 3.3333 0.249 -5.319 -97965 0.00165 
Q99JN2 KLHL22 3.0933 0.3002 -5.739 -98310 0.00107 
P62869 ELOB 1.8867 0.2762 -5.574 -95873 0.00938 
Q8BHL5 ELMO2 4.9967 0.0909 -3.015 -98641 0.00083 
Q8CIP4 MARK4 3.8867 0.2102 -4.633 -98641 0.00147 
P31650 SLC6A11 3.6333 0.2637 -5.475 -97210 0.00342 
P97315 CSRP1 1.13 0.5826 -6.902 -97962 0.00165 
O88935 SYN1 0.3733 0.4485 -6.577 -97595 0.00243 
Q5SSM3 ARHGAP44 5.6733 0.0632 -2.213 -98641 0.00083 
Q7TME0 PLPPR4 6.64 0.0008 1.9925 -98311 0.00154 
Q9CQU5 ZWINT 1.53 0.2088 -4.612 -97965 0.00165 
Q9JM76 ARPC3 4.4267 0.2473 -5.302 -96349 0.00586 
P62631 EEF1A2 5.5 0.0451 -1.599 -97962 0.00193 
Q8CI08 SLAIN2 4.1767 0.2893 -5.67 -97602 0.00243 
S4R1Y1 CUL9 1.7567 0.2525 -5.355 -97598 0.00208 
Q68FH0 PKP4 6.64 0.0008 1.9925 -97962 0.00154 
Q3TEA8 HP1BP3 2.38 0.2096 -4.624 -96795 0.00416 
Q9DCB4 ARPP21 6.64 0.0008 1.9925 -97962 0.00142 
Q9QYG0 NDRG2 3.4533 0.253 -5.368 -95351 0.01408 
O55022 PGRMC1 6.64 0.0008 1.9925 1 0.50437 
A0A0R4J0A6 SLC17A6 2.74 0.249 -5.32 -98957 0.00062 
E9PXF8 SBF2 4.4033 0.2508 -5.339 -97595 0.00193 
Q9D6F9 TUBB4A 4.86 0.0697 -2.446 -98312 0.00107 
A2AEW9 GRIPAP1 1.89 0.5233 -6.785 -97208 0.00504 
Q9CXS4 CENPV 3.5 0.2473 -5.286 -96792 0.00454 
Q9Z1S5 SEPTIN3 1.11 0.4449 -6.532 -98310 0.00124 
Q04447 CKB 5.25 0.1227 -3.563 -97206 0.00276 
P04627 ARAF 3.1667 0.2767 -5.579 -98311 0.00107 
H3BIW6 PLCH2 3.09 0.3619 -6.09 -97595 0.00193 
A6ZI47 ALDOART2 1.83 0.6022 -6.932 -19 0.0136 




Q60930 VDAC2 4.1267 0.1523 -4.04 -96351 0.0067 
A0A1Y7VL44 TTC7B 0.0833 0.6863 -7.056 -97962 0.00154 
Q8C570 RAE1 3.4933 0.2958 -5.704 -98311 0.00107 
Q9Z268 RASAL1 0.4933 0.3197 -5.862 -97598 0.00208 
Q80T41 GABBR2 4.95 0.1751 -4.307 -98311 0.00137 
Q921F2 TARDBP -2.483 0.4114 -6.298 -11 0.04484 
Q6PER3 MAPRE3 3.0767 0.0149 0.1677 -98641 0.00094 
V9GXM1 ARFGAP1 3.4267 0.4449 -6.453 -19 0.017 
P28741 KIF3A -0.687 0.274 -5.553 -98311 0.00159 
P10922 H1-0 4.83 0.2044 -4.566 -96349 0.0067 
A2A699 FAM171A2 2.6733 0.0807 -2.788 -96792 0.00454 
P60843 EIF4A1 6.64 0.0008 1.9925 1 0.50437 
H3BKQ7 PPP1R9A 6.64 0.0008 1.9925 -96792 0.00454 
D3YYK8 MAPRE2 3.17 0.2742 -5.559 -21 0.01074 
P70372 ELAVL1 0.3867 0.4576 -6.611 -94785 0.02345 
Q8K212 PACS1 2.3067 0.4449 -6.457 -97595 0.00205 
A0A1D5RMH7 PSD3 3.59 0.2637 -5.478 -97962 0.00252 
G3UXL2 PRPS1L3 4.7267 0.223 -4.773 -97206 0.00393 
Q9D1P2 KAT8 6.64 0.0008 1.9925 -17 0.01784 
F6RJV6 LANCL2 2.9633 0.1358 -3.78 -97962 0.00142 
Q9DBE7 STAU1 6.64 0.0008 1.9925 1 0.50437 
A0A087WNT1 ELOC 3.3967 0.2473 -5.262 -96795 0.00393 
E9Q4Z6 DZANK1 1.4367 0.2634 -5.47 -97598 0.00208 
A0A0G2JGW6 CDKL5 2.88 0.3218 -5.876 -97962 0.00165 
Q3UID0 SMARCC2 2.9133 0.3782 -6.171 -97595 0.00193 
O35465 FKBP8 2.3267 0.4449 -6.441 -15 0.02345 
B9EJA2 CTTNBP2 2.5233 0.3101 -5.799 -97206 0.00262 
Q542V3 SRSF4 4.38 0.1216 -3.548 -21 0.01035 
A0A0R4J1F4 MADD 4.4267 0.2473 -5.302 -21 0.01427 
P68181 PRKACB 5.51 0.0807 -2.783 -97595 0.00193 
Q3TLP8 RAC1 2.0533 0.0591 -2.061 -97595 0.00261 
Q80UG5 SEPTIN9 1.05 0.3681 -6.116 -94785 0.02345 
Q8CG76 AKR7A2 6.64 0.0008 1.9925 1 0.50437 
P62317 SNRPD2 0.1733 0.8093 -7.178 -95871 0.00938 
P49615 CDK5 2.7067 0.018 -0.093 -99548 0.0005 
Q7TNC4 LUC7L2 3.2367 0.2676 -5.511 -13 0.03379 
O88685 PSMC3 2.8333 0.3333 -5.94 -95351 0.01528 
P31324 PRKAR2B 3.3033 0.268 -5.514 -97595 0.00243 




Q60737 CSNK2A1 2.95 0.3093 -5.793 -96792 0.00393 
P12849 PRKAR1B 6.3033 0.0084 0.7643 -97595 0.00261 
P16054 PRKCE 1.7667 0.2525 -5.353 -19 0.02345 
Q9R0P9 UCHL1 4.1267 0.1526 -4.062 -97598 0.00243 
G3X932 ARHGAP39 2.03 0.4761 -6.675 -97206 0.00276 
O54962 BANF1 1.5633 0.3423 -5.998 -9 0.01867 
Q8R071 ITPKA 2.92 0.3218 -5.877 -96351 0.00586 
P62743 AP2S1 2.51 0.1397 -3.852 -9 0.01867 
P33173 KIF1A 3.23 0.2618 -5.455 -97595 0.00261 
Q9D898 ARPC5L 5.37 0.1021 -3.221 -96349 0.00586 
E0CXB9 CTNNA2 5.66 0.0637 -2.262 -97595 0.00261 
Q9DB41 SLC25A18 2.7533 0.3562 -6.069 -97598 0.00208 
Q62189 SNRPA 0.54 0.8614 -7.21 -13 0.0317 
Q9CXY6 ILF2 1.5467 0.3093 -5.793 -97206 0.00276 
P31938 MAP2K1 3.0233 0.3174 -5.842 -98311 0.00159 
A0A286YCV9 KIF13B 6.64 0.0008 1.9925 1 0.50437 
P49025 CIT 2.71 0.0092 0.6676 -19 0.017 
Q9CQ69 UQCRQ 2.9 0.0744 -2.589 -96349 0.00586 
Q9QY76 VAPB 1.1967 0.3128 -5.819 -97597 0.00208 
O70251 EEF1B -0.103 0.9852 -7.254 -96349 0.00586 
Q69ZH9 ARHGAP23 5.94 0.0333 -1.113 -96795 0.00393 
B2RRE7 OTUD4 5.4533 0.0885 -2.966 -96349 0.00838 
Q9ESJ4 NCKIPSD 1.64 0.2508 -5.337 -97595 0.00261 
Q8VEG4 EXD2 1.0033 0.3194 -5.858 -97206 0.00276 
B7ZBV9 KCNQ2 1.7833 0.5452 -6.835 -96795 0.00393 
Q9Z2D6 MECP2 3.4267 0.2473 -5.162 -15 0.02345 
P62897 CYCS -0.477 0.4594 -6.617 -94144 0.0412 
Q8BLG0 PHF20 6.64 0.0008 1.9925 -15 0.02345 
Q9JLJ2 ALDH9A1 6.64 0.0008 1.9925 1 0.50437 
Q9EP53 TSC1 2.2967 0.2906 -5.679 -17 0.02102 
S4R2G0 DGKI 5.7333 0.058 -1.985 -96795 0.00393 
Q78ZA7 NAP1L4 4.3667 0.1257 -3.617 -96351 0.00643 
Q5SVG5 AP1B1 6.64 0.0008 1.9925 -5 0.1741 
Q9DCL9 PAICS 6.64 0.0008 1.9925 1 0.50437 
Q8CCT4 TCEAL5 5 0.1645 -4.193 -97598 0.00243 
Q8BK64 AHSA1 2.8 0.3425 -6.008 -96792 0.00416 
Q922P9 GLYR1 2.7767 0.3423 -5.995 -19 0.0136 
O35344 KPNA3 2.2133 0.6797 -7.047 -95352 0.01528 
Q80TK0 KIAA1107 0.7833 0.3423 -6.003 -96792 0.00454 




G5E8Z3 2310050C09RIK 1.9433 0.5409 -6.824 -96349 0.0067 
Q920P5 AK5 4.8133 0.2079 -4.6 -97596 0.00261 
Q9WV69 DMTN 4.4267 0.2473 -5.302 -97206 0.00262 
Q8BP92 RCN2 5.2433 0.042 -1.498 -97210 0.00342 
Q5PR73 DIRAS2 5.9533 0.0322 -1.052 -97206 0.00393 
Q8VHQ9 ACOT11 -0.537 0.3444 -6.016 -97962 0.00142 
Q9R0L7 AKAP8L 3.8067 0.216 -4.689 -96350 0.00643 
Q9QYB8 ADD2 2.5867 0.4449 -6.502 -96350 0.0067 
A2AL85 ASPH 6.64 0.0008 1.9925 1 0.50437 
D3Z2H2 CTNND1 6.64 0.0008 1.9925 1 0.50437 
P62334 PSMC6 1.21 0.4449 -6.541 -94144 0.0412 
Q91WG5 PRKAG2 6.64 0.0008 1.9925 -96351 0.00643 
Q80X90 FLNB 6.64 0.0008 1.9925 1 0.50437 
P62881 GNB5 5.5133 0.0807 -2.772 -17 0.01784 
Q8K341 ATAT1 4.4667 0.1081 -3.331 -97206 0.00311 
O54946 DNAJB6 5.9967 0.03 -0.848 -96792 0.00454 
Q8VHH5 AGAP3 1.5533 0.2473 -5.167 -97598 0.00208 
Q9JKC6 CEND1 1.6033 0.2742 -5.557 -19 0.0136 
P58404 STRN4 3.1033 0.2844 -5.629 -96792 0.00504 
E9PW37 RASAL2 3.3767 0.3331 -5.937 -97962 0.00208 
Q8BKI2 TNRC6B 0.7033 0.4457 -6.558 -94144 0.0412 
Q61990 PCBP2 0.0167 1 -7.258 -97595 0.00193 
Q60972 RBBP4 1.4667 0.3338 -5.944 -99260 0.00091 
A0A5F8MQC8 TECR 6.64 0.0008 1.9925 -7 0.09747 
P62821 RAB1A 3.96 0.2191 -4.713 -95871 0.00938 
Q61753 PHGDH 2.8667 0.2473 -5.15 -95351 0.01408 
Q63844 MAPK3 2.68 0.4149 -6.316 -97206 0.00262 
P08752 GNAI2 4.46 0.1081 -3.335 -97595 0.00261 
O88703 HCN2 2.4767 0.4267 -6.359 -17 0.02102 
P84104 SRSF3 4.68 0.2332 -4.862 -96349 0.0067 
P56564 SLC1A3 5.5367 0.0779 -2.695 -95872 0.00938 
P81122 IRS2 1.55 0.4449 -6.537 -17 0.017 
O35098 DPYSL4 2.2467 0.4619 -6.626 -96350 0.0067 
Q62418 DBNL -1.157 0.5005 -6.733 -13 0.0419 
Q8R191 SYNGR3 0.29 0.8761 -7.219 -97598 0.00205 
Q6AXD2 ABI2 6.64 0.0008 1.9925 -96795 0.00393 
P60122 RUVBL1 6.64 0.0008 1.9925 -95872 0.00938 
Q02248 CTNNB1 4.4267 0.2473 -5.302 -15 0.02576 
Q9WTM5 RUVBL2 4.7267 0.223 -4.773 -95351 0.01408 
Q9ET77 JPH3 5.1633 0.1366 -3.793 -96792 0.00454 




A0A5F8MQ25 PPP6R2 0.3333 0.4638 -6.634 -95871 0.01096 
Q8K4P8 HECW1 4.3867 0.2529 -5.365 -96795 0.00416 
E9Q401 RYR2 3.4667 0.2473 -5.093 -15 0.03379 
Q8R349 CDC16 2.76 0.0318 -0.997 -15 0.02345 
J3QMG3 VDAC3 4.2133 0.2834 -5.62 -95352 0.01528 
E9QP99 GOLGA3 2.3733 0.4374 -6.4 -15 0.02345 
H7BWY4 DLG1 5.34 0.1069 -3.309 -96792 0.00393 
Q8C163 EXOG 3.05 0.3173 -5.839 -13 0.03379 
Q9WV55 VAPA 1.59 0.6125 -6.948 -96349 0.00586 
Q9JJD0 THAP11 1.8967 0.5213 -6.78 -95872 0.00938 
Q9D823 RPL37 4.33 0.1272 -3.642 -15 0.03379 
A2A7S7 YARS 2.5033 0.4091 -6.289 -13 0.03379 
O89053 CORO1A 2.43 0.0942 -3.078 -97210 0.00342 
P35802 GPM6A 4.7767 0.1269 -3.633 -97206 0.00276 
Q8VDP4 CCAR2 0.67 0.4732 -6.665 -17 0.01784 
E9PX29 SPTBN4 2.8867 0.3467 -6.025 -13 0.03379 
Q9D051 PDHB 4.0233 0.2473 -5.052 -98310 0.00107 
A0A0R4J008 HDAC2 4.1467 0.1641 -4.188 -96349 0.00586 
Q8BH66 ATL1 4.75 0.22 -4.728 -96792 0.00454 
A2AH22 AMBRA1 3.0533 0.3057 -5.775 -95871 0.01096 
O70589 CASK 2.68 0.3647 -6.1 -7 0.03868 
Q64336 TBR1 0.2533 0.4834 -6.692 -96349 0.0067 
Q8C729 FAM126B 3.1467 0.3018 -5.747 -95872 0.00938 
P26645 MARCKS 6.64 0.0008 1.9925 -7 0.09747 
A2ARS0 ANKRD63 3.2867 0.2529 -5.365 -95872 0.00938 
Q8BP00 IQCB1 5.5067 0.0809 -2.794 -96349 0.0067 
Q52KI8 SRRM1 3.1067 0.287 -5.65 -96793 0.00504 
D3YYH0 PEX5L 4.64 0.2427 -4.937 -96350 0.00643 
Q8BL97 SRSF7 3.0867 0.3174 -5.843 -95873 0.00938 
P58281 OPA1 1.4933 0.2473 -5.239 -95353 0.01528 
Q6PH08 ERC2 -0.507 0.7062 -7.081 -13 0.0419 
G3XA57 RAB11FIP2 -0.007 1 -7.258 -96349 0.00586 
Q9JJC6 RILPL1 2.9033 0.3352 -5.958 -15 0.02576 
Q9CWZ7 NAPG 2.2133 0.4449 -6.54 -96795 0.00393 
Q80Z38 SHANK2 2.6767 0.371 -6.137 -96792 0.00504 
Q5F2E7 NUFIP2 0.2667 0.5007 -6.733 -11 0.04484 
Q62093 SRSF2 3.8467 0.2861 -5.642 -97206 0.00276 
Q64337 SQSTM1 6.64 0.0008 1.9925 1 0.50437 
Q6P5B5 FXR2 2.17 0.4474 -6.569 -95873 0.00938 
Q8CHG7 RAPGEF2 1.1667 0.7261 -7.104 -96793 0.00454 




Q9JMK2 CSNK1E 3.51 0.2473 -5.039 -96792 0.00393 
E0CYQ0 KCTD17 6.64 0.0008 1.9925 -95871 0.01096 
A0A2R8VJW4 CLIP4 6.64 0.0008 1.9925 -13 0.0419 
Q8K596 SLC8A2 1.94 0.5026 -6.739 -95871 0.01096 
O88952 LIN7C 3.2567 0.2893 -5.669 -19 0.017 
Q80TZ3 DNAJC6 4.5767 0.2473 -5.051 -95873 0.00938 
Q61037 TSC2 4.73 0.2226 -4.767 -96792 0.00454 
O70172 PIP4K2A 4.4267 0.2473 -5.302 -11 0.04484 
Q9CYI4 LUC7L 6.64 0.0008 1.9925 1 0.50437 
Q80Y24 PRICKLE2 -0.58 0.7546 -7.13 -96792 0.00504 
A0A571BGH0 KCNAB2 4.4067 0.1145 -3.447 -96792 0.00504 
Q4KUS2 UNC13A 0.49 0.9141 -7.236 -95871 0.00885 
Q7TQD2 TPPP 3.1467 0.2739 -5.549 -95872 0.00938 
Q9D7M1 GID8 5.8533 0.042 -1.496 -95351 0.01408 
P02772 AFP 6.64 0.0008 1.9925 1 0.50437 
D3YZZ4 TSC22D4 6.06 0.0244 -0.537 -15 0.02576 
G3X920 ARMC8 3.55 0.2473 -4.97 -95872 0.00938 
Q6AXB7 FMR1 6.64 0.0008 1.9925 -94785 0.02345 
Q60854 SERPINB6 0.0867 0.6797 -7.045 -96351 0.00586 
Q8K3B1 FBXO45 1.25 0.2597 -5.44 -95351 0.01408 
Q3UHD6 SNX27 4.8567 0.1975 -4.51 -96792 0.00504 
Q5SRX1 TOM1L2 6.64 0.0008 1.9925 -95353 0.01528 
Q9QYB5 ADD3 5.5967 0.0706 -2.49 -96349 0.0067 
Q8C052 MAP1S -0.627 0.3352 -5.958 -96353 0.0067 
Q99KH2 CYTH2 2.4533 0.4251 -6.35 -96795 0.00416 
Q8CCJ4 AMER2 6.64 0.0008 1.9925 -11 0.05327 
P10852 SLC3A2 6.64 0.0008 1.9925 -95351 0.01408 
Q9QYH6 MAGED1 2.5533 0.397 -6.246 -95871 0.01096 
A0A0G2JDC3 MAP11 0.3467 0.4065 -6.277 -13 0.0419 
Q61553 FSCN1 4.8033 0.2094 -4.621 -95871 0.00938 
A0A087WNU5 ANK3 0.2867 0.4732 -6.664 -11 0.04484 
Q7TSE6 STK38L 1.31 0.2529 -5.361 -13 0.0317 
Q8VE33 GDAP1L1 1.8067 0.5411 -6.827 -11 0.04484 
Q9D0E3 LYSMD1 6.64 0.0008 1.9925 -95871 0.00885 
P67871 CSNK2B 1.12 0.2226 -4.762 -96797 0.00393 
Q9WTX2 PRKRA 2.2867 0.0226 -0.424 -95873 0.00938 
Q8R307 VPS18 5.5867 0.0717 -2.524 -97598 0.00208 
P16627 HSPA1L 0 1 -7.258 -95352 0.01528 
Q8C419 GPR158 1.55 0.504 -6.742 -96349 0.0067 




B1AXH1 NHSL2 2.09 0.4729 -6.66 -96792 0.00416 
Q80ZM5 H1F10 2.9467 0.316 -5.833 -95871 0.00938 
P21279 GNAQ -0.547 0.4478 -6.574 -95351 0.01408 
D3Z6D2 STAU2 6.64 0.0008 1.9925 -9 0.07001 
P62812 GABRA1 4.4267 0.2473 -5.302 -15 0.02576 
O35326 SRSF5 3.3467 0.2573 -5.408 -13 0.03379 
O55091 IMPACT 4.1733 0.2901 -5.674 -95871 0.01096 
Q80U93 NUP214 6.64 0.0008 1.9925 -95351 0.01408 
O89112 LANCL1 4.55 0.2473 -5.097 -95871 0.00938 
G3UZJ2 MAP2 4.8967 0.0716 -2.514 -6 0.04962 
A0A5F8MP75 MAPK10 4.5333 0.2473 -5.126 -95873 0.00938 
Q64521 GPD2 0.2833 0.8627 -7.211 -95871 0.00938 
Q7TT50 CDC42BPB 6.64 0.0008 1.9925 -95351 0.01408 
Q91WG7 DGKG 2.94 0.3277 -5.91 -96349 0.0067 
Q9DBE8 ALG2 -1.063 0.4449 -6.543 -13 0.0419 
Q3UGS4 MCRIP1 3.4467 0.2739 -5.551 -11 0.04484 
E9PVU7 PDE4D 6.64 0.0008 1.9925 -95351 0.01528 
B1AVH5 CORO2A 2.4933 0.2573 -5.409 -97598 0.00208 
Q0KK55 KNDC1 2.24 0.4449 -6.513 -95871 0.01096 
P84096 RHOG 0.1133 0.6179 -6.956 -96795 0.00416 
E9PWE8 DPYSL3 6.64 0.0008 1.9925 -94785 0.02345 
A0A1D5RM97 MAST3 6.64 0.0008 1.9925 -95353 0.01528 
Q8R0S4 CACNB4 6.64 0.0008 1.9925 -95353 0.01528 
Q61771 KIF3B 2.6867 0.3701 -6.128 -13 0.0419 
Q00PI9 HNRNPUL2 6.64 0.0008 1.9925 -95353 0.01528 
P19246 NEFH 0.5167 0.3725 -6.143 -17 0.01784 
Q3UHH1 ZSWIM8 5.4933 0.0825 -2.838 -95871 0.01096 
Q8R4E6 PURG 1.8433 0.0807 -2.784 -96349 0.0067 
Q8BSZ2 AP3S2 3.2633 0.2548 -5.389 -13 0.03379 
O70492 SNX3 1.4867 0.6385 -6.986 -96349 0.0067 
P56942 PMCH 6.64 0.0008 1.9925 -96795 0.00393 
A0A076FR46 SLC12A5 3.45 0.2473 -5.149 -95351 0.01408 
Q99P72 RTN4 2.75 0.5581 -6.859 -95351 0.01408 
Q8VHR5 GATAD2B 4.4033 0.2508 -5.339 -95351 0.01408 
O35127 GRCC10 6.64 0.0008 1.9925 -94143 0.0412 
Q8K4Q0 RPTOR 4.5233 0.2473 -5.143 -13 0.0419 
P58854 TUBGCP3 0.41 0.4457 -6.554 -95351 0.01408 
Q80TL4 PHF24 5.9133 0.0355 -1.234 -9 0.07001 
Q8CHT1 NGEF 6.64 0.0008 1.9925 -9 0.07001 




A0A0R4J102 CPEB3 3.7767 0.2102 -4.637 -96351 0.00586 
P97300 NPTN 2.9267 0.2473 -5.03 -96351 0.0067 
Q6PEB6 MOB4 6.64 0.0008 1.9925 -95872 0.00938 
Q8VEJ9 VPS4A 6.64 0.0008 1.9925 -95871 0.00885 
A0JP53 DGKH 3.3733 0.2473 -5.273 -94785 0.02345 
O55013 TRAPPC3 0.6867 0.3802 -6.18 -15 0.02345 
Q9D883 U2AF1 -0.463 0.9207 -7.238 -11 0.04484 
D3YWF6 OTUB1 6.64 0.0008 1.9925 -11 0.04484 
Q80X85 MRPS7 3.21 0.2911 -5.682 -11 0.04484 
Q8CI43 MYL6B 0.6467 0.9058 -7.233 -95871 0.00938 
Q99K46 USP11 0.4333 0.4457 -6.561 -95871 0.01096 
Q8CHG3 GCC2 4.5267 0.2473 -5.137 -96795 0.00393 
Q8R404 MICOS13 6.64 0.0008 1.9925 1 0.50437 
O88343 SLC4A4 2.7633 0.3538 -6.061 -94785 0.02345 
E9PUD2 DNM1L 5.61 0.0697 -2.443 -94785 0.02345 
Q62426 CSTB 3.78 0.2473 -5.14 -13 0.0317 
B1AZ46 BAIAP2 1.3467 0.3818 -6.186 -95872 0.00938 
Q61666 HIRA 1.34 0.4449 -6.539 -95351 0.01408 
Q8K0D0 CDK17 6.64 0.0008 1.9925 -11 0.05327 
P46471 PSMC2 6.64 0.0008 1.9925 -96797 0.00393 
Q9D0R8 LSM12 6.64 0.0008 1.9925 -95873 0.00938 
O55106 STRN 0.9367 0.5726 -6.885 -95871 0.00938 
P16125 LDHB 3.5467 0.266 -5.499 -95351 0.01408 
G3UX72 MCF2L -1.007 0.7847 -7.158 -15 0.02345 
Q9DB29 IAH1 6.64 0.0008 1.9925 1 0.50437 




2.22 0.4457 -6.56 -96349 0.0067 
G8JL68 MYEF2 6.64 0.0008 1.9925 -96351 0.00838 
P62137 PPP1CA 5.1867 0.1335 -3.732 -95351 0.01528 
Q8CH77 NAV1 6.64 0.0008 1.9925 -9 0.07001 
Q3THS6 MAT2A 6.64 0.0008 1.9925 1 0.50437 
P35278 RAB5C 5.6467 0.0647 -2.311 -94785 0.02345 
Q0VGU4 VGF 2.3167 0.3189 -5.852 -95351 0.01408 
A0A286YDR2 RAB3C 3.8367 0.225 -4.789 -11 0.04484 
E9Q450 TPM1 6.64 0.0008 1.9925 1 0.50437 
Q80XK6 ATG2B 6.64 0.0008 1.9925 -11 0.05327 
D3YZI9 PGBD5 4.91 0.0779 -2.697 -94785 0.02345 
Q9R1T4 SEPTIN6 6.64 0.0008 1.9925 -95351 0.01408 
A0A286YDL6 CAMK2G 3.3467 0.3503 -6.045 -95871 0.00885 




Q9QXD1 ACOX2 6.64 0.0008 1.9925 1 0.50437 
Q5M8N0 CNRIP1 4.15 0.1469 -3.961 -95352 0.01528 
Q920Q4 VPS16 4.43 0.2473 -5.297 -95351 0.01408 
Q62277 SYP 5.4567 0.0326 -1.076 -95871 0.00885 
Q6P5D3 DHX57 4.2567 0.1397 -3.855 -95351 0.01408 
B8XCJ6 UNC80 5.0433 0.1546 -4.091 -94785 0.02345 
Q6QWF9 CAMK2N1 6.64 0.0008 1.9925 -11 0.05327 
Q9QYS2 GRM3 -1.047 0.7995 -7.171 -17 0.01784 
Q7TNM2 TRIM46 5.1433 0.1395 -3.844 -95873 0.00938 
P70188 KIFAP3 4.4267 0.2473 -5.302 -95351 0.01408 
G3UYV7 RPS28 6.64 0.0008 1.9925 1 0.50437 
Q641P0 ACTR3B 5.36 0.1034 -3.25 -94785 0.02345 
B1AR13 CISD3 6.64 0.0008 1.9925 -95351 0.01408 
Q80YQ8 RMND5A 6.64 0.0008 1.9925 -5 0.1741 
Q9WTP6 AK2 6.64 0.0008 1.9925 1 0.50437 
Q9WUD1 STUB1 6.64 0.0008 1.9925 -95871 0.01096 
Q99LI8 HGS 2.2133 0.4449 -6.535 -95871 0.00885 
Q91YI1 ATG13 6.64 0.0008 1.9925 -95351 0.01408 
A0A0A0MQE5 CAMSAP1 6.64 0.0008 1.9925 -9 0.07001 
O88643 PAK1 2.7967 0.3482 -6.032 -11 0.04484 
A2A841 EPB41 6.64 0.0008 1.9925 1 0.50437 
Q80U95 UBE3C 6.64 0.0008 1.9925 -9 0.07001 
Q9CPW4 ARPC5 6.64 0.0008 1.9925 1 0.50437 
M0QWZ1 FAM193A 6.64 0.0008 1.9925 -3 0.22705 
Q9D154 SERPINB1A 2.7767 0.3509 -6.049 -95351 0.01528 
Q6NXL6 SENP5 1.9067 0.5419 -6.829 -94785 0.02345 
Q60676 PPP5C 2.2133 0.6797 -7.047 -94144 0.0412 
Q9Z1S3 RASGRP1 3.4967 0.4367 -6.397 -94785 0.02345 
O09172 GCLM 6.64 0.0008 1.9925 1 0.50437 
E9Q6Y8 USP31 6.64 0.0008 1.9925 -94785 0.02345 
Q791V5 MTCH2 6.64 0.0008 1.9925 1 0.50437 
F2Z471 VDAC1 4.1833 0.2486 -5.315 -95351 0.01408 
P12025 MDK 6.64 0.0008 1.9925 -94785 0.02345 
Q9QUG9 RASGRP2 6.64 0.0008 1.9925 -7 0.09747 
Q7TSC1 PRRC2A 5.3367 0.1075 -3.319 -95873 0.00938 
Q7TSY6 CELF4 6.13 0.0186 -0.178 -95351 0.01408 
Q9CQZ1 HSBP1 5.9233 0.0346 -1.189 -11 0.04484 
Q9R1V6 ADAM22 4.4267 0.2473 -5.302 -94144 0.0412 
Q05816 FABP5 2.5533 0.3978 -6.249 -94143 0.0412 
Q5U3K5 RABL6 5.28 0.1172 -3.48 -11 0.04484 




Q8C078 CAMKK2 5.42 0.0938 -3.069 -95351 0.01408 
A0A498WGK2 NARS 6.64 0.0008 1.9925 -94785 0.02345 
Q9CX86 HNRNPA0 6.64 0.0008 1.9925 -94144 0.0412 
P60766 CDC42 6.64 0.0008 1.9925 -9 0.06498 
Q6PD03 PPP2R5A 6.64 0.0008 1.9925 -7 0.09747 
Q9JKS5 HABP4 3.6467 0.2473 -5.127 -11 0.04484 
Q9Z2D1 MTMR2 2.4667 0.4162 -6.321 -94144 0.0412 
A0A1B0GRU0 SLC17A7 6.64 0.0008 1.9925 -94144 0.0412 
A0A140LHA2 BUB3 6.64 0.0008 1.9925 -5 0.13692 
Q60829 PPP1R1B 3.59 0.2508 -5.34 -94785 0.02345 
Q9WVK8 CYP46A1 6.64 0.0008 1.9925 -94785 0.02345 
S4R1M9 OSBPL10 6.64 0.0008 1.9925 -94144 0.0412 
P53994 RAB2A 4.3733 0.1243 -3.586 -11 0.04484 
A0A0A6YWB0 MBNL1 6.64 0.0008 1.9925 -7 0.09747 
Q78IK2 ATP5MD 6.1433 0.0182 -0.108 -9 0.06498 
Q3TDK6 ROGDI 6.64 0.0008 1.9925 -7 0.09747 
Q3U0V1 KHSRP 5.89 0.0379 -1.337 -15 0.02576 
Q62108 DLG4 6.64 0.0008 1.9925 -7 0.09747 
Q9EPW0 INPP4A 3.18 0.2975 -5.723 -94144 0.0412 
Q920M5 CORO6 6.64 0.0008 1.9925 -7 0.09747 
E9PXF0 PCDH17 -1.42 0.6589 -7.012 -11 0.04484 
Q9D880 TIMM50 -2.16 0.4511 -6.588 -11 0.04484 
E9QAQ3 ARHGAP26 6.64 0.0008 1.9925 -5 0.13692 
Q5SUT0 EWSR1 3.23 0.2597 -5.435 -95351 0.01408 
Q61425 HADH 6.64 0.0008 1.9925 1 0.50437 
O35737 HNRNPH1 4.4267 0.2473 -5.302 -94785 0.02345 
Q61081 CDC37 6.64 0.0008 1.9925 -94144 0.0412 
A0A1Y7VJN9 DTNA 2.2367 0.4449 -6.516 -11 0.04484 
Q8C5L3 CNOT2 6.64 0.0008 1.9925 1 0.50437 
O88532 ZFR 6.64 0.0008 1.9925 -5 0.1741 
Q920Q8 IVNS1ABP 6.64 0.0008 1.9925 1 0.50437 
P63213 GNG2 5.8167 0.0465 -1.651 -7 0.09747 
Q3TQB2 FOXRED1 6.64 0.0008 1.9925 -94785 0.02345 
Q60631 GRB2 0.56 0.53 -6.802 -94785 0.02345 
P47809 MAP2K4 6.0133 0.0282 -0.768 -95353 0.01528 
Q8CE90 MAP2K7 2 0.2637 -5.484 -15 0.02576 
Q9D289 TRAPPC6B 4.7633 0.2176 -4.701 -11 0.04484 




G3UZH5 TRAK2 6.64 0.0008 1.9925 -94144 0.0412 
P58391 KCNN3 -1.957 0.4986 -6.727 -11 0.04484 
P63141 KCNA2 6.0467 0.0255 -0.604 -94785 0.02345 
Q80UE6 WNK4 6.64 0.0008 1.9925 1 0.50437 
Q8VHI6 WASF3 6.64 0.0008 1.9925 -9 0.07001 
Q61029 TMPO 2.4967 0.4251 -6.353 -94144 0.0412 
Q9D9V3 ECHDC1 6.2867 0.0092 0.6727 1 0.50437 
Q80TJ1 CADPS 6.64 0.0008 1.9925 -7 0.09747 
Q99KX1 MLF2 6.64 0.0008 1.9925 -7 0.09747 
P10637 MAPT 4.61 0.1051 -3.274 -15 0.02345 
F6U2S8 WNK1 6.13 0.0186 -0.178 -9 0.07001 
J3QPR1 ATXN1 6.64 0.0008 1.9925 -5 0.1741 
Q9DCR2 AP3S1 6.64 0.0008 1.9925 -5 0.1741 
Q91Z61 DIRAS1 6.64 0.0008 1.9925 -7 0.09747 
Q6NSW3 SPHKAP 6.64 0.0008 1.9925 -3 0.22705 
Q9D1C8 VPS28 6.64 0.0008 1.9925 -9 0.07001 
Q99PU5 ACSBG1 6.64 0.0008 1.9925 -9 0.07001 





Appendix 5.3. All Significant OGT Interactors Identified in the Mouse Liver.  
 Columns are as described in Appendix 5.2.  
 
 
Accession Gene limmaFC limmapVal limmaB ibbFC ibbpVal 
Q8VDD5 MYH9 0.8533333 0.26557447 -6.40882 -1.5609 0.04135129 
Q8CGY8 OGT 6.64 4.12E-05 4.662049 -91.624 6.92E-09 
Q3UHF7 HIVEP2 2.3466667 0.01153018 -0.59452 -100000 2.01E-08 
Q61191 HCFC1 5.7766667 0.00128624 2.59425 -100000 1.22E-10 
Q8C196 CPS1 2.7666667 0.01009419 -0.36349 -4.3059 0.01063668 
P60710 ACTB 0.8133333 0.02668156 -2.05412 -1.5238 0.03247181 
A3KGU9 SPTAN1 1.2133333 0.01009419 -0.36447 1 0.52199355 
Q03172 HIVEP1 2.9633333 0.00891163 -0.12785 -100000 3.12E-09 
Q8R0Y6 ALDH1L1 2.7533333 0.01675747 -1.22154 -5.8631 0.00427884 
Q61768 KIF5B 2.57 0.01079824 -0.48081 -100000 5.16E-08 
Q6PD31 TRAK1 2.73 0.11642269 -4.74578 -100000 5.99E-07 
Q6P9N8 TRAK2 4.45 0.0202417 -1.55718 -100000 1.04E-08 
E9Q6J5 BOD1L 1.96 0.07695555 -3.99415 -100000 4.21E-06 
B1ASP2 JAK1 0.8433333 0.02804449 -2.1529 -1.507 0.03592652 
P63017 HSPA8 3.3433333 0.00399756 1.111258 -6.8947 0.00082695 
Q62261 SPTBN1 0.6666667 0.06082359 -3.58198 -100000 0.00018216 
A2A884 HIVEP3 -1 0.32680901 -6.95514 -97206 0.00624931 
P46735 MYO1B 1.7066667 0.00908761 -0.17139 -2.6595 0.00524808 
Q9JMH9 MYO18A 0.7766667 0.34554081 -7.04796 -3.5384 0.0157958 
E9Q175 MYO6 1.16 0.09773122 -4.43896 -2.311 0.04808187 
O35490 BHMT 3.0566667 0.00039486 3.687559 -3.0909 0.00996301 
Q7TMY8 HUWE1 1.59 0.01773568 -1.32363 -100000 2.23E-08 
Q8CAQ8 IMMT 5.0266667 0.00070083 3.219153 -100000 2.66E-08 
Q8K010 OPLAH 1.6333333 0.02419371 -1.87083 -4.842 0.00589535 
A0A0R4J049 PRMT5 1.6266667 0.05464446 -3.39796 -2.125 0.03671901 
Q8BTI8 SRRM2 1.1833333 0.12979472 -4.94773 -17.001 0.00093661 
P16460 ASS1 2.74 0.00247277 1.772051 -2.4723 0.01363853 
Q8BMS1 HADHA 1.7133333 0.00759805 0.1364 -2.5862 0.01194503 
Q91X77 CYP2C50 1.7 0.02577721 -1.99089 -1.7255 0.03454146 
Q8BG87 TET3 2.4466667 0.01053282 -0.4364 -100000 1.21E-07 
E9PYH6 SETD1A 1.6766667 0.03933283 -2.80515 -100000 2.00E-06 
Q9DBR7 PPP1R12A 1.42 0.06586981 -3.72051 -100000 2.90E-06 
Q8C9B9 DIDO1 1.09 0.08751501 -4.22161 -100000 1.09E-05 
P13020 GSN 1.1533333 0.04795323 -3.17703 -1.6667 0.10426026 
Q9WTI7 MYO1C 1.3666667 0.0368443 -2.66692 -2.5972 0.0356184 




Q9D8E6 RPL4 0.82 0.16063148 -5.31452 -2.0333 0.03101856 
P20029 HSPA5 2.0333333 0.00944931 -0.23483 -1.7428 0.03958913 
A0A0R4J135 SELENBP2 3.0166667 0.00107503 2.801134 -4.1578 0.0039124 
Q5SVJ0 CAMK2B 2.4666667 0.03843975 -2.7578 1 0.52199355 
P38647 HSPA9 2.79 0.02567503 -1.97701 -9.9424 0.00111666 
Q7TMM9 TUBB2A 2.0433333 0.02642579 -2.03652 -95353 0.02763432 
P83741 WNK1 1.5033333 0.1938357 -5.72005 -99827 0.00097107 
P10126 EEF1A1 2.2966667 0.00897423 -0.14302 -1.9032 0.02948305 
Q7TPH6 MYCBP2 1.63 0.03843975 -2.75986 1 0.52199355 
P12970 RPL7A 0.66 0.26557447 -6.51467 -1.7812 0.03711631 
P16546 SPTAN1 2.2433333 0.09104932 -4.28753 -100000 1.38E-06 
A0A0A0MQF6 GAPDH 2.0433333 0.03692363 -2.68154 -2.7894 0.01357397 
P61979 HNRNPK 1.67 0.00876718 -0.08446 -2.3684 0.02456875 
A0A0A0MQA5 TUBA4A 2.2066667 0.00961371 -0.27381 -8.9999 0.03344923 
Q3UPL0 SEC31A 2.97 0.02688339 -2.06884 -100000 4.71E-07 
P25444 RPS2 1.02 0.12947556 -4.93961 -2.0476 0.03558977 
Q9CWW7 CXXC1 3.24 0.01153018 -0.58659 -100000 3.77E-06 
Q99NF7 PPM1B 0.5833333 0.03463485 -2.55438 -1.8276 0.04091465 
Q8BGD9 EIF4B 1.8333333 0.00222101 1.929944 -3.1539 0.01722796 
P15105 GLUL 2.7833333 0.00068231 3.24815 -4.0589 0.00668249 
P17426 AP2A1 0.8633333 0.19606344 -5.74984 -32.995 0.01725639 
Q03265 ATP5F1A 2.24 0.00114336 2.733396 -11 0.00094125 
Q4JK59 TET2 1.42 0.18109362 -5.589 -100000 1.18E-06 
Q61699 HSPH1 1.27 0.23054183 -6.03718 -100000 0.00074443 
P47738 ALDH2 2.91 0.00668011 0.366728 -3.375 0.01363853 
Q8BWT1 ACAA2 2.66 0.02331766 -1.79321 -8.9999 0.00122229 
P17427 AP2A2 0.85 0.16915499 -5.4445 -3.3637 0.02195606 
Q9ERG0 LIMA1 1.3866667 0.03321037 -2.47261 -4.1333 0.00624931 
A2RSY1 KANSL3 2.2366667 0.03108513 -2.34073 -100000 2.95E-06 
Q9QXD6 FBP1 1.8666667 0.06499087 -3.68741 -7.8336 0.00251997 
P24270 CAT 1.1566667 0.11957992 -4.79009 -2.4 0.02661912 
P29341 PABPC1 1.7066667 0.06420655 -3.66617 -5.2223 0.00688348 
Q4LDG0 SLC27A5 2.0066667 0.00229487 1.878908 -4.6705 0.01634454 
P11499 HSP90AB1 1.6 0.00466194 0.905287 -3.6666 0.01134556 
O35488 SLC27A2 2.0466667 0.00293192 1.536826 -4.9673 0.01410674 
Q62167 DDX3X 1.4433333 0.09405296 -4.34066 -54.994 6.61E-05 
Q9Z1R2 BAG6 2.25 0.07704952 -3.99891 -100000 8.54E-05 
Q99J09 WDR77 1.4066667 0.06190286 -3.61273 -2.5 0.03379989 
Q569X9 CYP2C67 2.2933333 0.12015145 -4.81175 -3.8461 0.01348947 
P54869 HMGCS2 3.0266667 0.00743387 0.181193 -4.3066 0.0107389 




Q8BFR5 TUFM 2.8033333 0.02801646 -2.14716 -11.604 0.00158051 
P24549 ALDH1A1 2.3233333 0.0101466 -0.38093 -7.2 0.00430638 
Q9R0H0 ACOX1 2.4966667 0.00693167 0.281043 -13.235 0.00117728 
P63038 HSPD1 3.05 0.00368777 1.229168 -5.2671 0.00873342 
P58252 EEF2 1.5433333 0.02180485 -1.67359 -6.6327 0.00732276 
P68372 TUBB4B 2.1866667 0.00680833 0.3231 -6.3925 0.00643242 
Q8VDM4 PSMD2 2.09 0.00869119 -0.05274 -12 0.00160202 
Q3ULD5 MCCC2 1.7833333 0.03852999 -2.76688 -9.3998 0.00270001 
Q3U1J4 DDB1 1.8233333 0.02200465 -1.70435 -19 0.00072302 
Q6P5E4 UGGT1 1.5933333 0.17102978 -5.47283 -11.332 0.00772892 
E9QAQ5 GSK3B 2.6433333 0.07074181 -3.84432 -100000 1.30E-05 
P68254 YWHAQ 3.0933333 0.00299178 1.505948 -100000 4.56E-05 
P51881 SLC25A5 2.4166667 0.00194414 2.101522 -2.7333 0.01791661 
P00186 CYP1A2 2.0833333 0.01991843 -1.52563 -4.3001 0.0106781 
P34914 EPHX2 1.5333333 0.14245045 -5.10156 -100000 6.63E-05 
Q91X20 ASH2L 2.1666667 0.21871601 -5.93894 -100000 8.38E-05 
P19096 FASN 1.96 0.0282766 -2.17279 -100000 7.39E-06 
G3X982 AOX3 3.0866667 0.00246235 1.784301 -100000 2.96E-06 
Q6A0A9 FAM120A 1.29 0.10823452 -4.61965 -9.0003 0.0044352 
Q8VDJ3 HDLBP 0.9366667 0.04635299 -3.11628 -3.1819 0.01961088 
G5E8R3 PCX 1.63 0.25990283 -6.27405 -13.903 0.00132147 
E9Q634 MYO1E 1.2166667 0.15473108 -5.24981 -5.5712 0.0073464 
P35700 PRDX1 2.6633333 0.01153018 -0.59616 -2.0588 0.04784266 
A0A0G2JGS4 CAMK2D 1.38 0.03618115 -2.6358 -100000 3.94E-05 
P05213 TUBA1B 1.66 0.02640562 -2.03104 -2.9333 0.01518533 
A0A0R4J2B6 RBBP5 2.61 0.04153623 -2.91863 -100000 5.38E-05 
Q91VR2 ATP5F1C 1.45 0.01689477 -1.24267 -1.4074 0.21177926 
Q8K2B3 SDHA 2.52 0.0052593 0.7297 -100000 7.70E-05 
P62983 RPS27A 0.9066667 0.15698191 -5.27887 -4 0.01135746 
Q91VR5 DDX1 1.51 0.0598876 -3.55073 -7.4999 0.00658736 
Q9EPU0 UPF1 1.3666667 0.10513373 -4.5636 -100000 0.000106 
P63328 PPP3CA 1.3033333 0.13469423 -5.00307 -96792 0.0085431 
A8DUK4 HBB-BS 1.17 0.12047424 -4.82127 -7.1841 0.00762802 
Q68FG2 SPTBN2 0.8366667 0.26557447 -6.40237 -100000 0.00020329 
D3YUP1 CARM1 0.33 0.71121362 -8.23335 -98642 0.00183098 
Q8BGH2 SAMM50 3.7166667 0.02356161 -1.81627 -100000 6.13E-06 
Q99PU7 BAP1 0.87 0.08396336 -4.14701 -100000 4.49E-05 
P00329 ADH1 2.0966667 0.00342283 1.329213 -3.5455 0.016215 
Q3UQ44 IQGAP2 1.4466667 0.04091178 -2.89414 -7.7499 0.00568843 
P17751 TPI1 2.3466667 0.01343203 -0.85514 -2.4166 0.051979 
Q9JJ28 FLII 1.1033333 0.16475095 -5.39082 -10.999 0.01833596 




Q8BG51 RHOT1 2.7033333 0.07236415 -3.88489 -100000 0.00056591 
Q925I1 ATAD3 2.5466667 0.02181133 -1.68752 -100000 9.08E-05 
P11352 GPX1 2.2666667 0.01178289 -0.6307 -3.3571 0.01223336 
Q3UH59 MYH10 0.59 0.38984787 -7.27812 -100000 7.95E-05 
Q9EQQ9 OGA 1.3933333 0.04783712 -3.16667 -97595 0.00589535 
Q8R326 PSPC1 3.9633333 0.03933283 -2.80357 -100000 7.39E-06 
Q9JHU4 DYNC1H1 0.3333333 0.53473354 -7.91332 -94785 0.04091465 
O09012 PEX5 2.2466667 0.03989753 -2.84486 -100000 0.00014102 
O08788 DCTN1 2.23 0.00088817 2.997754 1 0.52199355 
Q91VB8 HBA-A1 0.4666667 0.36127075 -7.13004 -100000 0.00018328 
P42669 PURA 1.4133333 0.06586981 -3.72082 -12 0.00341058 
P16015 CA3 1.5733333 0.02801646 -2.14721 -3 0.04307201 
Q922D8 MTHFD1 3.02 0.02412333 -1.8531 -100000 4.10E-05 
Q91X83 MAT1A 3.3933333 0.01682079 -1.23169 -3.8 0.01992088 
O88844 IDH1 1.1833333 0.16076563 -5.34404 -5.8332 0.01498441 
Q99JY0 HADHB 1.6933333 0.02577721 -1.99362 -2.0833 0.08347261 
P11725 OTC 2.5166667 0.01256825 -0.74969 -5.7144 0.00646197 
A2AN08 UBR4 0.8 0.15698191 -5.27824 -100000 2.97E-05 
Q3UKW2 CALM1 1.2266667 0.03783811 -2.71902 -1.8889 0.15689585 
P53395 DBT 0.8 0.47805356 -7.6409 -4.6666 0.02713591 
Q91Y97 ALDOB 1.7766667 0.05120701 -3.28813 -7.0005 0.00490976 
Q9D0E1 HNRNPM 1.83 0.20346267 -5.80713 -100000 0.00099254 
Q571I4 PRAG1 6.64 4.12E-05 4.662049 1 0.52199355 
P61965 WDR5 3.3533333 0.04298631 -2.98383 -100000 5.65E-05 
Q3U2G2 HSPA4 0.8066667 0.59018396 -8.03111 -100000 0.00104526 
Q6ZQ08 CNOT1 1.82 0.11106463 -4.67104 -100000 1.72E-05 
E9QPE7 MYH11 1.0433333 0.16076563 -5.34199 -100000 0.00074443 
P55096 ABCD3 2.0666667 0.01312265 -0.81422 -5.1666 0.01162608 
Q9WVL0 GSTZ1 2.6133333 0.00250224 1.745053 -100000 7.13E-05 
P62259 YWHAE 2.8366667 0.00904388 -0.15914 -2.6667 0.04153344 
A0A2I3BQP6 CAMK2G 0.8533333 0.26557447 -6.38259 -100000 0.00065747 
Q9QYJ0 DNAJA2 1.8433333 0.00649858 0.415221 -7.0847 0.01992088 
P62960 YBX1 0.6066667 0.01583496 -1.12951 -1.7273 0.18165123 
D3Z041 ACSL1 2.4766667 0.01453057 -0.9718 -100000 2.40E-05 
Q8K182 C8A 0.5133333 0.03824431 -2.73754 -1.9167 0.09380016 
P59759 MRTFB 0.24 0.52307375 -7.88457 -14.999 0.04391494 
P47754 CAPZA2 1.7066667 0.07369872 -3.91936 -8.9999 0.04091465 
Q99LF4 RTCB 1.5933333 0.00693167 0.286913 -6.9998 0.01217264 
Q8BGL3 SULT2A8 3.2433333 0.01773568 -1.31977 -38.998 0.00018216 
Q99MR8 MCCC1 2.2466667 0.0108209 -0.48915 -16.499 0.0013216 
Q91W50 CSDE1 1.3866667 0.0921803 -4.30734 -100000 0.00104526 




E9Q1S3 SEC23A 0.9666667 0.38049905 -7.2414 -100000 0.0007704 
Q9EP89 LACTB 1.9433333 0.07312492 -3.90551 -5.2 0.01291602 
Q99JY9 ACTR3 0.8866667 0.22624459 -6.00315 -4.0001 0.04391494 
Q8VC30 TKFC 3.3033333 0.01245781 -0.73249 -100000 4.61E-05 
Q8VCW8 ACSF2 2.17 0.07309126 -3.90174 -11.7 0.00362301 
Q8CGC7 EPRS 0.38 0.76656113 -8.29403 -5.2 0.01455336 
Q8VCB3 GYS2 2.5033333 0.02080449 -1.59936 -100000 0.00012559 
Q9D8N0 EEF1G 1.8533333 0.00665028 0.378897 -10.5 0.00643242 
P19253 RPL13A 0.6 0.34495564 -7.04446 -100000 0.00018844 
Q8BFQ4 WDR82 0.54 0.13954641 -5.06625 -97208 0.01015707 
F8VPU2 FARP1 0.91 0.27185299 -6.59536 -16.999 0.03671901 
Q01853 VCP 0.9566667 0.26557447 -6.52617 -100000 0.00027588 
G3X928 SEC23IP 1.3833333 0.29541247 -6.7773 -100000 6.63E-05 
G3X9T7 LGALS9 1.37 0.00876718 -0.07977 -2.7499 0.05568397 
Q9QXE0 HACL1 2.95 0.00129084 2.584239 -100000 0.00022415 
A0A1B0GSX0 LDHA 1.84 0.00946993 -0.24351 -2.875 0.04638834 
Q8BTM8 FLNA 0.9833333 0.1008434 -4.49294 -100000 0.00019797 
Q6XVG2 CYP2C54 1.85 0.01568888 -1.11185 -5.7999 0.01148581 
Q91X75 CYP2A5 1.5633333 0.08135896 -4.08263 -8.6663 0.0071733 
P18760 CFL1 1.14 0.26557447 -6.32129 -98310 0.0027158 
A2A5Y4 KANSL1 0.9933333 0.15209648 -5.21943 -100000 0.00051681 
Q3TXS7 PSMD1 0.0966667 0.97462879 -8.42527 -7.0001 0.01156507 
Q920I9 WDR7 6.64 4.12E-05 4.662049 1 0.52199355 
P42932 CCT8 1.9833333 0.00179572 2.203502 -100000 0.00041739 
A0A494B908 GSTP1 2.7866667 0.3817673 -7.2469 -100000 0.00033563 
P70333 HNRNPH2 1.9333333 0.01210718 -0.68338 1 0.52199355 
Q64458 CYP2C29 1.86 0.05874362 -3.51756 -5.6666 0.01950182 
P63101 YWHAZ 2.2766667 0.01840073 -1.38851 -9.4997 0.008081 
Q9DBN5 LONP2 1.6966667 0.44848644 -7.48764 -100000 6.61E-05 
Q8CC88 VWA8 2.7233333 0.38555763 -7.26258 -100000 0.00021581 
Q99K67 AASS 1.6866667 0.03363112 -2.49797 -100000 0.0009278 
P56399 USP5 2.1866667 0.33540823 -6.99303 -96793 0.01015707 
Q8JZN7 RHOT2 0.67 0.60572174 -8.0669 -100000 0.0001475 
Q9DBF1 ALDH7A1 2.2666667 0.03154909 -2.37351 -100000 7.72E-05 
Q5PRE5 PROSER1 1.6866667 0.08131375 -4.07881 -100000 0.00018328 
Q9QXF8 GNMT 2.3666667 0.00171195 2.269416 -4.9998 0.03379068 
A2AMW0 CAPZB 1.5933333 0.04698088 -3.13832 -5 0.01632804 
Q9CRB9 CHCHD3 5.22 0.09476445 -4.35968 -100000 3.87E-05 
Q9R112 SQOR 2.1266667 0.01560858 -1.09301 -100000 0.00038392 
P80315 CCT4 1.63 0.04998867 -3.24811 -6 0.03558977 
P97872 FMO5 1.9666667 0.01810557 -1.35665 -100000 3.47E-05 




Q8R570 SNAP47 6.64 4.12E-05 4.662049 -11 0.08613925 
A0A0R4IZY2 CYP2D26 2.48 0.04041605 -2.8737 -100000 0.00027414 
Q8CHR6 DPYD 0.0966667 0.99327983 -8.43007 -46.992 0.00299409 
Q8VEM8 SLC25A3 1.58 0.29449945 -6.77174 -99259 0.00122229 
Q9ERU9 RANBP2 0.7933333 0.47805356 -7.58068 -98310 0.00275368 
Q9EQ20 ALDH6A1 2.7733333 0.00247859 1.762742 -100000 9.81E-05 
Q5SRY7 FBXW11 1.43 0.02992316 -2.26744 -97595 0.00558987 
P80318 CCT3 1.9366667 0.0017347 2.248312 -97206 0.00668249 
P56480 ATP5F1B 1.1033333 0.00876718 -0.08838 -9.0001 0.00929561 
Q80XN0 BDH1 3.0733333 0.00975918 -0.30646 -100000 0.00022415 
Q05421 CYP2E1 2.0066667 0.01773568 -1.31979 -100000 0.00020329 
A0A0A0MQ68 GCDH 2.18 0.00224616 1.910338 -5 0.03781598 
P17225 PTBP1 1.3 0.2349259 -6.08336 -7.9998 0.01791661 
P32020 SCP2 2.0733333 0.00961371 -0.27506 -3.6667 0.03507164 
P12382 PFKL 6.0433333 0.00591385 0.562776 1 0.52199355 
Q569Z6 THRAP3 0.9366667 0.02852226 -2.18893 -1.5555 0.33386831 
Q9CY58 SERBP1 0.9433333 0.01939469 -1.47966 -100000 0.00062433 
Q922B2 DARS 1.18 0.07461502 -3.94253 -100000 0.00062433 
P80317 CCT6A 1.7333333 0.00674401 0.342751 -100000 0.00041739 
Q921H8 ACAA1A 4.3133333 0.1228738 -4.85582 -100000 0.0003896 
Q5YD48 A1CF 1.8733333 0.0319485 -2.39808 -10.333 0.02114943 
P80314 CCT2 2.0866667 0.03278935 -2.44289 -98642 0.00310589 
B1AU25 AIFM1 1.75 0.26557447 -6.3304 -100000 0.00040786 
P80316 CCT5 1.5533333 0.10746502 -4.60721 -97597 0.00668249 
P48776 TDO2 2.44 0.04389845 -3.02752 -7.3573 0.0166 
Q9WU78 PDCD6IP 0.97 0.2672631 -6.55103 -14.999 0.04091465 
P80313 CCT7 0.96 0.5485502 -7.94809 -100000 0.00054794 
O88451 RDH7 3.7 0.015069 -1.03665 -100000 7.13E-05 
P26443 GLUD1 1.73 0.02200465 -1.70893 -28.996 0.02114943 
Q8BVQ9 PSMC2 2.02 0.01079824 -0.47682 -100000 0.00033327 
P20152 VIM 1.1166667 0.26557447 -6.5106 -98641 0.00219055 
P63037 DNAJA1 1.9333333 0.0052593 0.726123 -7.4998 0.01722796 
Q8BG05 HNRNPA3 0.8133333 0.03836604 -2.74576 -4.3334 0.04341826 
P29788 VTN 0.81 0.04041605 -2.87328 -2.3333 0.1076925 
P23116 EIF3A 0.4666667 0.67033637 -8.1737 -11.666 0.02467716 
Q9CW42 1-Mar 2.13 0.00433924 1.002156 -8.9999 0.00568843 
P60335 PCBP1 2.0733333 0.0580735 -3.49172 -98310 0.00247938 
P61161 ACTR2 1.1033333 0.47805356 -7.67403 -96349 0.01291602 
H7BX95 SRSF1 1.41 0.015069 -1.02946 -3.3333 0.13281593 
Q64459 CYP3A11 1.4466667 0.0398377 -2.83908 -99260 0.00157768 
P11714 CYP2D9 2.28 0.00246235 1.783578 -8.0001 0.01410674 




Q01279 EGFR 2.52 0.00910187 -0.1793 -100000 0.00040786 
Q3UMP4 SERBP1 6.64 4.12E-05 4.662049 1 0.52199355 
A2AS03 HELZ2 0.0266667 1 -8.43414 -42.992 0.01217264 
P11983 TCP1 1.0466667 0.10007783 -4.47694 -99550 0.00094125 
O09173 HGD 2.84 0.02461983 -1.90381 -100000 0.00094125 
Q9CQA3 SDHB 2.2366667 0.04160557 -2.92503 -100000 0.00062433 
A0A0R4J0B4 CMAS 1.3033333 0.02567503 -1.97926 -99827 0.00080344 
P62141 PPP1CB 1.7033333 0.30894414 -6.8514 -97597 0.00668249 
P24456 CYP2D10 2.1633333 0.01991843 -1.52104 -100000 0.00071431 
Q9JLV1 BAG3 3.9466667 0.17985419 -5.56891 -100000 0.00040786 
A0A0R4J0I1 SERPINA3K -0.053333 0.98962034 -8.42916 -100000 0.0002828 
Q7TMK9 SYNCRIP 0.5266667 0.40089488 -7.32053 -97962 0.00568843 
O70475 UGDH 2.12 0.00743387 0.177285 -100000 0.00099254 
P68510 YWHAH 2.4966667 0.32391254 -6.9392 -95353 0.02763432 
Q5SYD0 MYO1D 1.2266667 0.06148184 -3.60006 -100000 0.0013216 
Q8BG95 PPP1R12B 6.64 4.12E-05 4.662049 1 0.52199355 
O70325 GPX4 2.14 0.03363112 -2.49597 -97962 0.0033964 
Q3TUQ7 PRKAA1 3.1766667 0.03387284 -2.51584 -99259 0.0011878 
Q8CCJ9 PHF20L1 -0.386667 0.83627173 -8.35558 -100000 0.00040786 
P62827 RAN 0.3533333 0.04820073 -3.18761 -2.2 0.16793858 
A0A1B0GS91 SVIL 1.2333333 0.18585927 -5.63657 -100000 0.00062433 
D6REV1 ASXL2 -0.2 0.90543071 -8.40031 -99259 0.0012034 
P50247 AHCY 0.93 0.16070491 -5.33511 -11 0.00489983 
Q91ZJ5 UGP2 0.6466667 0.64056326 -8.12637 -22.998 0.02238739 
F8WJE3 KANSL2 3.11 0.3386165 -7.00844 -97962 0.00327471 
P43277 H1-3 0.6433333 0.47494682 -7.56645 -97602 0.00558987 
Q62095 DDX3Y 1.6333333 0.03198109 -2.40453 100000 0.99998586 
Q60598 CTTN 1.2533333 0.01827017 -1.3739 -95872 0.01722796 
A0A494BB75 WDR26 1.67 0.28321197 -6.68787 -18.999 0.03055265 
Q61937 NPM1 0.7466667 0.0110361 -0.52103 1 0.52199355 
Q9JI90 RNF14 2.8033333 0.37087101 -7.20038 -96792 0.01015707 
P99024 TUBB5 1.6133333 0.03287831 -2.45068 -97966 0.0033964 
Q9Z2X1 HNRNPF 1.5333333 0.02419371 -1.87009 -1.8333 0.26057561 
Q8K0T0 RTN1 6.64 4.12E-05 4.662049 1 0.52199355 
Q8BH95 ECHS1 2.3466667 0.01855649 -1.40488 -6.6666 0.01304322 
Q61171 PRDX2 1.6833333 0.03372194 -2.5057 -6.4999 0.02763432 
Q99P30 NUDT7 3.0866667 0.00967833 -0.28969 -23.999 0.00122229 
Q78JT3 HAAO 1.92 0.07228374 -3.88021 -100000 0.00078846 
Q3U741 DDX17 0.0233333 0.99584046 -8.43066 -14.999 0.04391494 
Q9Z2I9 SUCLA2 3.68 0.1250633 -4.88752 -98310 0.00275368 




Q9QXX4 SLC25A13 0.48 0.88338888 -8.38659 -100000 0.0002828 
Q3UHB8 CCDC177 6.64 4.12E-05 4.662049 1 0.52199355 
O88962 CYP8B1 3.1 0.0806797 -4.06502 -100000 0.00030463 
Q6PAJ1 BCR 6.64 4.12E-05 4.662049 1 0.52199355 
Q80U23 SNPH 6.64 4.12E-05 4.662049 1 0.52199355 
Q9D826 PIPOX 2.44 0.01565022 -1.10338 -98957 0.00146248 
O88587 COMT 0.74 0.67326995 -8.17844 -5.5 0.04212434 
E9Q456 TPM1 0.9266667 0.18905079 -5.67206 -100000 0.00037822 
Q9D2G2 DLST 2.2433333 0.04795323 -3.17549 -100000 0.00040786 
Q3UMT1 PPP1R12C 1.9033333 0.00122278 2.658984 -95353 0.02763432 
Q3UZ39 LRRFIP1 1.2166667 0.02109085 -1.62277 -7.9997 0.02082518 
Q9D1M0 SEC13 2.2433333 0.01911364 -1.45492 -99828 0.00099254 
Q9DBM2 EHHADH -1.16 0.59875679 -8.04913 -30.996 0.01148581 
Q60960 KPNA1 1.41 0.34554081 -7.04929 -96792 0.0085431 
O70503 HSD17B12 1.1333333 0.015069 -1.03151 -100000 0.00040786 
Q8BFU3 RNF214 6.64 4.12E-05 4.662049 1 0.52199355 
A0A338P6K9 QSER1 6.64 4.12E-05 4.662049 1 0.52199355 
O54950 PRKAG1 2.1933333 0.10862188 -4.62724 -99550 0.00094125 
A0A0R4J1E2 EEF1D 1.32 0.04357798 -3.01001 -2.4 0.138805 
Q9WV68 DECR2 2.5633333 0.00200092 2.062412 -99827 0.00080344 
G3UZ26 SHMT1 1.3666667 0.00747301 0.164269 -26.997 0.01410674 
P21126 UBL4A 5.32 0.10678643 -4.59585 -98956 0.00153041 
Q9JM52 MINK1 6.64 4.12E-05 4.662049 1 0.52199355 
A0A1L1SV25 ACTN4 1.3233333 0.08253479 -4.11174 -100000 0.00074443 
Q9CQE8 RTRAF 1.2666667 0.09660182 -4.39457 -13.999 0.01148581 
O54749 CYP2J5 1.7133333 0.05811395 -3.49605 -98957 0.00288779 
Q8C2Q7 HNRNPH1 -1.136667 0.5485502 -7.94875 -100000 0.00074443 
G3X972 SEC24C 0.7266667 0.41800276 -7.37967 -99827 0.00078061 
Q8CI32 BAG5 3.0866667 0.03321037 -2.47031 1 0.52199355 
P61982 YWHAG 3.3566667 0.00518932 0.756224 -99259 0.00113133 
Q3UG20 KMT2E 6.64 4.12E-05 4.662049 -4.9999 0.26057561 
Q9EQF5 DPYS -0.533333 0.74957403 -8.27625 -100000 0.00023968 
D3YVL0 MOV10 1.33 0.02515812 -1.94244 -99260 0.00157768 
P49429 HPD 1.38 0.17992616 -5.57383 -11 0.01876614 
P08113 HSP90B1 1.26 0.00277081 1.611098 -99548 0.00157768 
Q61694 HSD3B5 2.64 0.0009922 2.885872 -15 0.00700417 
O70194 EIF3D -0.433333 0.81656796 -8.33951 -98957 0.00353512 
Q99L90 MCRS1 0.2833333 0.75006331 -8.27713 -96350 0.01291602 
Q9JJV2 PFN2 6.64 4.12E-05 4.662049 1 0.52199355 
Q9CZ13 UQCRC1 0.3666667 0.60235132 -8.05758 -99550 0.00094125 




Q3U3J1 BCKDHA 1.32 0.19385777 -5.72231 -24.997 0.01950182 
G5E8G6 MYO5B 0.7466667 0.47805356 -7.59759 -99553 0.00116811 
P70694 AKR1C6 1.36 0.00200647 2.0527 -99827 0.00157768 
P97742 CPT1A 2.21 0.00399756 1.116195 -100000 0.00040786 
P38060 HMGCL 1.42 0.26557447 -6.47972 -98641 0.00296581 
Q9WV32 ARPC1B -0.66 0.67033637 -8.17338 -9.9996 0.02763432 
A0A0N4SVL0 EIF4G3 6.64 4.12E-05 4.662049 1 0.52199355 
Q62318 TRIM28 0.98 0.36849719 -7.18258 -95871 0.01722796 
P50544 ACADVL 1.3033333 0.16504449 -5.39782 -98311 0.00362301 
P07901 HSP90AA1 1.0833333 0.12015145 -4.81502 -96795 0.0085431 
Q5U4C1 GPRASP1 6.64 4.12E-05 4.662049 1 0.52199355 
Q61584 FXR1 1.01 0.23193459 -6.05318 -18.999 0.03055265 
A2AG10 NUP62CL 1.1766667 0.18767487 -5.6538 -99259 0.00113133 
Q9CQF3 NUDT21 0.4433333 0.69068436 -8.20402 -98642 0.00296581 
Q14CH0 FAM171B 6.64 4.12E-05 4.662049 1 0.52199355 
Q62425 NDUFA4 1.6433333 0.01857555 -1.41117 -1.8571 0.21555176 
A2A9M4 DOCK7 6.64 4.12E-05 4.662049 1 0.52199355 
A0A452J8A5 ECI1 3.7733333 0.20743072 -5.8545 -7.0001 0.019885 
Q8JZU2 SLC25A1 2.3533333 0.00368777 1.224394 -12 0.01721898 
P70392 RASGRF2 6.64 4.12E-05 4.662049 1 0.52199355 
P99029 PRDX5 2.3466667 0.0052702 0.717014 -97965 0.00372498 
Q8CBY8 DCTN4 6.64 4.12E-05 4.662049 -2 0.52199355 
O88441 MTX2 0.79 0.15163189 -5.21287 -100000 0.00034199 
Q61696 HSPA1A 2.3133333 0.03154909 -2.37214 -98641 0.00219055 
K3W4R2 MYH14 0.3733333 0.46354024 -7.53165 -98641 0.00262189 
Q9DD20 METTL7B 4.07 0.16070491 -5.32479 -97962 0.0071848 
P97765 WBP2 1.04 0.47810397 -7.74083 -97965 0.00372498 
Q78PY7 SND1 0.24 0.60083806 -8.05348 -99548 0.00128004 
Q9R0P5 DSTN 1.73 0.27774406 -6.64801 -94785 0.04091465 
Q9D1H7 GET4 2.6866667 0.00693167 0.282303 -20.999 0.01879409 
Q6GT24 PRDX6 0.7933333 0.55928242 -7.9721 -98310 0.00310589 
Q8BX10 PGAM5 0.6533333 0.47805356 -7.72495 -96349 0.01291602 
E9Q509 PKLR 1.0166667 0.32204954 -6.92651 -98641 0.00219055 
Q6PHQ9 PABPC4 1.1866667 0.20470983 -5.82277 -97206 0.00668249 
P68033 ACTC1 1.7833333 0.19548469 -5.74176 -97595 0.00430638 
Q8QZR5 GPT 1.7666667 0.00890243 -0.12056 -99259 0.00113133 
Q8VCQ8 CALD1 1.46 0.16848167 -5.43232 -99550 0.00094125 
Q9WTX5 SKP1 2.4933333 0.02867896 -2.20071 -97595 0.00589535 
P55937 GOLGA3 1.2933333 0.28876457 -6.72595 -98956 0.0018932 
P62196 PSMC5 2.4166667 0.00648153 0.425027 -99548 0.00094125 
Q9CQV8 YWHAB 1.6533333 0.23513967 -6.08645 -96349 0.01148581 




Q99PU8 DHX30 1.0733333 0.3703385 -7.19304 -94785 0.04091465 
O54754 AOX1 1.0466667 0.26557447 -6.34611 -97595 0.00845527 
P58871 TNKS1BP1 -1.836667 0.44148275 -7.4648 -96792 0.00929561 
D3Z2H9 TPM3-RS7 1.2433333 0.03688522 -2.67623 -97214 0.00624931 
Q9Z2I8 SUCLG2 2.0033333 0.03074504 -2.31726 -99259 0.00113133 
Q8R086 SUOX 0.5566667 0.55874876 -7.96987 -98641 0.00219055 
Q7TNV0 DEK 0.16 0.83201079 -8.35145 -22.998 0.03043969 
A0A1L1SVH5 RBPMS2 2.3933333 0.01312265 -0.81844 -97962 0.00372498 
P68040 RACK1 1.0666667 0.06082359 -3.57978 -97206 0.00814964 
Q99KB8 HAGH 0.3933333 0.60433795 -8.06296 -13 0.01223336 
A0A0B4J1E7 KPNA4 4.4533333 0.10974754 -4.65212 -98310 0.00256543 
P16331 PAH 1.3266667 0.13780348 -5.04172 -99827 0.00078061 
P63168 DYNLL1 1.8333333 0.03618115 -2.63806 1 0.52199355 
Q8BGQ7 AARS 0.74 0.14431985 -5.12661 -98311 0.00362301 
Q5DTT2 PSD 6.64 4.12E-05 4.662049 1 0.52199355 
E9QMC2 GRM5 6.64 4.12E-05 4.662049 1 0.52199355 
E9PVC6 EIF4G1 -0.366667 0.58005316 -8.01011 -97595 0.00845527 
Q6ZWY3 RPS27L 1.6733333 0.00876764 -0.09442 -1.6667 0.34133733 
Q8K0S0 PHYHIP 6.64 4.12E-05 4.662049 1 0.52199355 
A0A494BA32 GPAM 0.32 0.47805356 -7.61383 -98311 0.00310589 
D3YZC9 SF1 6.64 4.12E-05 4.662049 1 0.52199355 
Q8VH51 RBM39 0.1466667 0.90363518 -8.39779 -96792 0.01015707 
Q63886 UGT1A1 2.5766667 0.03133241 -2.35576 -98311 0.00353512 
Q91V92 ACLY -0.023333 0.98059073 -8.42703 -97962 0.00568843 
P35505 FAH 1.12 0.16504449 -5.39588 -97206 0.00814964 
P07310 CKM 6.64 4.12E-05 4.662049 -18.999 0.03055265 
Q9D1I2 CARD19 2.9733333 0.09009915 -4.27026 -98956 0.00175067 
Q8CI08 SLAIN2 6.64 4.12E-05 4.662049 1 0.52199355 
Q68FH0 PKP4 6.64 4.12E-05 4.662049 1 0.52199355 
Q91W43 GLDC 1.0066667 0.27075117 -6.5803 -98310 0.0033964 
A0A494B923 PAPSS2 1.3833333 0.29083666 -6.74574 -97595 0.00589535 
Q8QZY1 EIF3L 3.3733333 0.26557447 -6.46635 -97597 0.00668249 
Q8VC28 AKR1C13 3.3833333 0.26557447 -6.50931 -97208 0.01015707 
Q9DCB4 ARPP21 6.64 4.12E-05 4.662049 1 0.52199355 
Q9QYG0 NDRG2 2.0733333 0.02181133 -1.68664 -97206 0.00814964 
Q9WU79 PRODH 3.6766667 0.24463762 -6.16254 -98642 0.00183098 
O55022 PGRMC1 1.86 0.03933283 -2.80657 -98310 0.00310589 
Q3UEL5 UROC1 -0.873333 0.27355023 -6.60626 -97962 0.00568843 
O35945 ALDH1A7 2.02 0.03952797 -2.82088 -6.9997 0.15689585 
Q6P3A8 BCKDHB 1.38 0.23123598 -6.04537 -97206 0.00814964 




A8Y5N4 HSD17B13 1.9333333 0.00499494 0.81134 -98641 0.0019049 
D3Z5I1 ZC3HAV1 0.5666667 0.48770796 -7.7816 -97208 0.01015707 
Q9Z1S5 SEPTIN3 2.05 0.03010895 -2.28016 1 0.52199355 
Q91WT9 CBS 4.4433333 0.10624409 -4.58617 -98310 0.00256543 
Q9ET01 PYGL 0.5333333 0.47805356 -7.73356 -18.999 0.03055265 
Q60930 VDAC2 3.8466667 0.19386991 -5.72449 -95871 0.01722796 
A0A1Y7VL44 TTC7B 6.64 4.12E-05 4.662049 1 0.52199355 
Q80T41 GABBR2 6.64 4.12E-05 4.662049 1 0.52199355 
Q921F2 TARDBP 0.3166667 0.83627173 -8.35527 -95871 0.01722796 
Q9DBL1 ACADSB 2.1033333 0.49714453 -7.81442 -97207 0.00698254 
Q91WT7 AKR1C14 2.29 0.04389845 -3.02534 -16.999 0.04646419 
P14685 PSMD3 5.0166667 0.16470583 -5.38814 -96349 0.01148581 
Q3TJZ6 FAM98A 1.62 0.10414467 -4.54518 -14.999 0.04391494 
A0A1W2P7A1 RPS12 1.4333333 0.03430709 -2.53733 -3 0.09355795 
P60843 EIF4A1 1.6766667 0.01009419 -0.36841 -97962 0.00430638 
H3BKQ7 PPP1R9A 6.64 4.12E-05 4.662049 1 0.52199355 
Q8VBT2 SDS 3.6733333 0.23166827 -6.04974 -97962 0.00372498 
P70372 ELAVL1 1.5233333 0.04277601 -2.97001 -95871 0.01722796 
E9QM77 ATXN2 1.3233333 0.18108524 -5.58676 -98641 0.00262189 
G3UXL2 PRPS1L3 6.64 4.12E-05 4.662049 1 0.52199355 
Q9D1P2 KAT8 6.64 4.12E-05 4.662049 -4.9999 0.26057561 
Q8JZR0 ACSL5 2.4666667 0.08253479 -4.11446 -97210 0.00721975 
P10649 GSTM1 0.5833333 0.32204954 -6.92706 -98310 0.00275368 
A0A0R4J1F4 MADD 6.64 4.12E-05 4.662049 1 0.52199355 
P68181 PRKACB 6.64 4.12E-05 4.662049 1 0.52199355 
A2AAN2 SRP68 0.59 0.03688522 -2.67387 -16.999 0.03202093 
Q80UG5 SEPTIN9 1.59 0.00621919 0.491375 -16.999 0.03671901 
Q8CG76 AKR7A2 1.8533333 0.26557447 -6.3582 -97206 0.00668249 
Q5BL07 PEX1 6.64 4.12E-05 4.662049 1 0.52199355 
P05784 KRT18 0.7 0.23539391 -6.09109 -98641 0.00262189 
P12849 PRKAR1B 6.64 4.12E-05 4.662049 1 0.52199355 
D3Z139 ESRP2 1.5 0.10921019 -4.64063 -16.999 0.03671901 
O54962 BANF1 6.64 4.12E-05 4.662049 1 0.52199355 
P62743 AP2S1 0.2366667 0.70068823 -8.21792 -96351 0.01291602 
Q922Q1 2-Mar 1.8033333 0.04864419 -3.20717 -11 0.01722796 
P54775 PSMC4 1.95 0.08362646 -4.13849 -96792 0.01015707 
Q62189 SNRPA 0.1333333 0.87087963 -8.37865 -96792 0.00929561 
A0A286YCV9 KIF13B 0.95 0.40240785 -7.32706 -97206 0.00624931 
Q8BH00 ALDH8A1 5.01 0.16548508 -5.4037 -97206 0.00814964 
Q9CQ69 UQCRQ 0.7333333 0.36005889 -7.12248 -96353 0.01291602 




Q91WL5 CYP4A12A 1.9133333 0.26557447 -6.33132 -97210 0.00721975 
O70251 EEF1B 1.3833333 0.04848607 -3.19921 -2.3333 0.24116815 
P60229 EIF3E -1.753333 0.35331732 -7.08549 -97206 0.00814964 
Q80X98 DHX38 0.5366667 0.60572174 -8.06637 -14.999 0.04391494 
Q61133 GSTT2 1.8033333 0.11520085 -4.72878 -16.999 0.03671901 
Q05915 GCH1 1.5666667 0.26557447 -6.35473 -97595 0.00668249 
Q9DAW9 CNN3 6.64 4.12E-05 4.662049 -3.9999 0.2579867 
P26369 U2AF2 0.93 0.02501794 -1.93029 -96349 0.01291602 
Q91V41 RAB14 0.99 0.03104349 -2.33471 -8.9997 0.10426026 
Q9JLJ2 ALDH9A1 0.8033333 0.49202264 -7.80081 -96793 0.01015707 
S4R2G0 DGKI 6.64 4.12E-05 4.662049 1 0.52199355 
Q9R190 MTA2 0.4633333 0.05386555 -3.36799 -97595 0.0047905 
Q91XD4 FTCD 1.0566667 0.36127075 -7.12963 -96349 0.0157301 
E9QAT4 SEC16A -0.14 0.84252854 -8.36019 -97962 0.00430638 
Q61817 CREB3 1.8266667 0.05456044 -3.39244 -97595 0.00430638 
Q9DCL9 PAICS 5.0333333 0.16082603 -5.34893 -18.999 0.026492 
Q9CZS1 ALDH1B1 2.07 0.10000413 -4.47312 -97206 0.00624931 
E9PVP0 STARD10 0.9266667 0.24868362 -6.19314 -98957 0.00157768 
Q8BK64 AHSA1 6.64 4.12E-05 4.662049 1 0.52199355 
P10605 CTSB 2.6033333 0.42543772 -7.40823 -96349 0.01291602 
O35344 KPNA3 6.64 4.12E-05 4.662049 -94785 0.04091465 
P32233 DRG1 0.93 0.08616354 -4.19139 -16.999 0.03671901 
E9QNL5 SULT1A1 2.4033333 0.02331766 -1.79742 -16.999 0.03671901 
Q810B6 ANKFY1 2.0066667 0.52307375 -7.88422 -95353 0.02763432 
Q9WV69 DMTN 6.64 4.12E-05 4.662049 1 0.52199355 
Q8CHT0 ALDH4A1 1.8166667 0.20622198 -5.83724 -97962 0.00353512 
Q9R0L7 AKAP8L 6.64 4.12E-05 4.662049 1 0.52199355 
D3Z2H2 CTNND1 1.4 0.02787677 -2.12901 -97965 0.00372498 
Q9JIK5 DDX21 2.2566667 0.47810397 -7.73793 -14.999 0.04391494 
Q91WG5 PRKAG2 6.64 4.12E-05 4.662049 1 0.52199355 
Q80X90 FLNB -1.21 0.17885918 -5.55269 -97206 0.00668249 
Q61990 PCBP2 3.1666667 0.29024431 -6.73779 -95351 0.02613381 
A0A0R4J0G4 RANBP10 1.5833333 0.04540077 -3.08421 -12.999 0.0533588 
Q60972 RBBP4 -0.493333 0.78021462 -8.30767 -95871 0.01722796 
A0A5F8MQC8 TECR 2.3633333 0.08453009 -4.16187 -96792 0.00814964 
Q63844 MAPK3 6.64 4.12E-05 4.662049 1 0.52199355 
P08752 GNAI2 6.64 4.12E-05 4.662049 1 0.52199355 
Q61233 LCP1 2.0566667 0.01186193 -0.6451 -96792 0.00814964 
P84104 SRSF3 1.71 0.0319485 -2.39903 1 0.52199355 
Q6AXD2 ABI2 6.64 4.12E-05 4.662049 1 0.52199355 
P60122 RUVBL1 6.64 4.12E-05 4.662049 -94144 0.06862082 




Q5F2F2 ABHD15 4.4266667 0.26557447 -6.5253 -14.999 0.04391494 
Q99LX0 PARK7 0.9133333 0.06553018 -3.70398 -16.999 0.03202093 
Q9D6Y7 MSRA 3.5866667 0.24055695 -6.13504 -96349 0.01148581 
J3QMG3 VDAC3 4.8766667 0.19188661 -5.70032 -94785 0.04091465 
Q9WV55 VAPA 6.64 4.12E-05 4.662049 1 0.52199355 
Q9JJD0 THAP11 1.42 0.11470985 -4.7203 -96349 0.01148581 
Q9QZD8 SLC25A10 -1.873333 0.26557447 -6.4395 -14.999 0.04091465 
Q8K0E8 FGB 0.36 0.32158861 -6.92276 -95871 0.019885 
Q9CRB3 URAH 3.3966667 0.00647032 0.433702 -98957 0.00157768 
P14152 MDH1 0.6066667 0.40571105 -7.3387 -95871 0.019885 
Q8VDP4 CCAR2 6.64 4.12E-05 4.662049 1 0.52199355 
O09061 PSMB1 1.0433333 0.02180485 -1.6777 -6.9999 0.0738844 
E9Q616 AHNAK 2.42 0.29212642 -6.75531 -96349 0.01291602 
Q9EQ32 PIK3AP1 4.8233333 0.20383635 -5.81162 -16.999 0.03202093 
Q9D0I9 RARS 2.26 0.0295548 -2.24621 -12.999 0.05568397 
D3YYH0 PEX5L 6.64 4.12E-05 4.662049 1 0.52199355 
Q62093 SRSF2 1.3466667 0.03046466 -2.30049 1 0.52199355 
Q64337 SQSTM1 4.9533333 0.1768368 -5.53308 -14.999 0.04391494 
P61620 SEC61A1 1.1166667 0.31402562 -6.88315 -96349 0.01291602 
Q9JMK2 CSNK1E 6.64 4.12E-05 4.662049 1 0.52199355 
A0A2R8VJW4 CLIP4 6.64 4.12E-05 4.662049 1 0.52199355 
Q7TNG8 LDHD 1.6666667 0.16070491 -5.33785 -95871 0.01640025 
Q61037 TSC2 6.64 4.12E-05 4.662049 1 0.52199355 
Q9D819 PPA1 3.0133333 0.32741295 -6.95865 -95353 0.02763432 
Q9D7M1 GID8 6.64 4.12E-05 4.662049 -3 0.33386831 
Q9D1Q6 ERP44 0.29 0.69843168 -8.215 -95871 0.01640025 
P55264 ADK 1.8066667 0.10362516 -4.53559 -96792 0.00929561 
Q6AXB7 FMR1 6.64 4.12E-05 4.662049 1 0.52199355 
Q9DBS5 KLC4 -0.416667 0.76563806 -8.29264 -96349 0.01148581 
Q5SRX1 TOM1L2 6.64 4.12E-05 4.662049 1 0.52199355 
D3Z7C6 PTGES3 1.58 0.04540077 -3.08352 -12.999 0.06953933 
Q8CCJ4 AMER2 6.64 4.12E-05 4.662049 1 0.52199355 
Q91YQ5 RPN1 0.7733333 0.27036519 -6.57393 -95871 0.01640025 
Q5HZI1 MTUS1 1.1233333 0.37109004 -7.20557 -95873 0.01722796 
Q78IK4 APOOL 2.4466667 0.46369672 -7.53301 -97598 0.0047905 
A6ZI44 ALDOA 0.95 0.29449945 -6.77128 -95872 0.01722796 
P62835 RAP1A 2.7833333 0.37109004 -7.20482 -95353 0.02763432 
Q9D0E3 LYSMD1 6.64 4.12E-05 4.662049 1 0.52199355 
Q8R307 VPS18 6.64 4.12E-05 4.662049 1 0.52199355 
Q80ZM5 H1F10 6.64 4.12E-05 4.662049 1 0.52199355 
P21279 GNAQ 6.64 4.12E-05 4.662049 1 0.52199355 




D3Z6D2 STAU2 6.64 4.12E-05 4.662049 1 0.52199355 
P62812 GABRA1 6.64 4.12E-05 4.662049 1 0.52199355 
Q80U93 NUP214 6.64 4.12E-05 4.662049 1 0.52199355 
A0A5F8MP75 MAPK10 6.64 4.12E-05 4.662049 1 0.52199355 
P53996 CNBP 0.9933333 0.26337304 -6.2947 -95872 0.01722796 
Q7TT50 CDC42BPB 6.64 4.12E-05 4.662049 1 0.52199355 
Q91WG7 DGKG 6.64 4.12E-05 4.662049 1 0.52199355 
E9PVU7 PDE4D 6.64 4.12E-05 4.662049 1 0.52199355 
A0A2I3BQW0 ASXL1 6.64 4.12E-05 4.662049 -96795 0.0085431 
Q8BGT5 GPT2 0.0933333 0.98448066 -8.42813 -96349 0.01291602 
Q8BI84 MIA3 -0.993333 0.42606419 -7.41199 -95871 0.019885 
Q8BFY6 PEF1 2.7033333 0.39103474 -7.28367 -95873 0.01722796 
P26150 HSD3B3 0.5866667 0.07428911 -3.93341 -96792 0.00814964 
E9PWE8 DPYSL3 6.64 4.12E-05 4.662049 1 0.52199355 
Q8BFW7 LPP 6.64 4.12E-05 4.662049 -94785 0.04091465 
Q8R0S4 CACNB4 6.64 4.12E-05 4.662049 1 0.52199355 
Q00PI9 HNRNPUL2 6.64 4.12E-05 4.662049 1 0.52199355 
P10518 ALAD -2.006667 0.00124447 2.634648 -2 0.43157443 
Q8CGK3 LONP1 4.5233333 0.09744718 -4.41583 -95871 0.019885 
P11679 KRT8 2.4233333 0.47494682 -7.56651 -96792 0.01015707 
A0A286YCT4 SSR1 1.1266667 0.04325203 -2.99609 -1.4 0.52199355 
A2AS89 AGMAT 2.0166667 0.03952797 -2.81994 -96349 0.0157301 
Q8BRK8 PRKAA2 0.3266667 0.49142719 -7.79426 -95872 0.01722796 
D3Z6I8 TPM3 1.55 0.04160557 -2.92823 -2 0.52199355 
P97300 NPTN 6.64 4.12E-05 4.662049 1 0.52199355 
P26231 CTNNA1 2.2533333 0.47805356 -7.70027 -95351 0.02763432 
Q6PEB6 MOB4 6.64 4.12E-05 4.662049 1 0.52199355 
Q8VEJ9 VPS4A 6.64 4.12E-05 4.662049 1 0.52199355 
Q9D8W5 PSMD12 6.64 4.12E-05 4.662049 -11 0.08613925 
Q9DBK0 ACOT12 6.64 4.12E-05 4.662049 -96349 0.01148581 
Q9D2R8 MRPS33 6.4466667 0.00194291 2.10884 1 0.52199355 
Q9D883 U2AF1 1.5333333 0.14018664 -5.07744 -94785 0.04091465 
A0A0R4J0I6 ACAD11 6.64 4.12E-05 4.662049 -95871 0.01722796 
Q99L04 DHRS1 2.29 0.00135204 2.529549 -96350 0.01245573 
Q60936 COQ8A 0.5966667 0.66506216 -8.1649 -95353 0.02763432 
Q8R404 MICOS13 5.4366667 0.08848591 -4.23965 -95353 0.02763432 
Q8BJY1 PSMD5 4.9966667 0.16848167 -5.4346 -95351 0.02613381 
P63158 HMGB1 -0.056667 0.90474388 -8.39909 -95871 0.01640025 
Q9D0R8 LSM12 6.64 4.12E-05 4.662049 1 0.52199355 




Q9D832 DNAJB4 6.64 4.12E-05 4.662049 1 0.52199355 
G8JL68 MYEF2 6.64 4.12E-05 4.662049 1 0.52199355 
Q543K9 PNP 1.8366667 0.04298631 -2.984 -12.999 0.05568397 
G3UY93 VARS 2.2233333 0.47805356 -7.72461 -95353 0.02763432 
Q3UMU9 HDGFL2 6.64 4.12E-05 4.662049 1 0.52199355 
Q9DBR0 AKAP8 2.7266667 0.38475871 -7.25829 -95871 0.01640025 
Q3THS6 MAT2A 3.3 0.27360311 -6.61119 -95873 0.01722796 
P56593 CYP2A12 4.9233333 0.18223793 -5.59957 -95871 0.019885 
Q9JK92 HSPB8 0.0166667 1 -8.43406 -95353 0.02763432 
P14602 HSPB1 0.8866667 0.24171578 -6.14317 -95352 0.02763432 
E9Q450 TPM1 6.64 4.12E-05 4.662049 -3.9999 0.2579867 
Q80XK6 ATG2B 6.64 4.12E-05 4.662049 1 0.52199355 
Q9DCW4 ETFB 1.69 0.10921019 -4.64274 -95871 0.01722796 
Q9DBG1 CYP27A1 0.66 0.47805356 -7.61954 -96349 0.01148581 
Q9QXD1 ACOX2 6.64 4.12E-05 4.662049 -14.999 0.04391494 
B1AT82 PRPSAP1 6.64 4.12E-05 4.662049 -3.9999 0.2579867 
Q920Q4 VPS16 6.64 4.12E-05 4.662049 1 0.52199355 
Q7TMQ7 WDR91 -0.456667 0.23350213 -6.06776 -95353 0.02763432 
Q9JIA7 SPHK2 6.64 4.12E-05 4.662049 -2 0.52199355 
Q6QWF9 CAMK2N1 6.64 4.12E-05 4.662049 1 0.52199355 
B1AR34 ASGR1 1.1233333 0.36849719 -7.18213 -96349 0.01291602 
Q9WUR2 ECI2 5.3466667 0.10245202 -4.51729 -96792 0.00929561 
Q91WT8 RBM47 0.5766667 0.56791702 -7.98915 -96793 0.01015707 
A0A1Y7VN70 GLRX5 6.64 4.12E-05 4.662049 -94144 0.06862082 
P70188 KIFAP3 6.64 4.12E-05 4.662049 1 0.52199355 
G3UYV7 RPS28 2.21 0.01638707 -1.18487 -95871 0.01640025 
Q641P0 ACTR3B 6.64 4.12E-05 4.662049 1 0.52199355 
Q9Z1D1 EIF3G 1.1566667 0.02017651 -1.54799 -6.9998 0.15689585 
B2RQE8 ARHGAP42 1.21 0.08227595 -4.10238 -95871 0.01722796 
Q6IR34 GPSM1 6.64 4.12E-05 4.662049 1 0.52199355 
A2ADA6 ACAP3 6.64 4.12E-05 4.662049 1 0.52199355 
B1AR13 CISD3 6.64 4.12E-05 4.662049 1 0.52199355 
Q9WUD1 STUB1 6.64 4.12E-05 4.662049 1 0.52199355 
Q91XE9 CREB3L3 6.64 4.12E-05 4.662049 -8.9997 0.10426026 
P68369 TUBA1A 2.1033333 0.0398377 -2.8358 1 0.52199355 
A2A841 EPB41 0.31 0.49922224 -7.82091 -95351 0.02613381 
Q80U95 UBE3C 6.64 4.12E-05 4.662049 1 0.52199355 
P23475 XRCC6 6.64 4.12E-05 4.662049 1 0.52199355 
Q5XG73 ACBD5 1.2433333 0.03843975 -2.75984 -95351 0.02613381 
M0QWZ1 FAM193A 6.64 4.12E-05 4.662049 -2 0.52199355 
Q7TPV4 MYBBP1A 0.29 0.27980743 -6.66294 -94785 0.04091465 




Q8K2C9 HACD3 1.68 0.10513404 -4.56912 -95353 0.02763432 
Q791V5 MTCH2 2.09 0.08362646 -4.13832 -96349 0.01148581 
Q80U04 PJA2 6.64 4.12E-05 4.662049 1 0.52199355 
E9Q3V2 SLC35A3 0.76 0.26557447 -6.40791 -95351 0.02613381 
Q7TSY6 CELF4 6.64 4.12E-05 4.662049 1 0.52199355 
Q99KK2 CMAS 1.8333333 0.02419371 -1.86789 6.9998 0.95168916 
Q9CQZ1 HSBP1 6.64 4.12E-05 4.662049 1 0.52199355 
Q5U3K5 RABL6 6.64 4.12E-05 4.662049 1 0.52199355 
B2RSH2 GNAI1 6.64 4.12E-05 4.662049 1 0.52199355 
A0A498WGK2 NARS 6.64 4.12E-05 4.662049 1 0.52199355 
P40124 CAP1 6.64 4.12E-05 4.662049 1 0.52199355 
Q9CX86 HNRNPA0 6.64 4.12E-05 4.662049 1 0.52199355 
Q6ZWU9 RPS27 2.2333333 0.01560858 -1.09463 -6.9998 0.15689585 
A0A140LHA2 BUB3 6.64 4.12E-05 4.662049 1 0.52199355 
F6WHQ7 GSTM1 0.6166667 0.0275432 -2.10645 4.9999 0.92709827 
S4R1M9 OSBPL10 6.64 4.12E-05 4.662049 1 0.52199355 
Q920M5 CORO6 6.64 4.12E-05 4.662049 1 0.52199355 
E9PXF0 PCDH17 6.64 4.12E-05 4.662049 1 0.52199355 
E9QAQ3 ARHGAP26 6.64 4.12E-05 4.662049 1 0.52199355 
Q61425 HADH -2.87 0.02817268 -2.16345 -3.9999 0.2579867 
Q99JI4 PSMD6 1.75 0.03478411 -2.56822 -94785 0.04091465 
Q9EQQ2 YIPF5 6.64 4.12E-05 4.662049 -6.9998 0.15689585 
Q9D7N3 MRPS9 6.64 4.12E-05 4.662049 -2 0.52199355 
Q61081 CDC37 6.64 4.12E-05 4.662049 1 0.52199355 
Q8C5L3 CNOT2 6.64 4.12E-05 4.662049 -94785 0.04091465 
E9Q4D5 REM2 6.64 4.12E-05 4.662049 1 0.52199355 
Q3TQB2 FOXRED1 6.64 4.12E-05 4.662049 1 0.52199355 
A0A0R4J094 FAHD2A 6.64 4.12E-05 4.662049 -3 0.33386831 
G3UX79 MRPS18B 6.64 4.12E-05 4.662049 1 0.52199355 
S4R2A9 SEC31A 6.64 4.12E-05 4.662049 -8.9997 0.11265511 
B2RXQ2 PPFIA1 6.64 4.12E-05 4.662049 1 0.52199355 
G3UZH5 TRAK2 6.64 4.12E-05 4.662049 -2 0.52199355 
P58391 KCNN3 5.95 0.02787677 -2.13168 1 0.52199355 
A0A2R8VK76 CPSF1 6.64 4.12E-05 4.662049 -4.9999 0.26057561 
A0A1B0GS70 PSMA1 0.3666667 0.4160534 -7.37209 -95352 0.02763432 
B1AZS9 PRDX4 2.7933333 0.37109004 -7.20388 -95352 0.02763432 
A0A1B0GR85 2900026A02RIK 1.8466667 0.01449795 -0.96351 -96795 0.0085431 
Q8R4H2 ARHGEF12 6.64 4.12E-05 4.662049 1 0.52199355 
P0C027 NUDT10 6.64 4.12E-05 4.662049 1 0.52199355 




Q62392 PHLDA1 6.64 4.12E-05 4.662049 -6.9998 0.15689585 
Q9D9V3 ECHDC1 3.4733333 0.26482644 -6.30549 -95351 0.02613381 
Q8VHW2 CACNG8 6.64 4.12E-05 4.662049 1 0.52199355 
Q80TJ1 CADPS 6.64 4.12E-05 4.662049 1 0.52199355 
P10637 MAPT 6.3966667 0.00313607 1.442439 1 0.52199355 
Q8BGZ2 FAM168A 6.64 4.12E-05 4.662049 1 0.52199355 
Q9DC71 MRPS15 6.64 4.12E-05 4.662049 -3 0.33386831 
F6U2S8 WNK1 6.64 4.12E-05 4.662049 1 0.52199355 
Q9Z140 CPNE6 0.82 0.04389845 -3.03083 1 0.52199355 
P70266 PFKFB1 -1.956667 0.5348154 -7.91484 -94785 0.04091465 
E9QQ25 SPEG 4.28 0.29083666 -6.74447 -95872 0.01722796 
Q9D8X5 CNOT8 6.64 4.12E-05 4.662049 -4.9999 0.26057561 
P48758 CBR1 6.64 4.12E-05 4.662049 1 0.52199355 
Q61187 TSG101 6.64 4.12E-05 4.662049 -3 0.33386831 
Q91Z61 DIRAS1 6.64 4.12E-05 4.662049 1 0.52199355 
Q8K019 BCLAF1 0.4766667 0.53473354 -7.91399 -94785 0.04091465 
I7HPV9 PREX1 6.64 4.12E-05 4.662049 1 0.52199355 
E9Q3B9 MGLL 6.64 4.12E-05 4.662049 1 0.52199355 
Q60973 RBBP7 6.64 4.12E-05 4.662049 1 0.52199355 
Q9D1C8 VPS28 6.64 4.12E-05 4.662049 1 0.52199355 
Q91W64 CYP2C70 6.64 4.12E-05 4.662049 -94785 0.04091465 







Appendix 5.4. O-GlcNAc Sites and Regions Identified in the Mouse Brain.  





Site ID Constraints 
A0A075B6D7 1 304 
A0A075B6D7 1 164 
A0A087WNU5 1 (1 of 268,269) 
A0A087WNU5 1 (1 of 2278,2280,2283,2284,2286,2287) 
A0A087WNU5 1 (1 of 224,226,227,231) 
A0A087WNU5 1 (1 of 578,580) 
A0A087WNU5 1 261 
A0A087WNU5 1 401 
A0A087WNU5 1 274 
A0A087WNU5 1 275 
A0A087WNU5 1 273 
A0A087WNU5 1 276 
A0A087WNU5 1 407 
A0A087WNU5 1 280 
A0A087WNU5 1 408 
A0A087WNU5 1 412 
A0A087WNU5 1 321 
A0A087WNU5 1 323 
A0A087WNU5 1 206 
A0A087WNU5 1 210 
A0A087WNU5 1 470 
A0A087WNU5 1 471 
A0A087WNU5 1 345 
A0A087WNU5 1 346 
A0A087WNU5 1 474 
A0A087WNU5 1 349 
A0A087WNU5 1 357 
A0A087WNU5 1 486 
A0A087WNU5 1 487 
A0A087WNU5 1 871 
A0A087WNU5 1 238 
A0A087WNU5 1 369 
A0A087WNU5 1 243 
A0A087WNU5 1 500 
A0A087WNU5 1 372 
A0A087WNU5 1 379 




A0A087WNU5 1 383 
A0A087WNV1 1 (1 of 267,269,270) 
A0A087WNV1 1 322 
A0A087WNV1 1 258 
A0A087WNV1 1 260 
A0A087WNV1 1 262 
A0A087WNV1 1 327 
A0A087WNV1 1 251 
A0A087WP54 1 536 
A0A087WPX3 1 975 
A0A087WQC5 1 191 
A0A087WSE3 1 (1 of 2550,2552,2553,2557,2565,2568,2569,2571,2573,2574,2575,2576,2578,2584,2585) 
A0A087WSE3 1 (1 of 2625,2630,2632,2634,2636,2637,2638,2647,2648,2649,2650,2655,2656,2659,2676) 
A0A0A0MQC7 1 (1 of 704,705,706,708,714,719) 
A0A0A0MQC7 1 688 
A0A0A0MQC7 1 555 
A0A0A0MQC7 1 725 
A0A0A0MQE5 1 387 
A0A0A6YVZ3 2 (2 of 120,122,123,124,126,129,130,131,133,134,137,138,141,145) 
A0A0A6YWC8 1 33 
A0A0A6YWG7 1 (1 of 727,729,731,732,733,740) 
A0A0A6YWG7 1 1313 
A0A0A6YWG7 1 1512 
A0A0A6YWG7 1 1513 
A0A0A6YWG7 1 1356 
A0A0A6YWG7 1 1589 
A0A0A6YXG1 3 
(3 of 2010,2011,2015,2016,2017,2018,2019,2020,2021,2025)&(2 of 
2005,2007,2010,2011,2015,2016,2017,2018,2019,2020,2021,2025)&(1 of 
2005,2007,2010,2011,2015,2016,2017,2018,2019,2020,2021,2025,2028,2029) 
A0A0A6YXG1 1 2009 
A0A0A6YY91 1 (1 of 986,987,990) 





A0A0A6YY91 1 (1 of 1019,1024,1027,1031,1036,1037,1040) 
A0A0A6YY91 1 (1 of 858,859) 
A0A0A6YY91 1 (1 of 875,877,879,880,883,885,888,889,890,900,902,903,906,910,911) 
A0A0A6YY91 1 856 
A0A0G2JDK2 1 290 
A0A0G2JDK2 1 71 
A0A0G2JEG6 1 (1 of 702,705,706,708) 
A0A0G2JEG6 1 1075 
A0A0G2JEG8 1 336 




A0A0G2JER6 1 108 
A0A0G2JER6 1 111 
A0A0G2JGK8 1 (1 of 82,88,89,90,93,94) 
A0A0J9YU75 1 (1 of 134,137,139,140,145,146,151,152) 
A0A0J9YUN4 1 (1 of 740,747,748,749,751,752,761,767) 
A0A0N4SW73 1 (1 of 1211,1212,1214,1215,1218,1219) 
A0A0N4SW73 1 (1 of 1226,1228,1229,1234,1239,1243,1244,1247) 
A0A0N4SW73 1 (1 of 702,705,711,712,713,715,722,723,725,728,729) 
A0A0R4J060 1 (1 of 592,593,601,608,612,618,619,623,625,627,629,630,632,637,638) 
A0A0R4J060 1 280 
A0A0R4J060 1 320 
A0A0R4J060 1 279 
A0A0R4J092 1 91 
A0A0R4J0B3 1 (1 of 746,747,754,757,760,763,767,768) 
A0A0R4J0W7 1 1280 
A0A0R4J0W7 1 535 
A0A0R4J102 1 219 
A0A0R4J138 1 (1 of 165,173,178,187,191) 
A0A0R4J1F4 1 (1 of 699,700,701,702,703,704,706,707,708,710,711,715,718,723,724) 
A0A0R4J1F4 1 (1 of 828,829,832,833,835,838,839,847,850,851) 
A0A0R4J274 1 (1 of 217,220,223,226,227,229,233,234,237) 
A0A0R4J2A2 1 398 
A0A0R4J2B5 1 348 
A0A0U1RPA0 1 (1 of 35,36,39,41,42,43,46,47,48,49) 
A0A0U1RPL0 1 (1 of 266,267) 
A0A0U1RPL0 2 (2 of 450,457,459,467,471,472,474,478,479,480) 
A0A0U1RPL0 1 680 
A0A0U1RPL0 1 675 
A0A0U1RPL0 1 676 
A0A0U1RPL0 1 437 
A0A140LHQ8 1 (1 of 343,344) 
A0A140LHQ8 1 (1 of 381,382,388,396,399,403) 
A0A140LHQ8 2 (2 of 236,237,239,240,243,246,247,248,254,262,263,265,266,267,269,270,271) 
A0A140LHQ8 1 (1 of 346,348,356,358,365,366,375) 
A0A140LHQ8 1 (1 of 416,421,422,436,437,442,444) 
A0A140LHQ8 1 337 
A0A140LIW3 1 708 
A0A140T8S0 1 346 
A0A1B0GRV3 1 248 
A0A1B0GSU0 1 (1 of 607,608) 
A0A1B0GT88 1 (1 of 470,473,476) 
A0A1C7ZMY3 1 (1 of 341,343,345,348) 




A0A1C7ZMY3 1 (1 of 452,453,456,457,465,475,477,479,480) 
A0A1C7ZMY3 1 (1 of 188,196) 
A0A1C7ZMY3 1 (1 of 902,903,904,910,911,912,913,915,916,918,919,921,922,924,925,930,933,935) 
A0A1C7ZMY3 1 1065 
A0A1C7ZMY3 1 1070 
A0A1C7ZMY3 1 1135 
A0A1C7ZMY3 1 1071 
A0A1C7ZMY3 1 1075 
A0A1C7ZMY3 1 759 
A0A1C7ZMY3 1 183 
A0A1C7ZMY3 1 669 
A0A1D5RLD8 1 208 
A0A1D5RLN6 1 355 
A0A1D5RLV3 1 (1 of 2919,2920,2922,2923,2926,2927,2928,2929) 
A0A1D5RLV7 1 2254 
A0A1D5RLY6 1 (1 of 694,701,704,705,707,709,712,714,716,724,730,732) 
A0A1D5RM55 1 118 
A0A1D5RM83 1 (1 of 287,289,293,301,307) 
A0A1L1SR84 2 (2 of 896,907,908,917,920,921,922,925,933) 
A0A1L1SR84 1 (1 of 1326,1327,1330,1331) 
A0A1L1SR84 1 1123 
A0A1W2P6Y4 1 390 
A0A1W2P7D7 1 (1 of 144,149,152) 
A0A1W2P7D7 1 153 
A0A1W2P7K6 1 (1 of 16,18,19,30,34,35,36,38) 
A0A1W2P882 1 (1 of 242,245,251,254,255,257,262,263,264,265,267,268,269,274,279) 
A0A1Y7VIR0 1 45 
A0A1Y7VJH3 1 (1 of 382,389,390) 
A0A1Y7VNM3 1 167 
A0A286YDC8 1 (1 of 219,220,229,235,242,247,253,254,259,262,266) 
A0A286YDC8 1 (1 of 273,275,279,283,285,292,293) 
A0A286YDC8 1 343 
A0A286YDY4 2 (2 of 480,482,483,487,489) 
A0A2I3BPN6 1 486 
A0A2I3BQ43 1 (1 of 540,541,542,544,550,556,558,566,567) 
A0A2R8VKG2 1 (1 of 1926,1931,1933,1938) 
A0A2R8VKG2 1 1896 
A0A2R8VKG2 1 1921 
A0A2R8VKG2 1 1501 
A0A2R8VKG2 1 1838 
A0A338P689 1 (1 of 310,315,331,332) 
A0A338P6P6 1 554 




A0A494B9T4 1 (1 of 36,37,42,43,46,47) 
A0A498WGM0 1 (1 of 191,196,197,199,200,202,203,206,209,210) 
A0A498WGM0 1 (1 of 242,245,246,247,249,259,263) 
A0A498WGM0 1 58 
A0A498WGM0 1 52 
A0A498WGM0 1 55 
A0A571BDM4 1 43 
A0A571BDM4 1 37 
A0A571BDN3 1 709 
A0A571BET0 1 (1 of 1082,1087,1092,1093,1094) 
A0A571BET0 1 (1 of 2212,2216,2220,2223,2225,2226,2228,2233) 
A0A571BEZ4 1 376 
A0A5F8MPJ2 1 (1 of 229,230,231,233,240,241,242,246,248,254,255) 
A0A5F8MPJ2 1 861 
A0A5F8MPY3 1 392 
A0A5F8MQ25 1 (1 of 876,879,881) 
A0A5F8MQ25 1 (1 of 840,843) 
A0A5F8MQ25 1 852 
A0A5F8MQ25 1 886 
A2A468 1 (1 of 641,642,644,646,647,649,652,653,654,655,656,658,660,661,662,663,668) 
A2A484 1 (1 of 755,756,757,758,763,767,771) 
A2A654 1 (1 of 2058,2059,2060,2061,2066,2067,2068,2069,2071) 
A2A654 1 (1 of 1739,1742,1743,1744) 
A2A654 1 (1 of 1750,1751,1753,1754,1755,1756,1757,1758,1760) 
A2A654 1 1713 
A2A690 1 (1 of 163,168,169,171,172,173,176) 
A2A690 1 (1 of 129,132,133,135,136,137,138,140,144,145,148,149,154,155) 
A2A690 1 (1 of 268,272,273,274) 
A2A690 1 (1 of 1871,1875,1876,1879,1882,1884,1885,1894,1896,1899,1900,1902) 
A2A690 1 1643 
A2A690 1 1651 
A2A690 1 1956 
A2A690 1 1943 
A2A6H0 1 77 
A2A841 1 (1 of 769,771,777,780,791,794,796,797,799,800,801,802,803,804,805,806,809) 
A2A841 1 765 
A2A884 1 (1 of 1465,1467,1468,1470,1471,1474) 
A2A884 1 (1 of 390,392,398,402) 
A2A884 1 (1 of 1527,1536,1537,1541,1543,1544) 
A2A884 1 984 
A2A884 1 1074 
A2A884 1 1070 




A2ADM8 1 (1 of 1512,1516,1521,1522,1525,1526,1528,1529) 
A2ADY9 1 (1 of 115,120,121,127,128) 
A2AFG7 1 (1 of 574,578,584,588,589,596) 
A2AFG7 1 667 
A2AG50 1 (1 of 184,187,193,196,197,198,203,205,206,207,212,213) 
A2AGT5 1 (1 of 1914,1916,1917,1918,1920,1921) 
A2AGT5 1 1904 
A2AGT5 1 1925 
A2AGT5 1 1910 
A2AH22 1 (1 of 322,329,334) 
A2AH22 1 441 
A2AH22 1 442 
A2AH25 1 20 
A2AJA9 1 (1 of 100,105,109) 
A2AJA9 1 349 
A2AKB4 1 1215 
A2AKB9 1 (1 of 357,358,361,362,363) 
A2AKB9 1 364 
A2ALK6 1 535 
A2ALS5 1 (1 of 606,610,611,616,618,619,620,621,624,625,629) 
A2ALS5 1 (1 of 454,456,457,458,460,462,464) 
A2AMI6 1 (1 of 187,188,190,196,202,208,211,217,218,221,224) 
A2API8 1 (1 of 459,461,463,473) 
A2AQ25 1 (1 of 359,361,363,365) 
A2AQ25 1 (1 of 1716,1731,1732,1734,1737) 
A2AQ25 2 (2 of 1893,1894,1895,1896,1897,1898,1899,1902,1905,1907,1908) 
A2AQ25 1 (1 of 1814,1815,1816,1819,1821,1824,1825,1833,1836,1839,1840,1843) 
A2AQ25 1 1348 
A2AQ25 1 357 
A2AQ25 1 1070 
A2AQH4 1 646 
A2ARP8 1 (1 of 2021,2027,2032) 
A2ARP8 1 (1 of 2632,2633,2639,2641,2642,2653) 
A2ARP8 1 (1 of 1007,1008,1009,1013,1024,1026,1029,1034,1035,1036) 
A2ARP8 1 (1 of 1076,1077,1080,1081,1087,1090,1092,1096,1099) 
A2ARP8 1 (1 of 1038,1044,1047,1064,1065,1067,1068,1070) 
A2ARP8 1 (1 of 808,809,814,819) 
A2ARP8 1 (1 of 2464,2468,2471,2472,2473,2476,2477,2481,2482) 
A2ARP8 1 (1 of 1472,1479,1485,1487,1489,1492,1502,1505,1513,1514,1516,1518,1521) 
A2ARP8 1 2433 
A2ARP8 1 2147 
A2ARP8 1 1115 




A2AUX5 1 (1 of 728,734) 
A2AUY4 1 (1 of 277,285,287,289,295) 
A2AW73 1 1014 
A2AWI9 1 (1 of 263,267,268,272,276,277,278,279,281,282,283,286,292,314,316) 
A2BH40 1 (1 of 127,128,129,130,139) 
A2BH40 1 256 
A2RSY1 1 534 
A6H619 1 (1 of 1359,1363,1364,1365,1366,1368,1369,1376) 
B0QZH6 1 (1 of 332,339,342,349) 
B0R0Y8 1 (1 of 84,85,87) 
B1AQX6 1 (1 of 670,671) 
B1AQX6 1 (1 of 333,336,340,341,342,349,353,357,359,361) 
B1AQX6 1 (1 of 563,564,566,568,569,575) 
B1AQX6 1 320 
B1AQX6 1 1057 
B1AQX6 1 516 
B1AQX6 1 1065 
B1AQX6 1 662 
B1AQX6 1 989 
B1ARU4 1 (1 of 533,534,541,542,544,545,546) 
B1ATU4 1 (1 of 489,490) 
B1AUB8 1 (1 of 200,203,204,206,208,210,211,212,215,218) 
B1AUB8 2 (1 of 327,331,332,333,334,340,342,343,345,348,351,352)&(2 of 327,331,332,333,334) 
B1AUB8 1 347 
B1AUB8 1 350 
B1AUC0 1 (1 of 456,460,461,462,463,469,471,472) 
B1AV60 1 (1 of 1472,1473,1474,1475,1476,1479,1481,1482,1484,1485,1488,1491,1492) 
B1AVN9 1 208 
B1AWN6 1 1970 
B1AXH1 1 (1 of 359,361,368,374,377,378,383,385,386,388,389,390) 
B1AXH1 2 (2 of 309,311,312,319) 
B1AXH1 1 443 
B1AZP2 1 (1 of 259,260,261,264,275,278,283,285) 
B1B0C7 1 3059 
B1B0C7 1 847 
B2RRI2 1 125 
B2RUJ2 1 1068 
B2RUQ2 1 (1 of 361,364,366,367,369) 
B2RXW8 1 (1 of 1233,1235,1238,1240) 
B7ZCA7 1 258 
B7ZCJ0 1 (1 of 313,314,315,318,321,328,329,331) 
B7ZCJ0 1 (1 of 1561,1565,1569,1570,1571,1572,1575,1576,1577,1578,1579,1580,1581,1584,1585,1588,1589) 




B7ZCJ0 1 355 
B7ZCJ0 1 356 
B7ZCJ0 1 228 
B7ZCJ0 1 307 
B7ZCJ0 1 628 
B8JJI7 1 (1 of 1003,1004,1011,1015,1016,1017,1019,1021,1022,1024,1026,1027) 
B8QI36 1 1184 
B9EIX2 1 (1 of 1312,1314,1321,1324,1325,1327) 
B9EJA2 1 580 
B9EKS2 2 (2 of 410,415,421,426,427,429,430,431,433,434) 
B9EKS2 1 (1 of 648,651,652,655,658,660,661,662,663,665,666,668,669) 
D3YTS3 1 1517 
D3YU15 1 158 
D3YUC9 1 11 
D3YUI2 1 449 
D3YUI2 1 450 
D3YUL8 1 184 
D3YUV1 1 540 
D3YUV1 1 543 
D3YYH0 1 (1 of 55,63,64,66,70,71,79,83,85,87) 
D3YYY8 1 252 
D3YZU1 1 (1 of 1064,1066,1067,1071,1073,1076,1077,1078,1081,1082) 
D3YZU1 1 (1 of 1960,1962,1965,1966,1967,1968,1975,1976,1978,1980,1981,1983,1985,1986) 
D3YZU1 1 (1 of 919,921,925,934,935,942,943,948,949,950) 
D3YZU1 1 1891 
D3YZU1 1 1796 
D3YZU1 1 933 
D3YZU1 1 1862 
D3YZU1 1 973 
D3YZU1 1 1137 
D3Z197 1 (1 of 265,266,269,270,272,273,274) 
D3Z1S6 1 210 
D3Z3F8 1 478 
D3Z3U7 1 328 
D3Z3U7 1 324 
D3Z3U7 1 327 
D3Z4J9 1 95 
D3Z5K8 1 769 
D3Z6L3 2 (2 of 373,374,375,378) 
D3Z6Q4 1 (1 of 477,478) 
D3Z6Q4 1 (1 of 423,425,428,431,435,437,438,440,444,447,451,454,455,456,457,460) 
D3Z752 1 58 




D3Z768 1 545 
E0CXP6 1 (1 of 38,39,44,49) 
E0CZ72 1 (1 of 555,557,562,567,572,574,581,583,585) 
E0CZD9 1 (1 of 142,150,151,154,157,158,162,163,164,165) 
E9PU87 1 (1 of 950,952,953,955,957,958,965) 
E9PU87 1 7 
E9PUF4 1 (1 of 645,647,648,655,657,658,665,666,667,668,671) 
E9PV14 1 (1 of 1166,1168,1169) 
E9PV14 1 (1 of 1482,1483) 
E9PV14 1 (1 of 1152,1153) 
E9PV14 1 (1 of 1479,1480) 
E9PV14 1 1409 
E9PV14 1 1470 
E9PV14 1 1477 
E9PV14 1 1481 
E9PV14 1 1417 
E9PV14 1 1450 
E9PV14 1 1453 
E9PV14 1 1424 
E9PV14 1 1457 
E9PV14 1 1426 
E9PV14 1 1430 
E9PV14 1 1398 
E9PV14 1 988 
E9PV14 1 1469 
E9PV14 1 1150 
E9PV26 2 (2 of 531,532,534,544,548,549,550,551,552,554,559,560,561,564) 
E9PV26 1 74 
E9PV69 1 111 
E9PV73 1 175 
E9PWM3 1 (1 of 828,831,836,837) 
E9PWM3 1 (1 of 595,599,601,602,603,604,607,610,611,612,616,617) 
E9PWM3 1 (1 of 866,874,875) 
E9PWM3 1 210 
E9PX52 1 (1 of 837,838,839,843,844,845) 
E9PX52 2 (2 of 756,762,768,770,773,774,776,780,781,782,783) 
E9PX52 1 (1 of 853,854,856,864) 
E9PXL0 1 (1 of 155,156,157,158,168,171) 
E9PYK3 1 (1 of 1229,1239,1241,1242,1249) 
E9PYL2 1 (1 of 993,995,999,1014,1015,1026,1031,1046) 
E9PZ12 1 (1 of 702,705,706,709,710,715,717) 
E9PZ12 1 (1 of 860,861,864,867) 




E9PZ43 1 (1 of 631,632,634,635,638,639,642,643) 
E9PZ43 1 (1 of 161,173,175,183,184,192,194,196,201) 
E9PZ43 1 (1 of 468,470,472,475,481) 
E9PZ43 1 333 
E9Q0A7 1 (1 of 355,356,359,360,362,365,367,373,375,377,378) 
E9Q0A7 1 167 
E9Q0A7 1 182 
E9Q0A7 1 183 
E9Q160 1 (1 of 189,192,197,200,203,205,207,208) 
E9Q1M1 1 (1 of 1379,1384,1388,1389,1392,1394,1396,1397,1399,1402) 
E9Q1M1 1 1030 
E9Q1M6 1 (1 of 1786,1789,1792,1793,1797,1798,1800,1801,1802) 
E9Q1M6 1 (1 of 2085,2088,2091,2098,2100,2104,2107) 
E9Q1M6 1 1816 
E9Q1M6 1 2096 
E9Q2B2 1 (1 of 2022,2025,2026,2027,2028,2031,2032,2034,2037,2038,2039) 
E9Q2B2 1 (1 of 2,3,4,14,15,18) 
E9Q2B2 1 (1 of 1827,1834,1835,1839) 
E9Q2B2 1 (1 of 2165,2166,2171,2180,2189,2190,2191,2195,2196) 
E9Q2B2 1 (1 of 1969,1973,1975,1985,1986,1988) 
E9Q2B2 1 (1 of 1847,1851) 
E9Q2B2 1 1833 
E9Q2B2 1 51 
E9Q2B2 1 1429 
E9Q2K2 1 69 
E9Q323 1 (1 of 92,93) 
E9Q3C1 1 395 
E9Q3G8 1 (1 of 925,926,927,929,931,932) 
E9Q3G8 2 (2 of 1158,1165,1167,1168,1169) 
E9Q3G8 1 (1 of 554,557,559,561,562,563,565,568,569,570,575,579,580,581) 
E9Q3G8 1 (1 of 1123,1127,1130,1134,1135,1138,1140,1142,1147) 
E9Q3G8 1 705 
E9Q3G8 1 513 
E9Q3G8 1 899 
E9Q3G8 1 934 
E9Q3G8 1 1101 
E9Q3G8 1 1102 
E9Q3G8 1 627 
E9Q3G8 1 1044 
E9Q3G8 1 628 
E9Q3G8 1 1046 
E9Q3M9 1 (1 of 337,338,342,346,352,355,358,360,364,365,372) 




E9Q3W4 1 2457 
E9Q4K0 1 (1 of 449,450,452,454,457,459,463,464,465) 
E9Q4K0 1 (1 of 397,399) 
E9Q4K0 1 (1 of 297,298) 
E9Q4K0 1 392 
E9Q4K0 1 304 
E9Q4K0 1 308 
E9Q4K0 1 309 
E9Q4K0 1 382 
E9Q4K0 1 383 
E9Q5Z1 1 (1 of 6,7,10,13) 
E9Q616 1 (1 of 5376,5377,5378,5383,5384) 
E9Q6H8 1 (1 of 483,484) 
E9Q6H8 1 389 
E9Q6R4 1 (1 of 1580,1583,1584,1587) 
E9Q6R4 1 (1 of 745,749,752,756,765,767,769,770,771,776,778) 
E9Q6Y8 1 (1 of 1161,1163,1164,1165,1166,1167,1168,1171,1172) 
E9Q777 1 (1 of 689,691,701,703,706,708,709) 
E9Q7E9 1 (1 of 415,417,422,423) 
E9Q7M2 1 (1 of 113,121,128,130,131,135,136,138,140,145,147,148) 
E9Q7M2 1 (1 of 743,744,745) 
E9Q7M2 1 (1 of 539,540,541,548,554,556,559,560,564,567,571,573,583) 
E9Q7M2 1 (1 of 767,768) 
E9Q7M2 1 758 
E9Q804 1 (1 of 2372,2375,2378,2381,2382,2384,2387,2391,2393,2394) 
E9Q804 1 (1 of 1833,1834,1838,1839,1840,1841,1843,1845,1848,1853,1854,1856,1857) 
E9Q804 1 (1 of 2185,2191,2192,2193,2195) 
E9Q804 1 1825 
E9Q804 1 1826 
E9Q804 1 1996 
E9Q804 1 1820 
E9Q804 1 1821 
E9Q828 1 (1 of 1135,1136,1138,1143) 
E9Q828 1 1155 
E9Q828 1 1125 
E9Q828 1 1151 
E9Q828; 
F7AAP4 1 (1 of 1135,1136) 
E9Q828; 
F7AAP4 1 1125 
E9Q842 1 1532 
E9Q842 1 1285 
E9Q9C4 1 (1 of 381,383,385,387) 




E9Q9C4 1 414 
E9Q9C4 1 303 
E9QA68 2 (2 of 111,116,117,119,120,123,125,127,128,129,131,132,134,135,136,137,139) 
E9QA68 1 115 
E9QAT4 1 (1 of 1087,1094,1099,1103,1106,1110,1112,1119,1122,1125,1136,1137,1139,1141,1142,1143,1145,1146) 
E9QAT4 1 (1 of 2027,2028,2030,2034) 
E9QAT4 1 2013 
E9QAT4 1 69 
E9QAT4 1 70 
E9QAT4 1 127 
E9QKB1 1 (1 of 159,161,162,163,164,165,166,169,174,178,179) 
E9QKW9 1 (1 of 130,132,135,138,139) 
E9QKW9 1 (1 of 279,281,282,285,286,289) 
E9QKW9 1 (1 of 86,117,123,125,127) 
E9QKW9 1 133 
E9QLT6 1 (1 of 545,547,551) 
E9QLZ1 1 (1 of 1033,1036,1049,1051,1055,1056,1061,1062,1070,1073,1075,1076) 
E9QLZ1 1 444 
E9QM73 1 (1 of 1514,1523,1524,1525,1527,1530,1535,1540,1550,1553,1556,1558,1560,1563,1566) 
E9QM73 1 (1 of 1018,1019,1023,1028,1030,1035,1036,1037,1042,1048,1072,1082,1083,1085,1089,1092,1093) 
E9QM73 1 1698 
E9QM73 1 1917 
E9QM73 1 1918 
E9QMN5 1 178 
E9QMN5 1 326 
E9QN14 1 (1 of 982,983,987,991) 
E9QNF7 1 (1 of 75,77,79) 
E9QP99 1 207 
F2Z3U3 1 (1 of 763,767,775,777,789,793,795,796) 
F2Z3U3 1 197 
F2Z3U3 1 614 
F6R6F1 1 245 
F6RXJ8 1 (1 of 187,188,198) 
F6SEU4 1 (1 of 907,912,913) 
F6SEU4 1 (1 of 816,817,822,823,824,825,828) 
F6SEU4 1 (1 of 1070,1074,1076) 
F6SEU4 1 (1 of 892,895,897,898,900) 
F6SEU4 1 809 
F6SEU4 1 1137 
F6SEU4 1 1140 
F6SEU4 1 983 
F6SEU4 1 1144 




F6TAR7 1 (1 of 101,103,104,105,106,108,112,114,115,126,127,128) 
F6TYF8 1 (1 of 124,125,132) 
F6TYF8 1 (1 of 159,161,162,163,164,165,166,168,169,170,171,173,177,182,188) 
F6U2S8 1 (1 of 246,247,248,249,251,255,257,258,269,270,271) 
F6VBT9 1 (1 of 241,243,246,247,251,252,255,257) 
F6W0G8 1 119 
F6WMD1 1 (1 of 62,66) 
F6Y6L6 1 132 
F6Y6L6 1 127 
F6YR19 2 (2 of 4,17,20,21,22,26,27,31) 
F6YTL8 1 (1 of 483,487,495,497,498,501) 
F6Z9T5 1 (1 of 139,155,156,159) 
F6Z9T5 1 (1 of 104,110) 
F6ZKM7 1 (1 of 65,66) 
F7AAP4 1 (1 of 1146,1149,1151,1152,1155,1156,1159,1160,1165) 
F7B4D5 1 (1 of 55,57,58,63,65,67,68,69) 
F7BE84 1 (1 of 1157,1158,1159,1160,1161,1163,1166,1171,1174,1176,1178,1185) 
F7BE84 1 1297 
F7BJK1 1 (1 of 879,881,883,884,893,896,900,905,907,909,910) 
F7BJK1 1 (1 of 1044,1046,1053,1055,1056,1061,1063,1066,1069) 
F7CC56 1 (1 of 521,522,523,526,529,532) 
F7CPX0 1 156 
F7D291 1 199 
F7D3N3 1 327 
F7D4S5 1 (1 of 379,380,382,385,386,392,395) 
F7D4S5 1 364 
F8VPJ6 1 439 
F8VPM9 1 (1 of 1565,1566,1583) 
F8VPM9 1 1706 
F8VPM9 1 1771 
F8VPP8 1 (1 of 960,961,964,972,974,977,978,979,980) 
F8VPZ9 1 (1 of 431,432,433,435,445) 
F8VPZ9 1 1225 
F8VQJ3 1 1216 
F8VQJ3 1 1241 
F8VQJ3 1 1106 
F8WHT3 1 (1 of 2119,2126,2127) 
F8WHT3 1 1984 
F8WHT3 1 1803 
F8WIK5 1 310 
G3UX48 1 (1 of 42,43,46,47,53,59,61,64) 
G3UX48 1 (1 of 616,625,631) 




G3UZM1 1 (1 of 1428,1431) 
G3UZX7 1 (1 of 494,501,503) 
G3X8R8 1 (1 of 627,630,631,637,642,643,649,654,660,661,663,665) 
G3X8R8 1 (1 of 849,850,862,866,869) 
G3X8R8 1 256 
G3X8R8 1 225 
G3X8R8 1 218 
G3X8R8 1 248 
G3X932 1 (1 of 498,504,505,506,507,508,521) 
G3X972 1 (1 of 65,66,72,81,82,96,97,98) 
G3X9H5 1 1154 
G3X9H5 1 1158 
G3X9J0 1 (1 of 1550,1553,1556,1563,1568,1569,1570,1572,1575,1576,1577) 
G3X9V4 1 (1 of 1353,1354,1356,1357,1367,1372) 
G3X9V4 1 (1 of 1255,1259,1273,1274,1277,1278,1279) 
G3X9V4 1 1030 
G3X9Z4 1 (1 of 169,174,175,178,181,182,184,186,187) 
G5E832 1 (1 of 2081,2083,2086,2089,2090,2095) 
G5E8D8 1 (1 of 607,608,610,612,618,622) 
G5E8J9 1 (1 of 622,630,631,632,635) 
G5E8J9 1 (1 of 727,728) 
G5E8J9 1 (1 of 750,751) 
G5E8J9 1 731 
G5E8J9 1 740 
G5E8J9 1 758 
G5E8J9 1 735 
G5E8T6 1 (1 of 824,829) 
G5E8T6 1 266 
H3BJL2 1 (1 of 779,780) 
H3BJY2 1 (1 of 815,819,820,825,827,828,829,831,832,833,835) 
H3BKJ6 1 (1 of 83,90,97,103,108,110,112) 
H3BKQ7 1 (1 of 195,199,201,203,206,212,219,220) 
H9KV15 1 (1 of 1086,1089,1090,1092) 
H9KV15 1 (1 of 256,262,264) 
H9KV15 1 250 
H9KV15 1 251 
H9KV15 1 1614 
I7HIP8 1 (1 of 404,408,409,412,413,417,418) 
J3KMT7 1 (1 of 339,342,343,344,345) 
J3KMT7 1 (1 of 296,297,300,303,304,305,306,307,309,310) 
J3QNM3 1 (1 of 240,245,246,248,249,251,252,259,260,265,270) 
J3QNM3 1 290 




J3QNM3 1 297 
J3QNM3 1 283 
J3QNM3 1 347 
J3QPR1 1 23 
K3W4L3 1 82 
K3W4L3 1 459 
K3W4L3 1 213 
M0QWN7 1 (1 of 419,420) 
O08553 1 507 
O08579 1 (1 of 176,177,181,185,186,187,188,189,190,192,193,194,195,196,197,199,200,203) 
O08599 1 (1 of 506,507,509,511,512,513,516) 
O08599 1 504 
O08715 1 (1 of 351,356,359,360,365,366,370,371) 
O08785 1 446 
O08789 1 158 
O08919 1 (1 of 345,354,357,365,368,369,370,373,379,385,386,388,389,395) 
O08919 1 (1 of 263,265,268,269,270) 
O08919 1 285 
O09117 1 (1 of 238,239,242,244,246,247,249,251,258,259) 
O35126 1 (1 of 353,357,365,366,367) 
O35607 1 (1 of 547,548,549,550,555,559,561) 
O35633 1 15 
O35738 1 (1 of 91,92,94,97,98,99,102,104,106,108,109,111,112,113,114,115,116,117,118,119,120,121) 
O35927 1 (1 of 452,453,454,457,458,463) 
O35927 1 (1 of 329,330,333,336,337,339,340,341,347,348,349,352,355,357,359) 
O35927 1 320 
O35927 1 447 
O35927 1 267 
O35927 1 268 
O35927 1 269 
O35927 1 435 
O35927 1 307 
O35927 1 437 
O35927 1 319 
O35954 1 1226 
O54818 1 (1 of 156,157) 
O55042 1 64 
O55042 1 72 
O55042 1 81 
O55042 1 53 
O55042 1 54 
O55042 1 59 




O70305 1 (1 of 382,383,386,387,389,390,392) 
O70305 1 (1 of 635,636,641,643,644,647) 
O70305 1 (1 of 778,779,780,781,783,789) 
O70305 1 (1 of 812,816,817,818,819,820,821,824,825,827,828) 
O70305 2 (2 of 174,175,182,186,187,189,200,201,202) 
O70305 1 745 
O70305 1 852 
O70318 1 (1 of 886,888,891,902,907,910,912,913,915,917,918,919,920,921,922,925) 
O70400 1 128 
O70400 1 135 
O70507 1 1022 
O88492 1 354 
O88492 1 189 
O88492 1 222 
O88531 1 (1 of 234,241) 
O88531 1 199 
O88532 1 (1 of 102,111,114,116,121) 
O88532 1 (1 of 9,11,15) 
O88532 1 (1 of 458,459) 
O88532 1 (1 of 443,445,447,448,452,455) 
O88532 1 195 
O88532 1 422 
O88532 1 135 
O88532 1 136 
O88532 1 167 
O88532 1 202 
O88532 1 423 
O88532 1 300 
O88532 1 429 
O88532 1 148 
O88532 1 180 
O88704 1 (1 of 791,792,798,801) 
O88704 2 (2 of 634,639,640,641,642,643,644,646,647) 
O88712 1 (1 of 357,360,364,380) 
O88735 1 (1 of 452,453,456,457,463) 
O88737 1 (1 of 2671,2672,2677,2679) 
O88737 1 (1 of 689,692,694,696,699,700,704,705,706,708,711,723,727,733,735) 
O88737 1 (1 of 283,284,289) 
O88737 1 (1 of 2649,2651,2656) 
O88737 1 (1 of 3175,3181,3182,3187) 
O88737 1 (1 of 1921,1927) 
O88737 1 (1 of 1932,1934,1936) 




O88737 1 (1 of 1623,1626,1644) 
O88737 1 (1 of 301,307,308,311,312) 
O88737 1 (1 of 3710,3711,3715,3717,3718) 
O88737 1 (1 of 1525,1530) 
O88737 1 (1 of 3254,3256) 
O88737 1 (1 of 3509,3512,3516,3519) 
O88737 1 (1 of 2542,2544,2547,2550) 
O88737 1 (1 of 3225,3227,3230,3231) 
O88737 1 (1 of 2022,2023) 
O88737 1 (1 of 990,991,992,996,997,999,1001,1002,1004,1005,1007,1008,1010,1011,1016,1018,1019,1021) 
O88737 1 (1 of 1423,1429,1430)&(1 of 1429,1430,1435) 
O88737 3 (3 of 1711,1712,1727,1729,1733,1735,1736,1738,1740,1743,1744) 
O88737 1 (1 of 3787,3810) 
O88737 1 (1 of 2858,2860,2866,2868,2872) 
O88737 1 (1 of 1159,1161,1170,1173,1175,1177,1179,1181,1182,1183,1184,1186,1187) 
O88737 1 (1 of 2905,2908,2924,2930) 
O88737 1 (1 of 742,743,747,756,760,765,766,767,768) 
O88737 1 (1 of 3825,3830) 
O88737 1 (1 of 2165,2180) 
O88737 1 (1 of 912,913,920,928,930,931) 
O88737 1 (1 of 3573,3578,3580,3590) 
O88737 1 (1 of 3768,3772,3773) 
O88737 1 (1 of 3739,3742) 
O88737 1 (1 of 326,328,329,332,340,345) 
O88737 1 (1 of 2046,2048) 
O88737 1 1537 
O88737 1 2058 
O88737 1 1554 
O88737 1 2067 
O88737 1 2068 
O88737 1 2070 
O88737 1 2074 
O88737 1 1563 
O88737 1 1566 
O88737 1 2091 
O88737 1 1582 
O88737 1 2096 
O88737 1 2098 
O88737 1 2099 
O88737 1 2112 
O88737 1 1606 
O88737 1 2122 




O88737 1 2141 
O88737 1 2658 
O88737 1 2659 
O88737 1 2660 
O88737 1 2661 
O88737 1 2662 
O88737 1 1131 
O88737 1 3179 
O88737 1 2158 
O88737 1 1649 
O88737 1 1650 
O88737 1 3190 
O88737 1 1655 
O88737 1 1654 
O88737 1 2682 
O88737 1 3195 
O88737 1 2685 
O88737 1 3197 
O88737 1 640 
O88737 1 2177 
O88737 1 1666 
O88737 1 2694 
O88737 1 2188 
O88737 1 2189 
O88737 1 2700 
O88737 1 2703 
O88737 1 3216 
O88737 1 1683 
O88737 1 3222 
O88737 1 1690 
O88737 1 2714 
O88737 1 1691 
O88737 1 1707 
O88737 1 3250 
O88737 1 1233 
O88737 1 2787 
O88737 1 1258 
O88737 1 1259 
O88737 1 3818 
O88737 1 3822 
O88737 1 2295 
O88737 1 1274 




O88737 1 3841 
O88737 1 2818 
O88737 1 2819 
O88737 1 3842 
O88737 1 2316 
O88737 1 2317 
O88737 1 2318 
O88737 1 2841 
O88737 1 1824 
O88737 1 292 
O88737 1 1828 
O88737 1 3878 
O88737 1 1324 
O88737 1 1326 
O88737 1 2352 
O88737 1 2354 
O88737 1 1337 
O88737 1 3902 
O88737 1 3401 
O88737 1 1354 
O88737 1 3403 
O88737 1 3928 
O88737 1 3932 
O88737 1 1373 
O88737 1 1374 
O88737 1 1375 
O88737 1 1378 
O88737 1 1384 
O88737 1 1386 
O88737 1 1391 
O88737 1 1394 
O88737 1 1395 
O88737 1 1916 
O88737 1 1917 
O88737 1 2941 
O88737 1 1919 
O88737 1 1407 
O88737 1 2945 
O88737 1 1404 
O88737 1 387 
O88737 1 1417 
O88737 1 1418 




O88737 1 1942 
O88737 1 1943 
O88737 1 1437 
O88737 1 1445 
O88737 1 1962 
O88737 1 1460 
O88737 1 2488 
O88737 1 1464 
O88737 1 2493 
O88737 1 1472 
O88737 1 1987 
O88737 1 1988 
O88737 1 2501 
O88737 1 1990 
O88737 1 1488 
O88737 1 2514 
O88737 1 2524 
O88737 1 2017 
O88737 1 1506 
O88737 1 1510 
O88737 1 1511 
O88737 1 3047 
O88737 1 2027 
O88737 1 1517 
O88737 1 2541 
O88737 1 2029 
O88845 1 (1 of 194,197,198,200) 
O88878 1 (1 of 117,120,125,128,130,132,135,136,137,139) 
O88935 1 (1 of 436,437,438,443) 
O88935 1 (1 of 448,449) 
O88935 1 (1 of 9,11,23,36,39,43,46,48,50) 
O88935 1 518 
O88935 1 71 
O88935 1 70 
O88935 1 262 
O88935 1 618 
O88935 1 650 
O88935 1 523 
O88935 1 332 
O88935 1 526 
O88935 1 664 
O88935 1 432 




O88935 1 87 
O88935 1 55 
O88935 1 568 
O88935 1 94 
O88935 1 575 
P04627 1 10 
P05064 1 354 
P06537 1 (1 of 268,271,274,275,277,278) 
P06537 1 43 
P06837 1 (1 of 86,88,89,95,96) 
P06837 1 166 
P08046 1 117 
P08113 1 64 
P08113 1 219 
P08414 1 (1 of 5,8,11,12,15,16,18,20,21,33) 
P08551 1 (1 of 402,404,405) 
P08551 1 38 
P08551 1 41 
P08551 1 48 
P08551 1 27 
P08551 1 414 
P08553 1 845 
P08553 1 430 
P08553 1 47 
P08553 1 49 
P08553 1 50 
P08553 1 28 
P09055 1 (1 of 586,588,593,596,602) 
P0C090 1 (1 of 789,792,793,794,799,801,803,806,810) 
P0C090 1 (1 of 492,493,497,499,501,502,504) 
P0C090 2 (2 of 552,555,560,561,565,569,573) 
P0C090 1 907 
P0C090 1 592 
P0C090 1 754 
P0C090 1 471 
P0C090 1 472 
P0C090 1 895 
P0C7T6 1 (1 of 201,202,203,205,206,215,217) 
P0C7T6 2 (1 of 29,30,31,33,34,37,39,40,43,46)&(2 of 29,30,31,33) 
P0C7T6 1 22 
P0C7T6 1 23 
P0CG14 1 (1 of 291,293,295,297,300,305,309,311) 




P11531 1 (1 of 2425,2426,2427,2430,2432,2434,2436,2439,2441,2444) 
P11881 1 2500 
P12960 1 (1 of 468,475) 
P14231 1 120 
P14602 1 (1 of 63,71,78) 
P14869 1 (1 of 273,285,286) 
P14873 1 (1 of 1702,1706,1708,1714,1718,1720,1725,1727,1728,1729,1730,1733,1735,1739,1745,1747) 
P14873 1 1778 
P14873 1 794 
P14873 1 2028 
P16951 1 (1 of 287,289,292,296,302,303,304,305,307,310,314,315,318,321,322) 
P16951 1 272 
P17426 1 (1 of 635,636,637,647,649,650,652,653,655,657) 
P19246 1 54 
P20029 1 (1 of 638,644,649,650) 
P20357 1 (1 of 496,500,506,511,512) 
P20357 1 (1 of 1057,1064) 
P20357 1 (1 of 1176,1186,1191,1192) 
P20357 1 (1 of 1289,1292,1299,1303,1304,1305,1310,1312,1314) 
P20357 1 777 
P20357 1 1034 
P20357 1 361 
P20357 1 239 
P20357 1 787 
P20357 1 472 
P25444 1 (1 of 281,285,292,293) 
P27612 1 (1 of 481,482,485,487,490,495) 
P27671 1 807 
P28652 1 (1 of 331,333,334) 
P28652 1 (1 of 306,307,311) 
P28652 1 320 
P28652 1 328 
P28652 1 325 
P28652 1 327 
P29341 1 531 
P31361 1 (1 of 3,6,14,17,20,24,54,58,59) 
P32211 1 (1 of 310,313,314,315,319,320,327) 
P35436 1 (1 of 974,976,987,991,995,1001,1002,1004) 
P40124 1 242 
P41969 1 278 
P42128 1 (1 of 515,516,517,520,528,531,532,534,535,538,541) 
P42128 1 663 




P42227 1 717 
P43300 1 (1 of 370,372,373,376,378,385) 
P43300 1 384 
P43352 1 (1 of 309,310,313,316) 
P45481 1 (1 of 316,317,319,320,325,329,330,336,341,344) 
P45481 1 2360 
P45481 1 147 
P46660 1 (1 of 46,50,51) 
P46660 1 72 
P46660 1 440 
P46660 1 55 
P46935 1 (1 of 370,371,375,376,377,380,381) 
P47708 1 346 
P47941 1 (1 of 195,197,212,213,214,218,221,222,232,233) 
P48318 1 (1 of 3,4,5,7,10,11,12,20,21,26,27,30,39) 
P48432 1 (1 of 252,253,259) 
P48432 1 248 
P48432 1 258 
P48678 1 644 
P49442 1 394 
P50516 1 257 
P50516 1 260 
P51141 1 (1 of 389,390,391,392,393,395,396,397,410) 
P51141 1 383 
P52963 1 (1 of 620,629) 
P53783 1 332 





P55194 1 (1 of 491,492,496,503,509,510,514) 
P55194 1 519 
P56546 1 414 
P56671 1 (1 of 141,155,162,168,169,170,178) 
P58389 1 322 
P58871 1 260 
P58929 1 404 
P59111 1 (1 of 1089,1090,1091) 
P59114 1 (1 of 135,137,138,140,143,144,146,150,152) 
P59326 1 (1 of 284,289,291,319) 
P59326 1 196 








P59764 1 1806 
P59823 1 (1 of 567,575,585,587,590,595,596,597,601) 
P60469 1 (1 of 1188,1191,1193) 
P60469 1 639 
P60469 1 519 
P60879 1 115 
P60904 1 (1 of 167,169,177,179,181,182,185,188,191,194) 
P62484 1 297 
P62500 1 444 
P62908 1 242 
P63248 1 (1 of 59,60,61,64,74,76) 
P63248 1 29 
P63250 1 (1 of 16,17,18,19,20,22) 
P70121 2 (2 of 217,224,226,227,228,232,234,235,236,237,238) 
P70232 1 (1 of 823,824) 
P70257 1 (1 of 452,453,454,455,463,466,468,471,472,475,476) 
P70257 1 272 
P70257 1 470 
P70326 1 352 
P70326 1 345 
P70326 1 348 
P70365 1 (1 of 642,644) 
P70365 1 401 
P70365 1 643 
P70392 1 (1 of 760,762,763,764,765,766,767,769,770,771,772,774,778,783,788) 
P70670 1 240 
P81122 1 (1 of 924,933,936,937,938,939,942,944,945,948,949,952,954,957,958,959,961) 
P81122 1 (1 of 1137,1138,1140,1142,1143,1144,1145,1146,1148,1151,1153,1158) 
P83510 1 (1 of 914,915,917,922,930,931,932) 
P83510 1 577 
P83510 1 539 
P83741 2 (2 of 1806,1808,1817,1818,1820,1821,1822,1823,1825) 
P83741 3 (3 of 1655,1658,1661,1662,1663,1665,1669,1671,1674,1680,1681,1683,1687,1688,1689,1694) 
P83741 1 (1 of 2281,2291,2292,2297,2298,2301,2304,2306,2307,2312) 
P83741 1 (1 of 2365,2367,2372,2377) 
P83741 1 (1 of 1270,1271,1274,1280,1281,1282,1290,1292,1294,1295,1297,1303) 
P83741 1 (1 of 1229,1230,1239,1240,1241,1243,1248) 
P83741 1 1860 
P83741 1 2376 
P83741 1 1801 
P83741 1 1803 
P83741 1 1841 




P83741 1 1844 
P83741 1 1845 
P83741 1 1945 
P97300 1 230 
P97379 1 235 
P97379 1 245 
P97460 1 (1 of 447,458,462,465,469,470,472,476) 
P97765 1 (1 of 229,244,245) 
P97772 1 (1 of 1159,1162,1164,1165,1168,1169,1172,1174,1178,1183,1186) 
P97789 1 (1 of 1660,1664,1668,1669,1670,1671,1672,1679,1680,1684,1686,1692) 
P97855 1 (1 of 260,266,268) 
P99027 1 (1 of 64,74,79,86) 
Q00422 1 (1 of 254,264,275,280,282,283) 
Q01705 1 900 
Q02248 1 (1 of 102,111,112,120) 
Q02248 1 23 
Q02614 1 233 
Q03717 1 576 
Q05186 1 49 
Q05512 1 (1 of 408,409,418,419,421,423) 
Q05512 1 (1 of 502,504,508) 
Q08274 1 (1 of 453,457,461,465,467,468) 
Q08874 1 (1 of 93,95,101,104,105,108,110) 
Q08890 1 284 
Q09XV5 1 (1 of 168,169,171,173,184,185,186,194) 
Q09XV5 1 2524 
Q0KL02 1 (1 of 2355,2356,2359,2360) 
Q0P5V2 1 (1 of 352,356,358,360,365,371) 
Q0VGT3 1 (1 of 251,252,254,255,256,257,258,260,262,265,266,278,281,282) 
Q0VGT3 1 (1 of 417,421,422,423,425,426,427,433,436) 
Q0VGT3 1 (1 of 349,350,351) 
Q0VGT3 1 (1 of 687,691,692,697,699,707,708,709) 
Q0VGT3 1 301 
Q0VGY8 1 (1 of 1673,1674,1675,1676,1677,1678,1680,1681,1682,1683,1684,1686) 
Q0VGY8 1 (1 of 1554,1555,1561) 
Q0VGY8 1 (1 of 288,299,300,302) 
Q148V7 1 169 
Q148V7 1 468 
Q148V7 1 469 
Q149F3 1 (1 of 69,71,78,83,90,92,93,97) 
Q14AX6 2 (2 of 588,589,590,592,593,595,597,604) 
Q14AX6 1 1359 




Q14BB9 1 (1 of 107,123,124,125) 
Q14BI1 1 319 
Q14CH0 1 616 
Q1HKZ5 1 566 
Q1HKZ5 1 559 
Q2M3X8 1 337 
Q2NL51 2 (2 of 448,454,457,458,459,463,464,468,472,479,482,483,485,488,489,490) 
Q2PFD7 1 245 
Q2WF71 1 (1 of 669,676,677,681) 
Q3TBU7 1 193 
Q3TN34 1 (1 of 428,431,437,444,445) 
Q3TN34 1 456 
Q3TN34 1 489 
Q3TN34 1 522 
Q3TN85 1 (1 of 123,125,128,129,130,131,132,133,136,138,140,143,144,146,147) 
Q3TN85 1 (1 of 92,94,100,101,109,112,117,118) 
Q3U0V1 1 96 
Q3U0V1 1 192 
Q3U1N2 2 (2 of 117,138,142,144,146,147,151) 
Q3U3C9 1 213 
Q3U3E2 1 205 
Q3UCQ1 1 (1 of 539,540,543,547,549) 
Q3UDC3 1 (1 of 415,416) 
Q3UH45 1 401 
Q3UH60 1 222 
Q3UH68 1 (1 of 950,951,952,953) 
Q3UH68 1 (1 of 510,511,515,518,521,523,525) 
Q3UH68 1 (1 of 500,502,505,506) 
Q3UHC0 3 (3 of 754,755,756,757,761,763,764,766,767,768,769,770,771) 
Q3UHC0 1 (1 of 1443,1444,1446,1447,1451,1453,1456,1458) 
Q3UHC0 1 (1 of 1602,1603,1604,1607,1608,1609,1612) 
Q3UHC1 1 (1 of 651,656,662,664,666,668) 
Q3UHD9 1 (1 of 79,80,81,82,85,94,99) 
Q3UHD9 1 (1 of 270,274,281,284,288,297,298,300,302,303,304,314) 
Q3UHF7 1 (1 of 1308,1320) 
Q3UHF7 1 (1 of 1163,1164,1167,1168) 
Q3UHF7 1 (1 of 1501,1502,1503,1505,1506,1508,1510,1511,1512,1517,1519) 
Q3UHF7 1 (1 of 1293,1294,1296,1298) 
Q3UHF7 1 (1 of 2013,2014) 
Q3UHF7 1 (1 of 2141,2148) 
Q3UHF7 1 (1 of 2366,2367) 
Q3UHF7 1 416 




Q3UHF7 1 420 
Q3UHF7 1 548 
Q3UHF7 1 1316 
Q3UHF7 1 392 
Q3UHF7 1 339 
Q3UHF7 1 916 
Q3UHF7 1 2005 
Q3UHF7 1 2004 
Q3UHF7 1 1271 
Q3UHF7 1 251 
Q3UHG7 1 20 
Q3UHJ0 1 (1 of 729,732,740,746,747,749,751,754) 
Q3UHJ0 1 (1 of 679,680,685,688,691,692,702) 
Q3UHJ0 1 (1 of 441,445,448,450,455,460) 
Q3UHJ0 1 416 
Q3UHJ0 1 578 
Q3UHJ0 1 360 
Q3UHJ0 1 648 
Q3UHJ0 1 572 
Q3UHJ0 1 638 
Q3UHK8 1 (1 of 1614,1621,1623,1626,1627,1628) 
Q3UHK8 1 (1 of 1592,1594,1595,1596,1597,1600,1601,1604,1605,1606,1609,1610) 
Q3UHK8 1 1622 
Q3UHL1 1 (1 of 446,449,452,453) 
Q3UHL1 1 (1 of 470,480,481,487,493,494) 
Q3UHL1 1 457 
Q3UHL1 1 459 
Q3UHT7 1 (1 of 43,45,51,58,59,65,72,73,74) 
Q3UHT7 1 381 
Q3UHT7 1 7 
Q3UNH4 1 (1 of 315,316,321,323) 
Q3UNH4 1 (1 of 780,786) 
Q3UNH4 1 (1 of 263,267,268,270,275,276,284,295,297,299,300) 
Q3UNH4 1 607 
Q3UNH4 1 343 
Q3UPH1 1 (1 of 162,170,174,176,177) 
Q3UPH1 1 189 
Q3UPH1 1 157 
Q3UQN2 1 (1 of 487,491,492,494,495,499) 
Q3URQ4 1 (1 of 10,18,27,31,33,34,35,39) 
Q3UVX5 1 (1 of 1065,1069,1073,1077,1078,1087,1091,1092) 
Q3UVX5 1 (1 of 1046,1047,1048,1049,1052) 




Q3UZB0 1 106 
Q3UZG4 1 100 
Q3ZB59 1 326 





Q4ACU6 1 (1 of 1320,1321,1331,1332,1335,1338,1342,1343,1351,1355,1362) 
Q4ACU6 1 (1 of 818,831,836,838) 
Q4FE56 1 2551 
Q4JIM5 1 (1 of 614,615,618,619,621) 
Q4JIM5 1 (1 of 860,872,874,876) 
Q4VAA2 1 (1 of 167,178,180,182,189) 
Q501J7 1 (1 of 192,193,194,195,197,198,199,201,202,205,206,209,212) 
Q501J7 1 190 
Q501J7 1 231 
Q52KI8 1 885 
Q571G4 1 (1 of 106,109,111) 
Q571G4 1 261 
Q571G4 1 238 
Q571K4 1 408 
Q59J78 1 (1 of 143,147,148,149) 
Q5DTX6 1 (1 of 59,60,63,67,69) 
Q5F2E7 1 (1 of 369,373,374,376,378,379,381,382,383,384,385,386,389,391,393,394,395) 
Q5F2E7 1 (1 of 407,409,410,412,414,422,425,429,436,437,441,443,446,447,449,451,457,460) 
Q5F2E7 1 380 
Q5FWH2 1 459 
Q5HZI2 1 (1 of 55,58,69,70,71,77) 
Q5QNQ6 1 140 
Q5RJH6 1 (1 of 948,949) 
Q5SFM8 1 (1 of 465,466,471,472,474,475,477,483,495,497,498,499) 
Q5SFM8 1 546 
Q5SPL2 1 472 
Q5SPX8 1 (1 of 479,483,486,489,501) 
Q5SQX6 1 1251 
Q5SQX6 1 1252 
Q5SRX1 1 (1 of 188,191,193,194,199,201,202,209,211,215,218) 
Q5SRX1 1 177 
Q5SRX1 1 187 
Q5SSM3 1 (1 of 661,663,671,674,676,678,681,682,684,689,695,698,702,705,711,713,716,717,718) 
Q5SUE8 1 199 
Q5SUH7 1 (1 of 265,268,270,271,272,273) 
Q5SUH7 1 622 




Q5SWZ5 1 (1 of 178,179,180,181,184,185,187,188,189,190,193,199,200) 
Q5SX19 1 (1 of 178,181) 
Q5SXC4 1 (1 of 108,110,111,123,124) 
Q5SXC4 1 117 
Q5SXC4 1 118 
Q5XJV5 1 (1 of 1714,1715,1719,1724,1725,1726,1733) 
Q5XJV5 1 (1 of 1777,1780,1782,1783,1787,1788,1792,1795,1796,1799,1803,1805,1808,1809) 
Q5XJV5 1 1646 
Q5XJV5 1 1551 
Q60598 1 345 
Q60737 1 (1 of 344,347,348,353,356,357,360,362,370) 
Q60737 1 378 
Q60829 1 42 
Q60865 1 (1 of 418,428,434,435,436,437,441,443,450,453) 
Q60865 1 (1 of 468,470,473,476,477,479,480,481,486,495,496) 
Q60902 1 (1 of 850,851,852,853,859,860) 
Q60987 1 (1 of 432,433,434,435,436,441,442,447) 
Q61001 1 (1 of 960,961,963,966,969,977,978,984) 
Q61001 1 (1 of 2862,2867,2887,2890) 
Q61001 1 (1 of 2396,2397) 
Q61001 1 (1 of 2422,2427) 
Q61097 2 (2 of 429,430,431,434,435,436,437,438,439,440,442,443,449,450,451,454,455,457,458,463) 
Q61140 1 (1 of 81,88,101,104,109,115,123,125) 
Q61191 2 (2 of 427,441,446,453,457,458,459,460,466,470,471,473,476) 
Q61191 2 (2 of 726,727,733,734,737,738,739) 
Q61191 1 (1 of 1055,1058,1061,1062) 
Q61191 1 (1 of 666,669,674,678) 
Q61191 2 (1 of 612,619,620,622,623,627,628,629,634)&(2 of 612,619,620,622,623,627,628,629) 
Q61191 1 (1 of 586,587) 
Q61191 1 (1 of 1494,1495,1497,1499,1500,1506,1516) 
Q61191 1 771 
Q61191 1 515 
Q61191 1 518 
Q61191 1 775 
Q61191 1 779 
Q61191 1 651 
Q61191 1 652 
Q61191 1 787 
Q61191 1 405 
Q61191 1 800 
Q61191 1 806 
Q61191 1 808 




Q61191 1 694 
Q61191 1 831 
Q61191 1 703 
Q61191 1 579 
Q61191 1 1224 
Q61191 1 588 
Q61191 1 1238 
Q61191 1 1241 
Q61191 1 603 
Q61191 1 861 
Q61191 1 1246 
Q61191 1 480 
Q61191 1 490 
Q61191 1 495 
Q61191 1 1139 
Q61191 1 1148 
Q61191 1 638 
Q61315 1 (1 of 859,864,865,870,871,872) 
Q61315 1 (1 of 2708,2711,2713,2717,2722) 
Q61315 1 923 
Q61548 1 (1 of 600,605,606,608,613,621,625,627) 
Q61548 1 (1 of 305,306,312,313) 
Q61548 1 (1 of 321,324,325,333,335,341,342) 
Q61548 1 624 
Q61548 1 309 
Q61548 1 310 
Q61548 1 303 
Q61644 1 (1 of 334,335,336) 
Q61644 1 329 
Q61818 1 (1 of 1714,1716,1717,1718,1723,1724,1726,1728,1729,1731) 
Q61827 1 134 
Q62073 1 421 
Q62073 1 383 
Q62261 1 (1 of 2327,2330,2331,2334,2336,2337,2339,2340) 
Q62261 1 2323 
Q62277 1 (1 of 268,284,308,309,311) 
Q62311 1 (1 of 480,481,483,485) 
Q62311 1 (1 of 586,587,589,590,594,595,600,602) 
Q62417 1 (1 of 105,109,111,118,125,126,127,131,133,139,140,143,144,148,149,150,155) 
Q62417 1 1200 
Q62417 1 1199 
Q62418 1 (1 of 279,280) 




Q62418 1 314 
Q62418 1 278 
Q62419 1 284 
Q62440 1 (1 of 282,284,287,288,290,291,293,294,295,296) 
Q62441 1 (1 of 292,295,298,299,300,301,302,304,305) 
Q62441 1 330 
Q62448 1 505 
Q62504 1 (1 of 2879,2883,2893,2895,2896,2899,2903) 
Q62504 1 (1 of 3114,3119,3120,3127) 
Q62504 1 2520 
Q62523 1 (1 of 294,295,297,298,300,305,307) 
Q62523 1 170 
Q62523 1 237 
Q63943 1 (1 of 133,134,145,149,152,153,157,160,161,162,165,167,170,171,172,174) 
Q64092 1 (1 of 545,550,551,553,557) 
Q640Q5 1 (1 of 231,235,237) 
Q640R3 1 (1 of 333,334,335,343,345) 
Q64213 1 (1 of 331,332,333,337,338) 
Q64213 1 328 
Q64213 1 315 
Q64213 1 38 
Q64213 1 31 
Q64332 1 (1 of 422,426,432,433,438,440,446,447) 
Q64332 1 (1 of 480,483,486,487,488,489,490,491,492,493,494,495,496,497,498,499,508,509,510,515,516,517,518,520) 
Q64332 1 98 
Q64332 1 44 
Q64332 1 77 
Q64332 1 50 
Q64332 1 24 
Q64332 1 95 
Q64336 1 647 
Q64700 1 (1 of 656,658,659,661,662) 
Q68ED7 2 (2 of 411,413,416,417,421,423,429,436,437) 
Q68FE6 2 





Q68FF6 1 570 
Q68FG2 1 2354 
Q68FG2 1 2101 
Q68FG2 1 2134 
Q68FG2 1 2359 
Q68FH0 1 (1 of 238,239,242,246,248,250,252,258,261,262,263,264) 




Q68FH0 1 (1 of 197,202) 
Q68FH0 1 225 
Q68FH0 1 226 
Q68FH0 1 1087 
Q69ZA1 2 (2 of 1278,1285,1286,1287,1288,1289,1291) 
Q69ZI1 1 512 
Q69ZI1 1 524 
Q69ZI1 1 527 
Q69ZR2 1 (1 of 1481,1482,1485,1490,1492,1493,1497,1498,1500,1503) 
Q69ZR2 1 1359 
Q69ZS8 1 (1 of 41,49,55,56,58,63,67,71) 
Q69ZW3 1 764 
Q69ZX8 1 (1 of 418,419) 
Q69ZX8 1 (1 of 276,277,279,280,282,286,287,290) 
Q69ZX8 1 423 
Q69ZX8 1 580 
Q69ZX8 1 534 
Q69ZX8 1 383 
Q6A037 1 (1 of 560,571,573) 
Q6A058 1 328 
Q6A058 1 93 
Q6A058 1 366 
Q6A070 1 (1 of 1120,1123,1124,1126,1131,1132,1135,1138,1144,1149) 
Q6A070 1 (1 of 1354,1356) 
Q6A0A2 1 632 
Q6A0A2 1 51 
Q6AXB7 1 (1 of 325,336,337,340,343) 
Q6DFV5 1 1668 
Q6DID3 1 (1 of 734,739,741,745,749,750,761) 
Q6KCD5 1 (1 of 1433,1437) 
Q6KCD5 1 160 
Q6NS60 1 387 
Q6NSW3 1 (1 of 1244,1256,1263) 
Q6NSW3 1 405 
Q6NXI6 1 (1 of 432,438,441,442,452,453,457,459,461) 
Q6NXI6 1 (1 of 992,995,996,998,999,1009,1010) 
Q6NXI6 1 (1 of 547,549,551,559,560,564,566,573,576,577,579,580,581,583,586,587,588,590) 
Q6NXI6 1 616 
Q6NXI6 1 417 
Q6NXI6 1 418 
Q6NXJ0 1 531 
Q6NZN0 1 696 




Q6P9N8 1 895 
Q6P9N8 1 902 
Q6P9N8 1 798 
Q6P9Q6 1 (1 of 306,310,315,317,319,325) 
Q6PAJ1 1 150 
Q6PAL7 1 (1 of 1574,1588,1590,1592,1593) 
Q6PAL7 1 (1 of 1070,1071,1073,1076,1079,1080,1081,1082,1083,1084,1088) 
Q6PB44 1 (1 of 818,827,828) 
Q6PB44 1 (1 of 836,837,844,845,861,868,875) 
Q6PB44 1 1552 
Q6PB44 1 881 
Q6PB75 1 420 
Q6PCX9 1 695 
Q6PD26 1 372 
Q6PD28 1 (1 of 9,10,12,13,15,16,20) 
Q6PD31 1 (1 of 444,445,449,452) 
Q6PD31 1 (1 of 827,828,830,832,835,837) 
Q6PDK2 2 (2 of 2738,2740,2741) 
Q6PDK2 1 2359 
Q6PDX6 1 53 
Q6PFD5 1 (1 of 750,753,757,766) 
Q6PFD5 1 (1 of 553,555,558,559,560,562,566,568) 
Q6PFD5 1 579 
Q6PFD5 1 587 
Q6PFD5 1 578 
Q6PFD9 1 (1 of 223,224,230,231,234,235,236,238,242,243,244,245,246,248,251) 
Q6PIJ4 1 (1 of 1138,1143,1146,1147,1148,1151,1154,1158) 
Q6PIJ4 1 (1 of 1025,1027,1030,1031,1036,1037) 
Q6PIJ4 1 1064 
Q6PIJ4 1 838 
Q6PIJ4 1 1172 
Q6PIJ4 1 1270 
Q6QI06 1 (1 of 1216,1218,1221,1223,1224,1225,1226,1229,1230,1232,1233,1234,1236) 
Q6ZPG2 1 328 
Q6ZPJ0 1 174 
Q6ZPJ0 1 175 
Q6ZQ08 1 (1 of 1043,1044,1045,1046) 
Q6ZQ08 1 1040 
Q6ZQ08 1 1041 
Q6ZQ08 1 1050 
Q6ZQ08 1 1037 
Q6ZQ29 1 (1 of 430,443,455,456,457,458,459,460) 




Q6ZQH8 1 1524 
Q7M739 1 1672 
Q7TMY8 1 (1 of 2910,2917,2918,2922,2923,2925,2926,2927,2928) 
Q7TMY8 1 (1 of 3246,3247,3248) 
Q7TMY8 1 (1 of 2619,2632,2633,2635,2636,2640,2642,2643,2646,2649) 
Q7TMY8 1 (1 of 3794,3795,3797,3798,3801,3803,3804) 
Q7TN29 1 197 
Q7TNC6 1 1013 
Q7TPB0 1 (1 of 560,562,563,564,565,567,568,570,571) 
Q7TPB0 1 379 
Q7TPS5 1 (1 of 249,250,259,260,262) 
Q7TQ95 1 (1 of 411,418,421,424) 
Q7TQD2 1 (1 of 15,19) 
Q7TQD2 1 154 
Q7TQD2 1 158 
Q7TQH0 1 (1 of 681,682,683,684,686,687) 
Q7TQH0 1 (1 of 419,421,422,424,428,432,436,437) 
Q7TQH0 1 (1 of 266,267,270,271,273,274,276) 
Q7TQH0 2 (2 of 456,463,465,473,477,478,480,484,485,486,494,496,499) 
Q7TQH0; 
A0A0U1RPL0 1 (1 of 463,465,473,477,478,480,484,485,486) 
Q7TQH0; 
A0A0U1RPL0 1 (1 of 681,682) 
Q7TQH0; 
A0A0U1RPL0 1 683 
Q7TQH0; 
A0A0U1RPL0 1 686 
Q7TSI3 1 (1 of 691,692,694,695,698,700,701,707,709,711,714,721,726) 
Q7TSJ2 1 (1 of 79,86) 
Q7TSJ2 1 (1 of 34,37,58) 
Q7TSJ2 1 (1 of 774,776,778,779) 
Q7TSJ2 1 705 
Q7TSJ2 1 386 
Q7TSJ2 1 294 
Q7TSJ2 1 425 
Q7TSJ2 1 110 
Q7TSJ2 1 340 
Q7TSJ2 1 182 
Q7TSJ2 1 246 
Q7TT18 1 (1 of 1022,1025,1026,1027,1028,1030,1031,1032,1036) 
Q7TT18 2 (2 of 740,746,749,753,755,756,758,761,762,763,767,768) 
Q7TT50 1 (1 of 984,986,988,991,992,993) 
Q80TE4 1 1533 
Q80TE4 1 1079 




Q80TE7 1 (1 of 864,865,867,868,869) 
Q80TI1 1 (1 of 1146,1153,1156) 
Q80TR1 1 (1 of 1439,1448,1464,1465) 
Q80TZ3 1 (1 of 605,623,627,628,629,631,632,639) 
Q80TZ3 1 593 
Q80TZ3 1 588 
Q80TZ3 1 733 
Q80TZ3 1 591 
Q80TZ9 1 (1 of 1223,1229,1230,1242) 
Q80U23 1 24 
Q80U40 1 681 
Q80U40 1 682 
Q80U40 1 683 
Q80U56 1 620 
Q80U72 1 (1 of 936,939,943,948,949,951,955,959,961,962) 
Q80U78 1 (1 of 798,800,801,803,804,807,809,810,811,814,815,816) 
Q80U78 1 212 
Q80U93 1 (1 of 1566,1567,1569,1573,1574,1580,1586) 
Q80U93 1 (1 of 612,614,618,621,626,627,628,629) 
Q80U93 1 (1 of 430,431,433,437,439,440,452,454,455,461,465,466,467,472,476,478,481,485,486) 
Q80U93 1 (1 of 1257,1263,1272,1279,1282,1285,1286,1289,1290,1291,1293,1296,1300,1303,1304,1305) 
Q80U93 1 (1 of 1109,1115,1116,1118,1120,1121) 
Q80U93 1 (1 of 1204,1206,1209,1210,1211,1213) 
Q80U93 1 (1 of 1505,1506,1518,1520,1521,1524,1526,1527,1529,1536,1537,1540,1543,1544) 
Q80U93 1 (1 of 1336,1337,1342,1345,1347) 
Q80U93 1 513 
Q80U93 1 1314 
Q80U93 1 1091 
Q80U93 1 1316 
Q80U93 1 1576 
Q80U93 1 652 
Q80U93 1 1557 
Q80U93 1 504 
Q80U93 1 506 
Q80U93 1 507 
Q80UE4 1 (1 of 708,716,718,719,721,723,724,725,726,727,728,731) 
Q80UE4 1 713 
Q80UG5 1 182 
Q80UY2 1 (1 of 258,260,261,262,264,265,266,268,271,273,276,279,282,289,294) 
Q80VC9 1 (1 of 946,947,952,958,962,963) 
Q80VJ2 1 (1 of 66,67,78,79) 
Q80VP1 1 (1 of 469,472,485,488,493,497) 




Q80VP1 1 416 





Q80X50 1 (1 of 388,400,402,404,405,406,407,408,409,414,415,416,418,420) 
Q80X50 1 (1 of 480,481,482,487,490,491,495,496,497) 
Q80X50 1 297 
Q80X50 1 473 
Q80X50 1 879 
Q80X50 1 464 
Q80X50 1 625 
Q80X50 1 466 
Q80X50 1 345 
Q80X80 1 450 
Q80X80 1 420 
Q80X80 1 447 
Q80XI3 1 (1 of 176,177,179,186,192,198,201,207,208,211,214) 
Q80XI3 1 (1 of 314,316,317,319,322,325,327,330) 
Q80XI3 1 265 
Q80XK6 1 (1 of 239,240,244,245,250) 
Q80XP9 1 (1 of 566,567,568,571,578,580,581,582,585,589,590,593,594,595,596) 
Q80XP9 1 (1 of 1373,1377,1392,1394,1395,1399,1400,1402,1403,1406) 
Q80YA3 1 (1 of 415,416,418,421,424,427,435,437,439,440,441,442,445,447,451,453,458) 
Q80YA3 1 360 
Q80YA9 1 (1 of 731,732,733,735,736,738,740,741) 
Q80YA9 1 328 
Q80YA9 1 329 
Q80YA9 1 750 
Q80YF9 1 (1 of 1039,1042,1045,1048,1051,1054,1055) 
Q80YR4 1 (1 of 560,563,564,568,569,575,578,579) 
Q80ZX0 1 (1 of 111,118,122,129,131,133,135,136,138,142,143) 
Q80ZX0 1 299 
Q811P8 1 (1 of 1433,1434,1439,1440,1441,1442,1446,1450,1451,1453,1465) 
Q811P8 1 920 
Q811P8 1 1027 
Q811P8 1 1918 
Q8BFU3 1 (1 of 612,613,614,619) 
Q8BFU3 1 132 
Q8BFW7 1 (1 of 179,181,195,199,210,212,213,215,216,217,218) 
Q8BFW7 1 11 
Q8BG40 1 461 
Q8BG75 1 328 




Q8BG87 1 (1 of 495,496,497,503,506) 
Q8BG95 1 542 
Q8BGD5 1 794 
Q8BGZ2 1 97 
Q8BH48 1 150 
Q8BH93 1 (1 of 2,6,15,16,23,25) 
Q8BHL3 2 (2 of 66,67,69,70,72,73,75,76,78,79,80,81,86,90) 
Q8BHL3 1 120 
Q8BHL3 1 162 
Q8BHL3 1 43 
Q8BHL3 1 44 
Q8BHR8 1 (1 of 171,176,177,178,179) 
Q8BHR8 1 288 
Q8BHR8 1 289 
Q8BI84 1 1720 
Q8BI84 1 1718 
Q8BJ05 1 (1 of 251,252,255) 
Q8BJ05 1 (1 of 369,370,373) 
Q8BJ05 1 360 
Q8BJ42 1 584 
Q8BJ42 1 811 
Q8BJ42 1 594 
Q8BJ42 1 595 
Q8BJ42 1 633 
Q8BJH1 1 184 
Q8BJH1 1 194 
Q8BJH1 1 237 
Q8BJM5 2 (2 of 141,146,151,154) 
Q8BJM5 1 371 
Q8BJM5 1 374 
Q8BJY1 1 (1 of 486,497,498) 
Q8BKP1 1 103 
Q8BLK9 1 (1 of 567,576,577,580,581,583,585) 
Q8BMB0 1 (1 of 226,228,231,232,234,235,237,238,239) 
Q8BMB0 1 (1 of 498,499,500,502,505) 
Q8BMB0 1 (1 of 1039,1047,1050,1051,1053) 
Q8BMB0 1 192 
Q8BMB0 1 200 
Q8BMB0 1 521 
Q8BMB0 1 1069 
Q8BMB0 1 247 
Q8BMC3 1 (1 of 17,18) 




Q8BNW9 2 (2 of 395,397,399) 
Q8BNW9 1 400 
Q8BPN8 1 (1 of 1943,1947,1952,1955,1956,1957,1962,1967) 
Q8BPN8 1 1941 
Q8BPN8 1 949 
Q8BRM2 1 (1 of 80,82,87,90,92,93,94,95) 
Q8BRT1 1 (1 of 475,476,477,480,481,483,484) 
Q8BRT1 1 352 
Q8BSS9 1 (1 of 702,703,705,707,709,711,712,715,716,717,720,723,724) 
Q8BSS9 1 552 
Q8BSS9 1 547 
Q8BSS9 1 1254 
Q8BT14 1 (1 of 550,551,555,557,558,560,568,569,572,573) 
Q8BT14 1 331 
Q8BT14 1 316 
Q8BTI8 1 2200 
Q8BTI8 1 2205 
Q8BTI8 1 2199 
Q8BTJ4 1 281 
Q8BTJ4 1 261 
Q8BU11 1 (1 of 405,406,407,409,413,420) 
Q8BU25 1 267 
Q8BUV3 1 (1 of 222,226,227,230,231,232,233,236) 
Q8BUV3 1 250 
Q8BUV3 1 260 
Q8BW96 1 352 
Q8BWT5 1 (1 of 134,135,136,137,138,139,141,142,143,144,145) 
Q8BWW4 1 (1 of 569,578,579,581,583,586,590,592,595,596) 
Q8BX02 1 421 
Q8BXL9 2 (2 of 162,169,170,175,176,177,178,179,180,181,182,183,186,187,188,189) 
Q8BYI9 1 (1 of 580,583,586,587,588,591,592) 
Q8BYK6 1 (1 of 362,370,372,383,385,387,388) 
Q8BYK6 1 (1 of 207,210,213,214,215,218,219,222,229,230,236,237) 
Q8BYK6 1 201 
Q8BYK6 1 205 
Q8BYK6 1 167 
Q8C0C0 1 (1 of 150,155,159,166,168,172,173,180) 
Q8C0I4 1 (1 of 751,752,755,757) 
Q8C0I4 1 (1 of 150,151) 
Q8C0Q2 1 730 
Q8C0Q2 1 581 
Q8C0T5 1 (1 of 1578,1579) 




Q8C0T5 1 1402 
Q8C0T5 1 1135 
Q8C0T5 1 1400 
Q8C0T5 1 1114 
Q8C0T5 1 1403 
Q8C0T5 1 1404 
Q8C120 1 (1 of 589,593,595,600,601,604,606,609,617,619,621) 
Q8C180 1 (1 of 326,327,328,329,330,331,333,339) 
Q8C2Q3 1 280 
Q8C2Q3 1 244 
Q8C2Q3 1 254 
Q8C2Q3 1 231 
Q8C3W1 1 (1 of 249,252,254,268) 
Q8C483 1 (1 of 530,534) 
Q8C5L3 2 (2 of 99,101,104,108,111,113,114,118,120,123,126,128) 
Q8C5L3 1 155 
Q8C729 1 440 
Q8C729 1 318 
Q8C790 1 298 
Q8C8T7 1 591 
Q8C9B9 2 (2 of 1273,1274,1279,1280,1281,1282,1284,1287,1288,1292,1293,1294,1296,1299,1302,1303) 
Q8CAF4 1 (1 of 732,734,737,740,741,743,744,745,746,747,752,757,759,761,763,764,765) 
Q8CAQ8 2 (2 of 182,184,185,190,191,192) 
Q8CAQ8 1 180 
Q8CAQ8 1 181 
Q8CC35 1 (1 of 863,864,869,875,879,882,884,886,887,890,893,895) 
Q8CC35 1 448 
Q8CC35 1 551 
Q8CC35 1 393 
Q8CC35 1 397 
Q8CC35 1 752 
Q8CC35 1 753 
Q8CC35 1 506 
Q8CC35 1 507 
Q8CCN5 1 806 
Q8CDG3 1 1072 
Q8CDG3 1 1075 
Q8CDJ3 1 (1 of 448,454,456,458,459,462,467,468,469,475,476,480,482,483) 
Q8CF89 1 393 
Q8CF89 1 394 
Q8CFI0 1 482 
Q8CFN5 1 (1 of 140,146,150,151,154,158,162,163,176) 




Q8CG79 1 339 
Q8CGA2 1 146 
Q8CGI1 1 (1 of 719,723,730,731,732,735,737,741,744) 
Q8CGI1 1 709 
Q8CGY8 1 (1 of 3,4,11,12,15) 
Q8CGY8 1 393 
Q8CGZ0 1 (1 of 378,382,383,397,398) 
Q8CGZ0 1 403 
Q8CH77 1 (1 of 617,619,621,625,627,628,630,632) 
Q8CH77 1 543 
Q8CHC4 1 (1 of 963,965,967) 
Q8CHC4 1 1288 
Q8CHC4 1 1081 
Q8CHC4 1 1341 
Q8CHH5 1 (1 of 577,582,584) 
Q8CHH5 1 (1 of 594,596,597,599,601,604) 
Q8CHI8 1 (1 of 2532,2534,2535,2538,2545) 
Q8CHI8 1 (1 of 695,698,699,700,701,702,703,704,709,711,716) 
Q8CHI8 1 (1 of 2594,2595,2596) 
Q8CHI8 1 (1 of 2932,2936,2937,2940) 
Q8CHI8 1 2624 
Q8CHI8 1 2607 
Q8CHP6 1 (1 of 651,653,656,659,671,672) 
Q8CHP6 1 238 
Q8CHS8 1 (1 of 171,172,178,180,181,182,183,184,185,187) 
Q8CHS8 1 174 
Q8CHU3 1 (1 of 369,375,380) 
Q8CHU3 1 358 
Q8CHU3 1 359 
Q8CI08 2 (2 of 480,484,486,488,491,492,495,497,498,499,500,509,515,516,520,522,524) 
Q8CI51 1 115 





Q8JZP2 1 487 
Q8JZS0 1 (1 of 5,7,8,11,16,18,24) 
Q8K004 1 402 
Q8K021 1 (1 of 2,6,22,24,27) 
Q8K021 1 (1 of 312,315,322,323,326,327) 
Q8K021 1 67 
Q8K021 1 59 
Q8K099 1 (1 of 604,605,608) 




Q8K0L9 1 (1 of 461,464,465,472,473) 
Q8K0L9 1 480 
Q8K0L9 1 449 
Q8K0L9 1 268 
Q8K0L9 1 436 
Q8K0L9 1 444 
Q8K0T0 1 275 
Q8K0T0 1 278 
Q8K0U4 1 (1 of 656,661,662,663) 
Q8K0U4 1 20 
Q8K0V4 1 (1 of 425,426,428,429,434,439,441,442,443,446,447,449,450,456,457,465,466,467) 
Q8K1M6 1 (1 of 544,550,558) 
Q8K1S4 1 (1 of 465,469,470,472,473,480) 
Q8K212 2 (1 of 65,66,67,68,69,70,71,72,73)&(2 of 56,57,58,72,73)&(1 of 67,68,69,70,71,72,73,80) 
Q8K212 1 (1 of 758,760,761,768,772,774,777,778,779,782,783,784,787) 
Q8K212 1 64 
Q8K212 1 59 
Q8K310 1 33 
Q8K382 1 (1 of 991,993,1002,1003,1004) 
Q8K3X4 1 (1 of 265,285,287,289,290,293,294,295,296,297,298) 
Q8K3X4 1 (1 of 149,159,162,163,164) 
Q8K3Z9 1 (1 of 582,586,587,588,595,600) 
Q8K3Z9 1 (1 of 604,606,613,621,622,623,624,626) 
Q8K3Z9 3 (3 of 711,713,715,719,720,721,722,725,726,728,729,730,731,735,738,739,740,742) 
Q8K3Z9 1 (1 of 649,650,658,660,664,665,667,668,670) 
Q8K3Z9 1 661 
Q8K3Z9 1 653 
Q8K4I3 1 (1 of 558,559,560,561,562,564,565,567,568,570,571,572) 
Q8K4Q0 1 (1 of 696,700,704,706) 
Q8K558 1 (1 of 244,247,250,253,255,256,261,262,269) 
Q8R001 1 (1 of 207,208,211,215,216,218,221,222) 
Q8R191 1 (1 of 175,178,182,187,200,205,207,210,214,216,219,220,221) 
Q8R1Q8 1 (1 of 412,414,415,419,421,427) 
Q8R3B7 1 360 
Q8R3E3 1 (1 of 389,390,391,394,395,400) 
Q8R3L8 1 (1 of 410,411,412,413,419,420) 
Q8R3V5 1 312 
Q8R3V5 1 293 
Q8R4S0 1 (1 of 47,51,52) 
Q8R550 1 580 
Q8R5H6 1 (1 of 293,295,298,299,301,310) 
Q8VBX6 1 (1 of 342,345,346,347,351,353,354,355,356,357,358,359,360) 




Q8VCF0 1 330 
Q8VCF0 1 307 
Q8VCF0 1 222 
Q8VD37 1 (1 of 503,504,505,506,508,509,510,512,514,517,518,520,523,524) 
Q8VD37 1 423 
Q8VD37 1 420 
Q8VD37 1 255 
Q8VD65 1 (1 of 878,879) 
Q8VD65 1 909 
Q8VDQ8 1 366 
Q8VDZ4 1 386 
Q8VE52 1 (1 of 438,457,461,462,463) 
Q8VHG2 1 755 
Q8VHG2 1 196 
Q8VHR5 1 (1 of 288,289,290) 
Q8VHR5 1 585 
Q8VHR5 1 298 
Q8VHR5 1 495 
Q8VHW2 1 (1 of 374,377) 
Q8VHW2 1 379 
Q8VI33 1 (1 of 202,206,207,208,217,221) 
Q91VX2 1 (1 of 386,392,393,399,401,405,406,414,419,422) 
Q91VX2 1 1020 
Q91VX2 1 469 
Q91W39 1 (1 of 401,404,405,410,416,418,420,426,427) 
Q91W39 1 521 
Q91W39 1 524 
Q91WJ0 1 445 
Q91WJ0 1 439 
Q91X45 1 (1 of 216,218,221,223,224,225,226,228,235,236,242,247,255) 
Q91X51 1 (1 of 216,220,223,224,225,228,244,245,251) 
Q91X58 1 (1 of 157,158,159,160,163,165) 
Q91X58 1 150 
Q91X58 1 167 
Q91XV3 1 (1 of 160,169) 
Q91XV3 1 192 
Q91XV3 1 217 
Q91XV3 1 187 
Q91XV3 1 173 
Q91YD9 1 293 
Q91YE8 1 (1 of 783,784,785,794,797,798) 
Q91YS8 1 (1 of 360,369,370) 




Q91Z67 1 990 
Q91Z69 1 981 
Q91ZZ3 1 58 
Q91ZZ3 1 53 
Q91ZZ3 1 71 
Q922J3 1 (1 of 144,146,149,154,157,158,159,162,164,171,173,174) 
Q922J3 1 150 
Q922Y1 1 192 
Q924A2 1 (1 of 1851,1852,1855,1866) 
Q924A2 1 (1 of 1465,1468,1472,1473,1489,1491) 
Q924A2 2 (2 of 1872,1877,1878,1880,1887,1890,1895,1896) 
Q924A2 1 (1 of 1029,1033,1034) 
Q924A2 1 1907 
Q924A2 1 2044 
Q924S8 1 (1 of 162,165,166) 
Q925J9 1 (1 of 1261,1265,1267,1269,1271,1272,1273,1274,1276,1277,1278,1280,1281,1283,1284,1285,1291,1292) 
Q99JX3 1 (1 of 410,411,413,417,418,421) 
Q99JX3 1 (1 of 366,371,379,380,383,389,390,398,403,404) 
Q99JX3 1 426 
Q99K90 1 456 
Q99KP6 1 (1 of 133,148,149,152,169) 
Q99LD8 1 261 
Q99LD8 1 167 
Q99LI5 1 (1 of 861,862,864,867,870,874,877,881,882) 
Q99LI8 1 300 
Q99LI8 1 295 
Q99P69 1 24 
Q99P72 1 (1 of 686,687,690,694,697) 
Q99P72 1 (1 of 7,8,11,12,13,16) 
Q99P72 1 (1 of 200,202,203,210,215,218,221,223,226,227,229) 
Q99P72 1 (1 of 165,167,171,179,185,186) 
Q99P72 1 113 
Q99P72 1 509 
Q99P72 1 510 
Q9CPR8 1 279 
Q9CQ25 1 (1 of 89,94,98,100,101,102,103,104,106) 
Q9CQU0 1 134 
Q9CQV4 1 (1 of 435,436,440,453,462,463) 
Q9CR95 2 (2 of 218,225,233,238,239,240,246,247,248,256,257,259,260,261,270) 
Q9CR95 1 (1 of 179,181,185) 
Q9CR95 1 202 
Q9CR95 1 162 




Q9CS74 1 640 
Q9CWK8 1 (1 of 93,94,97,101,104,106,107) 
Q9CX80 1 184 
Q9CX80 1 188 
Q9CYZ8 1 360 
Q9CZ62 1 473 
Q9CZW6 1 357 
Q9D032 1 (1 of 374,381,383,385,387) 
Q9D2H6 1 (1 of 357,359,364,370,374,377,378,379,380,382,385) 
Q9D415 1 (1 of 616,631,636,642,643,644,645,646,649,651,652) 
Q9D415 1 535 
Q9D4H9 1 (1 of 132,134,136,140,144,145,148,149,154,155,157,160,161,162,163,164,165,166,171) 
Q9D7N9 1 161 
Q9D824 1 204 
Q9D824 1 229 
Q9DAM7 1 72 
Q9DAM7 1 73 
Q9DAM7 1 76 
Q9DAM7 1 69 
Q9DAU1 1 (1 of 155,156) 
Q9DBF1 1 (1 of 520,521,523,527,528,529) 
Q9DBG5 1 (1 of 69,71,72) 
Q9DBG5 1 128 
Q9DBG5 1 76 
Q9DBN4 1 (1 of 70,76,78,79,83,85,88,90,91) 
Q9DBN4 1 (1 of 171,174,175,177,178,179,183) 
Q9DBR7 1 (1 of 631,645,646,647,648,650,651,652) 
Q9DBR7 1 (1 of 571,572,573) 
Q9DBR7 1 (1 of 374,379,381,385,386,387,388,396,399,401,402,406,408,409) 
Q9DBR7 1 577 
Q9DBR7 1 585 
Q9DBR7 1 589 
Q9DBR7 1 656 
Q9DBR7 1 566 
Q9DBR7 1 759 
Q9DBR7 1 570 
Q9DBR7 1 637 
Q9DBR7 1 575 
Q9DC07 1 (1 of 61,63,64,68) 
Q9DC07 1 113 
Q9DC28 1 (1 of 337,344,347,349,350,352,355,356) 
Q9DC28 1 382 




Q9DCP9 1 (1 of 9,12,26,36,43) 
Q9DCS9 1 (1 of 17,21,24,25,31,34) 
Q9DCT8 1 (1 of 74,82,88) 
Q9EP53 1 1071 
Q9EPN1 2 (2 of 1792,1796,1797,1801,1805,1809,1811,1812,1813,1814,1822) 
Q9EPN1 1 (1 of 1487,1488,1491,1492,1500,1502,1505,1507) 
Q9EPN1 1 (1 of 1202,1203,1204,1208,1209,1211) 
Q9EPN1 1 (1 of 997,999,1001,1004,1006,1011,1012,1014) 
Q9EPN1 1 1637 
Q9EQC8 1 228 
Q9EQF6 1 520 
Q9EQT6 1 (1 of 90,101,104,105,108,113,118,120) 
Q9EQZ7 1 1528 
Q9ERQ3 1 468 
Q9ERU9 1 (1 of 2317,2320,2328,2329,2330,2335,2336,2337,2338,2339,2341,2342) 
Q9ERU9 1 (1 of 1719,1725,1731) 
Q9ERU9 1 (1 of 1304,1306,1307,1308,1313) 
Q9ERU9 1 1138 
Q9ES97 1 (1 of 342,343) 
Q9ES97 1 385 
Q9ES97 1 8 
Q9ES97 1 377 
Q9ES97 1 14 
Q9ES97 1 206 
Q9ES97 1 146 
Q9ES97 1 18 
Q9ES97 1 345 
Q9ES97 1 61 
Q9ES97 1 446 
Q9ESC8 1 85 
Q9ESJ4 1 (1 of 196,200,203,204,206,207,209,210,212,213,214,215,218,221,223,224,226,231,233,235) 
Q9ESJ4 1 249 
Q9ET43 1 241 
Q9ET54 1 (1 of 763,767,769,770,771,773,774,775,776,779,782,784) 
Q9JHC9 1 (1 of 372,374,375,376,380) 
Q9JI44 1 (1 of 415,418,422,424,426,433) 
Q9JI46 1 (1 of 153,158,159,161,162,163,165) 
Q9JIL5 1 (1 of 844,850,851) 
Q9JIL5 1 825 
Q9JKD3 1 (1 of 221,224,226,230,232) 
Q9JKR6 1 (1 of 598,607,612) 
Q9JKR6 1 933 




Q9JKV1 1 220 
Q9JKV1 1 213 
Q9JKV1 1 223 
Q9JL04 1 373 
Q9JL04 1 263 
Q9JL60 1 442 
Q9JLV1 1 (1 of 160,162,163,170) 
Q9JLV1 1 (1 of 372,373,380,382,386,390) 
Q9JM52 1 (1 of 545,546,554,557,559,565,567) 
Q9JM52 1 601 
Q9JMD0 2 (2 of 273,279,282,283,284,285,286,288,289,291,293,295,297,298) 
Q9QWH1 1 (1 of 10,11) 
Q9QXD8 1 (1 of 105,112,113,114,120,123) 
Q9QXE7 1 (1 of 120,122,123,124,127,128) 
Q9QXS6 1 (1 of 331,333,336,337,338,339,340,341,342,343,344) 
Q9QY01 1 (1 of 749,750,751,754,755,756,757,760,763,765) 
Q9QY01 1 613 
Q9QY76 1 144 
Q9QYB5 1 (1 of 402,409,411,414,419,423) 
Q9QYB5 1 (1 of 2,3,5,6,11,12,17) 
Q9QYB8 1 (1 of 396,403,405) 
Q9QYB8 1 (1 of 629,632,636,656,662) 
Q9QYB8 1 533 
Q9QYC0 1 (1 of 480,481,482,483,494) 
Q9QYC0 1 (1 of 408,415,417,420,423,427,429,431) 
Q9QYC0 1 (1 of 558,559) 
Q9QYC0 1 11 
Q9QYC0 1 557 
Q9QYC0 1 17 
Q9QYC0 1 540 
Q9QYC0 1 542 
Q9QYE6 1 158 
Q9QYG0 1 370 
Q9QYH6 1 (1 of 19,23,29,37,42,43,46,50,55,58,59,63) 
Q9QYX7 1 (1 of 3052,3057)&(1 of 3057,3060) 
Q9QYX7 1 (1 of 2697,2702,2707,2710,2711,2714,2720) 
Q9QYX7 1 (1 of 2326,2327,2328,2332,2361,2362,2367) 
Q9QYX7 1 (1 of 2922,2924,2926) 
Q9QYX7 1 (1 of 2279,2280) 
Q9QYX7 2 (1 of 702,703,705,709,711,712,716,717,723,724)&(2 of 702,703,716,717) 
Q9QYX7 1 (1 of 3651,3661,3662,3664,3666,3667,3669,3670,3673,3675) 
Q9QYX7 1 (1 of 2394,2398) 




Q9QYX7 2 (2 of 2727,2729,2731,2732,2735,2736,2738,2740,2749,2750,2755,2756,2757) 
Q9QYX7 1 (1 of 4580,4583,4584,4587,4588,4589,4592,4598,4600,4602) 
Q9QYX7 1 (1 of 3443,3444,3449,3454,3457,3462) 
Q9QYX7 1 (1 of 3763,3765) 
Q9QYX7 1 (1 of 1954,1957,1966,1967,1968,1974,1982,1985,1986,1987,1988) 
Q9QYX7 1 (1 of 4016,4020,4028,4029,4030) 
Q9QYX7 1 (1 of 2068,2072,2073,2082,2085) 
Q9QYX7 1 (1 of 745,746,748,752,755,757,761) 
Q9QYX7 1 (1 of 4149,4150,4151,4152,4153,4154,4159,4160) 
Q9QYX7 1 (1 of 4265,4268,4269,4273,4275) 
Q9QYX7 1 (1 of 4830,4831,4835) 
Q9QYX7 1 (1 of 3947,3948,3951,3952,3955,3956,3958,3961,3970,3971) 
Q9QYX7 1 (1 of 2191,2199,2206,2208,2210,2213,2222,2224,2225,2230) 
Q9QYX7 1 2050 
Q9QYX7 1 2948 
Q9QYX7 1 518 
Q9QYX7 1 2315 
Q9QYX7 1 2960 
Q9QYX7 1 2961 
Q9QYX7 1 2836 
Q9QYX7 1 661 
Q9QYX7 1 2839 
Q9QYX7 1 2456 
Q9QYX7 1 2455 
Q9QYX7 1 2969 
Q9QYX7 1 2971 
Q9QYX7 1 2972 
Q9QYX7 1 2717 
Q9QYX7 1 3991 
Q9QYX7 1 2968 
Q9QYX7 1 2845 
Q9QYX7 1 2843 
Q9QYX7 1 1826 
Q9QYX7 1 2978 
Q9QYX7 1 2722 
Q9QYX7 1 2983 
Q9QYX7 1 2472 
Q9QYX7 1 4137 
Q9QYX7 1 2476 
Q9QYX7 1 2988 
Q9QYX7 1 3630 
Q9QYX7 1 2481 




Q9QYX7 1 4146 
Q9QYX7 1 3895 
Q9QYX7 1 3770 
Q9QYX7 1 2491 
Q9QYX7 1 3903 
Q9QYX7 1 3904 
Q9QYX7 1 2881 
Q9QYX7 1 2626 
Q9QYX7 1 707 
Q9QYX7 1 2889 
Q9QYX7 1 2890 
Q9QYX7 1 2382 
Q9QYX7 1 3920 
Q9QYX7 1 3921 
Q9QYX7 1 2386 
Q9QYX7 1 2517 
Q9QYX7 1 856 
Q9QYX7 1 4313 
Q9QYX7 1 2268 
Q9QYX7 1 733 
Q9QYX7 1 864 
Q9QYX7 1 2789 
Q9QYX7 1 2664 
Q9QYX7 1 2793 
Q9QYX7 1 3436 
Q9QYX7 1 3053 
Q9QYX7 1 2669 
Q9QYX7 1 3058 
Q9QYX7 1 2291 
Q9QYX7 1 4212 
Q9QYX7 1 502 
Q9QYX7 1 3065 
Q9QYX7 1 2686 
Q9QYY0 1 (1 of 365,367,369,371,372,382,384) 
Q9QYY0 1 (1 of 274,276,277,278,286,289,291,293,298) 
Q9QYY0 1 322 
Q9QYY0 1 412 
Q9QZ04 1 (1 of 824,825,827,831,832) 
Q9QZN4 1 261 
Q9QZS8 1 (1 of 391,400,403,406,408,410,411,415,416,418) 
Q9R0K7 1 1179 
Q9R190 1 (1 of 52,53,54,57) 




Q9R1E0 1 646 
Q9R1L5 1 (1 of 1145,1146,1149,1155,1156,1158,1159,1160,1163,1164,1165,1168,1171,1172,1174) 
Q9WTQ5 1 861 
Q9WTS4 2 (2 of 1505,1509,1513) 
Q9WTS4 1 (1 of 225,228,236,237,238,241,247,252,258) 
Q9WTS4 1 685 
Q9WU42 1 (1 of 1778,1781,1782,1783,1784,1785,1796,1799,1800,1805,1806) 
Q9WU42 1 1944 
Q9WU42 1 2089 
Q9WU42 1 1532 
Q9WU42 1 1844 
Q9WUM3 1 421 
Q9WUU8 1 (1 of 70,73,76,77,80,83,91,95) 
Q9WUU8 1 (1 of 103,105,108,109,110,112,114,115,118,126) 
Q9WUU8 1 104 
Q9WV18 1 (1 of 436,438,441,442) 
Q9WV30 1 (1 of 674,676,677,680,684,688,693,696,700,701,709,713) 
Q9WV60 1 (1 of 389,395,398,400) 
Q9WV69 1 (1 of 90,91,92,96,103) 
Q9WV69 1 (1 of 123,124,133,134,138) 
Q9WV69 1 16 
Q9WV69 1 18 
Q9WV69 1 285 
Q9WV69 1 110 
Q9WV92 1 (1 of 580,584,585,586,588,591) 
Q9WV92 1 (1 of 850,852,853,855,856)&(1 of 856,857) 
Q9WV92 1 814 
Q9WV92 1 847 
Q9WV92 1 822 
Q9WV92 1 470 
Q9WV92 1 858 
Q9WV92 1 859 
Q9WV92 1 798 
Q9WVG6 1 7 
Q9WVG6 1 15 
Q9WVI9 1 (1 of 362,364,365,367,368,371,374) 
Q9WVJ0 1 (1 of 933,941,943) 
Q9WVJ0 1 1046 
Q9Z0F7 1 67 
Q9Z0F7 1 54 
Q9Z0P4 1 (1 of 103,108) 
Q9Z0P4 1 (1 of 273,283,284,298,313) 




Q9Z0R4 1 718 
Q9Z0U1 1 451 
Q9Z0U1 1 999 
Q9Z1R2 1 (1 of 448,451,465,474,477,488,498,501) 
Q9Z1R2 1 (1 of 189,194,200,203,206,208,213,215,216,221) 
Q9Z1R2 1 (1 of 92,96,99,100,102,104,106,108,117) 
Q9Z2A0 1 (1 of 31,33,37,38,43,46) 
Q9Z2C4 2 (2 of 647,649,650,651) 
Q9Z2C4 1 667 
Q9Z2D6 1 434 
Q9Z2Y3 1 (1 of 242,248,249,256) 
S4R180 1 (1 of 11,19,22,23,27,28,32,39) 
S4R1C4 1 1120 
S4R1M9 1 221 
S4R2F3 1 (1 of 2754,2755,2759,2767,2769,2771,2773,2775,2778,2783) 
S4R2F3 1 (1 of 3710,3714,3720,3733) 
S4R2F3 1 (1 of 2183,2186,2192,2193,2195) 
S4R2F3 1 (1 of 2818,2822,2823,2831,2832,2833,2835,2836) 
S4R2F3 1 (1 of 2320,2322,2324,2327,2331) 
S4R2F3 1 3787 
S4R2F3 1 3212 
S4R2F3 1 3213 
S4R2F3 1 2959 
S4R2F3 1 817 
S4R2J9 1 (1 of 2419,2426,2427,2429,2432,2436,2438) 
S4R2J9 1 (1 of 2161,2171) 
S4R2J9 1 (1 of 2179,2183,2184,2185,2187,2188,2192,2193,2195,2197) 
S4R2J9 1 (1 of 2136,2138,2141,2142,2144,2145,2146,2150,2153) 
S4R2J9 1 (1 of 2714,2716,2717,2721,2723,2728) 
S4R2J9 1 (1 of 374,375,376,385) 
S4R2J9 1 (1 of 202,203,206,207) 
S4R2J9 1 2280 
S4R2J9 1 2635 
S4R2J9 1 876 
S4R2J9 1 1931 
S4R2J9 1 880 
S4R2K9 2 (1 of 1676,1679,1681,1683,1689,1690)&(2 of 1683,1689,1690) 
S4R2K9 2 (2 of 1623,1624,1627,1628,1631) 
S4R2K9 1 (1 of 1538,1541,1543,1544,1546) 
S4R2K9 1 (1 of 1694,1697,1698,1700,1701) 
S4R2K9 2 (2 of 1661,1664,1665,1667,1671,1672) 
S4R2K9 1 (1 of 1506,1508,1509,1513) 




S4R2K9 1 (1 of 2127,2129,2133,2136,2137,2153,2155) 
S4R2K9 1 (1 of 1603,1605,1608,1617,1618,1620,1621) 
S4R2K9 2 (2 of 1550,1551,1555,1556,1557,1558,1559) 
S4R2K9 1 (1 of 1779,1782,1786,1790) 
S4R2K9 2 (2 of 1745,1746,1748,1752,1753,1756,1759,1761) 
S4R2K9 1 (1 of 2165,2169,2170,2176,2183) 
S4R2K9 1 (1 of 1520,1522,1524,1525,1526,1528,1530,1532,1534) 
S4R2K9 2 (2 of 1767,1768,1769,1770,1775) 
S4R2K9 1 (1 of 1857,1859,1860,1862) 
S4R2K9 1 (1 of 1562,1564,1568) 
S4R2K9 1 (1 of 1636,1637,1639,1641,1645) 
S4R2K9 1 (1 of 1488,1491,1492,1494,1500,1501) 
V9GWT6 1 (1 of 105,109,110,115,116,120,122,134,137,138,142) 
V9GWW6 1 (1 of 325,331,334,336,337,339,341) 
V9GWW6 1 621 
V9GXD9 1 (1 of 464,466,470,472,480,481) 
V9GXD9 1 (1 of 635,637,638,645,649,654,655) 
V9GXD9 1 627 
V9GXJ1 1 (1 of 130,132,135,137,138,139,143) 






Appendix 5.5. O-GlcNAc Sites and Regions Identified in the Mouse Liver.  






Site ID Constraints 
A0A087WNL7 1 (1 of 2684,2687,2688,2689,2690,2691,2693,2694,2695) 
A0A087WPF5 1 (1 of 151,152,153,154,157,159) 
A0A087WPF5 1 161 
A0A087WQI5 1 68 
A0A0A0MQE8 1 (1 of 1893,1894,1895,1898,1899,1900,1902,1906,1910) 
A0A0A0MQE8 1 (1 of 347,351,354,358,359,360) 
A0A0A0MQM6 1 163 
A0A0A6YWC8 1 34 
A0A0G2JDK2 1 290 
A0A0G2JDK2 1 71 
A0A0G2JDW6 1 91 
A0A0G2JG52 1 (1 of 1203,1205,1207,1208,1211,1213,1214,1215,1217,1218,1219,1222,1223,1225,1227,1228) 
A0A0N4SUU0 1 120 
A0A0N4SUU0 1 307 
A0A0R4IZZ6 1 852 
A0A0R4J060 1 (1 of 592,593,601,608,612,618,619,623,625,627,629,630,632,637,638) 
A0A0R4J060 1 (1 of 802,806,807,813,815,817,819,825,828,832,839) 
A0A0R4J060 1 (1 of 274,278,279,280,287,288,290) 
A0A0R4J060 1 320 
A0A0R4J092 1 115 
A0A0R4J092 1 91 
A0A0R4J0B2 1 529 
A0A0R4J0I1 1 (1 of 268,272) 
A0A0R4J0I1 1 187 
A0A0R4J112 1 (1 of 194,195,197,204,210,216,219,225,226,229,232) 
A0A0R4J131 1 138 
A0A0R4J135 1 (1 of 402,403,404,407) 
A0A0R4J138 1 (1 of 165,173,178,187,191) 
A0A0R4J2B5 1 348 
A0A0U1RPL0 1 432 
A0A140LHN0 1 31 
A0A1B0GR85 1 1085 
A0A1B0GRV3 1 (1 of 106,108,110,113,115,116,117,119,121,125,134) 
A0A1B0GRV3 1 248 




A0A1D5RLD8 1 208 
A0A1L1STC6 1 8305 
A0A1L1STC6 1 1956 
A0A1L1SUT5 1 (1 of 89,90,91,95) 
A0A1N9PTV1 1 (1 of 233,240,242,244,245,246) 
A0A1W2P7C1 1 290 
A0A1X7SB71 1 273 
A0A1Y7VNM3 1 167 
A0A286YDL1 1 (1 of 960,963,964) 
A0A2I3BPN6 1 486 
A0A2R8VHH9 1 203 
A0A338P689 1 (1 of 310,315,331,332) 
A0A338P6K9 1 (1 of 162,163,166,169) 
A0A338P6K9 1 (1 of 19,22) 
A0A338P6K9 1 45 
A0A338P6K9 1 63 
A0A338P6U8 1 1637 
A0A3B2W837 1 95 
A0A494B968 1 33 
A0A5F8MQ25 1 (1 of 865,866,876,879,881,886,890) 
A2A484 1 (1 of 755,756,757,758,763,767,771) 
A2AC24 1 140 
A2ADS6 1 (1 of 335,338,341,351) 
A2AGT5 1 (1 of 1899,1900,1901,1904,1910,1914,1916,1917,1918,1920,1921,1925,1933) 
A2AH22 1 441 
A2AKB9 2 (2 of 314,318) 
A2AKB9 1 364 
A2AMI6 1 (1 of 187,188,190,196,202,208,211,217,218,221,224) 
A2AQ25 1 (1 of 1893,1894,1895,1896,1897,1898,1899,1902,1905,1907,1908) 
A2AS44 1 226 
A2AS70 1 (1 of 262,265,267,268,274,276,278,281) 
A2AS70 1 (1 of 413,416,418,419,421,423,424,425,428,432,434,435,436,437) 
A2ASS6 1 (1 of 24801,24803,24807,24808,24810,24812,24816) 
A2ASS6 1 (1 of 32261,32264) 
A2ASS6 2 (2 of 299,301,305,307) 
A2ASS6 1 (1 of 20562,20573) 
A2AUY4 1 (1 of 3,9,10,13,14,15,16,18,19,20,21,24,27,30) 
A2AVJ7 1 (1 of 103,110,119,123) 
A2AVJ7 1 111 
A2AWI9 1 (1 of 263,267,268,272,276,277,278,279,281,282,283,286,292,314,316) 
A2AWL7 1 (1 of 1654,1655,1658,1659,1660,1664,1666) 
A2BH40 1 (1 of 697,699,703,706,710) 




A2BH40 1 256 
A2RSY1 1 (1 of 699,700,701,702,707,709,710,711,713,716,717,718,720,726,729) 
A2RSY1 1 (1 of 538,539) 
A2RSY1 1 (1 of 786,790,795,796,798,799,800) 
A2RSY1 1 859 
A2RSY1 1 534 
A6H619 1 (1 of 1359,1363,1364,1365,1366,1368,1369,1376) 
A9C497 1 (1 of 170,173) 
A9Z1V5 1 382 
B1AUC0 1 (1 of 456,460,461,462,463,469,471,472) 
B2RRI2 1 125 
B2RUJ2 1 (1 of 1125,1131,1132,1136,1140) 
B2RUJ2 1 1068 
B2RUQ2 1 (1 of 361,364,366,367,369) 
B2RUQ2 1 (1 of 1618,1621,1624) 
B2RXQ9 1 367 
B9EKS2 2 (2 of 410,415,421,426,427,429,430,431,433,434) 
B9EKS2 1 (1 of 652,655)&(1 of 655,658) 
B9EKS2 1 661 
D3YUC9 1 11 
D3YUL8 2 (2 of 745,746,749,757) 
D3YUL8 1 184 
D3YUL8 1 742 
D3Z197 1 (1 of 265,266,269,270,272,273,274) 
D3Z2E7 1 (1 of 415,417) 
D3Z2E7 1 (1 of 883,887) 
D3Z2E7 1 408 
D3Z2E7 1 434 
D3Z2E7 1 392 
D3Z3D5 1 74 
D3Z3F8 1 478 
D3Z3U7 1 328 
D3Z3U7 1 327 
D3Z5U3 1 89 
D3Z7I3 1 (1 of 280,281,282,283,285) 
D6RI42 1 313 
D6RIL1 1 (1 of 283,286,287) 
E9PUF4 1 (1 of 645,647,648,655,657,658,665,666,667,668,671) 
E9PUL9 1 (1 of 539,541,543,545) 
E9PVA6 1 (1 of 551,555) 
E9PVA6 1 556 
E9PYH6 1 (1 of 256,258,259,264,267,268,271,274,275) 




E9PYK3 1 (1 of 1229,1239,1241,1242,1249) 
E9PYK3 1 1749 
E9PZD2 1 384 
E9PZD2 1 395 
E9PZD2 1 373 
E9PZD2 1 406 
E9PZD2 1 439 
E9PZD2 1 253 
E9Q030 1 (1 of 178,179,180,183,186,190) 
E9Q1M6 1 (1 of 1630,1631,1634,1635) 
E9Q1M6 2 (2 of 1485,1509,1511,1512,1513,1514,1515,1519,1521,1522,1523,1524,1526) 
E9Q1M6 1 (1 of 1783,1784) 
E9Q1M6 1 1800 
E9Q1M6 1 1801 
E9Q1M6 1 2091 
E9Q1M6 1 2096 
E9Q1M6 1 1780 
E9Q1M6 1 1816 
E9Q1P8 1 (1 of 359,364,365,366,367) 
E9Q1S3 1 183 
E9Q2B2 1 (1 of 1002,1003) 
E9Q2B2 1 (1 of 989,990) 
E9Q2B2 1 993 
E9Q2B2 1 1986 
E9Q2B2 1 2027 
E9Q2B2 1 2189 
E9Q2B2 1 14 
E9Q2B2 1 51 
E9Q2B2 1 1429 
E9Q2I4 1 (1 of 53,57,58,59,65,75,80) 
E9Q3C1 1 395 
E9Q3E2 1 (1 of 393,397) 
E9Q3G8 1 (1 of 766,767) 
E9Q3G8 1 (1 of 620,626,628,629,630,634,639,640,642,643,644,651) 
E9Q3G8 1 (1 of 554,557,559,561,562,563,565,568,569,570,575,579,580,581) 
E9Q3G8 1 (1 of 1158,1165,1167,1169) 
E9Q3G8 1 (1 of 532,533,546,548) 
E9Q3G8 1 513 
E9Q3G8 1 514 
E9Q3G8 1 899 
E9Q3G8 1 517 
E9Q3G8 1 909 




E9Q3G8 1 1044 
E9Q3G8 1 1046 
E9Q3G8 1 925 
E9Q3G8 1 542 
E9Q3G8 1 927 
E9Q3G8 1 934 
E9Q3G8 1 705 
E9Q3G8 1 200 
E9Q3G8 1 1102 
E9Q3G8 1 1006 
E9Q3G8 1 882 
E9Q3G8 1 627 
E9Q3G8 1 759 
E9Q3W4 1 (1 of 2452,2456,2457,2461,2462) 
E9Q5Z1 1 (1 of 6,7,10,13) 
E9Q605 1 686 
E9Q616 1 5376 
E9Q6A7 1 (1 of 1595,1598,1601,1602,1604,1605,1606,1609,1611) 
E9Q6A7 2 (2 of 1943,1944,1945,1946,1951,1952,1953,1954,1956) 
E9Q7D5 1 (1 of 496,498,499,500,504,506) 
E9Q7E2 1 656 
E9Q7M2 1 (1 of 113,121,128,130,131,135,136,138,140,145,147,148) 
E9Q7W0 1 (1 of 450,451,455,458,460,462,467,470,471,473,474,475,477,478,479,480,482,485) 
E9Q804 1 (1 of 2068,2070,2075,2076,2085,2090,2091,2092,2093,2094,2096,2097,2098,2101,2102,2109,2121,2125) 





E9Q804 2 (2 of 2000,2001,2004,2005,2006,2007,2009,2010,2011,2013,2016,2017,2020,2023,2028) 
E9Q804 1 1996 
E9Q804 1 2381 
E9Q804 1 1839 
E9Q804 1 2192 
E9Q804 1 2036 
E9Q804 1 152 
E9Q804 1 154 
E9Q804 1 1820 
E9Q804 1 1821 
E9Q9B1 1 (1 of 3,7,9,11,14,15,16,17,18,19,20,22,23,25,27,29,30,32) 
E9Q9M8 1 (1 of 443,444,446,449,450,453,457,458,461,463,466,467,468,471) 
E9QA68 2 (2 of 111,115,116,117,119,120,123,125,127,128,129,131,132,134,135,136,137,139) 
E9QAN9 1 (1 of 458,459,460,461,464,467,469) 
E9QAN9 1 451 




E9QAT4 1 68 
E9QAT4 1 69 
E9QAT4 1 70 
E9QAT4 1 2028 
E9QAT4 1 2011 
E9QAT4 1 127 
E9QL43 1 238 
E9QLT6 1 608 
E9QLT6 1 592 
E9QLT6 1 547 
E9QML5 1 1370 
E9QMU3 1 (1 of 452,453) 
E9QPR4 1 (1 of 1986,1987,1988,1992) 
E9QQ33 1 (1 of 523,525,526,531) 
E9QQ33 1 511 
F2Z3U3 1 (1 of 763,767,775,777,789,793,795,796) 
F6S4K9 1 (1 of 297,300,302) 
F6S4K9 1 286 
F6S4K9 1 103 
F6SPQ1 1 (1 of 177,181,182,192) 
F6SPQ1 1 153 
F6TB64 1 823 
F6VJC5 1 (1 of 115,116,117,118,119,120,121,123,128,136,142,143,144,146,147,157,159,165,169) 
F6VJC5 1 (1 of 72,73) 
F6VJC5 1 58 
F6VJC5 1 100 
F6VJC5 1 71 
F6WV21 1 854 
F6Y6L6 1 132 
F6Y6L6 1 127 
F6YTG0 1 22 
F6YTL8 1 (1 of 222,225,228,229,232,240,245) 
F6YTL8 1 (1 of 1037,1047) 
F6Z9A1 1 (1 of 72,77,78,79) 
F6Z9T5 1 110 
F6ZBY9 1 (1 of 292,295,298,299,300,301,302,304,305) 
F6ZBY9 1 330 
F6ZDS4 1 (1 of 1730,1731,1732,1736,1742) 
F6ZDS4 1 1746 
F8VPJ6 1 439 
F8VPM9 1 (1 of 1565,1566,1583) 
F8VPM9 1 1706 




F8VPM9 1 2647 
F8VPZ9 1 (1 of 707,712,713,719,723,727,739,742) 
F8VPZ9 1 (1 of 1217,1225,1226) 
F8VPZ9 1 (1 of 431,432,433,435,445) 
F8VQJ3 1 (1 of 1216,1223) 
F8VQJ3 1 (1 of 1201,1205,1206) 
F8VQJ3 1 1380 
F8WHT3 1 1984 
F8WHT3 1 1803 
F8WHT3 1 1798 
F8WI14 1 (1 of 532,536,544) 
F8WI14 1 (1 of 436,446) 
F8WJ05 1 591 
G3UX48 1 (1 of 42,43,46,47,53,59,61,64) 
G3UZX7 1 (1 of 494,501,503) 
G3X8T2 1 413 
G3X928 1 (1 of 142,145,149,150,151,155,158,159,166) 
G3X928 1 607 
G3X972 1 (1 of 65,66,81,82,96,97,98) 
G3X972 1 72 
G3X9Z4 1 (1 of 169,174,175,178,181,182,184,186,187) 
H3BJL2 1 (1 of 779,780) 
H3BLE4 1 (1 of 138,140,149) 
H9KV15 1 1092 
H9KV15 1 262 
H9KV15 1 1614 
H9KV15 1 250 
H9KV15 1 251 
I7HIP8 1 (1 of 404,408,409,412,413,417,418) 
J3QNT7 1 (1 of 395,403,404,406,407,409) 
J3QNT7 1 167 
J3QQ16 1 1846 
J3QQ16 1 113 
J3QQ16 1 1950 
K3W4L3 1 237 
K3W4L3 1 82 
K3W4L3 1 459 
K3W4L3 1 213 
K4DI63 1 36 
O08755 1 (1 of 440,450,452,454,455,456,457,458,459,460,461,463) 
O08785 1 707 
O08785 1 446 




O09000 1 853 
O09117 1 259 
O09159 1 369 
O09173 1 438 
O35126 1 (1 of 353,357,365,366,367) 
O35516 1 175 
O35738 1 (1 of 91,92,94,97,98,99,102,104,106,108,109,111,112,113,114,115,116,117,118,119,120,121) 
O35984 1 323 
O55042 1 (1 of 44,53,54) 
O55042 1 72 
O55111 1 939 
O55111 1 1060 
O70305 1 (1 of 778,779,780,781,783,789) 
O70305 1 (1 of 174,175,182,186,187,200,201,202) 
O70305 1 (1 of 635,636,641,643,644,647) 
O70305 1 745 
O70305 1 189 
O70305 1 727 
O70318 1 (1 of 886,888,891,902,907,910,912,913,915,917,918,919,920,921,922,925) 
O70400 1 128 
O70400 1 135 
O88531 1 199 
O88532 1 (1 of 148,149,157) 
O88532 1 (1 of 102,111,114,116,121) 
O88532 1 195 
O88532 1 423 
O88532 1 135 
O88532 1 136 
O88532 1 202 
O88532 1 167 
O88532 1 300 
O88532 1 180 
O88569 1 199 
O88587 1 (1 of 260,261,265) 
O88935 1 (1 of 510,512,518,520,523,526) 
O89017 1 (1 of 79,84) 
O89017 1 95 
P05784 1 (1 of 7,8,9,11,12) 
P05784 1 32 
P05784 1 31 
P06537 1 43 
P07724 1 (1 of 89,92) 




P08113 1 (1 of 245,246,248) 
P08113 1 64 
P0C090 1 (1 of 789,792,793,794,799,801,803,806,810) 
P0C090 1 (1 of 754,755) 
P0C090 1 (1 of 552,555,560,561,565,569,573) 
P0C090 1 592 
P0C090 1 907 
P0C7T6 1 (1 of 29,30,31,33,34,37,39,40,43,46) 
P0C7T6 1 22 
P0DOV2 1 137 
P0DOV2 1 130 
P10605 2 (2 of 199,204) 
P10605 1 (1 of 210,216,218,228,229,231,233,235) 
P11276 1 1008 
P11276 1 432 
P11679 1 489 
P11679 1 482 
P11679 1 34 
P11725 1 81 
P14602 1 178 
P14602 1 63 
P14869 1 286 
P16951 1 (1 of 287,289,292,296,302,303,304,305,307,310,314,315,318,321,322) 
P16951 1 272 
P20029 1 638 
P22361 1 (1 of 325,327,328,335,336,337,343,345,352,354,359,360,363,364) 
P22361 1 (1 of 285,303,304,309,310,311,313,315) 
P24369 1 117 
P24527 1 (1 of 156,158,162) 
P27612 1 (1 of 481,482,485,487,490,495) 
P28665 1 1144 
P29341 1 485 
P33215 1 (1 of 325,329,330,331,332,338) 
P40124 1 (1 of 217,221,224,227,242,243,244,245,247,250,252) 
P42128 1 (1 of 691,699,701,702,705,710,717) 
P42128 1 (1 of 663,671,675,676,677,678,679,681,682,683) 
P42128 1 563 
P42128 1 541 
P42227 1 (1 of 714,716,717,719,721,727) 
P43883 1 (1 of 23,24,25,30,31,35,36) 
P43883 1 107 
P43883 1 59 




P45481 1 2360 
P45481 1 147 
P47941 1 (1 of 195,197,212,213,214,218,221,222,232,233) 
P48678 1 611 
P48678 1 644 
P48678 1 613 
P49429 1 (1 of 226,230,235) 
P49442 1 394 
P50247 1 2 
P51141 1 (1 of 379,380,383,384,387) 
P54254 1 (1 of 357,364,365,366,368,376,377) 
P54254 1 81 
P54254 1 23 





P58462 1 476 
P58462 1 446 
P58871 1 298 
P58871 1 260 
P58929 1 404 
P59326 1 196 
P59326 1 198 
P59759 1 (1 of 838,839,851,855,858) 
P59759 1 245 
P59759 1 214 
P59759 1 207 
P59764 1 1796 
P59764 1 1806 
P62806 1 (1 of 81,83) 
P62908 1 242 
P62960 1 (1 of 2,3,7,19,23,27,28,30,34,41,42) 
P70121 1 (1 of 163,168,172,173,174,177,179) 
P70121 1 (1 of 224,226,227) 
P70121 1 (1 of 245,248,249,252,254,265,268,273) 
P70121 1 235 
P70121 1 228 
P70121 1 238 
P70257 1 (1 of 452,453,454) 
P70257 1 272 
P70257 1 470 
P70665 1 357 




P70699 1 925 
P70699 1 142 
P81269 1 (1 of 181,182,184,186,187,191,195,196,199,202,204,205) 
P82343 1 (1 of 419,420,424,425,429) 
P83741 1 (1 of 1801,1803,1806,1808,1817,1818,1820,1821,1822,1823,1825,1829) 
P83741 1 (1 of 2376,2377) 
P83741 1 (1 of 1270,1271,1274,1280,1281,1282,1290,1292,1294,1295,1297,1303) 
P83741 1 (1 of 1841,1843) 
P83741 1 1860 
P83741 1 1230 
P83741 1 1844 
P83741 1 1945 
P83741 1 2365 
P97364 1 448 
P97366 1 (1 of 37,39,41,43,47,51,53,55,58,59,60,61,62,63,64,66,67,69,71,73,74,76) 
P97379 1 235 
P97855 1 266 
P99027 1 74 
Q00422 1 264 
Q00422 1 275 
Q02614 1 233 
Q02614 1 244 
Q02614 1 241 
Q02614 1 239 
Q02780 1 (1 of 383,387,389,390,395,396,407) 
Q02780 3 (3 of 479,483,484,485,486,492,494,495,497,499,500,502,503,504) 
Q02780 1 (1 of 352,355,356,358,360,362,363,364,367,370,378) 
Q02780 1 293 
Q03265 1 (1 of 419,423) 
Q06890 1 329 
Q07797 1 71 
Q07968 1 548 
Q08122 1 (1 of 328,331,332,333,334) 
Q08122 1 289 
Q08874 1 (1 of 93,95,101,104,105,108,110) 
Q09XV5 1 2524 
Q14AX6 1 588 
Q14AX6 1 589 
Q2PFD7 1 (1 of 240,245,246,247,248,251) 
Q2PFD7 1 (1 of 633,638) 
Q3TJD7 1 (1 of 190,191,196,203,204,209,214,215,217,219,220) 
Q3TN85 1 (1 of 123,125,128,129,130,131,132,133,136,138,140,143,144,146,147) 




Q3TN85 1 118 
Q3TRM4 1 (1 of 1348,1350,1351) 
Q3TZR9 1 (1 of 444,451,452,455,459) 
Q3U0V1 1 192 
Q3U0V1 1 96 
Q3U1C4 1 (1 of 36,38,39,41) 
Q3U2P1 1 (1 of 15,24,26,28,31,38,41,45,46,47,52,57) 
Q3U2P1 1 (1 of 236,239,247,248,254,255,260,272) 
Q3U3C9 1 125 
Q3UCQ1 1 (1 of 539,540,543,547,549) 
Q3UFM6 1 (1 of 434,441,443,444,445,450,452) 
Q3UH06 1 (1 of 988,991,993,995,1001) 
Q3UH06 1 1000 
Q3UH06 1 1099 
Q3UHC0 1 (1 of 1602,1603,1604,1607,1608,1609,1612) 
Q3UHC0 1 (1 of 754,755,756,757,761,763,764,766,767,768,769,770,771,776,779,784) 
Q3UHF7 1 (1 of 404,406,412,416) 
Q3UHF7 1 (1 of 1308,1316,1320) 
Q3UHJ0 1 416 
Q3UHJ0 1 360 
Q3UHK8 1 1251 
Q3UHK8 1 1606 
Q3UHK8 1 1621 
Q3UHK8 1 1622 
Q3UHK8 1 1623 
Q3UMF0 1 (1 of 912,913,915,917,933) 
Q3UMF0 1 (1 of 714,717,718,721,723,727,728,730,734,738) 
Q3UMF0 1 963 
Q3UMF0 1 868 
Q3UMF0 1 869 
Q3UMF0 1 1014 
Q3UMF0 1 863 
Q3UPF5 1 (1 of 467,468,469,477,483,487) 
Q3UPF5 1 (1 of 557,558,559,562,564,567,570) 
Q3UPH1 1 162 
Q3UPH1 1 157 
Q3UQN2 1 (1 of 477,487,491,492,494,495,499) 
Q3UQN2 1 (1 of 507,508,509,510,512,513,514,516,518,522,524,528) 
Q3URQ4 1 (1 of 10,18,27,31,33,34,35,39) 
Q3UYJ1 1 (1 of 136,137,140,141,144,145) 
Q3UYJ1 1 212 
Q3UYJ1 1 149 




Q4FE56 1 2551 
Q4G0F8 1 (1 of 862,864,865,868,869,870,871) 
Q4VAA2 1 178 
Q501J7 2 (1 of 192,199,201,202)&(1 of 199,201,202,205,206)&(1 of 205,206,209,212) 
Q501J7 1 (1 of 296,297,298,301,307,309,310) 
Q501J7 1 (1 of 244,245) 
Q501J7 1 194 
Q501J7 1 195 
Q501J7 1 231 
Q501J7 1 186 
Q501J7 1 190 
Q52KG4 1 (1 of 262,263,266) 
Q52KI8 1 (1 of 461,463) 
Q52KI8 1 (1 of 879,882,885) 
Q52KI8 1 892 
Q571G4 1 (1 of 106,109,111) 
Q571G4 1 (1 of 284,286,288,290,295,296,299,300,301,303) 
Q571G4 1 261 
Q571G4 1 238 
Q571K4 1 408 
Q571K4 1 412 
Q59J78 1 148 
Q5EBG8 1 (1 of 181,190,193) 
Q5F2E7 1 (1 of 381,382,383,384,385,386) 
Q5F2E7 1 (1 of 407,409,410,412,414,422,425,429,436,437,441,443,446,447,449,451,457,460) 
Q5F2E7 1 379 
Q5F2E7 1 380 
Q5F4T0 1 (1 of 1382,1383,1384,1386) 
Q5FWH2 1 459 
Q5SFM8 1 (1 of 465,466,471,472,474,475,477,483,495,497,498,499) 
Q5SFM8 1 546 
Q5SQA7 1 (1 of 29,31,34,35,37,38,40,41,42,43) 
Q5SRX1 1 (1 of 187,188,191,193,194,199,201,202,209,211,215,218) 
Q5SXC4 1 (1 of 126,127,130,131,137,138,140,141,142,143,144,146,149,150,151,153,154,155,156,162) 
Q5SXC4 1 (1 of 108,110,111,117,118,123,124) 
Q5U5Q9 1 (1 of 417,418,423,426,427,429,434,435) 
Q5YD48 1 (1 of 526,533,534,537,539,540,542) 
Q5YD48 1 557 
Q5YD48 1 566 
Q60737 1 (1 of 344,347,348,353,356,357,360,362,370,378) 
Q60775 1 470 
Q60865 1 (1 of 418,428,434,435,436,437,441,443,450,453) 




Q60953 1 (1 of 404,409,416,417,421,422,423,424) 
Q61033 1 (1 of 157,158,159,163,165,166,167,171) 
Q61147 1 139 
Q61191 2 (2 of 427,441,446,453,457,458,459,460,466,470,471,473,476) 
Q61191 1 (1 of 784,787) 
Q61191 1 (1 of 702,703) 
Q61191 1 (1 of 583,586,587,588) 
Q61191 2 (2 of 612,619,620,622,623,627,628,629,634) 
Q61191 1 (1 of 1243,1245,1247) 
Q61191 1 515 
Q61191 1 771 
Q61191 1 517 
Q61191 1 518 
Q61191 1 779 
Q61191 1 651 
Q61191 1 652 
Q61191 1 405 
Q61191 1 669 
Q61191 1 801 
Q61191 1 806 
Q61191 1 808 
Q61191 1 685 
Q61191 1 562 
Q61191 1 563 
Q61191 1 694 
Q61191 1 831 
Q61191 1 579 
Q61191 1 592 
Q61191 1 1235 
Q61191 1 1238 
Q61191 1 1495 
Q61191 1 1241 
Q61191 1 603 
Q61191 1 861 
Q61191 1 1246 
Q61191 1 480 
Q61191 1 490 
Q61191 1 495 
Q61191 1 1138 
Q61191 1 1139 
Q61191 1 1148 
Q61471 1 (1 of 171,172,176,178,179,181,185) 




Q61666 1 547 
Q61827 1 (1 of 142,146,147,148,149,153,156) 
Q61827 1 134 
Q62009 1 603 
Q62073 1 383 
Q62261 1 2322 
Q62261 1 2323 
Q62311 1 (1 of 356,358,360) 
Q62311 1 (1 of 480,481,483,485,490,492,494) 
Q62311 1 586 
Q62311 1 594 
Q62311 1 590 
Q62318 1 (1 of 4,8,12,15,18,21,23,26,30) 
Q62452 2 (2 of 333,335,338) 
Q62452 1 71 
Q62504 3 (3 of 347,350,351) 
Q62504 1 (1 of 2879,2883,2893,2895,2896,2899,2903) 
Q62504 1 (1 of 2523,2527,2528,2529,2530,2531) 
Q62504 1 2520 
Q62504 1 2786 
Q62523 1 (1 of 170,171,180) 
Q62523 1 305 
Q62523 1 237 
Q63880 1 313 
Q63886 1 91 
Q64092 1 (1 of 545,550,551,553,557) 
Q64213 1 (1 of 331,332,333) 
Q64213 1 (1 of 111,114) 
Q64213 1 328 
Q64213 1 337 
Q67FY2 1 (1 of 931,933,935,939,943,944,946) 
Q68ED7 1 (1 of 411,413,416,417,421,423,429,436,437) 
Q68FG2 1 (1 of 2133,2134,2138,2144,2146,2148,2149) 
Q68FG2 1 2354 
Q68FG2 1 2101 
Q68FG2 1 2359 
Q69ZA1 1 (1 of 1340,1341,1343,1349,1350,1355,1356,1357) 
Q69ZA1 1 (1 of 1278,1285,1286,1287,1288,1289,1291) 
Q69ZK6 1 (1 of 1855,1857,1861,1862,1863,1867,1869,1874,1875) 
Q69ZK6 1 1250 
Q69ZR2 1 (1 of 1359,1361,1362) 
Q69ZR2 1 (1 of 1481,1482,1485,1490,1492,1493,1497,1498,1500,1503) 




Q69ZR2 1 1574 
Q69ZR2 1 1575 
Q6A065 1 (1 of 1315,1317,1318,1319,1321,1324,1325,1326,1328,1329,1332,1333,1336,1340) 
Q6A0A2 1 632 
Q6A0A2 1 51 
Q6DFZ1 1 1781 
Q6DID3 1 (1 of 734,739,741,745,749,750,761) 
Q6KCD5 1 160 
Q6KCD5 1 161 
Q6NS59 1 749 
Q6NXI6 1 (1 of 432,438,441,442,452,453,457,459,461) 
Q6NXI6 1 (1 of 622,623) 
Q6NXI6 1 417 
Q6NXI6 1 418 
Q6NXI6 1 616 
Q6NXI6 1 1010 
Q6NXI6 1 573 
Q6NZN0 1 696 
Q6P2K6 1 (1 of 46,49,54) 
Q6P2K6 1 774 
Q6P6L0 1 1106 
Q6PAL7 1 1593 
Q6PB44 1 (1 of 880,881,882,885,891,892,894) 
Q6PB44 1 (1 of 1540,1552,1553,1557) 
Q6PB75 1 (1 of 415,419,420,424) 
Q6PD26 1 372 
Q6PDI6 1 (1 of 536,550,551,552,553,555,556,567,569,570) 
Q6PDK2 1 2359 
Q6PFD9 1 (1 of 223,224,230,231,234,235,236,238,242,243,244,245,246,248,251) 
Q6PFD9 1 (1 of 1080,1081,1082,1085,1092,1095,1098) 
Q6PFD9 1 1033 
Q6PIJ4 1 (1 of 1073,1076,1077,1084) 
Q6PIJ4 1 (1 of 1030,1031) 
Q6PIJ4 1 (1 of 809,814,817) 
Q6PIJ4 1 (1 of 1113,1118,1120,1123,1124,1125,1127,1130,1136) 
Q6PIJ4 1 1027 
Q6PIJ4 1 1284 
Q6PIJ4 1 838 
Q6PIJ4 1 1064 
Q6PIJ4 1 1170 
Q6PIJ4 1 1138 
Q6PIJ4 1 1270 




Q6XBJ3 1 (1 of 207,213) 
Q6XBJ3 1 92 
Q6XLQ8 1 133 
Q6ZPG2 1 328 
Q6ZPJ0 1 (1 of 169,173,178,179,182,183) 
Q6ZPJ0 1 (1 of 157,158,159,160,161,164,165,167) 
Q6ZPJ0 1 174 
Q6ZPJ0 1 175 
Q6ZQ08 1 1037 
Q6ZQ08 1 1040 
Q6ZQ08 1 1041 
Q6ZQ08 1 1042 
Q6ZQ08 1 1050 
Q6ZQH8 1 1524 
Q6ZQH8 1 1526 
Q78PY7 1 333 
Q7M6Y3 2 (1 of 359,362,363,364,370)&(1 of 370,378)&(1 of 378,379,381,382,383,385,386) 
Q7M6Y3 1 565 
Q7M6Y3 1 356 
Q7M6Y3 1 453 
Q7SIG6 1 (1 of 759,765,771,773,776,777,779,783,784,785,786) 
Q7TMY8 1 (1 of 2910,2917,2918,2922,2923,2925,2926,2927,2928) 
Q7TMY8 1 (1 of 2619,2632,2633,2635,2636,2640,2642,2643,2646,2649) 
Q7TN29 1 197 
Q7TQH0 1 (1 of 419,421,422,424,428,432,436,437) 
Q7TQH0 1 (1 of 682,683) 
Q7TQH0 1 (1 of 266,267,270,271,273,274,276) 
Q7TQH0 1 (1 of 456,463,465,473,477,478,480,484,485,486,494,496,499) 
Q7TQH0 1 681 
Q7TQH0 1 686 
Q7TQH0 1 687 
Q7TSI3 1 (1 of 691,692,694,695,698,700,701,707,709,711,714,721,726) 
Q7TT18 1 (1 of 753,755) 
Q7TT18 1 (1 of 893,894,895,896,902,903,911,914,919) 
Q7TT18 1 (1 of 758,761,762) 
Q7TT18 1 1028 
Q7TT18 1 1030 
Q7TT18 1 1032 
Q7TT18 1 749 
Q7TT18 1 948 
Q7TT18 1 955 
Q80TG1 1 (1 of 759,760,761,762,764,765,766,768,769,770,772,777,778,779) 




Q80U72 1 936 
Q80U78 1 (1 of 798,800,801,803,804,807,809,810,811,814,815,816) 
Q80U93 1 (1 of 1559,1560,1562) 
Q80U93 1 (1 of 645,646,648,651,652,655,656) 
Q80U93 1 (1 of 1899,1900,1907,1908,1913,1914,1920) 
Q80U93 1 (1 of 1569,1573,1576) 
Q80U93 1 (1 of 585,589,590,595,596,597,598,599,601,606,607,608) 
Q80U93 1 (1 of 1505,1506,1518,1520,1521,1524,1526,1527,1529,1536,1537,1540,1543,1544) 
Q80U93 1 1152 
Q80U93 1 513 
Q80U93 1 1314 
Q80U93 1 1091 
Q80U93 1 516 
Q80U93 1 1060 
Q80U93 1 1574 
Q80U93 1 1337 
Q80U93 1 683 
Q80U93 1 1167 
Q80U93 1 1362 
Q80U93 1 627 
Q80U93 1 626 
Q80U93 1 1557 
Q80U93 1 504 
Q80U93 1 1049 
Q80U93 1 634 
Q80U93 1 507 
Q80VJ2 1 79 
Q80VP1 1 (1 of 411,415,416,418,419,420) 
Q80VP1 1 (1 of 500,506,511,514,516,526,528) 
Q80WC3 1 283 
Q80WC7 1 (1 of 186,188) 
Q80WC7 1 (1 of 451,457,458,463,465,466,470,474,475) 
Q80WC7 1 193 





Q80X50 1 (1 of 642,643,647,651,652,654,659,661) 
Q80X50 1 (1 of 388,400,402,404,405,406,407,408,409,414,415,416,418,420) 
Q80X50 1 (1 of 280,282,285,286,295,297) 
Q80X50 1 (1 of 311,313,314,319,320,325,329,337,339) 
Q80X50 1 345 
Q80X50 1 473 




Q80Y98 1 478 
Q80YA3 1 360 
Q80YR4 1 (1 of 693,708,715,716,720,721,723,728,730,731,732,733,734,735,736,737,738,739) 
Q80YR4 1 (1 of 560,563,564,568,569,575,578,579) 
Q80Z38 1 1292 
Q811P8 1 (1 of 1007,1010,1012,1016,1027,1028,1030) 
Q811P8 1 (1 of 409,413) 
Q8BFR4 1 (1 of 356,357) 
Q8BFR4 1 (1 of 267,270,272,273) 
Q8BFW7 1 (1 of 25,26,28,33,35,37,38) 
Q8BFW7 1 11 
Q8BFW7 1 212 
Q8BFW7 1 195 
Q8BG87 1 (1 of 495,496,497,503,506) 
Q8BGD9 1 (1 of 340,348,350,351,352,354,355) 
Q8BGD9 1 495 
Q8BGS1 1 (1 of 385,386,387,398) 
Q8BHL3 1 (1 of 32,43,44,46,47) 
Q8BI72 1 315 
Q8BI72 1 460 
Q8BI84 1 633 
Q8BI84 1 253 
Q8BJ05 1 (1 of 369,370,373) 
Q8BJ05 1 255 
Q8BJM5 1 374 
Q8BJM5 1 375 
Q8BKI2 1 (1 of 1503,1504,1506,1508,1509,1512,1513,1516,1523,1525,1528,1530,1534,1535,1536) 
Q8BL65 1 (1 of 278,279,280,282,285,289,290,291,292,294,296) 
Q8BL65 1 363 
Q8BL65 1 381 
Q8BMB0 1 (1 of 226,228,231,232,234,235,237,238,239) 
Q8BMB0 1 (1 of 465,466,468,470) 
Q8BMB0 1 192 
Q8BMB0 1 200 
Q8BMB0 1 521 
Q8BMB0 1 1069 
Q8BMB0 1 499 
Q8BMB0 1 1047 
Q8BMB0 1 247 
Q8BT14 1 316 
Q8BTI8 1 (1 of 2254,2262,2264,2266,2268,2271,2277,2278,2279) 
Q8BTI8 1 2245 




Q8BTI8 1 2414 
Q8BTI8 1 2426 
Q8BTI8 1 2205 
Q8BTJ4 1 281 
Q8BTJ4 1 261 
Q8BU11 1 406 
Q8BUV3 1 260 
Q8BWW4 1 578 
Q8BX02 1 346 
Q8BYK6 1 (1 of 219,222) 
Q8BYK6 1 201 
Q8BYK6 1 205 
Q8BYK6 1 229 
Q8BYK6 1 167 
Q8BYR2 1 (1 of 473,475,478,481,483,484,486,489) 
Q8BZH4 1 (1 of 358,359,360) 
Q8BZH4 1 (1 of 251,252,254,255,256,257,258,260,262,265,266,278,281,282) 
Q8BZH4 1 297 
Q8BZH4 1 426 
Q8BZH4 1 431 
Q8C052 1 (1 of 694,701,704,705,707,709,712,714,716,724,730,732) 
Q8C0C0 1 (1 of 264,265) 
Q8C0C0 1 159 
Q8C0Q2 1 (1 of 227,236,239) 
Q8C0Q2 1 730 
Q8C0Q2 1 581 
Q8C180 1 (1 of 326,327,328,329,330,331,333,339) 
Q8C2Q3 1 256 
Q8C2Q3 1 521 
Q8C2Q3 1 244 
Q8C2Q3 1 280 
Q8C2Q3 1 254 
Q8C5L3 1 (1 of 99,101,104,108,111) 
Q8C5L3 1 (1 of 118,120,123) 
Q8C5L3 1 128 
Q8C5L3 1 114 
Q8C5R2 1 390 
Q8CBF3 1 (1 of 931,934,938,939,944,947,948,957) 
Q8CDG3 1 1072 
Q8CDG3 1 1075 
Q8CDG3 1 1076 
Q8CF89 1 393 




Q8CFE4 1 (1 of 720,722,728,729,731,732,734,736,737) 
Q8CFE4 1 (1 of 622,630,631,632,635) 
Q8CFE4 1 741 
Q8CG79 1 339 
Q8CGA2 1 312 
Q8CGA2 1 313 
Q8CGA2 1 146 
Q8CGA2 1 311 
Q8CGB6 1 (1 of 899,901,902,905,908,909,913,914,915) 
Q8CGB6 1 1008 
Q8CGI1 1 (1 of 47,49,50,54) 
Q8CGI1 1 709 
Q8CGN4 1 (1 of 588,589,592,593,595,604,605,606) 
Q8CGZ0 1 (1 of 363,373,378,382,383,397,398,402,403) 
Q8CHC4 1 (1 of 1075,1080,1081,1084,1088) 
Q8CHC4 1 1341 
Q8CHI8 1 (1 of 695,698,699) 
Q8CHI8 1 (1 of 1205,1208) 
Q8CHI8 1 (1 of 2592,2594,2595,2596,2599) 
Q8CHI8 1 2624 
Q8CHI8 1 709 
Q8CHI8 1 2662 
Q8CHI8 1 2535 
Q8CHI8 1 2607 
Q8CHP6 1 (1 of 108,109,110,112,114,116,119,120,122,124,125,128,130) 
Q8CHP6 1 238 
Q8CHS8 1 174 
Q8CHY6 1 (1 of 61,62,67,69) 
Q8CHY6 1 (1 of 201,202,205,206,207,208) 
Q8CHY6 1 (1 of 582,585,586,589,594,596) 
Q8CHY6 1 178 
Q8CHY6 1 621 
Q8CHY6 1 179 
Q8CHY6 1 325 
Q8CI08 1 (1 of 480,484,486,488,491,492,495,497,498,499,500,509,515,516,520,522,524) 
Q8CI51 1 (1 of 118,119,120,121) 
Q8CI51 1 (1 of 308,309,313,318,319,322,325,327,332,335,336,339) 
Q8CI51 1 115 
Q8CI51 1 110 
Q8CI51 1 111 
Q8K0E8 1 (1 of 368,378) 
Q8K0L9 1 (1 of 492,494,495,497,502,506,513,514,519) 




Q8K0L9 1 449 
Q8K0L9 1 268 
Q8K0L9 1 465 
Q8K0L9 1 436 
Q8K0L9 1 473 
Q8K0L9 1 447 
Q8K1N2 1 (1 of 546,549,550,551) 
Q8K212 1 (1 of 52,53,54,55,56,57,58,59,64,65,66,67,68,69,70,71,72,73,80,82) 
Q8K2K6 1 291 
Q8K2K6 1 362 
Q8K2K6 1 300 
Q8K2K6 1 302 
Q8K2K6 1 367 
Q8K3X4 1 (1 of 265,285,287,289,290,293,294,295,296,297,298) 
Q8K3X4 1 (1 of 195,198,199,200,203,204,207) 
Q8K3X4 1 159 
Q8K3Z9 1 (1 of 713,715,719,720,721,722,725,726,728,729,730,731,735,738,739,740,742) 
Q8K3Z9 1 (1 of 582,586,587,588,595,600) 
Q8K3Z9 1 711 
Q8K3Z9 1 653 
Q8K3Z9 1 661 
Q8K3Z9 1 631 
Q8K3Z9 1 665 
Q8K558 1 (1 of 244,247,250,253,255,256,261,262,269) 
Q8QZR3 1 (1 of 272,277,282,284) 
Q8QZR3 1 83 
Q8R084 1 98 
Q8R0X2 1 126 
Q8R0X2 1 111 
Q8R1S4 1 (1 of 319,320,322,323,326,330,336) 
Q8R1S4 1 580 
Q8R242 1 285 
Q8R3B7 1 360 
Q8R3E3 1 (1 of 389,390,391,394,395,400) 
Q8R3L8 1 411 
Q8R4I1 1 (1 of 689,690,696,697,698,699,700,701,702,703,704,705,706,707,708,710,713) 
Q8R4R6 1 (1 of 295,296,297,303) 
Q8R4Y4 1 1532 
Q8VC97 1 (1 of 378,391,392) 
Q8VCF0 1 (1 of 278,280) 
Q8VCF0 1 (1 of 309,310) 
Q8VCF0 1 (1 of 235,239,242,244,247,250,251,253,254,255,256,257,259) 




Q8VCF0 1 298 
Q8VCF0 1 273 
Q8VCF0 1 370 
Q8VCF0 1 307 
Q8VCF0 1 373 
Q8VCF0 1 215 
Q8VCF0 1 315 
Q8VCF0 1 222 
Q8VCF0 1 319 
Q8VDM6 1 730 
Q8VEB4 1 288 
Q8VFP9 1 (1 of 279,282,291) 
Q8VHR5 1 (1 of 489,490) 
Q8VHR5 1 (1 of 288,289,290,298,303,304,305,306) 
Q8VHR5 1 585 
Q8VHR5 1 498 
Q8VHR5 1 495 
Q8VI33 1 (1 of 206,207,208,217,221) 
Q8VI33 1 202 
Q8VIJ6 1 644 
Q91VX2 1 (1 of 877,881) 
Q91VX2 1 (1 of 386,392,393,399,401,405,406,414,419,422) 
Q91VX2 1 (1 of 652,655,658,659,660,661) 
Q91VX2 1 (1 of 631,632,634,638,642) 
Q91VX2 1 1108 
Q91VX2 1 469 
Q91VX2 1 1018 
Q91VX2 1 1020 
Q91VX2 1 1117 
Q91W39 1 (1 of 520,521) 
Q91W39 1 (1 of 401,404,405,410,416,418,420,426,427) 
Q91W39 1 524 
Q91WT8 1 490 
Q91WT8 1 523 
Q91WT8 1 508 
Q91X51 1 (1 of 216,220,223,224,225,228,244,245,251) 
Q91XD6 1 137 
Q91XT4 1 804 
Q91XT4 1 78 
Q91YD3 1 399 
Q91Z96 1 (1 of 375,376,379,380,381,384,387,388,390) 
Q922J3 1 (1 of 144,146,149,150,154,157,158,159,162,164,171,173,174) 




Q924A2 1 1785 
Q924A2 1 1034 
Q924A2 1 772 
Q924A2 1 2044 
Q925J9 1 (1 of 996,998,1000) 
Q925J9 1 (1 of 1261,1265,1267,1269,1271,1272,1273,1274,1276,1277,1278,1280,1281,1283,1284,1285,1291,1292) 
Q99JX3 1 (1 of 432,435,443,448,451) 
Q99JX3 1 425 
Q99JX3 1 426 
Q99JX3 1 417 
Q99K90 1 456 
Q99KG3 1 (1 of 510,514,515,518,519,521,523,525,527,530) 
Q99KN9 1 (1 of 316,319,320) 
Q99KN9 1 328 
Q99KN9 1 630 
Q99KP6 1 (1 of 133,148,149,152,169) 
Q99LI5 1 (1 of 861,862,864,867,870,874,877,881,882) 
Q99LI5 1 889 
Q99LI8 1 (1 of 299,300,306,309,310,314,315) 
Q99LI8 1 295 
Q99MZ3 1 522 
Q99NG0 2 (2 of 1072,1073,1074,1083,1084,1085) 
Q99PP2 1 (1 of 1353,1358,1359,1362,1366,1367,1368,1369,1371) 
Q9CS72 1 (1 of 1127,1128,1129,1131,1133,1136,1137,1138,1139,1140) 
Q9CS74 1 640 
Q9CWK8 1 (1 of 93,94,97,101,104,106,107) 
Q9CX80 1 (1 of 180,187,188) 
Q9CZN7 2 (2 of 184,186,187,192) 
Q9D1J3 1 186 
Q9D1J3 1 115 
Q9D1M0 1 315 
Q9D2H6 1 (1 of 357,359,364,370,374,377,378,379,380,382,385) 
Q9D2H6 1 (1 of 186,187,188,189,190,191,195) 
Q9D4H9 1 (1 of 132,134,136,140,144,145,148,149,154,155,157,160,161,162,163,164,165,166,171) 
Q9D787 1 (1 of 493,499,500,501,502,504,506) 
Q9D7N9 1 161 
Q9D824 1 229 
Q9D824 1 228 
Q9D824 1 204 
Q9D824 1 205 
Q9DB43 1 165 
Q9DBF1 1 (1 of 476,487,488) 




Q9DBG5 1 (1 of 152,158,165) 
Q9DBG5 1 128 
Q9DBG5 1 72 
Q9DBG5 1 76 
Q9DBR7 1 (1 of 625,628,631) 
Q9DBR7 1 (1 of 645,646,647,648,650) 
Q9DBR7 1 (1 of 399,401,402) 
Q9DBR7 1 (1 of 564,566,569,570,572,573,575,577,578) 
Q9DBR7 1 379 
Q9DBR7 1 381 
Q9DBR7 1 571 
Q9DBR7 1 637 
Q9DC28 1 382 
Q9DCS9 1 25 
Q9DCT8 1 (1 of 74,82,88) 
Q9EQC8 1 228 
Q9ERG0 1 (1 of 324,325,326,329,334,341,344) 
Q9ERU9 1 (1 of 2317,2320,2328,2329,2330,2335,2336,2337,2338,2339,2341,2342) 
Q9ERU9 1 (1 of 1304,1306,1307,1308,1313) 
Q9ERU9 1 (1 of 1038,1044,1046,1047,1056,1057,1060,1062,1064,1070,1071,1081,1087,1091,1093) 
Q9ERU9 1 1138 
Q9ET54 1 (1 of 767,769,770,771,773,774,775,776) 
Q9ET54 1 763 
Q9JHC9 1 (1 of 499,502,507) 
Q9JHC9 1 (1 of 372,374,375) 
Q9JHC9 1 380 
Q9JHE7 1 (1 of 107,111,112,114,118) 
Q9JI46 1 (1 of 153,158,159,161,162,163,165) 
Q9JKR6 1 (1 of 580,582,583,589,590,591,598,607,612,633,634,639) 
Q9JKR6 1 (1 of 513,517,518) 
Q9JKR6 1 933 
Q9JKV1 1 221 
Q9JKV1 1 220 
Q9JKV1 1 213 
Q9JL19 1 (1 of 1742,1748,1752,1753,1754,1762) 
Q9JL19 1 (1 of 1234,1235,1238) 
Q9JL19 1 (1 of 1712,1713,1717,1722,1723,1724,1731,1738,1739) 
Q9JL19 1 1243 
Q9JL19 1 1644 
Q9JLV1 1 (1 of 162,163) 
Q9JLV1 1 320 
Q9JLV1 1 170 




Q9JLV1 1 183 
Q9JLV1 1 188 
Q9QXD8 1 (1 of 105,112,113,114,120,123) 
Q9QXE0 1 (1 of 71,77) 
Q9QXE7 1 123 
Q9QY76 1 144 
Q9QYC0 1 542 
Q9QYE6 1 158 
Q9QYG0 1 370 
Q9QYS9 1 (1 of 211,217,221) 
Q9QYY0 1 322 
Q9QZM0 3 
(2 of 104,113,114,117,118,119,122,123,124,125,126,127,128,129,130,131,139,140,141)&(3 of 
113,114,117,118,119,122,123,124,125,126,127,128,129,130,131) 
Q9QZM0 1 138 
Q9R013 1 (1 of 358,362) 
Q9R013 1 (1 of 105,109) 
Q9R0N4 1 469 
Q9R1E0 1 (1 of 644,645,646,648,651) 
Q9WTN3 1 250 
Q9WU42 1 (1 of 1778,1781,1782,1783,1784,1785,1796,1799,1800,1805,1806) 
Q9WU42 1 1843 
Q9WU42 1 1532 
Q9WU42 1 1844 
Q9WU42 1 1531 
Q9WUM3 1 421 
Q9WUU8 1 (1 of 103,104,105,108,109,110,112,114,115,118,126) 
Q9WUU9 1 18 
Q9WV30 1 (1 of 674,676,677,680,684,688,693,696,700,701,709,713) 
Q9WV54 1 (1 of 254,259,260,261) 
Q9WV69 1 (1 of 105,113,114) 
Q9WV69 1 (1 of 284,285) 
Q9WV69 1 (1 of 10,11,14,16,17,18) 
Q9WV69 1 110 
Q9WVJ3 1 396 
Q9Z0M5 1 321 
Q9Z0M5 1 153 
Q9Z0R6 1 217 
Q9Z0U1 1 (1 of 441,442,446,451,454) 
Q9Z0U1 1 999 
Q9Z103 1 412 
Q9Z1A1 1 (1 of 122,132,133,134,140,151,153,154) 
Q9Z1A1 1 373 




Q9Z2D6 1 434 
S4R2A9 1 (1 of 90,91,92,101,114,118) 
S4R2A9 1 499 
S4R2A9 1 500 
S4R2A9 1 542 
S4R2A9 1 543 
S4R2J9 1 (1 of 2280,2281,2282,2283,2284) 
S4R2J9 1 (1 of 202,203,206,207) 
S4R2J9 1 2146 
S4R2J9 1 2630 
S4R2J9 1 1931 
S4R2J9 1 2188 
S4R2J9 1 2635 
S4R2J9 1 880 
S4R2J9 1 2193 
S4R2J9 1 2419 
S4R2J9 1 2138 
S4R2J9 1 2171 
V9GXJ1 1 (1 of 130,132,135,137,138,139,143) 
V9GXT3 1 (1 of 1452,1454,1461,1463,1465,1468,1469,1471,1472,1474,1475,1477,1479) 
V9GXT3 1 1223 






Appendix 5.6. Python and R Code for All Analyses.  
 All code was run in Jupyter notebook (v7.12). Also see 5.9. Experimental Methods. 
 
A5.6.1. Pre-Processing of Proteome Discoverer Output.  
#import python packages  
import re 
import sys 
import pandas as pd 
import networkx as nx 
import itertools as it 
from collections import namedtuple 
import numpy as np 
import matplotlib 
import matplotlib.pyplot as plt 
from IPython.display import display 
from functools import reduce 
import seaborn as sns; sns.set() 
from io import StringIO 
from matplotlib_venn import venn2_unweighted #the unweighted is if you want to make circles that are the same size 
from matplotlib_venn import venn2 #also import the normal one 
 









#magic function to show plots inline 
%matplotlib inline 
#import the proteins files from each of the 293T, brain, and liver PD searches  
 
#list the filenames 
fname0 = './293T_Interactome_Full/293T_Interactome_Repeat_Full_100-(2)_Proteins.txt' 
fname1 = './293T_Interactome_SwissProt/293T_Interactome_Repeat_SwissProt_100-(3)_Proteins.txt' 
fname2 = './Brain_Interactome_Full/Brain_Interactome_Full-(1)_Proteins.txt' 
fname3 = './Brain_Interactome_SwissProt/Brain_Interactome_SwissProt-(2)_Proteins.txt' 
fname4 = './Liver_Interactome_Full/Liver_Interactome_Full-(1)_Proteins.txt' 
fname5 = './Liver_Interactome_SwissProt/Liver_Interactome_SwissProt-(1)_Proteins.txt' 
fname6 = './LiverBrain_Interactome_Full/LiverBrain_Interactome_Full_Proteins.txt' 
fname7 = './LiverBrain_Interactome_SwissProt/LiverBrain_Interactome_SwissProt_Proteins.txt' 
fnames = [fname0, fname1, fname2, fname3, fname4, fname5, fname6, fname7] #concatenate into a single list 
 
#import all of the files into dfs 
 
#make lists for for loop 
list_exp = ['293TF', '293TSP', 'BrainF', 'BrainSP', 'LiverF', 'LiverSP', 'LiverBrainF', 'LiverBrainSP'] 
 
#define all the dfs in a for loop 
for i in range(8): 
    locals()['df{}'.format(list_exp[i])] = pd.read_csv(fnames[i], sep='\t') 
 
 
#set only these columns to keep 
cols_to_keep = ['Accession', 'Description', 'Abundance Ratios log2 by Bio Rep SampleTrial 1  ControlTrial 1',  
                'Abundance Ratios log2 by Bio Rep SampleTrial 2  ControlTrial 2',  
                'Abundance Ratios log2 by Bio Rep SampleTrial 3  ControlTrial 3'] 
 
cols_to_keep2 = ['Accession', 'Description', 'Abundance Ratio log2 F1 Medium  F1 Light',  
                 'Abundance Ratio log2 F2 Medium  F2 Light', 'Abundance Ratio log2 F3 Medium  F3 Light',  
                 'Abundance Ratio log2 F4 Medium  F4 Light', 'Abundance Ratio log2 F5 Medium  F5 Light',  
                 'Abundance Ratio log2 F6 Medium  F6 Light'] 
     
#make a list for these new dfs 
list_df = ['293Full', '293SwissProt', 'BrainFull', 'BrainSwissProt', 'LiverFull', 'LiverSwissProt', 'LiverBrainFull',  
          'LiverBrainSwissProt'] 
 
#use a for loop to get the relevant info from the first 6 dfs (also remove contaminant proteins) 
#also get gene symbols from fasta lines and make all caps 
#remove all IgGs and only keep proteins identified with 'High' confidence 
 
for i in range(6): 
    locals()['df{}'.format(list_df[i])] = \ 
    locals()['df{}'.format(list_exp[i])][locals()['df{}'.format(list_exp[i])].Contaminant == False] 
    locals()['df{}'.format(list_df[i])] = \ 
    locals()['df{}'.format(list_exp[i])][locals()['df{}'.format(list_exp[i])]['Protein FDR Confidence Combined'] == 'High'] 
    locals()['df{}'.format(list_df[i])] = locals()['df{}'.format(list_df[i])][~locals()['df{}'.format(list_df[i])].\ 
                                                                               Description.str.contains('contaminant')] 




                                                                               Description.str.contains('Immunoglobulin')] 
    locals()['df{}'.format(list_df[i])] = locals()['df{}'.format(list_df[i])][~locals()['df{}'.format(list_df[i])].\ 
                                                                               Description.str.contains('Ig ')] 
    locals()['df{}'.format(list_df[i])] = locals()['df{}'.format(list_df[i])][cols_to_keep] 
    locals()['df{}'.format(list_df[i])]['Gene'] = \ 
    locals()['df{}'.format(list_df[i])]['Description'].str.extract('GN=(.*) PE=') 
    locals()['df{}'.format(list_df[i])].Gene = locals()['df{}'.format(list_df[i])].Gene.str.upper() 
 
#do the same for the remaining 2 (liver and brain combined) 
for i in range(6,8): 
    locals()['df{}'.format(list_df[i])] = \ 
    locals()['df{}'.format(list_exp[i])][locals()['df{}'.format(list_exp[i])].Contaminant == False] 
    locals()['df{}'.format(list_df[i])] = \ 
    locals()['df{}'.format(list_exp[i])][locals()['df{}'.format(list_exp[i])]['Protein FDR Confidence Combined'] == 'High'] 
    locals()['df{}'.format(list_df[i])] = locals()['df{}'.format(list_df[i])][~locals()['df{}'.format(list_df[i])].\ 
                                                                               Description.str.contains('contaminant')] 
    locals()['df{}'.format(list_df[i])] = locals()['df{}'.format(list_df[i])][~locals()['df{}'.format(list_df[i])].\ 
                                                                               Description.str.contains('Immunoglobulin')] 
    locals()['df{}'.format(list_df[i])] = locals()['df{}'.format(list_df[i])][~locals()['df{}'.format(list_df[i])].\ 
                                                                               Description.str.contains('Ig ')] 
    locals()['df{}'.format(list_df[i])] = locals()['df{}'.format(list_df[i])][cols_to_keep2] 
    locals()['df{}'.format(list_df[i])]['Gene'] = \ 
    locals()['df{}'.format(list_df[i])]['Description'].str.extract('GN=(.*) PE=') 
    locals()['df{}'.format(list_df[i])].Gene = locals()['df{}'.format(list_df[i])].Gene.str.upper() 
#now we need to count the heavy and ligth PSMs for each of the trials and add to the df 
 
#make new dfs for the PSMs file as before 
f0 = './293T_Interactome_Full/293T_Interactome_Repeat_Full_100-(2)_PSMs.txt' 
f1 = './293T_Interactome_SwissProt/293T_Interactome_Repeat_SwissProt_100-(3)_PSMs.txt' 
f2 = './Brain_Interactome_Full/Brain_Interactome_Full-(1)_PSMs.txt' 
f3 = './Brain_Interactome_SwissProt/Brain_Interactome_SwissProt-(2)_PSMs.txt' 
f4 = './Liver_Interactome_Full/Liver_Interactome_Full-(1)_PSMs.txt' 
f5 = './Liver_Interactome_SwissProt/Liver_Interactome_SwissProt-(1)_PSMs.txt' 
f6 = './LiverBrain_Interactome_Full/LiverBrain_Interactome_Full_PSMs.txt' 
f7 = './LiverBrain_Interactome_SwissProt/LiverBrain_Interactome_SwissProt_PSMs.txt' 
fnames_psm = [f0, f1, f2, f3, f4, f5, f6, f7] 
list_exp2 = ['PSM293TF', 'PSM293TSP', 'PSMBrainF', 'PSMBrainSP', 'PSMLiverF', 'PSMLiverSP', 'PSMLiverBrainF',  
             'PSMLiverBrainSP'] 
for i in range(8): 
    locals()['df{}'.format(list_exp2[i])] = pd.read_csv(fnames_psm[i], sep='\t') 
 
#for the 293T files group the samples from the same trial but different runs together 
dfPSM293TF.loc[dfPSM293TF['File ID'] == 'F7', 'File ID'] = 'F1' 
dfPSM293TF.loc[dfPSM293TF['File ID'] == 'F8', 'File ID'] = 'F1' 
dfPSM293TF.loc[dfPSM293TF['File ID'] == 'F9', 'File ID'] = 'F2' 
dfPSM293TF.loc[dfPSM293TF['File ID'] == 'F10', 'File ID'] = 'F2' 
dfPSM293TF.loc[dfPSM293TF['File ID'] == 'F11', 'File ID'] = 'F3' 
dfPSM293TF.loc[dfPSM293TF['File ID'] == 'F12', 'File ID'] = 'F3' 
dfPSM293TSP.loc[dfPSM293TSP['File ID'] == 'F7', 'File ID'] = 'F1' 
dfPSM293TSP.loc[dfPSM293TSP['File ID'] == 'F8', 'File ID'] = 'F1' 
dfPSM293TSP.loc[dfPSM293TSP['File ID'] == 'F9', 'File ID'] = 'F2' 
dfPSM293TSP.loc[dfPSM293TSP['File ID'] == 'F10', 'File ID'] = 'F2' 
dfPSM293TSP.loc[dfPSM293TSP['File ID'] == 'F11', 'File ID'] = 'F3' 
dfPSM293TSP.loc[dfPSM293TSP['File ID'] == 'F12', 'File ID'] = 'F3' 
 
#name dfs 
list_df2 = ['m293Full', 'm293SP', 'mBranFull', 'mBrainSP', 'mLiverFull', 'mLiverSP', 'mLiverBrainFull', 'mLiverBrainSP'] 
     
#now use a for loop to count up the PSMS for each protein, file, and byonic node 
#then split the dfs by node and rename the counts column 
#merge the dfs with H and L counts 
#first do this for all the individual ones (since there are additional nodes in the LiverBrain combined file) 
for i in range(6): 
    locals()['dfpsm{}'.format(i)] = \ 
    locals()['df{}'.format(list_exp2[i])].groupby( 
        ['Identifying Node No', 'Master Protein Accessions', 'File ID']).size().reset_index(name='Counts') 
    dfs = [locals()['df{}'.format(list_df[i])]] 
    for j in range(3): 
        locals()['dfH{}psm{}'.format(j+1, i)] = \ 
        locals()['dfpsm{}'.format(i)][(locals()['dfpsm{}'.format(i)]['Identifying Node No'] == 2) & \ 
                                               (locals()['dfpsm{}'.format(i)]['File ID'] == ('F' + str(j+1)))] 
        locals()['dfL{}psm{}'.format(j+1, i)] = \ 
        locals()['dfpsm{}'.format(i)][(locals()['dfpsm{}'.format(i)]['Identifying Node No'] == 7) & \ 
                                               (locals()['dfpsm{}'.format(i)]['File ID'] == ('F' + str(j+1)))] 
        locals()['dfH{}psm{}'.format(j+1, i)].rename(columns={'Counts':'H{}Counts'.format(j+1),  
                                                              'Master Protein Accessions':'Accession'}, inplace=True) 
        locals()['dfL{}psm{}'.format(j+1, i)].rename(columns={'Counts':'L{}Counts'.format(j+1),  
                                                              'Master Protein Accessions':'Accession'}, inplace=True) 
        dfs.append(locals()['dfL{}psm{}'.format(j+1, i)]) 
        dfs.append(locals()['dfH{}psm{}'.format(j+1, i)]) 
    locals()['df{}'.format(list_df2[i])] = reduce(lambda left,right: pd.merge(left, right, on='Accession', how='left'),  
                                                  dfs).fillna(0) 
    locals()['df{}'.format(list_df2[i])] = \ 
    locals()['df{}'.format(list_df2[i])].loc[:, ~locals()['df{}'.format(list_df2[i])].columns.str.contains('_')] 
     
#now repeat the above for the combined  
for i in range(6,8): 
    locals()['dfpsm{}'.format(i)] = \ 
    locals()['df{}'.format(list_exp2[i])].groupby( 
        ['Identifying Node No', 'Master Protein Accessions', 'File ID']).size().reset_index(name='Counts') 
    dfs2 = [locals()['df{}'.format(list_df[i])]] 
    for j in range(3): 




        locals()['dfpsm{}'.format(i)][(locals()['dfpsm{}'.format(i)]['Identifying Node No'] == 2) & \ 
                                               (locals()['dfpsm{}'.format(i)]['File ID'] == ('F' + str(j+4)))] 
        locals()['dfLiverL{}psm{}'.format(j+1, i)] = \ 
        locals()['dfpsm{}'.format(i)][(locals()['dfpsm{}'.format(i)]['Identifying Node No'] == 7) & \ 
                                               (locals()['dfpsm{}'.format(i)]['File ID'] == ('F' + str(j+4)))] 
        locals()['dfLiverH{}psm{}'.format(j+1, i)].rename(columns={'Counts':'H{}CountsHep'.format(j+1),  
                                                              'Master Protein Accessions':'Accession'}, inplace=True) 
        locals()['dfLiverL{}psm{}'.format(j+1, i)].rename(columns={'Counts':'L{}CountsHep'.format(j+1),  
                                                              'Master Protein Accessions':'Accession'}, inplace=True) 
        dfs2.append(locals()['dfLiverL{}psm{}'.format(j+1, i)]) 
        dfs2.append(locals()['dfLiverH{}psm{}'.format(j+1, i)]) 
    for k in range(3,6): 
        locals()['dfBrainH{}psm{}'.format(k-2, i)] = \ 
        locals()['dfpsm{}'.format(i)][(locals()['dfpsm{}'.format(i)]['Identifying Node No'] == 11) & \ 
                                               (locals()['dfpsm{}'.format(i)]['File ID'] == ('F' + str(k-2)))] 
        locals()['dfBrainL{}psm{}'.format(k-2, i)] = \ 
        locals()['dfpsm{}'.format(i)][(locals()['dfpsm{}'.format(i)]['Identifying Node No'] == 10) & \ 
                                               (locals()['dfpsm{}'.format(i)]['File ID'] == ('F' + str(k-2)))] 
        locals()['dfBrainH{}psm{}'.format(k-2, i)].rename(columns={'Counts':'H{}CountsBrain'.format(k-2),  
                                                              'Master Protein Accessions':'Accession'}, inplace=True) 
        locals()['dfBrainL{}psm{}'.format(k-2, i)].rename(columns={'Counts':'L{}CountsBrain'.format(k-2),  
                                                              'Master Protein Accessions':'Accession'}, inplace=True) 
        dfs2.append(locals()['dfBrainL{}psm{}'.format(k-2, i)]) 
        dfs2.append(locals()['dfBrainH{}psm{}'.format(k-2, i)]) 
    locals()['df{}'.format(list_df2[i])] = reduce(lambda left,right: pd.merge(left, right, on='Accession', how='left'),  
                                                  dfs2).fillna(0) 
    locals()['df{}'.format(list_df2[i])] = \ 
    locals()['df{}'.format(list_df2[i])].loc[:, ~locals()['df{}'.format(list_df2[i])].columns.str.contains('_')] 
         
     
#make separate dfs for import into R (reading into R directly from pandas can be problematic) and export to txt 
 
list_df3 = ['293Fsc', '293SPsc', 'BrainFsc', 'BrainSPsc', 'LiverFsc', 'LiverSPsc', 'LiverBrainFsc', 'LiverBrainSPsc'] 
list_df4 = ['293Fr', '293SPr', 'BrainFr', 'BrainSPr', 'LiverFr', 'LiverSPr', 'LiverBrainFr', 'LiverBrainSPr'] 
 
#first for the individual ones 
for i in range(6): 
    locals()['df{}'.format(list_df3[i])] = locals()['df{}'.format(list_df2[i])].iloc[:,-6:] 
    locals()['df{}'.format(list_df3[i])].to_csv('df{}.txt'.format(list_df3[i]), sep='\t') 
    locals()['df{}'.format(list_df4[i])] = locals()['df{}'.format(list_df2[i])].iloc[:,2:5] 
    locals()['df{}'.format(list_df4[i])].to_csv('df{}.txt'.format(list_df4[i]), sep='\t') 
     
#then for the combined ones 
#first, split into separate dfs for liver and brain 
 
list_split = ['Hep', 'Brain'] #using Hep so can search for 'L' and 'H' to find H/L counts in ibb script 
 
#first output the spectral counts 
for i in range(6,8): 
    for j in list_split: 
        locals()['df{}_{}'.format(list_df3[i], j)] = \ 
        locals()['df{}'.format(list_df2[i])].iloc[:,locals()['df{}'.format(list_df2[i])].columns.str.contains( 
            '{}'.format(j))] 
        locals()['df{}_{}'.format(list_df3[i], j)].to_csv('df{}_{}.txt'.format(list_df3[i], j), sep='\t') 
         
#now output the ratios 
for i in range(6,8): 
    locals()['df{}_Liver'.format(list_df4[i])] = \ 
    locals()['df{}'.format(list_df2[i])].iloc[:, ( 
        locals()['df{}'.format(list_df2[i])].columns.str.contains('F4') |  
        locals()['df{}'.format(list_df2[i])].columns.str.contains('F5') |  
        locals()['df{}'.format(list_df2[i])].columns.str.contains('F6'))] 
    locals()['df{}_Brain'.format(list_df4[i])] = \ 
    locals()['df{}'.format(list_df2[i])].iloc[:, ( 
        locals()['df{}'.format(list_df2[i])].columns.str.contains('F1') |  
        locals()['df{}'.format(list_df2[i])].columns.str.contains('F2') |  
        locals()['df{}'.format(list_df2[i])].columns.str.contains('F3'))] 
    locals()['df{}_Liver'.format(list_df4[i])].to_csv('df{}_Liver.txt'.format(list_df4[i]), sep='\t') 




#now we can calculate the p-values from limma in R 
#limma is well-documented by bioconductor  
#do not need to re-run this cell with the rest of the notebook after saving output  
 
library(limma) #load the package 
 
#read in the files 
df1 = read.table("df293Fr.txt",sep="\t",header=TRUE,row.names=1) 
df2 = read.table("df293SPr.txt",sep="\t",header=TRUE,row.names=1) 
df3 = read.table("dfBrainFr.txt",sep="\t",header=TRUE,row.names=1) 
df4 = read.table("dfBrainSPr.txt",sep="\t",header=TRUE,row.names=1) 
df5 = read.table("dfLiverFr.txt",sep="\t",header=TRUE,row.names=1) 
df6 = read.table("dfLiverSPr.txt",sep="\t",header=TRUE,row.names=1) 
df7 = read.table("dfLiverBrainFr_Liver.txt",sep="\t",header=TRUE,row.names=1) 
df8 = read.table("dfLiverBrainSPr_Liver.txt",sep="\t",header=TRUE,row.names=1) 
df9 = read.table("dfLiverBrainFr_Brain.txt",sep="\t",header=TRUE,row.names=1) 
df10 = read.table("dfLiverBrainSPr_Brain.txt",sep="\t",header=TRUE,row.names=1) 
 
#perform limma 
f1 = eBayes(lmFit(df1)) 




f3 = eBayes(lmFit(df3)) 
f4 = eBayes(lmFit(df4)) 
f5 = eBayes(lmFit(df5)) 
f6 = eBayes(lmFit(df6)) 
f7 = eBayes(lmFit(df7)) 
f8 = eBayes(lmFit(df8)) 
f9 = eBayes(lmFit(df9)) 
f10 = eBayes(lmFit(df10)) 
 













#calculate the p-values from the ibb test in R 
#this is an unsupported package 
#see the documentation here: http://oncoproteomics.nl/statistical-analysis-of-count-data/ 
#do not need to re-run this cell with the rest of the notebook after saving output (it takes several hours) 
 
library(ibb) #load the package 
 
#read in the tables 
df1 = read.table("df293Fsc.txt", header = TRUE, row.names = 1, sep="\t") 
df2 = read.table("df293SPsc.txt", header = TRUE, row.names = 1, sep="\t") 
df3 = read.table("dfBrainFsc.txt", header = TRUE, row.names = 1, sep="\t") 
df4 = read.table("dfBrainSPsc.txt", header = TRUE, row.names = 1, sep="\t") 
df5 = read.table("dfLiverFsc.txt", header = TRUE, row.names = 1, sep="\t") 
df6 = read.table("dfLiverSPsc.txt", header = TRUE, row.names = 1, sep="\t") 
df7 = read.table("dfLiverBrainFsc_Hep.txt", header = TRUE, row.names = 1, sep="\t") 
df8 = read.table("dfLiverBrainSPsc_Hep.txt", header = TRUE, row.names = 1, sep="\t") 
df9 = read.table("dfLiverBrainFsc_Brain.txt", header = TRUE, row.names = 1, sep="\t") 
df10 = read.table("dfLiverBrainSPsc_Brain.txt", header = TRUE, row.names = 1, sep="\t") 
 
#vector of group indicators, light and heavy are each replicated three times as alternating L and H 
#i.e. this sets the groups as alternating just like in the file 
g1 = rep(c("L","H"),3) 
g2 = rep(c("L","H"),3) 
g3 = rep(c("L","H"),3) 
g4 = rep(c("L","H"),3) 
g5 = rep(c("L","H"),3) 
g6 = rep(c("L","H"),3) 
g7 = rep(c("L","H"),3) 
g8 = rep(c("L","H"),3) 
g9 = rep(c("L","H"),3) 
g10 = rep(c("L","H"),3) 
 
#make a matrix by counting all the rows in each column 
tx1 = colSums(df1) 
tx2 = colSums(df2)  
tx3 = colSums(df3)  
tx4 = colSums(df4)  
tx5 = colSums(df5)  
tx6 = colSums(df6)  
tx7 = colSums(df7)  
tx8 = colSums(df8) 
tx9 = colSums(df9)  
tx10 = colSums(df10) 
 
#now set the matrix of total sample counts as the average of both L and H rows (6 total columns) 
#this is the total sample counts for each condition to be used by the ibb test 
tx1 = c((tx1[1]+tx1[2])/2,(tx1[1]+tx1[2])/2,(tx1[3]+tx1[4])/2,(tx1[3]+tx1[4])/2,(tx1[5]+tx1[6])/2,(tx1[5]+tx1[6])/2) 
tx2 = c((tx2[1]+tx2[2])/2,(tx2[1]+tx2[2])/2,(tx2[3]+tx2[4])/2,(tx2[3]+tx2[4])/2,(tx2[5]+tx2[6])/2,(tx2[5]+tx2[6])/2) 
tx3 = c((tx3[1]+tx3[2])/2,(tx3[1]+tx3[2])/2,(tx3[3]+tx3[4])/2,(tx3[3]+tx3[4])/2,(tx3[5]+tx3[6])/2,(tx3[5]+tx3[6])/2) 
tx4 = c((tx4[1]+tx4[2])/2,(tx4[1]+tx4[2])/2,(tx4[3]+tx4[4])/2,(tx4[3]+tx4[4])/2,(tx4[5]+tx4[6])/2,(tx4[5]+tx4[6])/2) 
tx5 = c((tx5[1]+tx5[2])/2,(tx5[1]+tx5[2])/2,(tx5[3]+tx5[4])/2,(tx5[3]+tx5[4])/2,(tx5[5]+tx5[6])/2,(tx5[5]+tx5[6])/2) 
tx6 = c((tx6[1]+tx6[2])/2,(tx6[1]+tx6[2])/2,(tx6[3]+tx6[4])/2,(tx6[3]+tx6[4])/2,(tx6[5]+tx6[6])/2,(tx6[5]+tx6[6])/2) 
tx7 = c((tx7[1]+tx7[2])/2,(tx7[1]+tx7[2])/2,(tx7[3]+tx7[4])/2,(tx7[3]+tx7[4])/2,(tx7[5]+tx7[6])/2,(tx7[5]+tx7[6])/2) 
tx8 = c((tx8[1]+tx8[2])/2,(tx8[1]+tx8[2])/2,(tx8[3]+tx8[4])/2,(tx8[3]+tx8[4])/2,(tx8[5]+tx8[6])/2,(tx8[5]+tx8[6])/2) 
tx9 = c((tx9[1]+tx9[2])/2,(tx9[1]+tx9[2])/2,(tx9[3]+tx9[4])/2,(tx9[3]+tx9[4])/2,(tx9[5]+tx9[6])/2,(tx9[5]+tx9[6])/2) 
tx10 = c((tx10[1]+tx10[2])/2,(tx10[1]+tx10[2])/2,(tx10[3]+tx10[4])/2,(tx10[3]+tx10[4])/2,(tx10[5]+tx10[6])/2, 
         (tx10[5]+tx10[6])/2) 
 
 
#run the ibb test with 8 threads, one sample t-test that there are less spectral counts in the L  
# see also, http://oncoproteomics.nl/statistical-analysis-of-count-data/ 
# Note that this calculation takes a long time 
out1 = ibb.test(df1, tx1, g1, alternative = "less", n.threads=8) 
out2 = ibb.test(df2, tx2, g2, alternative = "less", n.threads=8) 
out3 = ibb.test(df3, tx3, g3, alternative = "less", n.threads=8) 
out4 = ibb.test(df4, tx4, g4, alternative = "less", n.threads=8) 
out5 = ibb.test(df5, tx5, g5, alternative = "less", n.threads=8) 
out6 = ibb.test(df6, tx6, g6, alternative = "less", n.threads=8) 
out7 = ibb.test(df7, tx7, g7, alternative = "less", n.threads=8) 
out8 = ibb.test(df8, tx8, g8, alternative = "less", n.threads=8) 




out10 = ibb.test(df10, tx10, g10, alternative = "less", n.threads=8) 
 









            "ibbOut_LiverBrainSP_Hep.txt",sep="\t",row.names=TRUE) 
write.table(cbind(df9,out9$fc,out9$p.value,p.adjust(out9$p.value,"BH")), 
            "ibbOut_LiverBrainF_Brain.txt",sep="\t",row.names=TRUE) 
write.table(cbind(df10,out10$fc,out10$p.value,p.adjust(out10$p.value,"BH")), 
            "ibbOut_LiverBrainSP_Brain.txt",sep="\t",row.names=TRUE) 
#now I will import the results of the limma and ibb analysis and reform the data frames with the p values 
 
#list the fnames 
fname_list = ['293F', '293SP', 'BrainF', 'BrainSP', 'LiverF', 'LiverSP', 'LiverBrainF', 'LiverBrainSP']  
final_df_list = ['293TFull', '293TSP', 'BrainFull', 'BrainSP', 'LiverFull', 'LiverSP', 'LiverBrainFull', 'LiverBrainSP'] 
list_split2 = ['Liver', 'Brain'] 
 
#use a for loop to import all the dfs, then only keep the index and the last column, finally merge everything and keep only 
    # relevant columns (and rename) 
#first for the first 6 
for i in range(6): 
    locals()['df_limma_{}'.format(fname_list[i])] = pd.read_csv('limmaOut_df{}.txt'.format(fname_list[i]), sep='\t') 
    locals()['df_ibb_{}'.format(fname_list[i])] = pd.read_csv('ibbOut_{}.txt'.format(fname_list[i]), sep='\t') 
    locals()['dflimmap_{}'.format(fname_list[i])] = locals()['df_limma_{}'.format(fname_list[i])].iloc[:,[0,-2,-1]] 
    locals()['dflimmap_{}'.format(fname_list[i])].columns = ['limmaFC', 'limmapVal', 'limmaB'] 
    locals()['dfibbp_{}'.format(fname_list[i])] = locals()['df_ibb_{}'.format(fname_list[i])].iloc[:,[6,-1]] 
    locals()['dfibbp_{}'.format(fname_list[i])].columns = ['ibbFC', 'ibbpVal'] 
    locals()['df_{}'.format(final_df_list[i])] = \ 
    locals()['df{}'.format(list_df2[i])].merge( 
        locals()['dflimmap_{}'.format(fname_list[i])].merge( 
            locals()['dfibbp_{}'.format(fname_list[i])], how='left', left_index=True, right_index=True), how='left',  
        left_index=True, right_index=True) 
    locals()['df_{}'.format(final_df_list[i])] = \ 
    locals()['df_{}'.format(final_df_list[i])][['Accession', 'Description', 'Gene', 'limmaFC', 'limmapVal', 'limmaB',  
                                                'ibbFC', 'ibbpVal']] 
 
#now repeat for the combined liver/brain 
for i in range(6,8): 
    for j in range(2): 
        locals()['df_limma{}_{}'.format(fname_list[i], list_split2[j])] = \ 
        pd.read_csv('limmaOut_df{}_{}.txt'.format(fname_list[i], list_split2[j]), sep='\t') 
        locals()['df_ibb{}_{}'.format(fname_list[i], list_split[j])] = \ 
        pd.read_csv('ibbOut_{}_{}.txt'.format(fname_list[i], list_split[j]), sep='\t') 
        locals()['dflimmap_{}_{}'.format(fname_list[i], list_split2[j])] = \ 
        locals()['df_limma{}_{}'.format(fname_list[i], list_split2[j])].iloc[:,[0,-2,-1]] 
        locals()['dflimmap_{}_{}'.format(fname_list[i], list_split2[j])].columns = \ 
        ['limmaFC{}'.format(list_split2[j]), 'limmapVal{}'.format(list_split2[j]), 'limmaB{}'.format(list_split2[j])] 
        locals()['dfibbp{}_{}'.format(fname_list[i], list_split[j])] = \ 
        locals()['df_ibb{}_{}'.format(fname_list[i], list_split[j])].iloc[:,[-3,-1]] 
        locals()['dfibbp{}_{}'.format(fname_list[i], list_split[j])].columns = \ 
        ['ibbFC{}'.format(list_split[j]), 'ibbpVal{}'.format(list_split[j])] 
         
for i in range(6,8): 
    locals()['df_{}'.format(final_df_list[i])] = \ 
    reduce(lambda left,right: pd.merge( 
        left, right, left_index=True, right_index=True, how='left'),  
           [locals()['df{}'.format(list_df2[i])], locals()['dflimmap_{}_Liver'.format(fname_list[i])],  
            locals()['dflimmap_{}_Brain'.format(fname_list[i])], locals()['dfibbp{}_Hep'.format(fname_list[i])],  
            locals()['dfibbp{}_Brain'.format(fname_list[i])]]) 
    locals()['df_{}'.format(final_df_list[i])] = \ 
    locals()['df_{}'.format(final_df_list[i])][['Accession', 'Description', 'Gene', 'limmaFCLiver', 'limmaFCBrain',  
                                                'limmapValLiver', 'limmapValBrain', 'limmaBLiver', 'limmaBBrain',  
                                                'ibbFCHep', 'ibbFCBrain', 'ibbpValHep', 'ibbpValBrain']] 
#now we will sort the data frame to keep only significant interactors 
#will take things with a pvalue < 0.5 in either the limma or ibb test 
#will also remove things with a negative fc (or positive in the ibb test) 
#will also keep things that have a pvalue <0.05 for either test for either the liver or brain 
 
#list final dfs 
list_final_df = ['293TF', '293TSwiss', 'BrainF', 'BrainSwiss', 'LiverF', 'LiverSwiss', 'LiverBrainF', 'LiverBrainSwiss'] 
 
for i in range(6): 
    locals()['df_{}'.format(list_final_df[i])] = \ 
    locals()['df_{}'.format(final_df_list[i])][((locals()['df_{}'.format(final_df_list[i])].limmaFC > 0) |  
                                              (locals()['df_{}'.format(final_df_list[i])].ibbFC < 0)) 
                                              & ((locals()['df_{}'.format(final_df_list[i])].limmapVal < 0.05) |  
                                                 (locals()['df_{}'.format(final_df_list[i])].ibbpVal < 0.05))] 
     
for i in range(6,8): 
    for j in range(2): 
        locals()['df_{}_{}'.format(list_final_df[i], list_split2[j])] = \ 
        locals()['df_{}'.format(final_df_list[i])][ 
            ((locals()['df_{}'.format(final_df_list[i])]['limmaFC{}'.format(list_split2[j])] > 0) |  
             (locals()['df_{}'.format(final_df_list[i])]['ibbFC{}'.format(list_split[j])] < 0)) &  
            ((locals()['df_{}'.format(final_df_list[i])]['limmapVal{}'.format(list_split2[j])] < 0.05) |  
              (locals()['df_{}'.format(final_df_list[i])]['ibbpVal{}'.format(list_split[j])] < 0.05))] 




#also export the whole dataframe as a csv  
 
#drop all rows with 0 for gene name (uncharacterized proteins etc...) and export gene lists to csvs 
 
#start with the first 6 individual ones 
for i in range(6): 
    locals()['df_{}'.format(list_final_df[i])] = \ 
    locals()['df_{}'.format(list_final_df[i])][locals()['df_{}'.format(list_final_df[i])].Gene != 0] 
    locals()['df_{}'.format(list_final_df[i])]['Gene'].to_csv('Interactors{}.csv'.format(list_final_df[i]),  
                                                              index=False, header=True) 
    locals()['df_{}'.format(list_final_df[i])].to_csv( 
        './20B25_Analyzed_PD_Output/Interactors{}.csv'.format(list_final_df[i]), index=False, header=True) 
     
#then do the liver/brain combined 
for i in range(6,8): 
    for j in range(2): 
        locals()['df_{}_{}'.format(list_final_df[i], list_split2[j])] = \ 
        locals()['df_{}_{}'.format(list_final_df[i], list_split2[j])][ 
            locals()['df_{}_{}'.format(list_final_df[i], list_split2[j])].Gene != 0] 
        locals()['df_{}_{}'.format(list_final_df[i], list_split2[j])]['Gene'].to_csv( 
            'Interactors{}{}.csv'.format(list_final_df[i], list_split2[j]), index=False, header=True) 
        locals()['df_{}_{}'.format(list_final_df[i], list_split2[j])].to_csv( 
            './20B25_Analyzed_PD_Output/Interactors{}_{}.csv'.format(list_final_df[i], list_split2[j]),  
            index=False, header=True) 
     
#now output the number of interactors in each condition, make a df export it to csv, and display it here 
 
df_num_ints = pd.DataFrame(np.empty((8,1))) 
 
for i in range(6): 
    df_num_ints.iloc[i] = len(locals()['df_{}'.format(list_final_df[i])]) 
    df_num_ints.columns = ['Interactors'] 
    df_num_ints.rename(index={i:list_final_df[i]}, inplace=True) 
     
#also calculate the combined number of interactors 
df_num_ints.iloc[6] = len(set((list(df_LiverBrainF_Liver.Accession) + list(df_LiverBrainF_Brain.Accession)))) 
df_num_ints.iloc[7] = len(set((list(df_LiverBrainSwiss_Liver.Accession) + list(df_LiverBrainSwiss_Brain.Accession)))) 
df_num_ints.rename(index={6:'LiverBrainF', 7:'LiverBrainSwiss'}, inplace=True) 
     
df_num_ints.Interactors = df_num_ints.Interactors.astype(int) 




#count up the number of substrates and display here  
#also export gene lists as with interactors 
 
#first import the files 
#list the filenames 
fnameg0 = './293T_Glycomics_Full/293T_Glycomics_Full_Proteins.txt' 
fnameg1 = './293T_Glycomics_SwissProt/293T_Glycomics_SwissProt_Proteins.txt' 
fnameg2 = './Brain_Glycomics_Full/Brain_Glycomics_Full_Proteins.txt' 
fnameg3 = './Brain_Glycomics_SwissProt/Brain_Glycomics_SwissProt_Proteins.txt' 
fnameg4 = './Liver_Glycomics_Full/Liver_Glycomics_Full_Proteins.txt' 
fnameg5 = './Liver_Glycomics_SwissProt/Liver_Glycomics_SwissProt_Proteins.txt' 
fnameg6 = './LiverBrain_Glycomics_Full/LiverBrain_Glycomics_Full_Proteins.txt' 
fnameg7 = './LiverBrain_Glycomics_SwissProt/LiverBrain_Glycomics_SwissProt_Proteins.txt' 
fnamesg = [fnameg0, fnameg1, fnameg2, fnameg3, fnameg4, fnameg5, fnameg6, fnameg7] #concatenate into a single list 
 
#import all of the files into dfs 
 
#make lists for for loop 
list_expg = ['293TFg', '293TSPg', 'BrainFg', 'BrainSPg', 'LiverFg', 'LiverSPg', 'LiverBrainFg', 'LiverBrainSPg'] 
 
#define all the dfs in a for loop 
for i in range(8): 
    locals()['df{}'.format(list_expg[i])] = pd.read_csv(fnamesg[i], sep='\t') 
 
 
#set only these columns to keep 
cols_to_keepg = ['Accession', 'Description', 'Modifications'] 
 
#make a list for these new dfs 
list_dfg = ['293Fullg', '293SwissProtg', 'BrainFullg', 'BrainSwissProtg', 'LiverFullg', 'LiverSwissProtg', 'LiverBrainFullg',  
           'LiverBrainSwissProtg'] 
 
#use a for loop to get the relevant info from all 8 dfs (also remove contaminant proteins) 
#also get gene symbols from fasta lines and make all caps 
#remove all non-glycosylated proteins 
#export list of substrate and sorted output 
 
for i in range(8): 
    locals()['df{}'.format(list_dfg[i])] = locals()['df{}'.format(list_expg[i])][locals()['df{}'.format(list_expg[i])].\ 
                                                                               Contaminant == False] 
    locals()['df{}'.format(list_dfg[i])] = locals()['df{}'.format(list_dfg[i])][~locals()['df{}'.format(list_dfg[i])].\ 
                                                                               Description.str.contains('contaminant')] 
    locals()['df{}'.format(list_dfg[i])].Modifications.fillna(' ', inplace=True) 
    locals()['df{}'.format(list_dfg[i])] = locals()['df{}'.format(list_dfg[i])][locals()['df{}'.format(list_dfg[i])].\ 
                                                                               Modifications.str.contains('GlcNAc')] 
    locals()['df{}'.format(list_dfg[i])] = locals()['df{}'.format(list_dfg[i])][cols_to_keepg] 
    locals()['df{}'.format(list_dfg[i])]['Gene'] = \ 
    locals()['df{}'.format(list_dfg[i])]['Description'].str.extract('GN=(.*) PE=') 




     
for i in list_dfg: 
    locals()['df{}'.format(i)] = locals()['df{}'.format(i)][locals()['df{}'.format(i)].Gene != 0] 
    locals()['df{}'.format(i)] = locals()['df{}'.format(i)][locals()['df{}'.format(i)].Gene != np.nan] 
    locals()['df{}'.format(i)]['Gene'].to_csv('Substrates{}.csv'.format(i.replace(r'g', '')), index=False, header=True) 
    locals()['df{}'.format(i)].to_csv( 
        './20B25_Analyzed_PD_Output/Substrates{}.csv'.format(i.replace(r'g', '')), index=False, header=True) 
     
#now output the number of interactors in each condition, make a df export it to csv, and display it here 
 
df_num_subs = pd.DataFrame(np.empty((8,1))) 
 
for i in range(8): 
    df_num_subs.iloc[i] = len(locals()['df{}'.format(list_dfg[i])]) 
    df_num_subs.columns = ['Substrates'] 
    df_num_subs.Substrates = df_num_subs.Substrates.astype(int) 
    df_num_subs.rename(index={i:list_dfg[i].replace(r'g', '')}, inplace=True) #remove g from index names as well this time 




#make new dfs with the relevant informaton for making Venn diagrams for the substrates 
 
#pick the relevant columns for the liver or the brain 
columnsLiver = ['Found in File in F1', 'Found in File in F2', 'Found in File in F3', 'Found in File in F4'] 
columnsBrain = ['Found in File in F5', 'Found in File in F6', 'Found in File in F7', 'Found in File in F8'] 
 
 
#check whether a protein was found in any of the files for the liver and make a new True/False column 'Liver' 
#then do the same thing for the brain 
 
#first make lists to make setting up a for loop easier 
list_venn = ['Liver', 'Brain'] 
list_venn1 = ['F', 'SP'] 
 
for i in range(2): 
    for j in range(2): 
        locals()['dfLiverBrain{}g'.format(list_venn1[i])]['{}'.format(list_venn[j])] =\ 
        locals()['dfLiverBrain{}g'.format(list_venn1[i])][locals()['columns{}'.format( 
            list_venn[j])]].ne('Not Found').any(axis=1) 
 
#now merge these back onto the processed df and make sets out of the unprot 
 
#mae a list to facilitate the for loop 
list_venn2 = ['Full', 'SwissProt'] 
 
for i in range(2): 
    locals()['df_venn{}'.format(list_venn2[i])] = \ 
    locals()['dfLiverBrain{}g'.format(list_venn2[i])].merge(locals()['dfLiverBrain{}g'.format(list_venn1[i])], how='left',  
                                                           on='Accession') 
    for j in list_venn: 
        locals()['set_subs{}{}'.format(j, list_venn1[i])] = \ 
        set(locals()['df_venn{}'.format(list_venn2[i])][locals()['df_venn{}'.format( 
            list_venn2[i])]['{}'.format(j)] == True].Accession) 
#make new dfs with the relevant informaton for making Venn diagrams for the interactors 
 
#make a list for the following for loop 
list_venni = ['F', 'Swiss'] 
 
for i in list_venni: 
    for j in list_split2: 
        locals()['set_ints{}_{}'.format(i, j)] = set(locals()['df_LiverBrain{}_{}'.format(i, j)].Accession) 
#now make the venn diagrams for the substrates and output to svg  
 
#Full proteome  
plt.figure(figsize=(7,7)) 











#set the font size 
for text in fig.set_labels: #need to call named object 'fig' from above, font size is set numerically 
    text.set_fontsize(36) #this is the label names 
for text in fig.subset_labels: 
    text.set_fontsize(28) #this will change the numbers 
 


















#set the font size 
for text in fig.set_labels: #need to call named object 'fig' from above, font size is set numerically 
    text.set_fontsize(36) #this is the label names 
for text in fig.subset_labels: 
    text.set_fontsize(28) #this will change the numbers 
     
plt.savefig('SubstrateOverlap_SwissProt.svg') #save figure 
 
plt.show() #show the plot 
 
#now make the venn diagrams for the interactors and output to svg  
 
#Full proteome  
plt.figure(figsize=(7,7)) 











#set the font size 
for text in fig.set_labels: #need to call named object 'fig' from above, font size is set numerically 
    text.set_fontsize(36) #this is the label names 
for text in fig.subset_labels: 
    text.set_fontsize(28) #this will change the numbers 
 















#set the font size 
for text in fig.set_labels: #need to call named object 'fig' from above, font size is set numerically 
    text.set_fontsize(36) #this is the label names 
for text in fig.subset_labels: 
    text.set_fontsize(28) #this will change the numbers 
     
plt.savefig('InteractorOverlap_SwissProt.svg') #save figure 
 
plt.show() #show the plot 
 
#now make the Venn diagrams for the substrates in the separate searches 
 
#makes sets of the brain and liver data for matplotlibvenn from the individual dfs 
for i in range(2): 
    for j in range(2): 
        locals()['set_subs2{}{}'.format(list_venn[i], list_venn2[j])] = \ 
        set(locals()['df{}{}g'.format(list_venn[i], list_venn2[j])]['Accession']) 
 
#now make the Venn diagrams as before 
#Full proteome  
plt.figure(figsize=(7,7)) 











#set the font size 
for text in fig.set_labels: #need to call named object 'fig' from above, font size is set numerically 
    text.set_fontsize(36) #this is the label names 
for text in fig.subset_labels: 


















#set the font size 
for text in fig.set_labels: #need to call named object 'fig' from above, font size is set numerically 
    text.set_fontsize(36) #this is the label names 
for text in fig.subset_labels: 
    text.set_fontsize(28) #this will change the numbers 
 
plt.show() #show the plot 
 
#now make the Venn diagrams for the interactors in the separate searches 
 
list_venn4 = ['F', 'Swiss'] 
 
#makes sets of the brain and liver data for matplotlibvenn from the individual dfs 
for i in range(2): 
    for j in range(2): 
        locals()['set_ints2{}{}'.format(list_venn[i], list_venn2[j])] = \ 
        set(locals()['df_{}{}'.format(list_venn[i], list_venn4[j])]['Accession']) 
 
#now make the Venn diagrams as before 
#Full proteome  
plt.figure(figsize=(7,7)) 











#set the font size 
for text in fig.set_labels: #need to call named object 'fig' from above, font size is set numerically 
    text.set_fontsize(36) #this is the label names 
for text in fig.subset_labels: 















#set the font size 
for text in fig.set_labels: #need to call named object 'fig' from above, font size is set numerically 
    text.set_fontsize(36) #this is the label names 
for text in fig.subset_labels: 
    text.set_fontsize(28) #this will change the numbers 
 
plt.show() #show the plot 
 
#now make the Venn diagram for the whole proteome 
 
#import the data from Huttlin 2010 (I preprocessed this so there are just 2 columns of protein names) 
#also see '19G30 Brain vs Liver Venn Diagrams Update' 
df_proteome = pd.read_csv('Proteome_Brain_Liver.csv') 
df_phosphoproteome = pd.read_csv('Phoshoproteome_Brain_Liver.csv') 
 
#make listsfor processing both datasets 
list_prot = ['', 'phospho'] 
list_prot2 = ['Brain', 'Liver'] 
 
#drop nans and make sets for each dataset 
for i in list_prot: 
    for j in list_prot2: 
        locals()['df_{}proteome{}'.format(i, j)] = locals()['df_{}proteome'.format(i)]['{}'.format(j)] 
        locals()['df_{}proteome{}'.format(i, j)].dropna(inplace=True) 
        locals()['set_{}proteome_{}'.format(i, j)] = set(locals()['df_{}proteome{}'.format(i, j)]) 
     
#now make the venn diagrams for the entire proteome and phosphoproteome and output to svg 
 
#Full proteome  
plt.figure(figsize=(7,7)) 














#set the font size 
for text in fig.set_labels: #need to call named object 'fig' from above, font size is set numerically 
    text.set_fontsize(36) #this is the label names 
for text in fig.subset_labels: 
    text.set_fontsize(28) #this will change the numbers 
 















#set the font size 
for text in fig.set_labels: #need to call named object 'fig' from above, font size is set numerically 
    text.set_fontsize(36) #this is the label names 
for text in fig.subset_labels: 
    text.set_fontsize(28) #this will change the numbers 
     
plt.savefig('PhosphoproteomeOverlap.svg') #save figure 
 
plt.show() #show the plot 
 
 
A5.6.2. Preprocesing of PPI Databases. 
 
#import python packages 
import pandas as pd 
import numpy as np 
from io import StringIO 
import urllib.request, urllib.parse, urllib.error,urllib.request,urllib.error,urllib.parse 
#first the BioGRID database 
fname = 'BIOGRID-ORGANISM-Homo_sapiens-3.5.181.tab2.txt' #set the filename 
dfbg = pd.read_csv(fname, sep='\t') #import as df 
 
#rename interactor columns 
dfbg.rename(columns={'Official Symbol Interactor A':'Interactor_A', 'Official Symbol Interactor B':'Interactor_B'},  
            inplace=True) 
 
#keep only physical interactions 
dfbg = dfbg[dfbg['Experimental System Type'] == 'physical'] 
 
#keep only relevant columns 
dfbg = dfbg[['Interactor_A', 'Interactor_B']]  
 
#make all strings uppercase and drop nans 
dfbg['Interactor_A'] = dfbg.Interactor_A.str.upper() 
dfbg['Interactor_B'] = dfbg.Interactor_B.str.upper() 
dfbg.dropna(inplace=True) 
 
dfbg.to_csv('BioGRID.txt', sep='\t', index=False) #export to tab delimited 
dfbg #inspect 
 
#now with the IntAct database 
fname1 = 'IntAct-human-human.txt' #set the filename 
dfi = pd.read_csv(fname1, sep='\t') #import as df 
dfi = dfi[['#ID(s) interactor A', 'ID(s) interactor B']] #keep only relevant columns 
dfi.columns = ['Interactor_A', 'Interactor_B'] #rename the columns as before 
 
#keep only PPIs by filtering for uniprot acessions only in both columns 
dfi = dfi[dfi.Interactor_A.str.contains('uniprot')] 
dfi = dfi[dfi.Interactor_B.str.contains('uniprot')] 
 
#groupby duplicates in both interactor A and B and count the number of times they are repeated 
#this also creates a new column ('Number') to track how many incidences of each pair there are  
dfi_1 = dfi.groupby(['Interactor_A', 'Interactor_B']).size().reset_index(name="Number") 
 
#make a new df with only interactions that have more than 1 entry in the database (multivalidated) 
dfi_mv = dfi_1[dfi_1.Number >1]  
 





#now will map the uniprot ids to their gene names 
 
#make a new df to prevent having to reimport the entire IntAct databse if the df needs to be reset for any reason 
dfia = dfi_1.copy() 
 
#first clean up the entries 
dfia.reset_index(inplace=True, drop=True) #reset the index 
dfia.drop(columns={'Number'}, inplace=True) #drop the number column 
 
#strip the uniprot ids 
dfia['Interactor_A'] = dfia['Interactor_A'].map(lambda x: x.lstrip('uniprotkb:')) 
dfia['Interactor_B'] = dfia['Interactor_B'].map(lambda x: x.lstrip('uniprotkb:')) 
 
#now remove the isoform identifiers 
dfia['Interactor_A'] = dfia['Interactor_A'].map(lambda x: x.split('-', 1)[0]) 
dfia['Interactor_B'] = dfia['Interactor_B'].map(lambda x: x.split('-', 1)[0]) 
 
#now make a list of uniprot ids to map to gene names 
dfmap = pd.DataFrame(pd.concat([dfia['Interactor_A'], dfia['Interactor_B']])) #concatenate the columns in a new df 
dfmap.drop_duplicates(inplace=True) #drop duplicates 
dfmap.columns = ['UniprotID'] #rename the column 
uniprot_input = list(dfmap.UniprotID) #make this item into a list for uploading 
#now query uniprot 
 
#define variables 
url = 'https://www.uniprot.org/uploadlists/' 
user_agent = 'Mozilla/5.0 (Windows NT 10.0; Win64; x64)' 
 
#make a dictionary for the requests 
params = { 
    "from":"ACC+ID", 
    "to":"ACC", 
    "format":"tab", 
    "columns": "genes(PREFERRED)", 




data = urllib.parse.urlencode(params, doseq=False) 
data = data.encode('ascii') 
headers = {"User-Agent": user_agent} 
request = urllib.request.Request(url, data, headers) 
response = urllib.request.urlopen(request) 
with urllib.request.urlopen(request) as f: 
   response = f.read().decode() 
 
#make a dataframe from the output 
df_res = pd.read_csv(StringIO(response), sep='\t') #use the stringIO package to parse the output instead of making a file 
df_res #inspect 
 
#make a dictionary from the uniprot output and rename the uniprot ids in the intact database  
#do the same for the multivalidated dataset (uses the same dictionary since it is a subset) 
 
#copy the multivalidated interactor database 
dfimv = dfi_mv.copy() 
 
#first rename the columns for convenience 
df_res.rename(columns={df_res.columns[0]: "Gene", df_res.columns[1]: "UniprotID"}, inplace=True) 
 
#set up the dictionary for mapping 
di = df_res.set_index('UniprotID')['Gene'].to_dict() 
 










#export the data to a txt as with the biogrid database 
dfia.to_csv('IntAct.txt', sep='\t', index=False) 




A5.6.3. Construction of PPI Networks. 
 
#import python packages  
import re 
import pandas as pd 
import numpy as np 
import matplotlib 
import matplotlib.pyplot as plt 
 







#magic function to show plots inline 
%matplotlib inline 
#load in BioGRID and IntAct databases (keeping naming consistent with Yao's script) 
 
#first BioGRID 
dfPPI = pd.read_csv('BioGRID.txt', sep='\t') 
 
#then IntAct 
dfPPI2 = pd.read_csv('IntAct.txt', sep='\t') 
#read in the OGT interactors and substrates 
 
#make a list for naming the binders and substrates lists 
list_lists = ['293T', 'Brain', 'Liver', 'LiverBrain'] 
 
#make a list for the filenames 
list_fnames = ['293TF', 'BrainF', 'LiverF', 'LiverBrainF'] 
 
#use a for loop to import all of them except the liver brain combined 
for i in range(3): 
    locals()['df_OGTInt{}'.format(list_fnames[i])] = pd.read_csv('Interactors{}.csv'.format(list_fnames[i])) 
     
#import the liver brain combined by concatenating the liver and brain datasets and dropping duplicates 
locals()['df_OGTInt{}'.format(list_fnames[3])] = \ 
pd.concat([pd.read_csv('Interactors{}Liver.csv'.format(list_fnames[3])),  
           pd.read_csv('Interactors{}Brain.csv'.format(list_fnames[3]))], axis=0) 
locals()['df_OGTInt{}'.format(list_fnames[3])].drop_duplicates(inplace=True) 
 
#make a new df and set up the columns as self interactors 
for i in range(4): 
    locals()['df_binders{}'.format(list_fnames[i])] = locals()['df_OGTInt{}'.format(list_fnames[i])].copy() 
    locals()['df_binders{}'.format(list_fnames[i])].columns = ['Interactor_A'] 
    locals()['df_binders{}'.format(list_fnames[i])]['Interactor_B'] = \ 
    locals()['df_binders{}'.format(list_fnames[i])]['Interactor_A'] 
    locals()['bind_list{}'.format(list_lists[i])] = \ 
    locals()['df_binders{}'.format(list_fnames[i])]['Interactor_A'].values.tolist() 
     
#now read in the substrates as with the interactors 
 
#make a list for the filenames 
list_fnames2 = ['293Full', 'BrainFull', 'LiverFull', 'LiverBrainFull'] 
 
#import everything with a for loop 
for i in list_fnames2: 
    locals()['dfOGTSubs{}'.format(i)] = pd.read_csv('Substrates{}.csv'.format(i)) 
     
for i in range(4): 
    locals()['df_subs{}'.format(list_fnames2[i])] = locals()['dfOGTSubs{}'.format(list_fnames2[i])].copy() 
    locals()['df_subs{}'.format(list_fnames2[i])].columns = ['Interactor_A'] 
    locals()['df_subs{}'.format(list_fnames2[i])]['Interactor_B'] = \ 
    locals()['df_subs{}'.format(list_fnames2[i])]['Interactor_A'] 
    locals()['subs_list{}'.format(list_lists[i])] = \ 
    locals()['df_subs{}'.format(list_fnames2[i])]['Interactor_A'].values.tolist() 
#filter the BioGRID database for interactions between ints and ints and ints and subs 
 
#filter for proteins that matched either an OGT interactor or an OGT substrate 
for i in list_lists: 
    locals()['bindsub_list{}'.format(i)] = locals()['bind_list{}'.format(i)] + locals()['subs_list{}'.format(i)] 
 
#find all the interactions from A to B in BioGRID that are from the bind list to the concatenated lists 
for i in list_lists: 
    locals()['dfPPIA{}'.format(i)] = dfPPI[dfPPI.Interactor_A.isin(locals()['bind_list{}'.format(i)]) &  
                                           dfPPI.Interactor_B.isin(locals()['bindsub_list{}'.format(i)])] 
     
#do the same for interactions from B to A 
for i in list_lists: 
    locals()['dfPPIB{}'.format(i)] = dfPPI[dfPPI.Interactor_B.isin(locals()['bind_list{}'.format(i)]) &  
                                           dfPPI.Interactor_A.isin(locals()['bindsub_list{}'.format(i)])] 
 
#swap the two columns in dfPPIB because the interactions are undirectional (we will define A to B) 
for i in list_lists: 
    locals()['colList{}'.format(i)] = list(locals()['dfPPIB{}'.format(i)]) 
    locals()['colList{}'.format(i)][0], locals()['colList{}'.format(i)][1] = \ 
    locals()['colList{}'.format(i)][1], locals()['colList{}'.format(i)][0] 
    locals()['dfPPIB{}'.format(i)].columns = locals()['colList{}'.format(i)] 
     
#put everything together in one dataframe and drop duplicates 
for i in list_lists: 
    locals()['dfPPI{}'.format(i)] = locals()['dfPPIA{}'.format(i)].append(locals()['dfPPIB{}'.format(i)]) 
    locals()['dfPPI{}'.format(i)].drop_duplicates(subset=['Interactor_A', 'Interactor_B'], inplace=True) 
    locals()['dfPPI{}'.format(i)].reset_index(inplace=True, drop=True) 
#filter against super-interactors 
 
#sort the df by number of times a protein appears in the Interactor_A column and make a new df 
for i in list_lists: 
    locals()['interactCount{}'.format(i)] = \ 
    locals()['dfPPI{}'.format(i)].groupby(['Interactor_A']).count().reset_index().rename( 
        columns={'Interactor_B':'TotalCount'}) 
     
#make a new df of interactors from OGT interactors in column A to substrates in column B and vice versa  




for i in list_lists: 
    locals()['dfPPIC{}'.format(i)] = \ 
    locals()['dfPPI{}'.format(i)][ 
        locals()['dfPPI{}'.format(i)].Interactor_A.isin(locals()['bind_list{}'.format(i)]) &  
        locals()['dfPPI{}'.format(i)].Interactor_B.isin(locals()['subs_list{}'.format(i)])] 
    locals()['dfPPID{}'.format(i)] = \ 
    locals()['dfPPI{}'.format(i)][ 
        locals()['dfPPI{}'.format(i)].Interactor_B.isin(locals()['bind_list{}'.format(i)]) &  
        locals()['dfPPI{}'.format(i)].Interactor_A.isin(locals()['subs_list{}'.format(i)])] 
    locals()['colList2{}'.format(i)] = list(locals()['dfPPID{}'.format(i)]) 
    locals()['colList2{}'.format(i)][0], locals()['colList2{}'.format(i)][1] = \ 
    locals()['colList2{}'.format(i)][1], locals()['colList2{}'.format(i)][0] 
    locals()['dfPPID{}'.format(i)].columns = locals()['colList2{}'.format(i)] 
     
#make a new dataframe of tha concatenated two previous dataframes (also drop duplicates and reset index) 
for i in list_lists: 
    locals()['bindsub{}'.format(i)] = locals()['dfPPIC{}'.format(i)].append(locals()['dfPPID{}'.format(i)]) 
    locals()['bindsub{}'.format(i)].drop_duplicates(subset=['Interactor_A', 'Interactor_B'], inplace=True) 
    locals()['bindsub{}'.format(i)].reset_index(drop=True, inplace=True) 
     
#make a new df grouped by the number of instances as before 
for i in list_lists: 
    locals()['bindsub{}'.format(i)] = \ 
    locals()['bindsub{}'.format(i)].groupby(['Interactor_A']).count().reset_index().rename( 
        columns={'Interactor_B':'SubsCount'}) 
     
# make two new dfs from binders in column A to binders in column B and vice versa  
#switching the columns for this second df as before 
for i in list_lists: 
    locals()['dfPPIE{}'.format(i)] = \ 
    locals()['dfPPI{}'.format(i)][ 
        locals()['dfPPI{}'.format(i)].Interactor_A.isin(locals()['bind_list{}'.format(i)]) &  
        locals()['dfPPI{}'.format(i)].Interactor_B.isin(locals()['bind_list{}'.format(i)])] 
    locals()['dfPPIF{}'.format(i)] = \ 
    locals()['dfPPI{}'.format(i)][ 
        locals()['dfPPI{}'.format(i)].Interactor_B.isin(locals()['bind_list{}'.format(i)]) &  
        locals()['dfPPI{}'.format(i)].Interactor_A.isin(locals()['bind_list{}'.format(i)])] 
    locals()['colList3{}'.format(i)] = list(locals()['dfPPIF{}'.format(i)]) 
    locals()['colList3{}'.format(i)][0], locals()['colList3{}'.format(i)][1] = \ 
    locals()['colList3{}'.format(i)][1], locals()['colList3{}'.format(i)][0] 
    locals()['dfPPIF{}'.format(i)].columns = locals()['colList3{}'.format(i)] 
     
#make a new df grouped by number of counts for these new dfs as before 
for i in list_lists: 
    locals()['bindbind{}'.format(i)] = locals()['dfPPIE{}'.format(i)].append(locals()['dfPPIF{}'.format(i)]) 
    locals()['bindbind{}'.format(i)].drop_duplicates(subset=['Interactor_A', 'Interactor_B'], inplace=True) 
    locals()['bindbind{}'.format(i)].reset_index(drop=True, inplace=True) 
    locals()['bindbind{}'.format(i)] = \ 
    locals()['bindbind{}'.format(i)].groupby(['Interactor_A']).count().reset_index().rename( 
        columns={'Interactor_B':'BinderCount'}) 
     
#add everything back into the interactCount df 
for i in list_lists: 
    locals()['interactCount{}'.format(i)] = \ 
    locals()['interactCount{}'.format(i)].merge( 
        locals()['bindsub{}'.format(i)], how='left', left_on='Interactor_A', right_on='Interactor_A') 
    locals()['interactCount{}'.format(i)] = \ 
    locals()['interactCount{}'.format(i)].merge( 
        locals()['bindbind{}'.format(i)], how='left', left_on='Interactor_A', right_on='Interactor_A') 
    locals()['interactCount{}'.format(i)].fillna(0, inplace=True) 
     
#drop highly interacting proteins, sort the dataframe, and reset the index 
for i in list_lists: 
    locals()['interactCount{}'.format(i)] = \ 
    locals()['interactCount{}'.format(i)][ 
        ~(locals()['interactCount{}'.format(i)].Interactor_A.str.contains('RPL') |  
          locals()['interactCount{}'.format(i)].Interactor_A.str.contains('RPS') |  
          locals()['interactCount{}'.format(i)].Interactor_A.str.contains('OGT') |  
          locals()['interactCount{}'.format(i)].Interactor_A.str.contains('HSP') |  
          locals()['interactCount{}'.format(i)].Interactor_A.str.contains('HNRP'))] 
    locals()['interactCount{}'.format(i)] = \ 
    locals()['interactCount{}'.format(i)].sort_values( 
        ['TotalCount','SubsCount','BinderCount','Interactor_A'], ascending=[0,0,0,0]) 
    locals()['interactCount{}'.format(i)].reset_index(drop=True, inplace=True) 
 
#remove things with too many interactions, total instances less than 30 
 
#make a list of superinteractors to remove 
for i in list_lists: 
    locals()['filtered{}'.format(i)] = \ 
    locals()['interactCount{}'.format(i)][locals()['interactCount{}'.format(i)].TotalCount < 30] 
    locals()['interactCount{}'.format(i)].reset_index(drop=True, inplace=True) 
    locals()['filterlist{}'.format(i)] = locals()['filtered{}'.format(i)].Interactor_A.values.tolist() 
     
#remove the super interactors from the PPI database 
for i in list_lists: 
    locals()['dfPPI{}'.format(i)] = \ 
    locals()['dfPPI{}'.format(i)][locals()['dfPPI{}'.format(i)].Interactor_A.isin(locals()['filterlist{}'.format(i)])] 
 
#remove OGT and keratin from the network 
for i in list_lists: 
    locals()['dfPPI{}'.format(i)] = \ 




    locals()['dfPPI{}'.format(i)] = \ 
    locals()['dfPPI{}'.format(i)][~locals()['dfPPI{}'.format(i)].Interactor_B.str.contains('OGT')] 
    locals()['dfPPI{}'.format(i)] = \ 
    locals()['dfPPI{}'.format(i)][~locals()['dfPPI{}'.format(i)].Interactor_A.str.contains('KRT')] 
    locals()['dfPPI{}'.format(i)] = \ 
    locals()['dfPPI{}'.format(i)][~locals()['dfPPI{}'.format(i)].Interactor_B.str.contains('KRT')] 
     
# Assuming OGT interactor/substrate named protA 
# Adds in pseudo protA-protA self interactions so that protA will be displayed  
# in cytoscape no matter if it has any interactions with any other OGT interactor/substrates. 
for i in range(4): 
    locals()['dfPPI{}'.format(list_lists[i])] = \ 
    locals()['dfPPI{}'.format(list_lists[i])].append(locals()['df_binders{}'.format(list_fnames[i])]) 
    locals()['dfPPI{}'.format(list_lists[i])] = \ 
    locals()['dfPPI{}'.format(list_lists[i])].append(locals()['df_subs{}'.format(list_fnames2[i])]) 
#now I will repeat the same thing for the IntAct database 
 
#find all the interactions from A to B in IntAct that are from the bind list to the concatenated lists 
for i in list_lists: 
    locals()['dfPPI2A{}'.format(i)] = dfPPI2[dfPPI2.Interactor_A.isin(locals()['bind_list{}'.format(i)]) &  
                                           dfPPI2.Interactor_B.isin(locals()['bindsub_list{}'.format(i)])] 
     
#do the same for interactions from B to A 
for i in list_lists: 
    locals()['dfPPI2B{}'.format(i)] = dfPPI2[dfPPI2.Interactor_B.isin(locals()['bind_list{}'.format(i)]) &  
                                           dfPPI2.Interactor_A.isin(locals()['bindsub_list{}'.format(i)])] 
 
#swap the two columns in dfPPI2B because the interactions are undirectional (we will define A to B) 
for i in list_lists: 
    locals()['col2List{}'.format(i)] = list(locals()['dfPPI2B{}'.format(i)]) 
    locals()['col2List{}'.format(i)][0], locals()['col2List{}'.format(i)][1] = \ 
    locals()['colList{}'.format(i)][1], locals()['colList{}'.format(i)][0] 
    locals()['dfPPI2B{}'.format(i)].columns = locals()['col2List{}'.format(i)] 
     
#put everything together in one dataframe and drop duplicates 
for i in list_lists: 
    locals()['dfPPI2{}'.format(i)] = locals()['dfPPI2A{}'.format(i)].append(locals()['dfPPI2B{}'.format(i)]) 
    locals()['dfPPI2{}'.format(i)].drop_duplicates(subset=['Interactor_A', 'Interactor_B'], inplace=True) 
    locals()['dfPPI2{}'.format(i)].reset_index(inplace=True, drop=True) 
     
#filter against super-interactors 
 
#sort the df by number of times a protein appears in the Interactor_A column and make a new df 
for i in list_lists: 
    locals()['interactCount2{}'.format(i)] = \ 
    locals()['dfPPI2{}'.format(i)].groupby(['Interactor_A']).count().reset_index().rename( 
        columns={'Interactor_B':'TotalCount'}) 
     
#make a new df of interactors from OGT interactors in column A to substrates in column B and vice versa  
#also switch the column names for B to A df as before 
for i in list_lists: 
    locals()['dfPPI2C{}'.format(i)] = \ 
    locals()['dfPPI2{}'.format(i)][locals()['dfPPI2{}'.format(i)].Interactor_A.isin(locals()['bind_list{}'.format(i)]) &  
                                   locals()['dfPPI2{}'.format(i)].Interactor_B.isin(locals()['subs_list{}'.format(i)])] 
    locals()['dfPPI2D{}'.format(i)] = \ 
    locals()['dfPPI2{}'.format(i)][locals()['dfPPI2{}'.format(i)].Interactor_B.isin(locals()['bind_list{}'.format(i)]) &  
                                   locals()['dfPPI2{}'.format(i)].Interactor_A.isin(locals()['subs_list{}'.format(i)])] 
    locals()['col2List2{}'.format(i)] = list(locals()['dfPPI2D{}'.format(i)]) 
    locals()['col2List2{}'.format(i)][0], locals()['col2List2{}'.format(i)][1] = \ 
    locals()['col2List2{}'.format(i)][1], locals()['col2List2{}'.format(i)][0] 
    locals()['dfPPI2D{}'.format(i)].columns = locals()['col2List2{}'.format(i)] 
     
#make a new dataframe of tha concatenated two previous dataframes (also drop duplicates and reset index) 
for i in list_lists: 
    locals()['bindsub2{}'.format(i)] = locals()['dfPPI2C{}'.format(i)].append(locals()['dfPPI2D{}'.format(i)]) 
    locals()['bindsub2{}'.format(i)].drop_duplicates(subset=['Interactor_A', 'Interactor_B'], inplace=True) 
    locals()['bindsub2{}'.format(i)].reset_index(drop=True, inplace=True) 
     
#make a new df grouped by the number of instances as before 
for i in list_lists: 
    locals()['bindsub2{}'.format(i)] = \ 
    locals()['bindsub2{}'.format(i)].groupby(['Interactor_A']).count().reset_index().rename( 
        columns={'Interactor_B':'SubsCount'}) 
     
# make two new dfs from binders in column A to binders in column B and vice versa  
#switching the columns for this second df as before 
for i in list_lists: 
    locals()['dfPPI2E{}'.format(i)] = \ 
    locals()['dfPPI2{}'.format(i)][locals()['dfPPI2{}'.format(i)].Interactor_A.isin(locals()['bind_list{}'.format(i)]) &  
                                   locals()['dfPPI2{}'.format(i)].Interactor_B.isin(locals()['bind_list{}'.format(i)])] 
    locals()['dfPPI2F{}'.format(i)] = \ 
    locals()['dfPPI2{}'.format(i)][locals()['dfPPI2{}'.format(i)].Interactor_B.isin(locals()['bind_list{}'.format(i)]) &  
                                   locals()['dfPPI2{}'.format(i)].Interactor_A.isin(locals()['bind_list{}'.format(i)])] 
    locals()['col2List3{}'.format(i)] = list(locals()['dfPPI2F{}'.format(i)]) 
    locals()['col2List3{}'.format(i)][0], locals()['col2List3{}'.format(i)][1] = \ 
    locals()['col2List3{}'.format(i)][1], locals()['col2List3{}'.format(i)][0] 
    locals()['dfPPI2F{}'.format(i)].columns = locals()['col2List3{}'.format(i)] 
     
#make a new df grouped by number of counts for these new dfs as before 
for i in list_lists: 
    locals()['bindbind2{}'.format(i)] = locals()['dfPPI2E{}'.format(i)].append(locals()['dfPPI2F{}'.format(i)]) 
    locals()['bindbind2{}'.format(i)].drop_duplicates(subset=['Interactor_A', 'Interactor_B'], inplace=True) 




    locals()['bindbind2{}'.format(i)] = \ 
    locals()['bindbind2{}'.format(i)].groupby(['Interactor_A']).count().reset_index().rename( 
        columns={'Interactor_B':'BinderCount'}) 
     
#add everything back into the interactCount2 df 
for i in list_lists: 
    locals()['interactCount2{}'.format(i)] = \ 
    locals()['interactCount2{}'.format(i)].merge( 
        locals()['bindsub2{}'.format(i)], how='left', left_on='Interactor_A', right_on='Interactor_A') 
    locals()['interactCount2{}'.format(i)] = \ 
    locals()['interactCount2{}'.format(i)].merge( 
        locals()['bindbind2{}'.format(i)], how='left', left_on='Interactor_A', right_on='Interactor_A') 
    locals()['interactCount2{}'.format(i)].fillna(0, inplace=True) 
     
#drop highly interacting proteins, sort the dataframe, and reset the index 
for i in list_lists: 
    locals()['interactCount2{}'.format(i)] = \ 
    locals()['interactCount2{}'.format(i)][ 
        ~(locals()['interactCount2{}'.format(i)].Interactor_A.str.contains('RPL') |  
          locals()['interactCount2{}'.format(i)].Interactor_A.str.contains('RPS') |  
          locals()['interactCount2{}'.format(i)].Interactor_A.str.contains('OGT') |  
          locals()['interactCount2{}'.format(i)].Interactor_A.str.contains('HSP') |  
          locals()['interactCount2{}'.format(i)].Interactor_A.str.contains('HNRP'))] 
    locals()['interactCount2{}'.format(i)] = \ 
    locals()['interactCount2{}'.format(i)].sort_values( 
        ['TotalCount','SubsCount','BinderCount','Interactor_A'], ascending=[0,0,0,0]) 
    locals()['interactCount2{}'.format(i)].reset_index(drop=True, inplace=True) 
     
#remove things with too many interactions, total instances less than 30 
 
#make a list of superinteractors to remove 
for i in list_lists: 
    locals()['filtered{}'.format(i)] = \ 
    locals()['interactCount{}'.format(i)][locals()['interactCount{}'.format(i)].TotalCount < 30] 
    locals()['interactCount{}'.format(i)].reset_index(drop=True, inplace=True) 
    locals()['filterlist{}'.format(i)] = locals()['filtered{}'.format(i)].Interactor_A.values.tolist() 
 
#remove the super interactors from the PPI database 
for i in list_lists: 
    locals()['dfPPI2{}'.format(i)] = \ 
    locals()['dfPPI2{}'.format(i)][locals()['dfPPI2{}'.format(i)].Interactor_A.isin(locals()['filterlist{}'.format(i)])] 
 
#remove OGT and keratin from the network 
for i in list_lists: 
    locals()['dfPPI2{}'.format(i)] = \ 
    locals()['dfPPI2{}'.format(i)][~locals()['dfPPI2{}'.format(i)].Interactor_A.str.contains('OGT')] 
    locals()['dfPPI2{}'.format(i)] = \ 
    locals()['dfPPI2{}'.format(i)][~locals()['dfPPI2{}'.format(i)].Interactor_B.str.contains('OGT')] 
    locals()['dfPPI2{}'.format(i)] = \ 
    locals()['dfPPI2{}'.format(i)][~locals()['dfPPI2{}'.format(i)].Interactor_A.str.contains('KRT')] 
    locals()['dfPPI2{}'.format(i)] = \ 
    locals()['dfPPI2{}'.format(i)][~locals()['dfPPI2{}'.format(i)].Interactor_B.str.contains('KRT')] 
     
# Assuming OGT interactor/substrate named protA 
# Adds in pseudo protA-protA self interactions so that protA will be displayed  
# in cytoscape no matter it has interaction to any other OGT interactor/substrates. 
for i in range(4): 
    locals()['dfPPI2{}'.format(list_lists[i])] = \ 
    locals()['dfPPI2{}'.format(list_lists[i])].append(locals()['df_binders{}'.format(list_fnames[i])]) 
    locals()['dfPPI2{}'.format(list_lists[i])] = \ 
    locals()['dfPPI2{}'.format(list_lists[i])].append(locals()['df_subs{}'.format(list_fnames2[i])]) 
#now merge the results from the two databases and export 
#also export the interactor and substrate lists with an additional column containing 1s for cytoscape 
#also export two additional columns, 'liver' and 'brain,' if the interactor or substrate is present in the liver or brain,  
    #respectively 
 
#combine the BioGRID and IntAct results and drop duplicates 
for i in list_lists: 
    locals()['df_combined{}'.format(i)] = \ 
    pd.concat([locals()['dfPPI{}'.format(i)], locals()['dfPPI2{}'.format(i)]], ignore_index=True) 
    locals()['df_combined{}'.format(i)].drop_duplicates(inplace=True) 
    locals()['df_combined{}'.format(i)].to_csv('PPINetwork{}F_ForCytoscape.csv'.format(i), index=False) 
     
#add in the column of 1s to the ints and subs and export to csv for cytoscape for the first three  
for i in range(3): 
    locals()['df_OGTInt{}'.format(list_fnames[i])]['OGT_Interactor'] = 1 
    locals()['dfOGTSubs{}'.format(list_fnames2[i])]['OGT_Substrate'] = 1 
    locals()['df_OGTInt{}'.format(list_fnames[i])].to_csv('OGTInts{}F_ForCytoscape.csv'.format(list_lists[i]), index=False) 
    locals()['dfOGTSubs{}'.format(list_fnames2[i])].to_csv('OGTSubs{}F_ForCytoscape.csv'.format(list_lists[i]), index=False) 
     
#now do the same for the combined dataset but also add in columns for whether it is in the liver or brain 
 
#import the output from the previous script for the interactors, make a new column for brain or liver, and merge it with the 
    #gene list (convert all 1s to ints as well) 
df_ints_brain = pd.read_csv('./20B25_Analyzed_PD_Output/InteractorsLiverBrainF_Brain.csv') 
df_ints_brain['BrainInt'] = 1 
df_ints_liver = pd.read_csv('./20B25_Analyzed_PD_Output/InteractorsLiverBrainF_Liver.csv') 
df_ints_liver['LiverInt'] = 1 
dfm_OGTIntLiverBrain = df_OGTIntLiverBrainF.merge(df_ints_brain, how='left', on='Gene') 
dfm_OGTIntLiverBrain = dfm_OGTIntLiverBrain.merge(df_ints_liver, how='left', on='Gene') 
dfm_OGTIntLiverBrain = dfm_OGTIntLiverBrain[['Gene', 'LiverInt', 'BrainInt']] 
dfm_OGTIntLiverBrain['OGT_Interactor'] = 1 






#for the substrates map the genes back to the uniprot ids and then use the original PD output 'found in' columns to make a  
    #liver and brain column 
 
#import the PD output 
df_PD = pd.read_csv('./LiverBrain_Glycomics_Full/LiverBrain_Glycomics_Full_Proteins.txt', sep='\t') 
 
#pick the relevant columns for the liver or the brain 
columnsLiver = ['Found in File in F1', 'Found in File in F2', 'Found in File in F3', 'Found in File in F4'] 
columnsBrain = ['Found in File in F5', 'Found in File in F6', 'Found in File in F7', 'Found in File in F8'] 
 
#make a new column with True or False for whether it is found in any of the files 
df_PD['LiverSub'] = df_PD[columnsLiver].ne('Not Found').any(axis=1) 
df_PD['BrainSub'] = df_PD[columnsBrain].ne('Not Found').any(axis=1) 
 
#slice out the relevant columns 
df_PD2 = df_PD[['Accession', 'LiverSub', 'BrainSub']] 
 
#replace true false with 1 or nan 
df_PD2.LiverSub[df_PD2.LiverSub == False] = np.nan 
df_PD2.BrainSub[df_PD2.BrainSub == False] = np.nan 
 
#import output from previous script of the processed substrates, merge with the df above, drop irrelevant columns, and add  
    #in a column of 1s (OGT_Substrate); also convert all 1s to ints 
df_out_subs = pd.read_csv('./20B25_Analyzed_PD_Output/SubstratesLiverBrainFull.csv') 
df_out_subs2 = df_out_subs.merge(df_PD2, how='left', on='Accession') 
df_subs_out = df_out_subs2[['Gene', 'LiverSub', 'BrainSub']] 
df_subs_out['OGT_Substrate'] = 1 
df_subs_out[['LiverSub', 'BrainSub']] = df_subs_out[['LiverSub', 'BrainSub']].astype('Int64') 
df_subs_out.to_csv('OGTSubsLiverBrainF_ForCytoscape.csv', index=False) 
 
#the indeivudal networks can now be loaded into cytoscape and visualized 
 
A5.6.4. Sites and Regions Analysis. 
 This script was run twice, first, with the data from searched against the full proteins, 
and second, with the data searched against the Swiss-Prot proteome. The analysis has 5 parts: 
1. Processing of the 293T, brain, and liver datasets separately. This will serve to calculate 
the total number of sites in each of the tissues. 
2. Processing with the multiple experiments sites and regions script to keep the ETD and 
EThcD runs separate and then calculating the overlap between them for 293T cells, brain, 
and liver.  
3. Filtering the input data by activation type and running the sites and regions separately for 
the 293T cells, brain, and liver. This will allow us to calculate both the total and stratified 
(i.e. regions vs sites with xx localization probability) number of sites and regions found 
by each activation method. 
4. Using the multiple experiments sites and regions script on the brain/liver combined 




5. Finally, using the multiple experiments sites and regions script for the BAP1 KO 
quantitative glycomics samples. Raw files are separated to compare top speed to top N 
before averaging the top speeed/top N for the analysis. Then, limma is used to find the 
significantly changing sites and normalize the rations to their protein expression 
#import python packages  
import re 
import sys 
import pandas as pd 
import networkx as nx 
import itertools as it 
from collections import namedtuple 
import numpy as np 
import matplotlib 
import matplotlib.pyplot as plt 
from IPython.display import display 
from functools import reduce 
import seaborn as sns; sns.set() 
from io import StringIO 
from matplotlib_venn import venn2_unweighted #the unweighted is if you want to make circles that are the same size 
from matplotlib_venn import venn2 #also import the normal one 
import pandas as pd 
import numpy as np 
from io import StringIO 
import urllib.request, urllib.parse, urllib.error,urllib.request,urllib.error,urllib.parse 
 









#magic function to show plots inline 
%matplotlib inline 
 
#ignore warnings  
import warnings 
warnings.filterwarnings("ignore") 
#Import the necessary files (I am only using the full proteome searches) 
 
#list the filenames 
fname0 = './293T_Glycomics_Full/293T_Glycomics_Full_PSMs.txt' 
fname1 = './Brain_Glycomics_Full/Brain_Glycomics_Full_PSMs.txt' 
fname2 = './Liver_Glycomics_Full/Liver_Glycomics_Full_PSMs.txt' 
fname3 = './LiverBrain_Glycomics_Full/LiverBrain_Glycomics_Full_PSMs.txt' 
fnameq = './BAP1KO_Glycomics_Full/BAP1KO_Glycomics_Full_PSMs.txt' 
fnamep = './BAP1KO_ProteinExpression_Full/BAP1KO_ProteinExpression_Full_Proteins.txt' #protein expression 
list_fnames = [fname0, fname1, fname2, fname3, fnameq] 
#Preprocess the data for the sites and regions script, starting with the individual runs 
#Partially based on preprocessPD.py from Mike Sweredoski 1/24/2020 
 
SITE_NAME = "GlcNAc502" #define the mod name 
 
#make a list for naming the dfs 
list_dfs = ['293T', 'Brain', 'Liver', 'LiverBrain', 'Quant'] 
 
#set up a for loop for completing the operations on all dfs 
for i in range(4): 
    locals()['df{}'.format(list_dfs[i])] = pd.read_csv(list_fnames[i], sep='\t').rename(columns={ 
        "Spectrum File":"RawFile","Master Protein Accessions":"Protein","First Scan":"ScanNumber", 
        "Activation Type":"Fragmentation"}) 
    locals()['df{}'.format(list_dfs[i])]['Fragmentation'] = \ 
    locals()['df{}'.format(list_dfs[i])]['Fragmentation'].map(lambda x: x.split(' ', 1)[0]) 
    locals()['df{}'.format(list_dfs[i])].Modifications.dropna(inplace=True) 
    locals()['df{}'.format(list_dfs[i])]["NumMods"] = locals()['df{}'.format(list_dfs[i])]["Modifications"].apply( 
        lambda s: s.count(SITE_NAME)) 
    locals()['df{}'.format(list_dfs[i])] = \ 
    locals()['df{}'.format(list_dfs[i])][locals()['df{}'.format(list_dfs[i])]["NumMods"]>0] 
    locals()['df{}'.format(list_dfs[i])]["Probabilities"] = \ 
    locals()['df{}'.format(list_dfs[i])]["ptmRS %s Site Probabilities"%SITE_NAME].apply( 
        lambda s: ";".join([str(round(float(v.split()[-1])/100, 3)) for v in s.split("; ")])) 
    locals()['df{}'.format(list_dfs[i])]["Positions"] = \ 
    locals()['df{}'.format(list_dfs[i])].apply(lambda x: ";".join( 
        [str(int(v.split("(")[1].split(")")[0])-1+x["Position in Protein"]) for v in x[ 
            "ptmRS %s Site Probabilities"%SITE_NAME].split("; ")]),axis=1) 
     
#repeat for the BAP1 KO run (different SITE_NAME) 






locals()['df{}'.format(list_dfs[i])] = pd.read_csv(list_fnames[i], sep='\t').rename(columns={ 
    "Spectrum File":"RawFile","Master Protein Accessions":"Protein","First Scan":"ScanNumber", 
    "Activation Type":"Fragmentation"}) 
locals()['df{}'.format(list_dfs[i])]['Fragmentation'] = \ 
locals()['df{}'.format(list_dfs[i])]['Fragmentation'].map(lambda x: x.split(' ', 1)[0]) 
locals()['df{}'.format(list_dfs[i])].Modifications.dropna(inplace=True) 
locals()['df{}'.format(list_dfs[i])]["NumMods"] = locals()['df{}'.format(list_dfs[i])]["Modifications"].apply( 
    lambda s: s.count(Q_SITE_NAME)) 
locals()['df{}'.format(list_dfs[i])] = \ 
locals()['df{}'.format(list_dfs[i])][locals()['df{}'.format(list_dfs[i])]["NumMods"]>0] 
locals()['df{}'.format(list_dfs[i])]["Probabilities"] = \ 
locals()['df{}'.format(list_dfs[i])]["ptmRS %s Site Probabilities"%Q_SITE_NAME].apply( 
    lambda s: ";".join([str(round(float(v.split()[-1])/100, 3)) for v in s.split("; ")])) 
locals()['df{}'.format(list_dfs[i])]["Positions"] = \ 
locals()['df{}'.format(list_dfs[i])].apply(lambda x: ";".join( 
    [str(int(v.split("(")[1].split(")")[0])-1+x["Position in Protein"]) for v in x[ 
        "ptmRS %s Site Probabilities"%Q_SITE_NAME].split("; ")]),axis=1) 
 
#choose columns to keep 
cols_to_keep = ["RawFile","Fragmentation","ScanNumber","Protein","Positions","Probabilities","NumMods"] 
 
for i in range(5): 
    locals()['df{}_table'.format(list_dfs[i])] = locals()['df{}'.format(list_dfs[i])][cols_to_keep] 
Part 1 
### Set All HCD Localization Probabilities Equal Across S/Ts ### 
 
#PD/ptmRS cannot handle glycan NLs, so the localization probabilities for HCD are patently wrong 
#Because the glycan is almost always lost, I will set the localization probability to equal for all S/Ts 
#This seems to be a reasonable assumption after manually curating dozens of sepctra 
 
#write a for loop to perform this for all dfs 
for i in list_dfs: 
    #count the number of S/Ts 
    locals()['df{}_table'.format(i)]['NumSites'] = locals()['df{}_table'.format(i)].Probabilities.str.count(';') + 1 
    #calculate the probability at each site based on the number of S/Ts (round to 3 decimals as in PD) 
    locals()['df{}_table'.format(i)]['Prob'] = round(1/locals()['df{}_table'.format(i)].NumSites, 3) 
    #define a function to make a repeating list of probability values based on the number of S/Ts 
    def repeat(row): 
        return [row.Prob]*row.NumSites 
    #apply this function to each df 
    locals()['df{}_table'.format(i)]['ProbList'] = locals()['df{}_table'.format(i)].apply(repeat, axis=1) 
    #transform the list into a semi-colon separated string for the sites and regions script 
    locals()['df{}_table'.format(i)]['ProbListFinal'] = locals()['df{}_table'.format(i)].ProbList.apply( 
        lambda s: ';'.join(map(str, s))) 
    #replace the probability values for HCD  
    locals()['df{}_table'.format(i)].loc[locals()['df{}_table'.format(i)].Fragmentation == 'HCD', 'Probabilities'] = \ 
    locals()['df{}_table'.format(i)].ProbListFinal 
    #remake the original table with the columns required for the sites and regions script 
    locals()['df{}_tableF'.format(i)] = locals()['df{}_table'.format(i)][cols_to_keep] 
    #export final tables to tsv files 
    locals()['df{}_tableF'.format(i)].to_csv( 
        './20D15_SitesAndRegions/{}_Preprocessed.txt'.format(i), sep='\t', index=False) 
%%capture 
#supresses the output of the cell 
 
#run the sites and regions script for each experiment 
%run -i SitesAndRegions.py 20D15_SitesAndRegions/293T_Preprocessed.txt 20D15_SitesAndRegions/maxparcon_293T.txt \ 
20D15_SitesAndRegions/bestms2_293T.txt 
%run -i SitesAndRegions.py 20D15_SitesAndRegions/Brain_Preprocessed.txt 20D15_SitesAndRegions/maxparcon_Brain.txt \ 
20D15_SitesAndRegions/bestms2_Brain.txt 
%run -i SitesAndRegions.py 20D15_SitesAndRegions/Liver_Preprocessed.txt 20D15_SitesAndRegions/maxparcon_Liver.txt \ 
20D15_SitesAndRegions/bestms2_Liver.txt 
%run -i SitesAndRegions.py 20D15_SitesAndRegions/LiverBrain_Preprocessed.txt \ 
20D15_SitesAndRegions/maxparcon_LiverBrain.txt 20D15_SitesAndRegions/bestms2_LiverBrain.txt 
%run -i SitesAndRegions.py 20D15_SitesAndRegions/Quant_Preprocessed.txt 20D15_SitesAndRegions/maxparcon_BAP1KO.txt \ 
20D15_SitesAndRegions/bestms2_BAP1KO.txt 
#import the sites and regions output into dfs and count the number of sites for each 
 
list_dfs2 = ['293T', 'Brain', 'Liver', 'LiverBrain', 'BAP1KO'] 
 
for i in list_dfs2: 
    locals()['dfallsites_{}'.format(i)] = pd.read_csv('./20D15_SitesAndRegions/bestms2_{}.txt'.format(i), sep='\t') 
    locals()['dfregions_{}'.format(i)] = pd.read_csv('./20D15_SitesAndRegions/maxparcon_{}.txt'.format(i), sep='\t') 
    #remove sites/regions that match to two master proteins 
    #this seems to happen sometimes when there is real evidence of two isoforms 
    #all cases checked were already explained by other data, so they can be reasonably ignored 
    locals()['dfregions_{}'.format(i)] = locals()['dfregions_{}'.format(i)][ 
        ~locals()['dfregions_{}'.format(i)].Protein.str.contains(';')] 
    locals()['dfallsites_{}'.format(i)] = locals()['dfallsites_{}'.format(i)][ 
        ~locals()['dfallsites_{}'.format(i)].Protein.str.contains(';')] 
     
#initialize an empty df 
df_numsites = pd.DataFrame(np.empty((5,5))) 
 
#calculate the number of sites, localized sites, and regions 
for i in range (5): 
    #set the column and index names 
    df_numsites.columns = [['Total Number of Sites', 'Localized Sites', 'Unlocalized Sites', 'Regions',  
                            'Percent Localized']] 
    df_numsites.rename(index={i:list_dfs2[i]}, inplace=True) 




    df_numsites.loc[list_dfs2[i], 'Total Number of Sites'] = \ 
    locals()['dfregions_{}'.format(list_dfs2[i])]['Min Sites'].sum() 
    #count the number of localized sites 
    df_numsites.loc[list_dfs2[i], 'Localized Sites'] = len( 
        locals()['dfregions_{}'.format(list_dfs2[i])][ 
            locals()['dfregions_{}'.format(list_dfs2[i])]['Site ID Constraints'].str.contains('of') == False]) 
    df_numsites.loc[list_dfs2[i], 'Unlocalized Sites'] = locals()['dfregions_{}'.format(list_dfs2[i])][ 
        locals()['dfregions_{}'.format(list_dfs2[i])][ 
            'Site ID Constraints'].str.contains('of') == True]['Min Sites'].sum() 
    df_numsites.loc[list_dfs2[i], 'Regions'] = len( 
        locals()['dfregions_{}'.format(list_dfs2[i])][ 
            locals()['dfregions_{}'.format(list_dfs2[i])]['Site ID Constraints'].str.contains('of') == True]) 
    df_numsites.loc[list_dfs2[i], 'Percent Localized'] = \ 
    (df_numsites.loc[list_dfs2[i], 'Localized Sites'].to_numpy() / df_numsites.loc[ 
        list_dfs2[i], 'Total Number of Sites'].to_numpy())*100 
 
df_numsites = df_numsites.astype(int) #convert to ints 
df_numsites.to_csv('TotalSitesAndRegionsAll.csv') #export  
df_numsites #inspect 
#make a pie chart of the sites and regions (with the sites stratified by localization probability) 
 
#add to the max parsimonious site constraints file whether each region is a site or a region 
for i in list_dfs2: 
    locals()['dfregions_{}'.format(i)].loc[ 
        locals()['dfregions_{}'.format(i)]['Site ID Constraints'].str.contains('of'), 'Type'] = 'Region' 
    locals()['dfregions_{}'.format(i)].loc[ 
        ~locals()['dfregions_{}'.format(i)]['Site ID Constraints'].str.contains('of'), 'Type'] = 'Site' 
     
#merge with best ms2 for sites file 
for i in list_dfs2: 
    locals()['dfmerge_{}'.format(i)] = locals()['dfallsites_{}'.format(i)].merge( 
        locals()['dfregions_{}'.format(i)], how='left', on='Region ID') 
    #now fill the bins with values for the pie chart 
    locals()['regions_{}'.format(i)] = locals()['dfregions_{}'.format(i)][ 
        locals()['dfregions_{}'.format(i)].Type == 'Region']['Min Sites'].sum() 
    locals()['bin975_{}'.format(i)] = len( 
        locals()['dfmerge_{}'.format(i)][(locals()['dfmerge_{}'.format(i)].Type == 'Site') &  
                                        (locals()['dfmerge_{}'.format(i)]['Best Probability'] < 0.975)]) 
    locals()['bin99_{}'.format(i)] = len( 
        locals()['dfmerge_{}'.format(i)][(locals()['dfmerge_{}'.format(i)].Type == 'Site') &  
                                        ((locals()['dfmerge_{}'.format(i)]['Best Probability'] >= 0.975) &  
                                         (locals()['dfmerge_{}'.format(i)]['Best Probability'] < 0.99))]) 
    locals()['bin991_{}'.format(i)] = len( 
        locals()['dfmerge_{}'.format(i)][(locals()['dfmerge_{}'.format(i)].Type == 'Site') &  
                                        ((locals()['dfmerge_{}'.format(i)]['Best Probability'] >= 0.99) &  
                                         (locals()['dfmerge_{}'.format(i)]['Best Probability'] < 1))]) 
    locals()['bin1_{}'.format(i)] = len( 
        locals()['dfmerge_{}'.format(i)][(locals()['dfmerge_{}'.format(i)].Type == 'Site') &  
                                         (locals()['dfmerge_{}'.format(i)]['Best Probability'] == 1)]) 
#make the pie charts 
for i in list_dfs2: 
    locals()['list_values_{}'.format(i)] = [locals()['regions_{}'.format(i)], locals()['bin975_{}'.format(i)],  
                                            locals()['bin99_{}'.format(i)], locals()['bin991_{}'.format (i)],  
                                            locals()['bin1_{}'.format(i)]] 
 
sns.set_context('paper') 
     
#make a list of labels and colors to use 
list_labels = ['Unlocalized', '<97.5%', '97.5-99%', '99-100%', '100%'] 
colors = ["#cbcdcd", "#f39b9f", "#9aacd7", "#be9ec7", "#b3e0a7"] 





p, tx, nums = plt.pie(list_values_293T, labels=list_labels, colors=colors, autopct="", explode=explode, startangle=90) 
for i, a in enumerate(nums): 
    a.set_text('{}'.format(list_values_293T[i])) 
local_prob_293T = str(round(dfmerge_293T[dfmerge_293T.Type == 'Site']['Best Probability'].mean()*100, 1)) + '%' 







p, tx, nums = plt.pie(list_values_Brain, labels=list_labels, colors=colors, autopct="", explode=explode, startangle=90) 
for i, a in enumerate(nums): 
    a.set_text('{}'.format(list_values_Brain[i])) 
local_prob_Brain = str(round(dfmerge_Brain[dfmerge_Brain.Type == 'Site']['Best Probability'].mean()*100, 1)) + '%' 







p, tx, nums = plt.pie(list_values_Liver, labels=list_labels, colors=colors, autopct="", explode=explode, startangle=90) 
for i, a in enumerate(nums): 
    a.set_text('{}'.format(list_values_Liver[i])) 
local_prob_Liver = str(round(dfmerge_Liver[dfmerge_Liver.Type == 'Site']['Best Probability'].mean()*100, 1)) + '%' 










p, tx, nums = plt.pie(list_values_LiverBrain, labels=list_labels, colors=colors, autopct="", explode=explode,  
                      startangle=90) 
for i, a in enumerate(nums): 
    a.set_text('{}'.format(list_values_LiverBrain[i])) 
local_prob_LiverBrain = str(round( 
    dfmerge_LiverBrain[dfmerge_LiverBrain.Type == 'Site']['Best Probability'].mean()*100, 1)) + '%' 







p, tx, nums = plt.pie(list_values_BAP1KO, labels=list_labels, colors=colors, autopct="", explode=explode, startangle=90) 
for i, a in enumerate(nums): 
    a.set_text('{}'.format(list_values_BAP1KO[i])) 
local_prob_BAP1KO = str(round(dfmerge_BAP1KO[dfmerge_BAP1KO.Type == 'Site']['Best Probability'].mean()*100, 1)) + '%' 




#Copy the dfs to new dfs for part 2 
#Make a new 'Experiment' column based on the raw file and export for the sites and regions multi-experiment script 
 
for i in list_dfs[0:4]: 
    locals()['df{}_tableF_2'.format(i)] = locals()['df{}_tableF'.format(i)].copy() 
    locals()['df{}_tableF_2'.format(i)].loc[ 
        locals()['df{}_tableF_2'.format(i)].RawFile.str.contains('ETD'), 'Experiment'] = 'ETD' 
    locals()['df{}_tableF_2'.format(i)].loc[ 
        locals()['df{}_tableF_2'.format(i)].RawFile.str.contains('EThcD'), 'Experiment'] = 'EThcD' 
    locals()['df{}_tableF_2'.format(i)].to_csv( 
        './20D15_SitesAndRegions/{}_Preprocessed_2.txt'.format(i), sep='\t', index=False) 
%%capture 
#supresses the output of the cell 
 
#run the sites and regions script for each experiment 
%run -i SitesAndRegionsMultiExperiment.py 20D15_SitesAndRegions/293T_Preprocessed_2.txt \ 
20D15_SitesAndRegions/maxparcon_293T_2.txt 20D15_SitesAndRegions/bestms2_293T_2.txt 
%run -i SitesAndRegionsMultiExperiment.py 20D15_SitesAndRegions/Brain_Preprocessed_2.txt \ 
20D15_SitesAndRegions/maxparcon_Brain_2.txt 20D15_SitesAndRegions/bestms2_Brain_2.txt 
%run -i SitesAndRegionsMultiExperiment.py 20D15_SitesAndRegions/Liver_Preprocessed_2.txt \ 
20D15_SitesAndRegions/maxparcon_Liver_2.txt 20D15_SitesAndRegions/bestms2_Liver_2.txt 
%run -i SitesAndRegionsMultiExperiment.py 20D15_SitesAndRegions/LiverBrain_Preprocessed_2.txt \ 
20D15_SitesAndRegions/maxparcon_LiverBrain_2.txt 20D15_SitesAndRegions/bestms2_LiverBrain_2.txt 
#reimport the output 
for i in list_dfs2[0:4]: 
    locals()['dfallsites2_{}'.format(i)] = pd.read_csv('./20D15_SitesAndRegions/bestms2_{}_2.txt'.format(i), sep='\t') 
    locals()['dfregions2_{}'.format(i)] = pd.read_csv('./20D15_SitesAndRegions/maxparcon_{}_2.txt'.format(i), sep='\t') 
    #remove sites/regions that match to two master proteins 
    #this seems to happen sometimes when there is real evidence of two isoforms 
    #all cases checked were already explained by other data, so they can be reasonably ignored 
    locals()['dfregions2_{}'.format(i)] = locals()['dfregions2_{}'.format(i)][ 
        ~locals()['dfregions2_{}'.format(i)].Protein.str.contains(';')] 
    locals()['dfallsites2_{}'.format(i)] = locals()['dfallsites2_{}'.format(i)][ 
        ~locals()['dfallsites2_{}'.format(i)].Protein.str.contains(';')] 
     
#add to the max parsimonious site constraints file whether each region is a site or a region 
for i in list_dfs2[0:4]: 
    locals()['dfregions2_{}'.format(i)].loc[ 
        locals()['dfregions2_{}'.format(i)]['Site ID Constraints'].str.contains('of'), 'Type'] = 'Region' 
    locals()['dfregions2_{}'.format(i)].loc[ 
        ~locals()['dfregions2_{}'.format(i)]['Site ID Constraints'].str.contains('of'), 'Type'] = 'Site' 
     
#merge the two dfs together and count up how many sites are found in the ETD vs EThcD runs 
for i in list_dfs2[0:4]: 
    locals()['dfmerge2_{}'.format(i)] = locals()['dfallsites2_{}'.format(i)].merge( 
        locals()['dfregions2_{}'.format(i)], how='left', on='Region ID') 
    #define a function to make a new column stating which experiment each region id belongs to and apply it to merged df 
    def experiment(x): 
        if x.Experiment.eq('ETD').all(): 
            return 'ETD' 
        elif x.Experiment.eq('EThcD').all(): 
            return 'EThcD' 
        else: 
            return 'Both' 
    locals()['df2_exp_{}'.format(i)] = locals()['dfmerge2_{}'.format(i)].groupby(['Region ID']).apply(experiment) 
    #make a new column in the regions df with the experiments each region was found in 
    locals()['dfregions2_{}'.format(i)]['Experiment'] = locals()['df2_exp_{}'.format(i)] 
    locals()['series2_{}'.format(i)] = locals()['dfregions2_{}'.format(i)].groupby('Experiment')['Min Sites'].sum() 
#Make Venn diagrams of the overlapping sites 
 
for i in list_dfs[0:4]: 
    plt.figure(figsize=(7,7)) 
    fig = venn2([locals()['series2_{}'.format(i)][1], locals()['series2_{}'.format(i)][2],  
                 locals()['series2_{}'.format(i)][0]], ('ETD', 'EThcD')) 
    plt.title('{}'.format(i), fontsize=42) 




    fig.get_patch_by_id('01').set_color('#aaaaaa') 
    fig.get_patch_by_id('10').set_edgecolor('none') 
    fig.get_patch_by_id('01').set_edgecolor('none') 
    fig.get_patch_by_id('10').set_alpha(0.75) 
    fig.get_patch_by_id('01').set_alpha(0.5) 
    fig.get_patch_by_id('11').set_color('#027FF0') 
    fig.get_patch_by_id('11').set_edgecolor('none') 
    fig.get_patch_by_id('11').set_alpha(0.5) 
    for text in fig.set_labels: #need to call named object 'fig' from above, font size is set numerically 
        text.set_fontsize(36) #this is the label names 
    for text in fig.subset_labels: 
        text.set_fontsize(28) #this will change the numbers 
    plt.savefig('./20D15_SitesAndRegions/{}_ET(hc)D_TrialOverlap.svg'.format(i)) 
    plt.show() 
Part 3 
#Copy the dfs to new dfs for part 2 
#Separate and export the data from the different fragmentation types separately 
 
list_frag = ['HCD', 'ETD', 'EThcD'] 
 
for i in list_dfs: 
    locals()['df{}_tableF_3'.format(i)] = locals()['df{}_tableF'.format(i)].copy() 
    for j in list_frag: 
        locals()['df{}_tableF_3_{}'.format(i,j)] = locals()['df{}_tableF_3'.format(i)][ 
            locals()['df{}_tableF_3'.format(i)].Fragmentation == j] 
        locals()['df{}_tableF_3_{}'.format(i,j)].to_csv( 
            './20D15_SitesAndRegions/{}_{}_Preprocessed_3.txt'.format(i,j), sep='\t', index=False) 
    locals()['df{}_tableF_3'.format(i)]['NumST'] = locals()['df{}_tableF_3'.format(i)].Probabilities.str.count(';') + 1 
%%capture 
#supresses the output of the cell 
 
#run the sites and regions script for each experiment 
%run -i SitesAndRegions.py 20D15_SitesAndRegions/293T_ETD_Preprocessed_3.txt \ 
20D15_SitesAndRegions/maxparcon_293T_ETD_3.txt 20D15_SitesAndRegions/bestms2_293T_ETD_3.txt 
%run -i SitesAndRegions.py 20D15_SitesAndRegions/293T_EThcD_Preprocessed_3.txt \ 
20D15_SitesAndRegions/maxparcon_293T_EThcD_3.txt 20D15_SitesAndRegions/bestms2_293T_EThcD_3.txt 
%run -i SitesAndRegions.py 20D15_SitesAndRegions/293T_HCD_Preprocessed_3.txt \ 
20D15_SitesAndRegions/maxparcon_293T_HCD_3.txt 20D15_SitesAndRegions/bestms2_293T_HCD_3.txt 
 
%run -i SitesAndRegions.py 20D15_SitesAndRegions/Brain_ETD_Preprocessed_3.txt \ 
20D15_SitesAndRegions/maxparcon_Brain_ETD_3.txt 20D15_SitesAndRegions/bestms2_Brain_ETD_3.txt 
%run -i SitesAndRegions.py 20D15_SitesAndRegions/Brain_EThcD_Preprocessed_3.txt \ 
20D15_SitesAndRegions/maxparcon_Brain_EThcD_3.txt 20D15_SitesAndRegions/bestms2_Brain_EThcD_3.txt 
%run -i SitesAndRegions.py 20D15_SitesAndRegions/Brain_HCD_Preprocessed_3.txt \ 
20D15_SitesAndRegions/maxparcon_Brain_HCD_3.txt 20D15_SitesAndRegions/bestms2_Brain_HCD_3.txt 
 
%run -i SitesAndRegions.py 20D15_SitesAndRegions/Liver_ETD_Preprocessed_3.txt \ 
20D15_SitesAndRegions/maxparcon_Liver_ETD_3.txt 20D15_SitesAndRegions/bestms2_Liver_ETD_3.txt 
%run -i SitesAndRegions.py 20D15_SitesAndRegions/Liver_EThcD_Preprocessed_3.txt \ 
20D15_SitesAndRegions/maxparcon_Liver_EThcD_3.txt 20D15_SitesAndRegions/bestms2_Liver_EThcD_3.txt 
%run -i SitesAndRegions.py 20D15_SitesAndRegions/Liver_HCD_Preprocessed_3.txt \ 
20D15_SitesAndRegions/maxparcon_Liver_HCD_3.txt 20D15_SitesAndRegions/bestms2_Liver_HCD_3.txt 
 
%run -i SitesAndRegions.py 20D15_SitesAndRegions/LiverBrain_ETD_Preprocessed_3.txt \ 
20D15_SitesAndRegions/maxparcon_LiverBrain_ETD_3.txt 20D15_SitesAndRegions/bestms2_LiverBrain_ETD_3.txt 
%run -i SitesAndRegions.py 20D15_SitesAndRegions/LiverBrain_EThcD_Preprocessed_3.txt \ 
20D15_SitesAndRegions/maxparcon_LiverBrain_EThcD_3.txt 20D15_SitesAndRegions/bestms2_LiverBrain_EThcD_3.txt 
%run -i SitesAndRegions.py 20D15_SitesAndRegions/LiverBrain_HCD_Preprocessed_3.txt \ 
20D15_SitesAndRegions/maxparcon_LiverBrain_HCD_3.txt 20D15_SitesAndRegions/bestms2_LiverBrain_HCD_3.txt 
 
%run -i SitesAndRegions.py 20D15_SitesAndRegions/Quant_ETD_Preprocessed_3.txt \ 
20D15_SitesAndRegions/maxparcon_BAP1KO_ETD_3.txt 20D15_SitesAndRegions/bestms2_BAP1KO_ETD_3.txt 
%run -i SitesAndRegions.py 20D15_SitesAndRegions/Quant_EThcD_Preprocessed_3.txt \ 
20D15_SitesAndRegions/maxparcon_BAP1KO_EThcD_3.txt 20D15_SitesAndRegions/bestms2_BAP1KO_EThcD_3.txt 
%run -i SitesAndRegions.py 20D15_SitesAndRegions/Quant_HCD_Preprocessed_3.txt \ 
20D15_SitesAndRegions/maxparcon_BAP1KO_HCD_3.txt 20D15_SitesAndRegions/bestms2_BAP1KO_HCD_3.txt 
#reimport the output and process as before also adding back in whether each is a site or a region 
#also match the raw file/scan number back to the preprocessed df which has the number of S/Ts 
 
#rename dfQuant_tableF_3 to dfBAP1KO... to make the scipt match 
dfBAP1KO_tableF_3 = dfQuant_tableF_3 
 
for i in list_dfs2: 
    for j in list_frag: 
        locals()['dfallsites3_{}_{}'.format(i,j)] = pd.read_csv( 
            './20D15_SitesAndRegions/bestms2_{}_{}_3.txt'.format(i, j), sep='\t') 
        locals()['dfregions3_{}_{}'.format(i,j)] = pd.read_csv( 
            './20D15_SitesAndRegions/maxparcon_{}_{}_3.txt'.format(i, j), sep='\t') 
        locals()['dfallsites3_{}_{}'.format(i,j)] = locals()['dfallsites3_{}_{}'.format(i,j)][ 
            ~locals()['dfallsites3_{}_{}'.format(i,j)].Protein.str.contains(';')] 
        locals()['dfregions3_{}_{}'.format(i,j)] = locals()['dfregions3_{}_{}'.format(i,j)][ 
            ~locals()['dfregions3_{}_{}'.format(i,j)].Protein.str.contains(';')] 
        locals()['dfregions3_{}_{}'.format(i,j)].loc[ 
            locals()['dfregions3_{}_{}'.format(i,j)]['Site ID Constraints'].str.contains('of'), 'Type'] = 'Region' 
        locals()['dfregions3_{}_{}'.format(i,j)].loc[ 
            ~locals()['dfregions3_{}_{}'.format(i,j)]['Site ID Constraints'].str.contains('of'), 'Type'] = 'Site' 
        locals()['dfmerge3_{}_{}'.format(i,j)] = locals()['dfallsites3_{}_{}'.format(i,j)].merge( 
            locals()['dfregions3_{}_{}'.format(i,j)], how='left', on='Region ID') 
        locals()['dfmerge3_{}_{}'.format(i,j)].rename( 
            columns={'Best Raw File':'RawFile', 'Best Scan Number':'ScanNumber'}, inplace=True) 
        locals()['dfmerge3_{}_{}'.format(i,j)] = locals()['dfmerge3_{}_{}'.format(i,j)].merge( 




        locals()['dfmerge3_{}_{}'.format(i,j)].drop( 
            columns={'Protein_y', 'Fragmentation', 'Protein', 'Positions', 'Probabilities', 'NumMods'}, inplace=True) 
        locals()['dfmerge3_{}_{}'.format(i,j)].rename(columns={'Protein_x':'Protein'}, inplace=True) 
#output the numbers of sites and regions in each df (see above for making dfs) 
for i in range(5): 
    locals()['df_numsites3_{}'.format(list_dfs2[i])] = pd.DataFrame(np.empty((3,7))) 
    for j in range(3): 
        locals()['df_numsites3_{}'.format(list_dfs2[i])].columns = ['Total Number of Sites', 'Localized Sites',  
                                                                     'Average Localization Probability', 'Single ST',  
                                                                     'Unlocalized Sites', 'Regions', 'Percent Localized'] 
        locals()['dftemp3_{}_{}'.format(list_dfs2[i], list_frag[j])] = \ 
        locals()['dfmerge3_{}_{}'.format(list_dfs2[i], list_frag[j])][['Region ID', 'NumST']] 
        locals()['dftemp3_{}_{}'.format(list_dfs2[i], list_frag[j])].drop_duplicates(inplace=True) 
        locals()['dfregions3_{}_{}'.format(list_dfs2[i],list_frag[j])] = \ 
        locals()['dfregions3_{}_{}'.format(list_dfs2[i],list_frag[j])].merge( 
            locals()['dftemp3_{}_{}'.format(list_dfs2[i], list_frag[j])], how='left', on='Region ID') 
        locals()['df_numsites3_{}'.format(list_dfs2[i])].rename(index={j:list_frag[j]}, inplace=True) 
        locals()['df_numsites3_{}'.format(list_dfs2[i])].loc[list_frag[j], 'Total Number of Sites'] = \ 
        locals()['dfregions3_{}_{}'.format(list_dfs2[i],list_frag[j])]['Min Sites'].sum() 
        locals()['df_numsites3_{}'.format(list_dfs2[i])].loc[list_frag[j], 'Localized Sites'] = len( 
            locals()['dfregions3_{}_{}'.format(list_dfs2[i],list_frag[j])][ 
                (locals()['dfregions3_{}_{}'.format(list_dfs2[i],list_frag[j])].Type == 'Site') & \ 
                (locals()['dfregions3_{}_{}'.format(list_dfs2[i],list_frag[j])].NumST != 1)]) 
        locals()['df_numsites3_{}'.format(list_dfs2[i])].loc[list_frag[j], 'Average Localization Probability'] = \ 
        (locals()['dfmerge3_{}_{}'.format(list_dfs2[i], list_frag[j])][ 
            (locals()['dfmerge3_{}_{}'.format(list_dfs2[i], list_frag[j])].Type == 'Site') & \ 
            (locals()['dfmerge3_{}_{}'.format(list_dfs2[i], list_frag[j])].NumST != 1)]['Best Probability'].mean())*100 
        locals()['df_numsites3_{}'.format(list_dfs2[i])].loc[list_frag[j], 'Single ST'] = len( 
            locals()['dfregions3_{}_{}'.format(list_dfs2[i],list_frag[j])][ 
                locals()['dfregions3_{}_{}'.format(list_dfs2[i],list_frag[j])].NumST == 1]) 
        locals()['df_numsites3_{}'.format(list_dfs2[i])].loc[list_frag[j], 'Unlocalized Sites'] = \ 
        locals()['dfregions3_{}_{}'.format(list_dfs2[i],list_frag[j])][ 
            locals()['dfregions3_{}_{}'.format(list_dfs2[i],list_frag[j])].Type == 'Region']['Min Sites'].sum() 
        locals()['df_numsites3_{}'.format(list_dfs2[i])].loc[list_frag[j], 'Regions'] = len( 
            locals()['dfregions3_{}_{}'.format(list_dfs2[i],list_frag[j])][ 
                locals()['dfregions3_{}_{}'.format(list_dfs2[i],list_frag[j])].Type == 'Region']) 
        locals()['df_numsites3_{}'.format(list_dfs2[i])].loc[list_frag[j], 'Percent Localized'] = \ 
        (locals()['df_numsites3_{}'.format(list_dfs2[i])].loc[list_frag[j], 'Localized Sites'] / \ 
        locals()['df_numsites3_{}'.format(list_dfs2[i])].loc[list_frag[j], 'Total Number of Sites'])*100 
        locals()['df_numsites3_{}'.format(list_dfs2[i])] = locals()['df_numsites3_{}'.format(list_dfs2[i])].astype({ 
            'Total Number of Sites':int, 'Localized Sites':int, 'Single ST':int, 'Unlocalized Sites':int, 'Regions':int}) 
#output the previous info to csv  files 
for i in list_dfs2: 







#Now I will calculate the overlap between ETD and EThcD localized sites only, first make sets of the sites 
 
#make a new list for just ETD and EThcD 
list_frag2 = ['ETD', 'EThcD'] 
 
#concatentate the protein and position ot make a unique site identifier 
#make sets out of these unique site identifiers for each sample 
for i in list_dfs2: 
    for j in list_frag2: 
        locals()['dfmerge3_{}_{}'.format(i,j)]['Site'] = \ 
        locals()['dfmerge3_{}_{}'.format(i,j)].Protein.str.cat( 
            locals()['dfmerge3_{}_{}'.format(i,j)].Position.astype(str), sep='@') 
        locals()['set3_{}_{}'.format(i,j)] = set( 
            locals()['dfmerge3_{}_{}'.format(i,j)][(locals()['dfmerge3_{}_{}'.format(i,j)].Type == 'Site') & \ 
                                                  (locals()['dfmerge3_{}_{}'.format(i,j)].NumST != 1)].Site) 
#Now make the Venn diagrams 
 
for i in list_dfs2: 
    plt.figure(figsize=(7,7)) 
    fig = venn2([locals()['set3_{}_ETD'.format(i)], locals()['set3_{}_EThcD'.format(i)]], ('ETD', 'EThcD')) 
    plt.title('{}'.format(i), fontsize=42) 
    fig.get_patch_by_id('10').set_color('#5b7992') 
    fig.get_patch_by_id('01').set_color('#aaaaaa') 
    fig.get_patch_by_id('10').set_edgecolor('none') 
    fig.get_patch_by_id('01').set_edgecolor('none') 
    fig.get_patch_by_id('10').set_alpha(0.75) 
    fig.get_patch_by_id('01').set_alpha(0.5) 
    fig.get_patch_by_id('11').set_color('#027FF0') 
    fig.get_patch_by_id('11').set_edgecolor('none') 
    fig.get_patch_by_id('11').set_alpha(0.5) 
    for text in fig.set_labels: #need to call named object 'fig' from above, font size is set numerically 
        text.set_fontsize(36) #this is the label names 
    for text in fig.subset_labels: 
        text.set_fontsize(28) #this will change the numbers 
    plt.savefig('./20D15_SitesAndRegions/{}_ET(hc)D_SiteOverlap.svg'.format(i)) 
    plt.show() 
#Now I will make the stacked bar graphs 
 
#set the context for searborn (and remove graph boarders) 
sns.set_style('ticks') 
sns.set_context('poster') 





#make a for loop to make the graphs for all samples 
for i in list_dfs2: 
    plt.figure() 
    g1 = sns.barplot(x = locals()['df_numsites3_{}'.format(i)].index,  
                     y = locals()['df_numsites3_{}'.format(i)]['Total Number of Sites'].values, color='#5b7992') 
    g2 = sns.barplot(x = locals()['df_numsites3_{}'.format(i)].index,  
                     y = (locals()['df_numsites3_{}'.format(i)]['Unlocalized Sites'].values + \ 
                          locals()['df_numsites3_{}'.format(i)]['Localized Sites'].values), color='#67b2f6ff') 
    g3 = sns.barplot(x = locals()['df_numsites3_{}'.format(i)].index,  
                     y = locals()['df_numsites3_{}'.format(i)]['Unlocalized Sites'].values, color='#d4d4d4') 
    for j in range(3): 
        g3.text(j, (locals()['df_numsites3_{}'.format(i)]['Total Number of Sites'][j] + \ 
                    locals()['df_numsites3_{}'.format(i)]['Total Number of Sites'].max()*0.05),  
                int(locals()['df_numsites3_{}'.format(i)]['Total Number of Sites'][j]), color='black', ha='center') 
    sns.despine() 
    plt.savefig('./20D15_SitesAndRegions/{}_StackedBar.svg'.format(i)) 
Part 4 
#Using the final table from part three I will make a separate column for 'Experiment' based on the raw file 
 
#copy the df from part 3 into a new df 
dfLiverBrain_tableF_4 = dfLiverBrain_tableF_3.copy() 
 
#add a new experiment column based on the raw file and export for SitesAndRegions script 
dfLiverBrain_tableF_4.loc[dfLiverBrain_tableF_4.RawFile.str.contains('Brain'), 'Experiment'] = 'Brain' 
dfLiverBrain_tableF_4.loc[dfLiverBrain_tableF_4.RawFile.str.contains('Liver'), 'Experiment'] = 'Liver' 
dfLiverBrain_tableF_4.to_csv('./20D15_SitesAndRegions/SiteOverlap_LiverBrain_Preprocessed_4.txt', sep='\t', index=False) 
%%capture 
#supresses the output of the cell 
 
#run the sites and regions script 
%run -i SitesAndRegionsMultiExperiment.py 20D15_SitesAndRegions/SiteOverlap_LiverBrain_Preprocessed_4.txt \ 
20D15_SitesAndRegions/maxparcon_LiverBrainOverlap_4.txt 20D15_SitesAndRegions/bestms2_LiverBrainOverlap_4.txt 
#Import the output and process as before 
dfallsites4 = pd.read_csv('./20D15_SitesAndRegions/bestms2_LiverBrainOverlap_4.txt', sep='\t') 
dfregions4 = pd.read_csv('./20D15_SitesAndRegions/maxparcon_LiverBrainOverlap_4.txt', sep='\t') 
dfallsites4 = dfallsites4[~dfallsites4.Protein.str.contains(';')] 
dfregions4 = dfregions4[~dfregions4.Protein.str.contains(';')] 
 
dfregions4.loc[dfregions4['Site ID Constraints'].str.contains('of'), 'Type'] = 'Region' 
dfregions4.loc[~dfregions4['Site ID Constraints'].str.contains('of'), 'Type'] = 'Site' 
 
dfmerge4 = dfallsites4.merge(dfregions4, how='left', on='Region ID') 
 
def experimentO(x): 
    if x.Experiment.eq('Brain').all(): 
        return 'Brain' 
    elif x.Experiment.eq('Liver').all(): 
        return 'Liver' 
    else: 
        return 'Both' 
df4_exp = dfmerge4.groupby(['Region ID']).apply(experimentO) 
dfregions4['Experiment'] = df4_exp 
 
series4_sites = dfregions4[dfregions4.Type == 'Site'].groupby('Experiment')['Min Sites'].sum() 
series4_sr = dfregions4.groupby('Experiment')['Min Sites'].sum() 




fig = venn2([series4_sites[1], series4_sites[2], series4_sites[0]], ('Brain', 'Liver')) 










for text in fig.set_labels: #need to call named object 'fig' from above, font size is set numerically 
    text.set_fontsize(36) #this is the label names 
for text in fig.subset_labels: 




###Sites and Regions### 
plt.figure(figsize=(7,7)) 
fig = venn2([series4_sr[1], series4_sr[2], series4_sr[0]], ('Brain', 'Liver')) 










for text in fig.set_labels: #need to call named object 'fig' from above, font size is set numerically 




for text in fig.subset_labels: 
    text.set_fontsize(28) #this will change the numbers 
plt.savefig('./20D15_SitesAndRegions/LiverBrain_SiteRegionOverlap_4.svg') 
plt.show() 
#I will also re-calculate the sites and regions for the brain and liver based on this combined dataset 
 
#Note, use this with caution, since the sites are counted as a site if they are a site in either of the two datasets 
#(although this is probably mostly alright, it is perfectly reasonable that the sites localized in the brain are not   
    #the same as some of the sites that were unlocalized in the liver) 
 
#initialize an empty df 
df_numsites4 = pd.DataFrame(np.empty((2,5))) 
 
#make a list for iterating over liver and brain 
list_lb = ['Brain', 'Liver'] 
 
#make a for loop to go through liver and brain 
for i in range(2): 
    df_numsites4.columns = ['Total Number of Sites', 'Localized Sites', 'Unlocalized Sites', 'Regions',  
                            'Percent Localized'] 
    df_numsites4.rename(index={i:list_lb[i]}, inplace=True) 
    df_numsites4.loc[list_lb[i], 'Total Number of Sites'] = dfregions4[ 
        (dfregions4.Experiment == '{}'.format(list_lb[i])) | (dfregions4.Experiment == 'Both')]['Min Sites'].sum() 
    df_numsites4.loc[list_lb[i], 'Localized Sites'] = dfregions4[ 
        ((dfregions4.Experiment == '{}'.format(list_lb[i])) | (dfregions4.Experiment == 'Both')) & \ 
        (dfregions4.Type == 'Site')]['Min Sites'].sum() 
    df_numsites4.loc[list_lb[i], 'Unlocalized Sites'] = dfregions4[ 
        ((dfregions4.Experiment == '{}'.format(list_lb[i])) | (dfregions4.Experiment == 'Both')) & \ 
        (dfregions4.Type == 'Region')]['Min Sites'].sum() 
    df_numsites4.loc[list_lb[i], 'Regions'] = len( 
        dfregions4[((dfregions4.Experiment == '{}'.format(list_lb[i])) | (dfregions4.Experiment == 'Both')) & \ 
                   (dfregions4.Type == 'Region')]) 
 
df_numsites4['Percent Localized'] = (df_numsites4['Localized Sites'] / df_numsites4['Total Number of Sites'])*100 
df_numsites4 = df_numsites4.astype({'Total Number of Sites':int, 'Localized Sites':int, 'Unlocalized Sites':int,  




#Using the final table from part three I will make a separate column for 'Experiment' based on the raw file as in part 4 
 
#copy the df from part 3 into a new df 
dfQuant_tableF_5 = dfQuant_tableF_3.copy() 
 
#make a list of experiment types 
list_mstype = ['TopN', 'TopSpeed'] 
 
#add a new experiment column based on the raw file and export for SitesAndRegions script 
for i in range(3): 
    for j in list_mstype: 
        dfQuant_tableF_5.loc[(dfQuant_tableF_5.RawFile.str.contains('_{}_'.format(i+1)) & \ 
                              dfQuant_tableF_5.RawFile.str.contains( 
            '{}'.format(j))), 'Experiment'] = '{}{}'.format(j,i+1) 
 
dfQuant_tableF_5.to_csv('./20D15_SitesAndRegions/Quant_Preprocessed_ByRawFile_5.txt', sep='\t', index=False) 
%%capture 
#supresses the output of the cell 
 
#run the sites and regions script 
%run -i SitesAndRegionsMultiExperiment.py 20D15_SitesAndRegions/Quant_Preprocessed_ByRawFile_5.txt \ 
20D15_SitesAndRegions/maxparcon_BAP1KO_ByRawFile_5.txt 20D15_SitesAndRegions/bestms2_BAP1KO_ByRawFile_5.txt 
#Import the output and process as before 
dfallsites5 = pd.read_csv('./20D15_SitesAndRegions/bestms2_BAP1KO_ByRawFile_5.txt', sep='\t') 
dfregions5 = pd.read_csv('./20D15_SitesAndRegions/maxparcon_BAP1KO_ByRawFile_5.txt', sep='\t') 
dfallsites5 = dfallsites5[~dfallsites5.Protein.str.contains(';')] 
dfregions5 = dfregions5[~dfregions5.Protein.str.contains(';')] 
 
dfregions5.loc[dfregions5['Site ID Constraints'].str.contains('of'), 'Type'] = 'Region' 
dfregions5.loc[~dfregions5['Site ID Constraints'].str.contains('of'), 'Type'] = 'Site' 
 
dfmerge5 = dfallsites5.merge(dfregions5, how='left', on='Region ID') 
 
#clean up this df 
dfmerge5.rename(columns={'Protein_x': 'Protein'}, inplace=True) 
dfmerge5.drop(columns={'Protein_y'}, inplace=True) 
 
#add whether sites/regions were found in top n, top speed, or both to the regions df 
def experimentR(x): 
    if x.Experiment.str.contains('TopSpeed').all(): 
        return 'TopSpeed' 
    elif x.Experiment.str.contains('TopN').all(): 
        return 'TopN' 
    else: 
        return 'Both' 
df5_exp = dfmerge5.groupby(['Region ID']).apply(experimentR) 
dfregions5['Experiment'] = df5_exp 
#Make a Venn diagram of the overlap between top speed and top n 
 
#make series for the Venn diagrams 
series5_sites = dfregions5[dfregions5.Type == 'Site'].groupby('Experiment')['Min Sites'].sum() 







fig = venn2([series5_sites[1], series5_sites[2], series5_sites[0]], ('Top N', 'Top Speed')) 










for text in fig.set_labels: #need to call named object 'fig' from above, font size is set numerically 
    text.set_fontsize(36) #this is the label names 
for text in fig.subset_labels: 




###Sites and Regions### 
plt.figure(figsize=(7,7)) 
fig = venn2([series5_sr[1], series5_sr[2], series5_sr[0]], ('Top N', 'Top Speed')) 










for text in fig.set_labels: #need to call named object 'fig' from above, font size is set numerically 
    text.set_fontsize(36) #this is the label names 
for text in fig.subset_labels: 
    text.set_fontsize(28) #this will change the numbers 
plt.savefig('./20D15_SitesAndRegions/BAP1KO_MethodOverlapSitesRegions_5.svg') 
plt.show() 
#Pull in the MS3 data from the psms file 
 
#reimport the psms file 
df5_psm = pd.read_csv(fnameq, sep='\t') 
 
#pull out just the relevant information 
df5_psm = df5_psm[['Spectrum File', 'First Scan', 'Abundance 127N', 'Abundance 129C', 'Abundance 130N']] 
 
#rename the columns to facilitate merging 
df5_psm.rename(columns={'Spectrum File':'Best Raw File', 'First Scan':'Best Scan Number'}, inplace=True) 
 
#now merge this with the sites and regions data frame on raw file and scan number 
df5_quant = dfmerge5.merge(df5_psm, how='left', on=['Best Raw File', 'Best Scan Number']) 
 
#normalize the abundances based on the summed abundance for each channel/raw file 
for i in set(df5_quant['Best Raw File']): 
     
    #127N 
    df5_quant.loc[df5_quant['Best Raw File'] == i, 'Norm-127N'] = \ 
    df5_quant.loc[df5_quant['Best Raw File'] == i, 'Abundance 127N'] / df5_quant.loc[ 
        df5_quant['Best Raw File'] == i, 'Abundance 127N'].sum() 
     
    #129C 
    df5_quant.loc[df5_quant['Best Raw File'] == i, 'Norm-129C'] = \ 
    df5_quant.loc[df5_quant['Best Raw File'] == i, 'Abundance 129C'] / df5_quant.loc[ 
        df5_quant['Best Raw File'] == i, 'Abundance 129C'].sum() 
     
    #130N 
    df5_quant.loc[df5_quant['Best Raw File'] == i, 'Norm-130N'] = \ 
    df5_quant.loc[df5_quant['Best Raw File'] == i, 'Abundance 130N'] / df5_quant.loc[ 
        df5_quant['Best Raw File'] == i, 'Abundance 130N'].sum() 
 
#take the ratios based on the experiment 
df5_quant.loc[df5_quant.Experiment.str.contains('1'), 'Ratio'] = \ 
df5_quant.loc[df5_quant.Experiment.str.contains('1'), 'Norm-130N'] / df5_quant.loc[ 
    df5_quant.Experiment.str.contains('1'), 'Norm-127N'] 
 
df5_quant.loc[df5_quant.Experiment.str.contains('2'), 'Ratio'] = \ 
df5_quant.loc[df5_quant.Experiment.str.contains('2'), 'Norm-129C'] / df5_quant.loc[ 
    df5_quant.Experiment.str.contains('2'), 'Norm-127N'] 
 
df5_quant.loc[df5_quant.Experiment.str.contains('3'), 'Ratio'] = \ 
df5_quant.loc[df5_quant.Experiment.str.contains('3'), 'Norm-130N'] / df5_quant.loc[ 
    df5_quant.Experiment.str.contains('3'), 'Norm-127N'] 
 
#make a new trial column based on the experiment (to facilitate averaging top speed and top n) 
for i in range(3): 
    df5_quant.loc[df5_quant.Experiment.str.contains('{}'.format(i+1)), 'Trial'] = 'Trial{}'.format(i+1) 
     
#average the ratios of top speed and top n trials and merge this into the regions df 
dfratios5 = dfregions5.merge( 
    df5_quant.groupby(['Region ID', 'Trial']).Ratio.mean().unstack().reset_index(), how='left', on='Region ID') 
 




dflimma5 = dfratios5[['Trial1', 'Trial2', 'Trial3']] 




#calculate the p-values for changing sites with limma in R 
 
library(limma) #load the package 
df1 = read.table("BAP1KO_SitesRegions_Ratios_Limma.txt",sep="\t",header=TRUE,row.names=1) #read in the file 
f1 = eBayes(lmFit(df1)) #perform limma 
write.table(topTable(f1,n=Inf,confint=.95),"BAP1KO_limmaOut.txt",sep="\t") #write table 
#Import the limma results and integrate them into the ratios table 
 
df5_limmaout = pd.read_csv('BAP1KO_limmaOut.txt', sep='\t') 
df5_limmaout.rename(columns={'adj.P.Val':'P-Val'}, inplace=True) 
dfratiosF5 = dfratios5.iloc[:, 0:6] 
dfratiosF5[['logFC', 'P-Val', 'B']] = df5_limmaout[['logFC', 'P-Val', 'B']] 
 
#add in a new column for the gene name (duplicate protein column) and prepare the list for querying uniport 
dfratiosF5.insert(1, 'Gene', dfratiosF5.Protein) 
uniprot_input = list(dfratiosF5.Protein) 
 
#Output the number of unique proteins 
print('The number of unique proteins is:') 
len(dfratiosF5.drop_duplicates('Protein')) 
#Query uniprot to get list of gene names 
 
#define variables 
url = 'https://www.uniprot.org/uploadlists/' 
user_agent = 'Mozilla/5.0 (Windows NT 10.0; Win64; x64)' 
 
#make a dictionary for the requests 
params = { 
    "from":"ACC+ID", 
    "to":"ACC", 
    "format":"tab", 
    "columns": "genes(PREFERRED)", 




data = urllib.parse.urlencode(params, doseq=False) 
data = data.encode('ascii') 
headers = {"User-Agent": user_agent} 
request = urllib.request.Request(url, data, headers) 
response = urllib.request.urlopen(request) 
with urllib.request.urlopen(request) as f: 
   response = f.read().decode() 
 
#make a dataframe from the output 
df_res = pd.read_csv(StringIO(response), sep='\t') 
df_res #inspect 
#Add the gene names to the ratios table from above based on the uniprot output 
#Then, normalize the ratios based on the protein expression ratios 
 
#rename the uniprot output columns 
df_res.rename(columns={df_res.columns[0]: "Gene", df_res.columns[1]: "UniprotID"}, inplace=True) 
 
#set up the dictionary for mapping 
di = df_res.set_index('UniprotID')['Gene'].to_dict() 
 
#replace the gene name column in the ratios df with the gene name based on the above dictionary 
dfratiosF5['Gene'].replace(di, inplace=True) 
 
#import the PD output for protein expression and get the gene name for merging with ratios df 
dfproteins = pd.read_csv(fnamep, sep='\t') 
dfproteins = dfproteins[['Description', 'Abundance Ratio log2 BAP1 KO  Control']] 
dfproteins['Gene'] = dfproteins.Description.str.extract('GN=(.*) PE=') 
dfproteins.rename(columns={'Abundance Ratio log2 BAP1 KO  Control':'logFC Protein'}, inplace=True) 
dfproteins = dfproteins.groupby('Gene', as_index=False).mean() 
 
#merge with ratios file (validating that there are not duplicate gene names in the proteins file) 
dfratiosproteins5 = dfratiosF5.merge(dfproteins, how='left', on='Gene', validate='m:1') 
 
#export this as a txt file 
dfratiosproteins5.to_csv('BAP1KO_SitesRegions_Ratios.csv', index=False) 
#Now I will correct the sites and regions ratios for changes in protein expression and re-run limma 
 
dflimmaC5 = dflimma5.copy() #make a copy of the original ratios table 
 
#define log protein expression value to subtract 
logPE = dfratiosproteins5['logFC Protein'].fillna(0) 
 
dflimmaC5[['Trial1', 'Trial2', 'Trial3']] = \ 
dflimmaC5[['Trial1', 'Trial2', 'Trial3']] - [logPE, logPE, logPE] 
 




#calculate the p-values for changing sites with limma in R 
 




df1 = read.table("BAP1KO_SitesRegions_RatiosCorrected_Limma.txt",sep="\t",header=TRUE,row.names=1) #read in the file 
f1 = eBayes(lmFit(df1)) #perform limma 
write.table(topTable(f1,n=Inf,confint=.95),"BAP1KO_limmaOut_Corrected.txt",sep="\t") #write table 
#Read the limma output back in, clean up, and export a new df with the final ratios 
#Also export a df with just Gene, Protein, and Site ID Constraints of significantly changing sites for cytoscape 
 
#import and clean up limma output 
df5_limmaoutC = pd.read_csv('BAP1KO_limmaOut_Corrected.txt', sep='\t') 
df5_limmaoutC.rename(columns={'adj.P.Val':'P-Val_Corrected', 'B':'B_Corrected', 'logFC':'logFC_Corrected'},  
                     inplace=True) 
 
#make a copy of the previous final ratios df and add the protein expression corrected columns in 
dfcorrectedratios5 = dfratiosproteins5.copy() 
dfcorrectedratios5[['logFC_Corrected', 'P-Val_Corrected', 'B_Corrected']] = df5_limmaoutC[['logFC_Corrected',  
                                                                                           'P-Val_Corrected',  
                                                                                           'B_Corrected']] 
 
#export final list of ratios 
dfcorrectedratios5.to_csv('BAP1KO_SitesRegions_Ratios_Corrected.csv', index=False) 
 
#export table for cytoscape 
 
#get relevant columns 
dfsrRatios_ForCytoscape = dfcorrectedratios5[['Gene', 'Protein', 'Site ID Constraints', 'logFC_Corrected',  
                                              'P-Val_Corrected', 'logFC Protein']] 
 
#add column for whether protein expression is corrected for 
dfsrRatios_ForCytoscape.loc[dfsrRatios_ForCytoscape['logFC Protein'].isnull(),  
                            'Corrected for Protein Expression'] = 'No' 
dfsrRatios_ForCytoscape.loc[~dfsrRatios_ForCytoscape['logFC Protein'].isnull(),  
                            'Corrected for Protein Expression'] = 'Yes' 
 
#drop log FC protein column, add an additional column for cytoscape splicing, and combine rows with the same gene 
dfsrRatios_ForCytoscape.drop(columns={'logFC Protein'}, inplace=True) 
dfsrRatios_ForCytoscape.loc[dfcorrectedratios5['P-Val_Corrected'] < 0.05, 'Significantly Changing Site'] = 1 
 
#concatentate sites/regions together with their position and fold change in a new column 
dfsrRatios_ForCytoscape['Sites_Regions'] = (dfsrRatios_ForCytoscape['Protein'] + '@' +  
                                                dfsrRatios_ForCytoscape['Site ID Constraints'] + ' (FC: ' +  
                                                dfsrRatios_ForCytoscape['logFC_Corrected'].round(2).astype(str) +')') 
 
#calculate the average fold change per gene and save in a separate df 
dfavgFC = dfsrRatios_ForCytoscape.groupby(['Gene'])['logFC_Corrected'].mean().reset_index() 
dfavgFC.rename(columns={'logFC_Corrected':'AvgLogFC'}, inplace=True) 
 
#store the concatenated sites/regions for each gene as a separate df 
dfsrconcat = dfsrRatios_ForCytoscape.groupby(['Gene'])['Sites_Regions'].apply('; '.join).reset_index() 
dfsrconcat.rename(columns={'Sites_Regions':'O-GlcNAc Sites and Regions'}, inplace=True) 
 
#store the concatenated significant sites/regions for each gene as a separate df 
dfsigsrconcat = dfsrRatios_ForCytoscape[dfsrRatios_ForCytoscape['Significantly Changing Site'] == 1].groupby( 
    ['Gene'])['Sites_Regions'].apply('; '.join).reset_index() 
dfsigsrconcat.rename(columns={'Sites_Regions':'Significant Sites and Regions'}, inplace=True) 
 
#combine everything together in the same df 
dfsrRatios_ForCytoscape = dfsrRatios_ForCytoscape.merge(dfavgFC, how='left', on='Gene') 
dfsrRatios_ForCytoscape = dfsrRatios_ForCytoscape.merge(dfsrconcat, how='left', on='Gene') 
dfsrRatios_ForCytoscape = dfsrRatios_ForCytoscape.merge(dfsigsrconcat, how='left', on='Gene') 
 
#export for loading into cytoscape 
dfsrRatios_ForCytoscape[['Gene', 'AvgLogFC', 'Corrected for Protein Expression', 'O-GlcNAc Sites and Regions',  
                         'Significant Sites and Regions']].to_csv('BAP1KO_SitesRegions_ForCytoscape.csv', index=False) 
 
A5.6.5. Sites and Regions Programs. 
 
A5.6.5.1. Code for SitesAndRegions.py. 
# ASSUME INPUT TABLE HAS THE FOLLOWING COLUMNS EXACTLY NAMED: "RawFile", "Protein", "ScanNumber", "NumMods", "Positions" (semicolon separated), "Probabilities" 
(semicolon separated) 
 
### USAGE: python SitesAndRegionsGeneric.py Input_SiteAndRegionsTable_Filename Output_MaxParSiteConstraints Output_BestMS2forSites 
### NOTE: rounding for probability threshold needs to be adjusted for the rounding of MS data anlysis program, e.g. in ProtomeDiscoverer 2/3 is 3 decimals (0.667) 
import re 
import sys 
import networkx as nx 
import itertools as it 




from collections import namedtuple 
 
# Define number of decimals to round probabilities 
roundto = 3 # For ProteomeDiscoverer 
 
YES = "YES" 
MAYBE = "MAYBE" 
NO = "NO" 
 
psmTable = pd.read_table(sys.argv[1]) 
 
requiredCols = ["RawFile","ScanNumber","Protein","Positions","Probabilities","NumMods"] 
for c in requiredCols: 
 assert c in psmTable.columns, "Missing %s in input table"%c 
 
regionID = 0 
fhMaxPar = open(sys.argv[2],'w') 
fhMaxPar.write("Protein\tRegion ID\tMin Sites\tSite ID Constraints\n") 
fhBestSiteMS2 = open(sys.argv[3],'w') 
fhBestSiteMS2.write("Protein\tPosition\tBest Probability\tBest Raw File\tBest Scan Number\tRegion ID\n") 
 
 
BestObservation = namedtuple("BestObservation",["RawFile","ScanNumber","Probability"]) 
MaybeGroup = namedtuple("MaybeGroup",["NumMods","Positions"]) 
 
# For each protein 
for prot,protPSMs in psmTable.groupby("Protein"): 
 print("Working on protein %s"%prot) 
 bestScanTable = {} # key: protein position, value: tuple(raw file,scan number, probability) 
 yesPositions = set() # set of accepted positions 
 maybeGroups = set() # set of maybe groups, where each group is tuple(nMods,set(positions)) 
  
 ### CLASSIFY EACH POSITION AS YES, NO, or MAYBE WITHIN EACH PSM 
 for psm in protPSMs.itertuples(): 
  # Split probabilities and positions into lists 
  siteProbs = list(map(float,psm.Probabilities.split(";"))) 
  siteLocs = list(map(int,psm.Positions.split(";"))) 
   
  # Check that number of probabilities and positions is the same 
  assert len(siteProbs)==len(siteLocs), "Number of probabilities does not equal number of positions for PSM: %s"%str(psm) 
   
  # Sort sites by highest probability to lowest 
  siteProbs,siteLocs = list(zip(*sorted(zip(siteProbs,siteLocs),reverse=True))) 
   
  # Determine which sites are YES (probability > nMods/(1+nMods), rounded [see above]), MAYBE (not YES, but needed to explain spectra), or NO (otherwise) 
  minYesProb = round(psm.NumMods/(1.+psm.NumMods), roundto) 
  siteCats = [] 
  for i in range(len(siteProbs)): 
   if siteProbs[i] > minYesProb: # Site probability is greater than required threshold, must include 
    siteCats.append(YES) 
   elif ( (i == 0) or ((siteProbs[i] == siteProbs[i-1]) and (siteCats[-1]==MAYBE)) or (sum(siteProbs[:i]) < (psm.NumMods-minYesProb)) ): # Either 
highest probability site doesn't pass threshold OR site has same probability of previous site that was also a MAYBE, OR need more sites to explain number of observed modifications 
    siteCats.append(MAYBE) 
   else: 
    siteCats.append(NO) 
   
  maybeList = [] # LIST OF MAYBE SITES POSITIONS 
  nYes = 0 
  for siteProb,siteLoc,siteCat in zip(siteProbs,siteLocs,siteCats): 
   
   if siteCat == YES: 
    # IF ALREADY YES, BUT WORSE PROBABILITY, UPDATE WITH BETTER EXAMPLE 
    if siteLoc in yesPositions: 
     if bestScanTable[siteLoc].Probability < siteProb: 
      bestScanTable[siteLoc] = BestObservation(psm.RawFile,psm.ScanNumber,siteProb) 
    # NOT PREVIOUS YES, SO SET BEST PROB AND ADD TO YES SET 
    else: 
     bestScanTable[siteLoc] = BestObservation(psm.RawFile,psm.ScanNumber,siteProb) 
     yesPositions.add(siteLoc) 
    nYes += 1 
   if siteCat == MAYBE: 
    maybeList.append(siteLoc) 
    if (not siteLoc in bestScanTable) or ((not siteLoc in yesPositions) and (bestScanTable[siteLoc].Probability < siteProb)): 
     bestScanTable[siteLoc] = BestObservation(psm.RawFile,psm.ScanNumber,siteProb) 
  if len(maybeList)>0: 
   maybeGroups.add(MaybeGroup(psm.NumMods-nYes,frozenset(maybeList))) 
 
 ### REMOVE KNOWN YES SITES FROM MAYBE GROUPS 
 changed = True 
 while changed: 
  changed = False 
  _maybeGroups = set() 
  for mgCount,mgPositions in maybeGroups: # for each maybe group, remove YES positions and decrease count 
   prevYesPositions = mgPositions & yesPositions  # find sites that are classified as YES for other PSMs 
   if len(prevYesPositions) > 0: # if some maybe group sites are YES in other PSMs, update the group 
    changed = True 
    # update required count and remove from set 
    _mgCount = mgCount - len(prevYesPositions) 
    _mgPositions = mgPositions - yesPositions 
    if _mgCount > 0: # if there are still maybe positions left.. 
     assert _mgCount <= len(_mgPositions), "Not enough remaining sites to cover required mods" 





      print("Converted MAYBE to YES via process of elmination for %s"%prot) 
      yesPositions.update(_mgPositions) 
     else: 
      _maybeGroups.add(MaybeGroup(_mgCount,_mgPositions)) 
   else: # no change to group, put back in new set 
    _maybeGroups.add(MaybeGroup(mgCount,mgPositions)) 
  maybeGroups = _maybeGroups # replace old set of groups with updated set 
  
 ### REMOVE ALL "SUBSET" GROUPS (another group has >= set of positions or >= required mods) 
 maybeGroups = list(maybeGroups) 
 subsetIndices = set() 
 for i in range(len(maybeGroups)): 
  for j in range(len(maybeGroups)): 
   if i != j: 
    if maybeGroups[i].NumMods >= maybeGroups[j].NumMods and maybeGroups[i].Positions.issuperset(maybeGroups[j].Positions): 
     subsetIndices.add(j) 
 _maybeGroups = [] 
 for i in range(len(maybeGroups)): 
  if not i in subsetIndices: 
   _maybeGroups.append(maybeGroups[i]) 
 maybeGroups = _maybeGroups 
  
 ### IDENTIFY REGIONS 
 while len(maybeGroups) > 0: 
  # SEED ALGORITHM WITH FIRST MAYBE GROUP 
  regionGroups = [maybeGroups.pop(0)] 
  regionPositions = set(regionGroups[0].Positions) 
  changed = True 
  while changed: # iterate while you keep adding new maybe groups 
   changed = False 
   for i in reversed(list(range(len(maybeGroups)))): # iterate through remaining groups 
    if not regionPositions.isdisjoint(maybeGroups[i].Positions): # if there is some overlap, add to region 
     regionGroups.append(maybeGroups.pop(i)) 
     regionPositions.update(regionGroups[-1].Positions) 
     changed = True 
   
  # FIND MIN NUMBER OF SITES TO SATISTFY ALL GROUPS IN REGION 
  satisfiedGroups = False 
  minNumSites = 0 
  while not satisfiedGroups: # TRY SUCESSIVELY LARGER NUMBER OF SITES 
   minNumSites += 1 
   for testSites in it.combinations(regionPositions,minNumSites): # TRY EACH COMBINATION OF POTENTIAL SITES 
    satisfiedGroups = True 
    testSet = set(testSites) 
    for mgCount,mgPositions in regionGroups: # TEST IF EACH MAYBE GROUP IS SATISFIED 
     if len(mgPositions&testSet) < mgCount: # IF THE TEST SET DOESN"T EXPLAIN THE GROUP, FLAG AS NOT 
SATISFIED 
      satisfiedGroups = False 
      break 
    if satisfiedGroups: 
     break 
   if satisfiedGroups: 
    break 
  maybeGroupStrs = [] 
  for mgCount,mgPositions in regionGroups: 
   maybeGroupStrs.append("(%d of %s)"%(mgCount,",".join(map(str,sorted(mgPositions))))) 
  fhMaxPar.write("%s\t%d\t%d\t%s\n"%(prot,regionID,minNumSites,"&".join(maybeGroupStrs))) 




  regionID += 1 
  
 ### OUTPUT YES SITES FROM PROTEIN 
 for sitePos in yesPositions: 










A5.6.5.2. Code for SitesAndRegionsMultiExperiment.py. 
### ASSUME INPUT TABLE HAS THE FOLLOWING COLUMNS EXACTLY NAMED: "RawFile", "Experiment", "Protein", "ScanNumber", "NumMods", "Positions" (semicolon 
separated), "Probabilities" (semicolon separated) 
 
### USAGE: python SitesAndRegionsGeneric.py Input_SiteAndRegionsTable_Filename Output_MaxParSiteConstraints Output_BestMS2forSites 








import networkx as nx 
import itertools as it 
import pandas as pd 
from collections import namedtuple 
 
# Define number of decimals to round probabilities 
roundto = 3 # For ProteomeDiscoverer 
 
YES = "YES" 
MAYBE = "MAYBE" 
NO = "NO" 
 
psmTable = pd.read_table(sys.argv[1]) 
 
requiredCols = ["RawFile","ScanNumber","Experiment","Protein","Positions","Probabilities","NumMods"] 
for c in requiredCols: 
 assert c in psmTable.columns, "Missing %s in input table"%c 
 
regionID = 0 
fhMaxPar = open(sys.argv[2],'w') 
fhMaxPar.write("Protein\tRegion ID\tMin Sites\tSite ID Constraints\n") 
fhBestSiteMS2 = open(sys.argv[3],'w') 
fhBestSiteMS2.write("Protein\tPosition\tExperiment\tBest Probability\tBest Raw File\tBest Scan Number\tRegion ID\n") 
 
 
BestObservation = namedtuple("BestObservation",["RawFile","ScanNumber","Probability"]) 
MaybeGroup = namedtuple("MaybeGroup",["NumMods","Positions"]) 
 
 
# For each protein 
for prot,protPSMs in psmTable.groupby("Protein"): 
 print("Working on protein %s"%prot) 
 bestScanTable = {} # key: protein position, value: tuple(raw file,scan number, probability) 
 yesPositions = set() # set of accepted positions 
 maybeGroups = set() # set of maybe groups, where each group is tuple(nMods,set(positions)) 
  
 ### CLASSIFY EACH POSITION AS YES, NO, or MAYBE WITHIN EACH PSM 
 for psm in protPSMs.itertuples(): 
  # Split probabilities and positions into lists 
  siteProbs = list(map(float,psm.Probabilities.split(";"))) 
  siteLocs = list(map(int,psm.Positions.split(";"))) 
   
  # Check that number of probabilities and positions is the same 
  assert len(siteProbs)==len(siteLocs), "Number of probabilities does not equal number of positions for PSM: %s"%str(psm) 
   
  # Sort sites by highest probability to lowest 
  siteProbs,siteLocs = list(zip(*sorted(zip(siteProbs,siteLocs),reverse=True))) 
   
  # Determine which sites are YES (probability > nMods/(1+nMods), rounded [see above]), MAYBE (not YES, but needed to explain spectra), or NO 
(otherwise) 
  minYesProb = round(psm.NumMods/(1.+psm.NumMods), roundto) 
  siteCats = [] 
  for i in range(len(siteProbs)): 
   if siteProbs[i] > minYesProb: # Site probability is greater than required threshold, must include 
    siteCats.append(YES) 
   elif ( (i == 0) or ((siteProbs[i] == siteProbs[i-1]) and (siteCats[-1]==MAYBE)) or (sum(siteProbs[:i]) < (psm.NumMods-minYesProb)) ): 
# Either highest probability site doesn't pass threshold OR site has same probability of previous site that was also a MAYBE, OR need more sites to explain number of observed modifications 
    siteCats.append(MAYBE) 
   else: 
    siteCats.append(NO) 
   
  maybeList = [] # LIST OF MAYBE SITES POSITIONS 
  nYes = 0 
  for siteProb,siteLoc,siteCat in zip(siteProbs,siteLocs,siteCats): 
   if siteCat == YES: 
    yesPositions.add(siteLoc) 
    nYes += 1 
   if siteCat == MAYBE: 
    maybeList.append(siteLoc) 
     
   if not siteLoc in bestScanTable: 
    bestScanTable[siteLoc] = {} 
   if not psm.Experiment in bestScanTable[siteLoc]: 
    bestScanTable[siteLoc][psm.Experiment] = BestObservation(psm.RawFile,psm.ScanNumber,siteProb) 
   else: 
    if bestScanTable[siteLoc][psm.Experiment].Probability < siteProb: 
     bestScanTable[siteLoc][psm.Experiment] = 
BestObservation(psm.RawFile,psm.ScanNumber,siteProb) 
    
  if len(maybeList)>0: 
   maybeGroups.add(MaybeGroup(psm.NumMods-nYes,frozenset(maybeList))) 
 
 ### REMOVE KNOWN YES SITES FROM MAYBE GROUPS 
 changed = True 
 while changed: 
  changed = False 
  _maybeGroups = set() 
  for mgCount,mgPositions in maybeGroups: # for each maybe group, remove YES positions and decrease count 
   prevYesPositions = mgPositions & yesPositions  # find sites that are classified as YES for other PSMs 
   if len(prevYesPositions) > 0: # if some maybe group sites are YES in other PSMs, update the group 
    changed = True 




    _mgCount = mgCount - len(prevYesPositions) 
    _mgPositions = mgPositions - yesPositions 
    if _mgCount > 0: # if there are still maybe positions left.. 
     assert _mgCount <= len(_mgPositions), "Not enough remaining sites to cover required mods" 
     if _mgCount == len(_mgPositions): # if exactly enough sites to cover required mods, make them 
all YES, should RARELY happen 
      print("Converted MAYBE to YES via process of elmination for %s"%prot) 
      yesPositions.update(_mgPositions) 
     else: 
      _maybeGroups.add(MaybeGroup(_mgCount,_mgPositions)) 
   else: # no change to group, put back in new set 
    _maybeGroups.add(MaybeGroup(mgCount,mgPositions)) 
  maybeGroups = _maybeGroups # replace old set of groups with updated set 
  
 ### REMOVE ALL "SUBSET" GROUPS (another group has >= set of positions or >= required mods) 
 maybeGroups = list(maybeGroups) 
 subsetIndices = set() 
 for i in range(len(maybeGroups)): 
  for j in range(len(maybeGroups)): 
   if i != j: 
    if maybeGroups[i].NumMods >= maybeGroups[j].NumMods and 
maybeGroups[i].Positions.issuperset(maybeGroups[j].Positions): 
     subsetIndices.add(j) 
 _maybeGroups = [] 
 for i in range(len(maybeGroups)): 
  if not i in subsetIndices: 
   _maybeGroups.append(maybeGroups[i]) 
 maybeGroups = _maybeGroups 
  
 ### IDENTIFY REGIONS 
 while len(maybeGroups) > 0: 
  # SEED ALGORITHM WITH FIRST MAYBE GROUP 
  regionGroups = [maybeGroups.pop(0)] 
  regionPositions = set(regionGroups[0].Positions) 
  changed = True 
  while changed: # iterate while you keep adding new maybe groups 
   changed = False 
   for i in reversed(list(range(len(maybeGroups)))): # iterate through remaining groups 
    if not regionPositions.isdisjoint(maybeGroups[i].Positions): # if there is some overlap, add to region 
     regionGroups.append(maybeGroups.pop(i)) 
     regionPositions.update(regionGroups[-1].Positions) 
     changed = True 
   
  # FIND MIN NUMBER OF SITES TO SATISTFY ALL GROUPS IN REGION 
  satisfiedGroups = False 
  minNumSites = 0 
  while not satisfiedGroups: # TRY SUCESSIVELY LARGER NUMBER OF SITES 
   minNumSites += 1 
   for testSites in it.combinations(regionPositions,minNumSites): # TRY EACH COMBINATION OF POTENTIAL SITES 
    satisfiedGroups = True 
    testSet = set(testSites) 
    for mgCount,mgPositions in regionGroups: # TEST IF EACH MAYBE GROUP IS SATISFIED 
     if len(mgPositions&testSet) < mgCount: # IF THE TEST SET DOESN"T EXPLAIN THE 
GROUP, FLAG AS NOT SATISFIED 
      satisfiedGroups = False 
      break 
    if satisfiedGroups: 
     break 
   if satisfiedGroups: 
    break 
  maybeGroupStrs = [] 
  for mgCount,mgPositions in regionGroups: 
   maybeGroupStrs.append("(%d of %s)"%(mgCount,",".join(map(str,sorted(mgPositions))))) 
  fhMaxPar.write("%s\t%d\t%d\t%s\n"%(prot,regionID,minNumSites,"&".join(maybeGroupStrs))) 
  for sitePos in regionPositions: 
   for eName in bestScanTable[sitePos]: 
   
 fhBestSiteMS2.write("%s\t%d\t%s\t%f\t%s\t%d\t%d\n"%(prot,sitePos,eName,bestScanTable[sitePos][eName].Probability,bestScanTable[sitePos][eName].RawFile,bestScanT
able[sitePos][eName].ScanNumber,regionID)) 
  regionID += 1 
  
 ### OUTPUT YES SITES FROM PROTEIN 
 for sitePos in yesPositions: 
  fhMaxPar.write("%s\t%d\t%d\t%d\n"%(prot,regionID,1,sitePos)) 










A5.6.6. 293T Interactor Volcano Plot. 
 






import pandas as pd 
import networkx as nx 
import itertools as it 
from collections import namedtuple 
import numpy as np 
import matplotlib 
import matplotlib.pyplot as plt 
from IPython.display import display 
from functools import reduce 
import seaborn as sns; sns.set() 
from io import StringIO 
from matplotlib_venn import venn2, venn2_unweighted, venn3_unweighted, venn2_circles, venn3_circles  
 
















#read in the interactors and PPI databases 
 
df = pd.read_csv('./20D21_Full_Interactomics_Dataset/AllProteinsInteracomtics293TF.csv') 
dfintact = pd.read_csv('IntAct.txt', sep='\t') #using the full rather than the multivalidated db 
dfbiogrid = pd.read_csv('BioGRID.txt', sep='\t') 
 
#remove entries from the interactomics dataset where the fold change of either ibb or limma was less/greater (respectively)  
    #than 0; these are clearly crapome proteins 
     
df = df[(df.limmaFC > 0) | (df.ibbFC < 0)] 
 
#select only the OGT interactors from the PPI databases 
dfbap1_intact = set(list(dfintact.loc[dfintact.Interactor_A == 'OGT', 'Interactor_B']) + list( 
    dfintact.loc[dfintact.Interactor_B == 'OGT', 'Interactor_A'])) 
dfbap1_biogrid = set(list(dfbiogrid.loc[dfbiogrid.Interactor_A == 'OGT', 'Interactor_B']) + list( 
    dfbiogrid.loc[dfbiogrid.Interactor_B == 'OGT', 'Interactor_A'])) 
#add an additional column specifying if a gene is a known interactor and if it is significant 
df['Known Interactor'] = df.Gene.isin((dfbap1_intact | dfbap1_biogrid)) 
df['Significant'] = (df.limmapVal < 0.05) | (df.ibbpVal < 0.05) 
 
#set OGT as a known interactor 
df.loc[df.Gene == 'OGT', 'Known Interactor'] = True 
 
#keep only relevant columns 
dfgraph = df[['Gene', 'limmapVal', 'ibbpVal', 'Known Interactor', 'Significant']] 
 
#take the negative log of both pvalues 
dfgraph[['limmapVal', 'ibbpVal']] = -np.log10(dfgraph[['limmapVal', 'ibbpVal']]) 
dfgraph.rename(columns={'limmapVal':'-Log(P-Value), SILAC Ratio', 'ibbpVal':'-Log(P-Value), Spectral Counts'}, inplace=True) 
 
#count the number of unknown interactors found 
print('The number of unknown interactors is:') 
len(dfgraph[(dfgraph.Significant == True) & (dfgraph['Known Interactor'] == False)]) 
 






#plot 4 scatter plots on top each other to highlight the known/unknown and significant/insignificant interactors 
g1 = sns.scatterplot( 
    x='-Log(P-Value), SILAC Ratio', y='-Log(P-Value), Spectral Counts',  
    data=dfgraph[(dfgraph.Significant == False) & (dfgraph['Known Interactor'] == False)],  
    facecolor='none', edgecolor='black', marker="o", legend=False, alpha=0.75) 
 
g2 = sns.scatterplot( 
    x='-Log(P-Value), SILAC Ratio', y='-Log(P-Value), Spectral Counts',  
    data=dfgraph[(dfgraph.Significant == True) & (dfgraph['Known Interactor'] == False)],  
    facecolor='none', edgecolor='blue', marker="o", legend=False, alpha=0.75) 
 
g3 = sns.scatterplot( 
    x='-Log(P-Value), SILAC Ratio', y='-Log(P-Value), Spectral Counts',  
    data=dfgraph[(dfgraph.Significant == False) & (dfgraph['Known Interactor'] == True)],  
    facecolor='red', edgecolor='none', marker="o", legend=False, alpha=0.75) 
 
g4 = sns.scatterplot( 
    x='-Log(P-Value), SILAC Ratio', y='-Log(P-Value), Spectral Counts',  
    data=dfgraph[(dfgraph.Significant == True) & (dfgraph['Known Interactor'] == True)],  
    facecolor='red', edgecolor='none', marker="o", legend=False, alpha=0.75) 
 
#define points to label 




       'RBM4'] 
 
#plot them as text objects 
for i in ptl: 
    g4.text((dfgraph['-Log(P-Value), SILAC Ratio'][dfgraph.Gene == i].max() + 0.1),  
            (dfgraph['-Log(P-Value), Spectral Counts'][dfgraph.Gene == i].max() - 0.08),  
            i, color='black', fontsize=12, weight='bold') 
     
#add in HIVEP1 and others on the far right 
g4.text((dfgraph['-Log(P-Value), SILAC Ratio'][dfgraph.Gene == 'HIVEP1'].min() + 0.1),  
            (dfgraph['-Log(P-Value), Spectral Counts'][dfgraph.Gene == 'HIVEP1'].max() - 0.08),  
            'HIVEP1', color='black', fontsize=12, weight='bold') 
 
g4.text((dfgraph['-Log(P-Value), SILAC Ratio'][dfgraph.Gene == 'GTSE1'].max() - .59),  
            (dfgraph['-Log(P-Value), Spectral Counts'][dfgraph.Gene == 'GTSE1'].max() - 0.08),  
            'GTSE1', color='black', fontsize=12, weight='bold', ha='left') 
 
g4.text((dfgraph['-Log(P-Value), SILAC Ratio'][dfgraph.Gene == 'KDM1B'].max() - .625),  
            (dfgraph['-Log(P-Value), Spectral Counts'][dfgraph.Gene == 'KDM1B'].max() - 0.08),  
            'KDM1B', color='black', fontsize=12, weight='bold', ha='left') 
 





A5.6.7. Querying the Uniprot Knowledgebase. 
 
#import required packages 
import re 
import sys 
import pandas as pd 
import networkx as nx 
import itertools as it 
from collections import namedtuple 
import numpy as np 
import matplotlib 
import matplotlib.pyplot as plt 
from IPython.display import display 
from functools import reduce 
import seaborn as sns; sns.set() 
from io import StringIO 
from matplotlib_venn import venn2_unweighted #the unweighted is if you want to make circles that are the same size 
from matplotlib_venn import venn2 #also import the normal one 
import pandas as pd 
import numpy as np 
from io import StringIO 
import urllib.request, urllib.parse, urllib.error,urllib.request,urllib.error,urllib.parse 
from Bio import SeqIO 
 
#magic function to show plots inline 
%matplotlib inline 
 
#ignore warnings  
import warnings 
warnings.filterwarnings("ignore") 
#Import the sites and regions final output and the final substrates and ints lists  
 
#make lists to import the filenames 
list_sr = ['293T', 'Liver', 'Brain'] 
list_ints = ['293TF', '293TSwiss', 'BrainF', 'BrainSwiss', 'LiverF', 'LiverSwiss'] 
list_subs = ['293Full', '293SwissProt', 'BrainFull', 'BrainSwissProt', 'LiverFull', 'LiverSwissProt'] 
 
#import the sites and regions from the full proteome 
for i in list_sr: 
    locals()['dfsrFull{}'.format(i)] = pd.read_csv('./20D15_SitesAndRegions/maxparcon_{}.txt'.format(i), sep='\t') 
 
#and for the SwissProt proteome 
for i in list_sr: 
    locals()['dfsrSwiss{}'.format(i)] = pd.read_csv('./20D22_SitesAndRegions_SwissProt/maxparcon_{}.txt'.format(i), sep='\t') 
     
#import the interactors 
for i in list_ints: 
    locals()['dfints{}'.format(i)] = pd.read_csv( 
        './20B25_Analyzed_PD_Output/Interactors{}.csv'.format(i))[['Accession', 'Gene']] 
     
#import the substrates 
for i in list_subs: 
    locals()['dfsubs{}'.format(i)] = pd.read_csv( 
        './20B25_Analyzed_PD_Output/Substrates{}.csv'.format(i))[['Accession', 'Modifications', 'Gene']] 
#Set up variables and query uniprot with a for loop (starting with full sites and regions) 
 
url = "https://www.uniprot.org/uploadlists/" 
user_agent = 'Mozilla/5.0 (Windows NT 10.0; Win64; x64)' 
 
#make a for loop for all three tissues 
for i in list_sr: 
    output = set(locals()['dfsrFull{}'.format(i)].Protein) #define 'output for setting the params' 




    #set values to query uniprot for 
    params = { 
        "from":"ACC+ID", 
        "to":"ACC", 
        "format":"tab", 
        "columns": "id,entry name,protein names(recommended name),reviewed,keywords,comment(FUNCTION),comment(PATHWAY)," 
        "go(biological process),go(molecular function),go(cellular component),comment(SUBCELLULAR LOCATION),comment(PTM)," 
        "feature(MODIFIED RESIDUE),feature(GLYCOSYLATION),comment(DOMAIN),feature(DOMAIN EXTENT),feature(COILED COIL)," 
        "feature(COMPOSITIONAL BIAS),feature(MOTIF),feature(REGION),feature(REPEAT),feature(ZINC FINGER)", 
        "query":" ".join(list(output))} 
     
    #query uniprot 
    data = urllib.parse.urlencode(params) 
    data = data.encode('ascii') 
    headers = {"User-Agent": user_agent} 
    request = urllib.request.Request(url, data, headers) 
    with urllib.request.urlopen(request) as f: 
       response = f.read().decode() 
     
    #read the response into a df, drop the last column (repeat of input list), and export to csv 
    locals()['dfres_srFull{}'.format(i)] = pd.read_csv(StringIO(response), sep='\t') 
    locals()['dfres_srFull{}'.format(i)].drop(locals()['dfres_srFull{}'.format(i)].columns[-1], axis=1, inplace=True) 
    locals()['dfres_srFull{}'.format(i)].to_csv('./20D22_UniprotOutput/RawOutput_srFull{}.csv'.format(i)) 
#Repeat for SwissProt sites and regions 
 
#make a for loop for all three tissues 
for i in list_sr: 
    output = set(locals()['dfsrSwiss{}'.format(i)].Protein) #define 'output for setting the params' 
     
    #set values to query uniprot for 
    params = { 
        "from":"ACC+ID", 
        "to":"ACC", 
        "format":"tab", 
        "columns": "id,entry name,protein names(recommended name),reviewed,keywords,comment(FUNCTION),comment(PATHWAY)," 
        "go(biological process),go(molecular function),go(cellular component),comment(SUBCELLULAR LOCATION),comment(PTM)," 
        "feature(MODIFIED RESIDUE),feature(GLYCOSYLATION),comment(DOMAIN),feature(DOMAIN EXTENT),feature(COILED COIL)," 
        "feature(COMPOSITIONAL BIAS),feature(MOTIF),feature(REGION),feature(REPEAT),feature(ZINC FINGER)", 
        "query":" ".join(list(output))} 
     
    #query uniprot 
    data = urllib.parse.urlencode(params) 
    data = data.encode('ascii') 
    headers = {"User-Agent": user_agent} 
    request = urllib.request.Request(url, data, headers) 
    with urllib.request.urlopen(request) as f: 
       response = f.read().decode() 
     
    #read the response into a df, drop the last column (repeat of input list), and export to csv 
    locals()['dfres_srSwiss{}'.format(i)] = pd.read_csv(StringIO(response), sep='\t') 
    locals()['dfres_srSwiss{}'.format(i)].drop(locals()['dfres_srSwiss{}'.format(i)].columns[-1], axis=1, inplace=True) 
    locals()['dfres_srSwiss{}'.format(i)].to_csv('./20D22_UniprotOutput/RawOutput_srSwiss{}.csv'.format(i)) 
#Now run for the interactors 
 
#make a for loop for all three tissues 
for i in list_ints: 
    output = set(locals()['dfints{}'.format(i)].Accession) #define 'output for setting the params' 
     
    #set values to query uniprot for 
    params = { 
        "from":"ACC+ID", 
        "to":"ACC", 
        "format":"tab", 
        "columns": "id,entry name,protein names(recommended name),reviewed,keywords,comment(FUNCTION),comment(PATHWAY)," 
        "go(biological process),go(molecular function),go(cellular component),comment(SUBCELLULAR LOCATION),comment(PTM)," 
        "feature(MODIFIED RESIDUE),feature(GLYCOSYLATION),comment(DOMAIN),feature(DOMAIN EXTENT),feature(COILED COIL)," 
        "feature(COMPOSITIONAL BIAS),feature(MOTIF),feature(REGION),feature(REPEAT),feature(ZINC FINGER)", 
        "query":" ".join(list(output))} 
     
    #query uniprot 
    data = urllib.parse.urlencode(params) 
    data = data.encode('ascii') 
    headers = {"User-Agent": user_agent} 
    request = urllib.request.Request(url, data, headers) 
    with urllib.request.urlopen(request) as f: 
       response = f.read().decode() 
     
    #read the response into a df, drop the last column (repeat of input list), and export to csv 
    locals()['dfres_ints{}'.format(i)] = pd.read_csv(StringIO(response), sep='\t') 
    locals()['dfres_ints{}'.format(i)].drop(locals()['dfres_ints{}'.format(i)].columns[-1], axis=1, inplace=True) 
    locals()['dfres_ints{}'.format(i)].to_csv('./20D22_UniprotOutput/RawOutput_ints{}.csv'.format(i)) 
#Finally run for the substrates 
 
#make a for loop for all three tissues 
for i in list_subs: 
    output = set(locals()['dfsubs{}'.format(i)].Accession) #define 'output for setting the params' 
     
    #set values to query uniprot for 
    params = { 
        "from":"ACC+ID", 
        "to":"ACC", 
        "format":"tab", 




        "go(biological process),go(molecular function),go(cellular component),comment(SUBCELLULAR LOCATION),comment(PTM)," 
        "feature(MODIFIED RESIDUE),feature(GLYCOSYLATION),comment(DOMAIN),feature(DOMAIN EXTENT),feature(COILED COIL)," 
        "feature(COMPOSITIONAL BIAS),feature(MOTIF),feature(REGION),feature(REPEAT),feature(ZINC FINGER)", 
        "query":" ".join(list(output))} 
     
    #query uniprot 
    data = urllib.parse.urlencode(params) 
    data = data.encode('ascii') 
    headers = {"User-Agent": user_agent} 
    request = urllib.request.Request(url, data, headers) 
    with urllib.request.urlopen(request) as f: 
       response = f.read().decode() 
     
    #read the response into a df, drop the last column (repeat of input list), and export to csv 
    locals()['dfres_subs{}'.format(i)] = pd.read_csv(StringIO(response), sep='\t') 
    locals()['dfres_subs{}'.format(i)].drop(locals()['dfres_subs{}'.format(i)].columns[-1], axis=1, inplace=True) 
    locals()['dfres_subs{}'.format(i)].to_csv('./20D22_UniprotOutput/RawOutput_subs{}.csv'.format(i)) 
 
 
A5.6.8. Domains and PTMs Bioinformatics Analysis. 
 
#import required packages 
import re 
import sys 
import pandas as pd 
import networkx as nx 
import itertools as it 
from collections import namedtuple 
import numpy as np 
import matplotlib 
import matplotlib.pyplot as plt 
from IPython.display import display 
from functools import reduce 
import seaborn as sns; sns.set() 
from io import StringIO 
from matplotlib_venn import venn2_unweighted #the unweighted is if you want to make circles that are the same size 
from matplotlib_venn import venn2 #also import the normal one 
import pandas as pd 
import numpy as np 
from io import StringIO 
import urllib.request, urllib.parse, urllib.error,urllib.request,urllib.error,urllib.parse 




#magic function to show plots inline 
%matplotlib inline 
 
#ignore warnings  
import warnings 
warnings.filterwarnings("ignore") 
#Import the outputs from the uniprot 
 
#folder location uniprot output 
ufolder = './20D22_UniprotOutput/' 
folderout = './20D23_BioinformaticsAnalyses/' 
srfolder = './20D15_SitesAndRegions/' 
srfolderswiss = './20D22_SitesAndRegions_SwissProt/' 
 
#define lists for for loop 
list_type_sr = ['Full', 'Swiss'] 
list_exp1 = ['293T', 'Brain', 'Liver'] 
list_exp2 = ['293', 'Brain', 'Liver'] 
list_type_subs = ['Full', 'SwissProt'] 
list_types_ints = ['F', 'Swiss'] 
 
#import the sr data 
for i in list_exp1: 
    for j in list_type_sr: 
        locals()['df_sr{}{}'.format(i,j)] = pd.read_csv('%sRawOutput_sr{}{}.csv'.format(j,i)%(ufolder), index_col=0) 
 
#import the interactors data 
for i in list_exp1: 
    for j in list_types_ints: 
        locals()['df_ints{}{}'.format(i,j)] = pd.read_csv('%sRawOutput_ints{}{}.csv'.format(i,j)%(ufolder), index_col=0) 
         
#import the substrates data 
for i in list_exp2: 
    for j in list_type_subs: 
        locals()['df_subs{}{}'.format(i,j)] = pd.read_csv('%sRawOutput_subs{}{}.csv'.format(i,j)%(ufolder), index_col=0) 
#Now I will reformat the uniprot data so that is easier to work with 
 
#first for the sites and regions 
#find the start and end of every decsription as well as start and end of the domain in aa numbers 
#extract the string in between for each of the above 
#make a list of lists for the domain start, end, and the domain names for each protein 





#make a list of the columns to tidy (domain will be separate because it has a different column name structure) 
list_t = ['Motif', 'Region', 'Repeat'] 
 
for i in list_exp1: 
    for j in list_type_sr: 
        #start with domain 
        locals()['df_sr{}{}'.format(i,j)]['DomainList'] = locals()[ 
            'df_sr{}{}'.format(i,j)]['Domain [FT]'].str.extractall('note="(.*?)"').unstack().apply( 
            lambda x: '@Unique@Joiner@'.join(x.dropna()), axis=1).str.split('@Unique@Joiner@') 
        locals()['df_sr{}{}'.format(i,j)]['DomainStart'] = locals()[ 
            'df_sr{}{}'.format(i,j)]['Domain [FT]'].str.extractall('DOMAIN\s(.*?)(?=\.|;)').unstack().apply( 
            lambda x: ','.join(x.dropna()), axis=1).str.split(',').apply(lambda x: [int(i) for i in x]) 
        locals()['df_sr{}{}'.format(i,j)]['DomainEnd'] = locals()[ 
            'df_sr{}{}'.format(i,j)]['Domain [FT]'].str.extractall('\.\.(.*?);').unstack().apply( 
            lambda x: ','.join(x.dropna()), axis=1).str.split(',').apply(lambda x: [int(i) for i in x])         
         
        #then do motif, region, and repeat 
        for k in list_t: 
            locals()['df_sr{}{}'.format(i,j)]['{}List'.format(k)] = locals()[ 
                'df_sr{}{}'.format(i,j)]['{}'.format(k)].str.extractall('note="(.*?)"').unstack().apply( 
                lambda x: '@Unique@Joiner@'.join(x.dropna()), axis=1).str.split('@Unique@Joiner@') 
            locals()['df_sr{}{}'.format(i,j)]['{}Start'.format(k)] = locals()[ 
                'df_sr{}{}'.format(i,j)]['{}'.format(k)].str.extractall( 
                '{}\s(.*?)(?=\.|;)'.format(str.upper(k))).unstack().apply( 
                lambda x: ','.join(x.dropna()), axis=1).str.split(',').apply(lambda x: [int(i) for i in x]) 
            locals()['df_sr{}{}'.format(i,j)]['{}End'.format(k)] = locals()[ 
                'df_sr{}{}'.format(i,j)]['{}'.format(k)].str.extractall('\.\.(.*?);').unstack().apply( 
                lambda x: ','.join(x.dropna()), axis=1).str.split(',').apply(lambda x: [int(i) for i in x])         
#Make the same columns for the subs and ints tables 
 
#ints 
for i in list_exp1: 
    for j in list_types_ints: 
        #start with domain 
        locals()['df_ints{}{}'.format(i,j)]['DomainList'] = locals()[ 
            'df_ints{}{}'.format(i,j)]['Domain [FT]'].str.extractall('note="(.*?)"').unstack().apply( 
            lambda x: '@Unique@Joiner@'.join(x.dropna()), axis=1).str.split('@Unique@Joiner@') 
        locals()['df_ints{}{}'.format(i,j)]['DomainStart'] = locals()[ 
            'df_ints{}{}'.format(i,j)]['Domain [FT]'].str.extractall('DOMAIN\s(.*?)(?=\.|;)').unstack().apply( 
            lambda x: ','.join(x.dropna()), axis=1).str.split(',').apply(lambda x: [int(i) for i in x]) 
        locals()['df_ints{}{}'.format(i,j)]['DomainEnd'] = locals()[ 
            'df_ints{}{}'.format(i,j)]['Domain [FT]'].str.extractall('\.\.(.*?);').unstack().apply( 
            lambda x: ','.join(x.dropna()), axis=1).str.split(',').apply(lambda x: [int(i) for i in x])         
         
        #then do motif, region, and repeat 
        for k in list_t: 
            locals()['df_ints{}{}'.format(i,j)]['{}List'.format(k)] = locals()[ 
                'df_ints{}{}'.format(i,j)]['{}'.format(k)].str.extractall('note="(.*?)"').unstack().apply( 
                lambda x: '@Unique@Joiner@'.join(x.dropna()), axis=1).str.split('@Unique@Joiner@') 
            locals()['df_ints{}{}'.format(i,j)]['{}Start'.format(k)] = locals()[ 
                'df_ints{}{}'.format(i,j)]['{}'.format(k)].str.extractall( 
                '{}\s(.*?)(?=\.|;)'.format(str.upper(k))).unstack().apply( 
                lambda x: ','.join(x.dropna()), axis=1).str.split(',').apply(lambda x: [int(i) for i in x]) 
            locals()['df_ints{}{}'.format(i,j)]['{}End'.format(k)] = locals()[ 
                'df_ints{}{}'.format(i,j)]['{}'.format(k)].str.extractall('\.\.(.*?);').unstack().apply( 
                lambda x: ','.join(x.dropna()), axis=1).str.split(',').apply(lambda x: [int(i) for i in x])   
             
#subs 
for i in list_exp2: 
    for j in list_type_subs: 
        #start with domain 
        locals()['df_subs{}{}'.format(i,j)]['DomainList'] = locals()[ 
            'df_subs{}{}'.format(i,j)]['Domain [FT]'].str.extractall('note="(.*?)"').unstack().apply( 
            lambda x: '@Unique@Joiner@'.join(x.dropna()), axis=1).str.split('@Unique@Joiner@') 
        locals()['df_subs{}{}'.format(i,j)]['DomainStart'] = locals()[ 
            'df_subs{}{}'.format(i,j)]['Domain [FT]'].str.extractall('DOMAIN\s(.*?)(?=\.|;)').unstack().apply( 
            lambda x: ','.join(x.dropna()), axis=1).str.split(',').apply(lambda x: [int(i) for i in x]) 
        locals()['df_subs{}{}'.format(i,j)]['DomainEnd'] = locals()[ 
            'df_subs{}{}'.format(i,j)]['Domain [FT]'].str.extractall('\.\.(.*?);').unstack().apply( 
            lambda x: ','.join(x.dropna()), axis=1).str.split(',').apply(lambda x: [int(i) for i in x])         
         
        #then do motif, region, and repeat 
        for k in list_t: 
            locals()['df_subs{}{}'.format(i,j)]['{}List'.format(k)] = locals()[ 
                'df_subs{}{}'.format(i,j)]['{}'.format(k)].str.extractall('note="(.*?)"').unstack().apply( 
                lambda x: '@Unique@Joiner@'.join(x.dropna()), axis=1).str.split('@Unique@Joiner@') 
            locals()['df_subs{}{}'.format(i,j)]['{}Start'.format(k)] = locals()[ 
                'df_subs{}{}'.format(i,j)]['{}'.format(k)].str.extractall( 
                '{}\s(.*?)(?=\.|;)'.format(str.upper(k))).unstack().apply( 
                lambda x: ','.join(x.dropna()), axis=1).str.split(',').apply(lambda x: [int(i) for i in x]) 
            locals()['df_subs{}{}'.format(i,j)]['{}End'.format(k)] = locals()[ 
                'df_subs{}{}'.format(i,j)]['{}'.format(k)].str.extractall('\.\.(.*?);').unstack().apply( 
                lambda x: ','.join(x.dropna()), axis=1).str.split(',').apply(lambda x: [int(i) for i in x]) 
#Test whether there are any lists of unequal length for the start and end positions of interests 
    #These will be fixed in the original uniprot output files (some regions etc... only have one amino acid) 
        #Single amino acid regions etc will be duplicated to give the same start and end position in the df 
            #Thus, there will be both a start and end position for every region, etc... and matching will be more  
            #straightforward 
 
#list the types of features  
list_topsi = ['Domain', 'Motif', 'Region', 'Repeat'] 
         




for i in list_exp1: 
    for j in list_type_sr: 
        for k in list_topsi: 
            locals()['test{}{}{}'.format(i,j,k)] = locals()['df_sr{}{}'.format(i,j)].dropna(subset=['{}Start'.format(k)]) 
            display('{}{}{}'.format(i,j,k), len( 
                locals()['test{}{}{}'.format(i,j,k)][ 
                    locals()['test{}{}{}'.format(i,j,k)]['{}Start'.format(k)].str.len() != \ 
                    locals()['test{}{}{}'.format(i,j,k)]['{}End'.format(k)].str.len()])) 
 
#now the ints 
for i in list_exp1: 
    for j in list_types_ints: 
        for k in list_topsi: 
            locals()['test{}{}{}'.format(i,j,k)] = locals()['df_ints{}{}'.format(i,j)].dropna(subset=['{}Start'.format(k)]) 
            display('{}{}{}'.format(i,j,k), len( 
                locals()['test{}{}{}'.format(i,j,k)][ 
                    locals()['test{}{}{}'.format(i,j,k)]['{}Start'.format(k)].str.len() != \ 
                    locals()['test{}{}{}'.format(i,j,k)]['{}End'.format(k)].str.len()])) 
#finally the subs 
for i in list_exp2: 
    for j in list_type_subs: 
        for k in list_topsi: 
            locals()['test{}{}{}'.format(i,j,k)] = locals()['df_subs{}{}'.format(i,j)].dropna(subset=['{}Start'.format(k)]) 
            display('{}{}{}'.format(i,j,k), len( 
                locals()['test{}{}{}'.format(i,j,k)][ 
                    locals()['test{}{}{}'.format(i,j,k)]['{}Start'.format(k)].str.len() != \ 
                    locals()['test{}{}{}'.format(i,j,k)]['{}End'.format(k)].str.len()])) 
 
# Prepare tables of top domains in the subs and ints for the different tissues (using the full and SwissProt protome) 
 
#first the ints 
for j in list_topsi: 
    for i in list_exp1: 
        for k in range(2): 
            locals()['dfintstop{}{}{}'.format(j,i,list_types_ints[k])] = locals()[ 
                'df_ints{}{}'.format(i,list_types_ints[k])]['{}List'.format(j)].explode().value_counts().rename( 
                '{}{}Counts'.format(i,list_type_sr[k])).reset_index().rename( 
                columns={'index':'{}{}{}'.format(i,list_type_sr[k],j)}) 
             
for i in list_topsi: 
    locals()['dfintslist{}'.format(i)] = [] 
    locals()['dfintslist{}'.format(i)].extend( 
        value for name, value in locals().items() if name.startswith('dfintstop{}'.format(i))) 
    pd.concat(locals()['dfintslist{}'.format(i)], axis=1).to_csv( 
        '%sInteractors_Top{}s.csv'.format(i)%(folderout), index=False) 
 
#then the subs 
for j in list_topsi: 
    for i in list_exp2: 
        for k in range(2): 
            locals()['dfsubstop{}{}{}'.format(j,i,list_type_subs[k])] = locals()[ 
                'df_subs{}{}'.format(i,list_type_subs[k])]['{}List'.format(j)].explode().value_counts().rename( 
                '{}{}Counts'.format(i,list_type_sr[k])).reset_index().rename( 
                columns={'index':'{}{}{}'.format(i,list_type_sr[k],j)}) 
             
for i in list_topsi: 
    locals()['dfsubslist{}'.format(i)] = [] 
    locals()['dfsubslist{}'.format(i)].extend( 
        value for name, value in locals().items() if name.startswith('dfsubstop{}'.format(i))) 
    pd.concat(locals()['dfsubslist{}'.format(i)], axis=1).to_csv( 
        '%sSubstrates_Top{}s.csv'.format(i)%(folderout), index=False) 
#Output the integrated tables for both substrates and interactors 
 
#add the gene names (from the PD output file) 
 
#name the folder 
folderpd = './20B25_Analyzed_PD_Output/' 
 
#ints 
for i in list_exp1: 
    for j in list_types_ints: 
        locals()['dfintsgenes{}{}'.format(i,j)] = pd.read_csv('%sInteractors{}{}.csv'.format(i,j)%(folderpd)) 
        locals()['df_ints{}{}'.format(i,j)] = locals()['df_ints{}{}'.format(i,j)].merge( 
            locals()['dfintsgenes{}{}'.format(i,j)][['Accession', 'Gene']], how='left', left_on='Entry',  
            right_on='Accession').drop(columns={'Accession'}) 
        cols = ([locals()['df_ints{}{}'.format(i,j)].columns[0]] +  
                [locals()['df_ints{}{}'.format(i,j)].columns[-1]] +  
                list(locals()['df_ints{}{}'.format(i,j)].columns[1:-1])) 
        locals()['df_ints{}{}'.format(i,j)] = locals()['df_ints{}{}'.format(i,j)][cols] 
         
#subs 
for i in list_exp2: 
    for j in list_type_subs: 
        locals()['dfsubsgenes{}{}'.format(i,j)] = pd.read_csv('%sSubstrates{}{}.csv'.format(i,j)%(folderpd)) 
        locals()['df_subs{}{}'.format(i,j)] = locals()['df_subs{}{}'.format(i,j)].merge( 
            locals()['dfsubsgenes{}{}'.format(i,j)][['Accession', 'Gene']], how='left', left_on='Entry',  
            right_on='Accession').drop(columns={'Accession'}) 
        cols = ([locals()['df_subs{}{}'.format(i,j)].columns[0]] +  
                [locals()['df_subs{}{}'.format(i,j)].columns[-1]] +  
                list(locals()['df_subs{}{}'.format(i,j)].columns[1:-1])) 
        locals()['df_subs{}{}'.format(i,j)] = locals()['df_subs{}{}'.format(i,j)][cols] 
 




for i in list_exp1: 
    for j in range(2): 
        locals()['df_ints{}{}'.format(i, list_types_ints[j])].to_csv( 
            '%sIntegratedInteractorsTable{}{}.csv'.format(i, list_type_sr[j])%(folderout), index=False) 
         
#output the subs 
for i in range(3): 
    for j in range(2): 
        locals()['df_subs{}{}'.format(list_exp2[i], list_type_subs[j])].to_csv( 
            '%sIntegratedSubstratesTable{}{}.csv'.format(list_exp1[i], list_type_sr[j])%(folderout), index=False) 
#Now check if a localized site is in a domain/motif/region/repeat 
 
#first load in the regions outputs into dfs (I will do both Swiss Prot and the full proteome) 
 
#make a list of folder names 
list_sr_proteome = [srfolder, srfolderswiss] 
 
#import the regions into dfs (remove lines with more than one protein as before) 
#make an additional column to indicate whether the line is a site or region 
#merge the data with the uniprot output 
for i in range(3): 
    for j in range(2): 
        locals()['dfregions_{}{}'.format(list_exp1[i], list_type_sr[j])] = pd.read_csv( 
            '%smaxparcon_{}.txt'.format(list_exp1[i])%(list_sr_proteome[j]), sep='\t') 
        locals()['dfregions_{}{}'.format(list_exp1[i], list_type_sr[j])] = \ 
        locals()['dfregions_{}{}'.format(list_exp1[i], list_type_sr[j])][ 
            ~locals()['dfregions_{}{}'.format(list_exp1[i], list_type_sr[j])].Protein.str.contains(';')] 
        locals()['dfregions_{}{}'.format(list_exp1[i], list_type_sr[j])].loc[ 
            locals()['dfregions_{}{}'.format(list_exp1[i], list_type_sr[j])]['Site ID Constraints'].str.contains('of'),  
            'Type'] = 'Region'  
        locals()['dfregions_{}{}'.format(list_exp1[i], list_type_sr[j])].loc[ 
            ~locals()['dfregions_{}{}'.format(list_exp1[i], list_type_sr[j])]['Site ID Constraints'].str.contains('of'),  
            'Type'] = 'Site' 
        locals()['dfmerged_{}{}'.format(list_exp1[i], list_type_sr[j])] = locals()['dfregions_{}{}'.format( 
            list_exp1[i], list_type_sr[j])].merge(locals()['df_sr{}{}'.format( 
            list_exp1[i], list_type_sr[j])], how='left', left_on='Protein', right_on='Entry') 
        locals()['dfmerged_{}{}'.format(list_exp1[i], list_type_sr[j])].drop(columns={'Entry'}, inplace=True) 
#Find sites that are within the bounds of domains/motifs/regions/repeats 
 
#define a function for finding sites that exist w/in features in the dfs 
def sitecheck(df, Name, Column1, Column2, SiteColumn): 
    return [df[Name][i] for i in range(len(df[Name])) if ( 
        (df[Column1][i] <= df[SiteColumn]) & (df[Column2][i] >= df[SiteColumn]))] 
 
#make a for loops to iterate over all dfs and all types 
#return the empty lists back into NaNs 
for i in list_exp1: 
    for j in list_type_sr: 
        locals()['dfsitemerged_{}{}'.format(i,j)] = locals()['dfmerged_{}{}'.format(i,j)][locals()[ 
            'dfmerged_{}{}'.format(i,j)].Type == 'Site'] 
        locals()['dfsitemerged_{}{}'.format(i,j)]['Site ID Constraints'] = \ 
        locals()['dfsitemerged_{}{}'.format(i,j)]['Site ID Constraints'].astype(int) 
        globals()['dfsitemerged_{}{}'.format(i,j)] = globals()['dfsitemerged_{}{}'.format(i,j)].fillna( 
            {column: {ind: [] for ind in globals()['dfsitemerged_{}{}'.format(i,j)].index}  
             for column in globals()['dfsitemerged_{}{}'.format(i,j)].columns}) 
        for k in list_topsi: 
            locals()['dfsitemerged_{}{}'.format(i,j)]['SitesIn{}s'.format(k)] = \ 
            locals()['dfsitemerged_{}{}'.format(i,j)].apply( 
                sitecheck, args=('{}List'.format(k), '{}Start'.format(k), '{}End'.format(k), 'Site ID Constraints'),  
                axis=1) 
        dfmaptemp = locals()['dfsitemerged_{}{}'.format(i,j)].applymap(lambda x: x == []) 
        locals()['dfsitemerged_{}{}'.format(i,j)] = locals()['dfsitemerged_{}{}'.format(i,j)][dfmaptemp == False] 
#Count the number of sites across all features for SwissProt and Full 
 
#initialize empty lists, append them with the sum of all counts over each feature, and finally sum and display 
for i in list_exp1: 
    for j in list_type_sr: 
        locals()['featurecount{}{}'.format(i,j)] = [] 
        for k in list_topsi: 
            locals()['featurecount{}{}'.format(i, j)].append(locals()['dfsitemerged_{}{}'.format(i,j)][ 
                'SitesIn{}s'.format(k)].explode().value_counts().sum()) 
        display('{}{}'.format(i,j), sum(locals()['featurecount{}{}'.format(i,j)])) 
 
#Now export the results for the top features for all sites in each tissue (from both the full and SwissProt proteome) 
 
#Based on the above, the liver/brain have many more annotated features in the full proteome while 293Ts have more 
    # annotated features in the SwissProt proteome (this is in line with the human SwissProt proteome being significantly 
    # more complete than the mouse SwissProt proteome) 
     
#export each feature as its own table as before 
for i in list_exp1: 
    for j in list_topsi: 
        for k in list_type_sr: 
            locals()['dfsitestop{}{}{}'.format(j,i,k)] = locals()['dfsitemerged_{}{}'.format(i,k)][ 
                'SitesIn{}s'.format(j)].explode().value_counts().rename('{}{}Counts'.format(i,k)).reset_index().rename( 
                columns={'index':'{}{}{}'.format(i,k,j)}) 
 
for i in list_topsi: 
    locals()['dfsiteslist{}'.format(i)] = [] 
    locals()['dfsiteslist{}'.format(i)].extend( 
        value for name, value in locals().items() if name.startswith('dfsitestop{}'.format(i))) 
    pd.concat(locals()['dfsiteslist{}'.format(i)], axis=1).to_csv( 




Integrating with PhosphoSitePlus Database 
#Define the folder name where the PhosphoSitePlus db was downloaded 
folderpsp = './20D28_PhosphoSitePlus/' 
 
#import the PTM datasets 
 
#make a list of the PTMs and other dbs to import 
list_dbs = ['Acetylation', 'Methylation', 'O-GalNAc', 'O-GlcNAc', 'Phosphorylation', 'Sumoylation', 'Ubiquitination',  
            'Disease-associated', 'Regulatory'] 
 
#import the dfs in a for loop and remove the dash from dfs containing it 
for i in list_dbs: 
    locals()['df_{}_Sites'.format(i)] = pd.read_csv('%s{}_site_dataset.txt'.format(i)%(folderpsp), sep='\t', header=2) 
 
df_OGlcNAc_Sites = locals()['df_O-GlcNAc_Sites'] 
df_OGalNAc_Sites = locals()['df_O-GalNAc_Sites'] 
df_Disease_Sites = locals()['df_Disease-associated_Sites'] 
     
#import the PTMVar dataset 
df_PTMVar_Sites = pd.read_csv('%sPTMVar.txt'%(folderpsp), sep='\t', header=6)  
#Extract the relevant columns from the datasets 
 
#make a new list of df names 
list_dbs2 = ['Acetylation', 'Methylation', 'OGalNAc', 'OGlcNAc', 'Phosphorylation', 'Sumoylation', 'Ubiquitination',  
            'Disease', 'Regulatory', 'PTMVar'] 
 
#take the columns of interest and split the modification residue into the site number only 
#rename the MOD_RSD column to the name of the modification  
for i in list_dbs2[0:7]: 
    locals()['df_{}_Sites'.format(i)] = locals()['df_{}_Sites'.format(i)][['ACC_ID', 'MOD_RSD', 'ORGANISM', 'DOMAIN']] 
 
#now extract from the other three datasets (also add a column to the disease and regulatory dfs to define mod type) 
df_Disease_Sites = df_Disease_Sites[['DISEASE', 'ALTERATION', 'ACC_ID', 'ORGANISM', 'MOD_RSD', 'DOMAIN', 'NOTES']] 
df_Disease_Sites.rename(columns={'NOTES':'NotesDisease'}, inplace=True) 
df_Disease_Sites['ModTypeDisease'] = df_Disease_Sites.MOD_RSD.map(lambda x: x.split('-')[1]) 
 
df_Regulatory_Sites = df_Regulatory_Sites[['ACC_ID', 'ORGANISM', 'MOD_RSD', 'ON_FUNCTION', 'ON_PROCESS', 'DOMAIN', 
                                           'ON_PROT_INTERACT', 'ON_OTHER_INTERACT', 'NOTES']] 
df_Regulatory_Sites.rename(columns={'NOTES':'NotesRegulatory'}, inplace=True) 
df_Regulatory_Sites['ModTypeRegulatory'] = df_Regulatory_Sites.MOD_RSD.map(lambda x: x.split('-')[1]) 
 
df_PTMVar_Sites = df_PTMVar_Sites[['FTID', 'dbSNP', 'MUT_RSD#', 'VAR_TYPE', 'DISEASE(s)', 'ACC_ID', 'MOD_RSD',  
                                   'RSD_CONSERVATION', 'MOD_TYPE']] 
df_PTMVar_Sites.rename(columns={'MOD_RSD':'OtherClosePTMs', 'ACC_ID':'Protein', 'MOD_Type':'ModTypePTMVar',  
                                'MUT_RSD#':'PTMVarSite'}, inplace=True) 
 
for i in list_dbs2[0:9]: 
    locals()['df_{}_Sites'.format(i)].MOD_RSD = locals()['df_{}_Sites'.format(i)].MOD_RSD.str.extract('[A-Za-z](.*?)-') 
    locals()['df_{}_Sites'.format(i)].rename( 
        columns={'MOD_RSD':'{}Site'.format(i), 'ACC_ID':'Protein', 'DOMAIN':'{}Domain'.format(i)}, inplace=True) 
#Move the protein to the first column for the PTMVar and Disease dfs to facilitate grouping below  
 
cols_disease = list(df_Disease_Sites.columns) 
cols_disease = [cols_disease[2]] + cols_disease[0:2] + cols_disease[3:] 
df_Disease_Sites = df_Disease_Sites[cols_disease] 
 
cols_ptm = list(df_PTMVar_Sites.columns) 
cols_ptm = [cols_ptm[5]] + cols_ptm[0:5] + cols_ptm[6:] 
df_PTMVar_Sites = df_PTMVar_Sites[cols_ptm] 
#Now merge these cleaned dfs with the respective regions df from above 
 
#first merge the site merged dfs back to the full region dfs 
for i in list_exp1: 
    for j in list_type_sr: 
        locals()['dfmergedF_{}{}'.format(i,j)] = locals()['dfmerged_{}{}'.format(i,j)].merge( 
            locals()['dfsitemerged_{}{}'.format(i,j)], how='left', on='Region ID', suffixes=('','_y')) 
        locals()['dfmergedF_{}{}'.format(i,j)].drop( 
            locals()['dfmergedF_{}{}'.format(i,j)].filter(regex='_y$').columns.tolist(), axis=1, inplace=True) 
 
#set up the PTMVar df for merging with the human sites dfs 
temp3 = df_PTMVar_Sites 
temp3 = temp3.astype(str) 
temp3.replace({'-':np.nan,'nan':np.nan}, inplace=True) 
temp4 = temp3.groupby('Protein').agg(lambda x: '@Unique@Identifier@'.join(x.fillna(''))).reset_index() 
for l in temp4.columns[1::]: 
    temp4[l] = temp4[l].str.split('@Unique@Identifier@') 
temp4.PTMVarSite = temp4.PTMVarSite.apply(lambda x: [int(i) for i in x]) 
         
#group each of the database lists by protein (start with human for the 293T cells) 
for i in list_type_sr: 
    locals()['dfsites_293T_{}'.format(i)] = locals()['dfmergedF_293T{}'.format(i)] 
    for j in list_dbs2[0:9]: 
        temp = locals()['df_{}_Sites'.format(j)][locals()['df_{}_Sites'.format(j)].ORGANISM == 'human'] 
        temp.drop(columns={'ORGANISM'}, inplace=True) 
        temp2 = temp.groupby('Protein').agg(lambda x: '@Unique@Identifier@'.join(x.fillna(''))).reset_index() 
        for k in temp2.columns[1::]: 
            temp2[k] = temp2[k].str.split('@Unique@Identifier@') 
        temp2['{}Site'.format(j)] = temp2['{}Site'.format(j)].apply(lambda x: [int(i) for i in x]) 
        locals()['dfsites_293T_{}'.format(i)] = locals()['dfsites_293T_{}'.format(i)].merge( 
            temp2, how='left', on='Protein') 





#Repeat for the liver and brain with the mouse entries (excluding O-GalNAc which has no mouse sites) 
for i in list_exp1[1::]: 
    for j in list_type_sr: 
        locals()['dfsites_{}_{}'.format(i,j)] = locals()['dfmergedF_{}{}'.format(i,j)] 
        for k in (list_dbs2[0:2] + list_dbs2[3:9]): 
            mtemp = locals()['df_{}_Sites'.format(k)][locals()['df_{}_Sites'.format(k)].ORGANISM == 'mouse'] 
            mtemp.drop(columns={'ORGANISM'}, inplace=True) 
            mtemp2 = mtemp.groupby('Protein').agg(lambda x: '@Unique@Identifier@'.join(x.fillna(''))).reset_index() 
            for l in mtemp2.columns[1::]: 
                mtemp2[l] = mtemp2[l].str.split('@Unique@Identifier@') 
            mtemp2['{}Site'.format(k)] = mtemp2['{}Site'.format(k)].apply(lambda x: [int(i) for i in x]) 
            locals()['dfsites_{}_{}'.format(i,j)] = locals()['dfsites_{}_{}'.format(i,j)].merge( 
                mtemp2, how='left', on='Protein') 
#Find sites that overlap with or are w/in 10aa of ptms 
 
#define functions to parse the data 
 
#first ptms 
def sitecheckptm10aa(df, PTM, Domain, SiteColumn): 
    return [[df[PTM][i], df[Domain][i]] for i in range(len(df[PTM])) if ( 
        ((df[PTM][i] - 10) <= df[SiteColumn]) & ((df[PTM][i] + 10) >= df[SiteColumn]))] 
def sitecheckptmSame(df, PTM, Domain, SiteColumn): 
    return [[df[PTM][i], df[Domain][i]] for i in range(len(df[PTM])) if (df[PTM][i] == df[SiteColumn])] 
 
#then regulatory sites 
def sitecheckRegulatorySame(df, PTM, Domain, SiteColumn): 
    return [[df[PTM][i], df[Domain][i], df['ModTypeRegulatory'][i], df['ON_FUNCTION'][i], df['ON_PROCESS'][i],  
             df['ON_PROT_INTERACT'][i], df['ON_OTHER_INTERACT'][i], df['NotesRegulatory'][i]] for i in range( 
        len(df[PTM])) if (df[PTM][i] == df[SiteColumn])] 
def sitecheckRegulatory10aa(df, PTM, Domain, SiteColumn): 
    return [[df[PTM][i], df[Domain][i], df['ModTypeRegulatory'][i], df['ON_FUNCTION'][i], df['ON_PROCESS'][i],  
             df['ON_PROT_INTERACT'][i], df['ON_OTHER_INTERACT'][i], df['NotesRegulatory'][i]] for i in range( 
        len(df[PTM])) if (((df[PTM][i] - 10) <= df[SiteColumn]) & ((df[PTM][i] + 10) >= df[SiteColumn]))] 
 
#then disease sites 
def sitecheckDiseaseSame(df, PTM, Domain, SiteColumn): 
    return [[df[PTM][i], df[Domain][i], df['ModTypeDisease'][i], df['DISEASE'][i], df['ALTERATION'][i],  
             df['NotesDisease'][i]] for i in range(len(df[PTM])) if (df[PTM][i] == df[SiteColumn])] 
def sitecheckDisease10aa(df, PTM, Domain, SiteColumn): 
    return [[df[PTM][i], df[Domain][i], df['ModTypeDisease'][i], df['DISEASE'][i], df['ALTERATION'][i],  
             df['NotesDisease'][i]] for i in range(len(df[PTM])) if  
            (((df[PTM][i] - 10) <= df[SiteColumn]) & ((df[PTM][i] + 10) >= df[SiteColumn]))]  
 
#finally PTMVar sites 
def sitecheckPTMVarSame(df, PTM, SiteColumn): 
    return [[df[PTM][i], df['MOD_TYPE'][i], df['FTID'][i], df['dbSNP'][i], df['VAR_TYPE'][i], df['DISEASE(s)'][i],  
            df['OtherClosePTMs'][i], df['RSD_CONSERVATION'][i]] for i in range(len(df[PTM])) if  
            (df[PTM][i] == df[SiteColumn])] 
def sitecheckPTMVar10aa(df, PTM, SiteColumn): 
    return [[df[PTM][i], df['MOD_TYPE'][i], df['FTID'][i], df['dbSNP'][i], df['VAR_TYPE'][i], df['DISEASE(s)'][i],  
            df['OtherClosePTMs'][i], df['RSD_CONSERVATION'][i]] for i in range(len(df[PTM])) if  
            (((df[PTM][i] - 10) <= df[SiteColumn]) & ((df[PTM][i] + 10) >= df[SiteColumn]))]  
 
#make a list to call the above functions 
list_func = ['10aa', 'Same'] 
 
#first do the ptms for 293Ts 
for i in list_type_sr: 
    for j in list_dbs2[0:7]: 
        temp = locals()['dfsites_293T_{}'.format(i)][locals()['dfsites_293T_{}'.format(i)].Type == 'Site'] 
        temp.dropna(subset=['{}Site'.format(j)], inplace=True) 
        temp['Site ID Constraints'] = temp['Site ID Constraints'].astype(int) 
        for k in list_func: 
            temp['{}{}Info'.format(j,k)] = temp.apply( 
                locals()['sitecheckptm{}'.format(k)], args=( 
                    '{}Site'.format(j), '{}Domain'.format(j), 'Site ID Constraints'), axis=1) 
            temp.loc[temp['{}{}Info'.format(j,k)].map(lambda x: len(x)) > 0, '{}{}'.format(j,k)] = 'Yes' 
            locals()['dfsites_293T_{}'.format(i)][['{}{}Info'.format(j,k), '{}{}'.format(j,k)]] = temp[[ 
                '{}{}Info'.format(j,k), '{}{}'.format(j,k)]] 
             
#then do the PTMs for the Brain and Liver 
for i in list_exp1[1:3]: 
    for j in list_type_sr: 
        for k in list_dbs2[0:2] + list_dbs2[3:7]: 
            temp = locals()['dfsites_{}_{}'.format(i,j)][locals()['dfsites_{}_{}'.format(i,j)].Type == 'Site'] 
            temp.dropna(subset=['{}Site'.format(k)], inplace=True) 
            temp['Site ID Constraints'] = temp['Site ID Constraints'].astype(int) 
            for l in list_func: 
                temp['{}{}Info'.format(k,l)] = temp.apply( 
                    locals()['sitecheckptm{}'.format(l)], args=( 
                        '{}Site'.format(k), '{}Domain'.format(k), 'Site ID Constraints'), axis=1) 
                temp.loc[temp['{}{}Info'.format(k,l)].map(lambda x: len(x)) > 0, '{}{}'.format(k,l)] = 'Yes' 
                locals()['dfsites_{}_{}'.format(i,j)][['{}{}Info'.format(k,l), '{}{}'.format(k,l)]] = temp[[ 
                    '{}{}Info'.format(k,l), '{}{}'.format(k,l)]] 
                 
#finally do disease and regulatory sites for 293Ts, brian, and liver and PTMVar sites for 293Ts (only human data) 
 
#293Ts disease and regulatory 
for i in list_type_sr: 
    for j in list_dbs2[7:9]: 
        temp = locals()['dfsites_293T_{}'.format(i)][locals()['dfsites_293T_{}'.format(i)].Type == 'Site'] 
        temp.dropna(subset=['{}Site'.format(j)], inplace=True) 




        for k in list_func: 
            temp['{}{}Info'.format(j,k)] = temp.apply( 
                locals()['sitecheck{}{}'.format(j,k)], args=( 
                    '{}Site'.format(j), '{}Domain'.format(j), 'Site ID Constraints'), axis=1) 
            temp.loc[temp['{}{}Info'.format(j,k)].map(lambda x: len(x)) > 0, '{}{}'.format(j,k)] = 'Yes' 
            locals()['dfsites_293T_{}'.format(i)][['{}{}Info'.format(j,k), '{}{}'.format(j,k)]] = temp[[ 
                '{}{}Info'.format(j,k), '{}{}'.format(j,k)]] 
 
#brain and liver disease and regulatory 
for i in list_exp1[1:3]:            
    for j in list_type_sr: 
        for k in list_dbs2[7:9]: 
            temp = locals()['dfsites_{}_{}'.format(i,j)][locals()['dfsites_{}_{}'.format(i,j)].Type == 'Site'] 
            temp.dropna(subset=['{}Site'.format(k)], inplace=True) 
            temp['Site ID Constraints'] = temp['Site ID Constraints'].astype(int) 
            for l in list_func: 
                temp['{}{}Info'.format(k,l)] = temp.apply( 
                    locals()['sitecheck{}{}'.format(k,l)], args=( 
                        '{}Site'.format(k), '{}Domain'.format(k), 'Site ID Constraints'), axis=1) 
                temp.loc[temp['{}{}Info'.format(k,l)].map(lambda x: len(x)) > 0, '{}{}'.format(k,l)] = 'Yes' 
                locals()['dfsites_{}_{}'.format(i,j)][['{}{}Info'.format(k,l), '{}{}'.format(k,l)]] = temp[[ 
                    '{}{}Info'.format(k,l), '{}{}'.format(k,l)]] 
             
#293Ts PTMVar sites 
for i in list_type_sr: 
    for j in list_dbs2[9:10]: 
        temp = locals()['dfsites_293T_{}'.format(i)][locals()['dfsites_293T_{}'.format(i)].Type == 'Site'] 
        temp.dropna(subset=['{}Site'.format(j)], inplace=True) 
        temp['Site ID Constraints'] = temp['Site ID Constraints'].astype(int) 
        for k in list_func: 
            temp['{}{}Info'.format(j,k)] = temp.apply( 
                locals()['sitecheck{}{}'.format(j,k)], args=('{}Site'.format(j), 'Site ID Constraints'), axis=1) 
            temp.loc[temp['{}{}Info'.format(j,k)].map(lambda x: len(x)) > 0, '{}{}'.format(j,k)] = 'Yes' 
            locals()['dfsites_293T_{}'.format(i)][['{}{}Info'.format(j,k), '{}{}'.format(j,k)]] = temp[[ 
                '{}{}Info'.format(j,k), '{}{}'.format(j,k)]] 
#Export these to save the full tables 
for i in list_exp1: 
    for j in list_type_sr: 
        locals()['dfsites_{}_{}'.format(i,j)].to_csv( 
            '%sIntegratedRegionsTable{}{}.csv'.format(i,j)%(folderout), index=False) 
#Export the top domains, disease, etc... from each sample 
 
#list of info to count up in regulatory sites  
list_reg = ['Function', 'Process', 'ProtInteraction', 'OtherInteraction'] 
 
#293T samples 
for i in list_exp1[0:1]: 
    for j in list_type_sr: 
        for k in list_func: 
            for l in (list_dbs2[0:2] + list_dbs2[3:7]): 
                locals()['dfptmstop{}{}{}{}'.format(i,j,k,l)] = locals()[ 
                    'dfsites_{}_{}'.format(i,j)]['{}{}Info'.format(l,k)][ 
                    locals()['dfsites_{}_{}'.format(i,j)]['{}{}Info'.format(l,k)].notnull()].apply( 
                    lambda x: [e[1] for e in x]).explode().value_counts().rename( 
                    '{}{}Counts'.format(l,k)).reset_index().rename(columns={'index':'{}{}Domains'.format(l,k)}) 
            for l in list_dbs2[7:8]: 
                locals()['dfptmstop{}{}{}{}'.format(i,j,k,l)] = locals()[ 
                    'dfsites_{}_{}'.format(i,j)]['{}{}Info'.format(l,k)][ 
                    locals()['dfsites_{}_{}'.format(i,j)]['{}{}Info'.format(l,k)].notnull()].apply( 
                    lambda x: [e[3] for e in x]).explode().value_counts().rename( 
                    '{}{}Counts'.format(l,k)).reset_index().rename(columns={'index':'{}{}'.format(l,k)}) 
            for l in list_dbs2[9:10]: 
                locals()['dfptmstop{}{}{}{}'.format(i,j,k,l)] = locals()[ 
                    'dfsites_{}_{}'.format(i,j)]['{}{}Info'.format(l,k)][ 
                    locals()['dfsites_{}_{}'.format(i,j)]['{}{}Info'.format(l,k)].notnull()].apply( 
                    lambda x: [e[5] for e in x]).explode().value_counts().rename( 
                    '{}{}Counts'.format(l,k)).reset_index().rename(columns={'index':'{}{}'.format(l,k)}) 
            for l in list_dbs2[8:9]: 
                for m in range(4): 
                    locals()['dfptmstop{}{}{}{}{}'.format(i,j,k,l,list_reg[m])] = locals()[ 
                        'dfsites_{}_{}'.format(i,j)]['{}{}Info'.format(l,k)][ 
                        locals()['dfsites_{}_{}'.format(i,j)]['{}{}Info'.format(l,k)].notnull()].apply( 
                        lambda x: [e[m+3] for e in x]).explode().value_counts().rename( 
                        '{}{}{}Counts'.format(l,list_reg[m],k)).reset_index().rename( 
                        columns={'index':'{}{}{}'.format(l,list_reg[m],k)}) 
 
#mouse samples 
for i in list_exp1[1:3]: 
    for j in list_type_sr: 
        for k in list_func: 
            for l in (list_dbs2[0:2] + list_dbs2[3:7]): 
                locals()['dfptmstop{}{}{}{}'.format(i,j,k,l)] = locals()[ 
                    'dfsites_{}_{}'.format(i,j)]['{}{}Info'.format(l,k)][ 
                    locals()['dfsites_{}_{}'.format(i,j)]['{}{}Info'.format(l,k)].notnull()].apply( 
                    lambda x: [e[1] for e in x]).explode().value_counts().rename( 
                    '{}{}Counts'.format(l,k)).reset_index().rename(columns={'index':'{}{}Domains'.format(l,k)}) 
            for l in list_dbs2[7:8]: 
                locals()['dfptmstop{}{}{}{}'.format(i,j,k,l)] = locals()[ 
                    'dfsites_{}_{}'.format(i,j)]['{}{}Info'.format(l,k)][ 
                    locals()['dfsites_{}_{}'.format(i,j)]['{}{}Info'.format(l,k)].notnull()].apply( 
                    lambda x: [e[3] for e in x]).explode().value_counts().rename( 
                    '{}{}Counts'.format(l,k)).reset_index().rename(columns={'index':'{}{}'.format(l,k)}) 




                for m in range(4): 
                    locals()['dfptmstop{}{}{}{}{}'.format(i,j,k,l,list_reg[m])] = locals()[ 
                        'dfsites_{}_{}'.format(i,j)]['{}{}Info'.format(l,k)][ 
                        locals()['dfsites_{}_{}'.format(i,j)]['{}{}Info'.format(l,k)].notnull()].apply( 
                        lambda x: [e[m+3] for e in x]).explode().value_counts().rename( 
                        '{}{}{}Counts'.format(l,list_reg[m],k)).reset_index().rename( 
                        columns={'index':'{}{}{}'.format(l,list_reg[m],k)}) 
                     
for i in list_exp1: 
    for j in list_type_sr: 
        locals()['dfptmslist{}{}'.format(i,j)] = [] 
        locals()['dfptmslist{}{}'.format(i,j)].extend( 
            value for name, value in locals().items() if name.startswith('dfptmstop{}{}'.format(i,j))) 
        pd.concat(locals()['dfptmslist{}{}'.format(i,j)], axis=1).to_csv( 
            '%sPTMs_TopInfo_{}{}Sites.csv'.format(i,j)%(folderout), index=False) 
#Export a count of the number of sites that are also, or within 10aa of, PTM/regulatory, etc... sites 
 
#construct series out of the df length data and concatentate them together for export as above 
 
#first for 293T cells 
for i in list_exp1[0:1]: 
    for j in list_type_sr: 
        for k in list_func: 
            for l in list_dbs2: 
                locals()['series{}{}{}{}'.format(i,j,k,l)] = pd.Series( 
                    [len(locals()['dfsites_{}_{}'.format(i,j)][ 
                        locals()['dfsites_{}_{}'.format(i,j)]['{}{}'.format(l,k)] == 'Yes']), 
                    len(locals()['dfsites_{}_{}'.format(i,j)][ 
                        locals()['dfsites_{}_{}'.format(i,j)].Type == 'Site'])], name='{}{}'.format(l,k), 
                    index=['Number','Total Sites']) 
                 
#for liver and brain 
for i in list_exp1[1:3]: 
    for j in list_type_sr: 
        for k in list_func: 
            for l in (list_dbs2[0:2] + list_dbs2[3:9]): 
                locals()['series{}{}{}{}'.format(i,j,k,l)] = pd.Series( 
                    [len(locals()['dfsites_{}_{}'.format(i,j)][ 
                        locals()['dfsites_{}_{}'.format(i,j)]['{}{}'.format(l,k)] == 'Yes']), 
                    len(locals()['dfsites_{}_{}'.format(i,j)][ 
                        locals()['dfsites_{}_{}'.format(i,j)].Type == 'Site'])], name='{}{}'.format(l,k), 
                    index=['Number','Total Sites']) 
 
#export 
for i in list_exp1: 
    for j in list_type_sr: 
        locals()['serieslist{}{}'.format(i,j)] = [] 
        locals()['serieslist{}{}'.format(i,j)].extend( 
            value for name, value in locals().items() if name.startswith('series{}{}'.format(i,j))) 
        pd.concat(locals()['serieslist{}{}'.format(i,j)], axis=1).to_csv( 
            '%sSiteOverlapCount_{}{}.csv'.format(i,j)%(folderout), index=True) 
#Prepare substrates and interactors tables for importing into cytoscape 
 
#I will integrate the sites and regions tables into the substrates table so the sites are visible in cytoscape 
 
#list columns to join 
joincols293T = ['Protein', 'Site ID Constraints'] 
joincolsmouse = ['Protein', 'Site ID Constraints'] 
for i in list_dbs2: 
    for j in list_func: 
        joincols293T.append('{}{}'.format(i,j)) 
for i in (list_dbs2[0:2] + list_dbs2[3:9]): 
    for j in list_func: 
        joincolsmouse.append('{}{}'.format(i,j)) 
for i in list_topsi: 
    joincols293T.append('SitesIn{}s'.format(i)) 
    joincolsmouse.append('SitesIn{}s'.format(i)) 
 
#list cols to join from integrated regions table (sites in features) 
colsfeatures = ['Protein', 'Region ID', 'Min Sites', 'Site ID Constraints', 'SitesInDomains', 'SitesInMotifs',  
                'SitesInRegions', 'SitesInRepeats'] 
         
#merge the original regions list with the substrates table and the sites in features column from the full regions table 
#also merge with the relevant PTM information from the integrated sites in PTMs table 
#finally group everything by gene/protien for output to cytoscape 
 
#first 293Ts 
for i in range(1): 
    for j in range(2): 
        locals()['dfcyto_{}{}'.format(list_exp1[i],list_type_sr[j])] = \ 
        locals()['dfregions_{}{}'.format(list_exp1[i],list_type_sr[j])].merge( 
            locals()['df_subs{}{}'.format(list_exp2[i],list_type_subs[j])], how='left', left_on='Protein',  
            right_on='Entry').merge(locals()['dfsites_{}_{}'.format(list_exp1[i], list_type_sr[j])][colsfeatures],  
                                    how='left', on=['Protein', 'Region ID', 'Min Sites', 'Site ID Constraints']) 
        locals()['dfcyto_{}{}'.format(list_exp1[i],list_type_sr[j])] = \ 
        locals()['dfcyto_{}{}'.format(list_exp1[i],list_type_sr[j])].merge( 
            locals()['dfsites_{}_{}'.format(list_exp1[i],list_type_sr[j])][joincols293T], how='left',  
            on=['Protein', 'Site ID Constraints'], suffixes=('','_y')) 
        locals()['dfcyto_{}{}'.format(list_exp1[i],list_type_sr[j])].drop( 
            list(locals()['dfcyto_{}{}'.format(list_exp1[i],list_type_sr[j])].filter(regex='_y')), axis=1, inplace=True) 
        locals()['dfcytoF_{}{}'.format(list_exp1[i],list_type_sr[j])] = \ 
        locals()['dfcyto_{}{}'.format(list_exp1[i],list_type_sr[j])].sort_values( 




        locals()['dfcyto_{}{}'.format(list_exp1[i],list_type_sr[j])]['Site ID Constraints'] = \ 
        (locals()['dfcyto_{}{}'.format(list_exp1[i],list_type_sr[j])]['Protein'] + '@' +  
         locals()['dfcyto_{}{}'.format(list_exp1[i],list_type_sr[j])]['Site ID Constraints']) 
        temp = locals()['dfcyto_{}{}'.format(list_exp1[i],list_type_sr[j])].groupby( 
            'Gene')[joincols293T[1:]].agg(lambda x: x.fillna('').astype(str).str.cat(sep='; ')).reset_index() 
        for k in joincols293T[1:]: 
            locals()['dfcytoF_{}{}'.format(list_exp1[i],list_type_sr[j])][k] = temp[k].values 
 
#then for mouse samples 
for i in range(1,3): 
    for j in range(2): 
        locals()['dfcyto_{}{}'.format(list_exp1[i],list_type_sr[j])] = \ 
        locals()['dfregions_{}{}'.format(list_exp1[i],list_type_sr[j])].merge( 
            locals()['df_subs{}{}'.format(list_exp2[i],list_type_subs[j])], how='left', left_on='Protein',  
            right_on='Entry').merge(locals()['dfsites_{}_{}'.format(list_exp1[i], list_type_sr[j])][colsfeatures],  
                                    how='left', on=['Protein', 'Region ID', 'Min Sites', 'Site ID Constraints']) 
        locals()['dfcyto_{}{}'.format(list_exp1[i],list_type_sr[j])] = \ 
        locals()['dfcyto_{}{}'.format(list_exp1[i],list_type_sr[j])].merge( 
            locals()['dfsites_{}_{}'.format(list_exp1[i],list_type_sr[j])][joincolsmouse], how='left',  
            on=['Protein', 'Site ID Constraints'], suffixes=('','_y')) 
        locals()['dfcyto_{}{}'.format(list_exp1[i],list_type_sr[j])].drop( 
            list(locals()['dfcyto_{}{}'.format(list_exp1[i],list_type_sr[j])].filter(regex='_y')), axis=1, inplace=True) 
        locals()['dfcytoF_{}{}'.format(list_exp1[i],list_type_sr[j])] = \ 
        locals()['dfcyto_{}{}'.format(list_exp1[i],list_type_sr[j])].sort_values( 
            by=['Gene', 'Status']).drop_duplicates(subset='Gene', keep='first').dropna(subset=['Gene']) 
        locals()['dfcyto_{}{}'.format(list_exp1[i],list_type_sr[j])]['Site ID Constraints'] = \ 
        (locals()['dfcyto_{}{}'.format(list_exp1[i],list_type_sr[j])]['Protein'] + '@' +  
         locals()['dfcyto_{}{}'.format(list_exp1[i],list_type_sr[j])]['Site ID Constraints']) 
        temp = locals()['dfcyto_{}{}'.format(list_exp1[i],list_type_sr[j])].groupby( 
            'Gene')[joincolsmouse[1:]].agg(lambda x: x.fillna('').astype(str).str.cat(sep='; ')).reset_index() 
        for k in joincolsmouse[1:]: 
            locals()['dfcytoF_{}{}'.format(list_exp1[i],list_type_sr[j])][k] = temp[k].values 
 
#export these new substrate tables 
for i in list_exp1: 
    for j in list_type_sr: 
        locals()['dfcytoF_{}{}'.format(i,j)].drop(['Protein', 'Region ID', 'Min Sites', 'Type'], axis=1).to_csv( 
            '%sCytoscape_IntegratedSubstratesTable{}{}.csv'.format(i, j)%(folderout), index=False) 
             
#finally filter the interactors table by unique genes and export 
for i in list_exp1: 
    for j in range(2): 
        locals()['df_ints{}{}'.format(i, list_types_ints[j])].sort_values(by=['Gene', 'Status']).drop_duplicates( 
            subset='Gene', keep='first').dropna(subset=['Gene']).to_csv( 






A5.6.9. Export Sites for Motif and Enrichment Analysis. 
 
#import required packages 
import re 
import sys 
import networkx as nx 
import itertools as it 
import pandas as pd 
import numpy as np 
from io import StringIO 
from Bio import SeqIO 
from IPython.display import display 
 
#ignore warnings  
import warnings 
warnings.filterwarnings("ignore") 
#Import all of the sites and regions files and take only sites from each 
 
#name the folders 
srfolder = './20D15_SitesAndRegions/' 
srfolderswiss = './20D22_SitesAndRegions_SwissProt/' 
folderout = './20D29_SitesWith10aa/' 
 
#make lists for importing the data 
list_sr_proteome = [srfolder, srfolderswiss] 
list_type_sr = ['Full', 'Swiss'] 
list_exp1 = ['293T', 'BAP1KO', 'Brain', 'Liver'] 
 
#import the regions into dfs with a for loop (remove lines with more than one protein as before) 
#make an additional column to indicate whether the line is a site or region 
#keep only the sites in a new df, rename the column to 'Site', and drop the 'Type' column 
for i in range(4): 
    for j in range(2): 
        locals()['dfregions_{}{}'.format(list_exp1[i], list_type_sr[j])] = pd.read_csv( 
            '%smaxparcon_{}.txt'.format(list_exp1[i])%(list_sr_proteome[j]), sep='\t') 
        locals()['dfregions_{}{}'.format(list_exp1[i], list_type_sr[j])] = \ 
        locals()['dfregions_{}{}'.format(list_exp1[i], list_type_sr[j])][ 
            ~locals()['dfregions_{}{}'.format(list_exp1[i], list_type_sr[j])].Protein.str.contains(';')] 




            locals()['dfregions_{}{}'.format(list_exp1[i], list_type_sr[j])]['Site ID Constraints'].str.contains('of'),  
            'Type'] = 'Region'  
        locals()['dfregions_{}{}'.format(list_exp1[i], list_type_sr[j])].loc[ 
            ~locals()['dfregions_{}{}'.format(list_exp1[i], list_type_sr[j])]['Site ID Constraints'].str.contains('of'),  
            'Type'] = 'Site' 
        locals()['dfsites_{}{}'.format(list_exp1[i], list_type_sr[j])] = \ 
        locals()['dfregions_{}{}'.format(list_exp1[i], list_type_sr[j])][ 
            locals()['dfregions_{}{}'.format(list_exp1[i], list_type_sr[j])].Type == 'Site'] 
        locals()['dfsites_{}{}'.format(list_exp1[i], list_type_sr[j])].rename( 
            columns={'Site ID Constraints':'Site'}, inplace=True) 
        locals()['dfsites_{}{}'.format(list_exp1[i], list_type_sr[j])].drop(columns={'Type'}, inplace=True) 
#Import the fasta files and use them to extract the 10 flanking amino acids 
 
#define a list for importing fasta files 
list_fasta = ['Uniprot', 'SwissProt'] 
 
#make a for loop for importing human databases 
for i in list_fasta: 
    locals()['seqDict_Human_{}'.format(i)] = {} 
    p = SeqIO.parse('%s20A25_{}_Human.fasta'.format(i)%(folderout), 'fasta') 
    for r in p: 
        locals()['seqDict_Human_{}'.format(i)][r.id.split("|")[1]] = str(r.seq) 
         
#repeat for the mouse databases 
for i in list_fasta: 
    locals()['seqDict_Mouse_{}'.format(i)] = {} 
    p = SeqIO.parse('%s20A21_{}_Mouse.fasta'.format(i)%(folderout), 'fasta') 
    for r in p: 
        locals()['seqDict_Mouse_{}'.format(i)][r.id.split("|")[1]] = str(r.seq) 
         
#add the sequences to the sites dfs as a new column 
#first for 293Ts 
for i in list_exp1[0:2]: 
    for j in range(2): 
        locals()['dfsites_{}{}'.format(i,list_type_sr[j])]['FASTA Sequence'] = \ 
        locals()['dfsites_{}{}'.format(i,list_type_sr[j])]['Protein'].map( 
            locals()['seqDict_Human_{}'.format(list_fasta[j])]) 
         
#then for the brain and liver 
for i in list_exp1[2:4]: 
    for j in range(2): 
        locals()['dfsites_{}{}'.format(i,list_type_sr[j])]['FASTA Sequence'] = \ 
        locals()['dfsites_{}{}'.format(i,list_type_sr[j])]['Protein'].map( 
            locals()['seqDict_Mouse_{}'.format(list_fasta[j])]) 
 
#pad the fasta sequence on both ends with underscores and pull out the relevant info: 
    #GlcNAc Site, 10 aa before, 10 aa after, and centered sequence 
for i in list_exp1: 
    for j in list_type_sr: 
        locals()['dfsites_{}{}'.format(i,j)]['FASTA Sequence'] = ('__________' +  
                                                              locals()['dfsites_{}{}'.format(i,j)]['FASTA Sequence'] +  
                                                              '__________') 
        locals()['dfsites_{}{}'.format(i,j)]['Length'] = locals()['dfsites_{}{}'.format(i,j)].apply( 
            lambda x: len(x['FASTA Sequence']), axis=1) 
        locals()['dfsites_{}{}'.format(i,j)].Site = locals()['dfsites_{}{}'.format(i,j)].Site.astype(int) 
        locals()['dfsites_{}{}'.format(i,j)]['GlcNAc AA'] = locals()['dfsites_{}{}'.format(i,j)].apply( 
            lambda x: x['FASTA Sequence'][x.Site + 9], axis=1) 
        locals()['dfsites_{}{}'.format(i,j)]['10 AA Before'] = locals()['dfsites_{}{}'.format(i,j)].apply( 
            lambda x: x['FASTA Sequence'][(x.Site - 1):(x.Site + 9)], axis=1) 
        locals()['dfsites_{}{}'.format(i,j)]['10 AA After'] = locals()['dfsites_{}{}'.format(i,j)].apply( 
            lambda x: x['FASTA Sequence'][(x.Site + 10):(x.Site + 20)], axis=1) 
        locals()['dfsites_{}{}'.format(i,j)]['Centered Sequence'] = \ 
        (locals()['dfsites_{}{}'.format(i,j)]['10 AA Before'] + locals()['dfsites_{}{}'.format(i,j)]['GlcNAc AA'] + 
        locals()['dfsites_{}{}'.format(i,j)]['10 AA After']) 
#Check to make sure none of the sites are out of sequence space and all of the sites are S/T  
 
for i in list_exp1: 
    for j in list_type_sr: 
        display('{}{}:'.format(i,j), len(locals()['dfsites_{}{}'.format(i,j)][ 
            (locals()['dfsites_{}{}'.format(i,j)]['GlcNAc AA'] != 'S') &  
            (locals()['dfsites_{}{}'.format(i,j)]['GlcNAc AA'] != 'T')]), len( 
            locals()['dfsites_{}{}'.format(i,j)][locals()['dfsites_{}{}'.format(i,j)].Length <  
                                                 locals()['dfsites_{}{}'.format(i,j)].Site.astype(int)]))  
 
#Export the relevant information as a csv file for Matt (he will do the seqeunce and motif analysis) 
for i in list_exp1: 
    for j in list_type_sr: 
        locals()['dfsites_{}{}'.format(i,j)][['Protein', 'Site', 'GlcNAc AA', '10 AA Before', '10 AA After',  
                                              'Centered Sequence']].to_csv( 
                                                  '%sGlcNAcCenteredSequence{}{}.csv'.format(i,j)%(folderout),  











import pandas as pd 
import numpy as np 
import matplotlib 





#Load in the networks for all tissues 
 
#set up lists for importing 
list_exp = ['293T', 'Brain', 'Liver', 'LiverBrain'] 
 
#first import the PPIs 
for i in list_exp: 
    locals()['df{}'.format(i)] = pd.read_csv('PPINetwork{}F_ForCytoscape.csv'.format(i)) 
     
#import the substrates and interacor lists and merge them into the above df 
for i in list_exp: 
    locals()['dfsubs{}'.format(i)] = pd.read_csv('OGTSubs{}F_ForCytoscape.csv'.format(i)) 
    locals()['dfints{}'.format(i)] = pd.read_csv('OGTInts{}F_ForCytoscape.csv'.format(i)) 
    locals()['df{}'.format(i)] = locals()['df{}'.format(i)].merge( 
        locals()['dfints{}'.format(i)], how='left', left_on='Interactor_B', right_on='Gene').drop('Gene', axis=1) 
    locals()['df{}'.format(i)] = locals()['df{}'.format(i)].merge( 
        locals()['dfsubs{}'.format(i)], how='left', left_on='Interactor_B', right_on='Gene').drop('Gene', axis=1) 
#Now calculate a score for each pair 
 
#Interactions with substrates (regardless of if those substrates are also interactors) are given one point 
#Interactors with interactors that are not substrates are given -0.5 points 
def score(df): 
    if df.OGT_Substrate == 1: 
        return 1 
    else: 
        return -0.5 
     
#calculate the score for each df and drop all of the instances of self interactions in the table 
#group the df by interactor a to make an adapter rank df   
for i in list_exp: 
    locals()['df{}'.format(i)]['Score'] = locals()['df{}'.format(i)].apply(score, axis=1) 
    locals()['df{}'.format(i)] = locals()['df{}'.format(i)][locals()[ 
        'df{}'.format(i)].Interactor_A != locals()['df{}'.format(i)].Interactor_B] 
    locals()['dfar_{}'.format(i)] = locals()['df{}'.format(i)].groupby( 
        'Interactor_A').Score.sum().reset_index().sort_values(by=['Score'], ascending=False) 
#Remove genes that are only substrates to make the final adapter ranking list 
 
#first merge the df with the interactor list and then drop all nan from the interactor column (and drop added columns) 
for i in list_exp: 
    locals()['dfarF_{}'.format(i)] = locals()['dfar_{}'.format(i)].merge( 
        locals()['dfints{}'.format(i)], how='left', left_on='Interactor_A', right_on='Gene').dropna( 
        subset=['OGT_Interactor']).drop(['OGT_Interactor', 'Gene'], axis=1) 
#Export the final adapter rank lists 
for i in list_exp: 
    locals()['dfarF_{}'.format(i)].to_csv('AdapterRankList_{}.csv'.format(i), index=False) 
 
 
A5.6.11. Generating Clustermaps after Enrichment Analysis. 
 
#import python packages  
import re 
import sys 
import pandas as pd 
import networkx as nx 
import itertools as it 
from collections import namedtuple 
import numpy as np 
import scipy 
from scipy.cluster.hierarchy import dendrogram, set_link_color_palette 
from fastcluster import linkage 
from matplotlib.colors import rgb2hex, colorConverter 
from collections import defaultdict 
import matplotlib 
import matplotlib.pyplot as plt 
from matplotlib.colors import LogNorm, PowerNorm, BoundaryNorm, ListedColormap 
from IPython.display import display 
from functools import reduce 
import seaborn as sns; sns.set() 
from io import StringIO 
from matplotlib_venn import venn2_unweighted #the unweighted is if you want to make circles that are the same size 
from matplotlib_venn import venn2 #also import the normal one 
import pandas as pd 
import numpy as np 
from io import StringIO 
from pylab import * 
from numpy import * 
from matplotlib.colors import LinearSegmentedColormap 
 






#ignore warnings  
import warnings 
warnings.filterwarnings("ignore") 
#Import the gProfiler output into dataframes 
#There are two files, one for the 293T cells and one with the combined liver and brain data 
 
#define the folders 
folder = './20C31 Cytoscape Networks/' 
folderout = './20E03_GO_ResultsAndClustermaps/' 
 
dfgprof293T = pd.read_csv('%s293T_GO_Analysis.csv'%(folder), header=17) 
dfgprofLiverBrain = pd.read_csv('%sLiverBrain_Separate_GO_Analysis.csv'%(folder), header=17) 
#Extract and separate all of the data into separate dfs 
 
#first, remake the dfs keeping only the relevant columns (p-values) 
 
#define a function for extracting out the relevant columns 
def colfilter(df): 
    return pd.concat([df[['source', 'term_name']], df.filter(regex='adjusted_p_value__')], axis=1) 
 
#extract out the columns for each df 
df293T = colfilter(dfgprof293T) 
dfLiverBrain = colfilter(dfgprofLiverBrain) 
 
#now make seperate dfs for each group 
 
#list group (they are the same for both dfs) 
list_go = df293T.source.drop_duplicates().to_list() 
list_gof = [s.replace('GO:', '') for s in list_go] #remove the colons to name the dfs 
 
#make the new dfs 
for i in range(11): 
    locals()['df293T{}'.format(list_gof[i])] = df293T[df293T.source == list_go[i]] 
    locals()['dfLiverBrain{}'.format(list_gof[i])] = dfLiverBrain[dfLiverBrain.source == list_go[i]] 
     
#format the tables for seaborn clustermap (drop source column and move term name to index) 
 
#list the experiments 
list_exp = ['293T', 'LiverBrain'] 
 
#reformat all tables and rename the columns 
for i in list_exp: 
    for j in list_gof: 
        locals()['df{}{}'.format(i,j)] = locals()['df{}{}'.format(i,j)].set_index( 
            locals()['df{}{}'.format(i,j)].term_name).drop(columns={'source', 'term_name'}) 
        locals()['df{}{}'.format(i,j)].columns  = \ 
        locals()['df{}{}'.format(i,j)].columns.str.lstrip('adjusted_p_value__') 
        locals()['df{}{}'.format(i,j)].columns = locals()['df{}{}'.format(i,j)].columns.str.replace('_', ' ') 
        locals()['df{}{}'.format(i,j)].index.name = 'Term' 
#In the LiverBrain df, make an additional column for which column has the highest significance for a given term  
    # (separately for the liver and brain) 
    # This can be used to color code the network clusters on the clustermaps to see unique ones 
     
#define functions to easily create the new column 
def liverclusterterms(row): 
    if (row.filter(regex='Liver') < 0.01).any(): 
        return row.filter(regex='Liver').index[(row.filter(regex='Liver') == row.filter(regex='Liver').min())][0] 
 
def brainclusterterms(row): 
    if (row.filter(regex='Brain') < 0.01).any(): 
        return row.filter(regex='Brain').index[(row.filter(regex='Brain') == row.filter(regex='Brain').min())][0] 
 
#aplly the functions to all of the dfs 
for i in list_exp[1:]: 
    for j in list_gof: 
        locals()['dfmap{}{}'.format(i,j)] = locals()['df{}{}'.format(i,j)].iloc[:,6:] 
        locals()['dfmap{}{}'.format(i,j)]['BrainCluster'] = locals()['dfmap{}{}'.format(i,j)].apply( 
            brainclusterterms, axis=1) 
        locals()['dfmap{}{}'.format(i,j)]['LiverCluster'] = locals()['dfmap{}{}'.format(i,j)].apply( 
            liverclusterterms, axis=1) 
#For just the liver and brain biological processes calculate the percent overlap of each cluster with all BP GO terms  
    # that were significant in the other organ 
     
#split into liver and brain dfs 
dfBrain = dfLiverBrainBP.filter(regex='Brain') 
dfLiver = dfLiverBrainBP.filter(regex='Liver') 
 
#drop rows that have no columns less than 0.01 
dfBrain = dfBrain[dfBrain < 0.01].dropna(how='all') 
dfLiver = dfLiver[dfLiver < 0.01].dropna(how='all') 
 
#initialize an empty list for liver and brain clusters to facilitate visualizing the data 
brainoverlap = [] 
liveroverlap = [] 
 
#first do the brain storing the values in a list 
for i in range(11): 
    overlap = set(dfBrain[dfBrain['Cluster{} Brain'.format(i+1)] < 0.01].index) & set(dfLiver.index) 
    brainoverlap.append(np.float64(len(overlap)) /  
                        np.float64(len(set(dfBrain[dfBrain['Cluster{} Brain'.format(i+1)] < 0.01].index)))) 




#then to the liver 
for i in range(14): 
    overlap = set(dfLiver[dfLiver['Cluster{} Liver'.format(i+1)] < 0.01].index) & set(dfBrain.index) 
    liveroverlap.append(np.float64(len(overlap)) /  
                        np.float64(len(set(dfLiver[dfLiver['Cluster{} Liver'.format(i+1)] < 0.01].index)))) 
 
dfoverlap = pd.DataFrame(data={'Brain':pd.Series(brainoverlap), 'Liver':pd.Series(liveroverlap)}) 
dfoverlap.index.rename('Cluster', inplace=True) 
dfoverlap 
Overall, can see that there is a pretty high degree of overlap between individual clusters and significant terms in the opposite tissue. However, 
the clusters are quite large and contain many terms (with a small number of genes). It is unlikely that the major functions of these clusters are as 
similar (i.e. the terms with many genes or with the most genes are likely quite different). 
#Now I will make colored labels for the network clusters to show next to the heat map (just for the liver vs brain) 
#This will be done all at once, but they can easily be remade with each individual heatmap if necessary 
 
#list GO terms from the liver and brain cluster column (see above) 
#set up a color palette based on the number of columns in each 
#set up a dictionary to map GO terms to colors (based on which cluster it is most significant in, again, see above) 
#map each go term to one of the colors  
#finally combine the row colors into a df for labeling on the clustermap 
for i in list_gof: 
    locals()['labels{}1'.format(i)] = locals()['dfmapLiverBrain{}'.format(i)]['BrainCluster'] 
    locals()['labels{}2'.format(i)] = locals()['dfmapLiverBrain{}'.format(i)]['LiverCluster'] 
    locals()['color_pal{}1'.format(i)] = sns.color_palette("Paired", len(locals()['labels{}1'.format(i)].unique())) 
    locals()['color_pal{}2'.format(i)] = sns.color_palette("Paired_r", len(locals()['labels{}2'.format(i)].unique())) 
    locals()['lut{}1'.format(i)] = dict(zip(locals()['labels{}1'.format(i)].unique(),  
                                            locals()['color_pal{}1'.format(i)])) 
    locals()['lut{}2'.format(i)] = dict(zip(locals()['labels{}2'.format(i)].unique(),  
                                            locals()['color_pal{}2'.format(i)])) 
    locals()['lut{}1'.format(i)][None] = (1, 1, 1) 
    locals()['lut{}2'.format(i)][None] = (1, 1, 1) 
    locals()['row_colors{}1'.format(i)] = locals()['labels{}1'.format(i)].map(locals()['lut{}1'.format(i)]) 
    locals()['row_colors{}2'.format(i)] = locals()['labels{}2'.format(i)].map(locals()['lut{}2'.format(i)]) 
    locals()['row_colorsdf{}'.format(i)] = pd.DataFrame( 
        locals()['row_colors{}1'.format(i)].rename('Brain')).join(locals()['row_colors{}2'.format(i)].rename('Liver')) 
#Repeat the above for the 293T data (making colored labels etc...) 
 
#define functions to easily create the new column 
def terms293T(row): 
    if (row < 0.01).any(): 
        return row.index[row == row.min()][0] 
 
#aplly the functions to all of the dfs 
for i in list_exp[0:1]: 
    for j in list_gof: 
        locals()['dfmap{}{}'.format(i,j)] = locals()['df{}{}'.format(i,j)].iloc[:,3:] 
        locals()['dfmap{}{}'.format(i,j)]['Cluster'] = locals()['dfmap{}{}'.format(i,j)].apply( 
            terms293T, axis=1) 
         
for i in list_gof: 
    locals()['labels293T{}'.format(i)] = locals()['dfmap293T{}'.format(i)]['Cluster'] 
    locals()['color_pal293T{}'.format(i)] = sns.color_palette("Paired", len(locals()['labels293T{}'.format(i)].unique())) 
    locals()['lut293T{}'.format(i)] = dict(zip(locals()['labels293T{}'.format(i)].unique(),  
                                            locals()['color_pal293T{}'.format(i)])) 
    locals()['lut293T{}'.format(i)][None] = (1, 1, 1) 
    locals()['row_colors293T{}'.format(i)] = locals()['labels293T{}'.format(i)].map(locals()['lut293T{}'.format(i)]) 
    locals()['row_colors293Tdf{}'.format(i)] = pd.DataFrame(locals()['row_colors293T{}'.format(i)]) 
#Now visualize the colormap for the liver/brain combined dataset 
 
#set the levels for a non-linear colormap by make a list of evenly spaced exponents 
levels = [10**(-(x+1)) for x in reversed(range(20))] 
 
#use BoundaryNorm to make an artificial log color scale 
log_norm = BoundaryNorm(levels, ncolors=250) 
 
#set legend font size 
plt.rcParams['legend.title_fontsize'] = 22 
 
#make the font bigger 
sns.set(font_scale=2) 
 
#make the clustermap (rasterize the image to avoid rendering the rectangles) 
g = sns.clustermap(dfLiverBrainBP.iloc[:,0:6], figsize=(15,10), cmap='Blues_r', col_cluster=False, yticklabels=False, 
                  row_colors=row_colorsdfBP, norm=log_norm, linewidths=0, cbar_pos=(0.235,0.845, 0.05, 0.2),  
                   rasterized=True) 
 
#create and ax object and format the color bar 
ax = g.ax_heatmap 
cbar = ax.collections[0].colorbar 
cbar.set_ticks([0.05, 1e-5, 1e-10, 1e-15, 5e-20]) 





#set x and y labels 
ax.set_ylabel('') 
ax.set_xticklabels(['All\nBrain', 'All\nLiver', 'Substrates\nBrain', 'Substrates\nLiver', 'Interactors\nBrain',  







#make a legend to identify the clusters 
 
#first clear the 'Brain/Liver' from the cluster names 
x = labelsBP1.unique() 
y = labelsBP2.unique() 
 
for i in range(len(x)): 
    if x[i] != None: 
        x[i] = re.sub(' Brain', '', x[i]) 
    else: 
        x[i] = x[i] 
         
for i in range(len(y)): 
    if y[i] != None: 
        y[i] = re.sub(' Liver', '', y[i]) 
    else: 
        y[i] = y[i] 
 
for i in range(len(x)): 
    g.ax_col_dendrogram.bar(0, 0, color=lutBP1[labelsBP1.unique()[i]], label=x[i], linewidth=0) 
for i in range(len(y)): 
    g.ax_row_dendrogram.bar(0, 0, color=lutBP2[labelsBP2.unique()[i]], label=y[i], linewidth=0) 
     
l1 = g.ax_col_dendrogram.legend(loc="center", title='Brain', ncol=5, bbox_to_anchor=(0.65, 1),  
                                bbox_transform=gcf().transFigure, prop={'size':15}) 
l2 = g.ax_row_dendrogram.legend(loc="center", title='Liver', ncol=5, bbox_to_anchor=(0.65, 0.89),  
                                bbox_transform=gcf().transFigure, prop={'size':15}) 
 
 
#make the dendrogram smaller  
row = g.ax_row_dendrogram.get_position() 
g.ax_row_dendrogram.set_position([row.x0+0.145, row.y0, row.width*0.25, row.height]) 
g.savefig('{}{}LiverBrain_Clustermap_BP.svg'.format(folder,folderout), dpi=2000) 
 




#make a new df that only contains clusters with significant functions, drop go terms that are not signficant 
#replace nan values with those from the original df (clustermap cannot take nans) 
dfBrainCM = dfLiverBrainBP.iloc[:,np.r_[6:8, 9:13, 14]] 
dfBrainCM = dfBrainCM[dfBrainCM < 0.01].dropna(how='all') 
dfBrainCM[dfBrainCM.isnull()] = dfLiverBrainBP.iloc[:,np.r_[6:8, 9:13, 14]] 
 
#set the levels for a non-linear colormap by make a list of evenly spaced exponents 
levels = [10**(-(x+1)) for x in reversed(range(10))] 
 
#use BoundaryNorm to make an artificial log color scale 
log_norm = BoundaryNorm(levels, ncolors=250) 
 





#make the clustermap 
g = sns.clustermap(dfBrainCM, figsize=(7,7), cmap='Blues_r', col_cluster=False, rasterized=True, 
                   yticklabels=False, row_colors=row_colors, norm=log_norm, linewidths=0, method='ward',  
                   cbar_pos=(0.4, 0.22, 0.3, 0.05), cbar_kws={'orientation':'horizontal'}) 
 
#create and ax object and format the color bar 
ax = g.ax_heatmap 
cbar = ax.collections[0].colorbar 
cbar.set_ticks([0.05, 5e-6, 5e-10]) 
cbar.set_ticklabels(['>1e-2', 1e-5, '<1e-10']) 
cbar.ax.tick_params(labelsize=12) 





#set x and y labels 
ax.set_ylabel('') 





#make the dendrogram smaller  
row = g.ax_row_dendrogram.get_position() 
g.ax_row_dendrogram.set_position([row.x0+0.145, row.y0, row.width*0.25, row.height]) 
plt.savefig('{}{}Brain_IndividualClusters_BP.svg'.format(folder,folderout), dpi=2000) 
 




#make a new df that only contains clusters with significant functions, drop go terms that are not signficant 
#replace nan values with those from the original df (clustermap cannot take nans) 
dfLiverCM = dfLiverBrainBP.iloc[:,np.r_[17:22, 24:28]] 
dfLiverCM = dfLiverCM[dfLiverCM < 0.01].dropna(how='all') 





#set the levels for a non-linear colormap by make a list of evenly spaced exponents 
levels = [10**(-(x+1)) for x in reversed(range(10))] 
 
#use BoundaryNorm to make an artificial log color scale 
log_norm = BoundaryNorm(levels, ncolors=250) 
 





#make the clustermap 
g = sns.clustermap(dfLiverCM, figsize=(7,7), cmap='Blues_r', col_cluster=False, rasterized=True, 
                   yticklabels=False, row_colors=row_colors, norm=log_norm, linewidths=0, method='ward',  
                   cbar_pos=(0.4, 0.22, 0.3, 0.05), cbar_kws={'orientation':'horizontal'}) 
 
#create and ax object and format the color bar 
ax = g.ax_heatmap 
cbar = ax.collections[0].colorbar 
cbar.set_ticks([0.05, 5e-6, 5e-10]) 
cbar.set_ticklabels(['>1e-2', 1e-5, '<1e-10']) 
cbar.ax.tick_params(labelsize=12) 





#set x and y labels 
ax.set_ylabel('') 





#make the dendrogram smaller  
row = g.ax_row_dendrogram.get_position() 
g.ax_row_dendrogram.set_position([row.x0+0.145, row.y0, row.width*0.25, row.height]) 
plt.savefig('{}{}Liver_IndividualClusters_BP.svg'.format(folder,folderout), dpi=2000) 
 
#Make the cluster specific cluster map for the 293T cells 
 
#make a new df that only contains clusters with significant functions, drop go terms that are not signficant 
#replace nan values with those from the original df (clustermap cannot take nans) 
df293TCM = df293TBP.iloc[:,3:8] 
df293TCM = df293TCM[df293TCM < 0.01].dropna(how='all') 
df293TCM[df293TCM.isnull()] = df293TBP.iloc[:,3:8] 
 
#set the levels for a non-linear colormap by make a list of evenly spaced exponents 
levels = [10**(-(x+1)) for x in reversed(range(20))] 
 
#use BoundaryNorm to make an artificial log color scale 
log_norm = BoundaryNorm(levels, ncolors=250) 
 





#make the clustermap 
g = sns.clustermap(df293TBP.iloc[:,0:8], figsize=(7,5), cmap='Blues_r', col_cluster=False, rasterized=True, 
                   yticklabels=False, row_colors=row_colors, norm=log_norm, linewidths=0, method='ward',  
                   cbar_pos=(0.4, 0.15, 0.3, 0.05), cbar_kws={'orientation':'horizontal'}) 
 
#create and ax object and format the color bar 
ax = g.ax_heatmap 
cbar = ax.collections[0].colorbar 
cbar.set_ticks([0.05, 5e-11, 5e-20]) 
cbar.set_ticklabels(['>1e-2', 1e-10, '<1e-20']) 
cbar.ax.tick_params(labelsize=12) 





#set x and y labels 
ax.set_ylabel('') 





#make the dendrogram smaller  
row = g.ax_row_dendrogram.get_position() 
g.ax_row_dendrogram.set_position([row.x0+0.145, row.y0, row.width*0.25, row.height]) 
plt.savefig('{}{}293T_IndividualClusters_BP.svg'.format(folder,folderout), dpi=2000) 
 
#Now, output the clustermaps for the remaining processes for 293T cells 
 
#make a list for the titles and for the functions to plot 
list_titles = ['GO Molecular Function', 'GO Cellular Component', 'KEGG Pathways', 'Reactome Pathways', 'WikiPathways', 
              'TRANSFAC Database', 'miRTarBase miRNA Interactions', 'Human Protein Atlas', 'CORUM Complexes',  
               'Human Phenotype Ontology'] 





#make the plots 
for i in list_gop: 
    #make a new df that only contains clusters with significant functions, drop go terms that are not signficant 
    #replace nan values with those from the original df (clustermap cannot take nans) 
    #reset the indices for all dfs because there are colons in some 
    plt.figure() 
    locals()['df293TCM{}'.format(i)] = locals()['df293T{}'.format(i)].iloc[:,3:8] 
    locals()['df293TCM{}'.format(i)] = locals()['df293TCM{}'.format(i)].reset_index(drop=True) 
    locals()['df293TCM{}'.format(i)] = \ 
    locals()['df293TCM{}'.format(i)][locals()['df293TCM{}'.format(i)] < 0.01].dropna(how='all') 
    locals()['df293TCM{}'.format(i)][locals()['df293TCM{}'.format(i)].isnull()] = \ 
    locals()['df293T{}'.format(i)].iloc[:,3:8].reset_index(drop=True) 
 
    #set the levels for a non-linear colormap by make a list of evenly spaced exponents 
    levels = [10**(-(x+1)) for x in reversed(range(10))] 
 
    #use BoundaryNorm to make an artificial log color scale 
    log_norm = BoundaryNorm(levels, ncolors=250) 
 
    #make the font bigger 
    sns.set(font_scale=1.75) 
 
    locals()['row_colors{}'.format(i)]=locals()['row_colors293T{}'.format(i)].reset_index( 
        drop=True)[locals()['df293TCM{}'.format(i)].index] 
 
    #make the clustermap 
    g = sns.clustermap(locals()['df293T{}'.format(i)].iloc[:,0:8].reset_index(drop=True), figsize=(7,5), cmap='Blues_r', 
                       col_cluster=False, rasterized=True, yticklabels=False,  
                       row_colors=locals()['row_colors{}'.format(i)], norm=log_norm, linewidths=0, method='ward',  
                       cbar_pos=(0.4, 0.15, 0.3, 0.05), cbar_kws={'orientation':'horizontal'}) 
 
    #set titles 
    g.ax_heatmap.set_title(list_titles[list_gop.index(i)], ha='center') 
     
    #create and ax object and format the color bar 
    ax = g.ax_heatmap 
    cbar = ax.collections[0].colorbar 
    cbar.set_ticks([0.05, 5e-6, 5e-10]) 
    cbar.set_ticklabels(['>1e-2', 1e-5, '<1e-10']) 
    cbar.ax.tick_params(labelsize=12) 
    cbar.set_label('p-value', fontsize=16, labelpad=7) 
    cbar.solids.set_edgecolor("face") 
    cbar.ax.xaxis.set_ticks_position('bottom') 
    cbar.ax.xaxis.set_label_position('top') 
 
    #set x and y labels 
    ax.set_ylabel('') 
    ax.set_xticklabels(['All', 'Subs', 'Ints', '1', '2', '3', '4', '5']) 
    plt.setp(g.ax_heatmap.xaxis.get_majorticklabels(), rotation=0) 
 
    #make the dendrogram smaller  
    row = g.ax_row_dendrogram.get_position() 
    g.ax_row_dendrogram.set_position([row.x0+0.145, row.y0, row.width*0.25, row.height]) 
    plt.savefig('{}{}293T_Clustermap_{}.svg'.format(folder,folderout,i), dpi=2000) 
 
#Make the plots for each database with the brain and liver samples 
 
#set the levels for a non-linear colormap by make a list of evenly spaced exponents 
levels = [10**(-(x+1)) for x in reversed(range(10))] 
 
#use BoundaryNorm to make an artificial log color scale 
log_norm = BoundaryNorm(levels, ncolors=250) 
 
#set legend font size 
plt.rcParams['legend.title_fontsize'] = 22 
 
#make a list for the titles and for the functions to plot (remove HPA) 
list_titlesm = ['GO Molecular Function', 'GO Cellular Component', 'KEGG Pathways', 'Reactome Pathways', 'WikiPathways', 
              'TRANSFAC Database', 'miRTarBase miRNA Interactions', 'CORUM Complexes', 'Human Phenotype Ontology'] 
list_gopm = list_gof[0:1] + list_gof[2:8] + list_gof[9:11] 
 




for i in list_gopm: 
    #make the clustermap (rasterize the image to avoid rendering the rectangles) 
    plt.figure() 
    g = sns.clustermap(locals()['dfLiverBrain{}'.format(i)].iloc[:,0:6].reset_index(drop=True), figsize=(15,10),  
                       cmap='Blues_r', col_cluster=False, yticklabels=False,  
                       row_colors=locals()['row_colorsdf{}'.format(i)].reset_index(drop=True),  
                       norm=log_norm, linewidths=0, cbar_pos=(0.235,0.845, 0.05, 0.2), rasterized=True) 
 
    #create and ax object and format the color bar 
    ax = g.ax_heatmap 
    cbar = ax.collections[0].colorbar 
    cbar.set_ticks([0.05, 5e-6, 5e-10]) 
    cbar.set_ticklabels(['>1e-2', 1e-5, '<1e-10']) 
    cbar.ax.tick_params(labelsize=15) 
    cbar.set_label('p-value', labelpad=15) 





    #set x and y labels 
    ax.set_ylabel('') 
    ax.set_xticklabels(['All\nBrain', 'All\nLiver', 'Substrates\nBrain', 'Substrates\nLiver', 'Interactors\nBrain',  
                        'Interactors\nLiver']) 
    plt.setp(g.ax_heatmap.xaxis.get_majorticklabels(), rotation=0) 
    cbar.ax.yaxis.set_label_position('left') 
 
    #make a legend to identify the clusters 
 
    #first clear the 'Brain/Liver' from the cluster names 
    x = locals()['labels{}1'.format(i)].unique() 
    y = locals()['labels{}2'.format(i)].unique() 
 
    for j in range(len(x)): 
        if x[j] != None: 
            x[j] = re.sub(' Brain', '', x[j]) 
        else: 
            x[j] = x[j] 
 
    for j in range(len(y)): 
        if y[j] != None: 
            y[j] = re.sub(' Liver', '', y[j]) 
        else: 
            y[j] = y[j] 
 
    for j in range(len(x)): 
        g.ax_col_dendrogram.bar(0, 0, color=locals()['lut{}1'.format(i)][locals()['labels{}1'.format(i)].unique()[j]],  
                                label=x[j], linewidth=0) 
    for j in range(len(y)): 
        g.ax_row_dendrogram.bar(0, 0, color=locals()['lut{}2'.format(i)][locals()['labels{}2'.format(i)].unique()[j]],  
                                label=y[j], linewidth=0) 
 
    l1 = g.ax_col_dendrogram.legend(loc="center", title='Brain', ncol=5, bbox_to_anchor=(0.65, 1),  
                                    bbox_transform=gcf().transFigure, prop={'size':15}) 
    l2 = g.ax_row_dendrogram.legend(loc="center", title='Liver', ncol=5, bbox_to_anchor=(0.65, 0.89),  
                                    bbox_transform=gcf().transFigure, prop={'size':15}) 
 
    #set titles 
    g.ax_heatmap.set_title(list_titlesm[list_gopm.index(i)], ha='center', pad=175) 
 
    #make the dendrogram smaller  
    row = g.ax_row_dendrogram.get_position() 
    g.ax_row_dendrogram.set_position([row.x0+0.145, row.y0, row.width*0.25, row.height]) 
    g.savefig('LiverBrain_Clustermap_{}.svg'.format(i), dpi=2000) 
#Export the cleaned dataframes to csv 
for i in list_exp: 
    for j in list_gof: 
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 The dynamic, inducible PTM of proteins with O-GlcNAc is an important regulator of 
diverse cellular processes. However, its study has lagged behind that of other PTMs, such as 
phosphorylation, due to unique difficulties in detecting and mapping O-GlcNAcylation sites. We 
previously developed (Chapter 5) a novel MS-based O-GlcNAcomics workflow for the high-
throughput detection of O-GlcNAcylation events across the proteome. There, we noticed that 
while both ETD and EThcD fragmentation were effective methods for sequencing O-
GlcNAcylated peptides, each method identified non-overlapping sets of O-GlcNAc peptides and 
sites. To our knowledge, systematic efforts to understand how O-GlcNAcylated peptides are 
optimally fragmented and identified using MS have not been undertaken. Herein, we report the 
first studies into the fragmentation of O-GlcNAc peptides by an array of ETD fragmentation 
methods, enabled by the development of our robust, streamlined chemoenzymatic labeling and 
enrichment workflow developed for O-GlcNAc peptides (Chapter 5). We find that fragmentation 
efficiency of O-GlcNAcylated peptides by different methods depends heavily on their charge 
density. For instance, at high charge densities (low m/z), ETD significantly outperforms EThcD, 
while the opposite is true at lower charge densities. In fact, ETD is essentially ineffective over 
1,000 m/z. Finally, ETD reaction time has little effect on fragmentation efficiency, with charge-
dependent time constants as low as 0.5τ having a minimal impact on the number of peptides or O-
GlcNAc sites identified. Taken together, these insights allowed the development of a novel, online 
MS decision tree to fragment O-GlcNAcylated peptides by either ETD or EThcD based on their 
m/z, significantly improving identification, site mapping, and instrument efficiency over ETD or 




mapping and identification of O-GlcNAc sites across diverse sample types and treatments, a 
critical endeavor for understanding the role O-GlcNAc in cellular function and disease. 
 
6.2. Introduction.  
 O-GlcNAc site mapping by MS has been actively investigated for almost three decades 
(reviewed in Chapters 2 and 4). However, given the lability of the modification to standard MS 
fragmentation, it was not until the advent of ETD-based fragmentation methods that localizing 
native O-GlcNAc sites to specific serine and threonine residues became reliable and robust.1 ETD 
relies on the transfer of electrons from a negatively charged reagent gas to peptide cations 
subsequently causing non-ergodic fragmentation along the peptide backbone, and thus generally 
leaves intact side chain modifications such as O-GlcANc and phosphorylation.2 However, while 
leaving PTMs intact, ETD often suffers from poor fragmentation efficiency along on the peptide 
backbone presumably because peptide fragments tend to remain non-covalently associated after 
electron transfer and fragmentation.3 This lack of fragmentation efficiency has been largely 
addressed with the advent of new supplemental activation (SA) methods such as ETD with CID 
SA (ETciD)3 and, more recently, EThcD.4 Yet, these methods often add significant time the 
instrument duty cycle resulting in a decrease in the overall number of peptides identifications.5,6 




 To better understand how O-GlcNAcylated peptides behave under various ETD 
fragmentation parameters, we first systematically subjected a synthetic, O-GlcNAcylated peptide 
to different ETD fragmentation parameters, including differing SA, ETD anion reagent and peptide 
cation amounts, and ETD reaction times. Then we used the information gathered therein to design 
a series of parameters to test in O-GlcNAcylated peptides enriched from 293T lysates using our 
chemoenzymatic labeling method (Chapter 5). We found not only that relationships between 
charge density and ETD fragmentation efficiency for unmodified peptides held for O-
GlcNAcylated peptides,6 but also, surprisingly, that SA was actually detrimental to fragmentation 
efficiency of peptides with a higher charge density. Finally, we found little difference in the 
fragmentation efficiency of O-GlcNAcylated peptides with a wide variety of ETD reaction times, 
although noting that set ETD reaction times of 100 or 200 ms (previously suggested as optimal for 
the fragmentation of glycosylated peptides8) underperformed charge dependent ETD reaction 
times with a set time constant, τ.10 The aforementioned observation suggests that the increased 
 
Fig. 6.1. Distribution of MS-GF+ Score for the Different ETD Fragmentation Reaction 
Conditions Outlined in Table 6.1.  
Note the decreasing score with increasing SA and relatively constant scores varying peptide 
cation and ETD anion reagent amounts. In general longer ETD reaction times reduce 




instrument cycle time inherent to ETD-MS analyses could be drastically reduced by decreasing 
ETD reaction time. Overall, these observations facilitated the development of a novel MS decision 
tree where O-GlcNAcylated peptides <625 m/z are fragmented by ETD and >625 m/z by EThcD, 
thus maximizing instrument efficiency and number of O-GlcNAcylated peptides identified in a 
single MS run.  
 
6.3. Optimization of ETD Fragmentation Parameters on Synthetic O-GlcNAc Peptides. 
 To first understand how O-GlcNAcylated peptides behaved under various ETD 
fragmentation conditions in the Orbitrap Fusion Tribrid (Thermo Fisher Scientific), the synthetic 
O-GlcNAc peptide, TAT[S(O-ß-GlcNAc)]SPASTPLSPM[R(13C6; 15N4)] (Peptide 11), was 
resuspended in 50:50 methanol:0.2% formic acid and directly injected into the instrument. We 
identified a clear peak at 572.9498 m/z, corresponding to the triply charged cation of the above 
peptide. This peak was then isolated 
and subjected to the ETD 
fragmentation reactions outlined in 
Table 6.1. Foremost, we sought to 
understand how ETD fragmentation 
efficiency various with increasing SA 
(as to our knowledge this has yet to be 
systematically explored). We also 
wanted to understand how increasing 
the peptide cation and anion gas 
amounts effected fragmentation 
 
Fig. 6.2. Distribution of All Peptide MS-GF+ 




(under various set ETD reaction times). Specifically, as the ETD reaction follows pseudo-first 
order kinetics, we wanted to ascertain whether we could increase fragmentation efficiency or 
decrease reaction time by increasing the precursor (i.e. peptide and ETD reagent gas) 
concentrations.10,11 
 Each method was run for 1 min to generate multiple spectra which were subsequently 
searched using MS-GF+.12 Score distributions for each method are plotted in Fig. 6.1. Here, we 
find a clear trend towards decreasing fragmentation efficiency with increasing SA energies 
(EThcD). We also find that varying the amounts of peptide cation or ETD anion reagent do not 
strongly affect the fragmentation efficiency, at least under the conditions and with the single 
peptide investigated here. Others have found an optimal ETD anion reagent amount around 4e5, 
the current default instrument settings.10 However, the data herein suggest that longer ETD 
reaction times are likely detrimental to, or at least not beneficial to, peptide fragmentation and 




instrument cycle time could be saved by employing charge-dependent (CD), e.g. ~42 ms for a 
doubly charged peptide, or faster ETD reaction times versus a fixed 100 ms reaction time. 
Method 
Number 
ETD Reaction Time SA 
Pep 
AGC 
ETD AGC Max IT Detector 
1 100 20 5.E+04 1.E+06 1000 Orbitrap 
2 CD 15 1.E+05 Default 120 Orbitrap 
3 100 0 5.E+04 1.E+06 1000 Orbitrap 
4 100 10 5.E+04 1.E+06 1000 Orbitrap 
5 100 30 5.E+04 1.E+06 1000 Orbitrap 
6 100 40 5.E+04 1.E+06 1000 Orbitrap 
7 100 50 5.E+04 1.E+06 1000 Orbitrap 
8 100 60 5.E+04 1.E+06 1000 Orbitrap 
9 100 70 5.E+04 1.E+06 1000 Orbitrap 
10 100 80 5.E+04 1.E+06 1000 Orbitrap 
11 100 90 5.E+04 1.E+06 1000 Orbitrap 
12 CD 20 5.E+04 Default 1000 Orbitrap 
13 100 20 5.E+04 1.E+06 1000 Orbitrap 
14 100 20 1.E+05 2.E+06 1000 Orbitrap 
15 100 20 2.E+05 4.E+06 1000 Orbitrap 
16 100 20 5.E+05 1.E+07 1000 Orbitrap 
17 100 20 1.E+06 2.E+07 1000 Orbitrap 
18 CD 20 2.E+05 Default 1000 Orbitrap 
19 200 20 5.E+04 1.E+06 1000 Orbitrap 
20 100 30 1.E+04 1.E+05 1000 Ion Trap 
21 75 20 5.E+04 1.E+06 1000 Orbitrap 
22 150 20 5.E+04 1.E+06 1000 Orbitrap 
23 CD 20 1.E+06 Default 1000 Orbitrap 
24 100 20 5.E+04 2.E+05 1000 Orbitrap 
25 100 20 5.E+04 5.E+06 1000 Orbitrap 
26 100 20 5.E+04 5.E+05 1000 Orbitrap 
27 100 20 5.E+04 2.E+06 1000 Orbitrap 
28 CD 20 1.E+04 Default 1000 Ion Trap 
Table 6.1. Direct Injection ETD Fragmentation Reaction Parameters.  
Peptide 11 was subjected to these 28 ETD fragmentation reactions. The blue highlighted cells 
represent increasing SA, the green highlighted cells represent increasing ETD anion regent and 
peptide cations at a fixed ratio of the two, and the orange highlighted cells represent increasing 
ETD anion reagent with fixed peptide cation amounts, in all cases with all other parameters fixed. 






 We next sought to apply the insights gained from the experiments with Peptide 11 to a 
mixture of 18 synthetic O-GlcNAcylated peptides (Table 6.2). The individual peptides were 
reconstituted in 0.2% formic acid at equal volumes to partially simulate the dynamic range present 
in shotgun proteomics experiments. We designed four online LC-MS methods for head-to-head 
comparison (Table 6.3), focusing on varying ETD reaction time and the two most promising SA 
energies. Again, after LC-MS analysis, we analyzed the data using MS-GF+ and extracted the 
scores for all spectra (Fig. 6.2). Here we again find similar fragmentation efficiencies across 
varying ETD reaction times (methods 1-3), including almost no difference even with reaction 
Peptide Sequence MW 









4 SGSP[S(O-ß-GlcNAc)]DNSGAEEMEVSLA[K(13C6; 15N2)] 2106.15 
5 SGSPSDN[S(O-ß-GlcNAc)]GAEEMEVSLA[K(13C6; 15N2)] 2106.15 
6 G[S(O-ß-GlcNAc)]APPGPVPEGSI[R(13C6; 15N4)] 1534.32 
7 TAT[S(O-ß-GlcNAc)]SPASTPLSPM[R(13C6; 15N4)] 1717.57 
8 T[C(CAM)]PVQLWV[S(O-ß-GlcNAc)]ATPPAGS[R(13C6; 15N4)] 2040.96 
9 AQPPSSAA[S(O-ß-GlcNAc)][R(13C6; 15N4)] 1184.89 
10 QV[T(O-ß-GlcNAc)]ITGSAASISLAQYLINA[R(13C6; 15N4)] 2391.32 
11 QVTI[T(O-ß-GlcNAc)]GSAASISLAQYLINA[R(13C6; 15N4)] 2391.32 
12 AIPV[S(O-ß-GlcNAc)]REE[K(13C6; 15N2)] 1239.31 
13 KKFELLP[T(O-ß-GlcNAc)]PPLSPSR[R(13C6; 15N4)] 2080.09 
14 YSPT[S(O-ß-GlcNAc)]PS[K(13C6; 15N2)] 1077.08 
15 QTTAPA[T(O-ß-GlcNAc)]MSTAASGTTMGVEQA[K(13C6; 15N2)] 2451.63 
16 ATPATEESTVPA[T(O-ß-GlcNAc)]QSSALPAA[K(13C6; 15N2)] 2339.46 
17 [S(O-ß-GlcNAc)]EASSSPPVVTSSSHS[R(13C6; 15N4)] 1915.63 
18 SEASSSPPVV[T(O-ß-GlcNAc)]SSSHS[R(13C6; 15N4)] 1915.6 
 




times as short as 10 ms. However, in this case, we also see that EThcD SA provides a small 
improvement to the overall score in contrast to the results with the single peptide. Given that the 
single peptide used for the previous analysis was triply charged and most of the peptides in this 
experiment were doubly charged, we then decided to break the scoring down further by peptide 
charge density. Previously, Coon and colleagues have shown that ETD fragmentation becomes 
highly favorable for peptides with lower length/charge (higher charge density).6,13 We indeed find 
a similar trend for O-GlcNAcylated peptides in this experiment (Figs. 6.3a and 6.3b). However, 
surprisingly, we find that SA is actually detrimental to the fragmentation of peptides at with higher 
charge densities (e.g. see left of Fig. 6.3b), a phenomenon that, to our knowledge, has not 
previously been described. There is also a clear drop-off for ETD spectra above a residue/charge 
of ~10. Finally, again, there is almost no difference between the MS-GF+ scores of peptides 
subjected to ETD reaction times as low as 10 ms, regardless of their length to charge. Overall, we 
observe a clear trend of increasing peptide fragmentation efficiency and MS-GF+ score at higher 
charge densities with the opposite being true at lower charge densities, providing the first 









Max IT Other 
1 0% CD 5.00E+04 1.00E+06 1000 ms  
2 0% 100 ms 5.00E+04 1.00E+06 1000 ms  
3 0% 10 ms 5.00E+04 1.00E+06 1000 ms 
No ETD on doubly 
charged ions 
4 20% CD 5.00E+04 1.00E+06 1000 ms  
 
 
Table 6.3. ETD Fragmentation Methods for LC-MS Analysis of Synthetic Peptide Mixture.  




6.4. Expanding Optimized ETD Fragmentation Parameters to Shotgun O-GlcNAcomics 
Experiments. 
 We hypothesized that the previous observation that ETD and EThcD fragmentation 
resulted in non-overlapping O-GlcNAc site identifications (Chapter 5) may be due to different 
fragmentation efficiencies of O-GlcNAcylated peptides by each method depending on their charge 
density. In fact, plotting m/z versus the Byonic score for all O-GlcNAcylated peptides identified 
in 293T cells in the aforementioned experiment reveals a strikingly similar trend to that seen with 
the O-GlcNAcylated peptide mixture (Fig. 6.4a). Plotting the Byonic delta mod score (Fig. 6.4.b), 
a measure of how well localized the O-GlcNAc site is, further confirms that ETD is better able to 
map O-GlcNAc sites at lower m/z and vice versa for EThcD. Finally, visualizing the m/z of all 
PSMs reveals strikingly different characteristics for those identified by ETD compared to those 
identified by EThcD (Fig. 6.4c). Repeating this process for the BAP1 KO dataset, where every O-
GlcNAcylated precursor was fragmented sequentially by ETD and EThcD, confirms this trend 
holds in spite of stochastic differences between samples and MS runs (Fig. 6.5a-c). We can also 
see that unique O-GlcNAcylated peptides identified by either method are also highly skewed 
towards those with low versus high m/z for ETD and EThcD, respectively (Fig. 6.5d). Moreover, 
this confirms that the same trend holds for both the Orbitrap and Ion Trap mass analyzers.  
To better understand how SA affects O-GlcNAcylated peptide fragmentation, we again 
enriched O-GlcNAcylated proteins from HEK 293T cell lysate using our previously described 
chemoenzymatic labeling and enrichment workflow (Chapter 5). Importantly, this workflow adds 




used for LC-MS. Thus, O-GlcNAcylated peptides enriched in this manner have significantly 
increased charge density, which is highly favorable for ETD fragmentation both as shown above 
 
Fig. 6.3. MS-GF+ Scores versus Charge Density for All Identified Spectra in Methods 1-4.  
The MS-GF+ score for each spectra is plotted against its length/charge for each method 
individually (a) and ETD methods versus EThcD methods (b). Note the clear benefit of ETD at 
lower length/charge and vice versa at higher length/charge as well as the slight benefit of CD or 10 
ms reaction times (methods 1 and 3 respectively) over a 100 ms reaction time (method 2), although 






for O-GlcNAcylated peptides and as previously described for unmodified peptides.14 After 
enrichment, O-GlcNAcylated peptides were subjected to our 300.1 m/z product-ion-triggered 
ETD/EThcD LC-MS. However, in this case, after observation of the 300.1 m/z product ion, 
precursors were fragmented sequentially by ETD or EThcD with 10, 20, or 30% SA. As a result, 
the fragmentation of every precursor by each of the above methods can be directly compared, 
 
Fig. 6.4. ETD and EThcD Differentially Fragment Peptides Proteome-Wide.  
There is a clear trend in fragmentation efficiency with ETD showing higher scores (a) and delta 
mod scores (b) at lower m/z and vice versa for EThcD. Interestingly, ETD is essentially ineffective 
for peptides above 1,000 m/z. There is also a clear difference in the m/z distributions of all peptides 
identified by ETD or EThcD (c) with ETD, again, showing a preference for lower m/z peptides. 
These data are from the 293T O-GlcNAcome defined in Chapter 4; all spectra were acquired in 




avoiding the stochastic differences between runs inherent to MS. As expected, we replicate the 
clear trend of ETD outperforming EThcD at lower m/z and vice versa at higher m/z (Fig. 6.6a). 
However, we do see significantly more peptides identified by EThcD at higher m/z, with no 
peptides over 1000 m/z identified by ETD as before (Fig 6.6a-b). Furthermore, plotting MaxQuant 
 
Fig. 6.5. Differences between ETD and EThcD Fragmentation Obtain with Spectra 
Acquired in the Same Run.  
(a-c) As in Fig. 6.4. (d) There is also a marked difference in m/z for the peptides uniquely 
identified by either ETD or EThcD, highlighting the importance of using both methods for 
complete coverage of the O-GlcNAcome. These data are from the BAP1 KO quantitative O-
GlcNAcome defined in Chapter 4. ETD and EThcD spectra were acquired together in the Ion 




score versus length/charge (Fig. 6.6c), we see essentially the same trend, which validates m/z as 
an appropriate substitute for length/charge in this case. Importantly, unlike length/charge, m/z is 
an actionable parameter in instrument method design; thus, in contrast to previous reports,6 it may 
be possible to use m/z to reliably sort peptides for fragmentation by ETD or EThcD.  
 
Fig. 6.6. Systematic Optimization of EThcD SA Reveals Preferences (Dis)Advantages of SA 
in Different m/z Regimes.  
(a) MaxQuant score versus m/z of every PSM identified by each fragmentation method. (b) Violin 
plots of the m/z of all peptides identified by each method shows clear differences in the peptide 
populations identified. (c) Plotting MaxQuant score versus length/charge gives a similar trend 







Next, we plotted the difference in MaxQuant score between each of the three SA conditions 
and ETD alone using only peptides that were identified by all four methods. We then used K-
Nearest Neighbors regression to estimate the trend in score difference between EThcD and ETD 
(Fig. 6.7a). Here, we see clear evidence that ETD fragmentation gives higher scores for peptides 
with lower m/z values, regardless of precursor charge. Furthermore, as m/z increases, there is also 
a clear advantage of 20% SA over 10 and 30%, indicating that this is likely the optimal SA for 
fragmenting O-GlcNAcylated peptides with higher m/z; in fact, there is minimal difference 
between 20 and 30% SA out to 1,500 m/z (Fig. 6.6a). We also performed the same analysis using 
the difference in O-GlcNAc localization probability (Fig. 6.7b). Again, we see the same trend of 
ETD outperforming EThcD at lower m/z values and EThcD with 20% SA outperforming the other 
methods at higher m/z values suggesting that peptide fragmentation (which correlates highly with 
overall score) as well as O-GlcNAc site mapping (localization probability) would be optimized by 
 
Fig. 6.7. ETD Outperforms EThcD at Lower m/z Values and Vice Versa at Higher m/z 
Values. 
(a) Difference in MaxQuant score (Δ MaxQuant Score) between EThcD with 10, 20, or 30% SA 
and ETD only for peptides identified by all 4 methods. (b) Difference in localization probability (Δ 
Localization Probability) as in (a). Lines represent the result of K-Nearest Neighbors (50) 
regression on each SA subset. In both cases, there is a clear advantage of ETD at lower m/z values 





a combination of ETD and EThcD with 20% SA. To our knowledge, this is the first such evidence 
of its kind; in fact it has been previously suggested that SA is universally beneficial for fragmenting 
unmodified peptides.3 
Having established a clear trend in O-GlcNAcylated peptide fragmentation with both ETD 
and EThcD, we also assessed (1) whether these trends held for ETciD and (2) if there were any 
 
Fig. 6.8. Systematic Comparison of ETD/EThcD with ETciD.  
(a-b) As in Fig. 6.6a-b. EThcD is with 20% SA. (c) Difference in MaxQuant score (Δ MaxQuant 
Score) between ETciD with 10, 20, or 30% SA and EThcD only for peptides identified by all 5 
methods (i.e. including ETD without SA). (d) Difference in localization probability (Δ 
Localization Probability) as in (c). Lines represent the result of K-Nearest Neighbors (50) 
regression on each SA subset. There is a slight advantage of EThcD over ETciD for MaxQuant 






advantages of CID versus HCD SA. Specifically, we created an MS method that fragments each 
precursor using ETD; EThcD (20% SA); and ETciD with 10, 20, and 30% SA. Again, we 
compared MaxQuant score versus m/z for all identified PSMs and saw the same clear trend in ETD 
and ETciD fragmentation as was observed for EThcD fragmentation (Fig. 6.8a-b). Interestingly, 
ETciD with 20% activation failed to identify any peptides greater than approximately 1,100 m/z 
while ETciD with 30% SA was roughly comparable to EThcD with 20% SA (Fig. 6.8b). We then 
plotted the difference in MaxQuant score (Fig. 6.8c) and localization probability (Fig. 6.8d) of 
ETciD with 10, 20, and 30% SA compared to EThcD with 20% SA. We did not compare the 
difference in MaxQuant score or localization probability directly with ETD given the same 
observed trend of ETD outperforming ETciD at lower m/z values as seen with EThcD. Overall, 
we find a slight underperformance of ETciD compared to EThcD for fragmentation (score) and 
essentially negligible differences for site mapping (localization probability) of O-GlcNAcylated 
peptides. However, if ETciD is employed, our data suggest that 30% SA is optimal.  
Taking the above data together, we hypothesized that 625 m/z may be an optimal decision 
boundary between ETD and EThcD fragmentation. With this in mind, we next tested whether 
different ETD reaction times could also affect fragmentation and site mapping. Importantly, the 
shorter instrument cycle times that would result by decreasing ETD reaction time (generally the 
most time intensive element of an MS workflow) would allow for additional peptides to be 
analyzed within a single MS experiment. In turn, these shorter instrument cycle times may increase 
the number of O-GlcNAcylated peptide identifications in large-scale proteomics experiments.10 
Moreover, due to the predominance of doubly-charged peptides in traditional proteomics 
experiments, efforts to optimize ETD reaction times for more highly charged peptides have been 




HCD product-ion triggered ETD/EThcD method described previously: (1) O-GlcNAcylated 
peptides less than 625 m/z were fragmented by ETD without supplemental activation, and (2) O-
GlcNAcylated peptides greater than 625 m/z were fragmented with EThcD (20% SA). In both 
cases, every precursor was subjected to 3 set ETD reaction times corresponding to an ETD reaction 
 
Fig. 6.9. Systematic Comparison of ETD Reaction Time Constants for O-GlcNAcylated 
Peptide Fragmentation and Site Mapping.  
(a-b) As in Fig. 6.6a-b. (c) Difference in MaxQuant score (Δ MaxQuant Score) between an ETD 
reaction time constant of 0.5 or 1τ and the instrument default of 2τ. (d) Difference in localization 
probability (Δ Localization Probability) as in (c). Lines represent the result of K-Nearest Neighbors 
(50) regression on each reaction time constant subset. There is perhaps a slight advantage of using 






time constant of 2 (instrument default charge depended ETD reaction time parameters), 1, and 
0.5τ.10 For simplicity, only triply charged peptides were fragmented and analyzed, which 
corresponds to an ETD reaction time of 42.75, 21.38, and 10.69 ms for time constants of 2, 1, and 
0.5τ respectively. Plotting MaxQuant score versus m/z for all PSMs (Fig. 6.9a), we do not see any 
clear relationship between m/z and score at different reaction times. In fact, the m/z distribution of 
peptides identified using all 3 reaction times are essentially the same (Fig. 6.9b). Finally, we 
plotted the difference in MaxQuant score (Fig. 6.9c) and localization probability (Fig. 6.9d) of 0.5 
and 1, versus 2τ, only for peptides identified by all 3 methods. As before, we estimated the trend 
in score and localization probability difference using K-Nearest Neighbors (50) regression. We do 
not see any clear advantages of faster ETD reaction times versus the instrument default of 2τ, 
although there might be a slight advantage for both score and localization probability of using an 
ETD reaction time constant of 1τ at higher m/z values.  
Finally, to see if EThcD SA might affect how the ETD reaction time constant relates to 
fragmentation and localization probability, we also repeated the experiment where every peptide 
is fragmented by ETD and EThcD with 10, 20, and 30% SA twice more using and ETD reaction 
time constants of 0.5 and 1τ for 3-6+ peptides (the original experiment was done with an ETD 
reaction time constant of 2τ) (Fig. 6.10). However, we did not observe any clear differences in 
either the trends of score or localization probability versus m/z or in how the different time 
constants affect score or localization probability with different EThcD SA. Overall, the above data 




time constants. This finding has the potential to lead to the development of MS methods with 
significantly reduced instrument cycle time. In our case particularly, the slight advantage of shorter 
ETD reaction times for the m/z regimes where EThcD is would be employed might help to offset 
the inherently longer cycle time of this method.  
 
Fig. 6.10. Relationship between Score and Localization Probability and Peptide m/z for all 
ETD Reaction Time Constants.  
(a, c, and e) Difference in MaxQuant score (Δ MaxQuant Score) between EThcD with 10, 20, or 
30% SA and ETD only for peptides identified by all 4 methods for ETD reaction time constants 2, 
1, and 0.5τ. (b, d, and f) Difference in localization probability (Δ Localization Probability) as in 











Using the above insights, we at last constructed an online LC-MS/MS decision tree that 
uses our previously developed HCD product ion trigger to fragment O-GlcNAcylated peptides less 
than 625 m/z by ETD and greater than 625 m/z by EThcD. We used this method to profile O-
GlcNAcylated peptides enriched from 293T cells as previously described and found a relatively 
even distribution of scores across all m/z values (Fig. 6.11), highlighting our ability to capture the 
advantages of ETD and EThcD in a single run. The same sample of O-GlcNAcylated peptides was 
also subjected to our previous HCD product ion-triggered EThcD method (which slightly 
outperformed ETD alone). In both cases, we analyzed the data using Proteome Discoverer using 
the same parameters as used previously in Chapter 5 to avoid any biases or artefacts that may 
arise from different search engines followed by the application of our sites and regions script as 
described in Chapter 5. Overall, we found essentially the same number of sites using each method 
(1,264 versus 1,268 for the decision tree and EThcD only methods, respectively). However, both 
methods acquired HCD spectra for all 
peptides which generally outperforms ETD 
and EThcD for raw identifications despite 
being essentially unable to localize O-
GlcNAc sites to specific S/T residues (see 
Chapter 5).  
We repeated the sites and regions 
analysis after separating the PSMs by 
fragmentation method and compared only 
ETD/EThcD to EThcD. Here, we found 
1,251 O-GlcNAc sites using the decision 
  
Fig. 6.11. O-GlcNAcylated Peptide 
Fragmentation by MS Decision Tree Results in 
an Even Distribution of Scores Across all m/z 
Values. 





tree compared to 1,177 found by EThcD alone, an increase of 6.3%. Notably, we also found that 
the percentage of sites that were localized was markedly higher for ETD spectra in this dataset 
71.5% versus 53.3% in the previous experiment (Chapter 5). This likely represents a large number 
of ETD spectra that are acquired for peptides not likely to fragment well by ETD alone, again 
underlining the significant savings in cycle time that this new decision tree method may bring. 
Finally, it is worth noting that the ThermoFisher instrument control software for the Orbitrap 
Fusion Tribrid (used for initial optimization experiments and those in Chapter 5) and Orbitrap 
Fusion Lumos (used for the direct comparison between the EThcD and decision tree methods) is 
not capable of implementing a true decision tree workflow. Herein, precursors are first sorted by 
m/z before being fragmented in order of decreasing intensity. Ideally, the intensity sort would 
happen first to avoid spending the additional time fragmenting low abundance precursors (whose 
resulting spectra are less likely to be matched) in the first m/z bin before moving to the second m/z 
bin. In the future, this method is likely to benefit greatly from modified instrument control software 
that is capable of sorting by intensity and subsequently fragmenting each precursor by ETD or 
EThcD depending on its m/z. Currently, our decision tree method is implemented by first 
performing fragmentation on the precursors less than 625 m/z first given the smaller bin size 
(overall we select precursors from 350 – 1800 m/z) and faster cycle time of ETD compared with 
EThcD. 
 
6.5. High pH Reversed-Phase Fractionation to Expand O-GlcNAc Proteome Depth. 
 After the significant improvement in and optimization of fragmentation parameters for O-
GlcNAcylated peptides, we next sought to apply these new methods along with advanced offline 




of O-GlcNAcylated peptides has not been previously performed, although fractionation on native 
peptides prior to O-GlcNAcomics experiments have been shown to increase O-GlcNAc proteome 
depth.15,16 We focused on high pH reversed-phase (HpHRP) given its recent explosion in success 
for in phosphoproteomics analyses.17,18 Specifically, because the amount of O-GlcNAcylated 
peptides that we are able to obtain from this workflow is relatively small, we were particularly 
focused on whether fractionation was appropriate for these samples. Thus, to first determine if 
HpHRP fractionation could increase the depth in our O-GlcNAcomics experiments, we subjected 
a portion of the same samples prepared to test the decision tree against EThcD fragmentation alone 
(Section 6.4) to offline HpHRP fractionation using the method outlined by Olsen and coworkers.17 
1 minute fractions were collected for 64 minutes and concatenated into 8 fractions for each sample. 
These 8 fractions were then subjected to LC-MS/MS analysis using our previously optimized 
decision tree method or our HCD product ion triggered EThcD method as before. Notably, this 
comparison will also shed light on how savings in instrument cycle time versus the complimentary 
fragmentation efficiencies of ETD and EThcD contribute to the improvements previously observed 
with the decision tree. In fractionated samples, there is a much lower demand for instrument cycle 
time.  
 In the combined fractionated samples from the decision tree, we found 1,594 O-GlcNAc 
sites compared to 1,448 with EThcD alone (including HCD spectra). This confirms a modest 
increase in O-GlcNAcome depth could be achieved by HpHRP fractionation. However, given the 
relatively small amount of material used in this analysis, it is likely that these benefits would be 
significantly amplified by the use of more material. In fact, injecting 2.5 times as much material 
(only possible for two out of the eight fractions) yielded about 50% more O-GlcNAc site 




decision tree (even including HCD spectra). As before, we also 
separated the PSMs by fragmentation type and repeated the sites and 
regions analysis on only the ETD/EThcD and EThcD spectra. Here, 
we identified 1,555 versus 1,358 sites with ETD/EThcD and EThcD 
alone, respectively. This represents a more dramatic 14.5% increase 
the total number of sites identified using the decision tree to perform 
ETD or EThcD depending on precursor m/z. Furthermore, comparing 
only localized, non-overlapping sites (Fig. 6.12), we found 1,115 
compared to 1,044 with the decision tree versus EThcD alone, 
representing a 6.8% increase in localized sites. Interestingly, the 
further advantage of the decision tree in fractionated samples highly 
suggests that savings in instrument cycle time contribute less to the 
increase in identification in comparison to the advantage of ETD over 
EThcD for both fragmentation and site localization at lower m/z values. Finally, the additional 
sites identified using the decision tree are highly orthogonal to those identified using EThcD alone 
as they were mapped to 728 unique protein groups versus 662, respectively, an increase of 10.0%. 
In total, fractionation also increased the number of proteins identified by 22.6 and 10.7% for the 
decision tree and EThCD runs, respectively, again indicating the utility of HpHRP fractionation 
for significantly increasing the O-GlcNAc proteome depth. 
 
6.6. Conclusion. 
 In summary, the experiments performed in this chapter represent the first systematic 
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we developed a novel MS-based decision tree for fragmenting O-GlcNAcylated peptides during 
online LC-MS/MS by either ETD or EThcD depending on their m/z. This method, after HpHRP 
fractionation, increased the number of sites identified by ETD/EThcD by 10.1% compared to 
EThcD alone. This increase in identified O-GlcNAc sites also translated to a 10.0% increase in the 
number of O-GlcNAcylated proteins identified, underlining the fact that there are different subsets 
of O-GlcNAcylated peptides that are identified by ETD versus EThcD. Overall, the power of our 
method to probe both of these subsets in a single MS run will greatly facilitate the mapping and 
identification of O-GlcNAc sites across diverse samples and treatments while maximizing 
instrument efficiency. 
 
6.7. Experimental Methods. 
 
6.7.1. Preparation and Direct Injection of Synthetic O-GlcNAc Peptide 11. 
Peptides in Table 6.2 were obtained from ThermoFisher Scientific (custom synthesis) in 
50:50 acetonitrile:0.1% trifluoroacetic acid (TFA). For direct injection experiments, 
approximately 1 mg of peptide 11 was dried by vacuum centrifugation and resuspended in 500 μL 
of 50:50 methanol:0.2% formic acid. This solution was then loaded into a syringe and injected into 
an Orbitrap Fusion Tribrid instrument at 100 nL/min. After manually inspecting both MS1 spectra 
and MS2 spectra (after fragmentation by HCD, ETD, and EThcD) to confirm the expected product 
ions, we targeted the triply charged precursor ion at 572.9498 m/z for analysis by the 28 methods 
in Table 6.1 Each method was run for 1 min to acquire multiple spectra of the peptide. MS1 





6.7.2. Preparation and MS Analysis of Synthetic 
Peptide Mixture.  
 Approximately 50 μL of each peptide were 
combined and dried by vacuum centrifugation (for 
concentrations see Table 6.4). The peptide mixture 
was then reconstituted in 10 μL 0.2% formic acid 
with bath sonication. These samples were 
subjected to LC-MS/MS analysis on a nanoflow 
LC system, EASY-nLC II, (ThermoFisher 
Scientific) coupled to an Orbitrap Fusion Tribrid 
mass spectrometer (ThermoFisher Scientific) 
equipped with a Nanospray Flex ion source. For 
the EASY-nLC II system, solvent A consisted of 
97.8% H2O, 2% ACN, and 0.2% formic acid and 
solvent B consisted of 19.8% H2O, 80% ACN, and 0.2% formic acid. 0.5 μL of the reconstituted 
mixture was then loaded onto a 16-cm analytical HPLC column (50 µm ID) packed in-house with 
ReproSil-Pur C18AQ 3 µm resin (120 Å pore size, Dr. Maisch, Ammerbuch, Germany) and 
separated using a 30 min gradient at a flow rate of 220 nL/min. The column was heated to 60 °C. 
The gradient was as follows: 2-30% Solvent B (30 min), 30-100% B (1 min), and 100% B (9 min). 
MS1 spectra were acquired at 120,000 resolution with a scan range from 350-1800 m/z; AGC was 
set to accumulate 50,000 ions, with a maximum injection time of 50 ms. Top speed (3 s cycle time) 
data-dependent MS2 analysis was then performed in which features were filtered for monoisotopic 




1 1866.65 25 
2 3264.23 10 
3 3264.23 10 
4 2106.15 17 
5 2106.15 34 
6 1534.32 13 
7 1717.57 4 
8 2040.96 3.75 
9 1184.89 13.5 
10 2391.32 5.75 
11 2391.32 25.25 
12 1239.31 2 
13 2080.09 1.75 
14 1077.08 2.25 
15 2451.63 12.75 
16 2339.46 13.5 
17 1915.63 26 
18 1915.6 5.75 





to exclude features after 1 time for 5 seconds with a 10 ppm mass tolerance and exclude isotopes 
turned on. HCD fragmentation was performed for every method with normalized collision energy 
of 28 after quadrupole isolation of features using an isolation window of 1.6 m/z, an AGC target 
of 1e5, and a maximum injection time of 100 ms. MS2 scans were then acquired at 30K resolution 
in Centroid mode with the scan range set to automatic. ETD fragmentation was performed as 
outlined in Table 6.3.  
 
6.7.3. Cell Culture.  
 The parental HEK-293T cell line was obtained from American Type Culture Collection 
(Manassas, VA). Cells were cultured in DMEM supplemented with high glucose, GlutaMAX, 10% 
fetal bovine serum (PBS), and 1x penicillin–streptomycin (P/S) (complete DMEM). 
 
6.7.4. Chemoenzymatic Labeling and Enrichment of O-GlcNAcylated Peptides from 293T Cell 
Lysate. 
 HEK-293T lysate (5 mg) was diluted with 1% SDS, 20 mM HEPES pH 7.6 to 2.5 mg/mL. 
Samples were reduced using 10 mM TCEP-HCl pH 7.6 for 10 min at RT and alkylated with 30 
mM iodoacetamide for 30 min at RT protected from light. Four volumes (~10 mL) of -20 °C 
acetone was added, and the sample was vortexed and incubated at -20 °C for 2 h. The precipitated 
protein was pelleted by centrifugation at 5,000 x g for 10 min at 4 °C. Acetone was removed, and 
the pellet was allowed to air dry. Dried protein was then redissolved at 5 mg/mL with 1 mL of 1% 
SDS, 20 mM HEPES pH 7.9 using probe sonication. Samples were then diluted with 2 mL of 2.5x 
GalT labeling buffer (50 mM HEPES pH 7.9, 125 mM NaCl, 5% IGEPAL CA-630), 1.2 mL of 




μL of 0.1 mM UDP-GalNAz, 250 μL of 2 mg/mL Y289L GalT, and 25 μL of 500 kU/mL PNGase 
F (New England Biolabs) were added with gentle mixing after each addition. The sample was 
rotated end-over-end overnight at 4 °C. The following day, 10 μL of 10 kU/mL calf intestinal 
phosphatase was added to the sample with incubation for 3 h at 37 °C. Samples were then acetone 
precipitated as described above. The protein pellet was redissolved at 5 mg/mL in 1 mL of 1% 
SDS, 20 mM HEPES pH 7.6. The solution was diluted with 2.85 mL of ddH2O and 0.15 mL of 
200 mM HEPES pH 7.6. In a separate tube, a 5x CuAAC mix was prepared by sequential addition 
of 785 μL of ddH2O, 10 μL of 50 mM biotin-Dmpt-alkyne in DMSO, 5 μL of 100 mM BTTAA 
(Click Chemistry Tools, Scottsdale, AZ) in DMSO, 100 μL of 50 mM CuSO4 (freshly prepared), 
and 100 μL of 100 mM sodium ascorbate (freshly prepared). The 5x mix was then added directly 
to the protein sample and mixed end-over-end for 1 h at RT followed by acetone precipitation. The 
protein was resuspended at 5 mg/mL in 1 mL of 5% sodium deoxycholate, 50 mM HEPES pH 7.6, 
10 mM EDTA to chelate residual Cu2+ and diluted with 4 mL of 50 mM HEPES pH 7.6. Then, 
10 μL of 1 M CaCl2 and 100 μg Pierce trypsin protease (1:50 w/w) was added, and the sample 
was rotated end-over-end overnight at 37 °C. Two 15-mL 10 kDa MWCO Amicon concentrator 
tubes were rinsed with 2 x 5 mL of 50% MeOH and 2 x 5 mL of ddH2O by centrifugation at 4,000 
x g for 5 min. Tryptic solutions were then centrifuged in the rinsed concentrator tubes at 4,000 x 
g for 20 min. The remaining residue was rinsed 2 x 2.5 mL of H2O by centrifugation, and the 
flowthrough fractions were combined. The sample was diluted two-fold with ddH2O. In a separate 
tube, 100 μL of a 50% slurry of high capacity Neutravidin agarose (ThermoFisher Scientific) was 
washed 2 x 5 min with 0.5 mL of 50% MeOH and 2 x 5 min with 0.5 mL of ddH2O. The agarose 
resin was then added to the sample and rotated end-over-end for 1 h at RT. The resin was pelleted 




Scientific) pre-rinsed twice with 50% MeOH and 50% ddH2O. Beads were washed 5 min each 
with the following solutions: 5 x 0.5 mL of 20 mM HEPES pH 7.6, 5 x 0.5 mL of 2 M NaCl, 3 x 
0.5 mL of ddH2O, 3 x 0.5 mL of 50% MeOH, 2 x 0.5 mL of ddH2O. Captured peptides were 
eluted in twice with 0.5 mL of 2% v/v NH2OH with end-over-end rotation for 1 h at RT. Elution 
fractions were combined and concentrated to dryness with vacuum centrifugation. The eluted 
peptides were redissolved in 20 μL of 0.2% formic acid and desalted with a C18 ZipTip pipette 
tip. 
 
6.7.5. HpHRP Fractionation of O-GlcNAcylated Peptides. 
 O-GlcNAcylated peptides enriched from 20 mg of 293T lysate were resuspended in 40 μL 
of 0.2% formic acid, and 10 μL was removed for direct MS analysis as described below. The 
remaining 30 μL was diluted to 100 μL with 100 mM ammonium hydroxide before fractionating 
on an Agilent (Santa Clara, CA) 1200 series HPLC system. Peptides were separated at a flow rate 
of 200 nL/min on an XBridge BEH C18 2.1 x 100mm (5μm) column (Waters, Milford, MA). 
Buffer A consisted of 10 mM ammonium hydroxide and buffer B consisted of 90:10 acetonitrile:10 
mM ammonium hydroxide. The gradient was as follows: 1% Solvent B (4 min), 1-30% B (50 
min), 30-60% B (4 min), 60-70% B (2 min), and 70-90% B (5 min). 64 1 min fractions were 
collected into 96 deep-well plates, and every eighth fraction was mixed. Concatenated fractions 
were then acidified to 1% formic acid and 0.1% TFA and partially dried by vacuum centrifugation 
to remove acetonitrile. Fractions were then desalted using an Oasis HLB μElution plate (Waters 
Milford, MA) following the manufacturer’s instructions. Desalted samples were then partially 
dried by vacuum centrifugation to remove acetonitrile reconstituted to 27 μL in 0.1% formic acid 




6.7.6. LC-MS/MS Analysis of O-GlcNAcylated Peptides from 293T Cell Lysates. 
 Chemoenzymatically labeled and enriched samples for initial decision tree optimization 
experiments were analyzed on a nanoflow LC system, EASY-nLC 1000 (ThermoFisher 
Scientific), coupled to an Orbitrap Fusion Tribrid mass spectrometer (ThermoFisher Scientific) 
equipped with a Nanospray Flex ion source. O-GlcNAcylated peptides enriched from 5 mg of 
293T lysate were resuspended in 10 μL of 0.2% formic acid, and 2 μL was directly loaded onto a 
PicoFrit column (New Objective, Woburn, MA) packed in house with ReproSil-Pur C18AQ 1.9 
µm resin (120 Å pore size, Dr. Maisch, Ammerbuch, Germany). The 20 cm x 50 µm ID column 
was heated to 60 °C. The peptides were separated with a 120-min gradient at a flow rate of 220 
nL/min. The gradient was as follows: 2-6% Solvent B (7.5 min), 6-25% B (82.5 min), and 25-40% 
B (30 min) and to 100% B (9 min). Solvent A and B were the same as described above. Full spectra 
were acquired over m/z 350-1800 in the Orbitrap (120 K resolution at 200 m/z); automatic gain 
control (AGC) was set to accumulate 50,000 ions, with a maximum injection time of 50 ms. Data-
dependent MS2 analysis was then performed in which features were filtered for monoisotopic 
peaks with a charge state of 3-8 and a minimum intensity of 25,000, with dynamic exclusion set 
to exclude features after 1 time for 15 seconds with a 10 ppm mass tolerance and exclude isotopes 
turned on using a top-speed approach (cycle time of 5 s). Multiple fragmentation methods were 
used as described in the text. In all cases, an HCD product ion triggered method was employed. 
The normalized collision energy was optimized at 28% for high collision dissociation (HCD) 
fragmentation. The intensity threshold for fragmentation was set to 25,000. HCD fragmentation 
spectra was collected in Orbitrap operating at 30K resolution at 200 m/z. For triggered ETD and 
EThcD methods, fragmentation was performed for precursor ions whose HCD spectra contained 




injection time set at 500 ms and the spectra were acquired in the Orbitrap operating at 30K 
resolution. ETD reaction times were set as described in the text above. 
 Chemoenzymatically labeled and enriched samples for the decision tree versus EThcD 
comparison (with and without fractionation) were analyzed on a nanoflow LC system, EASY-nLC 
1000 (ThermoFisher Scientific), coupled to an Orbitrap Fusion Lumos mass spectrometer 
equipped with a Nanospray Flex ion source. O-GlcNAcylated peptides enriched from 20 mg of 
293T lysate were resuspended in 40 μL of 0.2% formic acid and 4 μL was directly used for analysis 
before fractionation. Fractionated samples were prepared as described above, and 4 μL was used 
for analysis. In both cases, the samples were loaded onto a 360x75μm column/tip packed in house 
with ReproSil-Pur C18AQ 1.9 µm resin (120 Å pore size, Dr. Maisch, Ammerbuch, Germany) at 
1μL/min at 600 bar constant pressure for 15 μL. The column was heated to 60 °C. The peptides 
were separated with a 135-min gradient at a flow rate of 300 nL/min. Solvent A consisted of 99.9% 
water and 0.1% formic acid and Solvent B consisted of 80% acetonitrile, 19.9% water, and 0.1% 
formic acid. The gradient was as follows: 2-32% Solvent B (120 min), 32-63% B (10 min), 63-
100%B (2 min), and 100% B (3 min) Full spectra were acquired over m/z 350-1800 in the Orbitrap 
(120 K resolution at 200 m/z); automatic gain control (AGC) was set to accumulate 50,000 ions, 
with a maximum injection time of 50 ms. Data-dependent MS2 analysis was performed using a 
top-speed approach (cycle time of 5 s) as described above for HCD product ion triggered EThcD 
analyses. For the decision tree analyses, the HCD scans were performed separately for precursors 
350 – 625 m/z and 625 – 1800 m/z.  The presence of the 300.1 m/z product ion was then used to 
trigger ETD (350 – 625 m/z) or EThcD (625 – 1800 m/z) using charge dependent ETD reaction 





6.7.7. Data Analysis. 
 All raw files were searched using Proteome Discoverer 2.4.0.305 (ThermoFisher 
Scientific) with the Byonic (Protein Metrics, Cupertino, CA) search node v3.7.4. Peak lists were 
searched against the mouse UniProtKB databases (Mus musculus, retrieved January 21, 2020) 
supplemented with database of frequently observed contaminants (245 sequences). The following 
parameters were set: MS1 tolerance of 5 ppm, MS2 tolerance of 10 ppm, minimum peptide length 
of 6 amino acid, a maximum of three missed cleavages, carbamidomethylation of cysteine residues 
was set as a fixed modification, acetylation of the protein N-terminus and oxidation of methionine 
(common2) were set as a variable modifications, and the tagged O-GlcNAc was set as a variable 
modification (common 2). Data was filtered to a 1% false discovery rate on PSMs using the 
Percolator algorithm in Proteome Discoverer. Localization of O-GlcNAc sites was performed 
using the ptmRS node. For HCD spectra, equal localization probabilities were assigned to every 
serine/threonine due to neutral loss of the glycan. 
 Subsequent data analysis was performed using the Python language (Python Software 
Foundation. Python Language Reference, version 3.7.3. Available at http://www.python.org) with 
all Anaconda packages installed (Anaconda Software Distribution, version 4.8.3. Available at 
https://anaconda.com). K-Nearest Neighbors regression was performed using the Scikit-learn 
Python package (v0.22.1).19 Sites and regions analysis is described in Chapter 5. 
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7.1. Abstract.  
 O-GlcNAcylation is a widespread PTM of intracellular serine and threonine residues that 
is finely regulated in response to stimuli. However, methods to understand this regulation, 
especially in the context of disease, have lagged behind other PTMs due to unique difficulties in 
identifying, site mapping, and quantifying changes in O-GlcNAcylation across different stimuli or 
disease states. Herein, we present a new, integrated workflow for quantitative O-GlcNAcomics 
that builds isotopic encoding into our previously established chemoenzymatic labeling and 
enrichment workflow (Chapter 5). We then use this strategy along with our state-of-art MS 
decision tree and HpHRP fractionation techniques (Chapter 6) to profile changes in O-
GlcNAcylation in the livers of a mouse model of NAFLD, metabolic syndrome, and T2DM. Next, 
using advanced proteomics techniques to simultaneously profile protein expression to reveal 
relative O-GlcNAc site occupancy changes in diseased versus healthy livers. Finally, we integrate 
this information with previously identified liver OGT interactors (Appendix 5.3) to build a 
dynamic PPI network (dynamic NOTISE analysis) to better understand the regulation of O-
GlcNAcylation in the diseased liver. Overall, we identified 1,315 and 1,217 O-GlcNAc sites in 
WT and db/db livers (1,639 unique sites), improving our coverage of the mouse liver O-
GlcNAcome by almost 50%. Interestingly, there were 131 upregulated and 237 downregulated O-
GlcNAc regions (on 107 and 168 proteins, respectively), significantly challenging the theory that 
there is universal upregulation of O-GlcNAcylation in the context of hyperglycemia and metabolic 
disease. Lastly, we quantified 4,586 proteins, 2,654 of which were differentially expressed, 
suggesting a previously unrecognized widespread remodeling of the proteome in response to liver 
disease. Taken together, the rich datasets provided herein offer unprecedented insight into the 





 T2DM is a worldwide epidemic that is estimated to affect almost 10% of the global 
population aged 20-79.1 Although there have been a number of new therapies developed in the last 
20 years, we still lack any treatments that can reverse or cure the disease, and the number of people 
affected by this devastating disease only continues to rise. Furthermore, T2DM can severely 
detract from quality of life and is associated with a host of complications, including kidney failure, 
nerve damage, blindness, and increased risk for cardiovascular events, that together are responsible 
for upwards of 750 billion dollars in associated healthcare costs.1 The closely associated 
conditions, metabolic syndrome and NAFLD, often co-occur with T2DM and are characterized by 
derangements in lipid metabolism, obesity, and hypertension (metabolic syndrome) or abnormal 
accumulation of fat (>5% of hepatocytes) in the liver (NAFLD).2,3 Combined, they are estimated 
to affect almost 2 billion people worldwide.2,3 Despite the enormous burden of these disease on 
patients and society and an increasing, worldwide biomedical research effort, we still do not have 
a mechanistic understanding of their pathogenesis. In fact, one of the most interesting conundrums 
is why NAFLD is so closely associated with insulin resistance and T2DM; in theory, insulin 
resistance should cause decreased liver lipogenesis and, indeed, specific KO of the IR in the mouse 
liver results in markedly increased liver lipolysis and an overall decrease in liver weight.4-6 In 
contrast, perhaps the most common mouse model of T2DM, metabolic disease, and NAFLD, leptin 
receptor KO (which results in marked hyperphagia, obesity, and over recapitulates most of the 
features of metabolic syndrome and T2DM) mice (db/db mice) demonstrate profound 
accumulation of fat in the liver.  
 Recently, dysregulated O-GlcNAcylation in response to hyperglycemia has emerged as a 




resistance. O-GlcNAcylation is a ubiquitous PTM of signaling molecules and transcription factors 
in the liver, and in many instances, modification of proteins involved with lipogenesis and lipid 
metabolism results in a shift toward increased and de novo lipogenesis (discussed in detail in 
Chapter 1).7 However, methods to characterize O-GlcNAcylation in the context of fatty liver have 
been limited to studies of single proteins, and, to date, there has been no systematic account of 
how O-GlcNAcylation changes across the liver proteome in NAFLD/T2DM. Thus, such questions 
as whether increased O-GlcNAcylation is a general feature in diabetic livers and whether other 
pathways could be affected remain completely unexplored. These questions have remained 
unanswered largely because of a lack of robust tools for profiling dynamic changes in O-
GlcNAcylation at the systems-level.  
Herein, we develop a new quantitative O-GlcNAcomics technique that builds on the 
advances in chemoenzymatic labeling and MS methods in Chapters 5 and 6, respectively, to assay 
changing O-GlcNAcylation across the proteome in db/db versus WT mouse livers. An important 
feature of this workflow is the isotopic encoding of sample information in a novel cleavable biotin 
linker used for the labeling and enrichment of O-GlcNAcylated proteins. Like our previous biotin-
Dmpt-alkyne linker (Chapter 5), this linker allows for the quantitative labeling, enrichment, and 
gentle, hydroxylamine-mediated elution of O-GlcNAcylated proteins while still leaving the final 
peptides with an additional positive charge important for ETD fragmentation. However, unlike the 
quantitative O-GlcNAcomics strategy employed with biotin-Dmpt-alkyne, this linker (1) allows 
for labeling and combination of samples before enrichment and digestion, significantly decreasing 
intersample variability, and (2) does not require expensive TMT reagents which can reach tens of 
thousands of dollars when labeling large amounts of protein or many conditions. Using these new 




and db/db livers, respectively, a total of 1,639 unique sites. Importantly, we were also able to 
obtain quantitative information on 919 of these sites, representing the most extensive dynamic O-
GlcNAcome ever reported in the context of disease. Moreover, we identified 368 differentially 
expressed O-GlcNAcylated regions, significantly updating our understanding of aberrant O-
GlcNAcylation in diabetic livers. Additionally, to account for changes in protein expression, we 
also performed quantitative proteomics on these same samples and were able to identify changes 
in the relative O-GlcNAc site occupancy in 275 O-GlcNAcylated regions across 192 proteins. We 
also quantified 4,856 proteins, of which a staggering 2,654 were differentially expressed. This 
represents the most extensive dataset of differential protein expression in metabolic disease and 
suggests that there is widespread proteomic remodeling in fatty livers. Finally, we expand our 
previous NOTISE approach to integrate dynamic protein expression information and identify 
diverse cellular networks engaged by OGT in the diabetic liver. Interestingly, we find that there is 
a greater preponderance of downregulated O-GlcNAcylation sites and a slight inverse correlation 
between putative adapter protein expression and O-GlcNAcylation levels on target proteins. 
Overall, the data and insights provided by these first studies of dynamic O-GlcNAcylation in db/db 
mouse livers will undoubtedly stimulate new research into the role of O-GlcNAcylation in liver 
function and disease for years to come. 
 
7.3. Development of Biotin-Dmpt-Val0/6-Alkyne. 
 A key aspect of our chemoenzymatic enrichment protocol is the identification of a suitable, 
isotopically encoded biotin-alkyne linker for PTM functionalization. A number of cleavable 
linkers have been reported recently; however, many suffer disadvantages, ranging from relatively 




purification.8-10 In Chapter 5, we described the chemical optimization of our first-generation 
biotin-Dde-alkyne linker by replacement of the Dde group with the Dmpt group, which affords the 
higher stability necessary to survive standard trypsin digestion conditions. To quantify site-specific 
changes in protein O-GlcNAcylation, we sought to modify our linker with an isotopic tag. 
Previously, the addition of light and heavy amino acids such as valine or phenylalanine to encode 
each sample has been used successfully for numerous approaches including activity-based protein 
profiling and enrichment of azide- or alkyne-labeled proteins.11,12 Here, we report a simple 
modification of biotin-Dmpt-alkyne to incorporate light and heavy isotopes of valine (+6; 13C5, 
15N) to produce the pair of isotopically labeled, chemically cleavable biotin-Dmpt-Val0-alkyne 1 
and biotin-Dmpt-Val6-alkyne 2 (Fig. 7.1). Importantly, these modifications to the original linker 
scaffold minimally increase the residual mass left after cleavage and preserve the presence of a 
primary amine after cleavage (which adds an additional positive charge to peptides during the 
acidic conditions of LC-MS).  
 After preparation of this linker, we assessed its ability to quantitatively capture O-GlcNAc 
peptides while preserving information about sample abundance. Towards this end we labeled O-
GlcNAcylated peptides from 293T cell lysate with either biotin-Dmpt-Val0-alkyne or biotin-
Dmpt-Val6-alkyne. We then mixed portions of these samples together at defined ratios (1:5, 1:2, 
1:1, 2:1, and 5:1 Val6:Val0) and performed the streptavidin enrichment and digestion as described 
in Chapter 5. We subject a small about of this sample to HCD-MS analysis to determine if the 
 
 




valine 0/6 linker produced the same triggering diagnostic ions. Importantly, we clearly observed 
the same 300.1 m/z fragment representing cleavage of both the peptide bond between GalNAc and 
valine and the glycosidic bond between GalNAc and GlcNAc (see also Fig. 5.11). Interestingly, 
we also observed additional fragments at 399.2 and 405.2 m/z which represent the linker after 
cleavage of the glycosidic bond, but not the peptide bond. Nevertheless, we decided to move 
forward with using the same 300.1 m/z tag diagnostic ion to ensure consistent triggering between 
the two tags. Thus, we were able to use the same MS decision tree workflow from Chapter 6 to  
map 559 and 441 O-GlcNAc sites from the Val0 and Val6 tags, respectively. As noted in Chapter 
6, we again noticed a higher overall percentage of localized sites compared to previous 
experiments, with over 78 percent mapped to a single S/T for both tags.  
 
 
Fig. 7.2. Labeling with Biotin-Dmpt-Val0/6-Alkyne Labeling Yields Expected Ratios in a 
H:L Mixing Experiment. 
O-GlcNAcylated peptides from 293T cell lysate were labeled with either the Val0 or Val6 linker 
and mixed at the indicated ratios by weight. The calculated ratios for all non-redundant GlcNAc 
sites are plotted in (a). The ratios for all identified O-GlcNAcylated PSMs are plotted in (b). H: 





To calculate ratios for the different experiments, we used an innovative strategy to take 
advantage of the advanced PTM identification and localization, feature mapping, and label-free 
quantification abilities of MaxQuant13 to match sites with quantified isotope patterns. Briefly, we 
searched the data twice, once without quantification to identify the O-GlcNAcylation sites (site-
mapping search), and a second time looking for a +/- 6 Da isotope pattern across all features 
(quantification search). Children MS/MS scans from quantified features were then matched 
between the site identification and quantification runs using an in-house script. However, because 
we are inherently unable to ensure the same S/T was O-GlcNAcylated in both H/L peptides with 
this method, we performed the quantification at the region (O-GlcNAcylated peptide) level by 
removing all localization probability information before using our sites and regions script 
(Chapter 5) to enumerate non-redundant O-GlcNAcylation sites. In total, we quantified 284 O-
GlcNAc regions. Excitingly, their mean calculated ratios corresponded almost exactly their 
expected ratio based on how they were mixed (Fig. 7.2a). We also plotted the ratios of all O-
GlcNAc PSMs with matching isotope patterns (Fig. 7.2b) and similarly found that the ratios are 
consistent and as expected across a large ratio space. In summary, the characterization of biotin-





7.4. O-GlcNAc Site Mapping in db/db and WT Mouse Livers.  
 Having validated our new linker, we next applied it to understand differential O-
GlcNAcylation in the livers of db/db versus WT mice. We harvested livers from 8 week old WT 
and db/db mice and subjected lysate prepared from a single lobe to enrichment with biotin-Dmpt-
Val0-alkyne (WT) or biotin-Dmpt-Val6-alkyne (db/db). After labeling, protein mass was 
normalized and 5 mg from each condition (n=4) were combined before streptavidin capture, linker 
cleavage and trypsin digestion. O-GlcNAcylated peptides were then subjected to HpHRP 
fractionation, concatenated into 4-6 fractions, and subjected to LC-MS/MS analysis using the 
decision tree method on an Orbitrap Fusion Lumos. A second labeling and enrichment replicate 
 
 
Fig. 7.3. Workflow for LC-MS/MS Analysis of O-GlcNAcylated Peptides Purified from 
db/db and WT Mouse Livers. 
4 pairs of WT and db/db mice were selected at random, and peptides from each were labeled with 
the Val0 or Val6 linker, respectively, before combing 5 mg from each condition into pairs A-D for 
enrichment, digestion, fractionation, and LC-MS/MS analysis. 
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was also prepared and subjected to microscale HpHRP fractionation14 given the relatively small 
sample amounts. The overall workflow is outlined in Fig. 7.3. The data from these two experiments 
were then searched together in MaxQuant using the previously outlined strategy. In total, we 
identified 1,315 sites labeled with the Val0 tag (WT) and 1,217 sites labeled with the Val6 tag 
(db/db) (Appendix 7.1). Even without isotope pattern matching between the two tags, there was a 
high degree of overlap in sites identified by the two samples, with 1,181 sites shared between the 
two samples, 204 unique to db/db mouse livers, and 254 unique to WT mouse livers for a total of 
1,639 unique sites (Fig. 7.4a), suggesting that there are not massive shifts in the liver O-
GlcNAcome in response to metabolic derangement. As in the ratio tests described previously, the 
sites were extremely well localized, with 84% mapped to a single S/T in both samples with an 
average localization probability of 94.8 and 95.0% in WT and db/db livers, respectively (Figs. 
7.4b and 7.4c) Altogether, this rich dataset is a significant update to our understanding of O-
GlcNAcylation in the mouse liver, elucidating and mapping > 60% more O-GlcNAc sites than 




Fig. 7.4. O-GlcNAc Site Mapping in db/db and WT Mouse Livers. 
(a) Overlap in sites identified in db/db/ and WT mouse livers. (b-c) Pie charts of localization 





7.5. Quantitative Comparison of db/db and WT Liver Proteomes.  
 Because of the significant liver pathology associated with leptin receptor KO, we also 
performed quantitative protein expression profiling to better understand if changes in O-
GlcNAcylation were the result of changes in protein expression versus changes in OGT/OGA 
activity at individual sites. Towards this end, we performed TMT labeling on 100 μg of peptides 
from the same liver lysates used for O-GlcNAcomics. These peptides were also subjected to 
HpHRP fractionation, concatenated into 16 fractions, and subjected to LC-MS/MS analysis (Fig. 
7.5). Overall, we quantified 4,586 proteins in all 8 samples. Notably, there was a high correlation 
between log2 TMT intensities and sample of origin, demonstrating that intersample variation far 
 
 
Fig. 7.5. Workflow for Quantitative Proteomics in db/db vs WT Mouse Livers. 
Peptides from liver lysate used for quantitative O-GlcNAcomics (Fig. 7.3) were also TMT labeled 






outstrips intrasample variation (Fig. 7.6a). Interestingly, there was also significantly greater range 
in the db/db TMT intensities, suggesting that multiple proteins are highly differentially expressed 
in response to fatty liver (Fig. 7.6b). We then identified differentially expressed proteins in db/db 
versus WT samples using the limma-moderated t-test.15 Strikingly, we identified 2,654 
differentially expressed proteins, with greater than twice as many (1,880) upregulated than 
downregulated (774), suggesting a previously unrecognized and massive reorganization of the 
liver proteome in db/db mice (Fig. 7.7a). Hierarchical clustering analysis also grouped WT and 
db/db mice together, confirmed the relatively minimal intrasample variation, and demonstrated 
multiple co-regulated groups of up and downregulated proteins (Fig. 7.7b). The differentially 
expressed proteins were also involved in multiple pathways with top hits in MetaCore and 
Ingenuity Pathway Analysis focusing on expected pathways like lipid and bile acid metabolism as 
well as relatively less expected ones, ranging from mRNA splicing to cytoskeletal dynamics and 
FAK1 signaling (Appendix 7.1). Interestingly, we also found that both OGT and, to a much greater 
extent, OGA expression were upregulated in db/db livers (Fig 7.7c). This suggests cells are likely 
actively responding to global changes in O-GlcNAcylation as a result of metabolic derangement. 
 
 
Fig. 7.6. Protein Expression in db/db and WT Mouse Livers. 
(a) Heatmap of Pearson’s correlation coefficiencts calculated between the log2 TMT intensities of 






Finally, we calculated protein expression ratios for mouse pairs A-D (Fig. 7.3) to use for calculated 
relative O-GlcNAc site occupancy ratios. Altogether, our quantitative proteomics analysis updates 
our understanding of differential protein expression in db/db mice by more than a factor of two, 
which will undoubtedly inform future mechanistic studies of liver pathology in T2DM.  
 
7.6. Quantitative O-GlcNAcomics in db/db versus WT Mouse Livers.  
 With the protein expression and O-GlcNAcomics datasets in hand, we next set out to 
quantify differences in relative O-GlcNAcylation in peptide regions between db/db and WT mice. 
As described for the quantification during the linker validation, we removed all localization 
 
 
Fig. 7.7. Differentially Expressed Proteins in db/db Mouse Livers. 
(a) Volcano plot of the log2 fold change in expression vs the –log10 limma-moderated p-values. 
(b) Hierarchical clustering of scaled (to WT median) log2 TMT intensities shows clustering by 
condition and differential protein expression. (c) Expression levels of OGT and OGA are 
upregulated in db/db livers. *p < 5e-4 by limma-moderated t-test, corrected for multiple 







probability information before resubmitting the PSMs to our sites and regions script and matching 
the regions back to quantified isotope patterns from the quantification run. As a result, our 
quantification is performed at the region level (for cases with more than 1 S/T this essentially 
corresponds to the peptide level). Excitingly, we were able to quantify 916 regions (with 919 total 
sites) on 594 proteins (Appendix 7.2), slightly shy of our previous O-GlcNAcomics experiment 
in 293T cells, which have a significantly larger O-GlcNAcome than the mouse liver (Chapter 5). 
Notably, there was a high degree of overlap between peptides quantified in both biological and 
technical replicates (Fig. 7.8a-b) Correcting for changes in protein expression, we were able to 
quantify 597 regions (598 sites) on 536 proteins. Thus, along with the data presented in Chapter 
5, we present the two largest protein-expression corrected O-GlcNAcomics datasets ever reported. 
Importantly, correcting for protein expression markedly increased the number of O-GlcNAc 
regions found to be differentially regulated, highlighting the importance of performing protein 
expression normalization for quantitative O-GlcNAcomics experiments (Fig. 7.8a) We also found 
131 (96) upregulated regions on 107 (77) proteins and 237 (179) downregulated regions on 168 
(115) proteins (corrected for protein expression) (Fig. 7.8b). Interestingly, we found O-
 
 
Fig. 7.8. Overlap between Biological and Technical Quantitative O-GlcNAcomics 
Replicates 






GlcNAcylation was upregulated on 4/5 members of the perilipin (Plin) family of proteins, which 
sequester lipid droplets from metabolism by lipases.16 Recently, it was reported that Plin1 O-
GlcNAcylation opposes phosphorylation, which is necessary for lipid droplet breakdown.17 
Therefore, our results likely highlight a previously unrecognized role for Plin O-GlcNAcylation in 
fatty liver disease and strong evidence that O-GlcNAcylation may be playing a role in the 
paradoxical development of fatty liver in the context of insulin resistance. Specifically, increased  
perilipin O-GlcNAcylation (due to hyperglycemia induced flux through the HBP or modulation of 
other signaling mechanisms) may be preventing the breakdown of hepatocyte lipid droplets (the 
 
 
Fig. 7.9. Protien Expression Corrected O-GlcNAcomics in db/db versus WT Livers. 
(a) Correction for protein expression results in the identification of significantly more differentially 
O-GlcNAcylated regions as well as eliminates many sites that likely suggest only differential protein 
expression rather than O-GlcNAcylation. (b) Volcano plot of all quantified O-GlcNAcylated 
regions. Note the expression of multiple members of the Plin family as well as the opposed 
upregulation and downregulation of Elov6 and 3, respectively. Other selected, highly differentially 
expressed genes involved in metabolism, autophagy, transcriptional regulation, and detoxification. 
Ugta5: UDP-glucuronosyltransferase 1-5; Bhmt: betaine--homocysteine S-methyltransferase 1, 
Ctsf: cathespin F, Ppt2: lysosomal thioesterase PPT2, Manba: beta-mannosidase, Ces3b: 







main pathological feature of NAFLD) and significantly contributing to the buildup of intracellular 
lipids even in the context of insulin resistance.  
We also find two members of the elongation of very long chain fatty acid protein (Elovl) 
family, with Elovl6 having the highest upregulation of O-GlcNAcylation of any protein while 
Elovl3 had close to the lowest. Both Elovl3 and Elovl6 catalyze the rate limiting step in the long-
chain fatty acid elongation cycle but are known to have different substrate specificities.18,19 
Interestingly, Elovl6 KO mice have a profound resistance to the development of hyperinsulinemia  
and other features of T2DM, suggesting that this enzyme plays a major role in metabolic 
homeostasis.20 Relatively less is known about Elvol3, previously generated KO mice were only 
shown to have a sparse hair coat, defects in coat water repulsion, and increased trans-epidermal 
 
 
Fig. 7.10. S405 Is a Major Regulatory O-GlcNAcylation Site on OGA. 
(a) Chemoenzymatic labeling of O-GlcNAcylation WT and S405A mutant OGT reveals an almost 
complete absence of OGA activity responsive OGA O-GlcNAcylation in the absence of S405. (b) 
S405 is highly conserved and close to the known capase-3 cleavage site at D413. (c) O-







water loss.21 Nevertheless, this represents an interesting conundrum, that, taken with the striking 
Elvol6 KO mouse phenotype, is ripe for further investigation. Finally, we found that OGA O-
GlcNAcylation at S405, a site originally identified more than 10 years ago as being differentially 
O-GlcNAcylated in the brain in response to PUGNAc,22 was significantly downregulated in db/db 
mouse livers. To see (1) if this represents the major site of O-GlcNAc on OGA and (2) if this site 
is also dynamic to OGA inhibition in liver tissue, we overexpressed FLAG-tagged WT or S405A 
mutant OGA in HepG2 cells. After lysis, chemoenzymatic labeling with high MW PEG, and WB 
as described in Chapter 2, we noted an almost complete loss of O-GlcNAcylation on the S405A 
mutant (Fig. 7.9a). Moreover, inhibition of OGA activity with TMG markedly increased O-
GlcNAcylation at this site, suggesting that it is indeed responsive to OGA activity in hepatocytes. 
A recent report also found that O-GlcNAcylation at this site severely reduced protein half-life 
without directly affecting stability.23 Notably, this site highly conserved and close to the known 
caspase-3 cleavage site at D413 (Fig. 7.9b).24 To test if O-GlcNAcylation may be protecting OGA 
from caspase-3 mediated cleavage, we expressed 4 flag-tagged OGA constructs, WT, S405A, 
S405W, and D413A, in HepG2 cells before treating with activating anti-Fas antibody to induce 
apoptosis. Consistent with the suggestion that O-GlcNAcylation at S405 might regulate OGA 
stability, we find that TMG treatment increases the cleavage of OGA, a phenomena that can be 
almost entirely prevented by mutation of that site to alanine (Fig. 7.9c). Furthermore, the S405W 
O-GlcNAc mimetic25 showed increased baseline cleavage that was not further increased by TMG 
stimulation. Taken together, these multiple lines of evidence suggest that OGA expression, 
activity, and stability may be simultaneously upregulated in db/db livers, something that is also 




first in vivo evidence of homeostatic regulatory mechanisms for O-GlcNAc in the context of 
disease.  
In addition to the specific examples highlighted above, GO term analysis of proteins with 
upregulated O-GlcNAcylation revealed a strong enrichment for proteins involved in 
catabolism/metabolism and glucuronidation, phase II conjugation of compounds, and drug 
metabolism pathways. Proteins with downregulated O-GlcNAcylation were enriched for an array 
of biological processes, including regulation of gene expression, nucleic acid and protein 
biosynthesis, and various metabolic processes. There was also a strong enrichment for proteins 
involved in lysosomal and protein processing in the ER pathways. Overall, this data provides 
significant insight into the major regulatory functions of O-GlcNAcylation in response to 
 
 
Fig. 7.11. Dynamic NOTISE Analysis in db/db and WT Mouse Livers.  
Dynamic NOTISE analysis reveals widespread changes in O-GlcNAcylation and protein expression 
across every O-GlcNAc functional community in db/db mice. Protein expression is represented by 
node size and O-GlcNAcylation by node border color.  
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metabolic disease. We also provide the first systems-level evidence that O-GlcNAcylation is finely 
controlled in the context of hyperglycemia, with increased OGA activity and other regulatory 
mechanisms resulting in the downregulation of hundreds of O-GlcNAcylation sites rather than the 
universal upregulation (presumably in response to increased HBP flux) that has been previously 
suggested.26  
 
7.7. Dynamic NOTISE Analysis Reveals O-GlcNAcylation and Protein Expression Changes 
across the OGT Substrate Interactor PPI Network.  
 To gain a deeper understanding about how db/db affects OGT substrate interactor networks 
in metabolic disease, we expanded our previously developed NOTISE analysis (Chapter 5) to 
integrate the quantitative information about protein expression and O-GlcNAcylation provided 
above. Again, PPI network generation, GLay community clustering, and ClueGO-guided27 
annotation based on biological process GO terms resulted in 11 functionally distinct communities 
(Fig. 7.10). These communities were enriched for proteins involved in (1) metabolism, (2) gene 
expression, (3) cell junction assembly and maintenance, (4) glycogen metabolism, (5) actin 
cytoskeleton organization, (6) mRNA catabolism, (7) metabolism, (8) carboxylic acid catabolism 
and endocytosis/trafficking, and (9) histone methylation and telomere localization. Although many 
of these communities are similar, e.g. various facets of metabolism, histone modification, and actin 
cytoskeletal organization, we also see new communities involved in cell junction assembly and 
maintenance and glycogen metabolism which may represent, at least in part, the differential 
engagement of OGT substrate interactor networks in db/db mouse livers.  
Interestingly, we see widespread changes across every functional community in both O-




proportion of differential protein and O-GlcNAcylation expression, respectively, confirming for 
the first time at the systems level that O-GlcNAcylation is involved with multiple metabolic 
networks in response to T2DM/NAFLD. As we observed with the KO of putative adapter protein 
BAP1 in Chapter 5, we also observed both upregulation and downregulation of O-GlcNAcylation 
in substrates connected to putative adaptor proteins, further suggesting that OGT interacting 
proteins may be able to both facilitate and block O-GlcNAcylation of their interactors. To gain 
more insight into how OGT interactor expression affected the O-GlcNAcylation of OGT interactor 
interactors, we plotted the change in interactor expression of all interacting proteins relative to the 
O-GlcNAcylation of the proteins that those interactors interact with. Surprisingly, we found a 
small but significant negative correlation (Fig. 7.11a), suggesting that increased expression of 
OGT interactors might block rather than facilitate O-GlcNAcylation of secondary interactors. To 
try and differentiate whether this correlation was a result of other signaling mechanisms outside of 
OGT-protein interactions, we also repeated our adaptor rank analysis to score putative OGT 
 
 
Fig. 7.12. Correlation between OGT Interactor Protein Expression and Secondary 
Interactor O-GlcNAcylation.  
(a) There is a slight negative correlation (Spearman’s ρ: -0.0756, p-value: 6.55e-6) between the 
protein expression of OGT interacting proteins and the O-GlcNAcylation on associated secondary 
interactors. (b) This trend is preserved for interactors with an adaptor rank > 2 (Spearman’s ρ: -






adaptor proteins. Plotting only OGT interactors with an adaptor rank score of two (meaning that 
they interact with at least two more OGT substrates than other interactors), the weak but significant 
negative correlation is preserved (Fig. 7.11b). This analysis advances the idea that OGT-protein 
interactions may do more to block O-GlcNAcylation of secondary interactors than promote it (as 
the adaptor protein hypothesis originally envisioned).  
Finally, in addition to our adaptor rank program, quantitative NOTISE allows us to look 
for putative OGT adaptor/blocker proteins by searching for the interactors and their connect 
substrates that are (anti-)correlated. With stringent cutoffs for protein and O-GlcNAcylation fold 
change, as well as only accepting O-GlcNAcylation fold change that was corrected for protein 
expression, we identified multiple potential OGT adaptor/blocker-target pairs with a 
preponderance of the latter (i.e. increased expression leading to decreased O-GlcNAcylation of 
target proteins) (Appendix 7.4). Specifically, we identified a new putative targeting interaction 
between myb-binding protein 1A and basigin, which are known members of a PPI network that 
was recently implicated in the regulation of metabolism, autophagy, and of mammalian target of 
rapamycin (mTOR) signaling.28 We also found that increased WDR5 expression results in the 
downregulation of multiple sites on HCFC1 suggesting that, like with BAP1 KO in Chapter 5,  
HCFC1 O-GlcNAcylation may be blocked by OGT-adaptor or adaptor-HCFC1 binding. However, 
we readily admit that specific adaptor/blocker protein pairs identified by this analysis require 
future validation given the likely remodeling of signaling networks in db/db livers. However, as 
new tools for disrupting specific PPIs are becoming increasingly available,29 dynamic NOTISE is 
likely to serve an important role in identifying which PPIs to target in any given context. In 
summary, the powerful updates to our NOTISE analysis outlined herein significantly enhance our 




O-GlcNAcylation site and protein players involved in specific functional cellular networks, and 
provide a new framework for understanding OGT regulation.  
 
7.8. Conclusion.  
 We have integrated advanced tools in chemistry and MS to provide the first insights into 
how liver O-GlcNAcylation changes in response to metabolic disease. First, we combined novel 
MS tools (Chapter 6) with a new isotopically defined biotin-Dmpt-alkyne linker in the 
development of an expedient and robust workflow for quantitative O-GlcNAcomics. Importantly, 
in contrast to other techniques, which rely on metabolic labeling9 or use expensive TMT reagents,30 
this workflow allows for near quantitative enrichment of O-GlcNAcylated proteins at a 
significantly reduced cost. Furthermore, it is highly efficient for mapping O-GlcNAc sites to 
specific S/T, and we were able to localize nearly 80% of sites in db/db and WT mouse livers. Next, 
we applied this workflow to understand how O-GlcNAcylation changes in response to metabolic 
disease, the first large-scale simultaneous protein and PTM analysis to date in this context. Here, 
we identified thousands of differentially expressed proteins involved in multiple pathways ranging 
from metabolism to RNA splicing. We also identified hundreds of differentially O-GlcNAcylated 
proteins with a significant percentage of up and downregulated sites on proteins intimately 
involved in metabolism/catabolism of nucleic acids, proteins, carbohydrates, and toxins. Finally, 
we synthesize these datasets in a new dynamic NOTISE workflow that reveals key OGT substrates 
and interactors that are differentially expressed or O-GlcNAcylated in diabetic livers. This analysis 
also sheds new light on the role of OGT adaptor proteins in regulating OGT, suggesting that, in 
addition to targeting, OGT interactors are perhaps more likely to block O-GlcNAcylation of their 




pairs for further study. In total, the data gathered, processed, and synthesized herein represent an 
unprecedented and significant step towards a deeper mechanistic understanding of OGT 
(dys)regulation in the context of metabolic disease. 
 
7.9. Experimental Methods. 
 
7.9.1. Chemicals and Reagents. 
 All chemicals were purchased from Sigma-Aldrich (St. Louis, MO), and all cell culture 
materials were purchased from ThermoFisher Scientific (Waltham, MA) unless otherwise noted. 
All primers were purchased from Integrated DNA Technologies (Coralville, IA), and all molecular 
biology supplies were purchased from New England Biolabs (NEB, Ipswich, MA) unless 
otherwise indicated. 
 
7.9.2. Synthesis of Biotin-Dmpt-Val0/6-Alkyne. 
 
7.9.2.1. N-(tert-butoxycarbonyl)-N’-propargyl-L-valinamide (Boc-Val0-Alk, 3). 
Valine (200 mg, 1.71 mmol) and NaHCO3 (287 mg, 2 eq) were suspended in 3 mL H2O 
and cooled to 0 °C. Boc2O (410 mg, 1.1 eq) was dissolved in 3 mL THF and added dropwise to 
the mixture. The reaction was stirred at 0 °C for 1 h and then allowed to warm to RT overnight. 
The reaction was diluted with H2O and extracted twice with EtOAc. Organic layers were 
combined and extracted twice with sat. NaHCO3. Aqueous layers were combined, acidified to pH 
2 with ice-cold 1 N HCl, and extracted thrice with EtOAc. Organic layers were combined, dried 




Ar. To the solution was added sym-collidine (451 μL, 2 eq) and propargylamine (164 μL, 1.5 eq). 
The mixture was cooled to 0 °C, and COMU (1.10 g, 1.5 eq) was added slowly over 15 min. The 
reaction was stirred at 0 °C for 1 h and then allowed to warm to RT overnight. The solution was 
then diluted with EtOAc and extracted twice with dilute HCl (pH 2), twice with sat. NaHCO¬3, 
and twice with brine. The organic layer was dried over MgSO4 and concentrated. The product was 
further purified by flash silica column chromatography (2:1 hexanes/EtOAc) to yield a white solid 
(355 mg, 82% over two steps). 1H NMR (400 MHz, CDCl3): δ 6.68 (bs, 1H, NH), 5.18 (bs, 1H, 
NH), 4.13-3.90 (m, 3H, NCH2, Val-CαH), 2.20 (td, J = 2.6, 1.4 Hz, 1H, ≡CH), 2.10 (bs, 1H, Val-
CH), 1.43 (s, 9H, Boc-CH3), 0.94 (dd, J = 14.1, 6.8 Hz, 6H, Val-CH3). 13C NMR (100 MHz, 
CDCl3) δ 171.72, 171.69, 156.09, 80.13, 79.44, 71.66, 59.93, 31.12, 29.11, 28.64, 28.46, 19.36, 
18.11. ESI-HRMS (m/z): [M+H]+ calc’d for C13H22N2O3: 255.1703, found: 255.1700. 
 
7.9.2.2. N-(tert-butoxycarbonyl)-N’-propargyl-L-valinamide-13C5,15N (Boc-Val6-Alk, 4). 
Synthesized as described above (89% yield over two steps). 1H NMR (400 MHz, CDCl3): 
δ 7.18 (bs, 1H, NH), 5.50 (d, J = 9.0 Hz, 0.5H, 15NH), 5.27 (d, J = 9.0 Hz, 0.5H, 15NH),  4.23-
3.74 (m, 3H, NCH2, Val-13CαH), 2.17 (m, 1.5H, Val-13CH, ≡CH), 1.87 (bs, 0.5H, Val-13CH), 
1.40 (s, 9H, Boc-CH3), 1.07 (dp, J = 9.7, 4.8 Hz, 3H, Val-13CH3), 0.76 (dp, J = 10.3, 4.9 Hz, 3H, 
Val-13CH3). 13C NMR (100 MHz, CDCl3) δ 172.19, 171.93, 171.67, 156.24, 155.99, 79.90, 
79.54, 79.52, 71.43, 62.33, 61.89, 61.45, 60.27, 60.15, 59.92, 59.80, 59.74, 59.62, 59.39, 59.27, 
31.82, 31.47, 31.31, 31.12, 30.96, 30.77, 28.94, 28.44, 19.58, 19.41, 19.23, 19.07, 18.44, 18.09, 







trione (GA-Dmpt-Val0-Alk, 5). 
 Boc-Val0-Alk 3 (75.0 mg, 0.295 mmol) was dissolved in 4 mL 3:1 TFA/CH2Cl2 and stirred 
for 3 h at RT. The mixture was then concentrated and co-concentrated three times with EtOH to 
remove all residual TFA. The residue was then redissolved in 5 mL EtOH, and GA-Dmpt 4 (104 
mg, 1.3 eq) and DIEA (154 µL, 3 eq) were added. The reaction was refluxed for 3 h and then 
concentrated. The residue was redissolved in EtOAc and extracted with 1 M KHSO4 and brine. 
The organic layer was dried over Na2SO4, filtered, and concentrated. The compound was then 
purified by flash silica column chromatography (9:1 CH2Cl2/MeOH + 0.02% acetic acid) to afford 
a white solid (78.1 mg, 65% over two steps).1H NMR (400 MHz, MeOD-d4): δ 4.43 (d, J = 6.1 
Hz, 1H, Val-CαH), 4.01 (qd, J = 17.5, 2.6 Hz, 2H, NCH2), 3.27 (s, 6H, NCH3), 3.17 – 3.03 (m, 2H, 
CH2), 2.62 (t, J = 2.5 Hz, 1H, ≡CH), 2.49 (t, J = 7.0 Hz, 2H, CH2), 2.27 (h, J = 6.7, 1H, Val-CH), 
1.80 (ddt, J = 14.0, 11.7, 7.1 Hz, 2H, CH2), 1.06 (dd, J = 6.8, 5.4 Hz, 6H, Val-CH3). 13C NMR 
(101 MHz, MeOD-d4): δ 177.84, 177.06, 171.50, 152.86, 91.08, 80.12, 72.51, 63.57, 34.36, 33.42, 
30.42, 29.55, 28.17, 24.09, 19.36, 18.27. ESI-HRMS (m/z): [M+Na]+ calc’d for C19H26N4O6: 
429.1750, found: 429.1738. 
 
7.9.2.4. 5-(4-carboxy-1-(N-propargyl-L-valinamido)butylidine)-1,3-dimethylpyrimidine-2,4,6-
trione-13C5,15N (GA-Dmpt-Val6-Alk, 6). 
Synthesized as described above (60% yield over two steps). 1H NMR (400 MHz, MeOD-
d4): δ 13.11 (d, J = 8.4 Hz, 0.2H, 15NH), 12.89 (d, J = 8.4 Hz, 0.2H, 15NH), 4.60 (s, 0.5H, Val-
13CαH), 4.25 (s, 0.5H, Val-13CαH), 4.01 (qdd, J = 17.5, 3.6, 2.5 Hz, 2H, NCH2), 3.28 (s, 6H, NCH3), 




0.5H, Val-13CH), 2.11 (bs, 0.5H, Val-13CH), 1.91 – 1.73 (m, 2H, CH2), 1.22 (h, J = 5.0 Hz, 3H, 
Val-13CH3), 0.91 (h, J = 5.0 Hz, 3H, Val-13CH3). 13C NMR (101 MHz, MeOD-d4): δ 171.50 (d, J 
= 52.4 Hz), 152.86, 91.09, 80.12, 72.51, 63.54 (ddd, J = 52.5, 33.6, 10.7 Hz), 34.35, 33.39 (q, J = 
34.6 Hz), 30.42, 29.54, 28.16, 24.09, 19.35 (d, J = 35.2 Hz), 18.25 (d, J = 35.0 Hz). ESI-HRMS 





GA-Dmpt-Val0-Alk 7 (50.0 mg, 0.123 mmol) was dissolved in 2 mL DMF. DIEA (42.9 
µL, 2 eq) and HATU (56.1 mg, 1.2 eq) were then added sequentially. The reaction was stirred for 
5 min at RT, after which biotin-PEG4-amine (BroadPharm, 250 mg/mL in DMF, 250 µL, 1.1 eq) 
was added by syringe. The mixture was then stirred at RT for 1 h and then concentrated. The 
residue was redissolved in EtOAc and extracted with 1 M KHSO4 and brine. The organic layer 
was dried over Na2SO4, filtered, and concentrated. The product was then purified by flash silica 
column chromatography (9:1 CH2Cl2/MeOH) to afford an off-white solid (43.2 mg, 41% yield). 
1H NMR (400 MHz, DMSO-d6): δ 12.74 (d, J = 8.8 Hz, 1H, NH), 8.79 (t, J = 5.5 Hz, 1H, NH), 
8.03 (t, J = 5.6 Hz, 1H, NH), 7.84 (t, J = 5.6 Hz, 1H, NH), 6.43 (s, 1H, NH), 6.37 (s, 1H, NH), 
4.38 (dd, J = 8.9, 6.2 Hz, 1H, Val-CɑH), 4.30 (dd, J = 7.8, 5.0 Hz, 1H, biotin-CH), 4.12 (ddd, J = 
7.4, 4.5, 1.8 Hz, 1H, biotin-CH), 3.91 (qdd, J = 17.4, 5.4, 2.5 Hz, 2H, NCH2), 3.53 – 3.47 (m, 11H, 
NCH3, biotin-CH, OCH2), 3.40 (dt, J = 12.3, 5.9 Hz, 4H, OCH2), 3.28 – 3.04 (m, 12H, OCH2, 
NCH2), 3.03 – 2.90 (m, 2H, CH2), 2.81 (dd, J = 12.4, 5.0 Hz, 1H, biotin-CH), 2.57 (d, J = 12.4 Hz, 




Hz, 2H, biotin-CH2), 1.86 (bs, 1H, ≡CH), 1.73 – 1.53 (m, 3H, CH2, biotin-CH2), 1.56 – 1.38 (m, 
3H, biotin-CH2), 1.35 – 1.20 (m, 2H, biotin-CH2), 0.94 (d, J = 6.7 Hz, 6H, Val-CH3). 13C NMR 
(101 MHz, DMSO-d6): δ 175.80, 172.13, 171.68, 168.77, 162.73, 150.57, 89.15, 80.49, 73.31, 
69.80, 69.73, 69.58, 69.18, 69.11, 61.28, 61.05, 59.21, 55.46, 39.88, 38.59, 38.45, 35.11, 34.84, 
31.55, 28.89, 28.22, 28.13, 28.06, 27.56, 25.29, 23.41, 18.69, 17.80. ESI-HRMS (m/z): [M+Na]+ 





 Synthesized as described above (50% yield). 1H NMR (400 MHz, DMSO-d6): δ 12.85 (d, 
J = 8.5 Hz, 0.5H, 15NH), 12.63 (d, J = 8.4 Hz, 0.5H, 15NH), 8.82 (q, J = 5.2 Hz, 1H, NH), 8.04 (t, 
J = 5.5 Hz, 1H, NH), 7.85 (t, J = 5.6 Hz, 1H, NH), 6.44 (s, 1H, NH), 6.38 (s, 1H, NH), 4.57 (bs, 
0.5H, Val-13CɑH), 4.30 (dd, J = 7.8, 5.0 Hz, 1H, biotin-CH), 4.22 (bs, 0.5H, Val-13CɑH), 4.16 – 
4.08 (m, 1H, biotin-CH), 3.91 (qdt, J = 17.5, 5.6, 3.0 Hz, 2H, NCH2), 3.56 – 3.44 (s, 11H, NCH3, 
biotin-CH, OCH2), 3.40 (dt, J = 12.3, 5.9 Hz, 4H, OCH2), 3.28 – 3.04 (m, 12H, OCH2, NCH2), 
3.02 – 2.91 (m, 2H, CH2), 2.81 (dd, J = 12.4, 5.0 Hz, 1H, biotin-CH), 2.57 (d, J = 12.4 Hz, 1H, 
biotin-CH), 2.33 (bs, 0.5H, Val-13CH), 2.25 (t, J = 7.4 Hz, 2H, CH2), 2.06 (t, J = 7.4 Hz, 2H, biotin-
CH2), 1.99 (bs, 0.5H, Val-13CH), 1.87 (bs, 1H, ≡CH), 1.74 – 1.53 (m, 3H, CH2, biotin-CH2), 1.56 
– 1.39 (m, 3H, biotin-CH2), 1.38 – 1.19 (m, 2H, biotin-CH2), 1.09 (t, J = 5.3 Hz, Val-13CH3), 0.78 
(t, J = 5.2 Hz, Val-13CH3). 13C NMR (101 MHz, DMSO-d6): δ 175.85, 175.71, 172.15, 171.71, 
168.79 (d, J = 52.1 Hz), 162.76, 150.57, 89.14, 80.50, 73.29, 69.81, 69.74, 69.59, 69.19, 69.11, 




34.7 Hz), 28.91, 28.23, 28.12, 28.07, 27.56, 25.30, 23.45, 18.67 (d, J = 34.8 Hz), 17.82 (d, J = 35.1 
Hz). ESI-HRMS (m/z): [M+Na]+ calc’d for C3413C5H62N715NO11S: 879.4295, found: 879.4297. 
 
7.9.3. Cell Culture.  
 The parental HEK-293T and HepG2 cell lines were obtained from American Type Culture 
Collection (Manassas, VA). Both cell lines were cultured in DMEM supplemented with high 
glucose, GlutaMAX, 10% fetal bovine serum (PBS), and 1x penicillin–streptomycin (P/S) 
(complete DMEM). HepG2 cells were maintained on plates coated with 0.1% (w/v) collagen 
(C8919, Sigma-Aldrich).  
 
7.9.4. Chemoenzymatic Labeling and Enrichment of O-GlcNAcylated Proteins from 293T Cells. 
 Protein lysate (5 mg) was diluted with 1% SDS, 20 mM HEPES pH 7.6 to 2.5 mg/mL. 
Samples were reduced using 10 mM TCEP-HCl pH 7.6 for 10 min at RT and alkylated with 30 
mM iodoacetamide for 30 min at RT protected from light. Four volumes (~10 mL) of -20 °C 
acetone was added, and the sample was vortexed and incubated at -20 °C for 2 h. The precipitated 
protein was pelleted by centrifugation at 5,000 x g for 10 min at 4 °C. Acetone was removed, and 
the pellet was allowed to air dry. Dried protein was then redissolved at 5 mg/mL with 1 mL of 1% 
SDS, 20 mM HEPES pH 7.9 using probe sonication. Samples were then diluted with 2 mL of 2.5x 
GalT labeling buffer (50 mM HEPES pH 7.9, 125 mM NaCl, 5% IGEPAL CA-630), 1.2 mL of 
ddH2O, and 275 μL of 100 mM MnCl2. The mixture was chilled on ice for 5 min, and then 250 
μL of 0.1 mM UDP-GalNAz, 250 μL of 2 mg/mL Y289L GalT, and 25 μL of 500 kU/mL PNGase 
F (New England Biolabs) were added with gentle mixing after each addition. Sample was rotated 




was added to the sample with incubation for 3 h at 37 °C. Samples were then acetone precipitated 
as described above. The protein pellet was redissolved at 5 mg/mL in 1 mL of 1% SDS, 20 mM 
HEPES pH 7.6. The solution was diluted with 2.85 mL of ddH2O and 0.15 mL of 200 mM HEPES 
pH 7.6. In a separate tube, a 5x CuAAC mix was prepared by sequential addition of 785 μL of 
ddH2O, 10 μL of 50 mM biotin-Dmpt-Val0/6-alkyne in DMSO, 5 μL of 100 mM BTTAA (Click 
Chemistry Tools, Scottsdale, AZ) in DMSO, 100 μL of 50 mM CuSO4 (freshly prepared), and 
100 μL of 100 mM sodium ascorbate (freshly prepared). The 5x mix was then added directly to 
the protein sample and mixed end-over-end for 1 h at RT followed by acetone precipitation. The 
protein, mixed in equal (w/w) proportions as described in the next was resuspended at 5 mg/mL in 
2 mL of 5% sodium deoxycholate, 50 mM HEPES pH 7.6, 10 mM EDTA to chelate residual Cu2+ 
and diluted with 8 mL of 50 mM HEPES pH 7.6. Then, 20 μL of 1 M CaCl2 and 200 μg Pierce 
trypsin protease (1:50 w/w) was added, and the sample was rotated end-over-end overnight at 37 
°C. Two 15-mL 10 kDa MWCO Amicon concentrator tubes were rinsed with 2 x 5 mL of 50% 
MeOH and 2 x 5 mL of ddH2O by centrifugation at 4,000 x g for 5 min. Tryptic solutions were 
then centrifuged in the rinsed concentrator tubes at 4,000 x g for 20 min. The remaining residue 
was rinsed 2 x 2.5 mL of H2O by centrifugation, and the flowthrough fractions were combined. 
The sample was diluted two-fold with ddH2O. In a separate tube, 250 μL of a 50% slurry of high 
capacity Neutravidin agarose (ThermoFisher Scientific) was washed 2 x 5 min with 0.5 mL of 
50% MeOH and 2 x 5 min with 0.5 mL of ddH2O. The agarose resin was then added to the sample 
and rotated end-over-end for 1 h at RT. The resin was pelleted by centrifugation at 500 x g for 5 
min and then transferred to a 900 μL spin filter (ThermoFisher Scientific) pre-rinsed twice with 
50% MeOH and 50% ddH2O. Beads were washed 5 min each with the following solutions: 5 x 




50% MeOH, 2 x 0.5 mL of ddH2O. Captured peptides were eluted in twice with 0.5 mL of 2% v/v 
NH2OH with end-over-end rotation for 1 h at RT. Elution fractions were combined and 
concentrated to dryness with vacuum centrifugation. The eluted peptides were redissolved in 20 
μL of 0.2% formic acid and desalted with a C18 ZipTip pipette tip. 
 
7.9.5. Liver Lysate Preparation. 
 WT (C57BLKS/J, #000662) and db/db (BKS.Cg-Dock7m +/+ Leprdb/J, # 000642) mouse 
livers (n=4 each) harvested from 8 week old mice were ordered from The Jackson Laboratory (Bar 
Harbor, ME) and immediately transferred to LN2 upon receipt. A single lobe from each liver was 
used for analysis. Each lobe was first washed with ice cold PBS, pH 7.4 and rapidly lysed in 2% 
sodium deoxycholate (SDC) in 100 mM Triethylammonium bicarbonate buffer (TEAB) pH 8.5 
containing Roche cOmplete protease inhibitor cocktail and 0.1 mM TMG using a dounce 
homogenizer. The resulting lysate was then centrifuged at 21,130 x g to pellet debris and the oily 
supernatant removed before transferring to a new tube. Protein concentration was determined by 
BCA assay.  
 
7.9.6. Chemoenzymatic Labeling and Enrichment of O-GlcNAcylated Proteins from Mouse Livers.  
 Liver protein lysate (5 mg) was diluted to 2 mg/ml in 1% SDS in 20 mM HEPES before 
being subjected to chemoenzymatic labeling as described above, with the WT liver lysate being 






7.9.7. Preparation of Peptides for Quantitative Proteomics. 
 A 100 μg aliquot was removed from each liver lobe lysate prepared as described above and 
diluted to 0.5% SDC concentration in ice cold H2O containing protease inhibitors and 0.1 mg/ml 
TMG as described ablve. 0.25 U/μL of benzonase nuclease (Santa Cruz Biotechnology, Dallas, 
TX) was then added and the samples were left to rotate end-over-end for 30 minutes at 4 °C. 2 μg 
of Pierce MS Grade Trypsin Protease (ThermoFisher Scientific) (1:50 w/w enzyme:protein) was 
then added, and the samples were then left to digest for 20 hours at 37 °C. The following day, 
detergent was removed by acid precipitation (final concentration 5% formic acid) and phase 
transfer as previously described.31 Peptides were then dried by vacuum centrifugation, 
reconsitituted in 100 μL of 100 mM TEAB and labeled with the TMT10plex Isobaric Labeling Kit 
(ThermoFisher Scientific) per the manufacturer’s instructions. After labeling, peptides from all 
groups were combined and dried in a vacuum centrifuge.  
 
7.9.8. HpHRP Fractionation of Peptides. 
Both O-GlcNAcylated peptides (half of each sample was fractionated) and those for 
quantitative proteomics were reconstituted in 100 μL of 10 mM ammonium hydroxide and 
fractionated on an Agilent (Santa Clara, CA) 1200 series HPLC system. Peptides were separated 
at a flow rate of 200 nL/min on an XBridge BEH C18 2.1 x 100mm (5μm) column (Waters, 
Milford, MA). Buffer A consisted of 10 mM ammonium hydroxide and buffer B consisted of 90:10 
acetonitrile:10 mM ammonium hydroxide. The gradient was as follows: 1% Solvent B (4 min), 1-
30% B (50 min), 30-60% B (4 min), 60-70% B (2 min), and 70-90% B (5 min). 64 1 min fractions 
were collected into 96 deep-well plates. For quantitative proteomics fractions were concatenated 




Concatenated fractions were then acidified to 1% formic acid and 0.1% TFA and partially dried 
by vacuum centrifugation to remove acetonitrile. Fractions were then desalted using an Oasis HLB 
μElution plate (Waters Milford, MA) following the manufacturer’s instructions. Desalted samples 
were then partially dried by vacuum centrifugation to remove acetonitrile reconstituted to 10 μL 
in 0.1% formic acid for MS analysis. 
 
7.9.9. Microscale HpHRP Fractionation of O-GlcNAcylated Peptides.  
 For the second enrichment replicate, two of the liver pairs were subjected to microscale 
HpHPR fractionation using spin columns as previously described.14 Briefly, spin columns were 
prepared by adding Jupiter C18 slurry (5 μm, Phenomenex, Torrance, CA) to fritted spin columns 
(ThermoFisher Scientific). Peptides, reconstituted in 100 μL of 10 mM  ammonium hydroxide, 
were loaded onto the column, washed three times with 100 μL 10 mM ammonium hydroxide, and 
eluted with 7 fractions of 100 μL portions of 5%, 10%, 15%, 20%, 25%, 30%, and 90% acetonitrile 
in 100 mM NH4HCO3 pH 8.0. Each fraction was then dried by vacuum centrifugation and 
resuspended in 10 μL of 0.1% formic acid for MS analysis. 
 
7.9.10. MS Analysis for Protein Expression Profiling.  
 2 μL of each fraction was loaded onto a 360x100 μm precolumn prior (2cm Monitor C18, 
Waters) to separation on a 360x75μm column/tip (9cm BEH 1.7 μm, Waters) at 1μL/min at 600 
bar constant pressure for 15 μL. The column was heated to 60 °C. The peptides were separated 
with a 180 min gradient at a flow rate of 250 nL/min. Solvent A consisted of 99.9% water and 
0.1% formic acid and Solvent B consisted of 80% acetonitrile, 19.9% water, and 0.1% formic acid. 




95% B (2 min), and 95% B (18 min). Full spectra were acquired over m/z 350-1500 in the Orbitrap 
(70 K resolution at 200 m/z); automatic gain control (AGC) was set to accumulate 1,000,000 ions, 
with a maximum injection time of 100 ms. Data-dependent MS2 analysis was performed as 
described previously32 using a top 12 approach with HCD fragmentation with 32% normalized 
collision energy at 35 K resolution, an intensity threshold of 100,000 ions, a max injection time of 
120 ms, and an isolation window of 1.2 m/z. 
 
7.9.11. MS Analysis for O-GlcNAcomics Samples. 
 
7.9.11.1. Valine Linker Optimization Experiments.  
 Samples enriched using the biotin-Dmpt-Val0/6-alkyne linker were analyzed on a 
nanoflow LC system, EASY-nLC 1000 (ThermoFisher Scientific), coupled to an Orbitrap Fusion 
Tribrid mass spectrometer (ThermoFisher Scientific) equipped with a Nanospray Flex ion source. 
O-GlcNAcylated peptides enriched from each of the ratio pairs (2.5 mg total for each pair) were 
resuspended in 5 μL of 0.2% formic acid and 2 μL was directly loaded onto a PicoFrit column 
(New Objective, Woburn, MA) packed in house with ReproSil-Pur C18AQ 1.9 µm resin (120 Å 
pore size, Dr. Maisch, Ammerbuch, Germany). The 20 cm x 50 µm ID column was heated to 60 
°C. The peptides were separated with a 120-min gradient at a flow rate of 220 nL/min. The gradient 
was as follows: 2-6% Solvent B (7.5 min), 6-25% B (82.5 min), and 25-40% B (30 min) and to 
100% B (9 min). Solvent A and B were the same as described above. Full spectra were acquired 
over m/z 350-1800 in the Orbitrap (120 K resolution at 200 m/z); automatic gain control (AGC) 
was set to accumulate 50,000 ions, with a maximum injection time of 50 ms. Data-dependent MS2 




state of 3-8 and a minimum intensity of 25,000, with dynamic exclusion set to exclude features 
after 1 time for 15 seconds with a 10 ppm mass tolerance and exclude isotopes turned on using a 
top-speed approach (cycle time of 5 s). The HCD product ion triggered method decision tree 
method described in Chapter 6 was employed. Briefly, the normalized collision energy was 
optimized at 28% for high collision dissociation (HCD) fragmentation. The intensity threshold for 
fragmentation was set to 25,000. HCD fragmentation spectra was collected in Orbitrap operating 
at 30K resolution at 200 m/z separately for precursors 350 – 625 m/z and 625 – 1800 m/z.  The 
presence of the 300.1 m/z product ion was then used to trigger ETD (350 – 625 m/z) or EThcD 
(625 – 1800 m/z) using charge dependent ETD reaction times (with the instrument default 2τ time 
constant). AGC was set to 50,000 with a maximum injection time set at 500 ms and the spectra 
were acquired in the Orbitrap operating at 30K resolution. CD ETD reaction times were used. 
 
7.9.11.2. Mouse Liver Experiments. 
  Chemoenzymatically labeled and enriched samples were analyzed on a nanoflow LC 
system, EASY-nLC 1000 (ThermoFisher Scientific), coupled to an Orbitrap Fusion Lumos mass 
spectrometer equipped with a Nanospray Flex ion source. 4 μL of the unfractionated or 4 μL of 
each O-GlcANc peptide fraction was used for analysis. In both cases the samples were loaded onto 
a 360x75μm column/tip packed in house with ReproSil-Pur C18AQ 1.9 µm resin (120 Å pore size, 
Dr. Maisch, Ammerbuch, Germany) at 1μL/min at 600 bar constant pressure for 15 μL. The 
column was heated to 60 °C. The peptides were separated with a 135-min gradient at a flow rate 
of 300 nL/min. Solvent A consisted of 99.9% water and 0.1% formic acid and Solvent B consisted 
of 80% acetonitrile, 19.9% water, and 0.1% formic acid. The gradient was as follows: 2-32% 




were acquired over m/z 350-1800 in the Orbitrap (120 K resolution at 200 m/z); automatic gain 
control (AGC) was set to accumulate 50,000 ions, with a maximum injection time of 50 ms. Data-
dependent MS2 analysis was performed using a top-speed approach (cycle time of 5 s) as described 
above for HCD product ion triggered EThcD analyses. For the decision tree analyses, the HCD 
scans were performed separately for precursors 350 – 625 m/z and 625 – 1800 m/z.  The presence 
of the 300.1 m/z product ion was then used to trigger ETD (350 – 625 m/z) or EThcD (625 – 1800 
m/z) using CD ETD reaction times. 
 
7.9.12. Data Analysis. 
 
7.9.12.1. Quantitative Proteomics Data Analysis. 
Raw files were searched using MaxQuant version 1.6.14 against the mouse UniProt 
database downloaded on May 20, 2020 as well as a contaminant database (245 sequences). All 
fractions were searched together with the match between runs and dependent peptides option 
checked. MS2 reporter ion quantification was employed with TMT-labeled (Fig. 7.5) K and N-
termini were specified. A co-isolation threshold of 25% (maximum) was set for quantification. 
The enzyme digestion parameters were set to trypsin with up to three missed cleavages. N-terminal 
acetylation, methionine oxidations, and phosphorylation (STY) were included as variable 
modifications in the search. Carbamidomethylation of cysteine was specified as a fixed 
modification. A 1% false discovery rate threshold was specified at the peptide and protein level. 
All other parameters were left as specified in the default configuration. Ratios from proteins only 
identified by modified peptides were excluded. Protein expression ratios were then calculated as 





7.9.12.2. Quantitative O-GlcNAcomics Data Analysis. 
 All raw files were searched using MaxQuant version 1.6.1.0 against the mouse UniProt 
database downloaded on May 20, 2020. Two searches were performed. Unless otherwise 
mentioned, parameters were left at their default values. 
The first (quantification search) was performed with the enzyme digestion parameters were 
set to trypsin with 0 missed cleavages. No variable modifications were specified. 
Carbamidomethylation of cysteine was specified as a fixed modification. A 1% false discovery 
rate threshold was specified at the peptide and protein level. Standard type quantification with a 
multiplicity of 2 was selected with no light labels, and a +6 (15C5, 15N1) heavy label on the 
pyrrolysine. A maximum of 5 labeled amino acids was specified. The match between runs 
(including matching of unidentified features), dependent peptides, and re-quantify options were 
checked. Importantly, O-GlcNAcylated peptides should not be matched in this search, but rather 
isotope pairs are quantified and reported in the allPeptides file.  
The second search (site mapping search) was performed with the enzyme digestion 
parameters were set to trypsin with 3 missed cleavages. N-terminal acetylation, methionine 
oxidations, and Val0/6 labeled GlcNAc (+601.27076 and + 607.28456, respectively) were 
included as variable modifications in the search. Carbamidomethylation of cysteine was specified 
as a fixed modification. A 1% false discovery rate threshold was specified at the peptide and 
protein level with a minimum score and delta score threshold for modified peptides set to 25 and 




MS/MS scans were then registered between the two searches to match O-GlcNAcylated 
peptides identified in the first search to quantified isotope patterns identified in the second search 
as described in A7.5.1 and A7.5.3. 
 
7.9.12.3. General and Statistics. 
All data analysis was performed using the Python language (Python Software Foundation. 
Python Language Reference, version 3.7.3. Available at http://www.python.org) with all 
Anaconda packages installed (Anaconda Software Distribution, version 4.8.3. Available at 
https://anaconda.com). For the limma moderated t-test91 (package, limma v3.42.2the R language 
(R Development Core Team, version 3.6.1. Available at https://www.R-project.org) was employed 
using the rpy2 (Laurent Gautier, v2.9.4) python package. Multiple hypothesis testing correction 
was performed with either the Benjamini-Hochberg method. A p-value of less than 0.05 was 
considered significant. The PPI networks were constructed as outlined in A5.6.3. Code for all 
analyses and figures is in Appendix 7.5. 
 
7.9.13. Construction of OGA Mutants.  
 Myc-DDK-tagged OGA (NM_023799) was purchased from Origene (Rockville, MD). All 
point mutations were produced using the Q5 Site-Directed Mutagenesis Kit (NEB) according to 
the manufacturer’s protocols. All primers were designed with the NEBaseChanger software. The 
final plasmids were purified using ZymoPURE II Plasmid Kit (Zymo Research, Irvine, CA), 
sequenced (Laragen, Culver City, CA), and resolved by 1% agarose gel electrophoresis to ensure 
fidelity. Plasmids were transfected into HepG2 cells using (1 μg per well of a 12-well plate) 




7.9.14. Western Blotting. 
 Samples were diluted with 4x SDS-PAGE buffer (200 mM Tris-HCl pH 6.8, 400 mM DTT, 
8% SDS, 0.4% bromophenol blue, 40% glycerol), resolved on a NuPAGE 4-12% Bis-Tris protein 
gel (ThermoFisher Scientific), and transferred to Immobilion-FL PVDF membrane 
(MilliporeSigma, Burlington, MA). Blots were blocked for 1 h at RT with LiCor Odyssey Blocking 
Buffer (927-50003, LI-COR Biosciences, Lincoln NE) before probing overnight at 4 °C with 
FLAG (1:5000, F3165, Sigma-Aldrich) antibody. Blots were rinsed three times with TBST and 
then probed with the appropriate secondary antibodies in blocking buffer: anti-mouse AlexaFluor 
680 conjugate (A21057, ThermoFisher), or anti-mouse IgG DyLight 800 (A11357, 
ThermoFisher). Blots were washed 3 x 5 min with TBST and then imaged using an Odyssey 
Infrared Imaging System (LI-COR Biosciences). Images were processed using ImageStudio v5.2 
(LI-COR Biosciences).  
 
7.9.15. Chemoenzymatic Labeling with High MW PEG. 
 HepG2 cells expressing WT or mutant OGA were lysed in 2% SDS in HEPES pH 7.9 
containing Roche cOmplete protease inhibitor cocktail and 0.1 mM TMG. 150 μg of lysate from 
each condition was then subjected to chemoenzymatic labeling as previously described.34 Briefly, 
lysate containing 150 μg of protein was diluted to 200 μL in water, and proteins were precipitated 
by the addition of 3 volumes of methanol, 1 volume of chloroform, and 2.25 volumes of water 
followed by centrifugation at 21,130 x g for 5 minutes to reveal a disc-like protein pellet at the 
aqueous-organic interface. The aqueous layer was removed and pellet washed three times with 
2.25 volumes of methanol. Protein pellets were then resolubilized with 40 µL dissolution buffer 




labeling buffer (50 mM HEPES, 125 mM NaCl, 5% IGEPAL CA-630, pH 7.9) were added and 
the solution was vortexed gently before adding 10 µL Y289L GalT (1 mg/mL), and 10 µL of UDP-
GalNAz (0.5 mM in 10 mM HEPES, pH 7.9). The reaction was then left to rotate end-over-end at 
4 °C overnight. The following day, IAA was added to 12.5 mM final concentration to alkylate free 
cysteine residues, and the samples left to rotate end-over-end in the dark for 45 minutes. Proteins 
were then precipitated as before and redissolved in 180 μL of 1% SDS in TBS.35 20 μL of 10 mM 
DBCO-mPEG (A118, Click Chemistry Tools, Scottsdale, Arizona) was then added to the samples 
before vortexing briefly and incubating at 95 °C for 5 min. Proteins were then precipitated as 
described, except they were washed 5 times with 3 volumes of methanol. Pellets were then 
redissolved by boiling in 90 μL of 1 % SDS in TBS before analysis by WB as described above. 
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Appendix 7.1. O-GlcNAcylation Sites and Regions Identified in db/db and WT Mouse Livers. 
 





Site ID Constraints 
A0A087WNV1 1 (1 of 267,269,270,272) 
A0A087WNV1 1 260 
A0A087WNV1 1 262 
A0A087WNV1 1 327 
A0A087WNV1 1 251 
A0A087WNV1 1 319 
A0A087WP65 1 90 
A0A087WQ86 1 2161 
A0A087WQH5 1 579 
A0A087WQN7 1 1328 
A0A087WQN7 1 1332 
A0A087WRQ4 1 50 
A0A087WRU0 1 953 
A0A0A0MQ73 1 (1 of 2362,2366) 
A0A0A0MQ73 1 2359 
A0A0A0MQ98 1 1431 
A0A0A0MQ98 1 1492 
A0A0A0MQ98 1 2047 
A0A0A0MQB4 1 360 
A0A0A0MQJ4 1 (1 of 211,214,217,218,219) 
A0A0A0MQJ4 1 (1 of 165,166,168,170,171,172)&(1 of 172,174) 
A0A0A0MQJ4 1 163 
A0A0A0MQJ4 1 167 
A0A0A0MQJ4 1 204 
A0A0A0MQJ4 1 175 
A0A0A0MQJ4 1 159 
A0A0A6YVU8 1 (1 of 217,219) 
A0A0A6YVU8 1 213 
A0A0A6YVU8 1 220 
A0A0A6YVU8 1 221 
A0A0A6YVZ3 1 (1 of 130,131,133,134)&(1 of 129,130,131,133) 
A0A0A6YVZ3 1 (1 of 120,122,123,124,126) 
A0A0A6YWM5 1 600 
A0A0A6YXS8 1 65 




A0A0G2JDK2 1 290 
A0A0G2JDK2 1 291 
A0A0G2JDK2 1 71 
A0A0G2JDL6 1 75 
A0A0G2JDL6 1 76 
A0A0G2JDV2 1 663 
A0A0G2JEI9 1 85 
A0A0G2JF07 1 104 
A0A0G2JF07 1 108 
A0A0G2JFW6 1 (1 of 912,913) 
A0A0G2JFW6 1 359 
A0A0G2JFW6 1 525 
A0A0G2JFW6 1 334 
A0A0G2JFW6 1 533 
A0A0G2JFW6 1 409 
A0A0G2JFW6 1 346 
A0A0G2JFW6 1 540 
A0A0G2JFW6 1 927 
A0A0G2JGL7 1 (1 of 19,21) 
A0A0G2JGT1 1 (1 of 146,148,154,155,157) 
A0A0J9YU61 1 (1 of 440,441) 
A0A0J9YU61 1 706 
A0A0J9YU61 1 446 
A0A0J9YUF9 1 (1 of 145,148) 
A0A0J9YUF9 1 151 
A0A0J9YV30 1 116 
A0A0N4SUS4 1 1064 
A0A0N4SUV0 1 274 
A0A0N4SV80 1 1369 
A0A0N4SV80 1 1370 
A0A0R4J032 1 (1 of 275,278) 
A0A0R4J079 1 (1 of 317,318) 
A0A0R4J0D3 1 637 
A0A0R4J0I1 1 184 
A0A0R4J0I9 1 (1 of 726,732) 
A0A0R4J0I9 1 3784 
A0A0R4J0I9 1 4363 
A0A0R4J0I9 1 3788 
A0A0R4J0I9 1 4078 
A0A0R4J0I9 1 4367 
A0A0R4J0I9 1 2130 
A0A0R4J0I9 1 2617 
A0A0R4J0M5 1 201 
A0A0R4J0M9 1 1072 




A0A0R4J0X5 1 (1 of 90,92) 
A0A0R4J0X5 1 103 
A0A0R4J131 1 138 
A0A0R4J1H6 1 167 
A0A0R4J1T3 1 (1 of 547,551) 
A0A0R4J2B5 1 348 
A0A0U1RNH9 1 251 
A0A0U1RQB6 1 138 
A0A0U1RQB6 1 147 
A0A140LHQ8 1 (1 of 343,344) 
A0A140LHQ8 1 (1 of 327,328) 
A0A140LHQ8 1 337 
A0A140LHQ8 1 444 
A0A140LHQ8 1 181 
A0A140LHR4 1 120 
A0A140LHR4 1 116 
A0A140LIZ8 1 142 
A0A140T8T5 1 70 
A0A1B0GR76 1 (1 of 1435,1437) 
A0A1B0GR76 1 1204 
A0A1B0GR78 1 170 
A0A1B0GR78 1 172 
A0A1B0GR85 1 (1 of 1083,1084) 
A0A1B0GR85 1 1085 
A0A1B0GRB5 1 551 
A0A1B0GRJ0 1 1020 
A0A1B0GRV3 1 248 
A0A1B0GSG3 1 270 
A0A1B0GSN3 1 (1 of 20,21) 
A0A1B0GSY0 1 (1 of 525,526) 
A0A1B0GSY0 1 523 
A0A1B0GT43 1 108 
A0A1C7ZMY3 1 1071 
A0A1D5RLU0 1 (1 of 107,108) 
A0A1D5RML9 1 510 
A0A1I7Q4G8 1 (1 of 179,181) 
A0A1I7Q4G8 1 (1 of 182,184,185) 
A0A1I7Q4G8 1 (1 of 67,69) 
A0A1I7Q4G8 1 (1 of 61,62) 
A0A1I7Q4G8 1 328 
A0A1I7Q4G8 1 178 
A0A1I7Q4G8 1 206 
A0A1I7Q4G8 1 606 
A0A1L1SUN4 1 4 




A0A1L1SV73 1 (1 of 87,88) 
A0A1N9M4K1 1 285 
A0A1N9M4K1 1 357 
A0A1N9M4K1 1 286 
A0A1N9PTV1 1 246 
A0A1W2P7D7 1 152 
A0A1W2P7D7 1 153 
A0A1W2P7G2 1 103 
A0A1W2P7I2 1 (1 of 183,185) 
A0A1W2P7I2 1 128 
A0A1W2P7Q7 1 134 
A0A1Y7VJM4 1 123 
A0A1Y7VJM4 1 141 
A0A1Y7VK55 1 297 
A0A1Y7VLT3 1 82 
A0A1Y7VMI0 1 185 
A0A1Y7VMT6 1 (1 of 19,20) 
A0A1Y7VP49 1 79 
A0A2I3BPN6 1 486 
A0A2I3BQ92 1 67 
A0A2I3BQE0 1 (1 of 327,328,329,331,334) 
A0A2I3BQE1 1 143 
A0A2I3BRS9 1 23 
A0A2R8VHH9 1 203 
A0A2R8VHQ0 1 1000 
A0A2R8VHQ0 1 891 
A0A2R8VHW4 1 161 
A0A338P6J9 1 72 
A0A338P6J9 1 74 
A0A338P6J9 1 75 
A0A338P6J9 1 79 
A0A338P6J9 1 85 
A0A338P6K9 1 163 
A0A338P6K9 1 1067 
A0A338P6K9 1 45 
A0A338P6K9 1 303 
A0A338P6K9 1 63 
A0A338P771 2 (2 of 358,359,361,362,363) 
A0A3B2W7J8 1 785 
A0A3B2WBH9 1 (1 of 994,999) 
A0A3B2WBH9 1 451 
A0A3B2WCD8 1 96 
A0A3B2WCD8 1 145 
A0A3B2WCD8 1 192 




A0A3Q4L2X0 1 6 
A0A494B962 1 37 
A0A494B968 1 33 
A0A494B9T4 1 (1 of 36,37,42,43,46,47) 
A0A494BAF3 1 378 
A0A494BB11 1 262 
A0A571BEI2 1 487 
A0A571BFA7 1 (1 of 949,950,951,952,954) 
A0A5F8MPU2 1 668 
A0A5F8MPU2 1 805 
A0A5F8MPU2 1 807 
A0A5F8MPY2 1 64 
A0A5F8MPY2 1 74 
A0A5F8MPY2 1 79 
A0JNY3 1 296 
A0JNY3 1 301 
A2A5Y4 1 (1 of 822,823,824,825) 
A2A5Y4 1 832 
A2AC24 1 145 
A2AC24 1 140 
A2ADB1 1 (1 of 2486,2487,2489) 
A2ADB1 1 2496 
A2ADB1 1 2499 
A2ADB1 1 2504 
A2ADB1 1 2505 
A2ADB1 1 2762 
A2AEW0 1 (1 of 510,515,516,518,522) 
A2AFQ0 1 (1 of 2620,2633,2634,2636,2637,2641,2643,2644,2647,2650) 
A2AFQ0 1 3796 
A2AFQ0 1 2924 
A2AGG1 1 244 
A2AGJ9 1 55 
A2AH22 1 (1 of 441,442) 
A2AKB9 1 (1 of 356,357,358,361,362,363)&(1 of 354,355,356,357) 
A2AKB9 1 364 
A2AKB9 1 365 
A2AKI5 1 (1 of 829,835) 
A2AKJ2 1 33 
A2AKJ2 1 34 
A2AMY5 1 (1 of 657,658) 
A2AMY5 1 (1 of 1028,1030) 
A2AMY5 1 641 
A2AMY5 1 1001 
A2AMY5 1 1107 




A2AMY5 1 660 
A2AMY5 1 1019 
A2AP93 1 (1 of 378,382,383) 
A2APL5 1 206 
A2APT9 1 295 
A2AQE9 1 174 
A2AQE9 1 167 
A2AQW6 1 10 
A2ATI9 1 406 
A2ATI9 1 397 
A2ATI9 1 398 
A2ATI9 1 405 
A2ATR8 1 245 
A2AVJ7 1 111 
A2AVP4 1 (1 of 768,769) 
A2AVP4 1 895 
A2AVR3 1 82 
A2AWN8 1 225 
A2AWN8 1 223 
A2CEK6 1 170 
A2RSY1 1 539 
A2RSY1 1 534 
A6H619 1 1365 
A9C497 1 (1 of 170,173) 
B1AR09 1 (1 of 399,400,402,403,404,405)&(1 of 398,399) 
B1ARU1 1 1680 
B1ATR2 1 158 
B1ATR2 1 174 
B1ATR2 1 175 
B1AWT4 1 64 
B1AZ15 1 (1 of 819,824,826,827,830) 
B1AZ15 1 836 
B1AZ15 1 685 
B1AZ46 1 512 
B1AZA8 1 145 
B1B0C7 1 847 
B2RQE8 1 709 
B2RQG2 1 (1 of 1509,1511,1512,1513) 
B2RRC9 1 (1 of 1474,1476) 
B2RRC9 1 1309 
B2RUJ2 1 1068 
B2RUQ2 1 349 
B2RUQ2 1 367 
B2RXC8 1 462 




B7ZC18 1 691 
B7ZC23 1 (1 of 146,147) 
B7ZC23 1 140 
B7ZC94 1 (1 of 816,817,818,819,820,821)&(1 of 814,816,817) 
B7ZN55 1 (1 of 594,596) 
B7ZNH7 1 140 
B7ZNJ1 1 (1 of 435,436) 
B7ZNJ1 1 1000 
B7ZNJ1 1 524 
B7ZNJ1 1 1008 
B7ZNJ1 1 432 
B7ZNJ1 1 530 
B8JJB2 1 89 
B9EJX2 1 (1 of 831,833) 
B9EJX2 1 832 
C0HKG6 1 218 
C0HKG6 1 82 
D3YU17 1 430 
D3YUC9 1 2 
D3YUV1 1 542 
D3YUW8 1 (1 of 335,336) 
D3YUW8 1 (1 of 253,254) 
D3YUW8 1 149 
D3YUW8 1 263 
D3YVM4 1 169 
D3YVM4 1 172 
D3YWA4 1 75 
D3YXZ5 1 454 
D3YY42 1 19 
D3YYR9 1 65 
D3YYR9 1 55 
D3YYY8 1 252 
D3YZ00 1 272 
D3Z069 1 581 
D3Z0Y0 1 185 
D3Z0Y0 1 186 
D3Z216 1 456 
D3Z2E7 1 392 
D3Z2E7 1 434 
D3Z2L1 1 205 
D3Z2T4 1 (1 of 154,155,156) 
D3Z2T4 1 146 
D3Z3F1 1 (1 of 258,259) 
D3Z3F1 1 260 




D3Z3F1 1 190 
D3Z3F1 1 189 
D3Z3F8 1 474 
D3Z3F8 1 478 
D3Z3Q3 1 698 
D3Z3Q3 1 699 
D3Z3U7 1 328 
D3Z3U7 1 324 
D3Z5G4 1 195 
D3Z5G4 1 135 
D3Z5G4 1 136 
D3Z5G4 1 202 
D3Z5G4 1 148 
D3Z5G4 1 149 
D3Z5G4 1 157 
D3Z5I1 1 (1 of 467,468,469,477,483) 
D3Z5I1 1 (1 of 557,558,559,562,564) 
D3Z5I1 1 489 
D3Z5I1 1 487 
D3Z5I1 1 551 
D3Z5I1 1 567 
D3Z5I9 1 (1 of 739,740) 
D3Z5I9 1 738 
D3Z5X0 1 (1 of 41,42) 
D3Z656 1 1360 
D3Z656 1 1121 
D3Z656 1 1374 
D3Z665 1 175 
D3Z6W7 1 384 
D6RDD4 1 58 
D6REF0 1 65 
D6RGN2 1 60 
D6RGR1 1 115 
D6RGR1 1 91 
D6RHA2 1 (1 of 408,409) 
D6RHA2 1 413 
D6RJL6 1 40 
D6RJL6 1 17 
D6RJL6 1 22 
E0CXE3 1 673 
E0CY18 1 167 
E0CY18 1 150 
E0CY18 1 159 
E0CYH7 1 1055 




E0CYQ2 1 121 
E0CZ61 1 (1 of 38,39,44,49) 
E9PUF4 1 667 
E9PUM5 1 665 
E9PV38 1 478 
E9PV38 1 102 
E9PV69 1 126 
E9PV80 1 895 
E9PVA8 1 22 
E9PVC6 1 21 
E9PVC6 1 1015 
E9PWM3 1 595 
E9PWW2 1 208 
E9PWX8 1 1973 
E9PYK3 1 1750 
E9PYL2 1 (1 of 652,653) 
E9PYX7 1 561 
E9PZ00 1 210 
E9PZ00 1 330 
E9PZ00 1 454 
E9PZ00 1 79 
E9PZD2 1 384 
E9PZD2 1 373 
E9PZD2 1 406 
E9PZD2 1 439 
E9Q113 1 126 
E9Q150 1 608 
E9Q150 1 613 
E9Q1P8 1 (1 of 364,365,366,367) 
E9Q1S3 1 183 
E9Q284 1 (1 of 7,9) 
E9Q286 1 1564 
E9Q2M4 1 (1 of 442,443,444) 
E9Q2M5 1 624 
E9Q2T3 1 320 
E9Q3G8 1 (1 of 557,559,561,562,563)&(1 of 554,557,559,561) 
E9Q3G8 1 (1 of 1056,1057) 
E9Q3G8 1 (1 of 1048,1050,1053) 
E9Q3G8 1 705 
E9Q3G8 1 200 
E9Q3G8 1 1067 
E9Q3G8 1 1101 
E9Q3G8 1 1102 
E9Q3G8 1 1168 




E9Q3G8 1 1044 
E9Q3G8 1 1046 
E9Q3G8 1 569 
E9Q3G8 1 699 
E9Q3G8 1 925 
E9Q3G8 1 926 
E9Q3G8 1 927 
E9Q449 1 1346 
E9Q481 1 787 
E9Q4Q2 1 (1 of 331,332,333,337) 
E9Q4Q2 1 328 
E9Q5G1 1 (1 of 485,486) 
E9Q5Q0 1 (1 of 146,147,150,151,153,154,156) 
E9Q5Q0 1 (1 of 564,566) 
E9Q5Q0 1 561 
E9Q5Q0 1 563 
E9Q5Q0 1 567 
E9Q616 1 5376 
E9Q616 1 787 
E9Q616 1 5166 
E9Q638 1 (1 of 383,384,386) 
E9Q640 1 696 
E9Q6A7 1 1635 
E9Q6A7 1 1624 
E9Q6A7 1 1628 
E9Q6A7 1 1629 
E9Q6A7 1 1598 
E9Q6B8 1 287 
E9Q6E2 1 (1 of 345,346) 
E9Q6T8 1 697 
E9Q6T8 1 126 
E9Q6T8 1 127 
E9Q7B0 1 112 
E9Q7R8 1 14 
E9Q8A6 1 45 
E9Q8A6 1 43 
E9Q8A6 1 53 
E9Q8H9 1 (1 of 764,765) 
E9Q8H9 1 1024 
E9Q8H9 1 993 
E9Q8H9 1 1027 
E9Q8H9 1 1188 
E9Q8H9 1 735 
E9QA62 1 (1 of 213,214) 




E9QAF9 1 1666 
E9QAN9 1 451 
E9QAT4 1 (1 of 130,131,138) 
E9QAT4 1 68 
E9QAT4 1 69 
E9QAT4 1 70 
E9QAT4 1 60 
E9QAT4 1 127 
E9QJU8 1 345 
E9QJU8 1 334 
E9QKG6 1 (1 of 1421,1423) 
E9QKG6 1 1436 
E9QL13 1 280 
E9QL13 1 244 
E9QL13 1 254 
E9QLA5 1 (1 of 359,362,364,370,371,372,375,376,377,379,380) 
E9QLQ9 1 (1 of 2314,2315) 
E9QMU3 1 (1 of 452,453) 
E9QMU3 1 (1 of 456,457,463) 
E9QN70 1 1091 
E9QNG1 1 217 
F2Z4B7 1 426 
F6QJV5 1 90 
F6RDR0 1 70 
F6S4K9 1 103 
F6S5I0 1 (1 of 25,26,27,28,31,32,34,35,36,37,40) 
F6TS96 1 279 
F6UTU1 1 (1 of 93,94) 
F6V513 1 144 
F6V8M6 1 213 
F6V8M6 1 141 
F6V8M6 1 127 
F6VV02 1 36 
F6VV02 1 21 
F6W4D3 1 228 
F6WV21 1 (1 of 822,823,831,832,833,836,837,839) 
F6WV21 1 1173 
F6Y6L6 1 132 
F6YC79 1 (1 of 426,428,432) 
F6YIN5 1 (1 of 169,175,176,177) 
F6YIN5 1 163 
F6YIN5 1 164 
F6YT69 1 (1 of 82,85) 
F6YT69 1 79 




F6Z4B2 1 (1 of 932,934) 
F6Z4B2 1 (1 of 373,375) 
F6Z4B2 1 192 
F6Z4B2 1 615 
F6Z4B2 1 846 
F6Z4B2 1 568 
F6Z4B2 1 927 
F6Z9A1 1 77 
F6Z9A1 1 78 
F6Z9E6 1 212 
F6Z9T5 1 110 
F6ZBY9 1 321 
F7AYW2 1 (1 of 1037,1040) 
F7AYW2 1 1226 
F7AYW2 1 1045 
F7BXV7 1 6 
F7CDR2 1 (1 of 104,105,106) 
F7CDR2 1 101 
F7CIP8 1 (1 of 141,142) 
F7CIP8 1 32 
F7CIP8 1 137 
F7CIP8 1 108 
F7CIP8 1 105 
F7DE17 1 (1 of 588,590,594,597) 
F7DE17 1 (1 of 276,279,282,283,287,288,290) 
F7DE17 1 291 
F7DE17 1 133 
F7DE17 1 135 
F7DE17 1 586 
F7DE17 1 124 
F7DE17 1 125 
F8VPM9 1 (1 of 1790,1791) 
F8VPM9 1 1760 
F8VPM9 1 1706 
F8VPM9 1 1771 
F8VPM9 1 1711 
F8VPM9 1 2647 
F8VPM9 1 1694 
F8VPZ9 1 1225 
F8VQJ3 1 1201 
F8VQJ3 1 1223 
F8WHP5 1 (1 of 707,710,711,715) 
F8WHP5 1 697 
F8WI14 1 536 




F8WIE5 1 1569 
F8WIN6 1 48 
F8WIN6 1 250 
F8WIN6 1 246 
F8WJL9 1 (1 of 760,761) 
F8WJL9 1 (1 of 115,116,119) 
F8WJL9 1 121 
F8WJL9 1 751 
G3UWE3 1 602 
G3UWE3 1 431 
G3UXW9 1 (1 of 8,9,11,12,13,15,18) 
G3UXW9 1 518 
G3UY24 1 36 
G3UYL7 1 415 
G3UYV8 1 (1 of 46,47) 
G3UZP7 1 202 
G3UZP7 1 282 
G3X8Q1 1 2073 
G3X8R2 1 72 
G3X8R2 1 59 
G3X8T3 1 (1 of 344,346,347,350) 
G3X8T3 1 157 
G3X928 1 600 
G3X928 1 185 
G3X928 1 186 
G3X928 1 607 
G3X960 1 167 
G3X973 1 897 
G3X973 1 1538 
G3X973 1 1012 
G3X973 1 1532 
G3X973 1 2046 
G3X9D6 1 23 
G3X9K4 1 825 
G3X9T8 1 139 
G3X9Z4 1 181 
G5E8W7 1 208 
H3BIX4 1 81 
H3BK31 1 (1 of 224,226,227) 
H3BK31 1 232 
H3BK31 1 235 
H3BKD4 1 948 
H3BL34 1 296 
H3BL34 1 297 




H3BLE4 1 9 
H3BLE4 1 107 
H3BLE4 1 14 
H7BWY5 1 311 
H9KUY5 1 94 
H9KUY5 1 95 
H9KV01 1 1092 
H9KV01 1 262 
H9KV01 1 1614 
H9KV01 1 251 
H9KV01 1 250 
H9KV01 1 283 
H9KV01 1 1086 
I7HIP8 1 (1 of 417,418) 
I7HIP8 1 404 
I7HIP8 1 413 
I7HJQ9 1 658 
I7HJQ9 1 669 
J3QJX3 1 556 
J3QMX8 1 (1 of 393,396) 
J3QMX8 1 (1 of 380,381) 
J3QMX8 1 379 
J3QNY6 1 (1 of 782,784) 
J3QP71 1 (1 of 20,23,25) 
J3QP71 1 138 
J3QP71 1 28 
J3QPD5 1 4 
J3QPR1 1 81 
J3QPR1 1 26 
J3QPR1 1 23 
K4DI63 1 36 
K4DI63 1 6 
K4DI63 1 92 
M0QWZ1 1 992 
M0QWZ1 1 995 
O08553 1 512 
O08553 1 517 
O08750 1 275 
O09117 1 259 
O09159 1 369 
O35114 1 124 
O35114 1 47 
O35516 1 675 
O35516 1 175 




O35949 1 8 
O35949 1 4 
O55022 1 74 
O55042 1 72 
O55042 1 53 
O55042 1 54 
O55111 1 (1 of 1056,1059,1060,1063,1064,1069,1071,1072,1074) 
O70400 1 128 
O70400 1 248 
O70400 1 123 
O70400 1 135 
O88531 1 199 
O88569 1 199 
O88783 1 777 
O88783 1 1516 
O88783 1 973 
O88783 1 774 
O88904 1 (1 of 992,998,1001,1004,1008,1009) 
O88904 1 (1 of 158,159,160,161,163,164) 
O88904 1 853 
O88904 1 854 
O89017 1 95 
O89020 1 404 
O89103 1 279 
P01029 1 1388 
P01029 1 1326 
P01029 1 223 
P01902 1 199 
P04925 1 198 
P07361 1 106 
P07724 1 294 
P08046 1 117 
P08113 1 64 
P08113 1 42 
P08113 1 44 
P08113 1 219 
P08113 1 447 
P08228 1 99 
P08607 1 418 
P08607 1 224 
P08607 1 426 
P08607 1 71 
P09055 1 408 
P09055 1 521 




P0C7T6 1 (1 of 29,30,31,33,34,37) 
P0C7T6 1 40 
P0C7T6 1 22 
P0C7T6 1 23 
P0DOV2 1 (1 of 122,123,125) 
P0DOV2 1 137 
P0DOV2 1 130 
P10605 1 (1 of 231,233) 
P10605 1 39 
P11032 1 171 
P11438 1 (1 of 83,85) 
P11438 1 80 
P11679 1 489 
P11679 1 482 
P11881 1 2505 
P16301 1 43 
P16301 1 110 
P23953 1 81 
P24472 1 120 
P24668 1 83 
P26039 1 (1 of 2169,2170) 
P27773 1 91 
P28665 1 290 
P28665 1 995 
P28665 1 296 
P28665 1 1144 
P28665 1 1182 
P29341 1 485 
P29341 1 351 
P29788 1 (1 of 97,98) 
P29788 1 88 
P29788 1 243 
P33587 1 216 
P33587 1 292 
P35831 1 625 
P42128 1 (1 of 515,516) 
P42128 1 (1 of 535,538,541) 
P42128 1 663 
P42703 1 384 
P42703 1 674 
P42703 1 387 
P43883 1 (1 of 121,122) 
P43883 1 (1 of 101,102,107) 
P46978 1 546 




P48678 1 644 
P48678 1 613 
P49182 1 169 
P49182 1 404 
P54869 1 346 
P54869 1 348 
P56677 1 774 
P58252 1 404 
P58871 1 260 
P58929 1 404 
P62908 1 242 
P70274 1 193 
P70274 1 178 
P70324 1 (1 of 395,396) 
P70324 1 394 
P70670 1 240 
P70699 1 (1 of 915,919,925,928) 
P70699 1 (1 of 149,151,153) 
P70699 1 392 
P70699 1 142 
P70699 1 885 
P70699 1 469 
P70699 1 472 
P83741 1 (1 of 2376,2377) 
P83741 1 1860 
P83741 1 1930 
P83741 1 1836 
P83741 1 1843 
P83741 1 1844 
P83741 1 1845 
P83741 1 1945 
P83741 1 2365 
P97364 1 448 
P97370 1 199 
P97426 1 113 
Q00547 1 548 
Q00547 1 550 
Q01339 1 164 
Q01339 1 159 
Q01705 1 900 
Q02614 1 233 
Q02614 1 241 
Q02614 1 239 
Q03311 1 372 




Q05BG1 1 313 
Q06890 1 329 
Q06890 1 291 
Q07456 1 235 
Q07456 1 229 
Q07797 1 542 
Q07797 1 71 
Q07968 1 548 
Q07968 1 543 
Q14AX6 1 (1 of 1353,1354) 
Q14AX6 1 (1 of 588,589,590,592,593,595,597,604) 
Q14AX6 1 1359 
Q14BJ1 1 2 
Q14BJ1 1 4 
Q14BJ1 1 6 
Q3LFS7 1 72 
Q3TBU7 1 193 
Q3TC93 1 280 
Q3TCN2 1 514 
Q3TCN2 1 522 
Q3TIU4 1 27 
Q3TJI8 1 131 
Q3TN85 1 132 
Q3TVI8 1 453 
Q3TYD4 1 (1 of 498,499) 
Q3TZR9 1 444 
Q3U7T5 1 50 
Q3U7T5 1 55 
Q3U9N4 1 385 
Q3U9N4 1 278 
Q3UEQ1 1 184 
Q3UH06 1 (1 of 988,991,993,995) 
Q3UH06 1 1000 
Q3UH06 1 1001 
Q3UHJ0 1 360 
Q3UHJ0 1 354 
Q3UI14 1 438 
Q3UN10 1 (1 of 673,674,675)&(1 of 669,670,673) 
Q3UR03 1 22 
Q3UR91 1 664 
Q3UR91 1 85 
Q3UR91 1 589 
Q3USK2 1 382 
Q3UYJ1 1 124 




Q3UYJ1 1 212 
Q4G0F8 1 (1 of 875,876)&(1 of 875,878,880,881,882,884) 
Q4PZA2 1 632 
Q52KG4 1 262 
Q571K4 1 553 
Q571K4 1 385 
Q571K4 1 412 
Q58FA4 1 609 
Q59J78 1 148 
Q5DTZ3 1 245 
Q5DTZ3 1 207 
Q5F2E7 1 (1 of 381,382,383)&(1 of 383,384,385,386,389,391,393,394,395) 
Q5F2E7 1 369 
Q5F2E7 1 380 
Q5F2E7 1 373 
Q5QGU6 1 196 
Q5QGU6 1 198 
Q5RIM6 1 (1 of 1501,1503) 
Q5RIM6 1 (1 of 2,3,4) 
Q5RIM6 1 (1 of 1275,1278) 
Q5RIM6 1 2053 
Q5RIM6 1 1901 
Q5RIM6 1 14 
Q5RIM6 1 1874 
Q5RIM6 1 51 
Q5RIM6 1 1878 
Q5RIM6 1 1497 
Q5RIM6 1 1918 
Q5RJH6 1 578 
Q5RJH6 1 575 
Q5SFM8 1 546 
Q5SFM8 1 539 
Q5SQA7 1 34 
Q5SUH7 1 (1 of 258,259) 
Q5SUH7 1 320 
Q5SUH7 1 457 
Q5SUH7 1 299 
Q5SXC4 1 118 
Q5XJV5 1 (1 of 1650,1654) 
Q5XJV5 1 1646 
Q61001 1 928 
Q61001 1 2049 
Q61009 1 (1 of 332,333) 
Q61009 1 326 




Q61029 1 275 
Q61029 1 287 
Q61084 1 110 
Q61084 1 111 
Q61169 1 (1 of 499,502,503,505,509,511,512,513,514,515,517,521) 
Q61191 1 (1 of 1055,1058) 
Q61191 1 (1 of 583,586) 
Q61191 1 515 
Q61191 1 771 
Q61191 1 518 
Q61191 1 775 
Q61191 1 522 
Q61191 1 779 
Q61191 1 405 
Q61191 1 801 
Q61191 1 1061 
Q61191 1 1062 
Q61191 1 806 
Q61191 1 808 
Q61191 1 685 
Q61191 1 563 
Q61191 1 579 
Q61191 1 1220 
Q61191 1 1224 
Q61191 1 588 
Q61191 1 726 
Q61191 1 1495 
Q61191 1 1241 
Q61191 1 1497 
Q61191 1 858 
Q61191 1 603 
Q61191 1 861 
Q61191 1 1246 
Q61191 1 607 
Q61191 1 480 
Q61191 1 490 
Q61191 1 1139 
Q61191 1 1148 
Q61471 1 (1 of 171,172) 
Q61606 1 120 
Q61646 1 150 
Q61827 1 (1 of 133,134,135,138) 
Q61827 1 153 
Q62009 1 603 




Q62261 1 2322 
Q62261 1 2323 
Q62261 1 2316 
Q62311 1 (1 of 589,590,594,595,600,602) 
Q62311 1 481 
Q62311 1 586 
Q62313 1 112 
Q62419 1 284 
Q63880 1 313 
Q63886 1 91 
Q64511 1 1200 
Q68FG2 1 2354 
Q68FG2 1 2364 
Q68FG2 1 2101 
Q68FG2 1 2359 
Q69ZA1 1 1286 
Q69ZS0 1 840 
Q6A058 1 366 
Q6A0A2 1 632 
Q6A0A2 1 51 
Q6A0A9 1 504 
Q6DFZ1 1 1858 
Q6DFZ1 1 1781 
Q6DID3 1 819 
Q6KCD5 1 (1 of 1018,1020,1021) 
Q6KCD5 1 (1 of 1678,1679) 
Q6KCD5 1 1024 
Q6KCD5 1 161 
Q6P5E4 1 266 
Q6P5E4 1 271 
Q6P6J9 1 138 
Q6P6J9 1 150 
Q6PAL7 1 (1 of 800,801) 
Q6PAL7 1 1080 
Q6PAL7 1 1593 
Q6PAL7 1 1574 
Q6PD26 1 372 
Q6PDI5 1 (1 of 1669,1670) 
Q6PIJ4 1 (1 of 1076,1077) 
Q6PIJ4 1 (1 of 1138,1143,1146,1147,1148) 
Q6PIJ4 1 1027 
Q6PIJ4 1 838 
Q6PIJ4 1 1031 
Q6PIJ4 1 1064 




Q6PIJ4 1 1270 
Q6PIJ4 1 1151 
Q6XBJ3 1 (1 of 492,495,496,497,498,499,500,501,503) 
Q6XLQ8 1 136 
Q6XLQ8 1 133 
Q78PY7 1 909 
Q78T81 1 (1 of 186,187,188,190) 
Q78T81 1 180 
Q7M6Z4 1 248 
Q7M6Z4 1 252 
Q7M6Z4 1 254 
Q7M739 1 1672 
Q7M739 1 2055 
Q7TN29 1 197 
Q7TPN9 1 319 
Q7TT18 1 1032 
Q7TT50 1 (1 of 968,969,970) 
Q80U72 1 948 
Q80U78 1 (1 of 212,214,220,227,228,229,233) 
Q80U78 1 800 
Q80U93 1 (1 of 1357,1358) 
Q80U93 1 (1 of 645,646) 
Q80U93 1 513 
Q80U93 1 1314 
Q80U93 1 1316 
Q80U93 1 1317 
Q80U93 1 1574 
Q80U93 1 635 
Q80U93 1 652 
Q80U93 1 1362 
Q80U93 1 1204 
Q80U93 1 1557 
Q80U93 1 1109 
Q80U93 1 504 
Q80U93 1 1337 
Q80U93 1 506 
Q80U93 1 507 
Q80UF7 1 314 
Q80VP1 1 416 
Q80X50 1 480 
Q80X50 1 803 
Q80X50 1 879 
Q80X50 1 1009 
Q80X50 1 799 




Q80X81 1 12 
Q80YR4 1 564 
Q80YX8 1 65 
Q8BFR4 1 272 
Q8BFR4 1 270 
Q8BFW7 1 312 
Q8BFW7 1 11 
Q8BFW7 1 212 
Q8BG19 1 499 
Q8BGD9 1 (1 of 497,498,500,504,506,507) 
Q8BGD9 1 352 
Q8BGD9 1 355 
Q8BGD9 1 495 
Q8BGQ4 1 655 
Q8BGS1 1 (1 of 385,386,387,398) 
Q8BH35 1 45 
Q8BH80 1 144 
Q8BHE4 1 161 
Q8BHE4 1 162 
Q8BHL3 1 (1 of 44,46,47) 
Q8BHL3 1 43 
Q8BI72 1 (1 of 304,305,306) 
Q8BI72 1 326 
Q8BI72 1 199 
Q8BI72 1 328 
Q8BI72 1 395 
Q8BI72 1 315 
Q8BI72 1 187 
Q8BI72 1 317 
Q8BI84 1 1729 
Q8BI84 1 250 
Q8BI84 1 633 
Q8BI84 1 1754 
Q8BI84 1 253 
Q8BJ05 1 (1 of 369,370,373) 
Q8BJ05 1 132 
Q8BJ05 1 134 
Q8BJ05 1 360 
Q8BJ05 1 78 
Q8BJ05 1 251 
Q8BJ05 1 255 
Q8BJ71 1 52 
Q8BJ71 1 55 
Q8BJS4 1 (1 of 651,652,654,655) 




Q8BKI2 1 (1 of 1158,1159,1161) 
Q8BMB0 1 (1 of 1072,1073) 
Q8BMB0 1 (1 of 500,502,505) 
Q8BMB0 1 192 
Q8BMB0 1 200 
Q8BMB0 1 521 
Q8BMB0 1 1069 
Q8BMB0 1 499 
Q8BNV8 1 148 
Q8BP97 1 382 
Q8BS54 1 291 
Q8BTI8 1 (1 of 2199,2200) 
Q8BTI8 1 2245 
Q8BTI8 1 2341 
Q8BTI8 1 2122 
Q8BTI8 1 2123 
Q8BTI8 1 2188 
Q8BTI8 1 2414 
Q8BTI8 1 2205 
Q8BTJ4 1 281 
Q8BTJ4 1 261 
Q8BU25 1 267 
Q8BUN3 1 365 
Q8BUN3 1 366 
Q8BWS5 1 318 
Q8BX02 1 346 
Q8BX02 1 421 
Q8BYB9 1 205 
Q8BYK6 1 201 
Q8BYK6 1 205 
Q8BYK6 1 167 
Q8BYU6 1 320 
Q8BZX4 1 489 
Q8C0C0 1 265 
Q8C0C0 1 166 
Q8C0C0 1 150 
Q8C0C3 1 236 
Q8C0I4 1 751 
Q8C0Q2 1 733 
Q8C0Q2 1 730 
Q8C0Q2 1 236 
Q8C0Q2 1 581 
Q8C129 1 144 
Q8C180 1 (1 of 327,328) 




Q8C180 1 326 
Q8C341 1 531 
Q8C341 1 527 
Q8C5R2 1 390 
Q8C7E7 1 160 
Q8C8Z9 1 (1 of 601,605) 
Q8C8Z9 1 608 
Q8CBB6 1 113 
Q8CBB6 1 116 
Q8CCH2 1 208 
Q8CEC2 1 552 
Q8CF89 1 393 
Q8CFE4 1 640 
Q8CFE4 1 741 
Q8CFE4 1 630 
Q8CG48 1 867 
Q8CGM2 1 (1 of 3,4) 
Q8CGN4 1 588 
Q8CHH5 1 590 
Q8CHI8 1 2624 
Q8CHI8 1 2940 
Q8CHI8 1 709 
Q8CHS8 1 174 
Q8CI51 1 120 
Q8CI51 1 90 
Q8CI51 1 115 
Q8CI51 1 110 
Q8JZZ0 1 54 
Q8K099 1 (1 of 604,605,608) 
Q8K0D5 1 76 
Q8K0E8 1 378 
Q8K0L9 1 (1 of 303,304) 
Q8K0L9 1 480 
Q8K0L9 1 449 
Q8K0L9 1 451 
Q8K0L9 1 485 
Q8K0L9 1 263 
Q8K0L9 1 268 
Q8K0L9 1 16 
Q8K0L9 1 436 
Q8K0L9 1 309 
Q8K0L9 1 439 
Q8K0L9 1 444 
Q8K0L9 1 447 




Q8K2Q9 1 502 
Q8K3X4 1 204 
Q8K3Z9 1 664 
Q8K3Z9 1 665 
Q8K3Z9 1 653 
Q8QZR3 1 272 
Q8QZR3 1 277 
Q8R066 1 182 
Q8R080 1 (1 of 267,268) 
Q8R084 1 98 
Q8R0F3 1 140 
Q8R121 1 280 
Q8R242 1 285 
Q8R3E3 1 395 
Q8R3E3 1 391 
Q8R4R6 1 (1 of 296,297) 
Q8R4R6 1 55 
Q8R4R6 1 316 
Q8R4R6 1 53 
Q8R4R6 1 295 
Q8R4U0 1 1512 
Q8R4U0 1 910 
Q8VBZ3 1 297 
Q8VC97 1 392 
Q8VCF0 1 (1 of 309,310) 
Q8VCF0 1 298 
Q8VCF0 1 330 
Q8VCF0 1 370 
Q8VCF0 1 373 
Q8VCF0 1 374 
Q8VCF0 1 343 
Q8VCF0 1 314 
Q8VCF0 1 315 
Q8VCF0 1 319 
Q8VCI0 1 529 
Q8VCI0 1 450 
Q8VCI0 1 446 
Q8VCU1 1 313 
Q8VDZ4 1 386 
Q8VHR5 1 (1 of 587,589,591) 
Q8VHR5 1 (1 of 288,289,290) 
Q8VHR5 1 (1 of 487,489,490) 
Q8VHR5 1 585 
Q8VHR5 1 498 




Q8VHR5 1 495 
Q91WH2 1 (1 of 309,312,315) 
Q91WK2 1 14 
Q91WU0 1 81 
Q91X84 1 (1 of 320,322,326,327) 
Q91X84 1 321 
Q91XL1 1 316 
Q91XT4 1 (1 of 64,66) 
Q91XT4 1 68 
Q91XT4 1 78 
Q91YQ5 1 (1 of 386,391) 
Q91YQ5 1 302 
Q91YT7 1 202 
Q91YZ8 1 615 
Q921I1 1 514 
Q921I1 1 515 
Q921L6 1 308 
Q922U1 1 176 
Q99LI5 1 (1 of 861,862,864,867,870,874,877,881,882) 
Q99LI5 1 889 
Q99LI5 1 886 
Q99LI5 1 775 
Q99MZ3 1 618 
Q9CQW1 1 172 
Q9CR23 1 40 
Q9CS74 1 640 
Q9CWK8 1 (1 of 104,106,107) 
Q9CX80 1 184 
Q9CYA0 1 190 
Q9D0J8 1 5 
Q9D136 1 212 
Q9D136 1 262 
Q9D1M0 1 313 
Q9D1M0 1 315 
Q9D787 1 501 
Q9D7N9 1 (1 of 203,205) 
Q9D7N9 1 161 
Q9D8C4 1 (1 of 269,273,282,283,285,286) 
Q9D8N1 1 145 
Q9D9M9 1 78 
Q9DAC2 1 120 
Q9DAC2 1 141 
Q9DAC2 1 126 
Q9DB77 1 (1 of 441) 




Q9DBG5 1 128 
Q9DBG5 1 58 
Q9DBG5 1 76 
Q9DBG5 1 71 
Q9DBG6 1 105 
Q9DBG6 1 108 
Q9DBG6 1 103 
Q9DBJ3 1 251 
Q9DBR7 1 (1 of 645,646,647,648,650,651,652,653,656,658) 
Q9DBR7 1 637 
Q9DBS5 1 (1 of 609,611,612,616) 
Q9EP52 1 82 
Q9EPU0 1 951 
Q9EQQ9 1 405 
Q9ER39 1 161 
Q9ERG0 1 (1 of 324,325,326,329,334,341,344) 
Q9ERG0 1 279 
Q9ERU9 1 (1 of 2317,2320,2328,2329,2330) 
Q9ERU9 1 2339 
Q9ERU9 1 1457 
Q9ERU9 1 1138 
Q9ERU9 1 1592 
Q9ERU9 1 1599 
Q9ERZ6 1 396 
Q9ESC8 1 85 
Q9ESY9 1 107 
Q9ET43 1 241 
Q9JHP7 1 154 
Q9JI95 1 21 
Q9JKR6 1 (1 of 607,612) 
Q9JKR6 1 513 
Q9JKR6 1 933 
Q9JKR6 1 598 
Q9JKR6 1 871 
Q9JL60 1 442 
Q9JLV1 1 (1 of 380,382,386,390) 
Q9JLV1 1 320 
Q9JLV1 1 145 
Q9JLV1 1 177 
Q9JLV1 1 179 
Q9JLV1 1 372 
Q9JLV1 1 183 
Q9JLV1 1 188 
Q9QWV9 1 474 




Q9QYC7 1 629 
Q9QYE6 1 158 
Q9QYG0 1 (1 of 330,332) 
Q9QYG0 1 353 
Q9QYG0 1 370 
Q9QYG0 1 334 
Q9QYG0 1 335 
Q9QZN4 1 266 
Q9QZN4 1 261 
Q9QZS5 1 332 
Q9R013 1 358 
Q9R1E0 1 645 
Q9WU60 1 1084 
Q9WU60 1 413 
Q9WUD0 1 141 
Q9WUM3 1 421 
Q9WUU7 1 188 
Q9WUU7 1 183 
Q9WV54 1 259 
Q9WV69 1 18 
Q9WV69 1 285 
Q9WV69 1 110 
Q9WVF5 1 (1 of 525,530) 
Q9WVF5 1 350 
Q9WVJ3 1 396 
Q9Z0F7 1 27 
Q9Z0K8 1 134 
Q9Z103 1 412 
Q9Z2D6 1 (1 of 440,441) 
Q9Z2D6 1 434 
Q9Z329 1 2458 
S4R1I7 1 64 
S4R294 1 (1 of 2138,2140,2143,2144) 
S4R294 1 (1 of 2632,2633) 
S4R294 1 (1 of 2282,2283) 
S4R294 1 2148 
S4R294 1 1929 
S4R294 1 2284 
S4R294 1 1933 
S4R294 1 2637 
S4R294 1 2127 
S4R294 1 2285 
S4R294 1 209 
S4R294 1 882 




S4R294 1 2645 
S4R294 1 374 
S4R294 1 2101 
S4R294 1 2649 
S4R294 1 1918 
S4R2A9 1 495 
S4R2A9 1 499 
S4R2A9 1 500 
S4R2A9 1 542 
S4R2A9 1 927 
V9GX34 1 432 
V9GX34 1 439 
V9GXT3 1 (1 of 1391,1392,1394,1396,1399,1400,1404) 
V9GXT3 1 2186 
V9GXT3 1 1054 
V9GXT3 1 2183 
Z4YL55 1 208 
Z4YL55 1 205 






A7.1.2. GlcNAc Sites Identified with the Val6 Tag in db/db Mouse Livers. 
 
Protein Min Sites Site ID Constraints 
A0A087WNV1 1 (1 of 319,325) 
A0A087WNV1 1 251 
A0A087WNV1 1 260 
A0A087WNV1 1 262 
A0A087WNV1 1 327 
A0A087WP65 1 90 
A0A087WQ86 2 (2 of 153,154,155) 
A0A087WQH5 1 579 
A0A087WQN7 1 1664 
A0A087WQN7 1 1332 
A0A087WRU0 1 953 
A0A0A0MQ73 1 (1 of 2362,2366) 
A0A0A0MQ73 1 2359 
A0A0A0MQ98 1 (1 of 1489,1490) 
A0A0A0MQ98 1 1431 
A0A0A0MQ98 1 1492 
A0A0A0MQ98 1 2047 
A0A0A0MQJ4 1 (1 of 211,214,217,218,219) 
A0A0A0MQJ4 1 (1 of 166,167,168) 
A0A0A0MQJ4 1 (1 of 170,171) 
A0A0A0MQJ4 1 163 
A0A0A0MQJ4 1 165 
A0A0A0MQJ4 1 204 
A0A0A0MQJ4 1 175 
A0A0A0MQJ4 1 159 
A0A0A6YVU8 1 211 
A0A0A6YVU8 1 213 
A0A0A6YVU8 1 217 
A0A0A6YVU8 1 219 
A0A0A6YVU8 1 220 
A0A0A6YVU8 1 221 
A0A0A6YXS8 1 65 
A0A0A6YXS8 1 10 
A0A0B4J1G5 1 (1 of 285,286,287) 
A0A0G2JDK2 1 290 
A0A0G2JDK2 1 71 
A0A0G2JDL6 1 75 
A0A0G2JDL6 1 76 




A0A0G2JDV2 1 575 
A0A0G2JF07 1 104 
A0A0G2JF07 1 108 
A0A0G2JFD6 1 4 
A0A0G2JFW6 1 (1 of 1003,1004)&(1 of 1004,1005) 
A0A0G2JFW6 1 359 
A0A0G2JFW6 1 334 
A0A0G2JFW6 1 532 
A0A0G2JFW6 1 533 
A0A0G2JFW6 1 409 
A0A0G2JFW6 1 346 
A0A0G2JGT1 1 (1 of 146,148,154,155,157) 
A0A0J9YU61 1 446 
A0A0N4SUV0 1 274 
A0A0N4SV80 1 1370 
A0A0R4IZZ5 1 210 
A0A0R4J079 1 318 
A0A0R4J0D3 1 637 
A0A0R4J0H0 1 786 
A0A0R4J0I1 1 184 
A0A0R4J0I9 1 (1 of 2617,2622,2623) 
A0A0R4J0I9 1 3784 
A0A0R4J0I9 1 4363 
A0A0R4J0I9 1 3788 
A0A0R4J0I9 1 4078 
A0A0R4J0I9 1 2130 
A0A0R4J0I9 1 2132 
A0A0R4J0I9 1 726 
A0A0R4J0M9 1 1072 
A0A0R4J0M9 1 1075 
A0A0R4J0M9 1 1076 
A0A0R4J0X5 1 (1 of 90,92) 
A0A0R4J0X5 1 103 
A0A0R4J131 1 138 
A0A0R4J187 1 319 
A0A0R4J1H6 1 167 
A0A0R4J2B5 1 348 
A0A0U1RNM3 1 (1 of 107,113,114) 
A0A0U1RQB6 1 138 
A0A0U1RQB6 1 147 
A0A0U1RQB6 1 143 
A0A140LHQ8 1 (1 of 340,341,343,344) 
A0A140LHQ8 1 337 
A0A140LHQ8 1 442 




A0A140LHQ8 1 327 
A0A140LHR4 1 120 
A0A140T8T5 1 70 
A0A1B0GR78 1 170 
A0A1B0GR78 1 172 
A0A1B0GR85 1 (1 of 1083,1084) 
A0A1B0GR85 1 1085 
A0A1B0GRB5 1 551 
A0A1B0GRJ0 1 1020 
A0A1B0GRV3 1 248 
A0A1B0GS41 1 (1 of 365,367) 
A0A1B0GSG3 1 (1 of 269,270) 
A0A1B0GSY0 1 523 
A0A1B0GSY0 1 525 
A0A1B0GT43 1 108 
A0A1C7ZMY3 1 1065 
A0A1C7ZMY3 1 1071 
A0A1D5RLU0 1 (1 of 107,108) 
A0A1I7Q4G8 1 (1 of 61,62,67,69) 
A0A1I7Q4G8 1 328 
A0A1I7Q4G8 1 315 
A0A1I7Q4G8 1 206 
A0A1I7Q4G8 1 606 
A0A1L1SQN1 1 (1 of 196,197,199,200,201,207,208,210) 
A0A1L1SRY4 1 312 
A0A1L1SUR6 1 531 
A0A1N9M4K1 1 285 
A0A1N9M4K1 1 357 
A0A1N9M4K1 1 286 
A0A1N9PTV1 1 246 
A0A1W2P7C1 1 611 
A0A1W2P7D7 1 153 
A0A1W2P7G2 1 103 
A0A1W2P7I2 1 (1 of 183,185) 
A0A1W2P7Q7 1 134 
A0A1Y7VJM4 1 123 
A0A1Y7VK55 1 297 
A0A1Y7VMB1 1 7 
A0A1Y7VMT6 1 (1 of 19,20) 
A0A1Y7VP49 1 79 
A0A286YCQ0 1 (1 of 269,271) 
A0A2I3BPM1 1 64 
A0A2I3BPN6 1 (1 of 490,491) 
A0A2I3BPN6 1 486 




A0A2I3BQ92 1 67 
A0A2I3BQE0 1 328 
A0A2I3BQE1 1 143 
A0A2R8VHH9 1 203 
A0A2R8VHQ0 1 1000 
A0A2R8VHQ0 1 891 
A0A2R8VHW4 1 161 
A0A2R8VKN7 1 102 
A0A2R8W6T9 1 (1 of 171,173,174,175,178) 
A0A338P6F2 1 13 
A0A338P6J9 1 72 
A0A338P6J9 1 74 
A0A338P6J9 1 85 
A0A338P6J9 1 79 
A0A338P6K9 1 (1 of 162,163) 
A0A338P6K9 1 45 
A0A338P6K9 1 303 
A0A338P7E6 1 83 
A0A3B2W7J8 1 786 
A0A3B2WBH9 1 (1 of 441,442) 
A0A3B2WBH9 1 451 
A0A3B2WBH9 1 999 
A0A3B2WCD8 1 (1 of 194,196,201) 
A0A3B2WCD8 1 96 
A0A3B2WCD8 1 145 
A0A3B2WCD8 1 192 
A0A494B962 1 37 
A0A494B968 1 (1 of 33,35,37,41) 
A0A494BAF3 1 378 
A0A494BB11 1 262 
A0A571BDN3 1 659 
A0A571BEC9 1 288 
A0A571BEC9 1 321 
A0A571BEC9 1 354 
A0A571BEC9 1 585 
A0A571BEC9 1 618 
A0A571BEC9 1 1230 
A0A571BEC9 1 181 
A0A571BEC9 1 214 
A0A571BEC9 1 189 
A0A571BEC9 1 222 
A0A571BEC9 1 255 
A0A571BEI2 1 487 
A0A571BFA7 1 950 




A0A5F8MPD8 1 (1 of 473,474,478,481) 
A0A5F8MPS7 1 169 
A0A5F8MPU2 1 805 
A0A5F8MPU2 1 807 
A0A5F8MPY2 1 64 
A0A5F8MPY2 1 74 
A0A5F8MPY2 1 86 
A0A5K1VVQ1 1 8907 
A0A5K1VVQ1 1 8149 
A0A5K1VVQ1 1 8150 
A0A5K1VVQ1 1 8911 
A0JNY3 1 296 
A0JNY3 1 300 
A0JNY3 1 301 
A0JNY3 1 286 
A1L358 1 642 
A2A5Y4 1 (1 of 822,823,824,825,827,828,829) 
A2A5Y4 1 832 
A2A953 1 (1 of 63,64) 
A2AC24 1 140 
A2ACM0 1 700 
A2ADB1 1 (1 of 2486,2487,2489) 
A2ADB1 1 2496 
A2ADB1 1 2499 
A2ADB1 1 2504 
A2ADB1 1 2505 
A2ADB1 1 2762 
A2ADS8 1 (1 of 335,338,341,351) 
A2AFQ0 1 (1 of 2923,2924) 
A2AFQ0 1 3796 
A2AGJ9 1 55 
A2AKB9 1 (1 of 354,355) 
A2AKB9 1 (1 of 356,357,358,361,362) 
A2AKB9 1 363 
A2AKB9 1 364 
A2AKB9 1 365 
A2AKI5 1 829 
A2AKJ2 1 34 
A2AMY5 1 (1 of 1028,1030) 
A2AMY5 1 (1 of 1000,1001) 
A2AMY5 1 641 
A2AMY5 1 1107 
A2AMY5 1 1019 
A2AMY5 1 468 




A2AP93 1 383 
A2APL5 1 206 
A2APT9 1 295 
A2AQE9 1 174 
A2AS44 1 226 
A2ATI9 1 397 
A2ATI9 1 406 
A2ATR8 1 240 
A2AVP4 1 (1 of 768,769) 
A2AWN8 1 225 
A2AWN8 1 223 
A2RSY1 1 534 
A6H619 1 551 
A7TU71 1 1093 
A8Y5E6 1 200 
B1AR09 1 (1 of 398,399) 
B1AR76 1 305 
B1AR76 1 314 
B1ARD8 1 772 
B1ARD8 1 774 
B1ARU1 1 1680 
B1ATR2 1 (1 of 159,160,161,164,165,167) 
B1ATR2 1 158 
B1ATR2 1 173 
B1ATR2 1 174 
B1ATR2 1 175 
B1AUF2 1 502 
B1AYL1 1 853 
B1AYL1 1 855 
B1AZ15 1 (1 of 819,824,826,827,830) 
B1AZ15 1 836 
B1AZA8 1 145 
B1B0C7 1 847 
B2RQG2 1 (1 of 1509,1511,1512,1513) 
B2RQG2 1 1765 
B2RT14 1 116 
B2RUJ2 1 (1 of 1013,1018) 
B2RUJ2 1 1011 
B2RUJ2 1 1068 
B2RXC8 1 462 
B2RXS4 1 146 
B7ZC18 1 691 
B7ZC94 1 (1 of 811,813,814,816,817,818,819,820,821) 
B7ZCC2 1 179 




B7ZNH7 1 140 
B7ZNJ1 1 (1 of 435,436) 
B7ZNJ1 1 1000 
B7ZNJ1 1 524 
B7ZNJ1 1 1008 
B7ZNJ1 1 432 
B7ZNJ1 1 530 
B8JJB2 1 89 
C0HKG6 1 218 
D3YU17 1 430 
D3YUV1 1 542 
D3YUW8 1 149 
D3YUW8 1 254 
D3YVM4 1 169 
D3YWA4 1 72 
D3YWA4 1 75 
D3YXZ5 1 454 
D3YY42 1 (1 of 33,34,35,38) 
D3YY42 1 19 
D3YYR9 1 55 
D3YYY8 1 252 
D3Z069 1 459 
D3Z069 1 461 
D3Z0Y0 1 185 
D3Z216 1 456 
D3Z2E7 1 392 
D3Z2E7 1 434 
D3Z2L1 1 205 
D3Z3F1 1 (1 of 258,259,260,261,263,265,266,267,269) 
D3Z3F1 1 237 
D3Z3F1 1 190 
D3Z3F1 1 189 
D3Z3F8 1 474 
D3Z3F8 1 478 
D3Z3Q3 1 699 
D3Z3U7 1 328 
D3Z3U7 1 333 
D3Z4C0 1 387 
D3Z4Q7 1 54 
D3Z4U8 1 506 
D3Z5G4 1 195 
D3Z5G4 1 135 
D3Z5G4 1 202 
D3Z5G4 1 148 




D3Z5I1 1 (1 of 557,558,559,562,564) 
D3Z5I1 1 551 
D3Z5I1 1 567 
D3Z5I6 1 15 
D3Z5I9 1 (1 of 739,740) 
D3Z5I9 1 738 
D3Z656 1 1360 
D3Z656 1 1121 
D3Z656 1 1374 
D3Z665 1 (1 of 188,195,196) 
D3Z665 1 187 
D3Z6S3 1 112 
D3Z6S3 1 107 
D3Z6W7 1 384 
D3Z7R3 1 (1 of 92,93) 
D6RDD4 1 58 
D6RGR1 1 91 
D6RHA2 1 413 
D6RJL6 1 17 
E0CXE3 1 673 
E0CY18 1 167 
E0CY18 1 150 
E0CY18 1 159 
E0CYH7 1 (1 of 1045,1047,1049,1050,1051,1054) 
E0CYH7 1 1055 
E0CYN0 1 3 
E0CYN0 1 11 
E0CYN0 1 13 
E0CZ61 1 (1 of 44,49) 
E0CZ61 1 39 
E9PUF4 1 (1 of 665,666,667) 
E9PV38 1 (1 of 91,92) 
E9PV38 1 478 
E9PV38 1 102 
E9PV69 1 126 
E9PVA8 1 22 
E9PVC6 1 21 
E9PVC6 1 1015 
E9PWM3 1 595 
E9PWW2 1 208 
E9PWX8 1 1973 
E9PXN7 1 73 
E9PYK3 1 1212 
E9PYL2 1 (1 of 652,653) 




E9PYX7 1 (1 of 561,562) 
E9PZ00 1 210 
E9PZ00 1 330 
E9PZ00 1 454 
E9PZ00 1 79 
E9PZD2 1 384 
E9PZD2 1 373 
E9PZD2 1 406 
E9PZD2 1 439 
E9Q113 1 126 
E9Q150 1 608 
E9Q150 1 613 
E9Q1P8 1 (1 of 364,365,366,367) 
E9Q1S3 1 183 
E9Q2T3 1 320 
E9Q3G8 1 (1 of 1056,1057) 
E9Q3G8 1 (1 of 932,934,937) 
E9Q3G8 1 (1 of 1048,1050,1053) 
E9Q3G8 1 705 
E9Q3G8 1 1067 
E9Q3G8 1 1101 
E9Q3G8 1 1102 
E9Q3G8 1 561 
E9Q3G8 1 1044 
E9Q3G8 1 1046 
E9Q3G8 1 926 
E9Q3G8 1 927 
E9Q449 1 1346 
E9Q481 1 787 
E9Q4Q2 1 328 
E9Q5M6 1 1681 
E9Q5M6 1 1686 
E9Q5Q0 1 (1 of 146,147,150,151,153,154,156) 
E9Q5Q0 1 561 
E9Q5Q0 1 563 
E9Q5Q0 1 566 
E9Q5Q0 1 567 
E9Q616 1 5376 
E9Q640 1 696 
E9Q6A7 1 (1 of 1609,1611) 
E9Q6A7 1 1635 
E9Q6A7 1 1624 
E9Q6A7 1 1628 
E9Q6A7 1 1629 




E9Q6E2 1 346 
E9Q6R7 1 2210 
E9Q7B0 1 112 
E9Q7D5 1 496 
E9Q7D5 1 500 
E9Q7R8 1 14 
E9Q8A6 1 53 
E9Q8A6 1 43 
E9Q8A6 1 45 
E9Q8H9 1 735 
E9Q9Q7 1 108 
E9QAT4 1 (1 of 2010,2011) 
E9QAT4 1 68 
E9QAT4 1 69 
E9QAT4 1 70 
E9QAT4 1 422 
E9QAT4 1 60 
E9QAT4 1 127 
E9QAU4 1 1399 
E9QJU8 1 345 
E9QJU8 1 334 
E9QKG6 1 1436 
E9QKG6 1 1942 
E9QKT0 1 274 
E9QL13 1 280 
E9QL13 1 244 
E9QL13 1 254 
E9QLA5 1 (1 of 377,379,380) 
E9QLQ9 1 (1 of 2314,2315) 
E9QM14 1 276 
E9QMU3 1 (1 of 452,453,456,457,463) 
E9QN70 1 1091 
E9QNG1 1 217 
F2Z4B7 1 (1 of 195,197) 
F2Z4B7 1 190 
F6QJV5 1 90 
F6RDR0 1 70 
F6S4K9 1 103 
F6S5I0 1 26 
F6SSP6 1 463 
F6TS96 1 236 
F6TS96 1 279 
F6UVB2 1 23 
F6V513 1 144 




F6V8M6 1 (1 of 174,175,176,177) 
F6V8M6 1 123 
F6V8M6 1 141 
F6V8M6 1 134 
F6V8M6 1 127 
F6VV02 1 (1 of 31,32,36,37) 
F6VV02 1 21 
F6W4D3 1 228 
F6W6I1 1 64 
F6WV21 1 (1 of 822,823) 
F6XZS9 1 1074 
F6XZS9 1 197 
F6XZS9 1 189 
F6Y6L6 1 132 
F6Y6L6 1 127 
F6YC79 1 432 
F6YIN5 1 (1 of 175,176,177) 
F6YIN5 1 163 
F6YT69 1 82 
F6YT69 1 79 
F6YUG5 1 9 
F6Z4B2 1 (1 of 565,567,568) 
F6Z4B2 1 (1 of 614,615) 
F6Z4B2 1 192 
F6Z4B2 1 927 
F6Z9A1 1 77 
F6Z9E6 1 212 
F6Z9E6 1 207 
F6Z9T5 1 110 
F6ZBY9 1 321 
F7AYW2 1 (1 of 1037,1040) 
F7AYW2 1 1045 
F7CDR2 1 (1 of 99,100) 
F7CDR2 1 101 
F7CGP0 1 434 
F7CIP8 1 32 
F7CIP8 1 137 
F7CIP8 1 105 
F7DE17 1 291 
F7DE17 1 133 
F7DE17 1 586 
F7DE17 1 124 
F7DE17 1 125 
F8VPM9 1 (1 of 1790,1791,1805,1807) 




F8VPM9 1 2647 
F8VQJ3 1 1223 
F8WGL3 1 8 
F8WH96 1 102 
F8WHP5 1 697 
F8WI14 1 532 
F8WIE5 1 (1 of 1575,1577) 
F8WIE5 1 1569 
F8WIE5 1 1487 
F8WIN6 1 250 
F8WIN6 1 246 
F8WJL9 1 121 
F8WJL9 1 102 
F8WJL9 1 751 
G3UWE3 1 (1 of 453) 
G3UWE3 1 448 
G3UWE3 1 435 
G3UWE3 1 431 
G3UXW9 1 9 
G3UXW9 1 11 
G3UXW9 1 518 
G3UY24 1 36 
G3UZC7 1 681 
G3UZC7 1 771 
G3UZP7 1 202 
G3UZP7 1 282 
G3X8R2 1 72 
G3X8T3 1 157 
G3X928 1 600 
G3X928 1 185 
G3X928 1 186 
G3X928 1 607 
G3X960 1 167 
G3X973 1 897 
G3X973 1 1532 
G3X973 1 2046 
G3X9D6 1 23 
G3X9K4 1 825 
G3X9T8 1 139 
G3X9T8 1 140 
G3X9V4 1 944 
G5E850 1 5 
G5E874 1 1143 
G5E8W7 1 208 




H3BIX4 1 165 
H3BIZ9 1 241 
H3BK31 1 217 
H3BK31 1 235 
H3BKD4 1 948 
H3BL34 1 276 
H3BL34 1 277 
H3BLE4 1 (1 of 105,106,107,108,109,110,112) 
H3BLE4 1 9 
H3BLE4 1 149 
H3BLE4 1 14 
H3BLE9 1 33 
H9KUY5 1 (1 of 93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113) 
H9KV01 1 256 
H9KV01 1 1092 
H9KV01 1 1605 
H9KV01 1 262 
H9KV01 1 1614 
H9KV01 1 250 
H9KV01 1 1086 
I7HIP8 1 417 
I7HIP8 1 413 
I7HJQ9 1 658 
I7HJQ9 1 669 
J3QJX3 1 556 
J3QJX3 1 549 
J3QMX8 1 (1 of 376,393,396) 
J3QMX8 1 379 
J3QP71 1 (1 of 138,139) 
J3QP71 1 136 
J3QP71 1 25 
J3QP71 1 28 
J3QPR1 1 81 
J3QPR1 1 23 
J3QPR1 1 87 
K4DI63 1 36 
K4DI63 1 92 
L7N209 1 (1 of 290,291) 
M0QWF0 1 213 
M0QWZ1 1 992 
M0QWZ1 1 995 
O08553 1 512 




O08715 1 (1 of 351,356) 
O08715 1 371 
O09117 1 259 
O09159 1 369 
O35114 1 124 
O35490 1 389 
O35516 1 (1 of 667,671) 
O35516 1 675 
O35516 1 175 
O35887 1 133 
O35945 1 497 
O35949 1 (1 of 3,4,8) 
O55042 1 72 
O55042 1 44 
O55042 1 53 
O55042 1 54 
O55111 1 912 
O55111 1 1060 
O70400 1 128 
O70400 1 123 
O70400 1 135 
O88531 1 214 
O88531 1 199 
O88569 1 199 
O88783 1 (1 of 774,776) 
O88783 1 973 
O88904 1 854 
O89020 1 404 
O89103 1 262 
P01029 1 1388 
P01029 1 223 
P01902 1 199 
P04925 1 198 
P07361 1 106 
P07724 1 294 
P08113 1 64 
P08113 1 447 
P08226 1 134 
P08228 1 99 
P08607 1 426 
P08607 1 71 
P09055 1 408 
P09055 1 209 
P09055 1 214 




P0C7T6 1 22 
P0C7T6 1 23 
P0DOV2 1 (1 of 122,123) 
P0DOV2 1 130 
P10605 1 39 
P11438 1 80 
P11679 1 489 
P11679 1 482 
P11881 1 2505 
P11881 1 2500 
P12265 1 629 
P16301 1 110 
P23953 1 (1 of 271,276,277,278) 
P23953 1 81 
P25444 1 (1 of 285,292,293) 
P26039 1 (1 of 2169,2170) 
P27773 1 91 
P28665 1 (1 of 995,999) 
P28665 1 296 
P28665 1 290 
P28665 1 1144 
P28665 1 1182 
P29341 1 485 
P29341 1 351 
P29788 1 88 
P29788 1 243 
P33215 1 329 
P33587 1 216 
P33587 1 292 
P35831 1 625 
P35831 1 642 
P42703 1 384 
P43883 1 420 
P43883 1 102 
P43883 1 107 
P43883 1 45 
P43883 1 23 
P43883 1 122 
P43883 1 59 
P43883 1 30 
P48678 1 (1 of 633,637) 
P48678 1 629 
P48678 1 644 
P48678 1 613 




P49182 1 404 
P50247 1 2 
P51141 1 383 
P52430 1 326 
P52430 1 318 
P52430 1 255 
P58871 1 298 
P58871 1 260 
P58929 1 404 
P62908 1 242 
P63028 1 98 
P70274 1 193 
P70274 1 178 
P70324 1 (1 of 395,396) 
P70699 1 392 
P70699 1 885 
P70699 1 469 
P70699 1 142 
P83741 1 1860 
P83741 1 2376 
P83741 1 1836 
P83741 1 1841 
P83741 1 1843 
P83741 1 1844 
P83741 1 1845 
P83741 1 1945 
P83741 1 2365 
P97364 1 448 
P97370 1 199 
P97426 1 113 
Q01339 1 164 
Q01339 1 159 
Q01705 1 900 
Q01705 1 822 
Q02013 1 44 
Q02614 1 233 
Q02614 1 241 
Q02614 1 239 
Q03311 1 372 
Q05BG1 1 313 
Q06770 1 322 
Q06770 1 319 
Q06890 1 329 
Q06890 1 291 




Q07456 1 229 
Q07797 1 71 
Q07968 1 548 
Q07968 1 543 
Q3TBU7 1 193 
Q3TBU7 1 186 
Q3TBU7 1 188 
Q3TC93 1 280 
Q3TCN2 1 522 
Q3TJI8 1 131 
Q3TN85 1 (1 of 123,125,128,129,130,131,132,133,136,138,140,143,144,146,147) 
Q3TQC7 1 257 
Q3TWZ5 1 308 
Q3TZ89 1 979 
Q3TZR9 1 444 
Q3U332 1 (1 of 350,351) 
Q3U7T5 1 50 
Q3U7T5 1 55 
Q3U9N4 1 385 
Q3U9N4 1 278 
Q3UEI1 1 328 
Q3UEI1 1 4 
Q3UEI1 1 6 
Q3UEQ1 1 184 
Q3UH06 1 (1 of 1097,1099,1100,1101,1103,1106,1108,1111,1112) 
Q3UH06 1 (1 of 988,991) 
Q3UH06 1 1000 
Q3UHJ0 1 360 
Q3UHJ0 1 354 
Q3UI14 1 438 
Q3UIA2 1 803 
Q3UR91 1 85 
Q3URQ4 1 (1 of 31,33,34,35) 
Q3URQ4 1 (1 of 10,18,27) 
Q3USK2 1 382 
Q3UYJ1 1 212 
Q3V117 1 453 
Q3V1K7 1 151 
Q4G0F8 1 (1 of 875,876) 
Q4PZA2 1 (1 of 167,169,171) 
Q4PZA2 1 (1 of 247,249) 
Q4PZA2 1 632 
Q4VBF8 1 1114 
Q505F4 1 144 




Q571K4 1 (1 of 402,405,407,408) 
Q571K4 1 412 
Q59J78 1 148 
Q5DTZ3 1 245 
Q5DTZ3 1 207 
Q5F2E7 2 (1 of 381,382,383,384,385,386,389,391,393,394,395)&(1 of 369,373,381,393,394,395)&(1 of 
369,373,374) 
Q5F2E7 1 376 
Q5F2E7 1 380 
Q5RIM6 1 (1 of 1561,1562) 
Q5RIM6 1 (1 of 2,3,4) 
Q5RIM6 1 1056 
Q5RIM6 1 2053 
Q5RIM6 1 1901 
Q5RIM6 1 14 
Q5RIM6 1 1874 
Q5RIM6 1 51 
Q5RIM6 1 1878 
Q5RIM6 1 1494 
Q5RIM6 1 1497 
Q5RJH6 1 578 
Q5RJH6 1 575 
Q5SFM8 1 546 
Q5SQA7 1 (1 of 31,34) 
Q5SQA7 1 29 
Q5SUH7 1 320 
Q5SUH7 1 259 
Q5SUH7 1 316 
Q5XJV5 1 1646 
Q61001 1 2049 
Q61009 1 332 
Q61029 1 275 
Q61191 1 (1 of 583,586,587,588,592) 
Q61191 1 (1 of 771,775) 
Q61191 1 515 
Q61191 1 518 
Q61191 1 779 
Q61191 1 405 
Q61191 1 801 
Q61191 1 1061 
Q61191 1 806 
Q61191 1 808 
Q61191 1 685 
Q61191 1 563 




Q61191 1 1220 
Q61191 1 1224 
Q61191 1 726 
Q61191 1 1495 
Q61191 1 858 
Q61191 1 603 
Q61191 1 1246 
Q61191 1 480 
Q61191 1 490 
Q61191 1 495 
Q61191 1 1139 
Q61191 1 1148 
Q61391 1 287 
Q61471 1 (1 of 171,172) 
Q61827 1 (1 of 133,134,135,138) 
Q61827 1 153 
Q62009 1 603 
Q62086 1 256 
Q62261 1 2323 
Q62311 1 (1 of 480,481,483,485) 
Q62311 1 (1 of 594,595,600,602)&(1 of 590,594,595) 
Q62311 1 586 
Q62419 1 284 
Q63880 1 313 
Q63886 1 91 
Q68FG2 1 2354 
Q68FG2 1 2101 
Q68FG2 1 2359 
Q69ZA1 1 1286 
Q69ZL1 1 494 
Q6A058 1 366 
Q6A0A2 1 (1 of 46,50,51) 
Q6A0A2 1 (1 of 620,622) 
Q6A0A2 1 632 
Q6A0A9 1 (1 of 504,505,506,508,509,511) 
Q6DFV5 1 1668 
Q6DFZ1 1 1781 
Q6DID3 1 819 
Q6KCD5 1 (1 of 1678,1679) 
Q6KCD5 1 161 
Q6P5E4 1 266 
Q6P5E4 1 271 
Q6P6J9 1 145 
Q6P6J9 1 138 




Q6P6J9 1 167 
Q6PAL7 1 1593 
Q6PB44 1 880 
Q6PB44 1 881 
Q6PD26 1 372 
Q6PDI5 1 (1 of 1669,1670) 
Q6PIJ4 1 1027 
Q6PIJ4 1 838 
Q6PIJ4 1 1031 
Q6PIJ4 1 1064 
Q6PIJ4 1 1172 
Q6PIJ4 1 1077 
Q6PIJ4 1 1270 
Q6XLQ8 1 133 
Q78PY7 1 909 
Q7M739 1 1672 
Q7M739 1 1649 
Q7M739 1 2055 
Q7TN29 1 197 
Q7TPN9 1 319 
Q7TQE2 1 206 
Q7TT18 1 1032 
Q7TT50 1 (1 of 968,969,970,972,976,979) 
Q80U72 1 (1 of 936,939,943,948,949,951) 
Q80U93 1 (1 of 1566,1567,1569,1573,1574,1576,1580,1586) 
Q80U93 1 (1 of 645,646,648) 
Q80U93 1 (1 of 1357,1358) 
Q80U93 1 (1 of 1109,1115,1116,1118,1120,1121) 
Q80U93 1 513 
Q80U93 1 1314 
Q80U93 1 1313 
Q80U93 1 1316 
Q80U93 1 635 
Q80U93 1 652 
Q80U93 1 494 
Q80U93 1 1362 
Q80U93 1 1557 
Q80U93 1 502 
Q80U93 1 504 
Q80U93 1 1337 
Q80U93 1 506 
Q80U93 1 507 
Q80UF7 1 314 
Q80VP1 1 416 




Q80X50 1 (1 of 480,481,482,487,490,491,495,496,497) 
Q80X50 1 803 
Q80X50 1 799 
Q80X50 1 879 
Q80X81 1 12 
Q80YR4 1 (1 of 563,564,568,569) 
Q80YW7 1 (1 of 342,344) 
Q80YW7 1 346 
Q810N5 1 2 
Q810N9 1 (1 of 54,60) 
Q8BFR4 1 272 
Q8BFR4 1 267 
Q8BFR4 1 270 
Q8BFW7 1 312 
Q8BFW7 1 11 
Q8BFW7 1 212 
Q8BG19 1 499 
Q8BGD9 1 (1 of 504,506,507) 
Q8BGD9 1 352 
Q8BGD9 1 355 
Q8BGD9 1 495 
Q8BGQ4 1 650 
Q8BGQ4 1 655 
Q8BGS1 1 (1 of 385,386,387,398) 
Q8BH35 1 45 
Q8BH80 1 144 
Q8BHL3 1 43 
Q8BI72 1 (1 of 187,188,189,190) 
Q8BI72 1 (1 of 318,319) 
Q8BI72 1 199 
Q8BI72 1 328 
Q8BI72 1 395 
Q8BI72 1 315 
Q8BI72 1 317 
Q8BI84 1 1729 
Q8BI84 1 1766 
Q8BI84 1 250 
Q8BI84 1 633 
Q8BI84 1 1754 
Q8BI84 1 253 
Q8BJ05 1 (1 of 132,133) 
Q8BJ05 1 (1 of 77,78) 
Q8BJ05 1 360 
Q8BJ05 1 252 




Q8BJ05 1 255 
Q8BJ71 1 (1 of 51,52) 
Q8BJ71 1 55 
Q8BJS4 1 (1 of 651,652,654,655) 
Q8BJS4 1 648 
Q8BKI2 1 (1 of 1158,1159,1161) 
Q8BKI2 1 310 
Q8BM88 1 98 
Q8BMB0 1 (1 of 1072,1073) 
Q8BMB0 1 (1 of 196,200,202) 
Q8BMB0 1 192 
Q8BMB0 1 499 
Q8BMB0 1 1069 
Q8BMI0 1 806 
Q8BNV8 1 148 
Q8BP97 1 382 
Q8BTI8 1 (1 of 2199,2200) 
Q8BTI8 1 2341 
Q8BTI8 1 2122 
Q8BTI8 1 2123 
Q8BTI8 1 2414 
Q8BTI8 1 2205 
Q8BTJ4 1 281 
Q8BTJ4 1 261 
Q8BU11 1 406 
Q8BU25 1 267 
Q8BUN3 1 365 
Q8BUN3 1 366 
Q8BVZ1 1 55 
Q8BX02 1 346 
Q8BX02 1 421 
Q8BYK6 1 201 
Q8BYK6 1 205 
Q8BYK6 1 167 
Q8BYU6 1 320 
Q8C0C0 1 (1 of 594,597) 
Q8C0C0 1 150 
Q8C0C0 1 166 
Q8C0C3 1 (1 of 238,239) 
Q8C0C3 1 236 
Q8C0Q2 1 730 
Q8C0Q2 1 236 
Q8C0Q2 1 733 
Q8C180 1 (1 of 326,327,328) 




Q8C341 1 527 
Q8C5R2 1 390 
Q8C6E0 1 193 
Q8C7E7 1 192 
Q8C7E7 1 160 
Q8C8Z9 1 608 
Q8CBB6 1 113 
Q8CCH2 1 208 
Q8CF89 1 393 
Q8CFE4 1 622 
Q8CFE4 1 741 
Q8CFE4 1 630 
Q8CG48 1 867 
Q8CHI8 1 (1 of 2614,2617,2619,2620,2624,2626,2627,2628) 
Q8CHI8 1 (1 of 2932,2936,2937,2940) 
Q8CHI8 1 709 
Q8CHS8 1 174 
Q8CI51 1 110 
Q8CI51 1 208 
Q8CI51 1 115 
Q8CI51 1 118 
Q8CI51 1 120 
Q8CI51 1 90 
Q8JZK9 1 507 
Q8JZZ0 1 54 
Q8K099 1 (1 of 604,605,608) 
Q8K0E8 1 378 
Q8K0L9 1 (1 of 461,464,465,472,473) 
Q8K0L9 1 480 
Q8K0L9 1 449 
Q8K0L9 1 451 
Q8K0L9 1 485 
Q8K0L9 1 263 
Q8K0L9 1 268 
Q8K0L9 1 436 
Q8K0L9 1 309 
Q8K0L9 1 447 
Q8K2Q9 1 (1 of 492,493,494,496) 
Q8K2Q9 1 502 
Q8K382 1 1002 
Q8K3X4 1 204 
Q8K3Z9 1 (1 of 649,650,653) 
Q8K3Z9 1 664 
Q8K558 1 (1 of 253,255,256,261,262) 




Q8QZR3 1 272 
Q8R080 1 (1 of 267,268) 
Q8R084 1 98 
Q8R0F3 1 140 
Q8R121 1 280 
Q8R143 1 41 
Q8R242 1 285 
Q8R3E3 1 391 
Q8R4R6 1 (1 of 295,296,297,303) 
Q8R4R6 1 53 
Q8R4R6 1 55 
Q8R4U0 1 1512 
Q8VBZ3 1 297 
Q8VC34 1 9 
Q8VC97 1 392 
Q8VCF0 1 (1 of 255,256) 
Q8VCF0 1 298 
Q8VCF0 1 330 
Q8VCF0 1 370 
Q8VCF0 1 242 
Q8VCF0 1 373 
Q8VCF0 1 310 
Q8VCF0 1 343 
Q8VCF0 1 374 
Q8VCF0 1 314 
Q8VCF0 1 315 
Q8VCI0 1 529 
Q8VCI0 1 446 
Q8VCN5 1 (1 of 54,55,60) 
Q8VDZ4 1 386 
Q8VHR5 1 (1 of 587,589,591) 
Q8VHR5 1 585 
Q91W29 2 (2 of 20,22,24) 
Q91WK2 1 14 
Q91WP0 1 643 
Q91WU0 1 88 
Q91WU0 1 81 
Q91X84 1 (1 of 320,322,326,327) 
Q91X84 1 321 
Q91XD6 1 137 
Q91XD6 1 133 
Q91XL1 1 316 
Q91XT4 1 (1 of 70,74) 
Q91XT4 1 8 




Q91XT4 1 68 
Q91XT4 1 78 
Q91YQ5 1 (1 of 386,391) 
Q91YQ5 1 302 
Q91YT7 1 202 
Q921H8 1 243 
Q921I1 1 514 
Q921I1 1 515 
Q921L6 1 308 
Q922U1 1 176 
Q922U1 1 172 
Q99K94 1 (1 of 704,708,710) 
Q99LI5 1 (1 of 881,882) 
Q99LI5 1 (1 of 774,775,776,780,781,782) 
Q99LI5 1 889 
Q99LI5 1 886 
Q99LI5 1 239 
Q99MZ3 1 618 
Q9CQW1 1 172 
Q9CQW1 1 149 
Q9CS74 1 640 
Q9CU24 1 316 
Q9CWK8 1 (1 of 104,106,107) 
Q9CYA0 1 190 
Q9D0J8 1 5 
Q9D136 1 212 
Q9D136 1 262 
Q9D1M0 1 315 
Q9D787 1 501 
Q9D7N9 1 161 
Q9D8N1 1 (1 of 96,97) 
Q9D8N1 1 145 
Q9DAC2 1 120 
Q9DAC2 1 141 
Q9DAC2 1 126 
Q9DBG5 1 (1 of 138,139,141,142) 
Q9DBG5 1 128 
Q9DBG5 1 130 
Q9DBG5 1 71 
Q9DBG5 1 72 
Q9DBG5 1 137 
Q9DBG5 1 76 
Q9DBG5 1 83 
Q9DBG5 1 58 




Q9DBG5 1 127 
Q9DBG6 1 105 
Q9DBG6 1 108 
Q9DBR7 1 (1 of 625,628,631,637,645,646,647,648,650,651,652,653,656,658) 
Q9EP52 1 82 
Q9EQQ9 1 405 
Q9ER39 1 161 
Q9ERG0 1 (1 of 326,329,334,341,344)&(1 of 325,326) 
Q9ERG0 1 279 
Q9ERL9 1 (1 of 108,109) 
Q9ERU9 1 (1 of 2443,2444,2445,2447) 
Q9ERU9 1 1731 
Q9ERU9 1 2339 
Q9ERU9 1 1134 
Q9ERU9 1 1457 
Q9ERU9 1 1138 
Q9ERU9 1 1428 
Q9ERU9 1 1141 
Q9ERU9 1 1599 
Q9ERZ6 1 396 
Q9ESC8 1 689 
Q9ESC8 1 85 
Q9ESY9 1 107 
Q9ET43 1 241 
Q9JHP7 1 154 
Q9JI95 1 21 
Q9JKR6 1 513 
Q9JKR6 1 933 
Q9JKR6 1 598 
Q9JKR6 1 871 
Q9JL60 1 442 
Q9JLB4 1 2552 
Q9JLV1 1 (1 of 380,382,386) 
Q9JLV1 1 (1 of 186,187) 
Q9JLV1 1 (1 of 188,189) 
Q9JLV1 1 (1 of 289,291) 
Q9JLV1 1 320 
Q9JLV1 1 163 
Q9JLV1 1 179 
Q9JLV1 1 373 
Q9JLV1 1 183 
Q9QWV9 1 474 
Q9QYC7 1 572 
Q9QYC7 1 629 




Q9QYE6 1 158 
Q9QYG0 1 353 
Q9QYG0 1 370 
Q9QYG0 1 334 
Q9QYG0 1 335 
Q9QZN4 1 261 
Q9QZS5 1 332 
Q9R013 1 358 
Q9R182 1 117 
Q9R1E0 1 645 
Q9WU60 1 1084 
Q9WUM3 1 421 
Q9WUU7 1 188 
Q9WV54 1 259 
Q9WV69 1 18 
Q9WV69 1 285 
Q9WV69 1 110 
Q9WVJ3 1 396 
Q9Z0K8 1 149 
Q9Z0K8 1 134 
Q9Z103 1 412 
Q9Z2D6 1 434 
Q9Z2L6 1 238 
Q9Z2V4 1 549 
S4R1Q8 1 (1 of 318,319) 
S4R1Q8 1 2154 
S4R1Y6 1 (1 of 1507,1508,1512,1517) 
S4R294 1 (1 of 2138,2140,2143) 
S4R294 1 (1 of 2632,2633) 
S4R294 1 (1 of 2101,2102) 
S4R294 1 2148 
S4R294 1 2283 
S4R294 1 1933 
S4R294 1 2637 
S4R294 1 2285 
S4R294 1 209 
S4R294 1 882 
S4R294 1 2644 
S4R294 1 2645 
S4R294 1 374 
S4R294 1 1918 
S4R2A9 1 499 
S4R2A9 1 500 
S4R2A9 1 542 




V9GWU5 1 82 
V9GWU5 1 140 
V9GWU5 1 142 
V9GXT3 1 1054 
V9GXT3 1 1391 
Z4YL55 1 208 
Z4YL55 1 205 





Appendix 7.2. Pathway Analysis of Differentially Expressed Proteins in db/db Mouse Livers. 
 
A7.2.1. MetaCore Pathway Analysis. 












organization by the kinase 







BETA-PIX, Talin, RhoA, ROCK, Actomyosin, PAK, 
Rac1-related, Cdc42 subfamily, Vinculin, MSN (moesin), 
ERM proteins, F-Actin cytoskeleton, Spectrin, MRLC, 
PRK1, ARPC1B, RhoA-related, Myosin II, Cortactin, 
Caldesmon, CDC42, Actin cytoskeletal, Alpha-actinin, 
Filamin A, Alpha adducin, RhoC, PIP5KI, MyHC, 
MLCK, Paxillin, Rac1, RhoGDI alpha 
2 
CFTR folding and maturation 







OST complex, DNAJB6 (Hdj-1), PARP-1, GANAB, 
UGCGL1, Csp, Aha1, HSP40, Calnexin, HSP105, 
HSP90 alpha, Hdj-2, ERp29, Sti1, HSP70, BAG-3, 
HSP90 beta, p23 co-chaperone 






Talin, RhoA, ITGB1, Vitronectin, RelA (p65 NF-kB 
subunit), B-Raf, ROCK2, PKC-alpha, ITGB3, alpha-
V/beta-3 integrin, N-Ras, FAK1, MEK1/2, alpha-5/beta-1 
integrin, Actin cytoskeletal, CRK, SOS, NF-kB, RhoC, 




regulation of glucose and lipid 







VLDL, PPCKC, SREBP1 precursor, ACACA, ME1, 
SREBP1 (nuclear), SCD, ACACB, Insulin receptor, 
ANGPTL3, G6PT, HNF1-alpha, APOB, CYP7A1, 




regulation of xenobiotic 








CYP2C8, CYP27A1, ACLY, S14 protein, SR-BI, 
SULT2A1, CYP3A7, G6PT, CYP3A5, SLC21A2, 
ELOVL6, CYP7A1, CYP2A6, MRP3, CYP3A4, 




regulation of xenobiotic 








CYP2C8, CYP27A1, ACLY, S14 protein, SR-BI, 
SULT2A1, CYP3A7, G6PT, CYP3A5, SLC21A2, 
ELOVL6, CYP7A1, MRP3, CYP3A4, UGT1A4, 
ALAS1, CD36, MDR1, ABCC2, CYP2B6, UGT1A6 
7 
Immune response_Antigen 








MHC Class I alpha chain, TAP1 (PSF1), PDIA3, Beta-2-
microglobulin, Sec24, GANAB, UGCGL1, PSMB10, 
Endoplasmin, Calreticulin, PSMB2, TAP2 (PSF2), 
PSMB1, PSMB5, MHC class I, PSMB9, Calnexin, 
HSP90 alpha, Bleomycin hydrolase, Sec23, Tapasin, 










RACK1, eIF6 (ITGB4BP), eIF5B (IF-2), PABPC1, 
eIF3S8, RPS6, eIF1, eIF4A, eIF4E, eIF5, eIF3S7, 
eIF3S3, eIF4G1/3, PABPC4, PDK (PDPK1), p70 S6 
kinase2, eIF1A 
9 
HSP70 and HSP40-dependent 








Ubiquitin, PSMD1, DNAJB6 (Hdj-1), HSC70, ST13 
(Hip), HSP27, HSP40, HSP90 alpha, Hdj-2, HSP90, Sti1, 
HSP70, SGTA, HSP90 beta, Cathepsin D, HSPA1A 
10 
Glucocorticoid-induced 
elevation of intraocular 








RhoA, ITGB1, ROCK, PI3K cat class IA, GCR Beta, 
GCR, PI3K cat class IA (p110-beta), ITGB3, 
Antileukoproteinase 1, alpha-V/beta-3 integrin, EGFR, 
SERPINA3 (ACT), FAK1, Syndecan-4, CDC42, Actin 
cytoskeletal, Alpha-actinin, GCR Alpha, Filamin A, 












BETA-PIX, Talin, RhoA, RAP-1A, Pyk2(FAK2), 
ITGB1, PIPKI gamma, PI3K cat class IA, VCAM1, 
PAK, NCK1, PLC-beta, ICAM1, Vinculin, PKA-cat 




PAK2, FAK1, MEK1/2, CDC42, Fyn, CRK, AKT(PKB), 











RAP-1A, F-Actin, Vinculin, BAIAP2, F-Actin 
cytoskeleton, VAV-2, Beta-catenin, Cortactin, CDC42, 
Actin cytoskeletal, Alpha-actinin, Plakoglobin, p120-
catenin, WASF2, Alpha-catenin, Rac1 
13 
CAR-mediated direct 
regulation of xenobiotic 








GSTP1, PPCKC, CYP2A13, CYP1A2, CYP2C8, 
SULT2A1, CYP3A7, CYP3A5, AL1A1, CYP7A1, 
CYP2A6, MRP3, ACOX1, CYP3A4, NQO1, ALAS1, 










Importin (karyopherin)-beta, CRM1, NTF2, NUP58, 
RanBP1, NUP153, NUP54, Importin (karyopherin)-
alpha, RANBP3, RanGAP1, RanBP2, E2I, Ran 
15 
Inhibition of remyelination in 
multiple sclerosis: regulation 







Tubulin beta, RhoA, CDK5, Tubulin alpha, PCBP-1, 
ROCK2, PKC-alpha, alpha-V/beta-1 integrin, MRLC, 
FAK1, Myosin II, CDC42, Actin cytoskeletal, Fyn, 
MELC, hnRNP A2, Fibronectin, WASF2, Paxillin, Rac1, 











Plasminogen, Talin, RhoA, RAP-1A, ROCK, ICAM1, 
Vinculin, alpha-V/beta-3 integrin, MRLC, FAK1, CrkL, 
CDC42, Actin cytoskeletal, Fyn, Alpha-actinin, Plasmin, 
AKT(PKB), MELC, Fibronectin, MyHC, Intersectin, 
ILK, CXCR4, Paxillin, Rac1, IP3 receptor 
17 
Cell adhesion_Histamine H1 
receptor signaling in the 








Talin, RhoA, Pyk2(FAK2), ROCK, PLC-beta, Vinculin, 
PKC-alpha, ZO-1, MRLC, FAK1, Myosin II, Beta-
catenin, Actin cytoskeletal, Alpha-actinin, G-protein 
alpha-q/11, MELC, p120-catenin, Alpha-catenin, MLCK, 




actin cytoskeleton nucleation 








RhoA, DRF, Rac1-related, HDIA2, Cdc42 subfamily, 
DAAM1, BAIAP2, F-Actin cytoskeleton, RhoA-related, 
CDC42, Actin cytoskeletal, IQGAP1, WASF subunit, 
FHOD1, RhoC, PIP5KI, FNBP1, WASF2, CYFIP1, 
FNBP1L, Rac1 
19 








Talin, RhoA, RAP-1A, ROCK, VAMP3, G-protein 
alpha-s, alpha-IIb/beta-3 integrin, ITGA2B, PKC-alpha, 
PI3K cat class IA (p110-beta), ITGB3, RAP-1B, G-
protein alpha-i family, MRLC, LARG, Myosin II, Actin 
cytoskeletal, G-protein alpha-q, MELC, Syntaxin 4, 
Fibrinogen (fibrin), SNAP-23, PLC-beta3, G-protein 













Talin, RhoA, ROCK, PI3K cat class IA, ITGAV, 
Vinculin, alpha-V/beta-3 integrin, FAK1, CDC42, alpha-
5/beta-1 integrin, Actin cytoskeletal, Fyn, Alpha-actinin, 
ITGA5, Fibronectin, ILK, Rac1 
21 
Effect of H. pylori infection 








ITGB1, Vinculin, PKC-alpha, Lyn, ZO-1, FAK1, CrkL, 
Beta-catenin, Cortactin, alpha-5/beta-1 integrin, Actin 
cytoskeletal, Alpha-actinin, CRK, Csk, p120-catenin, 
Actin, Alpha-catenin, Paxillin, Rac1, VIL2 (ezrin) 
22 
Chemotaxis_Lysophosphatidic 







RhoA, ROCK, cPKC (conventional), G-protein alpha-12 
family, Caspase-7, PAK, AKT1, PLC-eta 1, PKC, PLC-
beta, Vinculin, PI3K cat class IA (p110-beta), alpha-
V/beta-3 integrin, EGFR, G-protein alpha-i family, H-
Ras, F-Actin cytoskeleton, Caspase-3, LARG, PRK1, 
FAK1, CREB1, Beta-catenin, MEK1/2, Rho GTPase, 
CDC42, Actin cytoskeletal, CRK, AKT(PKB), G-protein 
alpha-q/11, PDK (PDPK1), PLC-beta3, CD36, Paxillin, 
Rac1, IP3 receptor, mTOR, E3KARP (NHERF2), G-






regulation of xenobiotic 








GSTP1, PPCKC, CYP2A13, CYP1A2, CYP2C8, 
SULT2A1, CYP3A7, CYP3A5, AL1A1, CYP7A1, 
MRP3, ACOX1, CYP3A4, NQO1, ALAS1, MDR1, 
ABCC2, CYP2B6, UGT1A6 
24 
Cell adhesion_Endothelial cell 








RAP-1A, Plakophilin 4, Cingulin, AF-6, ZO-1, 
Desmoplakin, Beta-catenin, Actin cytoskeletal, Alpha-
actinin, Plakoglobin, p120-catenin, Vimentin, Claudin-3, 
Alpha-catenin, ZO-2 
25 








Ubiquitin, NSF, AP-2 alpha subunits, MSN (moesin), 
AP2A1, Beta-adaptin 2, 14-3-3, MEK1/2, Actin 
cytoskeletal, Actin cytoplasmic 2, HSP90, PKA-cat 
(cAMP-dependent), ACTB, Rac1, eEF1A, Tubulin (in 











SLC31A1, Pyk2(FAK2), CDK5, AKT1, ARP2, PKC, 
NCK1, F-Actin, Vinculin, PKC-alpha, VAV-2, FAK1, 
Beta-catenin, Cortactin, EBP50, CDC42, Actin 
cytoskeletal, Fyn, IQGAP1, ATOX1, WASF subunit, 
Dynamin-2, PKA-cat (cAMP-dependent), WASF2, 












Talin, MEK1(MAP2K1), Vitronectin, PIPKI gamma, 
Vinculin, alpha-V/beta-3 integrin, H-Ras, FAK1, Beta-
catenin, alpha-5/beta-1 integrin, Actin cytoskeletal, 
Alpha-parvin, Alpha-actinin, SOS, Beta-parvin, Filamin 
A, AKT(PKB), Fibronectin, ILK, Paxillin, Rac1 
28 
Development_Thromboxane 







RhoA, EGF, cPKC (conventional), G-protein alpha-12 
family, PI3K cat class IA, B-Raf, G-protein alpha-s, 
PKC, PLC-beta, EGFR, RAP-1B, G-protein alpha-i 
family, H-Ras, CREB1, Beta-catenin, MEK1/2, G-protein 
alpha-q, AKT(PKB), PKA-cat (cAMP-dependent), IP3 
receptor, G-protein alpha-13 
29 
Transcription_Sirtuin6 







PPCKC, Ubiquitin, SREBP1 precursor, ACACA, RelA 
(p65 NF-kB subunit), PARP-1, HMGCS1, SREBP1 
(nuclear), Histone H3, ICAM1, SCD, LDLR, AMPK beta 
subunit, G6PT, AMPK alpha subunit, ELOVL6, AMPK 
gamma subunit, KPYR, SMARCA5, HXK4, ACOX1, 
FASN, SREBP1 (Golgi membrane), CD36 
30 
Regulation of degradation of 







Ubiquitin, RNF5, SEC61 complex, USP19, UBE1, 
HSC70, Csp, Aha1, SUMO-2, HSP27, HSP105, UBE2J1, 
Hdj-2, HSP90, Sti1, HSP70, SAE1, E2I 
31 
Development_Signaling 








STAT3, ALDOB, APOA1, gp130, PI3K cat class IA, 
APOA2, CPSM, Transferrin, K-RAS, G6PT, HNF1-
alpha, APOC3, APOB, TAT, Beta-catenin, APOC2, SOS, 











RhoA, ROCK, PRK2, MSN (moesin), H-Ras, LARG, 
VAV-2, Cortactin, MEK1/2, CDC42, Actin cytoskeletal, 
Fyn, SOS, Dynamin-2, Actin, MLCK, Rac1, RhoGDI 
alpha, VIL2 (ezrin) 
33 
Development_VEGF 








MEK1(MAP2K1), RhoA, Pyk2(FAK2), PI3K cat class 
IA, PKC, NCK1, Vinculin, PKC-alpha, alpha-V/beta-3 
integrin, HSP27, H-Ras, PAK2, MEK3(MAP2K3), 
eIF4E, eNOS, FAK1, CREB1, Beta-catenin, CDC42, 
Actin cytoskeletal, Fyn, SOS, AKT(PKB), HSP90, 











MHC class II alpha chain, Cathepsin L, RhoA, Cathepsin 
F, PI3K cat class IA, AKT1, FCGRT, Rab-7, HSC70, 
PKC, SPPL2a, AP complex 2 medium (mu) chain, PKC-
alpha, MYO1E, Endoplasmin, CLEC10A, SWAP-70, Fc 
gamma RII beta, HSP90 alpha, CDC42, MANR, 
Legumain, HSP90, R-Ras, PDK (PDPK1), Dynamin-2, 
Cathepsin S, Cathepsin V, TAP, HSP90 beta, LRP1, 
Rac1, SPTBN2, mTOR, Tubulin (in microtubules) 
35 
Stem cells_Pancreatic cancer 







RhoA, Pyk2(FAK2), ROCK, G-protein alpha-i family, F-
Actin cytoskeleton, MRLC, LARG, FAK1, Myosin II, 
CDC42, Fyn, MELC, MyHC, MLCK, CXCR4, Rac1, IP3 





Cell adhesion_Role of 
tetraspanins in the integrin-







Talin, RhoA, ITGB1, ROCK, CD82, CD81, Vinculin, 
PKC-alpha, FAK1, CDC42, alpha-5/beta-1 integrin, 











MEK1(MAP2K1), EGF, PI3K cat class IA, eIF4G2, 
EGFR, H-Ras, eIF4A, MEK3(MAP2K3), eIF4E, eIF4B, 
eIF4H, CDC42, SOS, eIF4G1/3, AKT(PKB), MNK1, 
eIF4G1, PDK (PDPK1), p70 S6 kinase2, Rac1, mTOR 
38 








GSTP1, Casein kinase II, alpha chains, Ubiquitin, Casein 
kinase II, beta chain (Phosvitin), MEK1(MAP2K1), 
Thioredoxin, Heme oxygenase 1, PI3K cat class IA, 
CRM1, PKC, GSTA1, GCL reg, DJ-1, Actin cytoskeletal, 












RhoA, RAP-1A, ROCK, CDK5, B-Raf, ROCK2, EGFR, 
F-Actin cytoskeleton, GRB7, LARG, VAV-2, Cortactin, 
CDC42, Actin cytoskeletal, Fyn, CRMP2, Ephexin, 










PPCKC, RhoA, cPKC (conventional), ACACA, AKT1, 
SREBP1 (nuclear), PKC, PKC-alpha, SCD, Insulin 
receptor, IGF-2, G6PT, F-Actin cytoskeleton, Beta-
catenin, CDC42, HXK4, Filamin A, AKT(PKB), FASN, 














Tubulin beta, RhoA, CDK5, Tubulin alpha, PCBP-1, 
MAP4, ROCK2, CNP1, MRLC, TPPP (p24), FAK1, 
Myosin II, Cortactin, CDC42, Actin cytoskeletal, Fyn, 
MELC, hnRNP A2, WASF2, Paxillin, Rac1, Tubulin (in 
microtubules) 
42 
Cell adhesion_Endothelial cell 








Vitronectin, alpha-V/beta-3 integrin, F-Actin 
cytoskeleton, Beta-catenin, alpha-5/beta-1 integrin, 
PECAM1, Alpha-actinin, alpha-1/beta-1 integrin, 












Talin, RhoA, ROCK, PIPKI gamma, Vinculin, MRLC, 
FAK1, alpha-5/beta-1 integrin, Actin cytoskeletal, Alpha-
actinin, CRK, alpha-1/beta-1 integrin, MELC, 











Casein kinase II, beta chain (Phosvitin), 
MEK1(MAP2K1), RhoA, ROCK, p70 S6 kinases, AP-2 
alpha subunits, EGFR, SET, MRLC, eIF4E, Beta-adaptin 
2, 14-3-3, ARF6, AKT(PKB), MNK1, Beta-arrestin1, 
Casein kinase II, alpha' chain (CSNK2A2), MYLK1, 










Rab-4, Syntaxin 7, GS15, NSF, Rab-7, SAR1, VAMP8, 
Epsin 1, Myosin I, Syntaxin 5, HIP1, VPS45A, PREB, 
Rab-8, BIN1 (Amphiphysin II), Coatomer, GOS-28, 
Actin cytoskeletal, Optineurin, EEA1, PICALM, 











MBL2, C6orf134, Tubulin alpha, SR-BI, MSR1, 
Calreticulin, CDC42, MANR, AKT(PKB), NRF2, LRP1, 
CD36, Tubulin (in microtubules) 
47 
Adiponectin in pathogenesis 







PPCKC, SREBP1 precursor, AdipoR2, ACACA, 
SREBP1 (nuclear), SCD, ACACB, Insulin receptor, 












BETA-PIX, RhoA, ROCK, G-protein alpha-s, F-Actin 
cytoskeleton, CDC42, Actin cytoskeletal, LASP1, Alpha 
adducin, Beta adducin, MELC, PLC-beta3, PKA-cat 











RhoA, G-protein alpha-12 family, Tubulin alpha, 
ROCK2, Substance P receptor, MRLC, Myosin II, 













MEK1(MAP2K1), eEF2, PI3K cat class IA, eIF2B5, 
RPS6, Insulin receptor, H-Ras, eIF4A, eIF4E, eIF4B, 
eIF4H, SOS, eIF4G1/3, AKT(PKB), PDK (PDPK1), p70 
S6 kinase2, mTOR 
51 
Development_SDF-1 
signaling in hematopoietic 







RhoA, RAP-1A, Pyk2(FAK2), PI3K cat class IA, Lyn, 
H-Ras, FAK1, CrkL, MEK1/2, CDC42, CRK, PDK 










STAT3, SC5D, PDK1, eEF2, p70 S6 kinases, SREBP1 
(nuclear), G6PD, SCD, PDCD4, RPS6, eIF4A, eIF4E, 
eIF4B, CAD, HMGCS2, CBP80, p70 S6 kinase2, MVK, 
p27KIP1, UBF, PDIP46 
53 
Role of Tissue factor-induced 








MEK1(MAP2K1), RhoA, ROCK, G-protein alpha-12 
family, RelA (p65 NF-kB subunit), Fibrinogen alpha, 
PKC-alpha, EGFR, G-protein alpha-i family, MRLC, 
LARG, FAK1, Actin cytoskeletal, AKT(PKB), G-protein 
alpha-q/11, MELC, Fibrinogen (fibrin), PDK (PDPK1), 
PLC-beta3, MLCK, Paxillin, IP3 receptor 
54 
Mechanisms of drug 







ITGB1, PI3K cat class IA, VCAM1, RelA (p65 NF-kB 
subunit), B-Raf, CD81, alpha-V/beta-1 integrin, RPS6, 
alpha-V/beta-3 integrin, tBid, Caspase-3, FAK1, alpha-
5/beta-1 integrin, AKT(PKB), HSP70, PDK (PDPK1), 




upregulation in type 2 diabetes 







PPCKC, F261, G-protein alpha-s, PYGL, PLC-beta, PHK 
gamma (liver), G-protein alpha-i family, G6PT, Casein 
kinase II, PYC, CREB1, KPYR, PHK beta, G-protein 
alpha-q/11, PHK alpha (liver), HNF4-alpha, PLC-beta3, 










Casein kinase II, alpha chains, Plasminogen, Casein 
kinase II, beta chain (Phosvitin), MEK1(MAP2K1), 
Vitronectin, EGF, Nucleolin, gp130, PI3K cat class IA, 
EGFR, H-Ras, FAK1, Plasmin, SOS, AKT(PKB), ILK 
57 
Cell adhesion_Alpha-4 








BETA-PIX, ITGB1, PI3K cat class IA, VCAM1, F-Actin 
cytoskeleton, FAK1, ARF6, CDC42, Actin cytoskeletal, 
CRK, Filamin A, Fibronectin, PKA-cat (cAMP-
dependent), Paxillin, Rac1 






GSTP1, GPX3, GSTM5, GSTK1, 5-oxoprolinase, 
GCTG, GSTT2, GSTA1, G6PD, GCL reg, GPX4, 
GSTM1, GSTM2, MAAI, GSTA2, MGST, GSTA5, 
GSTT1, GSTM3, GSHR, GSTM4, GSTA4, CD13 
59 
Immune response_IL-3 







Talin, RAP-1A, ITGB1, p70 S6 kinases, cPKC 
(conventional), PI3K cat class IA, B-Raf, FLII, Lyn, 
RPS6, H-Ras, 14-3-3 zeta/delta, FAK1, CREB1, CrkL, 
MEK1/2, CDC42, alpha-5/beta-1 integrin, SOS, 
AKT(PKB), R-Ras, A-Raf-1, PDK (PDPK1), p27KIP1, 
PKA-cat (cAMP-dependent), Paxillin, Rac1, IP3 
receptor, mTOR 
60 








EGF, PI3K cat class IA, PKC-alpha, Neuregulin 1, 
PDCD4, EGFR, H-Ras, MEK3(MAP2K3), VAV-2, 
FAK1, MEK1/2, CDC42, Actin cytoskeletal, SOS, NF-
kB, AKT(PKB), PDK (PDPK1), p120-catenin, WASF2, 










RhoA, ROCK, PI3K cat class IA, NCK1, FLII, F-Actin 
cytoskeleton, PAK2, ARF6, Myosin II, CDC42, Fyn, 
AKT(PKB), Endophilin A2, CXCR4, ACTB, Rac1 
62 
Development_Role of CNTF 








STAT3, gp130, PI3K cat class IA, RelA (p65 NF-kB 
subunit), Annexin V, IMPA1, Caspase-3, CLIC4, 14-3-3, 
AKT(PKB), PDK (PDPK1), RhoGDI alpha, LIF receptor 
63 
Possible regulation of HSF-1/ 








PKC-alpha, SUMO-2, HSP27, HSP40, HSP90 alpha, 















Cathepsin L, Rab-4A, SEC61 complex, HYOU1, 
FCGRT, Rab-7, VAMP8, MSR1, Endoplasmin, 
Calreticulin, MHC class I, ARF6, HSP105, HSP90 alpha, 
MANR, HSP60, HSP90, Syntaxin 4, HSP70, Rab8B, 
SNAP-23, Cathepsin S, Rab-35, TAP, LRP1, Cathepsin 
B, EHD1, HSPA1A 
65 
Transport_The role of AVP in 
regulation of Aquaporin 2 and 







MYH9, RAP-1A, VAMP3, G-protein alpha-s, MRLC, 
CREB1, MRLC2, Myosin II, Actin cytoskeletal, 
Tropomyosin-1, Actin cytoplasmic 2, Syntaxin 4, MyHC, 
SNAP-23, PKA-cat (cAMP-dependent), VAMP2, 
MLCK, ACTB 
66 
Putative pathways of 
activation of monoclonal 








SSR-delta, DNAJB11, GRP78, DAD-1, ARMET, Kappa 
chain (Ig light chain), SRP-alpha, Cyclophilin B, IgJ, 












Heme oxygenase 1, ME1, GSTA1, G6PD, GCL reg, 











PPCKC, Ubiquitin, PI3K cat class IA, AKT1, RelA (p65 
NF-kB subunit), PARP-1, DEPTOR, G-protein alpha-i 
family, G6PT, Caspase-3, eNOS, Beta-catenin, 
AKT(PKB), PDK (PDPK1), CXCR4, Rac1, mTOR 
69 








Talin, PI3K cat class IA, Vinculin, H-Ras, 
MEK3(MAP2K3), FAK1, MMP-12, MEK1/2, Actin 
cytoskeletal, Alpha-parvin, Alpha-actinin, BPAG1, SOS, 
Beta-parvin, AKT(PKB), PDK (PDPK1), ILK, Paxillin 
70 









MEK1(MAP2K1), eEF2, PI3K cat class IA, ACLY, 
eIF2B5, RPS6, Insulin receptor, H-Ras, eIF4B, SOS, 
LIPS, AKT(PKB), PDHA (somatic), PDK (PDPK1), p70 
S6 kinase2, PKA-cat (cAMP-dependent), mTOR 
71 
Role of CNTF and LIF in 
regulation of oligodendrocyte 








STAT3, gp130, PI3K cat class IA, RelA (p65 NF-kB 
subunit), Annexin V, IMPA1, Caspase-3, CLIC4, 14-3-3, 
AKT(PKB), PDK (PDPK1), RhoGDI alpha, LIF receptor 
72 
HGF receptor (Met) and MSP 
receptor (RON) signaling 







STAT3, Pyk2(FAK2), PI3K cat class IA, AKT1, PKR, 
MEK3(MAP2K3), FAK1, CREB1, CrkL, MEK1/2, 
Alpha adducin, AKT(PKB), PDK (PDPK1), Paxillin, 










Talin, MEK1(MAP2K1), RhoA, RAP-1A, PI3K cat class 
IA, TRAF3, PLC-beta, H-Ras, RIPK1, FAK1, CDC42, 
CRK, SOS, AKT(PKB), G-protein alpha-q/11, 











Talin, MEK1(MAP2K1), RAP-1A, Pyk2(FAK2), 
VAMP3, AKT1, alpha-IIb/beta-3 integrin, PKC-alpha, 
PI3K cat class IA (p110-beta), ITGB3, Lyn, RAP-1B, 14-
3-3 zeta/delta, MEK3(MAP2K3), eNOS, Fyn, Alpha-
actinin, Filamin A, Syntaxin 4, Fibrinogen (fibrin), 
SNAP-23, Actin, IP3 receptor 
75 









RhoG, BETA-PIX, RhoA, RAP-1A, ROCK, PI3K cat 
class IA, AKT1, MSN (moesin), H-Ras, PAK2, MRLC, 
VAV-2, CREB1, Myosin II, CDC42, Actin cytoskeletal, 
SOS, AKT(PKB), PDK (PDPK1), ILK, Rac1, mTOR, 
Tubulin (in microtubules) 
76 








Casein kinase II, alpha chains, Casein kinase II, beta 
chain (Phosvitin), MEK1(MAP2K1), EGF, PI3K cat class 
IA, eIF2B5, PKR, Insulin receptor, EGFR, H-Ras, Casein 
kinase I, SOS, eIF2S1, AKT(PKB), PDK (PDPK1) 
77 








STAT3, TOP2 beta, Talin, RhoA, ITGB1, ROCK, gp130, 
VCAM1, ICAM1, Vinculin, alpha-5/beta-1 integrin, 






remodeling_ESR1 action on 








RhoA, PI3K cat class IA, ROCK2, MSN (moesin), ERM 
proteins, F-Actin cytoskeleton, FAK1, EBP50, 










Talin, ITGB1, G-protein alpha-12 family, PIPKI gamma, 
PLC-beta, alpha-IIb/beta-3 integrin, ITGA2B, ITGB3, 
alpha-V/beta-3 integrin, G-protein alpha-i family, FAK1, 
alpha-5/beta-1 integrin, Actin cytoskeletal, alpha-1/beta-1 
integrin, G-protein alpha-q/11, Fibrinogen (fibrin), 
Fibronectin, CXCR4, IP3 receptor 
80 
Immune response_Sublytic 








RhoA, C8, AKT1, GRP78, PKC, HSP27, EGFR, 
Endoplasmin, G-protein alpha-i family, H-Ras, 
MEK3(MAP2K3), GRP75, MEK1/2, Actin cytoskeletal, 











Talin, RhoA, RAP-1A, VAMP3, alpha-IIb/beta-3 
integrin, PKC-alpha, PI3K cat class IA (p110-beta), 
ITGB3, Lyn, RAP-1B, CDC42, Fyn, PECAM1, Syntaxin 
4, Fibrinogen (fibrin), SNAP-23, Rac1, IP3 receptor 
82 
Role of ER stress in obesity 







SREBP1 precursor, AdipoR2, PI3K cat class IA, GRP78, 
HMGCS1, SREBP1 (nuclear), PKR, SCD, LDLR, Insulin 
receptor, G6PT, CREB1, PTP-1B, HXK4, eIF2S1, 
DnaJB9, FASN, SREBP1 (Golgi membrane) 
83 
Immune response_IL-6-








STAT3, APCS, Heme oxygenase 1, gp130, SAA1, 
Fibrinogen alpha, SAA2, HP, CRP, G6PT, HNF1-alpha, 











Tubulin alpha, F-Actin, G-protein alpha-i family, H-Ras, 
PINCH-2, FAK1, Beta-catenin, Actin cytoskeletal, SOS, 










MEK1(MAP2K1), RAP-1A, B-Raf, SOS2, K-RAS, 











MBL2, C8, C4a, C1 inhibitor, C6, Factor I, C5a, 
C8alpha, C4b, Clusterin, C5, C8gamma, C8beta, C9, 
C5b, C4, MASP2 
87 
The role of PTEN and PI3K 







STAT3, MCAM, PI3K cat class IA, AKT1, B-Raf, alpha-
V/beta-3 integrin, N-Ras, Caspase-3, FAK1, Beta-
catenin, alpha-5/beta-1 integrin, AKT(PKB), RhoC, PDK 










Heme oxygenase 1, PI3K cat class IA, VCAM1, RelA 
(p65 NF-kB subunit), SPPL2a, ICAM1, Lyn, GCL reg, 
G-protein alpha-i family, MIF, MEK1/2, NF-kB, 











TPI1, AL1B1, ALD9A1, ACSL4, AKR1C4, AL3A2, 
ACSL5, AKR7A2, GPD1, ALDR, AKR1C1, AL7A1, 
GPAM, ALDX, PLCB, AK1BA, PLCC, GNPAT, PLCE 
90 








STAT3, MEK1(MAP2K1), EGF, gp130, PI3K cat class 
IA, RelA (p65 NF-kB subunit), K-RAS, Neuregulin 1, 











GSTP1, Casein kinase II, alpha chains, ELAVL1 (HuR), 
Thioredoxin, Heme oxygenase 1, ACACA, RelA (p65 
NF-kB subunit), SREBP1 (nuclear), PKC, IRP1, SCD, 
PKA-cat alpha, HSP27, DLC1 (Dynein LC8a), GRP75, 
AMPK alpha subunit, HDAC1, Pin1, NF-kB, SAE2, 
AKT(PKB), Catalase, FASN, NRF2, E2I, APEX, 
HSPA1A, mTOR 
92 
DeltaF508-CFTR traffic / ER-







Ubiquitin, Sec24, PIST (CAL), SAR1, PREB, Coatomer, 
Sec31, EBP50, Sec23 
93 








Ubiquitin, Sec24, PIST (CAL), SAR1, PREB, Coatomer, 





Development_The role of 
GDNF ligand family/ RET 
receptor in cell survival, 







STAT3, RhoA, RAP-1A, ITGB1, ROCK, PI3K cat class 
IA, B-Raf, NCK1, alpha-V/beta-3 integrin, N-Ras, H-
Ras, F-Actin cytoskeleton, VAV-2, FAK1, CREB1, 
MEK1/2, CDC42, CRK, SOS, NF-kB, AKT(PKB), PDK 
(PDPK1), Paxillin, Rac1, IP3 receptor 
95 
Development_Positive 
regulation of STK3/4 (Hippo) 
pathway and negative 








RhoA, MOBKL1A, MALS-3, SCRIB, G-protein alpha-s, 
Cullin 2, PKA-cat alpha, AMPK beta subunit, Alpha-1 
catenin, 14-3-3, AMPK alpha subunit, Casein kinase I 
epsilon, AMPK gamma subunit, Beta-catenin, EBP50, 
Actin cytoskeletal, PKA-cat (cAMP-dependent), Alpha-











Cullin 1, Ubiquitin, PDK1, RAP-1A, PI3K cat class IA, 
B-Raf, G-protein alpha-s, PKC, PLC-beta, cAMP-GEFII, 
RAP-1B, eNOS, CREB1, MEK1/2, AKT(PKB), G-
protein alpha-q/11, PDK (PDPK1), PKA-cat (cAMP-












STAT3, Pyk2(FAK2), PI3K cat class IA, PKC-alpha, 
Lyn, H-Ras, CrkL, MEK1/2, Fyn, SOS, AKT(PKB), 
PDK (PDPK1), c-Kit, p27KIP1, CXCR4, Paxillin, Rac1, 
IP3 receptor, mTOR 
98 
Development_Role of PKR1 








MEK1(MAP2K1), Pyk2(FAK2), ITGB1, PI3K cat class 
IA, PLC-beta, H-Ras, Beta-catenin, SOS, AKT(PKB), G-










Ubiquitin, PML, GCR, SAE1/2, RanGAP1, NF-kB, 
SAE2, TOP2, SAE1, RanBP2, E2I, CBX4 
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Regulation of lipid 
metabolism_Regulation of 
lipid metabolism via LXR, 







CYP51A1, SREBP1 precursor, Importin (karyopherin)-
beta, ACACA, ACLY, SREBP1 (nuclear), SCD, LDLR, 
AMPK beta subunit, AMPK alpha subunit, CREB1, 
AMPK gamma subunit, FASN, SREBP1 (Golgi 
membrane) 
101 
CCR7 signaling pathways in 








MEK1(MAP2K1), RhoA, RAP-1A, Pyk2(FAK2), 
ROCK, ICAM1, G-protein alpha-i family, H-Ras, 
Myosin II, CDC42, Actin cytoskeletal, SOS, AKT(PKB), 











STAT3, TTC1, PKC, PLC-beta, PKC-alpha, PI3K cat 
class IA (p110-beta), EGFR, G-protein alpha-i family, H-
Ras, CREB1, MEK1/2, NF-kB, AKT(PKB), G-protein 
alpha-q/11, PDK (PDPK1), SFK, PLC-beta3, PKA-cat 
(cAMP-dependent), IP3 receptor 
103 
Regulation of CFTR activity 







Casein kinase II, alpha chains, Casein kinase II, beta 
chain (Phosvitin), RACK1, Annexin V, G-protein alpha-
s, PP2A structural, AMPK beta subunit, G-protein alpha-i 
family, PDZK1, EBP50, PP2A regulatory, AMPK 
gamma1, Filamin A, PP2C, SNAP-23, PKA-cat (cAMP-
dependent), E3KARP (NHERF2), Tubulin (in 










RhoA, RhoGDI beta, ROCK, G-protein alpha-12 family, 
LARG, PRK1, FAK1, Fyn, Ephexin, G-protein alpha-
q/11, Rac1, RhoGDI alpha, VIL2 (ezrin) 
105 
G-protein signaling_G-Protein 







RhoA, Pyk2(FAK2), ROCK, PI3K cat class IA, PLC-
beta, H-Ras, LARG, SOS, NF-kB, AKT(PKB), G-protein 
alpha-q/11, PDK (PDPK1), IP3 receptor 
106 
Regulation of lipid 
metabolism_Insulin regulation 







MEK1(MAP2K1), SREBP1 precursor, INSIG2, 
ACACA, PI3K cat class IA, PDH, ACLY, SREBP1 
(nuclear), ODP2, PDH alpha, ELOVL1, SCD, Insulin 
receptor, H-Ras, ELOVL6, HXK4, SOS, LIPS, 
AKT(PKB), PDHA (somatic), PDK (PDPK1), FASN, 











STAT3, PI3K cat class IA, RelA (p65 NF-kB subunit), 
PKC, PLC-beta, G-protein alpha-i family, H-Ras, 
CREB1, MEK1/2, Rho GTPase, G-protein alpha-i3, 
AKT(PKB), G-protein alpha-q/11, PDK (PDPK1), G-










STAT3, Casein kinase II, beta chain (Phosvitin), 




PLC-beta, H-Ras, Caspase-3, eNOS, AMPK alpha 
subunit, SOS, AKT(PKB), HSP90, A-Raf-1, IP3 receptor 
109 
Development_Insulin, IGF-1 








G3P2, MEK1(MAP2K1), SREBP1 precursor, A-FABP, 
AKT1, SREBP1 (nuclear), COX II, SCD, PI3K cat class 
IA (p110-beta), Insulin receptor, CREB1, LIPS, 












MEK1(MAP2K1), RhoA, Pyk2(FAK2), eEF2, PI3K cat 
class IA (p110-beta), H-Ras, eIF4A, VAV-2, eIF4E, 
PRK1, G-protein alpha-11, G-protein alpha-q, eIF4G1/3, 
SOS1, p70 S6 kinase2, IP3 receptor, mTOR 
111 
Cell cycle_Influence of Ras 








STAT3, MEK1(MAP2K1), RhoA, PI3K cat class IA, 
RelA (p65 NF-kB subunit), ROCK2, H-Ras, MRLC, 
FAK1, CDC42, alpha-5/beta-1 integrin, AKT(PKB), 










Plasminogen, HC II, Fibrinogen alpha, Alpha 1-
antitrypsin, Protein C, Coagulation factor XIII A, 
SERPINF2, Fibrinogen beta, Coagulation factor XI, 
Fibrinogen gamma, Plasmin, CPB2, Plasma kallikrein, 
Fibrinogen (fibrin) 
113 








PPCKC, CYP2C8, SREBP1 (nuclear), GCR, ECHP, 
G6PT, CYP7A1, ACOX1, CYP3A4, HNF4-alpha, 
CYP2B6 
114 
Main pathways of Schwann 
cells transformation in 







MEK1(MAP2K1), ITGB1, EGF, PI3K cat class IA, K-
RAS, Neuregulin 1, RPS6, EGFR, N-Ras, H-Ras, FAK1, 
Beta-catenin, MEK1/2, BRD4, CDC42, B-FABP, 
AKT(PKB), PDK (PDPK1), SOX9, CXCR4, IP3 
receptor, mTOR 
115 
Activation of Cortisol 








RhoA, CYP11B1, ASAH, SREBP1 (nuclear), G-protein 
alpha-s, CYP11B2, FDX1, SF1, CREB1, MEK1/2, 
CYP17, CYP21A2, PKA-cat (cAMP-dependent), MDR1 
116 
SCAP/SREBP Transcriptional 








SREBP1 precursor, INSIG2, ACACA, ACLY, 
HMGCS1, SREBP1 (nuclear), ELOVL1, SCD, ELOVL6, 











RhoA, RAP-1A, NCK1, G-protein alpha-i family, H-Ras, 
GRB7, VAV-2, FAK1, CDC42, Fyn, Ephexin, 
ADAM10, Intersectin, Paxillin, Rac1 
118 
Role of cell adhesion 








MEK1(MAP2K1), ITGB1, Caspase-7, K-RAS, alpha-
V/beta-3 integrin, H-Ras, Caspase-3, FAK1, Beta-
catenin, alpha-5/beta-1 integrin, SOS, Plakoglobin, 
ITGA5, Fibronectin, Alpha-catenin 
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STAT3, Ubiquitin, MEK1(MAP2K1), RhoA, SREBP1 
precursor, PI3K cat class IA, SREBP1 (nuclear), LDLR, 
EGFR, G-protein alpha-i family, FAK1, NF-kB, 
AKT(PKB), PDK (PDPK1), FASN, SREBP1 (Golgi 
membrane), Cathepsin B, Paxillin, Rac1 
120 








PPCKC, CYP2C8, SREBP1 (nuclear), GCR, ECHP, 
G6PT, CYP7A1, ACOX1, CYP3A4, HNF4-alpha, 
CYP2B6 
121 








STAT3, MEK1(MAP2K1), Pyk2(FAK2), ITGB1, PI3K 
cat class IA, VCAM1, AKT1, ICAM1, PKC-alpha, H-
Ras, alpha-5/beta-1 integrin, SOS, PDK (PDPK1), 
Fibronectin, MDR1, IP3 receptor 
122 
KLF6 and regulation of KLF6 







EGF, PI3K cat class IA, AKT1, PARP-1, SFRS1 (SF2), 
EGFR, H-Ras, Caspase-3, SOS, PDK (PDPK1) 
123 
G-protein signaling_Cross-








RhoA, RAP-1A, PI3K cat class IA, B-Raf, H-Ras, 











STAT3, Talin, gp130, Vinculin, FAK1, CDC42, alpha-
5/beta-1 integrin, Actin cytoskeletal, Actin, Intersectin, 






dependent induction of EMT 







RhoA, PI3K cat class IA, RelA (p65 NF-kB subunit), 
ZO-1, H-Ras, Beta-catenin, Caldesmon, Tropomyosin-1, 
AKT(PKB), PDK (PDPK1), Fibronectin, Vimentin, 










MEK1(MAP2K1), EGF, PI3K cat class IA, EGFR, H-
Ras, Caspase-3, FAK1, Beta-catenin, alpha-5/beta-1 
integrin, SOS, AKT(PKB), PDK (PDPK1), ILK, Paxillin, 
mTOR 
127 
Airway smooth muscle 







RhoA, ROCK, G-protein alpha-s, PLC-beta, PKC-alpha, 
G-protein alpha-i family, MRLC, LARG, Telokin, Ca-
ATPase2, Myosin II, G-protein alpha-q/11, MELC, 
MyHC, PKA-cat (cAMP-dependent), MLCK, IP3 
receptor 
128 
Anti-apoptotic action of 







STAT3, EGF, AKT1, Neuregulin 1, EGFR, H-Ras, 
Caspase-3, VAV-2, MEK1/2, SOS, AKT(PKB), PDK 
(PDPK1), ITGA5, p27KIP1, Rac1, mTOR 
129 
Role of red blood cell 
adhesion to endothelium in 








RAP-1A, VCAM1, alpha-IIb/beta-3 integrin, alpha-
V/beta-3 integrin, RAP-1B, G-protein alpha-i family, 
BCAM, MEK1/2, Fibronectin, PKA-cat (cAMP-
dependent), CD47, CD147, CD36 
130 
Role of neuropeptides in 







Pyk2(FAK2), cPKC (conventional), G-protein alpha-12 
family, PKC, Neprilysin, PLC-beta, PKC-alpha, PI3K cat 
class IA (p110-beta), EGFR, H-Ras, Substance P 
receptor, MEK1/2, Fyn, G-protein alpha-q, SOS, 
AKT(PKB), G-protein alpha-q/11, IP3 receptor, mTOR 
131 
Transport_HDL-mediated 







APOA1, CES1, APOA2, SR-BI, Medium HDL, LCAT, 
Pre beta-1 HDL, Large alpha-1 HDL, Small HDL, 
APOE, PLTP, HDL, Nascent HDL, Large apoE-rich 
HDL 
132 
GLP-1 in inhibition of beta 
cell proliferation and function 







RAP-1A, AKT1, B-Raf, GLUT2, G-protein alpha-s, 
EGFR, IGF-2, CREB1, Beta-catenin, MEK1/2, HXK4, 
PDK (PDPK1), ADAM10, PKA-cat (cAMP-dependent) 
133 








Ubiquitin, RNF5, SEC61 complex, UBE1, HSC70, Csp, 
HSP105, UBE2J1, HSP90 
134 
Immune response_Fc gamma 








RhoA, Pyk2(FAK2), PI3K cat class IA, Vinculin, PKC-
alpha, Lyn, F-Actin cytoskeleton, ARF6, Myosin II, 













RhoA, ROCK, ICAM1, Lyn, HSP27, G-protein alpha-i 
family, F-Actin cytoskeleton, MEK3(MAP2K3), CDC42, 
Actin cytoskeletal, Fibrinogen gamma, AKT(PKB), 
Fibrinogen (fibrin), PDK (PDPK1), Rac1 
136 
wtCFTR and deltaF508 traffic 
/ Membrane expression 







Ubiquitin, Rab-4, RACK1, Annexin V, Calreticulin, 
EBP50, Filamin A, PIP5KI, SNAP-23, PKA-cat (cAMP-
dependent), EHD1, Rac1, E3KARP (NHERF2), Tubulin 
(in microtubules), VIL2 (ezrin) 
137 
Deficient alpha-MSH 







RhoA, PI3K cat class IA, B-Raf, PKA-cat alpha, N-Ras, 
CREB1, MEK1/2, AKT(PKB), PDK (PDPK1), PKA-cat 
(cAMP-dependent), SOX9, Rac1 
138 
IGF family, invasion and 







RhoA, ITGB1, Vitronectin, PI3K cat class IA, ITGAV, 
IGF-2, Alpha-1 catenin, Beta-catenin, alpha-V/beta-6 











NUMA1, Caspase-7, PARP-1, Tubulin alpha, ROCK2, 
tBid, Caspase-3, Lamin B1, Lamin A/C, DFF40 (CAD), 
Smac/Diablo, Bid 
140 
Immune response_Role of 








MEK1(MAP2K1), RACK1, Pyk2(FAK2), HLA-E, 
VCAM1, ICAM1, Lyn, H-Ras, MEK3(MAP2K3), SOS, 










ITGB1, Actomyosin, Cingulin, F-Actin, LYRIC, AF-6, 
ZO-1, Myosin II, ZO-3, CSDA, Claudin-3, Actin, ZO-2 
142 
Development_ACM2 and 







MEK1(MAP2K1), RAP-1A, Pyk2(FAK2), PLC-beta, 
PKC-alpha, EGFR, G-protein alpha-i family, H-Ras, 
CREB1, Caldesmon, Fyn, SOS, G-protein alpha-i2, IP3 
receptor 
143 
ESR1 (membrane) 36 kDa 








PI3K cat class IA, PLC-beta, PKC-alpha, EGFR, H-Ras, 
AL1A1, MEK1/2, G-protein alpha-q, SOS, AKT(PKB), 











Acid sphingomyelinase, Caspase-7, AKT1, PP2A 
structural, tBid, Caspase-3, RIPK1, HSP90 alpha, PP2A 











C8, C4a, C1 inhibitor, C6, CRP, Factor I, C5a, C8alpha, 
C4b, Clusterin, C5, C8gamma, C8beta, C9, C5b, C4 
146 
Chemotaxis_Inhibitory action 









Talin, Actomyosin, ICAM1, G-protein alpha-i family, 
MRLC, Myosin II, Actin cytoskeletal, Alpha-actinin, 
AKT(PKB), MELC, PDK (PDPK1), PIP5KI, MYLK1, 
Actin, MLCK, Rac1 
147 
Signal transduction_CXCR4 








Ubiquitin, MEK1(MAP2K1), RhoA, ROCK, PAK, RelA 
(p65 NF-kB subunit), K-RAS, N-Ras, G-protein alpha-i 
family, CREB1, Cortactin, MEK1/2, G-protein alpha-i2, 










Vitronectin, C8, CRIg, Factor B, C6, CRP, Factor I, C5a, 
Factor Bb, C8alpha, Clusterin, C5, Factor H, C9, C5b, 
Factor Ba 
149 
Proliferative action of Gastrin 







MEK1(MAP2K1), cPKC (conventional), PI3K cat class 
IA, PKC, PKC-alpha, EGFR, H-Ras, FAK1, CREB1, 
Beta-catenin, G-protein alpha-q, SOS, G-protein alpha-
q/11, PDK (PDPK1), p70 S6 kinase2, IP3 receptor 
150 
Fenofibrate in treatment of 








APOA1, APOA2, Fibrinogen alpha, SR-BI, Fibrinogen 
beta, APOC3, Fibrinogen gamma, ACOX1, Fibrinogen 
(fibrin), Acyl-CoA synthetase 
151 
DNA damage_Role of SUMO 







Ubiquitin, PML, SAE1/2, SAE2, AKT(PKB), SAE1, 
RanBP2, E2I 
152 
Proliferative action of Gastrin 







STAT3, MEK1(MAP2K1), RhoA, Pyk2(FAK2), PI3K 
cat class IA, PKC-alpha, H-Ras, LARG, FAK1, G-
protein alpha-q, SOS, PDK (PDPK1), p70 S6 kinase2, 
IP3 receptor 
153 








NUMA1, Caspase-7, PARP-1, BRE, HSP27, tBid, PAK2, 











MEK1(MAP2K1), cPKC (conventional), PI3K cat class 
IA, G-protein alpha-s, PKC-alpha, H-Ras, 
MEK3(MAP2K3), CDO1, CREB1, SOS, AKT(PKB), 
PDK (PDPK1), HPD, PKA-cat (cAMP-dependent), Rac1 
155 
Immune response_B cell 








MEK1(MAP2K1), VCAM1, RelA (p65 NF-kB subunit), 
B-Raf, NCK1, K-RAS, ICAM1, Lyn, N-Ras, H-Ras, 
MEK3(MAP2K3), VAV-2, MEK1/2, CDC42, Actin 
cytoskeletal, NF-kB, BCAP, AKT(PKB), SOS1, PDK 











EGF, PI3K cat class IA, DEPTOR, RPS16, RPL5, RPL7, 
RPL26, RPS6, RPL23, Insulin receptor, EGFR, RPL23a, 






Oxidative stress_Role of 
Sirtuin1 and PGC1-alpha in 








GSTP1, PRDX3, Thioredoxin, Heme oxygenase 1, 
GSTM5, PRDX5, GCL reg, MT-TRX, AMPK beta 
subunit, MSRA, AMPK alpha subunit, AMPK gamma 
subunit, PBEF, Catalase, NRF2, GSHR, NQO1 
158 
Role of growth factor 
receptors transactivation by 
Hyaluronic acid / CD44 







PI3K cat class IA, AKT1, PKC-alpha, EGFR, H-Ras, 
LARG, VAV-2, FAK1, MEK1/2, MDR1, Rac1, RhoGDI 
alpha 
159 
Role of adhesion of SCLC 







RhoA, ITGB1, VCAM1, CD81, ICAM1, alpha-V/beta-1 
integrin, FAK1, CDC42, alpha-5/beta-1 integrin, 
Fibronectin, CXCR4, Rac1 
160 








MEK1(MAP2K1), SREBP1 precursor, PI3K cat class IA, 
SREBP1 (nuclear), G-protein alpha-s, Insulin receptor, 
IGF-2, H-Ras, CREB1, SOS, AKT(PKB), IGF-2 












MEK1(MAP2K1), RAP-1A, B-Raf, K-RAS, N-Ras, H-
Ras, MEK3(MAP2K3), CDC42, R-Ras, Rac1 
162 
Development_S1P2 and S1P3 








MEK1(MAP2K1), RhoA, ROCK2, MYH11, H-Ras, 













Plasminogen, RhoA, PKC, alpha-V/beta-3 integrin, 
CREB1, Beta-catenin, CtBP, G-protein alpha-q, Plasmin, 
AKT(PKB), Fibronectin, LPP3, ILK 
164 
Role of alpha-6/beta-4 








EGF, PI3K cat class IA, AKT1, PKC-alpha, Neuregulin 
1, EGFR, eIF4E, Actin cytoskeletal, AKT(PKB), PDK 
(PDPK1), 14-3-3 theta, Rac1, IP3 receptor, mTOR 
165 








PPCKC, CYP2C8, GCR, SULT2A1, G6PT, CREB1, 
CYP7A1, HNF4-alpha, CD36 
166 








PPCKC, CYP2C8, GCR, SULT2A1, G6PT, CREB1, 
CYP7A1, HNF4-alpha, CD36 
167 
Autocrine production of 
eosinophil pro-survival 







ELAVL1 (HuR), PI3K cat class IA, AUF1, VCAM1, 










ITGB1, cPKC (conventional), Talin-1, PKC, PLC-beta, 
alpha-IIb/beta-3 integrin, MSN (moesin), Caspase-3, 
SLC21A2, Alpha-fodrin, Actin cytoskeletal, G-protein 
alpha-q, PTP-1B, Filamin A, Fibrinogen (fibrin), 
Fibronectin, MyHC, MYLK1, IP3 receptor 
169 








EGF, PI3K cat class IA, Neuregulin 1, EGFR, H-Ras, 
Beta-catenin, MEK1/2, SOS, NF-kB, AKT(PKB), Cullin 
3, PDK (PDPK1), p70 S6 kinase2, p27KIP1, Rac1, 
mTOR 
170 








ELAVL1 (HuR), EGF, PI3K cat class IA, RelA (p65 NF-
kB subunit), Neuregulin 1, alpha-V/beta-3 integrin, 
HSP27, EGFR, FAK1, Beta-catenin, G-protein alpha-q, 












STAT3, MEK1(MAP2K1), EGF, PI3K cat class IA, B-
Raf, K-RAS, NCOA3 (pCIP/SRC3), Neuregulin 1, 
EGFR, N-Ras, H-Ras, Beta-catenin, PP2A regulatory, 
HDAC1, SOS, AKT(PKB), PDK (PDPK1), DDX5 
172 
Development_G-protein-








MEK1(MAP2K1), RAP-1A, Pyk2(FAK2), G-protein 
alpha-12 family, B-Raf, G-protein alpha-s, PLC-beta, G-
protein alpha-i family, H-Ras, SOS, G-protein alpha-













Talin, alpha-IIb/beta-3 integrin, Vinculin, PI3K cat class 
IA (p110-beta), ITGB3, RAP-1B, G-protein alpha-i 
family, 14-3-3 zeta/delta, Actin cytoskeletal, Alpha-












STAT3, EGF, PI3K cat class IA, NCOA3 (pCIP/SRC3), 
Neuregulin 1, RPS6, EGFR, IGF-2, eIF4E, MEK1/2, 












MEK1(MAP2K1), Pyk2(FAK2), RelA (p65 NF-kB 
subunit), PKC-alpha, G-protein alpha-i family, H-Ras, G-
protein alpha-11, CDC42, G-protein alpha-q, SOS, NF-
kB, Rac1, IP3 receptor 
176 
Pancreatic cancer cell 








EGF, PI3K cat class IA, Neuregulin 1, EGFR, Beta-
catenin, Plakoglobin, AKT(PKB), PDK (PDPK1), 
Vimentin, mTOR 
177 
Regulation and signaling of 
HGF receptor (Met) and MSP 







STAT3, PI3K cat class IA, NCK1, K-RAS, PKC-alpha, 
H-Ras, MEK3(MAP2K3), FAK1, CREB1, CrkL, Beta-
catenin, CDC42, SOS, Alpha adducin, AKT(PKB), PDK 
(PDPK1), Paxillin, Rac1, Gamma adducin 
178 








PCC, PCCB, HADHA, MCC, MCCA, MUTA, PCCA, 
HMGCL, MMSA, HCD2, HCDH, MCEE, GABT, 
AOX1, HMGCS2, HIBCH, SCOT, ACDSB, ACAT1, 
MCCC2 
179 
Putative pathways for 
stimulation of fat cell 







SREBP1 precursor, A-FABP, PI3K cat class IA, GCR, 
SCD, GPD1, CREB1, Beta-catenin, AKT(PKB), PDK 
(PDPK1), FASN 
180 
Role of alpha-V/ beta-6 







Plasminogen, PKC, ITGAV, Caspase-3, MEK1/2, alpha-
V/beta-6 integrin, Plasmin, Fibronectin, ITGB6 
181 
G-protein 
signaling_Regulation of p38 








RhoA, Pyk2(FAK2), G-protein alpha-12 family, PLC-
beta, G-protein alpha-i family, MEK3(MAP2K3), LARG, 
VAV-2, PRK1, CDC42, G-protein alpha-q/11, Rac1 
182 
Immune response_IL-6 
signaling pathway via 








STAT3, gp130, PI3K cat class IA, Proepithelin, K-RAS, 
RPS6, N-Ras, H-Ras, eIF4E, CREB1, MEK1/2, SOS, 
AKT(PKB), MNK1, PDK (PDPK1), ADAM10, 
p27KIP1, IP3 receptor, mTOR 
183 
Chemoresistance pathways 
mediated by constitutive 
activation of PI3K pathway 








PI3K cat class IA, Caspase-7, PARP-1, RPS6, Caspase-3, 
FAK1, alpha-5/beta-1 integrin, AKT(PKB), PDK 
(PDPK1), Fibronectin, p70 S6 kinase2, c-Kit, mTOR 






ACACA, HADHA, SCS-G, BUP1, ACACB, ACAT2, 
HMGCL, MMSA, HCDH, GABT, ACADM, SUCLG2, 
HIBCH, SCOT, SUCLG1, ACAT1, ACSA 
185 
Effect of H. pylori infection 








MEK1(MAP2K1), RAP-1A, B-Raf, Lyn, EGFR, H-Ras, 
CREB1, CrkL, CRK, HDAC1, SOS1, Csk, p27KIP1, 
Histone H4, Rac1, IP3 receptor 
186 
Putative pathways of 
activation of classical 





















eEF2, NSF, cPKC (conventional), PIPKI gamma, PKC, 
PLC-beta, AP-2 alpha subunits, FMR1, AP complex 2 
medium (mu) chain, PKC-alpha, Beta-adaptin 2, ARF6, 
Actin cytoskeletal, G-protein alpha-q, Dynamin-2, 





Oxidative stress in adipocyte 
dysfunction in type 2 diabetes 







PRDX3, Heme oxygenase 1, A-FABP, Small LDL, 
GPX3, PI3K cat class IA, RelA (p65 NF-kB subunit), 
G6PD, AL3A2, Insulin receptor, APOE, AKT(PKB), 











Rich1, RhoGDI beta, Caspase-3, CDGAP, RHG7, 











MEK1(MAP2K1), RhoA, ROCK, PI3K cat class IA, 
PKC-alpha, FAK1, CDC42, G-protein alpha-q, 











RhoA, PI3K cat class IA, PLC-beta, ROCK2, G-protein 
alpha-i family, eNOS, G-protein alpha-q, AKT(PKB), 











RAP-1A, G-protein alpha-s, PKC, PHK alpha, PKC-
alpha, cAMP-GEFII, G-protein alpha-i family, PHK 
gamma, KDELR, CREB1, LIPS, PKA-cat (cAMP-
dependent) 
193 








MBL2, SP-A, Stabilin-2, alpha-V/beta-3 integrin, 





motor complex in axonal 







Ubiquitin, Importin (karyopherin)-beta, CDK5, DYNLL, 
Rab-7, MAPRE3(EB3), DYNLT, Importin 
(karyopherin)-alpha, BPAG1, AKT(PKB), PAFAH alpha 











MEK1(MAP2K1), RACK1, PI3K cat class IA, B-Raf, G-
protein alpha-s, Galpha(s)-specific peptide GPCRs, H-
Ras, CREB1, Beta-catenin, SOS, AKT(PKB), PDK 
(PDPK1), c-Kit, PKA-cat (cAMP-dependent) 
196 
Tissue Factor signaling in 







MEK1(MAP2K1), Pyk2(FAK2), EGF, G-protein alpha-
12 family, PI3K cat class IA, PKC-alpha, EGFR, H-Ras, 
SOS, AKT(PKB), G-protein alpha-q/11, Beta-arrestin1, 
IP3 receptor, mTOR 
197 
Immune response_IFN-
alpha/beta signaling via PI3K 







STAT3, p70 S6 kinases, PI3K cat class IA, AKT1, RelA 
(p65 NF-kB subunit), IFIT1, PKC-alpha, PDCD4, RPS6, 
DHFR, eIF4A, eIF4E, IFNAR2, CREB1, eIF4B, 
MEK1/2, NF-kB, eIF4G1/3, AKT(PKB), MNK1, PDK 
(PDPK1), p27KIP1 
198 
Role of Neuregulin 1 and 
Thymosin beta-4 in 








ITGB1, PI3K cat class IA, Neuregulin 1, alpha-5/beta-1 
integrin, Alpha-parvin, AKT(PKB), Thymosin beta-4, 
ITGA5, Fibronectin, ILK 
199 








DNAJB11, GRP78, PSMA7, PSMA5, DnaJB9, 
DNAJC3, PSMA6, ERP5 
200 
wtCFTR and deltaF508-CFTR 
traffic / Clathrin coated 








Epsin 1, Myosin I, HIP1, BIN1 (Amphiphysin II), Actin 
cytoskeletal, PICALM, Dynamin-2, Actin 
201 
Aberrant lipid trafficking and 









APCS, Vitronectin, CYP27A1, CD36L2, SR-BI, CRP, 
LDLR, Caspase-3, Clusterin, APOB, LDL, APOE, 
EEA1, HDL, Cathepsin D, CD36 


























NUMA1, Caspase-7, PARP-1, tBid, Caspase-3, RIPK1, 













MEK1(MAP2K1), p70 S6 kinases, G-protein alpha-i 
family, H-Ras, G-protein alpha-i3, SOS, Beta-arrestin1, 
Dynamin-2, p70 S6 kinase2, G-protein alpha-i2, mTOR 
206 
Development_PACAP 







MEK1(MAP2K1), RAP-1A, cPKC (conventional), B-
Raf, G-protein alpha-s, PLC-beta, cAMP-GEFII, 
Caspase-3, CREB1, G-protein alpha-q/11, PKA-cat 
(cAMP-dependent), IP3 receptor 
207 
Atorvastatin in treatment of 








MEK1(MAP2K1), RhoA, APOA1, GPX3, OATP8, 
APOC3, APOE, PLTP, GSHR, PON1, CD36, Rac1 
208 
VLDL, LDL dyslipidemia in 








Small LDL, Biglycan proteoglycan, SR-BI, MSR1, 
LDLR, VLDL1, Insulin receptor, APOC3, APOB, 
APOE, VLDL1 remnant, CD36 






STAT3, RhoA, PI3K cat class IA, B-Raf, N-Ras, 












Talin, RAP-1A, ITGB1, PI3K cat class IA, VCAM1, 
NCK1, ICAM1, Vinculin, PKC-alpha, MHC class I, 
CrkL, CDC42, Fyn, WASF2, Rac1 
211 
Regulation of lipid 
metabolism_Stimulation of 
Arachidonic acid production 







BETA-PIX, MEK1(MAP2K1), RhoA, Pyk2(FAK2), 
PKC, PKC-alpha, Monoglyceride lipase, 
MEK3(MAP2K3), G-protein alpha-11, ARF6, CDC42, 
G-protein alpha-q, G-protein alpha-i3, ADAM10, LPP3, 










MEK1(MAP2K1), PI3K cat class IA, RPS6, IGF-2, H-
Ras, 14-3-3 zeta/delta, eIF4E, CREB1, SOS, NF-kB, 
AKT(PKB), MNK1, PDK (PDPK1), p70 S6 kinase2 
213 
Pro-inflammatory action of 







ELAVL1 (HuR), MEK1(MAP2K1), RhoA, PI3K cat 
class IA, RelA (p65 NF-kB subunit), EGFR, H-Ras, 
LARG, FAK1, CREB1, G-protein alpha-q, SOS, 
AKT(PKB), G-protein alpha-q/11 
214 








RhoA, ITGB1, PI3K cat class IA, H-Ras, FAK1, 
MEK1/2, CDC42, SOS, NF-kB, AKT(PKB), PDK 










GCR Beta, GCR, FKBP4, GCR Alpha, NF-kB, HSP90, 
HSP70, E2I, p23 co-chaperone 
216 
Apoptosis and survival_Role 








Nucleolin, PI3K cat class IA, AKT1, Ebp1, DFF40 










Tubulin beta, Desmin, DCTN2, CDK5, Tubulin alpha, 











MEK1(MAP2K1), RAP-1A, SOS2, K-RAS, PKC-alpha, 
Lyn, N-Ras, H-Ras, CrkL, SOS, c-Kit, Rac1, IP3 receptor 
219 
Mechanisms of resistance to 








MEK1(MAP2K1), PI3K cat class IA, K-RAS, EGFR, H-
Ras, Beta-catenin, SOS, AKT(PKB), HSP90, PDK 











RhoA, ROCK2, PKC-alpha, MRLC, G-protein alpha-q, 











RhoA, Pyk2(FAK2), ROCK2, MSN (moesin), alpha-
V/beta-3 integrin, FAK1, CDC42, Actin cytoskeletal, 
PIP5KI, VIL2 (ezrin) 






Tubulin beta, Cingulin, Tubulin alpha, PKC, Connexin 
26, ZO-1, ZO-3, Actin, ZO-2, Tubulin (in microtubules) 
223 
Platelet activation as a result 








Plasminogen, RhoA, G-protein alpha-s, PKC, alpha-
IIb/beta-3 integrin, G-protein alpha-i family, Actin 
cytoskeletal, G-protein alpha-q, PDE2A, Plasmin, 
Fibrinogen (fibrin), PLC-beta3, PKA-cat (cAMP-














BETA-PIX, RhoA, ROCK, PKC, MRLC, CDC42, G-
protein alpha-q, G-protein alpha-i3, PDK (PDPK1), PLC-












Dyskerin (NAP57), hnRNP A1, PI3K cat class IA, PKC-
alpha, Ku70, AKT(PKB), HSP90, RPL22, PDK 
(PDPK1), hnRNP C, p23 co-chaperone 
226 
Role of Tissue factor in cancer 








MEK1(MAP2K1), PKC-alpha, Lyn, H-Ras, FAK1, 
CDC42, Actin cytoskeletal, SOS, Filamin A, AKT(PKB), 
Rac1 
227 
Putative pathways of MHC 
class I-dependent postsynaptic 








MHC Class I alpha chain, TAP1 (PSF1), Beta-2-
microglobulin, HLA-A, TAP2 (PSF2), MHC class I, 
PIRB, TAP 
228 
Role of GIP in pathogenesis of 







Ubiquitin, RAP-1A, B-Raf, G-protein alpha-s, cAMP-
GEFII, MEK3(MAP2K3), Caspase-3, AMPK alpha 












MEK1(MAP2K1), Pyk2(FAK2), PI3K cat class IA, PLC-
beta, EGFR, H-Ras, SOS, AKT(PKB), G-protein alpha-
q/11, PDK (PDPK1), p70 S6 kinase2, IP3 receptor, 
mTOR 
230 
Regulation of lipid 
metabolism_Insulin regulation 







MEK1(MAP2K1), PI3K cat class IA, PYGL, PHK alpha, 
PHK gamma (liver), Insulin receptor, G6PT, H-Ras, PHK 
gamma, HXK4, SOS, PHK beta, AKT(PKB), PDK 
(PDPK1), PKA-cat (cAMP-dependent) 
231 
Pioglitazone and 
Rosiglitazone in treatment of 








PPCKC, A-FABP, GLUT2, SR-BI, Insulin receptor, 
GPD1, HXK4, SORBS1, CD36 
232 
Pro-tumoral TNF-alpha 







ITGB1, RhoGDI beta, PI3K cat class IA, VCAM1, 
AKT1, Filamin-A (CTF), MHC class I, alpha-5/beta-1 
integrin, NF-kB, AKT(PKB), PDK (PDPK1), Fibronectin 
233 
Transcription_Sin3 and NuRD 







Mi-2, Histone H3, SAP18, Mi-2 beta, HDAC1, NRB54, 
PSF, RBBP4 (RbAp48), p66alpha, MTA2, ARID4A, 
Histone H4 
234 








PI3K cat class IA, H-Ras, VAV-2, FAK1, GSTM1, 
MEK1/2, SOS, AKT(PKB), PDK (PDPK1), Paxillin, 
Rac1 
235 
Statin action on the PI3K/ Akt 







RhoA, ROCK, p70 S6 kinases, PI3K cat class IA, eNOS, 
AKT(PKB), HSP90, p70 S6 kinase2, p27KIP1, NIP3, 
mTOR 






THEM2, PCC, PCCB, 3HIDH, MUTA, PCCA, MMSA, 
HCD2, HCDH, MCEE, ACSA 
237 
E-cadherin signaling and its 







Ubiquitin, RhoA, EGF, EGFR, Beta-catenin, Alpha-
actinin, IQGAP1, Plakoglobin, p120-catenin, Actin, 
Alpha-catenin 






MEK1(MAP2K1), Vitronectin, RelA (p65 NF-kB 
subunit), B-Raf, ICAM1, alpha-V/beta-3 integrin, G-
protein alpha-i family, Beta-catenin, NF-kB, AKT(PKB), 
PKA-cat (cAMP-dependent) 






PKC, Histone H3, HMGB1, Pin1, HP1 beta, Histone H2, 
Histone H2A, Histone H1.2, Histone H4, Histone H1 
240 
Transport_Macropinocytosis 







EGF, K-RAS, BAIAP2, EGFR, AMPK beta subunit, H-
Ras, VAV-2, AMPK alpha subunit, AMPK gamma 
subunit, CDC42, Actin cytoskeletal, SOS, AKT(PKB), 













Talin, RhoA, RAP-1A, ITGB1, VCAM1, ICAM1, 
Vinculin, PKA-cat alpha, G-protein alpha-i family, Csk, 











MEK1(MAP2K1), PI3K cat class IA, ATP1A1, ATP1B1, 
PLC-beta, PKC-alpha, G-protein alpha-i family, H-Ras, 











MEK1(MAP2K1), Pyk2(FAK2), PI3K cat class IA, G-
protein alpha-s, G-protein alpha-i family, H-Ras, Beta-
catenin, CDC42, SOS, AKT(PKB), G-protein alpha-q/11, 











RelA (p65 NF-kB subunit), G-protein alpha-s, ENPP1, 
H-Ras, eNOS, CREB1, ARF6, MEK1/2, SOS, 











RhoA, Vinculin, ZO-1, H-Ras, FAK1, CREB1, MEK1/2, 
CDC42, SOS, AKT(PKB), Beta-arrestin1, PDK 
(PDPK1), PLC-beta3, G-protein alpha-i2, Cathepsin B, 
Rac1, IP3 receptor 






ALDOB, F261, MANA, AMYP, ALDOA, F263, DHSO, 
HXK1, G6PT, KHK, GPI, ALDR, GALM, HXK4, 
AK1BA, AMYS, F16Q, PMM2, F16P 
247 
Development_PIP3 signaling 







G-protein alpha-12 family, PI3K cat class IA, RPS6, 
Insulin receptor, H-Ras, 14-3-3, CREB1, CDC42, PTP-
1B, SOS, AKT(PKB), PDK (PDPK1), mTOR 
248 
EGF- and HGF-dependent 



















MEK1(MAP2K1), RhoA, G-protein alpha-12 family, 
PLC-beta, G-protein alpha-i family, H-Ras, CDC42, IP3 
receptor 
250 
Translation_Role of Retinoic 








CRM1, FMR1, RPS6, H-Ras, eIF4E, PUR-alpha, 
MEK1/2, mTOR 
251 








MEK1(MAP2K1), PI3K cat class IA, G-protein alpha-s, 
EGFR, H-Ras, 14-3-3, SOS, PP2C, AKT(PKB), PDK 
(PDPK1), p70 S6 kinase2, PKA-cat (cAMP-dependent) 






CYP1A2, CYP2C8, UGT2B28, UGT1A10, SULT2A1, 
CYP3A5, SULT1E1, COMT, CYP3A4, SULT1A1, 
UGT2B17, UGT1A4 
253 
Down-regulation of mast cell 
functions through ITIM-








K-RAS, Lyn, alpha-V/beta-3 integrin, MHC class I, Fyn, 
PECAM1, SOS1, Csk, PIRB, c-Kit, CD47 
254 








RhoA, NCK1, BAIAP2, F-Actin cytoskeleton, PAK2, 
CDC42, Actin cytoskeletal, POR1, PIP5KI, WASF2, 
Rac1 
255 
Attenuation of IFN type I 







STAT3, TAP1 (PSF1), STAT2, HLA-A, TAP2 (PSF2), 
IFNAR2, MHC class I, PSMB9, Tapasin, TAP, Rac1 
256 
DeltaF508-CFTR traffic / 








Ubiquitin, Hrs, NSF, Rab-7, VPS45A, EEA1, Vps25, 
TSG101, VAMP2 
257 









STAT3, MEK1(MAP2K1), PI3K cat class IA, B-Raf, K-
RAS, EGFR, H-Ras, EML4, NF-kB, AKT(PKB) 
258 








Heme oxygenase 1, PSMA1, PSMB6, GCL reg, DJ-1, 














STAT3, MEK1(MAP2K1), EGFR, H-Ras, CREB1, Beta-
catenin, PTP-1B, SOS, AKT(PKB), PDK (PDPK1), 
AMACR, PKA-cat (cAMP-dependent), mTOR 
260 
Neurophysiological 








RhoA, cPKC (conventional), PKC, PLC-beta, ROCK2, 
PKC-alpha, G-protein alpha-i family, G-protein alpha-11, 
G-protein alpha-q, G-protein alpha-q/11, G-protein alpha-
i2, PKA-cat (cAMP-dependent), IP3 receptor 
261 
Development_Role of 
proteases in hematopoietic 







VCAM1, alpha-5/beta-1 integrin, DPP4, Fibronectin, c-












Casein kinase II, alpha chains, RACK1, Pyk2(FAK2), 
cPKC (conventional), CDK5, G-protein alpha-s, PKC, 
PLC-beta, CASK, G-protein alpha-i family, MALS, Fyn, 











STAT3, MEK1(MAP2K1), EGF, PI3K cat class IA, 
Caspase-7, PARP-1, NCK1, PKC-alpha, EGFR, H-Ras, 
FAK1, SOS, NF-kB, AKT(PKB), PDK (PDPK1), ILK, 
Rac1 
264 
Nicotine signaling in 








Plasminogen, CDK5, G-protein alpha-s, PLC-beta, G-
protein alpha-i family, CREB1, Casein kinase I epsilon, 
G-protein alpha-q, Plasmin, PKA-cat (cAMP-dependent), 












PPCKC, SREBP1 precursor, AdipoR2, ACACA, Raptor, 
Insulin receptor, G6PT, AMPK alpha subunit, CREB1, 
ACADM, ACOX1, mTOR 
266 
ERBB family and HGF 







STAT3, EGF, PI3K cat class IA, Neuregulin 1, EGFR, 
H-Ras, GRB7, MEK3(MAP2K3), Beta-catenin, MEK1/2, 
SOS, AKT(PKB), PDK (PDPK1), p27KIP1 
267 
Cell adhesion_Role of CDK5 






5 Talin, ITGB1, CDK5, Beta-catenin, Alpha-catenin 
268 
G-protein signaling_G-Protein 







MEK1(MAP2K1), RhoA, RAP-1A, ROCK, G-protein 
alpha-12 family, PI3K cat class IA, LARG, CDC42, R-
Ras, PKA-cat (cAMP-dependent), Rac1 
269 
wtCFTR and deltaF508-CFTR 
traffic / Generic schema 







Ubiquitin, Rab-4, Hrs, PIST (CAL), Rab-7, VAMP8, 
Coatomer, EBP50, Vps25, TSG101, VAMP2 
270 
Impaired macrophage 







GSTP1, RhoA, ROCK, SP-A, GCL reg, Calreticulin, 
GSTM1, GSTT1, NRF2, LRP1, Rac1 
271 
HDL dyslipidemia in type 2 








Small LDL, APOA1, LCAT, Pre beta-1 HDL, Large 











G-protein alpha-s, AMPK beta subunit, G-protein alpha-i 
family, AMPK alpha subunit, AMPK gamma subunit, 
KPYR, PKA-cat (cAMP-dependent), Acyl-CoA 
synthetase 
273 
Role of stellate cells in 








MEK1(MAP2K1), PI3K cat class IA, RelA (p65 NF-kB 
subunit), alpha-V/beta-3 integrin, EGFR, H-Ras, FAK1, 
Galectin-1, alpha-5/beta-1 integrin, SOS, AKT(PKB), 











RAP-1A, PI3K cat class IA, AUF1, CRM1, PKC, PLC-
beta, G-protein alpha-i family, H-Ras, eNOS, MEK1/2, 




mediated MAPK activation 







GSTP1, Pyk2(FAK2), EGFR, H-Ras, MEK3(MAP2K3), 
RIPK1, MEK1/2, CDC42, Fyn, CRK, SOS, SFK, Rac1, 





SDF-1 axis in endothelial 
progenitor cell recruitment in 







Heme oxygenase 1, ICAM1, RPS6, eNOS, AKT(PKB), 
PDK (PDPK1), ILK, CXCR4, Rac1, mTOR 
277 
Development_EGFR signaling 







EGF, PI3K cat class IA, K-RAS, EGFR, N-Ras, H-Ras, 
VAV-2, MEK1/2, SOS, Rac1 
278 
Development_Activation of 








RhoA, PI3K cat class IA, eIF4E, ARF6, G-protein alpha-




proliferation of Type C cells 







MEK1(MAP2K1), EGF, PI3K cat class IA, EGFR, H-
Ras, Fyn, SOS, AKT(PKB), PDK (PDPK1), p27KIP1 
280 
Rho-dependent regulation of 








RACK1, RhoA, ROCK, PKC, PLC-beta, G-protein 












RhoA, Pyk2(FAK2), ROCK, G-protein alpha-12 family, 
NCK1, EPHX2, ROCK2, Vinculin, MRLC, LARG, 
eNOS, FAK1, CRK, G-protein alpha-q/11, MLCK, 










Plasminogen, Vitronectin, MSN (moesin), EGFR, IGF-2, 
MMP-12, alpha-5/beta-1 integrin, Actin cytoskeletal, 
alpha-1/beta-1 integrin, Plasmin, Fibronectin, Kallikrein 










RhoA, Pyk2(FAK2), ROCK, PI3K cat class IA, Lyn, G-
protein alpha-i family, H-Ras, MEK1/2, CDC42, Actin 
cytoskeletal, SOS, Paxillin, Rac1, IP3 receptor 
284 








MEK1(MAP2K1), ITGB1, ROCK, AKT1, Raptor, B-
Raf, ITGB3, SRp55, AMPK alpha subunit, MEK1/2, 
RKIP, AKT(PKB), Nicastrin, mTOR 
285 
Development_WNT/Beta-








Casein kinase II, alpha chains, RhoA, G-protein alpha-s, 
DAAM1, MACF1, VAV-2, Casein kinase II, Casein 
kinase I epsilon, Beta-catenin, G-protein alpha-q, 
AKT(PKB), p120-catenin, PLC-beta3, Rac1 
286 
Development_Activation of 








MEK1(MAP2K1), RAP-1A, Pyk2(FAK2), B-Raf, PKC-
alpha, EGFR, H-Ras, G-protein alpha-11, CREB1, G-
protein alpha-q, SOS, IP3 receptor 
287 
Development_Ligand-
independent activation of 







MEK1(MAP2K1), EGF, PI3K cat class IA, G-protein 
alpha-s, NCOA3 (pCIP/SRC3), Neuregulin 1, EGFR, H-
Ras, SOS, AKT(PKB), PDK (PDPK1), PKA-cat (cAMP-
dependent) 






MEK1(MAP2K1), PI3K cat class IA, H-Ras, 
MEK3(MAP2K3), CrkL, CDC42, Fyn, CRK, SOS, 










RAP-1A, B-Raf, PLC-beta, HSP27, G-protein alpha-i 
family, C5a, F-Actin cytoskeleton, MEK1/2, CDC42, 










RhoA, AKT1, PLC-beta, G-protein alpha-i family, eNOS, 
CDC42, G-protein alpha-i3, AKT(PKB), PDK (PDPK1), 
G-protein alpha-i2, Rac1, IP3 receptor 
291 
Immune response_IL-11 
signaling pathway via 








p70 S6 kinases, gp130, RelA (p65 NF-kB subunit), 
ICAM1, RPS6, H-Ras, Caspase-3, CREB1, MEK1/2, 













MRLC, Myosin II, G-protein alpha-q, AKT(PKB), 
















MEK1(MAP2K1), PI3K cat class IA, VCAM1, K-RAS, 











PI3K cat class IA, PARP-1, CRM1, HMGB1, PKC-
alpha, MEK1/2, NF-kB, PDK (PDPK1), Karyopherin 










STAT3, MEK1(MAP2K1), PARP-1, PP2A structural, G-
protein alpha-i family, H-Ras, Caspase-3, PP2A 
regulatory, SOS, NF-kB, AKT(PKB), PDK (PDPK1), 
PKA-cat (cAMP-dependent) 
296 
Development_Role of CDK5 







DCTN2, PI3K cat class IA, CDK5, Beta-catenin, Actin 
cytoskeletal, Fyn, Pin1, AKT(PKB), PAFAH alpha 










STAT3, MEK1(MAP2K1), gp130, PI3K cat class IA, H-
Ras, LIFR, SOS, AKT(PKB), p70 S6 kinase2, mTOR 
298 
Impaired inhibitory action of 
lipoxins on neutrophil 







Talin, ICAM1, G-protein alpha-i family, MRLC, Myosin 
II, Actin cytoskeletal, Alpha-actinin, AKT(PKB), MELC, 
PDK (PDPK1), PIP5KI, MYLK1, MLCK, Rac1 
299 









Cullin 1, Tubulin beta, UBE1, Tubulin alpha, CASK, 
UBC7, HSP70, UBC6 
300 
Development_Dopamine D2 








MEK1(MAP2K1), PI3K cat class IA, EGFR, G-protein 
alpha-i family, H-Ras, SOS, AKT(PKB), PDK (PDPK1) 
301 
Muscle contraction_Oxytocin 








MEK1(MAP2K1), RhoA, eEF2, ROCK, cPKC 
(conventional), PKC, PKC-alpha, EGFR, H-Ras, LARG, 
G-protein alpha-i3, PGES2, G-protein alpha-q/11, PLC-
beta3, IP3 receptor 
302 
Development_Gastrin in cell 







STAT3, MEK1(MAP2K1), PI3K cat class IA, PKC-
alpha, EGFR, H-Ras, FAK1, CREB1, Beta-catenin, G-
protein alpha-q, SOS, G-protein alpha-q/11, PDK 
(PDPK1), p70 S6 kinase2, IP3 receptor 
303 
Development_Alpha-2 








MEK1(MAP2K1), Pyk2(FAK2), CYP2C8, PI3K cat 
class IA, Monoglyceride lipase, EGFR, G-protein alpha-i 
family, H-Ras, G-protein alpha-i3, SOS, AKT(PKB), 
PDK (PDPK1), PLC-beta3, G-protein alpha-i2, IP3 
receptor 
304 
Role of TNF-alpha, IL-1beta 
and IL-6 in development of 








STAT3, APOA1, AKT1, RelA (p65 NF-kB subunit), 
CRP, Insulin receptor, G6PT, APOB, HSP90 alpha, PTP-
1B, HXK4, mTOR 
305 








ELAVL1 (HuR), MEK1(MAP2K1), RhoA, PI3K cat 
class IA, PKC-alpha, EGFR, H-Ras, LARG, FAK1, 
CREB1, G-protein alpha-q, SOS, AKT(PKB), G-protein 
alpha-q/11, PDK (PDPK1), IP3 receptor 






Small LDL, APOA1, APOA2, SR-BI, Medium HDL, 
LDLR, VLDL1, LCAT, Pre beta-1 HDL, APOB, APOE, 
APOC2, PLTP, VLDL2, Nascent HDL, Large LDL 
307 
Transcription_Role of 
heterochromatin protein 1 








TIF1-beta, Mi-2, MeCP2, Histone H3, CtBP, HDAC1, 
HP1 beta, E2I, HP1 gamma, HP1, Histone H4 
308 
Immune response_M-CSF-







STAT3, MEK1(MAP2K1), RhoA, Pyk2(FAK2), PI3K 
cat class IA, PKC, MSR1, H-Ras, Beta-catenin, CDC42, 
Fyn, CRK, NF-kB, AKT(PKB), SOS1, PDK (PDPK1), 













RhoA, G-protein alpha-i family, FAK1, G-protein alpha-
q, AKT(PKB), PDK (PDPK1), PLC-beta3, G-protein 
alpha-i2, IP3 receptor, G-protein alpha-13 
310 
Anti-apoptotic action of 







RhoA, PI3K cat class IA, RelA (p65 NF-kB subunit), 
MEK3(MAP2K3), Caspase-3, LARG, FAK1, G-protein 
alpha-q, AKT(PKB), PDK (PDPK1) 
311 
Neurophysiological 
process_Ephrin-B receptors in 








BETA-PIX, NCK1, Synbindin, Cortactin, CDC42, Actin 
cytoskeletal, Fyn, Dynamin-2, Intersectin, Rac1 






VLDL, APOA1, SR-BI, NNMT, HDL proteins, LIPP, 










RhoA, ROCK, cPKC (conventional), PLC-beta, Ca-
ATPase2, CaMK I, CREB1, Calcipressin 1, PKA-cat 











STAT3, MEK1(MAP2K1), Pyk2(FAK2), EGF, AKT1, 
EGFR, H-Ras, Beta-catenin, SOS, AKT(PKB), PKA-cat 
(cAMP-dependent), VIL2 (ezrin) 
315 
Development_FGF2-







RhoA, PI3K cat class IA, CDC42, AKT(PKB), PDK 
(PDPK1), p27KIP1, Rac1 
316 








STAT3, MEK1(MAP2K1), Pyk2(FAK2), H-Ras, FAK1, 
HDAC1, SOS 
317 
Role of histone modificators 








Tubulin alpha, Histone H3, K-RAS, N-Ras, Caspase-3, 
HDAC1, p27KIP1, Histone H4, CDK6 
318 
Inhibition of Ephrin receptors 







RhoA, RAP-1A, ROCK, VAV-2, FAK1, Beta-catenin, 











Histone H3, SET, Histone H2B, Lamin B1, Lamin A/C, 
PHAP1 (pp32), Ku70, APEX, Histone H1 
320 
Development_ROBO2, 








MYH9, NCK1, ARF6, Myosin II, CDC42, alpha-5/beta-1 










G3P2, PPCKC, TPI1, ALDOB, ALDOA, GLUT2, 
HXK1, G6PT, PGAM4, GPI, PYC, KPYR, GALM, 
HXK4, ENO1, PGAM1, MDH1, PGK1, F16Q, F16P 






Junctin, MEK1(MAP2K1), PI3K cat class IA, PKC, 
EGFR, IGF-2, H-Ras, RKIP, SOS, GSTA2, AKT(PKB), 
IGF-2 receptor, PDK (PDPK1) 
323 
Hyaluronic acid/ CD44 







STAT3, RhoA, ROCK, AKT1, PDCD4, LARG, VAV-2, 
CDC42, Actin cytoskeletal, IQGAP1, Filamin A, DDX5, 
MDR1, Rac1 
324 
TGF-beta signaling via kinase 







Ubiquitin, MEK1(MAP2K1), ITGB1, RelA (p65 NF-kB 
subunit), ITGAV, Neuregulin 1, ITGB3, alpha-V/beta-3 













SEP15, Selenoprotein K, GPX3, DIO1, RPL30, 
Selenoprotein P, GPX4, SEPHS1, SEPX1 (Selenoprotein 










MEK1(MAP2K1), Vitronectin, PI3K cat class IA, PKC-
alpha, alpha-V/beta-3 integrin, H-Ras, alpha-5/beta-1 










AK2, NDPK C, PCY1A, UDP, BUP1, DPYD, DPYS, 
RRP46, KCY, RPB8, PR44 (DIS3), CTP synthase, 
RPB10, PD-ECGF (TdRPase), POLR2I, POLR2B, CDD, 












Casein kinase II, alpha chains, HECTD1, ITGB1, EGF, 
Insulin receptor, USP7, 14-3-3 zeta/delta, Alpha-1 
catenin, FAK1, 14-3-3, PP2C alpha, Beta-catenin, 
HSP105, AKT(PKB), PKA-cat (cAMP-dependent), ILK, 
Rac1 
329 
G protein-coupled receptors 







STAT3, RhoA, Pyk2(FAK2), EGF, G-protein alpha-12 
family, RelA (p65 NF-kB subunit), G-protein alpha-s, 
alpha-V/beta-3 integrin, EGFR, G-protein alpha-i family, 
Galpha(i)-specific peptide GPCRs, Galpha(q)-specific 
peptide GPCRs, AKT(PKB), G-protein alpha-q/11, PDK 
(PDPK1), PKA-cat (cAMP-dependent), CXCR4 
330 








HPGD, PI3K cat class IA, AKT1, EGFR, H-Ras, FAK1, 
Beta-catenin, MEK1/2, Actin cytoskeletal, SOS, 
AKT(PKB), ADAM10, Rac1, mTOR, VIL2 (ezrin) 
331 
Signal transduction_PDGF 








PDK1, RelA (p65 NF-kB subunit), MYH11, K-RAS, 
PI3K cat class IA (p110-beta), Transgelin, Beta-catenin, 
YB-1, NF-kB, AKT(PKB), SOS1, PDK (PDPK1), 










STAT3, MEK1(MAP2K1), RAP-1A, PI3K cat class IA, 
H-Ras, CrkL, Beta-catenin, CRK, SOS, AKT(PKB), 
PDK (PDPK1), Rac1 
333 
Transport_Alpha-2 adrenergic 








G-protein alpha-s, PKC, Sorcin, G-protein alpha-i family, 
G-protein alpha-q, G-protein alpha-i3, AKT(PKB), PDK 
(PDPK1), PLC-beta3, G-protein alpha-i2, PKA-cat 
(cAMP-dependent), IP3 receptor 
334 
HBV signaling via protein 







MEK1(MAP2K1), Pyk2(FAK2), cPKC (conventional), 
PKC, PKC-alpha, IGF-2, H-Ras, FAK1, SOS, Pin1 
335 
Development_SSTR2 in 







MEK1(MAP2K1), RAP-1A, PI3K cat class IA, B-Raf, 











MEK1(MAP2K1), RAP-1A, B-Raf, G-protein alpha-s, 
cAMP-GEFII, H-Ras, CREB1, KPYR, Alpha adducin, 
PKA-cat (cAMP-dependent) 
















PI3K cat class IA, VCAM1, K-RAS, HMGB1, ICAM1, 
FAK1, CREB1, MEK1/2, CDC42, NF-kB, AKT(PKB), 
Paxillin, Rac1 
339 
Regulation of VEGF 







STAT3, RhoA, ROCK, gp130, PI3K cat class IA, alpha-
V/beta-3 integrin, NF-kB, AKT(PKB), HSP90, RhoC, 
PDK (PDPK1), c-Kit, mTOR 
340 
Immune response_Induction 
of the antigen presentation 







TAP1 (PSF1), Beta-2-microglobulin, HLA-E, HLA-A, 
WDR5, PSMB10, TAP2 (PSF2), MHC class I, PSMB9, 
HLA-F, Tapasin, HLA-DQA1, Cathepsin S 
341 
Muscle contraction_GPCRs in 








RhoA, ROCK, G-protein alpha-12 family, G-protein 
alpha-s, PLC-beta, PKC-alpha, G-protein alpha-i family, 
MRLC, LARG, Telokin, Myosin II, G-protein alpha-q, 
G-protein alpha-q/11, MELC, MyHC, PKA-cat (cAMP-
dependent), MLCK, IP3 receptor 
342 
Immune response _CCR3 







MEK1(MAP2K1), RhoA, ROCK, ROCK2, PKC-alpha, 
G-protein alpha-i family, H-Ras, MRLC, VAV-2, Myosin 
II, Actin cytoskeletal, MELC, PDK (PDPK1), MyHC, 
MLCK, Rac1, IP3 receptor 
343 








BETA-PIX, cPKC (conventional), PI3K cat class IA, 
AKT1, PKC, PLC-beta, PKC-alpha, VAV-2, MEK1/2, 
Pin1, AKT(PKB), PDK (PDPK1), Rac1, IP3 receptor 
344 
Development_Activation of 








MEK1(MAP2K1), Pyk2(FAK2), PLC-beta, PKC-alpha, 






Neutrophil adhesion and 








GLG1, VCAM1, HMGB1, ICAM1, alpha-9/beta-1 
integrin, H-Ras, C5a, Substance P receptor, MEK1/2 
346 
Alternative complement 
cascade disruption in age-







Factor B, CRP, Factor I, C5a, Factor Bb, C5, Factor H, 
C5b, Factor Ba 
347 








EGF, PI3K cat class IA, B-Raf, K-RAS, EGFR, G-
protein alpha-i family, H-Ras, CREB1, Beta-catenin, 
MEK1/2, SOS, NF-kB, AKT(PKB), PKA-cat (cAMP-
dependent), ILK 
348 








PKC, PLC-beta, G-protein alpha-i family, eNOS, G-
protein alpha-11, G-protein alpha-q, G-protein alpha-i3, 
G-protein alpha-q/11, PKA-cat (cAMP-dependent), 
MLCK, IP3 receptor 
349 
Role of ZNF202 in regulation 
of expression of genes 


















MEK1(MAP2K1), RAP-1A, B-Raf, G-protein alpha-s, 
PI3K cat class IA (p110-beta), G-protein alpha-i family, 











Ubiquitin, MEK1(MAP2K1), PI3K cat class IA, H-Ras, 
Perlecan, Syndecan-4, CREB1, CRK, SOS, AKT(PKB), 
PDK (PDPK1), Rac1, IP3 receptor 
352 
Membrane-bound ESR1: 








MEK1(MAP2K1), G-protein alpha-s, PKC-alpha, EGFR, 
G-protein alpha-i family, H-Ras, eNOS, CREB1, G-
protein alpha-q, SOS, Striatin, PKA-cat (cAMP-
dependent), IP3 receptor 
353 
Development_Growth factors 
in regulation of 








PI3K cat class IA, RelA (p65 NF-kB subunit), 
Neuregulin 1, Lyn, 14-3-3 zeta/delta, Caspase-3, Fyn, 
AKT(PKB), PDK (PDPK1), mTOR 






PYGB, UGPA2, PYGL, HXK1, GLGB, GPI, PGMU, 
GALM, HXK4, GDE 
355 
Immune response_Regulation 







PI3K cat class IA, AP complex 2 medium (mu) chain, 
Lyn, H-Ras, Beta-adaptin 2, Fyn, SOS, NF-kB, 
AKT(PKB), PDK (PDPK1) 
356 








RelA (p65 NF-kB subunit), IGF-2, H-Ras, eIF4E, 
Clusterin, Beta-catenin, MEK1/2, SOS, NF-kB, 




induction of expression of 
mucins in normal and 







MEK1(MAP2K1), G-protein alpha-s, PLC-beta, PKC-
alpha, EGFR, G-protein alpha-i family, CREB1, NF-kB, 
G-protein alpha-q/11, PKA-cat (cAMP-dependent), IP3 
receptor 
358 
Role of cell adhesion in vaso-








GLG1, VCAM1, alpha-IIb/beta-3 integrin, ICAM1, 
alpha-V/beta-3 integrin, BCAM, PECAM1, Fibrinogen 











Caspase-7, BRE, tBid, Caspase-3, RIPK1, SODD, jBid, 
NF-kB, Smac/Diablo, GCK(MAP4K2), Bid 
360 
Selective Insulin resistance in 







PPCKC, AKT1, Insulin receptor, G6PT, KPYR, PTP-1B, 
HXK4, AKT(PKB), PDK (PDPK1) 
361 
Androstenedione and 








UGT2B28, AKR1C4, UGT1A10, AK1D1, AKR1C1, 













Tubulin beta, PI3K cat class IA, Tubulin alpha, Histone 
H3, Insulin receptor, PDK (PDPK1), Ran, Histone H1, 




Sphingosine 1-phosphate and 
Complement cascade in 








RhoA, RAP-1A, VCAM1, VAV-2, CREB1, CDC42, 
AKT(PKB), CXCR4, Rac1 
364 









Neprilysin, ENPEP, Tissue kallikreins, Carboxypeptidase 












RhoA, Pyk2(FAK2), ROCK, PI3K cat class IA, ICAM1, 
PKC-alpha, HIP1, MEK3(MAP2K3), Caspase-3, 
CREB1, NF-kB, AKT(PKB), HSP70, CXCR4, IP3 




AGTR1 signaling via p38, 







ELAVL1 (HuR), Pyk2(FAK2), p70 S6 kinases, PI3K cat 
class IA, CYP11B2, EGFR, H-Ras, eIF4E, CREB1, 
MEK1/2, Fyn, G-protein alpha-q, SOS, AKT(PKB), 
ATOX1, MNK1, Catalase, PDK (PDPK1), PKA-cat 
(cAMP-dependent), CaMK II delta 
367 
Activation of TNF-alpha-
dependent pro-tumoral effect 







VCAM1, RelA (p65 NF-kB subunit), G-protein alpha-s, 
K-RAS, ICAM1, H-Ras, RIPK1, ALDR, Beta-catenin, 
MEK1/2, SOS, NF-kB 
368 
Glucocorticoids-mediated 
inhibition of pro-constrictory 
and pro-inflammatory 








RhoA, RelA (p65 NF-kB subunit), GCR Beta, G-protein 
alpha-s, GCR, CD38, MRLC, Myosin II, GCR Alpha, 
NF-kB, PLA2, Histone H4 
369 
Neurophysiological 
process_HTR2A signaling in 







RACK1, Heme oxygenase 1, cPKC (conventional), PKC, 
PLC-beta, CDC42, AKT(PKB), G-protein alpha-q/11, 










STAT3, RhoA, ROCK, alpha-IIb/beta-3 integrin, G-
protein alpha-i family, F-Actin cytoskeleton, MEK1/2, 
NF-kB, AKT(PKB), PDK (PDPK1), CD163, mTOR 
371 
Immune response_IL-2 








STAT3, p70 S6 kinases, PI3K cat class IA, Lyn, RPS6, 
H-Ras, CrkL, MEK1/2, Fyn, NF-kB, AKT(PKB), SOS1, 
p70 S6 kinase2, p27KIP1, Rac1, mTOR 
372 
Transcription_Transcription 








PKC, PLC-beta, Insulin receptor, G-protein alpha-11, G-
protein alpha-q, G-protein alpha-q/11 


















STAT3, STAT2, PI3K cat class IA, PLC-beta, G-protein 
alpha-i family, F-Actin cytoskeleton, MEK3(MAP2K3), 
G-protein alpha-q, NF-kB, AKT(PKB), Beta-arrestin1, 
PKA-cat (cAMP-dependent), IP3 receptor 
375 
G-protein signaling_G-Protein 







STAT3, MEK1(MAP2K1), RAP-1A, B-Raf, G-protein 
alpha-i family, H-Ras, SOS, PKA-cat (cAMP-dependent) 
376 
Insulin-dependent stimulation 








SREBP1 precursor, INSIG2, ACACA, SREBP1 
(nuclear), Insulin receptor, PDK (PDPK1), FASN, 















MEK1(MAP2K1), Vitronectin, PI3K cat class IA, PKC, 
Neuregulin 1, Lyn, alpha-V/beta-3 integrin, EGFR, H-












PDK1, RAP-1A, PI3K cat class IA, RelA (p65 NF-kB 
subunit), B-Raf, ITGA2B, H-Ras, CREB1, CrkL, 











G-protein alpha-i family, VAV-2, CDC42, SOS, 
AKT(PKB), PDK (PDPK1), PLC-beta3, Rac1, IP3 
receptor, mTOR 
380 
Insulin-like growth factor 







MEK1(MAP2K1), PI3K cat class IA, PKC, IGF-2, H-













RhoA, PLC-beta, ROCK2, G-protein alpha-i family, G-
protein alpha-11, G-protein alpha-q, G-protein alpha-
q/11, G-protein alpha-i2, PKA-cat (cAMP-dependent), 
IP3 receptor 
382 
Dysregulation of Adiponectin 
secretion from adipocytes in 
obesity, type 2 diabetes and 







MEK1(MAP2K1), GSTK1, CDK5, SREBP1 (nuclear), 
ERO1Lalpha, CRP, Insulin receptor, ERp44, CREB1, 
AKT(PKB) 






CRYM, CRAT, AADAT, AGPHD1, ECHP, ACAT2, 
CAC, DHTKD1, HCD2, HCDH, CAT-3, AGXT2L2, 
AL7A1, ACAA1, CCBL2, ACAT1, AASS, CAT-2, 
GCDH 
384 









RhoA, ROCK, PKC-alpha, ERM proteins, Lyn, ARF6, 
Myosin II, CDC42, Fyn, AKT(PKB), SK4/IK1, PIP5KI, 











MEK1(MAP2K1), RAP-1A, cPKC (conventional), B-
Raf, G-protein alpha-s, PLC-beta, PKC-alpha, CREB1, 











STAT3, MEK1(MAP2K1), RACK1, PI3K cat class IA, 




transactivation of membrane 







ITGB1, PI3K cat class IA, FAK1, Beta-catenin, alpha-
5/beta-1 integrin, CRK, AKT(PKB), ITGA5, Fibronectin, 










MEK1(MAP2K1), RAP-1A, B-Raf, PLC-beta, G-protein 
alpha-i family, H-Ras, eNOS, CREB1, SOS, AKT(PKB), 
G-protein alpha-q/11, IP3 receptor 
389 
Signal transduction_CXCR4 
signaling via second 







STAT3, Ubiquitin, Pyk2(FAK2), G-protein alpha-s, G-
protein alpha-i family, MRLC, SK4/IK1, PLC-beta3, 
MLCK, CXCR4, Paxillin, IP3 receptor 
390 
HBV-dependent NF-kB and 








Pyk2(FAK2), PI3K cat class IA, RelA (p65 NF-kB 
subunit), PKC-alpha, H-Ras, FAK1, SOS, Pin1, NF-kB, 
AKT(PKB), PDK (PDPK1), p27KIP1 
391 
Interaction of deficient alpha-
MSH signaling with TNF-







ITGB1, TMSB4X, RelA (p65 NF-kB subunit), ICAM1, 
NF-kB, Catalase, Fibronectin, Vimentin, PKA-cat 
(cAMP-dependent) 






MEK1(MAP2K1), AKT1, B-Raf, N-Ras, H-Ras, CREB1, 






regulation of STK3/4 (Hippo) 
pathway and positive 








RhoA, MOBKL1A, EGF, G-protein alpha-12 family, 
EGFR, LARG, Actin cytoskeletal, RhoGAP5, G-protein 










MEK1(MAP2K1), EGF, PI3K cat class IA, Neuregulin 1, 
EGFR, H-Ras, GRB7, SOS, NF-kB, AKT(PKB) 
395 










Histone H3, alpha-IIb/beta-3 integrin, RAP-1B, Histone 
H2B, Fibrinogen (fibrin), Fibronectin, Histone H4, CD36 
396 
Development_Delta-type 








STAT3, MEK1(MAP2K1), Pyk2(FAK2), PKC-alpha, H-
Ras, SOS, Rac1, IP3 receptor 






RhoA, VCAM1, ROCK2, ICAM1, EGFR, MRLC, 
Myosin II, NF-kB 
398 
Development_NCAM1-
mediated neurite outgrowth, 








BETA-PIX, PKC, AP-2 alpha subunits, Agrin, H-Ras, 
Spectrin, Casein kinase II, FAK1, CREB1, MEK1/2, 
CDC42, Fyn, SOS, AKT(PKB), PKA-cat (cAMP-
dependent), IP3 receptor 
399 








STAT3, MEK1(MAP2K1), RhoA, EGF, PI3K cat class 
IA, EGFR, N-Ras, H-Ras, VAV-2, SOS, NF-kB, 
AKT(PKB), PDK (PDPK1), p27KIP1, Rac1, mTOR 
400 
Regulation of relaxation of 







RhoA, G-protein alpha-s, PGD2R, PKA-cat alpha, RAP-
1B, F-Actin cytoskeleton, 14-3-3, PKA-cat (cAMP-
dependent), MLCK, Rac1, IP3 receptor 
401 
LKB1 signaling pathway in 







STAT3, ITGB1, FAK1, AMPK alpha subunit, Beta-











EGF, PI3K cat class IA, EGFR, VAV-2, AKT(PKB), 
PDK (PDPK1), Rac1 
403 
Role of Leptin in regulation of 







STAT3, MEK1(MAP2K1), ACACA, AMPK alpha 
subunit, PTP-1B, AKT(PKB), mTOR 
404 
Development_Delta- and 
kappa-type opioid receptors 







PKC, G-protein alpha-i family, CREB1, Beta-arrestin1, 
Dynamin-2, p27KIP1, Histone H4 
405 
Regulation of lipid 
metabolism_Regulation of 








ACACA, SREBP1 (nuclear), ACACB, AMPK beta 
subunit, AMPK alpha subunit, AMPK gamma subunit 
406 
Transcription_Assembly of 
RNA Polymerase II 
preinitiation complex on 






6 AMH, DHFR, POLR2A, TFII-I, TFIIF, MDR1 






Ubiquitin, F263, alpha-V/beta-3 integrin, CDC42, ENO1, 











G-protein alpha-12 family, G-protein alpha-s, PKA-cat 
alpha, G-protein alpha-i family, PHK gamma, KDELR, 
CREB1, PP2A regulatory, PHK beta, PDK (PDPK1), 
PKA-cat (cAMP-dependent), G-protein alpha-13 
409 








STAT3, MEK1(MAP2K1), gp130, PI3K cat class IA, K-














STAT3, EGF, PI3K cat class IA, RelA (p65 NF-kB 
subunit), EGFR, H-Ras, Beta-catenin, SOS, AKT(PKB), 
DDX5, ILK, mTOR 
411 
Apoptotic pathways and 








MEK1(MAP2K1), B-Raf, PKC-alpha, DAPK1, tBid, 
Caspase-3, RIPK1, HDAC1, NF-kB, p70 S6 kinase2, 













RAP-1A, Pyk2(FAK2), B-Raf, PKC-alpha, H-Ras, 
eIF4E, eNOS, CREB1, MEK1/2, G-protein alpha-q, SOS, 
AKT(PKB), MNK1, PDK (PDPK1), PKA-cat (cAMP-
dependent), IP3 receptor, mTOR 
413 
Disruption of epithelial layer 







Plasminogen, ITGB1, Vitronectin, EGF, alpha-V/beta-1 
integrin, EGFR, alpha-5/beta-1 integrin, Plasmin, 
Fibronectin 
414 
Nicotine / Beta-adrenergic 







MEK1(MAP2K1), G-protein alpha-s, PKC-alpha, G-
protein alpha-i family, H-Ras, SOS, AKT(PKB), PDK 
(PDPK1), PKA-cat (cAMP-dependent) 
415 
Mechanism of action of CCR4 
antagonists in asthma and 







Talin, RAP-1A, ITGB1, PIPKI gamma, VCAM1, 
ICAM1, G-protein alpha-i family, PLC-beta3, IP3 
receptor 
416 
CCR4-dependent immune cell 
chemotaxis in asthma and 







Talin, RAP-1A, ITGB1, PIPKI gamma, VCAM1, 
ICAM1, G-protein alpha-i family, PLC-beta3, IP3 
receptor 
417 
Apoptosis and survival_Role 








MEK1(MAP2K1), PI3K cat class IA, CDK5, Neuregulin 
1, H-Ras, Caspase-3, SOS, AKT(PKB), PDK (PDPK1) 
418 
Chemotaxis_CCR4-induced 







Talin, RAP-1A, ITGB1, PIPKI gamma, VCAM1, 












Small LDL, IDL2, VLDL1, APOB, APOC2, VLDL2, 
VLDL1 remnant, Large LDL, IDL1 






G3P2, PDK1, Heme oxygenase 1, FECH, Ceruloplasmin, 
MSH2, ALDOA, F263, Transferrin, HXK1, GPI, 
Galectin-1, ENO1, PGK1, CXCR4, LRP1, NIP3, MDR1, 
AK3 
 
A7.2.2. Ingenuity Pathway Analysis. 
1. Categories 
2. Diseases or 
Functions Annotation 
3. p-value 
4. Predicted Activation 
State 
5. Activation z-score 
6. # Molecules 
Molecules 
1. RNA Post-Transcriptional 
Modification 



















1. Cancer,Cell Death and 
Survival,Organismal Injury and 
Abnormalities,Tumor 
Morphology 

















































































1. RNA Post-Transcriptional 
Modification 




















1. Organismal Survival 































































1. Organismal Survival 


























































1. Cancer,Cell Death and 
Survival,Organismal Injury and 
Abnormalities,Tumor 
Morphology 



















1. Cancer,Cell Death and 
Survival,Organismal Injury and 
Abnormalities,Tumor 
Morphology 















































































1. Gene Expression,Protein 
Synthesis 










l29 (includes others),RPL30,RPL37,RPL38,Rplp1 (includes 
others),RPS14,RPS17,RPS23,RPS24,RPS28,RPS29,RPS3,RPS4Y1,RPS5,RPS6KB2,RPS9,SARS1,SHMT
1,SYNCRIP,TCOF1,TPR,UPF1,XRN1 
1. Gene Expression,Protein 
Synthesis 










(includes others),RPL30,RPL37,RPL38,Rplp1 (includes 
others),RPS14,RPS17,RPS23,RPS24,RPS28,RPS29,RPS3,RPS4Y1,RPS5,RPS6KB2,RPS9,SARS1,SHMT
1,SYNCRIP,TCOF1,TPR,XRN1 
1. Lipid Metabolism,Molecular 
Transport,Small Molecule 
Biochemistry 

















1. Cancer,Cell Death and 
Survival,Organismal Injury and 
Abnormalities,Tumor 
Morphology 


















1. Cancer,Cell Death and 
Survival,Organismal Injury and 
Abnormalities,Tumor 
Morphology 


















1. Lipid Metabolism,Molecular 
Transport,Small Molecule 
Biochemistry 


















1. Lipid Metabolism,Molecular 
Transport,Small Molecule 
Biochemistry 















1. Amino Acid 
Metabolism,Small Molecule 
Biochemistry 










1. Cell Death and Survival 







































1. Neurological Disease 




































1. Neurological Disease 































1. Lipid Metabolism,Molecular 
Transport,Small Molecule 
Biochemistry 


















1. Drug Metabolism 













1. Cell Death and Survival 










































































1. Lipid Metabolism,Small 
Molecule Biochemistry 










1. Organismal Injury and 
Abnormalities,Renal and 
Urological Disease 
















1. Energy Production,Lipid 
Metabolism,Small Molecule 
Biochemistry 








1. Lipid Metabolism,Small 
Molecule Biochemistry 









1. Energy Production,Lipid 
Metabolism,Small Molecule 
Biochemistry 





















1. Lipid Metabolism,Small 
Molecule Biochemistry 








1. Cellular Assembly and 
Organization,Cellular Function 
and Maintenance 






1. Cell Signaling 









1. Lipid Metabolism,Nucleic 
Acid Metabolism,Small 
Molecule Biochemistry 




















1. Cellular Response to 
Therapeutics 










1. Cell Death and Survival 














1. Cancer,Organismal Injury 
and Abnormalities 















































































































































































































1. Cancer,Organismal Injury 
and Abnormalities 








































































































































































































1. Cancer,Organismal Injury 
and Abnormalities 











































































































































































































1. Cancer,Organismal Injury 
and Abnormalities 









































































































































































































1. Cancer,Organismal Injury 
and Abnormalities 


















































































































































































































































































































































































































1. Cancer,Organismal Injury 
and Abnormalities 













































































































































































































1. Cancer,Organismal Injury 
and Abnormalities 













































































































































































































1. Protein Synthesis 








































1. Infectious Diseases 


















































1. Protein Synthesis 





































































































































































































1. Molecular Transport 
















































1. Infectious Diseases 


























1. Infectious Diseases 























































1. Cellular Function and 
Maintenance 



















1. Infectious Diseases 



















1. Infectious Diseases 


















1. Infectious Diseases 

























1. Infectious Diseases 














1. Infectious Diseases 














1. Molecular Transport,Protein 
Trafficking 














1. Infectious Diseases 























1. Infectious Diseases 


























1. Cellular Function and 
Maintenance 
















1. Infectious Diseases 



















1. Protein Degradation,Protein 
Synthesis 




















1. Cellular Assembly and 
Organization,Cellular Function 
and Maintenance 








































1. Infectious Diseases 






























1. Infectious Diseases 














1. Cell Death and Survival 






































1. Cellular Assembly and 
Organization 




















1. Cellular Function and 
Maintenance 













1. Cell Death and Survival 






























1. Cell Death and Survival 




































Development and Function 











4x (includes others),VAV2,VCL,VIM,VTN 














1. Molecular Transport,RNA 
Trafficking 










1. Molecular Transport,RNA 
Trafficking 











































1. Infectious Diseases 

















1. Molecular Transport,RNA 
Trafficking 









1. Molecular Transport,RNA 
Trafficking 










1. Molecular Transport 





























1. Molecular Transport,Protein 
Trafficking 





























1. Cellular Assembly and 
Organization,Tissue 
Development 
















1. Molecular Transport 






















































1. Cell Morphology,Cellular 
Movement 















1. Inflammatory Response 



















1. Cellular Assembly and 
Organization 





















































































































1. Protein Synthesis 
















1. Cancer,Organismal Injury 
and Abnormalities 




















































































1. Cell-To-Cell Signaling and 
Interaction,Inflammatory 
Response 











1. Cellular Function and 
Maintenance 















1. Cellular Movement 




















































and Abnormalities,Skeletal and 
Muscular Disorders 








































1. Cellular Function and 
Maintenance 












Development and Function 










1. Cell-To-Cell Signaling and 
Interaction 
















1. Cellular Assembly and 
Organization 









1. Cell Death and Survival 
















1. Connective Tissue 
Disorders,Inflammatory 
Disease,Organismal Injury and 
Abnormalities,Skeletal and 
Muscular Disorders 



































System Development and 
Function,Tissue Development 















1. Cellular Function and 
Maintenance 











1. Cell Death and Survival 









1. Cell-To-Cell Signaling and 
Interaction 















1. Cellular Assembly and 
Organization,Cellular Function 
and Maintenance 



































1. Organismal Development 






















1. Organismal Development 






















1. Molecular Transport,Protein 
Trafficking 








1. Cellular Assembly and 
Organization,Cellular Function 
and Maintenance 












1. Cellular Function and 
Maintenance 













System Development and 
Function,Tissue Development 
































1. Cellular Assembly and 
Organization,Cellular Function 
and Maintenance 



























1. Cellular Function and 
Maintenance 









1. Cancer,Organismal Injury 
and Abnormalities,Respiratory 
Disease 














1. Cell-To-Cell Signaling and 
Interaction,Cellular Assembly 
and Organization 


















1. Cell Death and Survival 













1. Cellular Movement 












































System Development and 
Function,Tissue Development 













1. Molecular Transport 






















Tissue Development and 
Function 


















System Development and 
Function,Tissue Development 













1. Cellular Growth and 
Proliferation 














1. Cellular Function and 
Maintenance 
2. Engulfment by cervical 







1. Cell-To-Cell Signaling and 
Interaction 












1. Cell Death and 
Survival,Embryonic 
Development 
2. Cell viability of embryonic 










1. Cellular Movement 



















































1. Infectious Diseases 
2. Infection by Human 








System Development and 
Function,Immune Cell 
Trafficking 







































1. Cellular Function and 
Maintenance 
2. Endocytosis by cervical 







1. Cellular Movement,Immune 
Cell Trafficking 

















































































1. Cellular Function and 
Maintenance 



























Disease,Organismal Injury and 
Abnormalities 






















































Development and Function 













Disease,Organismal Injury and 
Abnormalities 





















































Appendix 7.3. All Quantified O-GlcNAc Regions. 
 logFC Protein: log2 fold change in protein expression. logFC_Corrected, and P-
Val_Corrected are the log2 fold change, p-value (after correction for multiple comparisons using 
the Benjamini-Hochberg method). If protein expression could not be quantified, these values 

















A0A087WNV1 Agfg1 (1 of 261,262,264) 1 -0.01 0.95 -7.2 -0.216474 0.166852 -5.769119 
A0A087WNV1 Agfg1 (1 of 251,252,253,258) 1 0.167 0.225 -5.9 -0.036573 0.796312 -7.358127 
A0A087WNV1 Agfg1 260 1 -0.01 0.952 -7.2 -0.215617 0.167762 -5.776142 
A0A087WNV1 Agfg1 327 1 0.154 0.205 -5.8 -0.050027 0.738148 -7.308137 
A0A087WP65 R3hdm1 90 1 -0.58 0.023 -2.2 -0.583806 0.021295 -2.710266 
A0A087WQH5 Fam135a 579 1 0.212 0.072 -4.3 0.2119017 0.12265 -5.364413 
A0A087WQN7 Xrn1 1332 1 0.518 0.017 -1.8 0.3940366 0.048126 -3.899879 
A0A087WRU0 Tns1 (1 of 
945,946,948,949,953) 
1 0.602 0.028 -2.2 0.4836636 0.064885 -4.014219 
A0A0A0MQ73 Kmt2d 2359 1 -0.59 0.008 -0.9 -0.586533 0.00728 -1.411378 




1 -0.36 0.26 -5.2 -0.362244 0.31976 -5.71707 
A0A0A0MQ98 Jmjd1c (1 of 1428,1431) 1 0.125 0.682 -6.3 0.1250652 0.725585 -6.59297 
A0A0A0MQ98 Jmjd1c 1492 1 0.358 0.264 -5.2 0.3580388 0.323535 -5.736607 
A0A0A0MQB4 Arhgap40 360 1 -1.21 0.028 -1.7 -1.211436 0.022556 -2.001187 




2 -0.32 0.044 -3.5 -0.53845 0.024594 -3.172693 
A0A0A0MQJ4 Phactr4 (1 of 159,160) 1 -0.19 0.549 -6.5 -0.240132 0.376465 -6.328126 
A0A0A0MQJ4 Phactr4 204 1 -0.11 0.443 -6.6 -0.326774 0.083957 -4.891739 
A0A0A6YVU8 Gm9774 (1 of 
217,219,220,221,222,22
3,224) 
1 0.785 0.001 2.93 0.7845268 0.000897 1.873024 
A0A0A6YVU8 Gm9774 211 1 0.72 0.002 1.45 0.7203284 0.001865 0.682729 
A0A0A6YVU8 Gm9774 213 1 0.818 0.002 2.63 0.8180414 0.000897 1.830331 




1 -0.03 0.919 -6.5 -0.03343 0.925722 -6.727357 
A0A0A6YXS8 Serpinc1 (1 of 63,65,69,74) 1 1.345 0.007 -0.1 1.5081956 0.003059 0.551337 
A0A0A6YXS8 Serpinc1 10 1 1.28 0.014 -1.1 1.4429022 0.005615 -0.386988 
A0A0B4J1G5 Elf2 (1 of 283,285,286,287) 1 -0.56 0.125 -4.1 -0.563931 0.148988 -4.733092 
A0A0G2JDK2 Gba 290 1 -0.73 0.002 1.86 -1.383069 0.000332 4.182709 
A0A0G2JDK2 Gba 71 1 -1.06 0.009 -0.5 -1.805993 0.00131 1.850317 
A0A0G2JDL6 Sbno1 (2 of 75,76)&(1 of 
71,75,76) 
2 -0.64 0.026 -2.4 -0.63753 0.021177 -2.700241 
A0A0G2JDV2 Tent4a (1 of 658,662,663,667) 1 -0.35 0.266 -5.2 -0.35477 0.327134 -5.751736 
A0A0G2JEI9 Rsbn1l (1 of 84,85,86,87,88,89) 1 -0.62 0.044 -2.9 -0.616458 0.042704 -3.421353 
A0A0G2JF07 Cfi (1 of 104,108) 1 -0.03 0.872 -7.1 -0.476605 0.029272 -3.157862 
A0A0G2JFD6 Elovl6 4 1 3.283 0.003 0.82 4.3480735 0.000647 2.827837 
A0A0G2JFW6 Rprd2 (1 of 349,355,358,359) 1 -0.23 0.448 -5.9 0.0166659 0.958612 -6.735344 








1 -0.29 0.05 -3.7 -0.698349 0.031525 -3.4972 
A0A0G2JFW6 Rprd2 (1 of 
909,912,913,915,916,92
6,927) 
1 -0.18 0.538 -6.1 0.0618038 0.857812 -6.701823 
A0A0G2JFW6 Rprd2 346 1 -0.41 0.028 -2.6 -0.642785 0.050253 -3.957643 
A0A0G2JFW6 Rprd2 334 1 -0.49 0.007 -0.6 -0.895395 0.009191 -1.750631 
A0A0G2JGT1 Fubp1 (1 of 
146,148,154,155,157) 
1 -0.71 0.168 -5 -1.305405 0.025611 -2.648267 
A0A0J9YU61 Clock 706 1 0.307 0.32 -5.5 0.3070801 0.382588 -5.965988 
A0A0J9YU61 Clock 446 1 0.351 0.102 -4.2 0.3506244 0.14144 -5.085919 
A0A0N4SUS4 Brpf1 (1 of 1057,1064) 1 0.239 0.231 -5.4 0.2388081 0.305552 -6.04094 
A0A0N4SUV0 Plekha5 274 1 0.153 0.24 -5.9 -0.123031 0.384645 -6.742712 
A0A0N4SV80 Zfp638 1370 1 -0.05 0.638 -7 -0.405488 0.021349 -2.970777 
A0A0R4IZZ5 Clec4f (1 of 
205,206,207,210,211) 
1 0.112 0.716 -6.4 -0.788164 0.069929 -3.670453 
A0A0R4J079 Acbd3 (1 of 313,317,318) 1 -0.1 0.731 -6.4 -0.13103 0.710981 -6.579231 
A0A0R4J0D3 Stt3b (1 of 636,637,640) 1 0.676 0.006 -0.5 0.4654033 0.0177 -2.708146 
A0A0R4J0H0 Eml4 (1 of 786,787) 1 0.354 0.266 -5.2 0.1738824 0.614831 -6.464591 
A0A0R4J0I1 Serpina3k (1 of 184,187) 1 -1.36 0.022 -1.3 -2.63026 0.002337 1.186814 
A0A0R4J0I9 Lrp1 (1 of 4359,4363,4367) 1 -0.08 0.8 -6.5 -0.409612 0.2682 -5.492277 
A0A0R4J0I9 Lrp1 (1 of 2617,2622,2623) 1 0.325 0.296 -5.4 -0.007411 0.983225 -6.737467 
A0A0R4J0I9 Lrp1 (1 of 
3784,3785,3788,3791) 
1 -0.01 0.988 -6.6 -0.338503 0.345166 -5.826259 
A0A0R4J0I9 Lrp1 2130 1 0.417 0.054 -3.8 0.1428748 0.469115 -6.935938 
A0A0R4J0I9 Lrp1 4078 1 -0.45 0.098 -4.7 -0.722303 0.017288 -2.670435 
A0A0R4J0M9 Vcpip1 (1 of 1066,1072) 1 0.391 0.105 -4.8 0.1196802 0.60963 -7.172674 
A0A0R4J0M9 Vcpip1 1075 1 0.741 0.002 2.47 0.4700058 0.014256 -2.411876 
A0A0R4J0X5 Serpina1c (1 of 90,92,103,105,106) 1 0.943 0.028 -2.2 0.8727801 0.06003 -3.896766 
A0A0R4J131 Btd 138 1 -0.61 0.011 -1.4 -0.986337 0.00072 2.348661 
A0A0R4J187 Xrcc6 (1 of 317,319) 1 0.719 0.08 -3.4 0.8817395 0.05309 -3.261349 
A0A0R4J1H6 Golga3 167 1 0.149 0.34 -6.4 -0.00906 0.955946 -7.42312 
A0A0R4J2B5 2310022A10
Rik 
348 1 -0.56 0.125 -4.1 -0.562896 0.149122 -4.738191 
A0A0U1RNH9 Pik3c2a 251 1 0.518 0.144 -4.3 0.5183046 0.175104 -4.958494 
A0A0U1RQB6 Crebbp 147 1 -0.23 0.448 -5.9 -0.230667 0.507226 -6.274563 
A0A140LHQ8 Picalm (1 of 442,444) 1 0.287 0.346 -5.6 -0.311756 0.376465 -5.945587 
A0A140LHQ8 Picalm 337 1 0.186 0.112 -4.9 -0.301412 0.067496 -4.58615 
A0A140LHQ8 Picalm 181 1 0.193 0.112 -4.9 -0.294127 0.072352 -4.689937 
A0A140LHR4 Serpinh1 (1 of 116,118,120,121) 1 -0.39 0.034 -3.1 -0.892218 0.002114 0.487535 
A0A140LIZ8 Zfp286 (1 of 142,144) 1 -0.89 0.053 -2.7 -0.892915 0.051555 -3.214027 
A0A140T8T5 Map4 70 1 0.175 0.241 -5.8 -0.109849 0.518865 -6.878455 
A0A1B0GR78 Stim1 (1 of 
170,172,173,175,177) 










A0A1B0GRB5 Nup98 (1 of 550,551) 1 -0.14 0.635 -6.3 -0.350246 0.330569 -5.772596 
A0A1B0GRJ0 Rab11fip1 (1 of 1019,1020) 1 0.35 0.27 -5.2 0.3496471 0.330647 -5.775349 
A0A1B0GRV3 Rfx1 248 1 -0.77 0.072 -3.1 -0.768724 0.073753 -3.758264 
A0A1B0GSG3 Nsd3 (1 of 
265,266,269,270,272,27
3,274) 
1 -1.48 0.017 -1.1 -1.483272 0.012683 -1.152575 
A0A1B0GSN3 Aldh16a1 (1 of 20,21) 1 0.026 0.886 -7.1 0.3716657 0.0912 -4.781834 
A0A1B0GT43 Erlin2 108 1 0.396 0.067 -4.1 0.4117387 0.043806 -4.014093 
A0A1C7ZMY3 Shank2 1071 1 1.21 1E-03 3.45 1.2104277 0.000455 3.506891 
A0A1D5RLU0 Tcf25 (1 of 101,107,108) 1 -0.9 0.052 -2.6 -1.034808 0.035692 -2.641877 
A0A1I7Q4G8 Gatad2a (1 of 61,62,67,69) 1 -0.29 0.067 -3.9 -0.509662 0.01817 -2.492531 
A0A1I7Q4G8 Gatad2a (1 of 176,178,179) 1 -0.01 0.979 -6.6 -0.234319 0.50169 -6.261055 
A0A1I7Q4G8 Gatad2a (1 of 
315,319,324,325,327,32
8,331,335,338,341) 
1 -0.21 0.289 -5.8 -0.443548 0.086681 -4.431213 
A0A1I7Q4G8 Gatad2a (1 of 
201,202,205,206,207,20
8) 
1 -0 0.996 -6.6 -0.244903 0.4851 -6.221118 
A0A1I7Q4G8 Gatad2a 606 1 0.144 0.57 -6.5 -0.072905 0.784898 -6.996831 
A0A1L1SUR6 1700017B05
Rik 
(1 of 530,531) 1 -0.37 0.251 -5.1 -0.371789 0.30957 -5.67244 
A0A1L1SV73 Usp47 (1 of 77,78,87,88) 1 -0.45 0.181 -4.7 -0.336664 0.346258 -5.834597 
A0A1N9M4K1 Siae 285 1 -0.93 0.002 1.98 -1.2258 0.000968 1.733645 
A0A1N9M4K1 Siae 357 1 -2.28 0.002 2.57 -2.798615 0.000551 3.61413 
A0A1N9PTV1 Fbrs 246 1 -0.23 0.227 -5.4 -0.232187 0.307651 -6.054924 
A0A1W2P7D7 Ncoa1 (1 of 152,153) 1 -0.33 0.287 -5.3 -0.332775 0.349751 -5.852165 
A0A1W2P7G2 Sarnp (1 of 
102,103,104,107,109,11
0,113) 
1 -0.37 0.02 -2.3 -1.148531 0.001155 1.462543 
A0A1W2P7I2 Epb41l2 (1 of 183,185) 1 -0.67 0.022 -1.7 -1.260384 0.006518 -0.602924 
A0A1W2P7Q7 Ccar1 (1 of 134,135,139) 1 0.409 0.217 -4.9 0.2055333 0.553435 -6.363517 
A0A1Y7VJM4 Ero1lb 123 1 -1 0.005 0.1 -0.995164 0.002413 0.278716 
A0A1Y7VK55 Nfic (1 of 
292,295,296,297,298,29
9,301) 
1 -0.64 0.036 -2.5 -1.071684 0.004899 -0.179856 
A0A1Y7VLT3 Prpf4b (1 of 82,84) 1 -0.65 0.028 -2.5 -0.64655 0.021828 -2.761408 
A0A1Y7VMT6 Erap1 (1 of 19,20,24,25) 1 -0.06 0.845 -6.5 -0.092291 0.792045 -6.658017 
A0A1Y7VP49 Ctsl 79 1 -0.92 0.01 -0.9 -1.245757 0.000871 2.3454 
A0A2I3BPM1 Ero1l 64 1 0.676 0.091 -3.5 0.6755876 0.10174 -4.19148 
A0A2I3BPN6 Taf4 486 1 -0.35 0.268 -5.2 -0.351169 0.330276 -5.768346 
A0A2I3BQ92 Mtss1 (1 of 
64,65,67,68,71,75,81) 
1 0 1 -6.6 -0.35281 0.328997 -5.760786 
A0A2I3BQE0 Stk3 (1 of 
327,328,329,331,334) 
1 0.446 0.031 -2.7 0.4460537 0.037637 -3.52517 
A0A2I3BQE1 AI182371 143 1 0.559 0.127 -4.1 -0.152833 0.660539 -6.524299 
A0A2I3BRS9 Mapk1ip1l (1 of 2,6,15,16,23,25) 1 -0.54 0.068 -3.6 -0.816047 0.026948 -2.719732 
A0A2R8VHH9 Naga 203 1 -1.31 7E-04 4.43 -2.315435 4.39E-05 8.86807 
A0A2R8VHQ0 Tns2 (1 of 
891,893,894,897,900,90
1,905,906,907) 
1 -0.47 0.172 -4.6 -0.731462 0.083571 -3.929183 




A0A2R8VHW4 Brd4 (1 of 
157,158,160,161,162) 
1 -0.27 0.08 -4.4 -0.624419 0.006638 -1.282076 
A0A2R8VKN7 Mzt2 (1 of 
89,94,98,100,101,102,10
3,104,106) 
1 0.181 0.545 -6.1 0.1813687 0.602925 -6.441865 
A0A2R8W6T9 Tmprss6 (1 of 
171,173,174,175,178) 
1 1.155 0.016 -1.3 1.1548445 0.010083 -1.243842 
A0A338P6F2 Osbpl11 13 1 0.019 0.938 -6.9 0.0191995 0.936952 -7.074347 
A0A338P6J9 Cast (1 of 81,83,85,86,87,89) 1 0.272 0.063 -4 0.2129286 0.14144 -5.547609 
A0A338P6J9 Cast 72 1 0.129 0.284 -6.2 0.070366 0.645915 -7.219387 
A0A338P6J9 Cast 79 1 0.27 0.041 -3.4 0.2108519 0.155243 -5.684873 
A0A338P6K9 Qser1 (1 of 162,163,166,169) 1 -0.07 0.581 -6.9 -0.068491 0.635104 -7.206369 
A0A338P6K9 Qser1 45 1 0.262 0.386 -5.7 0.2622097 0.453861 -6.153441 
A0A338P6K9 Qser1 303 1 0.275 0.203 -5.3 0.2747173 0.256179 -5.842739 
A0A338P6K9 Qser1 63 1 0.001 0.999 -6.6 0.0014868 0.996645 -6.73797 
A0A338P7E6 C2cd2 (1 of 75,83) 1 0.1 0.742 -6.4 0.0442329 0.902125 -6.719402 
A0A3B2W7J8 Plec 786 1 1.732 0.013 -0.6 1.8945749 0.006157 -0.123064 
A0A3B2WBH9 Tjp2 451 1 0.361 0.083 -4.2 0.0968884 0.614099 -7.02857 
A0A3B2WCD8 Khsrp (1 of 144,145,147) 1 -0.09 0.514 -6.6 -0.7161 0.006638 -0.990425 
A0A3B2WCD8 Khsrp (1 of 95,96,101) 1 -0.14 0.642 -6.3 -0.736058 0.082346 -3.90792 
A0A3B2WCD8 Khsrp 192 1 -0.14 0.635 -6.3 -0.739111 0.081485 -3.893827 
A0A494B962 Sil1 (1 of 37,38,39,40,41) 1 -0.27 0.144 -5.3 -0.516815 0.037451 -3.752513 
A0A494BB11 Tmx3 262 1 0.019 0.886 -7.2 -0.357837 0.03599 -3.691081 
A0A571BDN3 Nav3 (1 of 659,660) 1 0.028 0.934 -6.5 0.0279435 0.93612 -6.730556 
A0A571BEC9 Plin4 (1 of 320,321) 1 3.319 0.003 0.84 3.3188286 0.001177 2.014753 
A0A571BEC9 Plin4 (1 of 214,221,222) 1 3.694 0.003 1 3.6942406 0.000896 2.358149 
A0A571BEC9 Plin4 (1 of 353,354) 1 3.731 0.003 1.02 3.7306209 0.000883 2.388222 
A0A571BEC9 Plin4 (1 of 181,184,188,189) 1 3.338 0.003 0.85 3.3379597 0.001161 2.03383 
A0A571BFA7 Fam83h (1 of 
949,950,951,952,954) 
1 0.967 0.045 -2.4 0.7448317 0.079741 -3.867473 
A0A5F8MPS7 Acp2 169 1 0.182 0.545 -6.1 -0.184831 0.595436 -6.431099 
A0A5F8MPU2 Fnbp4 (1 of 805,806,807) 1 -0.22 0.475 -5.9 -0.215937 0.531113 -6.327571 
A0A5F8MPU2 Fnbp4 (1 of 
661,663,667,668,670,67
1,675,677) 
1 -0.51 0.147 -4.3 -0.512355 0.179088 -4.987939 
A0A5F8MPY2  74 1 0.13 0.267 -6.1 0.129835 0.349143 -6.629526 
A0JNY3 Gphn (1 of 
298,300,301,302,304) 
1 1.217 7E-04 4.39 1.4773733 0.000145 5.670724 
A0JNY3 Gphn 296 1 1.228 7E-04 4.22 1.4879236 0.000145 5.622954 




1 -0.36 0.263 -5.2 -0.358979 0.32309 -5.732247 
A2AC24 Wdr13 140 1 0.596 0.035 -3.1 0.5962968 0.025525 -3.219626 
A2ADB1 Spen (1 of 
2761,2762,2769,2771) 
1 -0.27 0.364 -5.6 -0.274454 0.431534 -6.103904 
A2ADB1 Spen 2496 1 -0.46 0.178 -4.6 -0.458692 0.219863 -5.252967 




A2AFQ0 Huwe1 (1 of 
3795,3796,3798,3799,38
02,3804,3805) 
1 0.696 0.02 -1.6 0.5181274 0.052168 -3.703784 
A2AGG1 Ttc17 (1 of 241,244) 1 -0.37 0.257 -5.1 -0.365568 0.317298 -5.701572 
A2AGJ9 Slc12a6 55 1 -0.4 0.229 -5 -0.395054 0.284419 -5.562177 
A2AKB9 Dcaf10 364 1 0.864 0.002 2.02 0.863718 0.001068 1.57309 
A2AKI5 Itgav (1 of 829,835) 1 -0.33 0.294 -5.4 -0.665981 0.104493 -4.237246 
A2AKJ2 Vim (1 of 32,33,34,35) 1 -0.54 0.136 -4.2 -0.969455 0.041547 -2.898829 
A2AMY5 Ubap2 (1 of 1000,1001) 1 0.143 0.635 -6.3 -0.119847 0.737204 -6.60452 
A2AMY5 Ubap2 (1 of 
630,631,633,637,641) 
1 0.356 0.265 -5.2 0.0932414 0.790145 -6.656387 
A2AMY5 Ubap2 (1 of 
1017,1019,1020,1022,10
28,1030) 
1 0.156 0.186 -5.6 -0.101376 0.523761 -7.042804 
A2AMY5 Ubap2 (1 of 
468,469,475,476,478) 
1 -0.05 0.696 -7.1 -0.306681 0.061452 -4.450473 
A2AMY5 Ubap2 (1 of 
651,654,657,658,659,66
0) 
1 0.197 0.514 -6 -0.066033 0.849313 -6.696744 
A2AMY5 Ubap2 1107 1 0.452 0.181 -4.7 0.1887983 0.589005 -6.418572 
A2AP93 Map3k7 (1 of 378,382,383) 1 0.98 0.044 -2.4 0.9801763 0.040509 -2.855911 
A2APL5 Slc1a2 (1 of 201,206,207) 1 0.904 0.003 0.67 0.5108731 0.141202 -5.541415 
A2APT9 Klhdc7a (1 of 293,294,295) 1 0.422 0.014 -1.8 0.1517321 0.368174 -6.6939 
A2AQE9 Atf2 174 1 -0.88 0.055 -2.7 -0.876823 0.053814 -3.28227 
A2ATI9 Gorasp2 397 1 -0.78 0.014 -1.5 -1.054557 0.002894 0.295484 
A2ATI9 Gorasp2 406 1 -0.48 0.035 -3.1 -0.723579 0.005795 -1.074623 
A2ATR8 Serping1 (1 of 
240,245,247,251,252) 
1 -0.55 0.129 -4.1 -0.842695 0.059859 -3.42927 
A2AVJ7 Rrbp1 (1 of 103,110,111,114) 1 -0.61 0.109 -3.8 -1.437479 0.013865 -1.284987 
A2AVP4 Rc3h2 (1 of 768,769) 1 0.662 0.095 -3.6 0.6617683 0.105756 -4.257376 
A2AVR3 Mroh7 (1 of 80,82) 1 1.676 0.014 -0.7 1.6759666 0.008831 -0.636717 
A2AWN8 Ythdf1 (1 of 224,225) 1 -0.24 0.067 -4.2 -0.236902 0.103418 -5.146342 
A2AWN8 Ythdf1 223 1 -0.69 0.002 1.57 -0.685254 0.001977 0.608837 
A2CEK6 Mup13 170 1 -1.71 0.013 -0.6 -1.711975 0.008269 -0.547195 




1 -0.77 0.004 0.58 -0.772816 0.003924 -0.223724 
A6H619 Phrf1 (1 of 547,549,551) 1 -0.04 0.892 -6.5 0.2224096 0.521881 -6.304576 
A6H619 Phrf1 (1 of 
1359,1363,1364,1365,13
66,1368,1369,1376) 
1 -0.75 0.075 -3.2 -0.482175 0.200017 -5.137209 
A8Y5E6 Plod1 200 1 0.071 0.818 -6.5 0.0708551 0.838287 -6.690556 
A9C497 Mup19 (1 of 170,173) 1 -2.42 0.006 0.24 -2.417213 0.003004 0.862403 
B1AR09 Mllt6 (1 of 
398,399,400,402,403,40
4,405) 
1 -0.91 0.047 -3 -0.912751 0.031859 -2.945138 
B1AR76 Bcas3 (1 of 305,309,313,314) 1 0.817 0.003 1.24 0.7861063 0.003243 0.080876 
B1ARU1 Macf1 1680 1 -0.36 0.265 -5.2 -0.315335 0.371573 -5.929876 
B1ATR2 Tex2 (1 of 
169,173,174,175,177,17
8,179,182,183) 




B1ATR2 Tex2 (1 of 
157,158,159,160,161,16
4,165,167) 
1 1.118 7E-04 4.68 1.112484 0.000455 3.573174 
B1AUF2 Ski 502 1 2.278 0.007 0.1 2.2781663 0.003531 0.628785 
B1AWT4 Rragd 64 1 -0.73 0.05 -3.1 -0.914123 0.010966 -1.376146 
B1AZ15 Cobll1 (1 of 
681,684,685,688,690,69
4,695,697,701,705) 
1 0.347 0.271 -5.2 0.059097 0.864027 -6.704902 
B1AZ15 Cobll1 836 1 0.436 0.009 -1.1 0.1351917 0.376465 -6.717466 
B1AZA8 Tmem245 145 1 0.94 0.012 -1.2 1.1920699 0.00701 -1.084586 
B1B0C7 Hspg2 847 1 -0.07 0.816 -6.5 -0.442025 0.234905 -5.334734 
B2RQE8 Arhgap42 709 1 0.275 0.364 -5.6 -0.220454 0.524418 -6.311574 
B2RQG2 Phf3 (1 of 
1509,1511,1512,1513) 
1 -0.15 0.418 -6.2 -0.1467 0.50169 -6.62613 
B2RT14 Ugt1a5 (1 of 116,117) 1 2.547 7E-04 5.38 3.9270384 0.000146 5.7165 
B2RUJ2 Erbin 1011 1 0.275 0.364 -5.6 0.1759447 0.612514 -6.458407 
B2RUJ2 Erbin 1068 1 0.103 0.402 -6.6 -0.048562 0.744292 -7.315058 
B2RUQ2 Usf3 (1 of 
361,364,366,367,369) 
1 -0.05 0.859 -6.5 -0.054707 0.87534 -6.70961 
B2RXC8 Ppp2r3a 462 1 0.851 0.058 -2.8 0.8512528 0.058242 -3.392119 
B2RXS4 Plxnb2 146 1 -1.25 0.003 1.12 -1.57138 0.000563 3.318975 
B7ZC18 Stat3 (1 of 
688,690,691,693,695,70
1) 
1 -0.19 0.353 -6 -0.565027 0.064151 -3.991013 
B7ZC23 Ncoa5 (1 of 
121,124,125,130,136,13
8,140,146,147) 
1 0.299 0.331 -5.5 -0.278947 0.425619 -6.085408 




1 -0.06 0.845 -6.5 -0.061017 0.859207 -6.702731 
B7ZNH7 Col14a1 140 1 0.529 0.018 -1.9 0.4607382 0.034217 -3.365405 
B7ZNJ1 Fn1 1008 1 -0.96 0.002 2.34 -1.088725 0.000598 2.83126 
B7ZNJ1 Fn1 530 1 -0.18 0.547 -6.1 -0.230721 0.507226 -6.274365 
B7ZNJ1 Fn1 524 1 -0.14 0.634 -6.3 -0.194814 0.577378 -6.399185 
B7ZNJ1 Fn1 432 1 0.035 0.763 -7.1 -0.091104 0.527086 -7.049604 
B8JJB2 Pdlim7 89 1 -0.23 0.451 -5.9 -0.215963 0.531113 -6.327482 
C0HKG6 Rnaset2b 218 1 -0.29 0.338 -5.5 -1.326206 0.017426 -1.624001 
D3YU17 Ncln 430 1 -0.23 0.271 -5.7 -0.203665 0.400747 -6.400974 
D3YUV1 Nrbp1 (1 of 
532,533,536,538,540,54
2,543) 
1 0.187 0.536 -6.1 0.1867889 0.591897 -6.424943 
D3YUW8 Pogz (1 of 253,254) 1 0.731 0.078 -3.3 0.7314546 0.083571 -3.929217 
D3YUW8 Pogz (1 of 263,264,265) 1 0.399 0.225 -4.9 0.3988869 0.281062 -5.543834 
D3YUW8 Pogz 149 1 0.2 0.164 -5.3 0.199842 0.241434 -6.018656 
D3YVM4 Pigr 169 1 0.566 0.124 -4.1 -0.211229 0.540203 -6.343996 
D3YWA4 Pcnp (1 of 72,74,75,80) 1 0.518 0.144 -4.3 0.2444029 0.485551 -6.223031 
D3YXZ5 Rbm47 (1 of 450,454) 1 -0.31 0.32 -5.5 -0.553489 0.153664 -4.784572 




D3YYR9 Ablim2 (1 of 
54,55,56,58,61,65,66,67,
68,70,72) 
1 -0.93 0.005 0.06 -0.928526 0.002698 0.139488 
D3YYY8 Arhgef26 252 1 -0.65 0.098 -3.6 -0.653315 0.108597 -4.297867 
D3Z069 Phldb2 581 1 -0.21 0.49 -6 -0.332232 0.349843 -5.854615 
D3Z0Y0 Hspa13 (1 of 185,186) 1 -0.36 0.185 -5.1 -1.387207 0.006186 -0.526953 
D3Z216 Tab2 456 1 -0.13 0.271 -6.1 -0.126703 0.35586 -6.6559 
D3Z2E7 Ifi207 (1 of 391,392) 1 -1.04 0.008 -0.6 -1.042878 0.004598 -0.438047 
D3Z2E7 Ifi207 434 1 -0.59 0.115 -4 -0.588365 0.138016 -4.61304 
D3Z2L1 Gtf3c2 (1 of 199,204,205,207) 1 -0.49 0.157 -4.4 -0.492022 0.192577 -5.088542 
D3Z3F1 Fip1l1 (1 of 
258,259,260,261,263,26
5,266,267,269) 
1 0.522 0.142 -4.3 0.5219231 0.172567 -4.940587 
D3Z3F1 Fip1l1 237 1 -0.31 0.025 -2.6 -0.30685 0.041731 -3.925446 
D3Z3F1 Fip1l1 189 1 -0.43 0.045 -3.3 -0.425119 0.049619 -3.938305 
D3Z3F8 Spg20 478 1 0.175 0.219 -5.6 0.1749908 0.306985 -6.284874 
D3Z3Q3 Smtn (1 of 
697,698,699,700,701,70
2,703,704,705,706,709) 
1 -0.15 0.606 -6.2 -0.15354 0.659413 -6.522398 
D3Z3U7 Tnk2 (1 of 
324,327,328,330,333) 
1 -0.67 0.002 1.88 -0.665094 0.001865 0.690358 
D3Z4C0 Farp2 387 1 0.468 0.171 -4.6 0.33654 0.346258 -5.835157 
D3Z4Q7 Slc39a14 54 1 0.706 0.083 -3.4 0.0521468 0.881105 -6.712191 
D3Z4U8 Dcaf11 (1 of 
492,493,496,502,506,50
7) 
1 0.988 0.044 -2.3 1.3673839 0.015976 -1.495606 
D3Z5G4 Zfr (1 of 148,149,157) 1 0.355 0.024 -2.6 0.061891 0.702093 -7.275155 
D3Z5G4 Zfr (1 of 135,136,142,144) 1 -0.17 0.558 -6.1 -0.403641 0.275131 -5.521019 
D3Z5G4 Zfr 202 1 -0.08 0.682 -6.7 -0.378143 0.119233 -4.852455 
D3Z5G4 Zfr 195 1 0.086 0.664 -6.7 -0.214962 0.376465 -6.323052 
D3Z5I1 Zc3hav1 (1 of 
557,558,559,562,564,56
7,570) 
1 0.406 0.075 -3.7 0.0739384 0.744292 -6.962575 
D3Z5I1 Zc3hav1 (1 of 489,490) 1 0.289 0.344 -5.6 -0.078605 0.821688 -6.679733 
D3Z5I1 Zc3hav1 487 1 0.112 0.715 -6.4 -0.255298 0.466777 -6.180809 
D3Z5I1 Zc3hav1 551 1 0.272 0.106 -4.6 -0.056832 0.744078 -7.167308 
D3Z5I9 Rbm33 (1 of 738,739,740) 1 0.183 0.3 -6.1 0.182661 0.346258 -6.452903 
D3Z5X0 Bpnt1 (1 of 41,42,44) 1 0.014 0.965 -6.6 -0.278651 0.425619 -6.086629 
D3Z656 Synj1 1374 1 -0.03 0.806 -7.2 -0.028892 0.833028 -7.380796 
D3Z665 Emc10 (1 of 
175,187,188,195,196,20
2) 
1 0.865 0.056 -2.8 0.7950793 0.068828 -3.639442 
D3Z6S3 Tssc4 (1 of 
107,111,112,114,118) 
1 0.444 0.186 -4.7 0.4436562 0.233701 -5.326751 
D3Z6W7 Gxylt1 384 1 -0.36 0.262 -5.2 -0.360444 0.321318 -5.725441 
D6RDD4 Gfra1 (1 of 58,61,63,64) 1 -0.27 0.22 -5.4 -0.268365 0.27324 -5.910346 
D6RGN2 Plcd4 (1 of 60,62,64) 1 -0.02 0.95 -6.5 -0.02082 0.950318 -6.733861 
D6RGR1 Manba 91 1 -2.02 0.002 2.18 -2.858491 0.000297 4.677454 




D6RJL6 Lin54 (1 of 14,16,17,22) 1 -0.3 0.036 -3.2 -0.295235 0.053814 -4.276978 
E0CXE3 Cntn6 (1 of 673,674) 1 -0.55 0.13 -4.1 -0.550253 0.155109 -4.800543 
E0CY18 Zfand2b (1 of 
157,158,159,160,163,16
5) 
1 -0.03 0.933 -6.5 -0.028512 0.93612 -6.730251 
E0CY18 Zfand2b 150 1 0.086 0.453 -6.7 0.0858182 0.528481 -7.052396 
E0CY18 Zfand2b 167 1 -0.06 0.553 -6.9 -0.063807 0.632831 -7.20269 
E0CYH7 Filip1l (1 of 
1045,1047,1049,1050,10
51,1054,1055) 
1 -0.27 0.365 -5.6 -0.273408 0.433052 -6.108186 
E0CYN0 Agmo 11 1 0.779 0.003 0.78 0.7299569 0.001776 0.766078 
E0CYQ2 Nudcd2 (1 of 112,117,121) 1 -0.47 0.17 -4.6 -0.253811 0.468057 -6.186641 
E0CZ61 Umad1 (1 of 38,39,44,49) 1 0.331 0.08 -4.2 0.3307456 0.098791 -4.875395 
E9PUF4 Rbm26 (1 of 
645,647,648,655,657,65
8,665,666,667,668,671) 
1 0.096 0.751 -6.4 -0.105032 0.769855 -6.634875 
E9PUM5 Gm4788 (1 of 658,665,667,669) 1 -0.64 0.1 -3.7 -1.53385 0.011456 -1.010877 
E9PV38 Ces2g 478 1 1.206 0.003 1.35 1.1732553 0.001345 1.188187 
E9PV38 Ces2g 102 1 -0.2 0.505 -6 -0.235905 0.50169 -6.255142 
E9PV69 Cacul1 (1 of 
111,116,117,118,119,12
0,125,126,127,128) 
1 0.15 0.617 -6.2 0.1496921 0.66675 -6.532657 
E9PVA8 Gcn1 (1 of 20,22) 1 -0.18 0.551 -6.1 -0.385083 0.297001 -5.60967 
E9PVC6 Eif4g1 21 1 0.447 0.006 -0.5 0.337801 0.030218 -3.445371 
E9PWM3 Armcx4 595 1 -0.06 0.755 -6.8 -0.063462 0.78714 -7.000108 
E9PWW2 Tor1aip1 (1 of 208,209) 1 -0.15 0.465 -6.3 -0.368663 0.128157 -4.951888 
E9PWX8 Mast4 (1 of 
1971,1972,1973,1977) 
1 -0.16 0.392 -6.1 -0.16366 0.468057 -6.555293 
E9PXN7 Ugt1a10 (1 of 69,73) 1 1.501 0.017 -1 1.5005638 0.012276 -1.103603 
E9PYK3 Parp4 (1 of 
1740,1746,1749,1750,17
53,1756,1757) 
1 0.005 0.989 -6.6 -0.481752 0.200064 -5.139298 
E9PYX7 Afdn (1 of 561,562) 1 0.297 0.333 -5.5 -0.003574 0.992572 -6.737869 
E9PZ00 Psap (1 of 322,330) 1 0.454 0.181 -4.6 0.266148 0.446192 -6.137652 
E9PZ00 Psap 210 1 -1 0.002 2.15 -1.25208 0.000647 2.671959 
E9PZ00 Psap 454 1 -0.26 0.074 -4.3 -0.507024 0.020541 -2.892048 
E9PZ00 Psap 79 1 -1.25 7E-04 5.11 -1.495084 0.000235 4.798108 
E9PZD2 Micall2 (1 of 366,369,372,373) 1 -0.56 0.012 -1.5 -0.560516 0.010719 -1.95876 
E9PZD2 Micall2 (1 of 383,384) 1 -0.15 0.626 -6.2 -0.146735 0.674155 -6.540391 
E9PZD2 Micall2 (1 of 431,432,438,439) 1 -0.08 0.795 -6.5 -0.079961 0.820482 -6.677729 
E9PZD2 Micall2 406 1 -0.7 0.004 0.55 -0.700684 0.002897 -0.006222 
E9Q113 Sp1 126 1 -0.13 0.31 -6.3 -0.127119 0.377767 -6.723592 
E9Q150 Dvl3 613 1 0.046 0.883 -6.5 0.0461226 0.897392 -6.717786 
E9Q1P8 Irf2bp2 (1 of 
359,364,365,366,367) 
1 -0.96 0.047 -2.4 -0.957157 0.042704 -2.948427 
E9Q1S3 Sec23a 183 1 -0.76 0.074 -3.2 -0.769476 0.073701 -3.754852 
E9Q284 Coil (1 of 2,7,9) 1 -0.85 0.058 -2.8 -0.853909 0.057886 -3.380628 
E9Q2M4 Zfp867 (1 of 440,442,443,444) 1 -0.38 0.275 -6.1 -0.378337 0.252395 -6.247233 




E9Q3G8 Nup153 (1 of 1056,1057) 1 -0.76 0.028 -2.2 -1.264453 0.002793 0.698885 




1 -0.75 0.075 -3.2 -1.4752 0.012847 -1.175626 
E9Q3G8 Nup153 (1 of 
925,926,927,929,931,93
2,934,937) 
1 -0.21 0.084 -4.5 -0.859925 0.002748 0.084763 
E9Q3G8 Nup153 (1 of 
1101,1102,1103,1104) 
1 -0.29 0.17 -5.3 -1.063142 0.008275 -1.336199 
E9Q3G8 Nup153 (1 of 
699,704,705,706,708) 
1 -0.72 0.003 0.97 -1.370673 0.000567 3.001431 
E9Q3G8 Nup153 200 1 -0.8 0.067 -3 -1.806006 0.00701 -0.322774 
E9Q3G8 Nup153 1067 1 -0.54 0.004 0.59 -1.192632 0.000758 2.258122 
E9Q3G8 Nup153 1044 1 -0.52 0.143 -4.3 -1.250629 0.020846 -1.869087 
E9Q3G8 Nup153 1046 1 -0.3 0.028 -2.8 -0.953992 0.002224 0.404222 
E9Q449 Dennd4c (1 of 1346,1347) 1 0.564 0.019 -2 0.4749033 0.040229 -3.628924 
E9Q4Q2 Sf1 328 1 -0.1 0.573 -6.5 -0.501416 0.067532 -4.073637 
E9Q5G1 Myo10 (1 of 484,485,486) 1 0.096 0.751 -6.4 0.095668 0.78714 -6.652155 
E9Q5Q0 Atxn2l (1 of 
561,562,563,564,566,56
7) 
1 0.557 0.004 0.23 0.5266927 0.005446 -0.969451 
E9Q5Q0 Atxn2l (1 of 
146,147,150,151,153,15
4,156) 
1 0.039 0.859 -6.9 -0.062124 0.78714 -7.000129 
E9Q616 Ahnak (1 of 
5376,5377,5378,5383,53
84) 
1 -1.01 0.056 -3.3 -1.286838 0.025743 -2.657765 
E9Q640 Rbm26 (1 of 
694,695,696,697,700) 
1 -0.52 0.098 -4.5 -0.696813 0.037067 -3.495612 
E9Q6A7 Bptf (1 of 
1624,1627,1628,1629) 
1 0.281 0.354 -5.6 0.2806959 0.423197 -6.07816 




1 -0.31 0.07 -4 -0.305519 0.098794 -4.882245 
E9Q6A7 Bptf 1635 1 -0.26 0.037 -3.3 -0.264689 0.065092 -4.538571 
E9Q6E2 Cdk8 (1 of 
345,346,347,348,354,35
5) 
1 0.628 0.104 -3.8 0.6278053 0.11959 -4.420853 
E9Q6R7 Utrn (1 of 2210,2211,2213) 1 1.155 0.005 0.55 0.9873753 0.006667 -0.657807 
E9Q6T8 Cic (1 of 122,126,127) 1 -1.2 0.028 -1.7 -1.198477 0.023203 -2.045639 
E9Q7B0 P4ha1 (1 of 107,112,115) 1 -0.07 0.832 -6.5 -0.066205 0.849313 -6.69653 
E9Q7D5 Arhgef5 (1 of 
496,498,499,500,504,50
6) 
1 1.264 0.001 3.29 1.2640924 0.000647 2.97649 
E9Q7R8 Slc29a1 (1 of 
14,18,19,21,24,27,28) 
1 -0.12 0.701 -6.4 -0.549249 0.155243 -4.805498 
E9Q8A6 Nr3c1 43 1 0.269 0.039 -3.3 -0.329694 0.043806 -4.02061 
E9Q8A6 Nr3c1 53 1 0.273 0.036 -3.2 -0.325617 0.043744 -4.007536 
E9Q8H9 Cfh (1 of 729,732,735,736) 1 -0.4 0.05 -3.7 -1.069814 0.000577 2.941196 
E9Q8H9 Cfh (1 of 764,765) 1 -0.62 0.106 -3.8 -1.315276 0.017852 -1.658678 
E9Q8H9 Cfh (1 of 
986,993,995,997,1001) 




E9Q8H9 Cfh 1024 1 -0.9 0.052 -2.6 -1.596315 0.010328 -0.842196 
E9Q8H9 Cfh 1188 1 -0.65 0.099 -3.7 -1.338473 0.017015 -1.585381 
E9Q9Q7 Ablim1 (1 of 108,109,110,113) 1 0.777 0.07 -3.1 0.7774894 0.072168 -3.718554 
E9QAN9 Ifi203 (1 of 449,451,456) 1 -0.83 0.061 -2.9 -0.831302 0.061812 -3.479022 
E9QAT4 Sec16a 69 1 -0.12 0.321 -6.3 -0.139613 0.33831 -6.59118 
E9QAT4 Sec16a 70 1 -0.09 0.458 -6.7 -0.114376 0.427164 -6.848821 
E9QAT4 Sec16a 127 1 -0 0.971 -7.2 -0.024113 0.857812 -7.393701 
E9QJU8 Trp53bp2 (1 of 334,345,348) 1 0.048 0.8 -6.8 0.0484992 0.828513 -7.029652 
E9QKG6 Ankrd17 (1 of 
1421,1423,1428,1429,14
31,1433,1434,1436) 
1 0.38 0.241 -5.1 0.358061 0.323535 -5.736504 
E9QKG6 Ankrd17 (1 of 
1935,1941,1942,1943,19
45) 
1 0.725 0.079 -3.3 0.7024482 0.092211 -4.064527 
E9QKT0 Mef2d (1 of 273,274) 1 0.065 0.834 -6.5 0.0648882 0.851432 -6.698151 
E9QL13 Rbm14 (1 of 242,244) 1 -0.22 0.156 -5.2 -0.725615 0.0081 -1.279466 
E9QL13 Rbm14 280 1 0.035 0.865 -6.9 -0.403616 0.108597 -4.73475 
E9QL13 Rbm14 254 1 0.1 0.742 -6.4 -0.362852 0.319631 -5.71424 
E9QLQ9 Apc (1 of 
2314,2315,2316,2318,23
19) 
1 0.02 0.938 -6.9 0.0201568 0.93612 -7.073938 
E9QM14 Cbll1 276 1 0.363 0.26 -5.1 0.3630236 0.319631 -5.713439 
E9QMU3 Map7 (1 of 
452,453,456,457,463) 
1 0.601 0.003 0.67 0.5440661 0.004799 -0.784252 
E9QN70 Lamb1 1091 1 -0.57 0.123 -4.1 -0.568708 0.146547 -4.709574 
F6QJV5 Tfg 90 1 0.692 0.002 1.63 0.6270244 0.002362 0.311115 
F6RDR0 Add1 (1 of 60,68,70) 1 0.123 0.505 -6.4 -0.068195 0.761179 -6.976897 
F6S4K9 Epb41 103 1 0.418 0.012 -1.5 0.1339298 0.358467 -6.666758 
F6S5I0 Mprip (1 of 
25,26,27,28,31,32,34,35,
36,37,40) 
1 1.643 0.002 2.01 2.4148656 0.000556 3.562397 
F6SSP6 Ubr4 463 1 0.713 0.021 -1.7 0.6336961 0.035692 -3.116199 
F6TS96 Tle3 (1 of 
275,278,279,280,281) 
1 0.287 0.346 -5.6 0.2873728 0.411202 -6.050272 
F6UVB2 4930404N11
Rik 
(1 of 16,23) 1 -0.5 0.156 -4.4 -0.497403 0.188398 -5.061925 
F6V513 Sorbs2 (1 of 143,144,145) 1 0.193 0.547 -6.7 -0.194268 0.523761 -6.889203 
F6V8M6 Atxn2 (1 of 
208,212,213,214,215,21
6,217,220,221,223,224) 
1 0.595 0.113 -3.9 0.3620701 0.31976 -5.717879 
F6V8M6 Atxn2 141 1 0.627 0.002 1.64 0.4582667 0.009191 -1.751323 
F6V8M6 Atxn2 127 1 0.647 0.002 1.91 0.4779378 0.008187 -1.577804 
F6VV02 Hgs (1 of 
17,21,22,28,31,32,36,37) 
1 0.632 0.003 1.18 0.4723709 0.011136 -2.02487 
F6W4D3 1300017J02
Rik 
228 1 0.444 0.141 -4.7 0.4444745 0.142324 -5.094429 
F6WV21 Asxl2 (1 of 
822,823,831,832,833,83
6,837,839) 
1 -1.43 0.003 1.46 -1.432988 0.00182 1.356763 




F6YIN5 Sec24b (1 of 
163,164,165,168,169,17
5,176,177) 
1 -0.31 0.031 -3 -0.471079 0.009951 -1.847747 
F6YT69 Reps1 (1 of 79,82,85) 1 0.165 0.579 -6.2 0.1649541 0.634748 -6.490687 
F6YUG5 Synrg (1 of 8,9,10,12,13) 1 0.535 0.043 -2.8 0.3321313 0.158551 -5.261159 
F6Z4B2 Ncor2 (1 of 845,846,847) 1 -1.22 0.028 -1.7 -1.223783 0.021828 -1.959195 
F6Z4B2 Ncor2 (1 of 611,614,615,619) 1 -0.14 0.728 -7 -0.135365 0.705312 -7.131436 
F6Z4B2 Ncor2 (1 of 926,927,932,934) 1 -0.19 0.131 -5.2 -0.189555 0.186935 -5.904145 
F6Z4B2 Ncor2 192 1 -0.06 0.744 -6.8 -0.060145 0.78714 -7.000449 
F6Z9A1 Senp6 (1 of 72,77,78,79) 1 0.63 0.006 -0.2 0.6297724 0.008067 -1.263935 
F6Z9E6 Psd3 212 1 0.522 0.142 -4.3 0.5218026 0.172567 -4.941183 
F6Z9T5 R3hdm2 110 1 0.171 0.482 -6.3 0.1706518 0.507226 -6.640328 
F6ZBY9 Tle4 321 1 -0.13 0.265 -6.1 -0.129233 0.34878 -6.627369 
F7AYW2 Prrc2b 1045 1 -0.45 0.023 -2.2 -0.448724 0.030831 -3.228309 
F7BXV7 Rapgef3 6 1 -0.06 0.926 -7.1 -0.056368 0.9123 -7.26859 
F7CDR2 Nfia (1 of 
96,99,100,101,102,103,1
04,105,106) 
1 0.171 0.258 -6 -0.118748 0.35586 -6.656412 
F7CIP8 Pcyox1 (1 of 137,138,141,142) 1 0.451 0.01 -1.2 0.3358289 0.042327 -3.946349 
F7CIP8 Pcyox1 32 1 0.493 0.014 -1.5 0.454565 0.026948 -3.055991 
F7CIP8 Pcyox1 105 1 0.338 0.036 -3.2 0.223088 0.108597 -5.218379 
F7DE17 Ankhd1 (1 of 
575,578,581,586,588,59
0,594,597) 
1 -0.11 0.596 -6.6 -0.512676 0.071194 -4.154388 
F7DE17 Ankhd1 (1 of 132,133,134,135) 1 -0.06 0.596 -6.9 -0.359476 0.03599 -3.69024 
F7DE17 Ankhd1 (1 of 
276,279,282,283,287,28
8,290,291,292) 
1 -0.01 0.949 -6.9 -0.301653 0.250861 -5.818504 
F7DE17 Ankhd1 (1 of 120,121,124,125) 1 0.159 0.179 -5.6 -0.139959 0.349751 -6.633544 
F8VPM9 Hivep1 (1 of 1770,1771) 1 -0.8 0.002 2.51 -0.798932 0.001003 1.680587 
F8VPM9 Hivep1 (1 of 
2646,2647,2651,2654) 
1 -0.58 0.117 -4 -0.582474 0.14093 -4.641929 
F8VQJ3 Lamc1 (1 of 1201,1205,1206) 1 0.039 0.907 -6.5 0.0389541 0.915125 -6.723562 
F8VQJ3 Lamc1 1223 1 -0.09 0.633 -6.6 -0.064831 0.772918 -6.987051 
F8WH96 Hint3 102 1 -0.09 0.461 -6.7 0.0682199 0.660831 -7.236984 
F8WHP5 Ddhd1 (1 of 
694,695,697,699,707,71
0,711,715) 
1 -0.68 0.091 -3.5 -0.675081 0.101741 -4.193889 
F8WI14 Ecm1 (1 of 532,536,544) 1 0.418 0.145 -5.1 0.1973758 0.457457 -6.752771 
F8WIE5 Hectd1 1569 1 0.62 0.008 -0.6 0.393422 0.061689 -4.236818 
F8WIN6 Phc3 250 1 -0.55 0.129 -4.1 -0.553016 0.153664 -4.786905 
F8WJL9 Bcorl1 (1 of 102,103) 1 0.369 0.254 -5.1 0.3694537 0.312582 -5.683393 
F8WJL9 Bcorl1 121 1 0.616 0.006 -0.5 0.6159693 0.005615 -1.027805 
F8WJL9 Bcorl1 751 1 0.348 0.271 -5.2 0.3477454 0.332151 -5.784081 
G3UWE3 Pias2 (1 of 
595,597,601,602,603) 
1 -0.24 0.438 -5.8 -0.235465 0.50169 -6.256786 
G3UWE3 Pias2 (1 of 430,431) 1 -0.57 0.124 -4.1 -0.565608 0.148129 -4.724838 
G3UWE3 Pias2 435 1 -0.55 0.132 -4.2 -0.546736 0.156475 -4.817905 
G3UXW9 Gps1 (1 of 
4,8,9,11,12,13,15,18) 




G3UY24 Esrra 36 1 -0.28 0.084 -4.5 -0.283103 0.098794 -5.088295 
G3UZP7 H2-D1 202 1 -0.32 0.136 -4.7 -1.107682 0.010508 -1.305334 
G3UZP7 H2-D1 282 1 -0.49 0.156 -4.4 -1.07282 0.032451 -2.497486 
G3X8Q1 Cabin1 2073 1 0.758 0.074 -3.2 2.4970511 0.002747 0.988487 
G3X8R2 Sra1 (1 of 59,60,71,72) 1 -0.07 0.535 -6.8 -0.667701 0.006638 -1.282233 
G3X8T3 Ctsa (1 of 157,160) 1 -0.25 0.48 -6.3 -0.559714 0.066927 -4.05856 
G3X928 Sec23ip 185 1 0.499 0.006 -0.5 0.3186742 0.063534 -4.498059 
G3X928 Sec23ip 186 1 0.526 0.009 -1.1 0.3462463 0.066498 -4.565719 
G3X928 Sec23ip 607 1 -0.4 0.222 -4.9 -0.572091 0.144616 -4.692933 
G3X960 Syde1 (1 of 159,167) 1 0.201 0.087 -4.6 0.2014495 0.142526 -5.563114 
G3X973 Stab1 897 1 -0.58 0.005 0.07 -0.927114 0.000841 2.118119 
G3X973 Stab1 1532 1 -0.7 0.003 1.33 -1.044919 0.000455 3.55611 
G3X973 Stab1 2046 1 -0.44 0.076 -3.8 -0.716487 0.026948 -2.712685 
G3X9D6 Apon (1 of 23,27,32) 1 0.352 0.268 -5.2 0.9936988 0.039421 -2.80221 
G3X9K4 Ppp6r2 825 1 0.841 1E-03 3.31 0.8409918 0.00072 2.342655 
G3X9T8 Cp 139 1 0.099 0.598 -6.9 -0.28923 0.131268 -5.449873 
G5E850 Cyb5a 5 1 0.538 0.136 -4.2 0.784118 0.070748 -3.68865 
G5E8W7 Ppt2 208 1 -1.44 0.004 1.05 -2.39839 0.000594 3.352623 
H3BIX4 Nptn (1 of 165,167,168) 1 0.922 0.05 -2.6 0.8084628 0.066022 -3.579776 
H3BIX4 Nptn 81 1 1.479 0.007 -0.1 1.4307177 0.003206 0.456325 
H3BIZ9 Aftph (1 of 240,241,242) 1 0.867 0.056 -2.8 0.8671764 0.055413 -3.32351 
H3BK31 Zhx1 (1 of 
217,224,226,227,228,23
2,234,235,236,237,238) 
1 -0.4 0.041 -3.1 -0.865619 0.008342 -1.350467 
H3BKD4 Asap1 948 1 0.066 0.832 -6.5 0.0659131 0.849313 -6.696892 
H3BL34 Ces1e 276 1 1.053 0.003 1.47 1.5826277 0.000418 4.000288 
H3BLE4 Eps15 (1 of 
103,105,106,107,108,10
9,110,112) 
1 0.237 0.435 -5.8 0.1872686 0.591424 -6.423427 
H3BLE4 Eps15 (1 of 138,140,149) 1 0.238 0.433 -5.8 0.1882661 0.589612 -6.420264 
H3BLE4 Eps15 14 1 0.516 0.144 -4.3 0.4664854 0.213776 -5.21461 
H3BLE9 Ugt3a1 (1 of 33,34) 1 0.843 0.011 -0.7 1.3801349 0.002053 1.177994 





1 -1.08 0.006 0.22 -1.080543 0.004996 -0.209172 
H9KV01 Son 250 1 -0.65 0.002 1.42 -1.055181 0.000551 3.210941 
H9KV01 Son 1092 1 -0.3 0.31 -5.8 -0.725921 0.043401 -3.445331 
H9KV01 Son 1614 1 -0.45 0.104 -4.8 -0.848229 0.014256 -2.411148 
H9KV01 Son 262 1 -0.82 0.016 -1.3 -1.271496 0.003396 0.367759 
I7HIP8 Nfib (1 of 
404,408,409,412,413,41
7,418) 
1 -0.18 0.351 -6 -0.513134 0.073701 -4.209754 
I7HJQ9 Mtmr1 (1 of 
658,659,661,663,665,66
9,670) 
1 0.165 0.351 -6.2 0.1646497 0.391795 -6.603384 




J3QMX8 Slc30a6 (1 of 
376,379,380,381,386,38
7,393,396) 
1 -0.38 0.013 -1.7 -0.381893 0.020875 -2.933064 
J3QNY6 Abcb11 (1 of 782,784) 1 -0.97 0.004 0.66 -0.861291 0.003004 0.229703 
J3QP71 Bsg (1 of 20,23,25,28,29) 1 0.785 0.027 -2.1 1.0451127 0.009327 -1.146807 
J3QP71 Bsg (1 of 
126,127,129,136,138,13
9) 
1 0.943 0.048 -2.5 1.1810266 0.024428 -2.106119 
J3QPD5 Gm9602 4 1 -1.16 0.008 -0.2 -1.161933 0.005563 -0.35981 
J3QPR1 Atxn1 81 1 -0.1 0.732 -6.4 -0.103855 0.771579 -6.637128 
J3QPR1 Atxn1 23 1 -0.7 0.002 2.17 -0.696081 0.001469 1.014921 
K4DI63 Creg1 36 1 0.276 0.133 -5.2 0.2764808 0.142526 -5.561987 
K4DI63 Creg1 92 1 1.059 0.024 -2.3 1.0592269 0.013438 -2.034978 
M0QWZ1 Fam193a (1 of 992,994,995,1002) 1 0.146 0.182 -5.6 0.1456184 0.282271 -6.360258 
O08553 Dpysl2 (1 of 514,517,518) 1 -0.32 0.056 -3.9 -0.800209 0.001592 0.906071 
O08553 Dpysl2 512 1 -0.18 0.547 -6.9 -0.655763 0.035118 -3.645988 
O08715 Akap1 (1 of 
351,356,359,360,365,36
6,370,371) 
1 0.791 0.067 -3.1 0.9868993 0.040012 -2.829153 
O08750 Nfil3 (1 of 274,275) 1 -0.03 0.926 -6.5 -0.030698 0.932983 -6.729021 
O09117 Sypl1 (1 of 
238,239,242,244,246,24
7,249,251,258,259) 
1 0.356 0.265 -5.2 0.356013 0.326203 -5.74599 
O09159 Man2b1 369 1 -0.98 0.003 1.02 -1.413234 0.00072 2.744173 
O35114 Scarb2 124 1 0.132 0.482 -6.7 -0.115211 0.603709 -7.163284 
O35490 Bhmt 389 1 2.402 0.006 0.22 4.0550027 0.00072 2.634718 
O35516 Notch2 175 1 -0.68 0.004 0.45 -0.682585 0.003143 -0.143528 
O35887 Calu 133 1 -0.39 0.229 -5 -0.75454 0.077296 -3.822931 
O35949 Elovl3 (1 of 3,4,8) 1 -1.92 7E-04 4.35 -1.920925 0.000193 5.184509 
O55022 Pgrmc1 74 1 -1.89 0.01 -0.4 -1.561488 0.010966 -0.935402 
O55042 Snca 72 1 0.282 0.353 -5.6 0.3439818 0.337199 -5.801309 
O55042 Snca 54 1 -0.14 0.596 -6.9 -0.366858 0.35586 -6.658167 
O70400 Pdlim1 (1 of 130,134,135) 1 0.162 0.268 -5.9 -0.267569 0.215291 -5.888492 
O70400 Pdlim1 128 1 0.31 0.075 -4.1 -0.119732 0.658149 -7.083001 
O70400 Pdlim1 248 1 -0.23 0.439 -5.8 -0.523688 0.171681 -4.931856 
O88531 Ppt1 214 1 0.29 0.344 -5.6 -0.347978 0.332151 -5.783014 
O88531 Ppt1 199 1 -0.53 0.054 -3.2 -1.118351 0.006638 -0.636261 
O88569 Hnrnpa2b1 (1 of 198,199) 1 -0.22 0.156 -5.2 -0.700878 0.006518 -0.953547 
O88783 F5 (1 of 
967,968,969,971,973,97
4) 
1 -0.33 0.223 -5.7 -0.329741 0.213776 -5.87668 
O88783 F5 (1 of 774,776,777) 1 -0.21 0.283 -6 -0.207064 0.31976 -6.344518 
O88783 F5 1516 1 0.217 0.272 -5.7 0.216655 0.346258 -6.217162 
O88904 Hipk1 (1 of 853,854) 1 -0.07 0.807 -6.5 -0.074669 0.830655 -6.685365 
O88904 Hipk1 (1 of 
992,998,1001,1004,1008
,1009) 
1 -0.02 0.955 -6.6 -0.017174 0.958139 -6.73518 
P01029 C4b 1388 1 -0.24 0.421 -5.8 -0.716604 0.087588 -3.998254 




P01902 H2-K1 199 1 -0.55 0.005 -0.2 -1.120759 0.000455 3.507821 
P04925 Prnp 198 1 1.004 0.007 -0.5 1.0035287 0.004598 -0.43989 
P07361 Orm2 106 1 2.565 8E-04 3.71 2.5650735 0.000235 4.844338 
P07724 Alb 294 1 -0.08 0.79 -6.5 -0.093692 0.789737 -6.655609 
P08113 Hsp90b1 64 1 0.007 0.985 -7.2 -0.862483 0.019994 -2.859131 
P08113 Hsp90b1 219 1 -0.84 0.015 -1.2 -1.686561 0.001345 1.811593 
P08113 Hsp90b1 447 1 -0.05 0.917 -6.9 -0.852481 0.077875 -4.289251 
P08226 Apoe 134 1 1.712 0.007 -0.5 2.0793971 0.001703 1.118043 
P08228 Sod1 99 1 0.063 0.751 -6.8 0.304224 0.195034 -5.520899 
P08607 C4bpa (1 of 218,224) 1 -0.06 0.857 -6.5 -0.355604 0.326333 -5.747881 
P08607 C4bpa 426 1 -0.05 0.8 -6.8 -0.369378 0.138977 -5.05528 
P08607 C4bpa 71 1 0.048 0.878 -6.5 -0.250526 0.473937 -6.199443 
P09055 Itgb1 (1 of 521,522,526) 1 -0.29 0.339 -5.5 -0.655971 0.108021 -4.285129 
P09055 Itgb1 (1 of 
208,209,214,215,218) 
1 -0.11 0.53 -6.4 -0.457978 0.072943 -4.190927 
P09055 Itgb1 408 1 -0.06 0.857 -6.5 -0.419798 0.256179 -5.44302 
P0C7T6 Atxn1l (1 of 22,23) 1 0.133 0.339 -6.4 0.1330167 0.387734 -6.753182 
P0C7T6 Atxn1l (1 of 
29,30,31,33,34,37,39,40,
43,46) 
1 0.029 0.932 -6.5 0.0288003 0.93612 -6.730094 
P0DOV2 Ifi204 (1 of 
122,123,125,129,130,13
1,136,137,138) 
1 -0.51 0.005 -0.2 -1.271593 0.000699 2.530471 
P10605 Ctsb (1 of 39,40) 1 0.636 0.102 -3.7 0.6099793 0.127695 -4.507439 
P11032 Gzma 171 1 -1.58 0.005 0.15 -1.581243 0.002174 0.732574 
P11438 Lamp1 80 1 0.438 0.03 -2.9 0.4028939 0.050204 -4.18027 
P11679 Krt8 489 1 0.255 0.047 -3.6 0.2552974 0.076231 -4.760499 
P11679 Krt8 482 1 0.25 0.061 -4 0.2496289 0.091376 -4.993772 
P11881 Itpr1 2505 1 0.538 0.037 -3.2 0.6578003 0.013863 -2.346137 
P12265 Gusb 629 1 0.271 0.37 -5.7 0.1522531 0.660831 -6.525853 
P16301 Lcat (1 of 43,46) 1 0.107 0.727 -6.4 -0.204369 0.555587 -6.36746 
P16301 Lcat (1 of 110,111) 1 0.488 0.159 -4.5 0.174694 0.614253 -6.462164 
P23953 Ces1c (1 of 81,82,88) 1 -0.58 0.12 -4 -1.020295 0.036972 -2.697984 
P24472 Gsta4 (1 of 120,126) 1 0.59 0.034 -2.4 1.1593955 0.004224 0.042731 
P25444 Rps2 (1 of 285,292,293) 1 0.192 0.525 -6.1 0.0054953 0.987893 -6.737703 
P26039 Tln1 (1 of 2169,2170,2171) 1 -0.24 0.087 -4.6 -0.498058 0.011456 -2.074107 
P27773 Pdia3 (1 of 86,89,91) 1 -0.5 0.049 -3 -1.190639 0.003572 0.285225 
P28665 Mug1 (1 of 
281,289,290,296,300) 
1 0.164 0.579 -6.2 -0.414622 0.262222 -5.468079 
P28665 Mug1 (1 of 995,999) 1 0.251 0.408 -5.8 -0.328007 0.35586 -5.873592 
P28665 Mug1 1144 1 0.546 0.037 -3.2 0.0283076 0.915468 -7.413386 
P28665 Mug1 1182 1 0.288 0.067 -3.9 -0.293304 0.099716 -4.894832 
P29341 Pabpc1 485 1 0.356 0.099 -4.5 -0.059822 0.773026 -7.192663 
P29341 Pabpc1 351 1 0.527 0.14 -4.3 0.0791346 0.821688 -6.678955 
P29788 Vtn 88 1 -0.57 0.043 -2.8 -1.186363 0.003834 0.162801 
P29788 Vtn 243 1 0.058 0.855 -6.5 -0.546892 0.156475 -4.817138 




P33587 Proc 292 1 0.496 0.156 -4.4 0.2313645 0.507226 -6.271993 
P35831 Ptpn12 (1 of 
622,623,625,626,628,63
0,632,635,636,639,642) 
1 0.49 0.158 -4.5 0.4898876 0.193844 -5.099094 
P42128 Foxk1 663 1 0.047 0.807 -6.8 0.0470959 0.833028 -7.032728 
P42703 Lifr 384 1 -2 0.001 3.09 -2.998257 5.60E-05 7.258781 
P43883 Plin2 (1 of 56,58,59,63,64) 1 1.936 0.004 0.77 2.6536076 0.008187 -0.944201 
P43883 Plin2 (1 of 120,121,122) 1 0.604 0.11 -3.9 0.6568611 0.107829 -4.280865 
P43883 Plin2 (1 of 101,102) 1 2.5 0.003 1.55 3.2009259 0.004899 -0.180999 
P43883 Plin2 107 1 2.283 0.002 2.66 2.984585 0.003127 0.511559 
P43883 Plin2 45 1 1.347 0.022 -1.4 2.7299552 0.002103 1.326078 
P48678 Lmna (1 of 
611,613,614,616,617,61
9,620,622,624) 
1 0.248 0.102 -4.5 -0.219255 0.219863 -5.91135 
P48678 Lmna 644 1 -0.16 0.288 -6.2 -0.595004 0.014256 -2.403956 
P49182 Serpind1 169 1 0.225 0.17 -5.5 -0.038349 0.821688 -7.373947 
P49182 Serpind1 404 1 0.209 0.487 -6 -0.1782 0.608127 -6.451576 
P50247 Ahcy 2 1 0.79 0.067 -3.1 1.4669261 0.013078 -1.199382 
P51141 Dvl1 (1 of 
379,380,383,384,387) 
1 0.443 0.186 -4.7 0.443452 0.233701 -5.327751 
P52430 Pon1 (1 of 
318,326,331,332,335) 
1 2.059 0.008 -0.1 2.7512709 0.002053 1.354893 
P52430 Pon1 255 1 1.613 1E-03 3.49 2.3043508 8.88E-05 6.618395 
P58871 Tnks1bp1 260 1 -0.12 0.278 -6.1 -0.440127 0.013519 -2.314552 
P58929 Gmeb2 (1 of 403,404,407) 1 -0.34 0.056 -3.6 -0.335717 0.076231 -4.551489 
P62908 Rps3 242 1 -0.31 0.11 -4.9 -0.670246 0.010122 -1.876427 
P70274 Selenop (1 of 178,179) 1 0.169 0.569 -6.2 -0.171275 0.620941 -6.472326 
P70274 Selenop 193 1 0.571 0.016 -1.6 0.3656829 0.119233 -5.126664 
P70699 Gaa (1 of 469,472) 1 -0.29 0.109 -4.9 -0.95786 0.00131 1.249819 
P70699 Gaa 392 1 -0.34 0.039 -3.3 -1.00748 0.000897 1.829811 
P70699 Gaa 885 1 -0.73 0.003 0.9 -1.401131 0.000113 6.041574 
P70699 Gaa 142 1 -1.17 8E-04 3.94 -1.840355 5.60E-05 7.496683 
P83741 Wnk1 (1 of 1944,1945,1946) 1 0.429 0.17 -5 0.2492371 0.384645 -6.352397 
P83741 Wnk1 (1 of 
2365,2367,2372,2376,23
77) 
1 0.399 0.225 -4.9 0.230758 0.507226 -6.274228 
P83741 Wnk1 1930 1 0.239 0.432 -5.8 0.0486697 0.890658 -6.715502 
P83741 Wnk1 1844 1 0.409 0.009 -1.1 0.1913915 0.24528 -6.213387 
P83741 Wnk1 1860 1 0.093 0.759 -6.4 -0.076052 0.828414 -6.683417 
P97364 Sephs2 (1 of 
434,444,448,451,452) 
1 0.544 0.133 -4.2 0.3925131 0.28746 -5.574311 
P97426 Ear1 113 1 -0.85 0.058 -2.8 -0.85101 0.058242 -3.393172 
Q01339 Apoh (1 of 159,164,169) 1 1.16 0.059 -3.4 1.2757704 0.035118 -3.087431 
Q01705 Notch1 900 1 -0.4 0.078 -3.8 -0.401739 0.104405 -4.676458 
Q02614 Sap30bp (1 of 
231,232,233,236,238,23
9,240,241,242,244,245) 
1 -0.6 0.02 -2.3 -0.597127 0.015064 -2.488541 




Q05BG1 Cnot4 313 1 0.369 0.254 -5.1 0.3962192 0.283763 -5.556605 
Q06890 Clu (1 of 291,292) 1 -0.02 0.951 -6.5 -0.254161 0.468057 -6.185269 
Q06890 Clu 329 1 0.5 0.087 -4.3 0.2898512 0.307292 -6.290179 
Q07456 Ambp 235 1 0.186 0.537 -6.1 0.0192946 0.953863 -6.734444 
Q07456 Ambp 229 1 0.349 0.27 -5.2 0.1828238 0.599895 -6.43736 
Q07797 Lgals3bp 71 1 -1.41 7E-04 5.93 -2.151658 4.39E-05 8.370117 
Q07968 F13b (1 of 543,548,549) 1 0.597 0.004 0.46 0.4743186 0.021414 -2.979763 
Q3LFS7 Ceacam1 (1 of 72,73) 1 0.131 0.664 -6.3 0.2916418 0.403532 -6.032258 
Q3TBU7 Agfg2 (1 of 
178,186,188,192,193,19
4,195,199,201) 
1 0.175 0.556 -6.1 -0.024622 0.942801 -6.732217 
Q3TC93 Hs1bp3 280 1 0.219 0.469 -5.9 -0.163978 0.635776 -6.493472 
Q3TCN2 Plbd2 (1 of 514,522) 1 -0.68 0.089 -3.5 -0.89223 0.051555 -3.216918 
Q3TJI8 Hsd11b1 131 1 0.17 0.567 -6.2 0.4520954 0.225322 -5.285379 




1 0.427 0.201 -4.8 0.5587231 0.151148 -4.758758 
Q3TQC7 Entpd5 (1 of 250,251,257,258) 1 2.381 0.006 0.2 3.3657668 0.001155 2.061235 
Q3TVI8 Pbxip1 453 1 -1.06 0.037 -2.1 -1.056945 0.033924 -2.557344 
Q3TWZ5 Txndc11 308 1 -0.95 0.047 -2.5 -0.952329 0.043172 -2.968007 
Q3TZR9 Atf7 444 1 -0.24 0.432 -5.8 -0.238849 0.496092 -6.244101 
Q3U332 Rin3 (1 of 350,351) 1 0.487 0.16 -4.5 0.2028686 0.558579 -6.372516 
Q3U7T5 Ctsc (1 of 50,55,60) 1 -0.69 0.024 -1.9 -1.721386 0.001037 2.209363 
Q3U9N4 Grn (1 of 278,279,283) 1 0.111 0.48 -6.6 -0.662256 0.015097 -2.234676 
Q3U9N4 Grn 385 1 -0.86 0.002 2.31 -1.663876 0.000104 6.22333 
Q3UEQ1 Inpp4a 184 1 -0.61 0.109 -3.9 -0.609323 0.127811 -4.510638 




1 0.386 0.238 -5 0.3857079 0.296596 -5.606704 
Q3UH06 Rreb1 1000 1 -0.14 0.2 -5.7 -0.140004 0.301982 -6.43341 
Q3UHJ0 Aak1 360 1 0.398 0.159 -5.4 0.1251213 0.730218 -7.300413 
Q3UIA2 Arhgap17 803 1 0.135 0.655 -6.3 -0.266994 0.44505 -6.13424 
Q3UN10 Wfs1 (1 of 
667,669,670,673,674,67
5) 
1 -1.57 0.016 -0.9 -2.10311 0.004487 0.306772 
Q3UR91 Pum2 664 1 -0.62 0.106 -3.8 -0.619973 0.122836 -4.458836 
Q3UR91 Pum2 85 1 -0.38 0.245 -5.1 -0.37708 0.305552 -5.647536 
Q3USK2 Csnk1d (1 of 382,383,384,387) 1 -0.14 0.322 -6.1 -0.144562 0.397372 -6.618689 




1 -0.58 0.12 -4 -0.576116 0.142526 -4.673147 
Q3UYJ1 Gata4 (1 of 
200,206,209,211,212,21
5,216) 
1 -0.18 0.547 -6.1 -0.180387 0.603942 -6.44489 
Q3V1K7 Slco2b1 151 1 0.591 0.052 -3.5 0.6409213 0.014441 -2.168377 
Q4G0F8 Ubn1 (1 of 
875,876,878,880,881,88
2,884) 




Q4PZA2 Ece1 632 1 0.808 0.027 -2.5 0.7220857 0.033221 -3.326576 
Q4VBF8 Sipa1l1 (1 of 1114,1116,1117) 1 1.21 0.028 -1.7 1.2097796 0.022556 -2.006847 
Q52KG4 Zbtb45 262 1 -0.24 0.31 -5.8 -0.244899 0.346258 -6.218449 
Q571K4 Tab3 (1 of 
402,405,407,408,411,41
2,413,415) 
1 0.481 0.067 -3.6 0.4809401 0.076231 -4.253135 
Q59J78 Ndufaf2 (1 of 143,147,148,149) 1 0.112 0.379 -6.5 0.2866177 0.103418 -5.14752 
Q5DTZ3 Mrtfb (1 of 
207,209,214,216,217,22
2,223,225) 
1 0.546 0.132 -4.2 0.5461825 0.156583 -4.820639 
Q5DTZ3 Mrtfb 245 1 0.603 0.004 0.51 0.6033527 0.003729 -0.428065 





1 0.181 0.156 -5.4 -0.13527 0.396642 -6.777403 
Q5RIM6 Ncor1 (1 of 1914,1918) 1 -0.92 0.049 -2.6 -0.924978 0.04645 -3.080103 
Q5RIM6 Ncor1 (1 of 45,46,51,54) 1 0.037 0.911 -6.5 0.0366841 0.919967 -6.725191 
Q5RIM6 Ncor1 (1 of 
1894,1900,1901,1902,19
06) 
1 0.085 0.781 -6.4 0.0850861 0.809844 -6.669861 
Q5RIM6 Ncor1 (1 of 1055,1056) 1 0.112 0.482 -6.6 0.111918 0.531113 -6.906935 
Q5RIM6 Ncor1 (1 of 
2036,2040,2042,2052,20
53,2055) 
1 0.024 0.941 -6.5 0.0243528 0.942801 -6.732342 
Q5RIM6 Ncor1 1497 1 -0.05 0.759 -7.1 -0.045975 0.779899 -7.343483 
Q5RIM6 Ncor1 1878 1 0.193 0.524 -6.1 0.1926278 0.581447 -6.406285 
Q5RIM6 Ncor1 14 1 -0.04 0.897 -6.5 -0.041268 0.910135 -6.721803 
Q5RJH6 Smg7 578 1 -0.04 0.682 -7 -0.044394 0.742219 -7.311977 
Q5SFM8 Rbm27 546 1 -0.65 0.051 -3.1 -0.653029 0.043951 -3.483543 
Q5SQA7 Tle1 (1 of 
29,31,34,35,37,38,40,41,
42,43) 
1 -0.73 0.079 -3.3 -0.729089 0.083957 -3.940181 
Q5SUH7 Clint1 (1 of 256,258,259) 1 0.04 0.738 -7.1 -0.141086 0.307183 -6.457071 
Q5SUH7 Clint1 320 1 0.21 0.08 -4.4 0.028538 0.838287 -7.383443 
Q5XJV5 Ncoa6 1646 1 -0.49 0.018 -1.9 -0.492138 0.023203 -2.847578 
Q61001 Lama5 2049 1 -0.44 0.067 -3.9 -0.440953 0.064885 -4.312666 
Q61009 Scarb1 (1 of 286,290) 1 -0.58 0.12 -4 -1.099606 0.030147 -2.397928 
Q61009 Scarb1 (1 of 326,332,333) 1 -0.47 0.17 -4.6 -0.993559 0.039421 -2.802763 
Q61029 Tmpo 275 1 0.291 0.516 -6.4 0.1241665 0.745838 -6.964415 




1 -1.17 0.03 -1.8 -1.167488 0.02524 -2.153535 
Q61191 Hcfc1 (1 of 
1235,1238,1240,1241,12
43,1245,1246,1247) 
1 -0.61 0.109 -3.9 -1.004314 0.038172 -2.760389 
Q61191 Hcfc1 (1 of 
1055,1058,1061,1062) 
1 -0.5 0.156 -4.4 -0.8908 0.051559 -3.222959 
Q61191 Hcfc1 (1 of 1223,1224) 1 0.171 0.458 -6.5 -0.23453 0.307292 -6.288777 
Q61191 Hcfc1 (1 of 
1138,1139,1141,1143) 




Q61191 Hcfc1 (1 of 
771,775,779,784,787,78
8,789) 
1 -0.88 0.01 -0.5 -1.344704 0.002739 0.744993 
Q61191 Hcfc1 (1 of 
1494,1495,1497,1499,15
00,1506,1516) 
1 -0.72 0.081 -3.4 -1.11149 0.02927 -2.354329 
Q61191 Hcfc1 (1 of 
562,563,566,569,574,57
5) 
1 -0.52 0.016 -2 -0.960534 0.001355 1.158326 
Q61191 Hcfc1 (1 of 515,517,518,522) 1 0.384 0.037 -3.2 -0.060891 0.725585 -7.296616 
Q61191 Hcfc1 (1 of 858,861,863) 1 -0.09 0.764 -6.4 -0.454322 0.223739 -5.274445 
Q61191 Hcfc1 (1 of 794,797,800,801) 1 -0.52 0.005 0.05 -0.964569 0.000556 3.084611 
Q61191 Hcfc1 480 1 -0.58 0.12 -4 -0.97178 0.04139 -2.889497 
Q61191 Hcfc1 579 1 -0.74 0.002 1.67 -1.180044 0.000332 4.13898 
Q61191 Hcfc1 1220 1 0.176 0.552 -6.1 -0.384575 0.297241 -5.612083 
Q61191 Hcfc1 806 1 0.036 0.737 -7.1 -0.408718 0.017298 -2.675209 
Q61191 Hcfc1 808 1 -0.2 0.11 -4.9 -0.644507 0.003206 -0.188573 
Q61191 Hcfc1 490 1 -0.37 0.148 -4.8 -0.845658 0.024464 -2.582243 
Q61191 Hcfc1 685 1 0.06 0.883 -6.9 -0.319513 0.384868 -6.354978 
Q61191 Hcfc1 726 1 -0.48 0.007 -0.8 -0.920628 0.00072 2.405713 
Q61191 Hcfc1 1148 1 -0.46 0.005 -0.2 -0.907268 0.000647 2.65829 
Q61471 Tob1 (1 of 
171,172,176,178,179,18
1,185) 
1 0.178 0.549 -6.1 0.1782841 0.608127 -6.451321 
Q61646 Hp (1 of 150,152) 1 -0.85 0.058 -2.8 -2.448091 0.002894 0.911837 
Q61827 Mafk (1 of 133,134,135,138) 1 -0.58 0.056 -3.6 -0.581555 0.043806 -3.786187 
Q61827 Mafk 153 1 -0.28 0.084 -4.3 -0.281783 0.120752 -5.147926 
Q62261 Sptbn1 2323 1 0.36 0.014 -1.8 0.3491898 0.026948 -3.294425 
Q62311 Taf6 (1 of 480,481,483,485) 1 0.014 0.911 -7.2 0.0144419 0.919967 -7.414751 
Q62311 Taf6 (1 of 
586,587,589,590,594,59
5,600,602) 
1 -0.22 0.475 -5.9 -0.215858 0.531113 -6.32785 
Q62419 Sh3gl1 284 1 0.106 0.727 -6.4 0.0234627 0.943661 -6.732747 
Q63880 Ces3a 313 1 -0.78 0.017 -1.4 -2.316689 0.000567 3.462067 
Q63886 Ugt1a1 91 1 0.829 0.02 -2.3 0.7586203 0.030078 -3.433477 
Q64511 Top2b 1200 1 -1.07 0.037 -2.1 -1.311478 0.017983 -1.67079 
Q68FG2 Sptbn2 (1 of 
2100,2101,2106,2111) 
1 0.369 0.098 -4.1 -0.05133 0.818531 -7.022383 
Q68FG2 Sptbn2 2359 1 0.344 0.094 -4.4 -0.061152 0.769855 -7.188626 
Q69ZA1 Cdk13 (1 of 
1278,1285,1286,1287,12
88,1289,1291) 
1 -0.34 0.11 -4.4 -0.339432 0.1519 -5.191846 
Q69ZL1 Fgd6 494 1 0.992 0.043 -2.3 0.9922157 0.039493 -2.808077 
Q6A058 Armcx2 366 1 1.016 0.041 -2.2 1.0162369 0.037159 -2.713767 
Q6A0A2 Larp4b (1 of 631,632,633) 1 -0.01 0.973 -6.6 -0.539704 0.160474 -4.852645 
Q6A0A2 Larp4b (1 of 41,46,50,51) 1 -0.24 0.132 -5 -0.74551 0.005286 -0.646688 
Q6DFV5 Helz 1668 1 0.726 0.079 -3.3 0.7261315 0.084694 -3.953904 
Q6DFZ1 Gbf1 (1 of 1857,1858) 1 0.299 0.263 -5.6 0.08263 0.772547 -6.986265 
Q6DFZ1 Gbf1 (1 of 
1780,1781,1782,1783) 




Q6DID3 Scaf8 819 1 -0.59 0.113 -3.9 -0.59449 0.135035 -4.583053 
Q6KCD5 Nipbl (1 of 1678,1679) 1 0.334 0.181 -5.4 0.3339417 0.179482 -5.668944 
Q6KCD5 Nipbl (1 of 160,161,162) 1 -0.03 0.917 -6.5 -0.034927 0.922643 -6.726385 
Q6P5E4 Uggt1 (1 of 266,271,276) 1 0.115 0.706 -6.4 -0.353582 0.328501 -5.757222 
Q6P6J9 Txndc15 (1 of 
138,145,150,151,153) 
1 0.824 0.039 -3 0.8710115 0.037638 -3.528469 
Q6PAL7 Ahdc1 (1 of 
1574,1588,1590,1592,15
93) 
1 0.023 0.918 -6.9 0.0232489 0.922643 -7.070159 
Q6PB44 Ptpn23 (1 of 
880,881,882,885,891,89
2,894) 
1 0.748 0.075 -3.2 0.6713908 0.103166 -4.211452 
Q6PD26 Pigs 372 1 0.022 0.919 -7.2 -0.775669 0.002739 0.107589 
Q6PDI5 Ecpas (1 of 1669,1670) 1 0.214 0.479 -5.9 0.2248902 0.518634 -6.295638 
Q6PIJ4 Nfrkb (1 of 
1073,1076,1077,1084) 
1 -0.11 0.718 -6.4 -0.110367 0.755978 -6.624365 
Q6PIJ4 Nfrkb (1 of 
1025,1027,1030,1031,10
36,1037) 
1 0.346 0.323 -5.9 0.3455294 0.317753 -6.09538 
Q6PIJ4 Nfrkb (1 of 
1166,1167,1170,1171,11
72,1174) 
1 0.046 0.744 -7 0.0456289 0.78714 -7.205254 
Q6PIJ4 Nfrkb 1064 1 -0.13 0.364 -6.3 -0.132413 0.442784 -6.722613 
Q6PIJ4 Nfrkb 838 1 -0.45 0.037 -3.2 -0.446062 0.034653 -3.621229 
Q6PIJ4 Nfrkb 1270 1 -0.03 0.938 -6.5 -0.025425 0.941654 -6.731835 
Q6XLQ8 Calu 133 1 -0.81 0.003 1.26 -1.133062 0.000841 2.11076 
Q78PY7 Snd1 909 1 0.392 0.231 -5 -0.090632 0.796061 -6.660825 
Q7M739 Tpr (1 of 2054,2055,2057) 1 0.002 0.994 -6.9 -0.164198 0.476248 -6.572806 
Q7M739 Tpr (1 of 
1656,1657,1658,1662,16
68,1672,1673,1675) 
1 -0.06 0.79 -7 -0.228241 0.328997 -6.383767 
Q7TN29 Smap2 197 1 -0.1 0.697 -6.7 -0.25854 0.336658 -6.184319 
Q7TPN9 Prr14 319 1 -0.47 0.054 -3.2 -0.469335 0.069023 -4.105223 
Q7TQE2 Zyx (1 of 206,207,210) 1 0.383 0.239 -5 0.4260048 0.250307 -5.412885 




1 -0.13 0.658 -6.3 -0.133834 0.705312 -6.572577 
Q7TT50 Cdc42bpb (1 of 
968,969,970,972,976,97
9) 
1 0.585 0.064 -3.5 0.341977 0.21503 -5.633897 
Q80U93 Nup214 (1 of 634,635,637,639) 1 -0.11 0.65 -7 -0.257499 0.332151 -6.570148 
Q80U93 Nup214 (1 of 
1336,1337,1342,1345,13
47) 
1 0.205 0.494 -6 0.1375443 0.699294 -6.563584 
Q80U93 Nup214 (1 of 
1109,1115,1116,1118,11
20,1121) 
1 0.164 0.579 -6.2 0.0541677 0.875976 -6.710163 
Q80U93 Nup214 (1 of 
645,646,648,651,652,65
5,656) 








1 -0.47 0.008 -0.9 -0.611043 0.005143 -0.894215 
Q80U93 Nup214 (1 of 506,507) 1 -0.17 0.135 -5.2 -0.309181 0.049506 -4.159988 
Q80U93 Nup214 (1 of 
1313,1314,1316,1317,13
19,1320) 
1 -0.19 0.151 -5.4 -0.336795 0.055822 -4.329447 
Q80U93 Nup214 504 1 -0.12 0.239 -5.9 -0.265468 0.07331 -4.70831 
Q80U93 Nup214 1362 1 -0.3 0.025 -2.6 -0.44795 0.012733 -2.22696 
Q80UF7 Ticam1 (1 of 
310,313,314,315,316) 
1 0.262 0.129 -4.9 0.2618029 0.164262 -5.563565 
Q80VP1 Epn1 (1 of 
411,415,416,418,419,42
0) 
1 0.471 0.067 -3.6 0.2586634 0.363806 -6.287676 
Q80X50 Ubap2l (1 of 875,879,883) 1 0.491 0.048 -3 0.4691682 0.06894 -4.101268 
Q80X50 Ubap2l (1 of 
798,799,802,803,804) 
1 0.19 0.178 -5.6 0.1028758 0.514601 -7.024042 
Q80X50 Ubap2l (1 of 
480,481,482,487,490,49
1,495,496,497) 
1 0.819 0.063 -2.9 0.646051 0.111664 -4.332771 
Q80X81 Acat3 12 1 1.229 8E-04 3.8 1.3616115 0.00072 2.436313 
Q80YR4 Znf598 (1 of 
560,563,564,568,569,57
5,578,579) 
1 -0.01 0.954 -6.9 -0.216113 0.368174 -6.299973 
Q80YX8 Mup21 65 1 -2.35 0.006 0.17 -2.348045 0.003206 0.748499 
Q810N5  (1 of 2,3,5) 1 1.572 0.016 -0.9 1.5719652 0.010777 -0.90714 
Q8BFR4 Gns (1 of 267,270,272,273) 1 0.042 0.8 -7.2 -0.238293 0.214861 -6.063819 
Q8BFW7 Lpp (1 of 
210,212,213,215,216,21
7,218) 
1 0.335 0.284 -5.3 0.2440793 0.485606 -6.224267 
Q8BFW7 Lpp 312 1 1.131 0.033 -1.9 1.040521 0.035118 -2.619942 
Q8BFW7 Lpp 11 1 0.566 0.006 -0.4 0.5995486 0.008275 -1.609246 
Q8BG19 Tmtc4 499 1 -0.28 0.36 -5.6 -0.277449 0.427164 -6.091592 
Q8BGD9 Eif4b 352 1 0.283 0.043 -3.5 0.1053524 0.50169 -6.998721 
Q8BGD9 Eif4b 355 1 0.113 0.49 -6.8 -0.064834 0.700214 -7.271747 
Q8BGD9 Eif4b 495 1 0.302 0.027 -2.7 0.1247199 0.386173 -6.748723 
Q8BGQ4 Pomt2 655 1 0.577 0.049 -3.4 0.5769975 0.040229 -3.625785 
Q8BGS1 Epb41l5 (1 of 385,386,387,398) 1 -0.53 0.137 -4.2 -0.789156 0.069929 -3.665997 
Q8BH35 C8b 45 1 -1.56 0.016 -0.9 -3.005937 0.001549 1.675063 
Q8BH80 Vapb (1 of 143,144) 1 1.083 7E-04 4.66 1.3681604 0.000297 4.459673 
Q8BHL3 Tbc1d10b (1 of 32,43,44,46,47) 1 -0.37 0.1 -4.5 -0.369163 0.104043 -4.952075 
Q8BI72 Cdkn2aip (1 of 317,318,319) 1 0.157 0.239 -5.9 0.1574071 0.303245 -6.438537 
Q8BI72 Cdkn2aip (1 of 
304,305,306,308,310,31
1,314,315) 
1 0.014 0.936 -7.2 0.0136519 0.936087 -7.418649 
Q8BI72 Cdkn2aip (1 of 
187,188,189,190,192,19
6,198,199) 
1 0.064 0.723 -7.1 0.06392 0.730573 -7.301265 
Q8BI72 Cdkn2aip (1 of 395,396) 1 0.1 0.742 -6.4 0.0999623 0.779447 -6.644416 




Q8BI84 Mia3 (1 of 250,253,254,257) 1 0.207 0.281 -6.2 -0.096441 0.620941 -7.189618 
Q8BI84 Mia3 1729 1 1.165 0.004 0.64 0.8613217 0.005933 -1.10639 
Q8BI84 Mia3 1754 1 0.911 0.002 1.95 0.6074721 0.006701 -1.30418 
Q8BI84 Mia3 1766 1 0.692 0.007 -0.5 0.3763327 0.062634 -4.260957 
Q8BI84 Mia3 633 1 0.126 0.527 -6.4 -0.187294 0.41174 -6.427643 
Q8BJ05 Zc3h14 (1 of 369,370,373) 1 -0.41 0.219 -4.9 -0.781056 0.071294 -3.70245 
Q8BJ05 Zc3h14 (1 of 75,77,78,81,82) 1 -0.13 0.682 -6.3 -0.499037 0.187682 -5.053845 
Q8BJ05 Zc3h14 (1 of 132,133,134,135) 1 0.135 0.465 -6.3 -0.272436 0.245298 -5.792713 
Q8BJ05 Zc3h14 360 1 -0.05 0.727 -7 -0.419838 0.039744 -3.606371 
Q8BJ05 Zc3h14 255 1 0.194 0.172 -5.3 -0.179932 0.305552 -6.277729 
Q8BJ71 Nup93 (1 of 51,52,55) 1 0.876 0.106 -4.8 0.3298067 0.518902 -7.033818 
Q8BJS4 Sun2 (1 of 
648,651,652,654,655) 
1 -0.09 0.857 -6.9 -0.463025 0.104931 -4.686353 
Q8BKI2 Tnrc6b (1 of 
304,310,311,312,314) 
1 0.119 0.696 -6.3 0.1188502 0.738316 -6.606676 
Q8BKI2 Tnrc6b (1 of 1158,1159,1161) 1 0.308 0.149 -4.8 0.3078583 0.196025 -5.527754 
Q8BM88 Ctso 98 1 1.772 7E-04 4.76 2.5058743 5.60E-05 7.171508 
Q8BMB0 Emsy (1 of 520,521,525) 1 -0.31 0.315 -5.4 -0.311175 0.376465 -5.948131 
Q8BMB0 Emsy (1 of 
498,499,500,502,505) 
1 -0.98 0.011 -0.7 -0.981124 0.008857 -1.073438 
Q8BMB0 Emsy 192 1 -0.7 0.003 1.25 -0.699764 0.002141 0.464348 
Q8BMB0 Emsy 1069 1 -0.81 0.002 1.59 -0.810146 0.001386 1.100206 
Q8BMB0 Emsy 200 1 -0.68 0.088 -3.5 -0.684389 0.098791 -4.149714 
Q8BNV8 A530064D0
6Rik 
(1 of 147,148) 1 -0.61 0.108 -3.8 -0.613515 0.125935 -4.490227 
Q8BP97 Rhbdd3 (1 of 380,382,385) 1 0.081 0.792 -6.5 0.08102 0.818531 -6.676142 
Q8BTI8 Srrm2 (1 of 2122,2123,2131) 1 -0.25 0.347 -6.4 -0.865083 0.026948 -3.30258 
Q8BTI8 Srrm2 2341 1 -0.65 0.004 0.48 -1.259471 0.000332 4.199532 
Q8BTI8 Srrm2 2205 1 -0.31 0.181 -5.6 -0.922417 0.012163 -2.153966 
Q8BTI8 Srrm2 2414 1 -0.64 0.1 -3.7 -1.365677 0.015991 -1.500857 
Q8BTJ4 Enpp4 281 1 -1.57 7E-04 6.38 -1.569568 8.88E-05 6.478766 
Q8BTJ4 Enpp4 261 1 -1.5 0.005 0.65 -1.495285 0.002535 0.854478 
Q8BU11 Tox4 (1 of 
405,406,407,409,413,42
0) 
1 0.395 0.229 -5 0.3950774 0.284419 -5.562065 
Q8BU25 Pamr1 267 1 -0.61 0.11 -3.9 -0.606002 0.12895 -4.526825 
Q8BUN3 Qrich1 (1 of 365,366,367) 1 -0.15 0.315 -6.3 -0.149256 0.35586 -6.653584 
Q8BVZ1 Plin5 (1 of 50,52,55,56,60) 1 1.575 0.016 -0.9 1.9375414 0.005713 -0.030022 
Q8BX02 Kank2 346 1 -0.14 0.533 -6.4 -0.691038 0.028325 -2.785959 
Q8BX02 Kank2 421 1 -0.2 0.498 -6 -0.78414 0.070748 -3.688552 
Q8BYB9 Poglut1 (1 of 205,206) 1 -0.59 0.115 -4 -0.589044 0.137867 -4.609714 
Q8BYK6 Ythdf3 201 1 -0.21 0.13 -5.2 -0.612078 0.004383 -0.653379 
Q8BYK6 Ythdf3 205 1 -0.05 0.682 -7.1 -0.455125 0.012592 -2.205601 
Q8BYK6 Ythdf3 167 1 0.058 0.855 -6.5 -0.335001 0.347834 -5.842117 
Q8BYU6 Tor1aip2 (1 of 320,323,327,331) 1 0.407 0.085 -4 0.3595692 0.153664 -5.211904 
Q8C0C0 Zhx2 (1 of 
150,155,159,166,168,17
2,173,180) 




Q8C0C0 Zhx2 (1 of 264,265) 1 -0.54 0.136 -4.2 -1.065592 0.03315 -2.524662 
Q8C0C3 Trappc12 (1 of 
232,234,236,237,238,23
9) 
1 1.111 0.034 -2 0.9561751 0.042704 -2.952405 
Q8C0Q2 Zhx3 (1 of 
581,585,587,588,591,59
5) 
1 -0.49 0.157 -4.4 -1.522743 0.011738 -1.041593 
Q8C0Q2 Zhx3 730 1 -0.42 0.007 -0.8 -1.147838 0.000586 2.90085 
Q8C0Q2 Zhx3 236 1 0.103 0.718 -6.7 -0.676989 0.1202 -4.865324 
Q8C180 Frs2 (1 of 
326,327,328,329,330,33
1,333,339) 
1 0.892 0.19 -5.2 0.8917475 0.146547 -5.138898 
Q8C341 Suco (1 of 
525,527,531,533,534) 
1 0.177 0.338 -6.4 0.177292 0.351011 -6.639111 
Q8C5R2 Proser2 (1 of 
381,384,385,389,390) 
1 0.618 0.004 0.52 0.5006685 0.020566 -2.901305 
Q8C7E7 Stbd1 160 1 0.792 0.061 -3.4 0.4888406 0.178487 -5.400633 
Q8C8Z9 Dtnb 608 1 0.539 0.008 -0.9 0.376624 0.098791 -5.082812 
Q8CBB6 Hist1h2bq 113 1 -0.74 0.007 -0.5 -1.032756 0.013874 -2.097591 
Q8CCH2 Nhlrc3 208 1 -0.78 0.005 0.32 -0.65635 0.014225 -2.129522 
Q8CF89 Tab1 (1 of 
389,393,394,397,398,39
9) 
1 0.337 0.076 -4.1 0.3369848 0.092266 -4.80083 
Q8CFE4 Scyl2 (1 of 
741,743,744,745,747,75
1,752,759,760,765) 
1 0.574 0.12 -4 0.1548394 0.65748 -6.518882 
Q8CFE4 Scyl2 630 1 1.235 0.027 -1.6 1.040431 0.035118 -2.620287 
Q8CGM2 Rp1l1 (1 of 3,4) 1 0.351 0.269 -5.2 0.3505147 0.330569 -5.771359 
Q8CHH5 Bicral 590 1 -0.45 0.181 -4.7 -0.452676 0.225122 -5.282528 
Q8CHI8 Ep400 709 1 0.003 0.996 -6.6 0.0026441 0.99427 -6.737924 
Q8CHS8 Vps37a (1 of 
171,172,174,178,180,18
1,182,183,184,185,187) 
1 0.236 0.079 -4.4 0.1860259 0.183314 -5.876876 
Q8CI51 Pdlim5 (1 of 118,119,120,121) 1 0.394 0.229 -5 0.2355057 0.50169 -6.256633 
Q8CI51 Pdlim5 (1 of 110,111) 1 0.365 0.014 -1.7 0.222619 0.117661 -5.31071 
Q8CI51 Pdlim5 (1 of 
208,210,211,214,216) 
1 0.649 0.098 -3.7 0.4910899 0.193085 -5.093149 
Q8CI51 Pdlim5 90 1 0.567 0.02 -2 0.4023883 0.087588 -4.733321 
Q8CI51 Pdlim5 115 1 0.63 0.003 0.7 0.4874706 0.016051 -2.573914 
Q8JZK9 Hmgcs1 (1 of 
506,507,510,512,516) 
1 1.557 0.016 -0.9 1.9557947 0.005593 0.008774 
Q8JZZ0 Ugt3a2 54 1 0.708 0.004 0.52 1.0837644 0.00055 3.270716 
Q8K099 Lrit1 (1 of 604,605,608) 1 -0.35 0.034 -3.1 -0.350301 0.040972 -3.894037 
Q8K0E8 Fgb 378 1 -0.88 0.004 0.71 -1.320204 0.000884 2.223496 
Q8K0L9 Zbtb20 (1 of 
461,464,465,472,473) 
1 -0.23 0.453 -5.9 -0.94261 0.043806 -3.007614 
Q8K0L9 Zbtb20 (1 of 444,447) 1 -0.62 0.016 -1.9 -1.159031 0.000873 2.021323 
Q8K0L9 Zbtb20 (1 of 
303,304,305,308,309) 
1 -0.42 0.204 -4.8 -1.024554 0.036538 -2.681463 
Q8K0L9 Zbtb20 (1 of 260,263,268,272) 1 -0.1 0.735 -6.4 -0.817772 0.064407 -3.538547 




Q8K0L9 Zbtb20 480 1 -0.29 0.035 -3.1 -0.825819 0.001355 1.146431 
Q8K0L9 Zbtb20 449 1 -0.48 0.014 -1.8 -1.016621 0.000897 1.83367 
Q8K0L9 Zbtb20 436 1 -0.57 0.006 -0.5 -1.109202 0.000551 3.148671 
Q8K2Q9 Shtn1 (1 of 
487,492,493,494,496,50
1,502,504) 
1 0.686 0.002 1.57 0.448591 0.020846 -2.924104 
Q8K3X4 Irf2bpl (1 of 
195,198,199,200,203,20
4,207) 
1 -0.33 0.294 -5.4 -0.326709 0.35586 -5.879403 
Q8K3Z9 Pom121 (2 of 
649,650,653,658,660,66
1,664,665,667,668,670) 
2 -0.23 0.115 -4.8 -0.22924 0.177728 -5.653918 
Q8QZR3 Ces2a 272 1 -0.72 0.028 -2.8 -1.558163 0.00125 1.326722 
Q8R066 C1qtnf4 (1 of 178,182) 1 0.139 0.654 -6.7 0.1392912 0.645915 -6.860488 
Q8R080 Gtse1 (1 of 267,268) 1 0.413 0.03 -2.6 0.413417 0.040509 -3.640169 
Q8R084 Ugt2b1 98 1 -0.5 0.023 -2.2 -1.271527 0.000883 2.253567 
Q8R0F3 Sumf1 140 1 -0.06 0.819 -7 -0.064179 0.810329 -7.220909 
Q8R121 Serpina10 (1 of 280,281,282) 1 0.057 0.82 -6.8 -0.396717 0.143364 -5.110131 
Q8R143 Pttg1ip 41 1 0.788 0.068 -3.1 0.9636015 0.042146 -2.922386 
Q8R242 Ctbs 285 1 -1.16 0.053 -3.2 -1.58196 0.012163 -1.536325 
Q8R3E3 Wipi1 (1 of 
389,390,391,394,395,40
0) 
1 0.139 0.344 -6.4 0.1392452 0.384645 -6.743123 
Q8R4R6 Nup35 53 1 -0.42 0.097 -4.5 -0.662956 0.016971 -2.384256 
Q8R4U0 Stab2 1512 1 -0.28 0.16 -4.9 -0.465309 0.069929 -4.125914 
Q8R4U0 Stab2 910 1 -0.44 0.186 -4.7 -0.580538 0.141334 -4.651428 
Q8VBZ3 Clptm1 297 1 0.153 0.593 -6.6 -0.096625 0.717517 -6.935686 
Q8VC34 Rpap2 (1 of 4,9,13,14) 1 0.956 0.047 -2.4 0.9564343 0.042704 -2.951355 
Q8VC97 Upb1 392 1 1.922 7E-04 4.65 2.566832 0.000214 5.015388 
Q8VCF0 Mavs (1 of 
309,310,314,315,316,31
9,321,324) 
1 0.801 0.001 2.84 0.8696328 0.002337 0.337088 
Q8VCF0 Mavs 298 1 0.154 0.465 -6.3 0.3653235 0.187682 -5.469724 
Q8VCF0 Mavs 330 1 0.969 0.005 0.05 1.1408073 0.003243 0.074162 
Q8VCF0 Mavs 370 1 0.628 0.002 1.55 0.6969903 0.003834 -0.477734 
Q8VCF0 Mavs 373 1 0.363 0.022 -2.4 0.4322044 0.016199 -2.587986 
Q8VCF0 Mavs 343 1 0.306 0.086 -4.3 0.2983858 0.1281 -5.22258 
Q8VCI0 Plbd1 529 1 -1.34 7E-04 4.85 -2.292171 4.39E-05 8.112516 
Q8VCI0 Plbd1 446 1 -1.66 0.016 -1.3 -2.672605 0.001454 1.654352 
Q8VCN5 Cth (1 of 54,55,60) 1 -0.05 0.883 -6.5 1.0461394 0.03487 -2.59845 
Q8VCU1 Ces3b 313 1 -1.09 0.036 -2 -2.753988 0.002053 1.358543 
Q8VDZ4 Zdhhc5 386 1 0.475 0.075 -3.7 0.3106131 0.186285 -5.454897 
Q8VHR5 Gatad2b (1 of 
487,489,490,495,496,49
8) 
1 -0.22 0.458 -5.9 -0.224672 0.518634 -6.296428 
Q8VHR5 Gatad2b (1 of 525,526) 1 -0.09 0.832 -7 -0.091508 0.811996 -7.22216 
Q8VHR5 Gatad2b (1 of 
288,289,290,298,303,30
4,305,306) 




Q8VHR5 Gatad2b 585 1 -0.39 0.013 -1.6 -0.388139 0.019994 -2.855242 
Q91WH2 Ugt2b38 (1 of 
299,300,309,312,315,31
8) 
1 0.09 0.765 -6.4 0.0899193 0.796312 -6.662016 
Q91WK2 Eif3h (1 of 
8,10,11,13,14,15,17) 
1 -0 1 -6.9 -0.289715 0.396322 -6.387769 
Q91WP0 Masp2 643 1 0.202 0.503 -6 -0.013102 0.967202 -6.736355 
Q91WU0 Ces1f 81 1 -0.09 0.664 -7 -0.306777 0.149143 -5.625577 
Q91X84 Crtc3 (1 of 
320,321,322,326,327) 
1 -0.08 0.54 -6.8 -0.082321 0.587401 -7.137343 
Q91XL1 Lrg1 316 1 -0.07 0.8 -7 -0.826311 0.062176 -4.250519 
Q91XT4 Sec16b 68 1 0.894 0.005 -0.1 0.9134948 0.005143 -0.889964 
Q91XT4 Sec16b 78 1 0.928 1E-03 3.38 0.947158 0.000883 1.978038 
Q91YQ5 Rpn1 (1 of 302,303,304,312) 1 0.106 0.727 -6.4 -0.49829 0.187947 -5.057538 
Q91YQ5 Rpn1 (1 of 386,391) 1 0.063 0.842 -6.5 -0.595926 0.134429 -4.576031 
Q91YT7 Ythdf2 (1 of 196,197,201,202) 1 0.131 0.351 -6.4 -0.36901 0.054626 -4.29603 
Q921I1 Tf 514 1 0.627 0.004 0.21 0.4869897 0.022556 -3.059094 
Q921L6 Cttn (1 of 307,308) 1 0.133 0.268 -6.1 -0.247428 0.153615 -5.661797 
Q922U1 Prpf3 176 1 0.251 0.1 -4.8 -0.255098 0.183738 -5.881037 
Q99LI5 Znf281 (1 of 
861,862,864,867,870,87
4,877,881,882) 
1 -0.87 0.056 -2.8 -0.86802 0.055378 -3.319893 
Q99LI5 Znf281 (1 of 
774,775,776,780,781,78
2) 
1 -0.12 0.691 -6.3 -0.121752 0.732536 -6.600354 
Q99LI5 Znf281 (1 of 236,238,239) 1 -0.59 0.114 -3.9 -0.592197 0.136176 -4.594277 
Q99LI5 Znf281 (1 of 886,888,889,891) 1 -0.61 0.003 1 -0.608121 0.003086 -0.107596 
Q99MZ3 Mlxipl (1 of 614,618,619) 1 0.551 0.004 0.15 0.4307038 0.014256 -2.405417 
Q9CQW1 Ykt6 172 1 0.227 0.298 -5.8 0.1941726 0.431248 -6.474847 
Q9CS74 Ecd 640 1 0.648 0.017 -1.8 0.648233 0.014646 -2.19268 
Q9CU24 Themis3 (1 of 313,316) 1 -0.81 0.014 -1.1 -0.813961 0.013874 -1.749061 
Q9CWK8 Snx2 (1 of 
93,94,97,101,104,106,10
7) 
1 0.057 0.855 -6.5 -0.350018 0.330569 -5.773644 
Q9CYA0 Creld2 190 1 -2.17 0.007 -0 -3.806059 0.000871 2.448945 
Q9D136 Ogfod3 (1 of 212,213) 1 -0.61 0.075 -4.1 -1.107538 0.008067 -1.268575 
Q9D136 Ogfod3 262 1 -0.23 0.184 -5.4 -0.736571 0.011107 -1.74846 
Q9D1M0 Sec13 315 1 0.069 0.727 -6.7 0.135931 0.530268 -6.686135 
Q9D787 Ppil2 (1 of 
493,499,500,501,502,50
4,506) 
1 0.208 0.087 -4.6 0.2083074 0.138638 -5.515583 
Q9D7N9 Apmap 161 1 1.208 0.005 -0 1.699568 0.000357 4.021981 
Q9D8N1  145 1 0.209 0.284 -5.7 0.2086235 0.356796 -6.266472 
Q9DAC2 C8g (1 of 120,126) 1 0.024 0.859 -7.2 -0.524484 0.0077 -1.477921 
Q9DAC2 C8g 141 1 0.842 0.001 2.9 0.2944519 0.05552 -4.321106 
Q9DBG5 Plin3 (1 of 
126,127,128,130,137,13
8,139,141,142) 
1 0.955 8E-04 3.9 0.9780874 0.000878 2.000083 
Q9DBG5 Plin3 (1 of 71,72) 1 0.37 0.112 -4.9 0.3929641 0.076231 -4.765187 




Q9DBG5 Plin3 76 1 0.769 0.004 0.55 0.7918137 0.003702 -0.410892 
Q9DBG6 Rpn2 (1 of 
77,82,86,93,94,98,103,1
05,108) 
1 -0.13 0.818 -6.8 -0.837798 0.109228 -4.746863 




1 0.121 0.692 -6.3 -0.189295 0.588491 -6.416989 
Q9EP52 Twsg1 82 1 -0.18 0.274 -6.1 -0.181503 0.308342 -6.466071 
Q9EPU0 Upf1 951 1 0.506 0.049 -3.4 0.275249 0.245298 -6.040002 
Q9EQQ9 Oga 405 1 -0.06 0.751 -7.1 -0.753151 0.008196 -1.584346 
Q9ER39 Tor1a 161 1 -0.66 0.096 -3.6 -1.227749 0.021717 -1.945779 
Q9ERG0 Lima1 (1 of 
324,325,326,329,334,34
1,344) 
1 0.529 0.139 -4.3 0.3511906 0.330276 -5.768248 
Q9ERG0 Lima1 279 1 0.558 0.127 -4.1 0.381097 0.30179 -5.628561 




1 0.121 0.542 -6.5 -0.16658 0.458026 -6.533599 
Q9ERU9 Ranbp2 (1 of 1426,1428) 1 -0.32 0.307 -5.4 -0.637152 0.115673 -4.375658 
Q9ERU9 Ranbp2 (1 of 
1134,1137,1138,1141) 
1 -0.33 0.104 -4.6 -0.618809 0.014571 -2.182683 
Q9ERU9 Ranbp2 (1 of 
2442,2443,2444,2445,24
47) 
1 0.383 0.24 -5 0.0991845 0.779899 -6.645841 
Q9ERU9 Ranbp2 (1 of 
1591,1592,1595,1599,16
00,1602,1603) 
1 0.019 0.953 -6.6 -0.301451 0.389025 -5.990348 
Q9ERU9 Ranbp2 1457 1 0.214 0.262 -5.6 -0.087492 0.700432 -6.917421 
Q9ERZ6 Fign (1 of 395,396) 1 3.145 0.004 0.75 3.1447525 0.001355 1.832471 
Q9ESC8 Aff4 (1 of 84,85,86) 1 -0.19 0.537 -6.1 -0.186102 0.592908 -6.427109 
Q9ESC8 Aff4 689 1 ##### 1 -6.9 8.07E-05 0.999722 -7.081112 
Q9ESY9 Ifi30 107 1 -0.46 0.073 -3.7 -0.45936 0.083957 -4.392169 
Q9ET43 Cldn12 241 1 -0.61 0.007 -0.4 -0.966983 0.00642 -0.930079 
Q9JHP7 Poglut2 154 1 0.055 0.859 -6.5 0.0551818 0.874897 -6.709117 
Q9JI95 Hspe1-rs1 21 1 -0.3 0.328 -5.5 -0.300931 0.389426 -5.992586 
Q9JKR6 Hyou1 (1 of 513,517,518) 1 -1.06 0.004 0.46 -1.993881 0.000382 4.160855 
Q9JKR6 Hyou1 933 1 -0.57 0.048 -3.6 -1.475295 0.001021 1.648389 
Q9JKR6 Hyou1 598 1 -0.85 0.023 -2.2 -1.779953 0.00072 2.618266 
Q9JKR6 Hyou1 871 1 -0.14 0.791 -6.8 -1.008247 0.077615 -4.283147 
Q9JL60 Gmeb1 (1 of 442,443) 1 -0.13 0.325 -6.2 -0.129186 0.425619 -6.684149 
Q9JLV1 Bag3 (1 of 289,291,297) 1 0.709 0.083 -3.4 0.2397889 0.494631 -6.240558 
Q9JLV1 Bag3 (1 of 
372,373,380,382,386,39
0) 
1 -0.17 0.569 -6.2 -0.638432 0.115259 -4.369481 
Q9JLV1 Bag3 (1 of 187,188,189) 1 0.704 0.005 -0.2 0.323997 0.105562 -5.178956 
Q9JLV1 Bag3 (1 of 162,163,170) 1 0.308 0.32 -5.5 -0.16149 0.641715 -6.50051 
Q9JLV1 Bag3 320 1 0.338 0.282 -5.3 -0.13162 0.710162 -6.577842 
Q9JLV1 Bag3 183 1 0.694 0.006 -0.5 0.3133588 0.124725 -5.385147 




Q9QYC7 Ggcx 572 1 0.389 0.082 -4.5 0.2666444 0.222205 -6.103249 
Q9QYC7 Ggcx 629 1 0.527 0.043 -3.5 0.4048939 0.091149 -4.986716 
Q9QYE6 Golga5 (1 of 
150,152,153,155,158,15
9,162,163,165,166,167) 
1 0.197 0.257 -6 0.0125697 0.943661 -7.421311 
Q9QYG0 Ndrg2 (1 of 
348,350,352,353,355,35
7,360) 
1 0.189 0.156 -5.4 0.3055432 0.064885 -4.5319 
Q9QYG0 Ndrg2 370 1 0.219 0.112 -4.9 0.3353544 0.043415 -3.994941 
Q9QYG0 Ndrg2 335 1 -0.03 0.952 -7.1 0.0736261 0.852642 -7.246967 
Q9QZN4 Fbxo6 261 1 0.026 0.938 -6.5 0.1934822 0.580022 -6.403518 
Q9QZS5 Sgk2 332 1 0.618 0.107 -3.8 0.5442069 0.157732 -4.830398 
Q9R013 Ctsf 358 1 -1.6 7E-04 4.67 -2.395331 5.60E-05 7.373964 
Q9R182 Angptl3 117 1 1.948 0.009 -0.3 2.2606867 0.003572 0.598082 
Q9R1E0 Foxo1 (1 of 
644,645,646,648,651) 
1 -0.3 0.136 -4.7 -0.304496 0.188973 -5.482053 
Q9WU60 Atrn (1 of 1083,1084) 1 -1.19 0.005 0.42 -1.191738 0.003834 0.170483 
Q9WU60 Atrn (1 of 412,413,417) 1 -0.21 0.481 -6 -0.212635 0.537509 -6.339117 
Q9WUD0 Cyp2b10 141 1 -0.94 0.048 -2.5 0.5819119 0.14101 -4.644686 
Q9WUM3 Coro1b 421 1 0.522 0.078 -3.8 0.3342037 0.183738 -5.439188 
Q9WUU7 Ctsz 188 1 -0.81 0.064 -3 -2.234032 0.003702 0.550664 
Q9WV54 Asah1 259 1 -0.95 0.003 0.75 -1.509057 0.000297 4.396113 
Q9WV69 Dmtn (1 of 
274,278,279,282,284,28
5) 
1 -0.31 0.138 -4.7 -0.31308 0.186422 -5.457471 
Q9WV69 Dmtn (1 of 10,11,14,16,17,18) 1 -0.11 0.713 -6.4 -0.113005 0.749121 -6.618991 
Q9WV69 Dmtn 110 1 -0.33 0.205 -5.3 -0.329933 0.225322 -5.693758 
Q9WVF5 Egfr (1 of 525,530) 1 -3.6 0.003 0.97 -5.483238 0.000418 3.381436 
Q9WVJ3 Cpq 396 1 -0.94 0.048 -2.5 -1.25936 0.020566 -1.840133 
Q9Z0K8 Vnn1 (1 of 149,150,152) 1 3.234 0.004 0.8 4.3046348 0.000662 2.800801 
Q9Z0K8 Vnn1 134 1 1.321 0.004 0.74 2.2953719 0.000699 3.038328 
Q9Z103 Adnp 412 1 -0.1 0.556 -6.5 -0.104936 0.630748 -6.839929 
Q9Z2D6 Mecp2 434 1 -0.56 0.044 -2.8 -1.394999 0.004383 -0.004989 
Q9Z2L6 Minpp1 238 1 2.057 0.008 -0.1 2.0566836 0.004799 0.215672 
Q9Z329 Itpr2 (1 of 
2458,2460,2463,2464,24
66) 
1 -0.65 0.098 -3.7 -1.017293 0.037135 -2.709656 
S4R294 Prrc2c (1 of 
2643,2644,2645,2646) 
1 0.008 0.983 -6.6 -0.433848 0.242667 -5.374686 
S4R294 Prrc2c (1 of 
2282,2283,2284,2285,22
86) 
1 -0.12 0.696 -6.3 -0.561487 0.149516 -4.745133 
S4R294 Prrc2c (1 of 
1929,1932,1933,1935,19
38,1940,1946) 
1 0.001 0.999 -6.6 -0.440813 0.235873 -5.340665 
S4R294 Prrc2c (1 of 
2632,2633,2634,2636,26
37,2638) 
1 0.011 0.952 -7.1 -0.357275 0.077898 -4.584461 








1 -0.01 0.954 -7.2 -0.372425 0.020846 -2.926743 
S4R294 Prrc2c (1 of 
1914,1917,1918,1921) 
1 -0.12 0.692 -6.3 -0.563194 0.149122 -4.736724 
S4R294 Prrc2c (1 of 
2114,2117,2125,2127,21
28,2133) 
1 -0.59 0.115 -3.9 -0.948502 0.043415 -2.983573 
S4R294 Prrc2c (1 of 373,374) 1 0.381 0.365 -6 -0.019378 0.958944 -7.078731 
S4R294 Prrc2c 2649 1 0.307 0.32 -5.5 -0.135402 0.702093 -6.568803 
S4R294 Prrc2c 882 1 0.193 0.104 -4.8 -0.172863 0.203306 -6.007123 
S4R294 Prrc2c 209 1 0.006 0.988 -6.6 -0.435952 0.241044 -5.364416 
S4R2A9 Sec31a (1 of 540,542,543,545) 1 -0.36 0.114 -4.4 -0.621477 0.040623 -3.331758 
S4R2A9 Sec31a (1 of 495,499,500,502) 1 0.682 0.055 -3.6 0.4316027 0.153664 -5.478714 
S4R2A9 Sec31a 927 1 -0.62 0.108 -3.8 -0.847365 0.058925 -3.408973 
V9GXT3 Nav2 (1 of 
1391,1392,1394,1396,13
99,1400,1404) 
1 -1.01 0.042 -2.3 -1.006722 0.037962 -2.750943 
Z4YL55 Cdan1 (1 of 205,208) 1 0.498 0.017 -1.8 0.4978215 0.021651 -2.744065 
 
 
Appendix 7.4. Putative Adaptor-Target Pairs Identified by Dynamic NOTISE Analysis. 
 Protein LogFC: Protein log2 fold change of the adapter protein (Adapter column), 
logFC_Corrected: protein expression corrected log2 fold change in O-GlcNAcylation of the 
target protein (in Target column), Score: adaptor protein rank score (see text above and in 
Chapter 5). 
 
A7.4.1. Adaptor Expression and Target O-GlcNAcylation Both Downregulated. 
 
Adaptor Target ProteinLogFC logFC_Corrected Score 
ACLY FN1 -1.3074 -1.0887 4 
ALDH1B1 FN1 -0.9213 -1.0887 0.5 




PSMB1 FN1 -0.8953 -1.0887 0 
PSMA7 FN1 -0.8136 -1.0887 1 
SHMT1 GORASP2 -0.5219 -1.0546 3.5 
PSMA7 EGFR -0.8136 -5.4832 1 
ALDH3A2 EGFR -0.8985 -5.4832 4 
SULT1A1 EGFR -0.7624 -5.4832 0 
ABCD3 EGFR -0.523 -5.4832 0.5 
ALDH1L1 HSP90B1 -0.8809 -0.8625 -1.5 
ALDH1L1 HSP90B1 -0.8809 -1.6866 -1.5 
ALDH1L1 HSP90B1 -0.8809 -0.8525 -1.5 
ALDH1B1 LGALS3BP -0.9213 -2.1517 0.5 
DERA LGALS3BP -0.5578 -2.1517 1 
ABCD3 PGRMC1 -0.523 -1.5615 0.5 
ACLY PPT1 -1.3074 -1.1184 4 
BCKDHB PPT1 -1.1838 -1.1184 2 
BCKDHB TCF25 -1.1838 -1.0348 2 
FMO5 OGA -0.5994 -0.7532 1 
FASN GRN -1.4115 -1.6639 2 
FASN KANK2 -1.4115 -0.7841 2 
 
 
A7.4.2. Adapter Expression and Target O-GlcNAcylation Both Upregulated. 
 
Adaptor Target ProteinLogFC logFC_Corrected PE_Corr Score 




MTA2 GPHN 0.50347 1.47737 Yes 2.5 
MTA2 GPHN 0.50347 1.48792 Yes 2.5 
VTN MPRIP 0.61906 2.41487 Yes 0.5 
CYP1A2 CYB5A 0.6175 0.78412 Yes 3 
NUDT21 XRCC6 0.57694 0.88174 Yes 10.5 
MYBBP1A XRCC6 0.55861 0.88174 Yes 6.5 
MYBBP1A BSG 0.55861 1.04511 Yes 6.5 
MYBBP1A BSG 0.55861 1.18103 Yes 6.5 
GRN CTSO 0.80027 2.50587 Yes 7 
FARP1 AKAP1 0.5208 0.9869 Yes 0.5 
HNRNPL LPP 0.53995 1.04052 Yes 0.5 
HSPA5 LPP 1.00527 1.04052 Yes 9.5 
HNRNPL MIA3 0.53995 0.86132 Yes 0.5 
MYBBP1A PLEC 0.55861 1.89457 Yes 6.5 
RRBP1 PLEC 0.82747 1.89457 Yes 1.5 
WDR5 MAVS 0.80661 0.86963 Yes 0 
WDR5 MAVS 0.80661 1.14081 Yes 0 
 
 
A7.4.3. Adapter Expression Downregulated and Target O-GlcNAcylation Upregulated. 
 
Adaptor Target ProteinLogFC logFC_Corrected Score 
PSMA7 MAVS -0.8136 0.86963 1 
PSMA7 MAVS -0.8136 1.14081 1 
GPT2 AHCY -1.0976 1.46693 1.5 
ACLY CTH -1.3074 1.04614 4 
PAPSS2 CTH -0.5972 1.04614 1.5 





A7.4.4. Adapter Expression Upregulated and Target O-GlcNAcylation Downregulated.  
 
Adaptor Target ProteinLogFC logFC_Corrected PE_Corr Score 
WDR5 HCFC1 0.80661 -1.0043 Yes 0 
WDR5 HCFC1 0.80661 -0.8908 Yes 0 
WDR5 HCFC1 0.80661 -1.3447 Yes 0 
WDR5 HCFC1 0.80661 -1.1115 Yes 0 
WDR5 HCFC1 0.80661 -0.9605 Yes 0 
WDR5 HCFC1 0.80661 -0.9646 Yes 0 
WDR5 HCFC1 0.80661 -0.9718 Yes 0 
WDR5 HCFC1 0.80661 -1.18 Yes 0 
WDR5 HCFC1 0.80661 -0.8457 Yes 0 
WDR5 HCFC1 0.80661 -0.9206 Yes 0 
WDR5 HCFC1 0.80661 -0.9073 Yes 0 
MTA2 TOP2B 0.50347 -1.3115 Yes 2.5 
LYAR ZHX1 0.60561 -0.8656 Yes 2 
COMT FN1 0.82553 -1.0887 Yes 0.5 
U2AF1 FN1 0.52959 -1.0887 Yes 0.5 
HMGB1 FN1 0.66856 -1.0887 Yes 7.5 
MYL1 FN1 1.22946 -1.0887 Yes 1 
GSTP1 FN1 2.94304 -1.0887 Yes 3 
DDOST FN1 0.58289 -1.0887 Yes 8 
NUDT21 FN1 0.57694 -1.0887 Yes 10.5 
HMGB1 PDIA3 0.66856 -1.1906 Yes 7.5 
GRN PDIA3 0.80027 -1.1906 Yes 7 
GSTP1 EGFR 2.94304 -5.4832 Yes 3 
PHLDA1 EGFR 1.85703 -5.4832 Yes 0.5 
GRN EGFR 0.80027 -5.4832 Yes 7 
AHSG EGFR 0.51067 -5.4832 Yes 4 
HMGB1 EGFR 0.66856 -5.4832 Yes 7.5 
RACK1 EGFR 0.5559 -5.4832 Yes 6 




LYAR RRBP1 0.60561 -1.4375 Yes 2 
HMGB1 MECP2 0.66856 -1.395 Yes 7.5 
MYBBP1A MECP2 0.55861 -1.395 Yes 6.5 
NUDT21 VIM 0.57694 -0.9695 Yes 10.5 
DDOST VIM 0.58289 -0.9695 Yes 8 
GRN VIM 0.80027 -0.9695 Yes 7 
MTA2 SRRM2 0.50347 -0.8651 Yes 2.5 
U2AF1 SRRM2 0.52959 -0.8651 Yes 0.5 
MTA2 SRRM2 0.50347 -1.2595 Yes 2.5 
U2AF1 SRRM2 0.52959 -1.2595 Yes 0.5 
MTA2 SRRM2 0.50347 -0.9224 Yes 2.5 
U2AF1 SRRM2 0.52959 -0.9224 Yes 0.5 
MTA2 SRRM2 0.50347 -1.3657 Yes 2.5 
U2AF1 SRRM2 0.52959 -1.3657 Yes 0.5 
DEK VTN 0.52272 -1.1864 Yes 5 
U2AF1 SON 0.52959 -1.0552 Yes 0.5 
U2AF1 SON 0.52959 -0.8482 Yes 0.5 
U2AF1 SON 0.52959 -1.2715 Yes 0.5 
ARPC1B CALU 1.18708 -0.7545 Yes -1.5 
ARPC1B CALU 1.18708 -1.1331 Yes -1.5 
U2AF1 PSAP 0.52959 -1.2521 Yes 0.5 
SSR1 PSAP 0.65844 -1.2521 Yes 0.5 
GRN PSAP 0.80027 -1.2521 Yes 7 
U2AF1 PSAP 0.52959 -1.4951 Yes 0.5 
SSR1 PSAP 0.65844 -1.4951 Yes 0.5 
GRN PSAP 0.80027 -1.4951 Yes 7 
DDOST HSP90B1 0.58289 -0.8625 Yes 8 
DDOST HSP90B1 0.58289 -1.6866 Yes 8 
DDOST HSP90B1 0.58289 -0.8525 Yes 8 
MYH11 PLBD2 0.6806 -0.8922 Yes -0.5 
DDOST RPN2 0.58289 -0.8378 Yes 8 
MTA2 AHNAK 0.50347 -1.2868 Yes 2.5 




CYP1A2 PGRMC1 0.6175 -1.5615 Yes 3 
DDOST PGRMC1 0.58289 -1.5615 Yes 8 
COMT GBA 0.82553 -1.3831 Yes 0.5 
COMT GBA 0.82553 -1.806 Yes 0.5 
U2AF1 SARNP 0.52959 -1.1485 Yes 0.5 
SSR1 HSPA13 0.65844 -1.3872 Yes 0.5 
DDOST PPT1 0.58289 -1.1184 Yes 8 
GSTP1 PPT1 2.94304 -1.1184 Yes 3 
GRN SERPING1 0.80027 -0.8427 Yes 7 
SFPQ PRRC2C 0.66456 -0.9485 Yes 1 
HNRNPH1 PGRMC1 0.60113 -1.5615 Yes 3 
EGFR PGRMC1 1.7656 -1.5615 Yes -1 
EGFR GRN 1.7656 -1.6639 Yes -1 
HSPA5 GRN 1.00527 -1.6639 Yes 9.5 
CAPZA1 GRN 0.66508 -1.6639 Yes 1 
HSPH1 SEC23A 0.74357 -0.7695 Yes -0.5 
MOV10 SEC31A 0.68709 -0.8474 Yes -1 
SRSF1 VTN 0.64771 -1.1864 Yes -2.5 
HNRNPM VTN 0.59945 -1.1864 Yes 0.5 
RBM39 VTN 0.55991 -1.1864 Yes 7.5 
SFPQ VTN 0.66456 -1.1864 Yes 1 
HSP90AA1 ZBTB20 0.73133 -0.9426 Yes -5 
HNRNPL ZBTB20 0.53995 -0.9426 Yes 0.5 
HSP90AA1 ZBTB20 0.73133 -1.159 Yes -5 
HNRNPL ZBTB20 0.53995 -1.159 Yes 0.5 
HSP90AA1 ZBTB20 0.73133 -1.0246 Yes -5 




HSP90AA1 ZBTB20 0.73133 -0.8178 Yes -5 
HNRNPL ZBTB20 0.53995 -0.8178 Yes 0.5 
HSP90AA1 ZBTB20 0.73133 -0.8101 Yes -5 
HNRNPL ZBTB20 0.53995 -0.8101 Yes 0.5 
HSP90AA1 ZBTB20 0.73133 -0.8258 Yes -5 
HNRNPL ZBTB20 0.53995 -0.8258 Yes 0.5 
HSP90AA1 ZBTB20 0.73133 -1.0166 Yes -5 
HNRNPL ZBTB20 0.53995 -1.0166 Yes 0.5 
HSP90AA1 ZBTB20 0.73133 -1.1092 Yes -5 
HNRNPL ZBTB20 0.53995 -1.1092 Yes 0.5 
HSPA5 VIM 1.00527 -0.9695 Yes 9.5 
TRIM28 VIM 0.52193 -0.9695 Yes 5 
RBM39 VIM 0.55991 -0.9695 Yes 7.5 
EGFR AHNAK 1.7656 -1.2868 Yes -1 
SRRM2 EPB41L2 0.6138 -1.2604 Yes 0.5 
RPL11 HP 0.50691 -2.4481 Yes 4 
HSP90B1 GBA 0.86973 -1.3831 Yes -0.5 
HSP90B1 GBA 0.86973 -1.806 Yes -0.5 
HSP90B1 CRELD2 0.86973 -3.8061 Yes -0.5 
HSPA5 RRAGD 1.00527 -0.9141 Yes 9.5 
HSPA5 HYOU1 1.00527 -1.9939 Yes 9.5 
HSPA5 HYOU1 1.00527 -1.4753 Yes 9.5 
HSPA5 HYOU1 1.00527 -1.78 Yes 9.5 






Appendix 7.5. Python and R Code for All Analyses.  
 All code was run in Jupyter notebook (v7.12). See also 7.9.12.3. General and Statistics. 
 
A7.5.1. Valine Linker Ratio Analysis.  
#Import python packages  
import re 
import sys 
import pandas as pd 
import networkx as nx 
import itertools as it 
from collections import namedtuple 
import numpy as np 
import matplotlib 
import matplotlib.pyplot as plt 
from IPython.display import display 
from functools import reduce 
import seaborn as sns; sns.set() 
from io import StringIO 
from matplotlib_venn import venn2_unweighted  
from matplotlib_venn import venn2  
import venn 
import pandas as pd 
import numpy as np 
from io import StringIO 
import urllib.request, urllib.parse, urllib.error,urllib.request,urllib.error,urllib.parse 
import math 
import scipy.stats as stats 
 









#magic function to show plots inline 
%matplotlib inline 
 




#Import the files 
 
#set folder names 
qfolder = './LinkerRatioTest_Quant/' 
sfolder = './LinkerRatioTest_Glycomics/' 
folderout = './Linker_RatioTesting_Analysis/' 
 
#import the files 
dfmsms = pd.read_csv('{}msms.txt'.format(sfolder), sep='\t') 
dfallpep = pd.read_csv('{}allPeptides.txt'.format(qfolder), sep='\t') 
 
#take the relevant info from the allPeptides file, remove unneeded spectra, and rename the MSMS Scan Number column for 
    #matching 
dfall2 = dfallpep[['Raw file', 'Charge', 'Mass', 'Pyl Count', 'Ratio H/L', 'MS/MS Count', 'MSMS Scan Numbers']] 
dfall2 = dfall2[(dfall2['Pyl Count'] != "") & (dfall2['MS/MS Count'] > 0)] 
dfall2.rename(columns={'MSMS Scan Numbers':'Scan number'}, inplace=True) 
 
#remove contaminants, reverse sequences, and peptides modified by both 601 and 607 from the msms file 
dfmsms2 = dfmsms[dfmsms.Reverse != '+'] 
dfmsms2 = dfmsms2[~dfmsms2.Proteins.str.contains('CON_')] 
dfmsms2 = dfmsms2[~(dfmsms2.Modifications.str.contains('GlcNAc601') & (dfmsms2.Modifications.str.contains('GlcNAc607')))] 
#Expand the scan number column of the all peptides file into duplicate rows and merge with the msms file 
 
#change the scan number to a list and explode values to duplicate rows 
dfall3 = dfall2.copy() 
dfall3['Scan number'] = dfall2['Scan number'].str.split(';') 
dfall4 = dfall3.explode('Scan number') 
dfall5 = dfall4.copy() 
dfall5['Scan number'] = dfall4['Scan number'].astype(int) 
 
#merge this with the msms file on raw file, change, and scan number 
dfm = dfmsms2.merge(dfall5, on=['Raw file', 'Scan number', 'Charge'], how='left') 
 
#renmae the all peptides mass 
dfm.rename(columns={'Mass_y':'Mass_QuanSearch'}, inplace=True) 
#Preproces this data for the sites and regions script (first with the 601, then with the 607 tag) 






MOD_NAME = "GlcNAc601" 
pepProbPatt = re.compile(r'[A-Z][(]?\d?[.]?\d*[)]?') 
 
PepInfo = namedtuple("PepInfo",["Protein","StartPos"]) 
peptideInfo = {} 
 
# Get peptide start positions 
pepDF = pd.read_csv("{}peptides.txt".format(sfolder), sep='\t') 
for peptide in pepDF[["id","Leading razor protein","Start position"]].itertuples(): 
    if math.isnan(peptide[3]): 
        peptideInfo[peptide.id] = PepInfo(peptide[2],-1) 
    else: 
        peptideInfo[peptide.id] = PepInfo(peptide[2],int(peptide[3])) 
 
msmsDF = dfm 
msmsDF = msmsDF[msmsDF[MOD_NAME]>0] 
msmsDF["Protein"] = msmsDF["Peptide ID"].apply(lambda x: peptideInfo[x].Protein) 
msmsDF["StartPos"] = msmsDF["Peptide ID"].apply(lambda x: peptideInfo[x].StartPos) 
msmsDF = msmsDF[msmsDF["StartPos"]>=0] 
msmsDF.rename(columns={"Raw file":"RawFile","Scan number":"ScanNumber",MOD_NAME:"NumMods", "Ratio H/L":"Ratio"}, 
              inplace=True) 
msmsDF["Probabilities"] = msmsDF.apply( 
    lambda x: ";".join([aa[2:-1] for pp,aa in enumerate(pepProbPatt.findall( 
        x["%s Probabilities"%MOD_NAME])) if len(aa) > 1]),axis=1) 
msmsDF["Positions"] = msmsDF.apply( 
    lambda x: ";".join([str(pp+x["StartPos"]) for pp,aa in enumerate(pepProbPatt.findall( 
        x["%s Probabilities"%MOD_NAME])) if len(aa) > 1]),axis=1) 
 
msmsDF[["RawFile","Protein","ScanNumber","NumMods","Positions","Probabilities","Ratio"]].to_csv( 
    '{}LinkerTest_601_Preprocessed.txt'.format(folderout), sep="\t", index=False) 
 
###GlcNAc607 
MOD_NAME = "GlcNAc607" 
pepProbPatt = re.compile(r'[A-Z][(]?\d?[.]?\d*[)]?') 
 
PepInfo = namedtuple("PepInfo",["Protein","StartPos"]) 
peptideInfo = {} 
 
# Get peptide start positions 
pepDF = pd.read_csv("{}peptides.txt".format(sfolder), sep='\t') 
for peptide in pepDF[["id","Leading razor protein","Start position"]].itertuples(): 
    if math.isnan(peptide[3]): 
        peptideInfo[peptide.id] = PepInfo(peptide[2],-1) 
    else: 
        peptideInfo[peptide.id] = PepInfo(peptide[2],int(peptide[3])) 
 
msmsDF = dfm 
msmsDF = msmsDF[msmsDF[MOD_NAME]>0] 
msmsDF["Protein"] = msmsDF["Peptide ID"].apply(lambda x: peptideInfo[x].Protein) 
msmsDF["StartPos"] = msmsDF["Peptide ID"].apply(lambda x: peptideInfo[x].StartPos) 
msmsDF = msmsDF[msmsDF["StartPos"]>=0] 
msmsDF.rename(columns={"Raw file":"RawFile","Scan number":"ScanNumber",MOD_NAME:"NumMods", "Ratio H/L":"Ratio"}, 
              inplace=True) 
msmsDF["Probabilities"] = msmsDF.apply( 
    lambda x: ";".join([aa[2:-1] for pp,aa in enumerate(pepProbPatt.findall( 
        x["%s Probabilities"%MOD_NAME])) if len(aa) > 1]),axis=1) 
msmsDF["Positions"] = msmsDF.apply( 
    lambda x: ";".join([str(pp+x["StartPos"]) for pp,aa in enumerate(pepProbPatt.findall( 
        x["%s Probabilities"%MOD_NAME])) if len(aa) > 1]),axis=1) 
 
msmsDF[["RawFile","Protein","ScanNumber","NumMods","Positions","Probabilities","Ratio"]].to_csv( 
    '{}LinkerTest_607_Preprocessed.txt'.format(folderout), sep="\t", index=False) 
%%capture 
#supresses the output of the cell 
 
#Run the sites and regions script for each experiment 
%run -i SitesAndRegions.py ./Linker_RatioTesting_Analysis/LinkerTest_601_Preprocessed.txt \ 
./Linker_RatioTesting_Analysis/maxparcon_601.txt ./Linker_RatioTesting_Analysis/bestms2_601.txt 
%run -i SitesAndRegions.py ./Linker_RatioTesting_Analysis/LinkerTest_607_Preprocessed.txt \ 
./Linker_RatioTesting_Analysis/maxparcon_607.txt ./Linker_RatioTesting_Analysis/bestms2_607.txt 
#Import the sites and regions output into dfs and count the number of sites for each 
 
list_dfs2 = ['601', '607'] 
list_exp = ['WT', 'db/db'] 
 
for i in list_dfs2: 
    locals()['dfallsites_{}'.format(i)] = pd.read_csv('{}bestms2_{}.txt'.format(folderout, i), sep='\t') 
    locals()['dfregions_{}'.format(i)] = pd.read_csv('{}maxparcon_{}.txt'.format(folderout, i), sep='\t') 
    #remove sites/regions that match to two master proteins 
    #this seems to happen sometimes when there is real evidence of two isoforms 
    #all cases checked were already explained by other data, so they can be reasonably ignored 
    locals()['dfregions_{}'.format(i)] = locals()['dfregions_{}'.format(i)][ 
        ~locals()['dfregions_{}'.format(i)].Protein.str.contains(';')] 
    locals()['dfallsites_{}'.format(i)] = locals()['dfallsites_{}'.format(i)][ 
        ~locals()['dfallsites_{}'.format(i)].Protein.str.contains(';')] 
     
#initialize an empty df 
df_numsites = pd.DataFrame(np.empty((2,5))) 
 
#calculate the number of sites, localized sites, and regions 
for i in range (2): 
    #set the column and index names 
    df_numsites.columns = [['Total Number of Sites', 'Localized Sites', 'Unlocalized Sites', 'Regions',  
                            'Percent Localized']] 




    #count the total number of sites 
    df_numsites.loc[list_dfs2[i], 'Total Number of Sites'] = \ 
    locals()['dfregions_{}'.format(list_dfs2[i])]['Min Sites'].sum() 
    #count the number of localized sites 
    df_numsites.loc[list_dfs2[i], 'Localized Sites'] = len( 
        locals()['dfregions_{}'.format(list_dfs2[i])][ 
            locals()['dfregions_{}'.format(list_dfs2[i])]['Site ID Constraints'].str.contains('of') == False]) 
    df_numsites.loc[list_dfs2[i], 'Unlocalized Sites'] = locals()['dfregions_{}'.format(list_dfs2[i])][ 
        locals()['dfregions_{}'.format(list_dfs2[i])][ 
            'Site ID Constraints'].str.contains('of') == True]['Min Sites'].sum() 
    df_numsites.loc[list_dfs2[i], 'Regions'] = len( 
        locals()['dfregions_{}'.format(list_dfs2[i])][ 
            locals()['dfregions_{}'.format(list_dfs2[i])]['Site ID Constraints'].str.contains('of') == True]) 
    df_numsites.loc[list_dfs2[i], 'Percent Localized'] = \ 
    (df_numsites.loc[list_dfs2[i], 'Localized Sites'].to_numpy() / df_numsites.loc[ 
        list_dfs2[i], 'Total Number of Sites'].to_numpy())*100 
 
df_numsites.rename(index={'601':'601 WT', '607':'607 db/db'}, inplace=True) 
df_numsites = df_numsites.astype(int) #convert to ints 
df_numsites.to_csv('{}SitesAndRegionsCount.csv'.format(folderout)) #export  
df_numsites #inspect 
 
#Now perform the quantitative analysis to visualize ratios across the different mixtures 
 
#Preprocess the msms file 
 
#copy the previous df 
dfmq = dfm.copy() 
 
#remove the 601/607 identifier 
dfmq.replace(['GlcNAc601', 'GlcNAc607'], 'GlcNAc', inplace=True) 
 
#remove psms where the number of mods is not equal to the number of mods used for the ratio calculation 
#this will remove all sites without ratios 
dfmqf = dfmq[(dfmq.GlcNAc601 == dfmq['Pyl Count']) | (dfmq.GlcNAc607 == dfmq['Pyl Count'])] 
 
#set new mod name 
MOD_NAME = "GlcNAc" 
pepProbPatt = re.compile(r'[A-Z][(]?\d?[.]?\d*[)]?') 
 
PepInfo = namedtuple("PepInfo",["Protein","StartPos"]) 
peptideInfo = {} 
 
# Get peptide start positions 
pepDF = pd.read_csv("{}peptides.txt".format(sfolder), sep='\t') 
for peptide in pepDF[["id","Leading razor protein","Start position"]].itertuples(): 
    if math.isnan(peptide[3]): 
        peptideInfo[peptide.id] = PepInfo(peptide[2],-1) 
    else: 
        peptideInfo[peptide.id] = PepInfo(peptide[2],int(peptide[3])) 
 
msmsDF = dfmqf 
msmsDF = msmsDF[msmsDF.Modifications.str.contains("GlcNAc")] 
msmsDF["Protein"] = msmsDF["Peptide ID"].apply(lambda x: peptideInfo[x].Protein) 
msmsDF["StartPos"] = msmsDF["Peptide ID"].apply(lambda x: peptideInfo[x].StartPos) 
msmsDF = msmsDF[msmsDF["StartPos"]>=0] 
msmsDF.rename(columns={"Raw file":"RawFile","Scan number":"ScanNumber", "Ratio H/L":"Ratio"}, 
              inplace=True) 
msmsDF['NumMods'] = msmsDF[["GlcNAc601","GlcNAc607"]].sum(axis=1) 
 
#enumerate separately for 601 and 607 (there should be no overlapping sites) 
#convert site prob columns to string 
msmsDF[["GlcNAc601 Probabilities","GlcNAc607 Probabilities"]] = \ 
msmsDF[["GlcNAc601 Probabilities","GlcNAc607 Probabilities"]].astype(str) 
msmsDF.loc[msmsDF.GlcNAc601 > 0, "Probabilities"] = msmsDF.apply( 
    lambda x: ";".join([aa[2:-1] for pp,aa in enumerate(pepProbPatt.findall( 
        x["GlcNAc601 Probabilities"])) if len(aa) > 1]),axis=1) 
msmsDF.loc[msmsDF.GlcNAc607 > 0, "Probabilities"] = msmsDF.apply( 
    lambda x: ";".join([aa[2:-1] for pp,aa in enumerate(pepProbPatt.findall( 
        x["GlcNAc607 Probabilities"])) if len(aa) > 1]),axis=1) 
msmsDF.loc[msmsDF.GlcNAc601 > 0, "Positions"] = msmsDF.apply( 
    lambda x: ";".join([str(pp+x["StartPos"]) for pp,aa in enumerate(pepProbPatt.findall( 
        x["GlcNAc601 Probabilities"])) if len(aa) > 1]),axis=1) 
msmsDF.loc[msmsDF.GlcNAc607 > 0, "Positions"] = msmsDF.apply( 
    lambda x: ";".join([str(pp+x["StartPos"]) for pp,aa in enumerate(pepProbPatt.findall( 
        x["GlcNAc607 Probabilities"])) if len(aa) > 1]),axis=1) 
 
df1_table = msmsDF[["RawFile","Protein","ScanNumber","NumMods","Positions","Probabilities","Ratio"]] 
#Set localization probabilities to equal and export for sites and regions script 
 
#set columns to keep in final df 
cols_to_keep = ["RawFile","Protein","ScanNumber","NumMods","Positions","Probabilities","Ratio"] 
 
#copy the df 
df2_table = df1_table.copy() 
 
#keeping the for loop structure from the previous script 
i = 2 
#count the number of S/Ts 
locals()['df{}_table'.format(i)]['NumSites'] = locals()['df{}_table'.format(i)].Probabilities.str.count(';') + 1 
#calculate the probability at each site based on the number of S/Ts (round to 3 decimals as in MQ) 
locals()['df{}_table'.format(i)]['Prob'] = round(1/locals()['df{}_table'.format(i)].NumSites, 3) 
#define a function to make a repeating list of probability values based on the number of S/Ts 
def repeat(row): 




#apply this function to each df 
locals()['df{}_table'.format(i)]['ProbList'] = locals()['df{}_table'.format(i)].apply(repeat, axis=1) 
#transform the list into a semi-colon separated string for the sites and regions script 
locals()['df{}_table'.format(i)]['ProbListFinal'] = locals()['df{}_table'.format(i)].ProbList.apply( 
    lambda s: ';'.join(map(str, s))) 
#replace all probability values 
locals()['df{}_table'.format(i)]['Probabilities'] = locals()['df{}_table'.format(i)].ProbListFinal 
#remake the original table with the columns required for the sites and regions script 
locals()['df{}_tableF'.format(i)] = locals()['df{}_table'.format(i)][cols_to_keep] 
 
#make a new column to denote the experiment 
 
#set lists for experiment identifiers 
list_ratio = ['H1L1', 'H1L2', 'H1L5', 'H2L1', 'H5L1'] 
list_replicate = ['john', 'Matt'] #based on raw file 
 
 
#add the experiment identifier column (keep the replicates split just in case for future analysis) 
for i in range(5): 
    for j in range(2): 
        df2_tableF.loc[(df2_tableF.RawFile.str.contains('{}'.format(list_ratio[i])) &  
                        df2_tableF.RawFile.str.contains( 
                            '{}'.format(list_replicate[j]))), 'Experiment_Split'] = '{}_{}'.format(list_ratio[i],j+1) 
 
#also make a new column with an experiment identifier based on the mixing (replicate information is stripped) 
df2_tableF['Experiment'] = df2_tableF['Experiment_Split'].apply(lambda x: x.split('_')[0]) 
         
#export final table to txt file for sites and regions multi-experiment script 
df2_tableF.to_csv('{}QuantSitesAndRegions_Preprocessed.txt'.format(folderout), sep='\t', index=False) 
%%capture 
#supresses the output of the cell 
 
#Run the sites and regions multi experiment script 
%run -i SitesAndRegionsMultiExperiment.py ./Linker_RatioTesting_Analysis/QuantSitesAndRegions_Preprocessed.txt \ 
./Linker_RatioTesting_Analysis/maxparcon_Quant.txt ./Linker_RatioTesting_Analysis/bestms2_Quant.txt 
#Import the output and as in the 20D09 script 
dfallsitesq = pd.read_csv('{}bestms2_Quant.txt'.format(folderout), sep='\t') 
dfregionsq = pd.read_csv('{}maxparcon_Quant.txt'.format(folderout), sep='\t') 
dfallsitesq = dfallsitesq[~dfallsitesq.Protein.str.contains(';')] 
dfregionsq = dfregionsq[~dfregionsq.Protein.str.contains(';')] 
dfregionsq.loc[dfregionsq['Site ID Constraints'].str.contains('of'), 'Type'] = 'Region' 
dfregionsq.loc[~dfregionsq['Site ID Constraints'].str.contains('of'), 'Type'] = 'Site' 
dfmergeq = dfallsitesq.merge(dfregionsq, how='left', on='Region ID') 
 
#clean up this df 
dfmergeq.rename(columns={'Protein_x': 'Protein'}, inplace=True) 
dfmergeq.drop(columns={'Protein_y'}, inplace=True) 
#Merge with the preprocssed dataframe to get the ratios at the non-redundant sites level 
 
#copy the df 
dfratios = df2_tableF.copy() 
 
#merge with previous table on raw file, scan number, and protein 
#note that all proteins that don't match will be discarded (decided based on score by the sites and regions script) 
    #these may be real sites, but they will be ignored for the quantification, if there are really 2 peptides matching  
    #to the same precursor, there is no way to quantify them seperately anyway 
dfmergeqf = dfmergeq.rename(columns={'Best Scan Number':'ScanNumber', 'Best Raw File':'RawFile'}) 
dfq = dfmergeqf.merge(dfratios, on=['RawFile', 'ScanNumber', 'Protein', 'Experiment']) 
 
print('In total we quantified {} regions.'.format(len(dfregionsq))) 
 
#Make violin plots of the ratios from each experiment (both for the original and non-redundant sites) 
 
#log transform the values 
dfq['LogRatio'] = np.log2(dfq.Ratio) 
df2_tableF['LogRatio'] = np.log2(df2_tableF.Ratio) 
 




#remove the outlines from the violin plot 
def patch_violinplot(palette, n): 
    from matplotlib.collections import PolyCollection 
    ax = plt.gca() 
    violins = [art for art in ax.get_children() if isinstance(art, PolyCollection)] 
    colors = sns.color_palette(palette, n_colors=n) * (len(violins)//n) 
    for i in range(len(violins)): 
        violins[i].set_edgecolor(colors[i])                 
 
plt.figure(figsize=(7,7)) 
g = sns.violinplot(x='Experiment', y='LogRatio', data=dfq, order=['H1L5', 'H1L2', 'H1L1', 'H2L1', 'H5L1']) 
ax1 = g.axes 
ax1.axhline(np.log2(0.2), ls='--', color=sns.color_palette()[0], zorder=1, linewidth=2) 
ax1.axhline(np.log2(0.5), ls='--', color=sns.color_palette()[1], zorder=1, linewidth=2) 
ax1.axhline(np.log2(1), ls='--', color=sns.color_palette()[2], zorder=1, linewidth=2) 
ax1.axhline(np.log2(2), ls='--', color=sns.color_palette()[3], zorder=1, linewidth=2) 











g = sns.violinplot(y='LogRatio', x='Experiment', data=df2_tableF) 
ax1 = g.axes 
ax1.axhline(np.log2(0.2), ls='--', color=sns.color_palette()[0], zorder=1, linewidth=2) 
ax1.axhline(np.log2(0.5), ls='--', color=sns.color_palette()[1], zorder=1, linewidth=2) 
ax1.axhline(np.log2(1), ls='--', color=sns.color_palette()[2], zorder=1, linewidth=2) 
ax1.axhline(np.log2(2), ls='--', color=sns.color_palette()[3], zorder=1, linewidth=2) 








A7.5.2. Protein Expression Analysis and Visualization.  
#Import python packages  
import re 
import sys 
import pandas as pd 
import networkx as nx 
import itertools as it 
from collections import namedtuple 
import numpy as np 
import matplotlib 
import matplotlib.pyplot as plt 
from IPython.display import display 
from functools import reduce 
import seaborn as sns; sns.set() 
from io import StringIO 
from matplotlib_venn import venn2_unweighted #the unweighted is if you want to make circles that are the same size 
from matplotlib_venn import venn2 #also import the normal one 
import pandas as pd 
import numpy as np 
from io import StringIO 
import urllib.request, urllib.parse, urllib.error,urllib.request,urllib.error,urllib.parse 
from scipy import stats  
from decimal import * 
import math 
 









#magic function to show plots inline 
%matplotlib inline 
 




#Load in the protein expression data from MaxQuant 
 
#define folder location 
folder = './Liver_Protein_Expression/' 
 
#read in files 
df = pd.read_csv('{}proteinGroups.txt'.format(folder), sep='\t') 
dfmsms = pd.read_csv('{}msms.txt'.format(folder), sep='\t') 
 
#remove potential contaminants and reverse seqeunces 
dfprot = df[(df.Reverse != '+') & (df['Potential contaminant'] != '+') & (df['Only identified by site'] != '+')] 
dfmsms2 = dfmsms[dfmsms.Reverse != '+'] 
#Prepare the df, normalize the TMT reporter intensity by the summed intensity, and scale log2 reporter intensity by WT  
 
#first gather only the relevant info from the prot groups 
 
#list columns to keep 
keepcols = ['Majority protein IDs', 'Fasta headers', 'Reporter intensity 1', 'Reporter intensity 2', 
            'Reporter intensity 3', 'Reporter intensity 4', 'Reporter intensity 5', 'Reporter intensity 6',  
            'Reporter intensity 7', 'Reporter intensity 8'] 
 
df1 = dfprot[keepcols] #take only relevent colunmns 
 
#extract the gene names from the FASTA header 
df1.insert(loc=1, column='Gene', value=df1['Fasta headers'].str.extract('GN=(.*?) PE=')) 
 
#remove values where reporter ion intensities are all 0 
#these arise when there are no PSMs that meet the cutoff for isolation interference 
df1 = df1[(df1[df1.filter(regex = 'Reporter').columns] != 0).all(axis=1)] 
 
#set a new df for the normalized values 





#normalize the columns 
for i in dfnorm.filter(regex = 'Reporter').columns: 
    dfnorm[i] = df1[i]/df1[i].sum() 
     
#swtich columns 4 and 5 (4 is dbdb and 5 is wt) and rename the columns 
coltitles = ['Reporter intensity 5', 'Reporter intensity 4'] 
dfnorm[['Reporter intensity 4', 'Reporter intensity 5']] = dfnorm.reindex(columns=coltitles) 
wtcols = dfnorm.columns[3:7].str.replace('Reporter intensity ', 'WT-', regex=True) 
dbdbcols = dfnorm.columns[7:].str.replace('Reporter intensity ', 'db/db-', regex=True) 
dfnorm.columns = list(dfnorm.columns[0:3]) + list(wtcols) + list(dbdbcols) 
 
#take the -log2 of all columns 
dflog = dfnorm.copy() 
dflog.loc[:,'WT-1':'db/db-8'] = np.log2(dflog.loc[:,'WT-1':'db/db-8']) 
 
#scale the values by median WT intensity 
dfscaled = dflog.copy() 
dfscaled.loc[:,'WT-1':'db/db-8'] = dflog.loc[:,'WT-1':'db/db-8'].sub(dflog.loc[:,'WT-1':'WT-4'].median(axis=1), axis=0) 
#Make a clustermap for protein expression 
 




#make the clustermap 
g = sns.clustermap(dfscaled.loc[:,'WT-1':'db/db-8'], cmap='bwr', vmin=-3, vmax=3, method='ward', linewidths=0, 
               yticklabels=False, figsize=(15,10)) 
 
#make a correlation heatmap 




#make a violin and box plot of the scaled data to make sure it looks alright 
 
plt.figure(figsize=(12,7)) 
sns.violinplot(x='level_1', y=0, data=dfscaled.loc[:,'WT-1':'db/db-8'].stack().reset_index()) 
plt.ylabel('') 
plt.ylabel('Scaled Log2 TMT Intensity') 
 
#remove the outlines from the violin plot 
def patch_violinplot(palette, n): 
    from matplotlib.collections import PolyCollection 
    ax = plt.gca() 
    violins = [art for art in ax.get_children() if isinstance(art, PolyCollection)] 
    colors = sns.color_palette(palette, n_colors=n) * (len(violins)//n) 
    for i in range(len(violins)): 











#Export df for limma 
#first I will export the intensities for analyzing protein differential expression 
#then I will export the ratios used for the O-GlcNAcomics for normalization (will not run limma here) 
 
#export the scaled intensities 
dfscaled.loc[:, 'WT-1':'db/db-8'].to_csv('df_limma_pe.txt', sep='\t') 
 




#prepare a df with the ratios 
df_A = dflog['db/db-5'].sub(dflog['WT-1'], axis=0) 
df_B = dflog['db/db-6'].sub(dflog['WT-2'], axis=0) 
df_C = dflog['db/db-7'].sub(dflog['WT-3'], axis=0) 
df_D = dflog['db/db-8'].sub(dflog['WT-4'], axis=0) 
 
#concatenate into a single dataframe 
df_ratios = pd.concat([df_A, df_B, df_C, df_D], axis=1) 
#rename the columns 
df_ratios.columns = ['A', 'B', 'C', 'D'] 
 
#merge back with the original df of protein names 
dfcorrection = pd.concat([dfscaled.loc[:,dfscaled.columns[0:3]], df_ratios], axis=1) 
 













#read in the values 
df = read.table('df_limma_pe.txt', sep='\t', header=TRUE, row.names=1) #read in the file 
 
#set the experiment design 
cond = factor(rep(c('WT','dbdb'), each=4)) 
design = model.matrix(~0+cond) 
colnames(design) = levels(cond) 
 
#set up the contrast (db/db vs WT) 
contrast = makeContrasts(Diff=dbdb-WT, levels=design) 
 
#run lmfit, contrasts, and ebayes 
f1 = lmFit(df, design) 
f2 = contrasts.fit(f1, contrast) 
f3 = eBayes(f2) 
 
#write the table 
write.table(topTable(f3, coef='Diff', n=Inf, confint=.95), 'PE_limmaOut.csv', sep=',', col.names=NA) 
 
#Read in the limma output, merge it back with the original df and export lists of up- and downregulated proteins 
 
#read in limma output and concatenate 
dflimma = pd.read_csv('PE_limmaOut.csv', index_col=0) 
dfde = pd.concat([dfscaled.loc[:,dfscaled.columns[0:3]], dflimma], axis=1) 
 
#find upregulated proteins 
dfup = dfde[(dfde.logFC > 0) & (dfde['adj.P.Val'] < 0.05)] 
dfdown = dfde[(dfde.logFC < 0) & (dfde['adj.P.Val'] < 0.05)] 
 
#export gene lists for pathway analysis 
dfup[['Gene', 'logFC']].to_csv('Proteins_Upregulated.csv', index=False) 
dfdown[['Gene', 'logFC']].to_csv('Proteins_Downregulated.csv', index=False) 
#Export final df and output relevant info 
dfde.to_csv('Proteins_All.csv', index=False) 
 
print('The number of differentially expressed proteins is:', len(dfde[(dfde['adj.P.Val'] < 0.05)])) 
print('There are {} upregulated and {} downregulated proteins.'.format(len(dfup), len(dfdown))) 
print('Total number of proteins quantified:', len(dfde)) 
print('Percent of proteins differentially expressed:', len(dfde[(dfde['adj.P.Val'] < 0.05)])/len(dfde)*100) 
 
#Make the volcano plot for the differentially expressed proteins 
 
#copy the df and take the negative log10 of the p value 
dfvolcano = dflimma.copy() 
dfvolcano['NegLogP'] = -np.log10(dfvolcano['adj.P.Val']) 
 
#make the plot 
plt.figure(figsize=(7,7)) 
g = sns.scatterplot(x='logFC', y='NegLogP', data=dfvolcano, edgecolor='k', facecolor='none', marker='o', s=25) 
ax1 = g.axes 




#Make box plots of OGT and OGA 
 
dfplots = dfscaled.T.drop(index={'Majority protein IDs', 'Fasta headers'}) 
 
dfplots.columns = dfplots.iloc[0] 
dfplots.drop(index={'Gene'}, inplace=True) 
 
dfplots.index = dfplots.index.str.replace('-(.?)', '', regex=True) 
dfplots = dfplots.reset_index().rename(columns={'index':'Condition'}) 
#dfplots.rename(index={'index'}, inplace=True) 
 
dfogt = dfplots[['Condition', 'Ogt']] 
dfogt['Gene'] = 'Ogt' 
dfogt.rename(columns={'Ogt':'Expression'}, inplace=True) 
dfoga = dfplots[['Condition', 'Oga']] 




df_toplot = pd.concat([dfogt,dfoga], ignore_index=True) 
 
fig, ax = plt.subplots(figsize=(7,7)) 
g = sns.stripplot(x='Gene', y='Expression', data=df_toplot, hue='Condition', dodge=True, s=10, zorder=1) 
g = sns.boxplot(x='Gene', y='Expression', data=df_toplot, hue='Condition', dodge=True) 
 
lgnd = plt.legend() 
lgnd.legendHandles[3]._sizes = [1000] 
 
handles, labels = ax.get_legend_handles_labels() 
ax.legend(handles=handles[2:4], labels=labels[2:4], frameon=False, bbox_to_anchor=(1.25, 0.6)) 
 












#Export gene grouped protein logFC for cytoscape 
dfde_cytoscape = dfde[['Gene', 'logFC', 'adj.P.Val']] 
dfde_cytoscape.loc[dfde_cytoscape['adj.P.Val'] < 0.05, 'SigProtFC'] = 'Yes' 
dfde_cytoscape.drop(columns={'adj.P.Val'},inplace=True) 




dfcytoscape = dfcyto1.merge(dfde_cytoscape[['Gene', 'SigProtFC']], on='Gene', how='left') 
dfcytoscape.Gene = dfcytoscape.Gene.str.upper() 
dfcytoscape.to_csv('ProteinFC_ForCytoscape.csv', index=False) 
 
A7.5.3. Sites and Regions Analysis.  
The sites and regions is implemented as described in Chapter 5, see A5.6.5 for code. This 
analysis will have the following parts: 
1. Preprocessing the quantitative information. The msms scan numbers from the search 
including the O-GlcNAc modifications sites will be matched to those identified as 
coming from quantified precursors in the search not including the modifications but 
looking for +/- 6 isotope patterns. Ultimately, this will add H/L ratios to the msms file 
that can be used after the sites and regions analysis in part 3. This code is the result of 
discussions with Mike Sweredoski and partially inspired by his script, 
matchFoundPeptideRatios.py. 
2. Perform sites and regions of each 601 and 607 dataset independently. This will give the 
“db/db sites” and the “WT sites” as separate tables. 
3. The localization probabilities will then be set equal and 601/607 data removed to create a 
GlcNAc database in both conditions. This will then be subjected to the experiment 
specific sites and regions analysis (based on liver pair, technical replicates will be 




4. Calculate the overlap between sites identified in the db/db vs WT livers using the 
multiexperiment sites and regions script. 
#import python packages  
import re 
import sys 
import pandas as pd 
import networkx as nx 
import itertools as it 
from collections import namedtuple 
import numpy as np 
import matplotlib 
import matplotlib.pyplot as plt 
from IPython.display import display 
from functools import reduce 
import seaborn as sns; sns.set() 
from io import StringIO 
from matplotlib_venn import venn2_unweighted  
from matplotlib_venn import venn2  
import venn 
import pandas as pd 
import numpy as np 
from io import StringIO 
import urllib.request, urllib.parse, urllib.error,urllib.request,urllib.error,urllib.parse 
import math 
 









#magic function to show plots inline 
%matplotlib inline 
 




#Import the files 
 
#set folder names 
qfolder = './Liver_Quant/' 
sfolder = './Liver_Glycomics/' 
 
#import the files 
dfmsms = pd.read_csv('{}msms.txt'.format(sfolder), sep='\t') 
dfallpep = pd.read_csv('{}allPeptides.txt'.format(qfolder), sep='\t') 
 
#take the relevant info from the allPeptides file, remove unneeded spectra, and rename the MSMS Scan Number column for 
    #matching 
dfall2 = dfallpep[['Raw file', 'Charge', 'Mass', 'Pyl Count', 'Ratio H/L', 'MS/MS Count', 'MSMS Scan Numbers']] 
dfall2 = dfall2[(dfall2['Pyl Count'] != "") & (dfall2['MS/MS Count'] > 0)] 
dfall2.rename(columns={'MSMS Scan Numbers':'Scan number'}, inplace=True) 
 
#remove contaminants, reverse sequences, and peptides modified by both 601 and 607 from the msms file 
dfmsms2 = dfmsms[dfmsms.Reverse != '+'] 
dfmsms2 = dfmsms2[~dfmsms2.Proteins.str.contains('CON_')] 
dfmsms2 = dfmsms2[~(dfmsms2.Modifications.str.contains('GlcNAc601') & (dfmsms2.Modifications.str.contains('GlcNAc607')))] 
 
Part 1 
#Expand the scan number column of the all peptides file into duplicate rows and merge with the msms file 
 
#change the scan number to a list and explode values to duplicate rows 
dfall3 = dfall2.copy() 
dfall3['Scan number'] = dfall2['Scan number'].str.split(';') 
dfall4 = dfall3.explode('Scan number') 
dfall5 = dfall4.copy() 
dfall5['Scan number'] = dfall4['Scan number'].astype(int) 
 
#merge this with the msms file on raw file, change, and scan number 
dfm = dfmsms2.merge(dfall5, on=['Raw file', 'Scan number', 'Charge'], how='left') 
 







#Preproces this data for the sites and regions script (first with the 601, then with the 607 tag) 
#adapted from 'preprocessMQ.py' written by Mike Sweredoski on Jan 24, 2020 
 
###GlcNAc601 
MOD_NAME = "GlcNAc601" 
pepProbPatt = re.compile(r'[A-Z][(]?\d?[.]?\d*[)]?') 
 
PepInfo = namedtuple("PepInfo",["Protein","StartPos"]) 
peptideInfo = {} 
 
# Get peptide start positions 
pepDF = pd.read_csv("{}peptides.txt".format(sfolder), sep='\t') 
for peptide in pepDF[["id","Leading razor protein","Start position"]].itertuples(): 
    if math.isnan(peptide[3]): 
        peptideInfo[peptide.id] = PepInfo(peptide[2],-1) 
    else: 
        peptideInfo[peptide.id] = PepInfo(peptide[2],int(peptide[3])) 
 
msmsDF = dfm 
msmsDF = msmsDF[msmsDF[MOD_NAME]>0] 
msmsDF["Protein"] = msmsDF["Peptide ID"].apply(lambda x: peptideInfo[x].Protein) 
msmsDF["StartPos"] = msmsDF["Peptide ID"].apply(lambda x: peptideInfo[x].StartPos) 
msmsDF = msmsDF[msmsDF["StartPos"]>=0] 
msmsDF.rename(columns={"Raw file":"RawFile","Scan number":"ScanNumber",MOD_NAME:"NumMods", "Ratio H/L":"Ratio"}, 
              inplace=True) 
msmsDF["Probabilities"] = msmsDF.apply( 
    lambda x: ";".join([aa[2:-1] for pp,aa in enumerate(pepProbPatt.findall( 
        x["%s Probabilities"%MOD_NAME])) if len(aa) > 1]),axis=1) 
msmsDF["Positions"] = msmsDF.apply( 
    lambda x: ";".join([str(pp+x["StartPos"]) for pp,aa in enumerate(pepProbPatt.findall( 
        x["%s Probabilities"%MOD_NAME])) if len(aa) > 1]),axis=1) 
 
msmsDF[["RawFile","Protein","ScanNumber","NumMods","Positions","Probabilities","Ratio"]].to_csv( 
    '601_Preprocessed.txt', sep="\t", index=False) 
 
###GlcNAc607 
MOD_NAME = "GlcNAc607" 
pepProbPatt = re.compile(r'[A-Z][(]?\d?[.]?\d*[)]?') 
 
PepInfo = namedtuple("PepInfo",["Protein","StartPos"]) 
peptideInfo = {} 
 
# Get peptide start positions 
pepDF = pd.read_csv("{}peptides.txt".format(sfolder), sep='\t') 
for peptide in pepDF[["id","Leading razor protein","Start position"]].itertuples(): 
    if math.isnan(peptide[3]): 
        peptideInfo[peptide.id] = PepInfo(peptide[2],-1) 
    else: 
        peptideInfo[peptide.id] = PepInfo(peptide[2],int(peptide[3])) 
 
msmsDF = dfm 
msmsDF = msmsDF[msmsDF[MOD_NAME]>0] 
msmsDF["Protein"] = msmsDF["Peptide ID"].apply(lambda x: peptideInfo[x].Protein) 
msmsDF["StartPos"] = msmsDF["Peptide ID"].apply(lambda x: peptideInfo[x].StartPos) 
msmsDF = msmsDF[msmsDF["StartPos"]>=0] 
msmsDF.rename(columns={"Raw file":"RawFile","Scan number":"ScanNumber",MOD_NAME:"NumMods", "Ratio H/L":"Ratio"}, 
              inplace=True) 
msmsDF["Probabilities"] = msmsDF.apply( 
    lambda x: ";".join([aa[2:-1] for pp,aa in enumerate(pepProbPatt.findall( 
        x["%s Probabilities"%MOD_NAME])) if len(aa) > 1]),axis=1) 
msmsDF["Positions"] = msmsDF.apply( 
    lambda x: ";".join([str(pp+x["StartPos"]) for pp,aa in enumerate(pepProbPatt.findall( 
        x["%s Probabilities"%MOD_NAME])) if len(aa) > 1]),axis=1) 
 
msmsDF[["RawFile","Protein","ScanNumber","NumMods","Positions","Probabilities","Ratio"]].to_csv( 
    '607_Preprocessed.txt', sep="\t", index=False) 
%%capture 
#supresses the output of the cell 
 
#Run the sites and regions script for each experiment 
%run -i SitesAndRegions.py 601_Preprocessed.txt maxparcon_601.txt bestms2_601.txt 
%run -i SitesAndRegions.py 607_Preprocessed.txt maxparcon_607.txt bestms2_607.txt 
#Import the sites and regions output into dfs and count the number of sites for each 
 
list_dfs2 = ['601', '607'] 
list_exp = ['WT', 'db/db'] 
 
for i in list_dfs2: 
    locals()['dfallsites_{}'.format(i)] = pd.read_csv('bestms2_{}.txt'.format(i), sep='\t') 
    locals()['dfregions_{}'.format(i)] = pd.read_csv('maxparcon_{}.txt'.format(i), sep='\t') 
    #remove sites/regions that match to two master proteins 
    #this seems to happen sometimes when there is real evidence of two isoforms 
    #all cases checked were already explained by other data, so they can be reasonably ignored 
    locals()['dfregions_{}'.format(i)] = locals()['dfregions_{}'.format(i)][ 
        ~locals()['dfregions_{}'.format(i)].Protein.str.contains(';')] 
    locals()['dfallsites_{}'.format(i)] = locals()['dfallsites_{}'.format(i)][ 
        ~locals()['dfallsites_{}'.format(i)].Protein.str.contains(';')] 
     
#initialize an empty df 
df_numsites = pd.DataFrame(np.empty((2,5))) 
 
#calculate the number of sites, localized sites, and regions 
for i in range (2): 
    #set the column and index names 




                            'Percent Localized']] 
    df_numsites.rename(index={i:list_dfs2[i]}, inplace=True) 
    #count the total number of sites 
    df_numsites.loc[list_dfs2[i], 'Total Number of Sites'] = \ 
    locals()['dfregions_{}'.format(list_dfs2[i])]['Min Sites'].sum() 
    #count the number of localized sites 
    df_numsites.loc[list_dfs2[i], 'Localized Sites'] = len( 
        locals()['dfregions_{}'.format(list_dfs2[i])][ 
            locals()['dfregions_{}'.format(list_dfs2[i])]['Site ID Constraints'].str.contains('of') == False]) 
    df_numsites.loc[list_dfs2[i], 'Unlocalized Sites'] = locals()['dfregions_{}'.format(list_dfs2[i])][ 
        locals()['dfregions_{}'.format(list_dfs2[i])][ 
            'Site ID Constraints'].str.contains('of') == True]['Min Sites'].sum() 
    df_numsites.loc[list_dfs2[i], 'Regions'] = len( 
        locals()['dfregions_{}'.format(list_dfs2[i])][ 
            locals()['dfregions_{}'.format(list_dfs2[i])]['Site ID Constraints'].str.contains('of') == True]) 
    df_numsites.loc[list_dfs2[i], 'Percent Localized'] = \ 
    (df_numsites.loc[list_dfs2[i], 'Localized Sites'].to_numpy() / df_numsites.loc[ 
        list_dfs2[i], 'Total Number of Sites'].to_numpy())*100 
 
df_numsites.rename(index={'601':'601 WT', '607':'607 db/db'}, inplace=True) 
df_numsites = df_numsites.astype(int) #convert to ints 
df_numsites.to_csv('SitesAndRegionsCount.csv') #export  
df_numsites #inspect 
 
#Make pie charts of the sites and regions (with the sites stratified by localization probability) 
 
#add to the max parsimonious site constraints file whether each region is a site or a region 
for i in list_dfs2: 
    locals()['dfregions_{}'.format(i)].loc[ 
        locals()['dfregions_{}'.format(i)]['Site ID Constraints'].str.contains('of'), 'Type'] = 'Region' 
    locals()['dfregions_{}'.format(i)].loc[ 
        ~locals()['dfregions_{}'.format(i)]['Site ID Constraints'].str.contains('of'), 'Type'] = 'Site' 
     
#merge with best ms2 for sites file 
for i in list_dfs2: 
    locals()['dfmerge_{}'.format(i)] = locals()['dfallsites_{}'.format(i)].merge( 
        locals()['dfregions_{}'.format(i)], how='left', on='Region ID') 
    #now fill the bins with values for the pie chart 
    locals()['regions_{}'.format(i)] = locals()['dfregions_{}'.format(i)][ 
        locals()['dfregions_{}'.format(i)].Type == 'Region']['Min Sites'].sum() 
    locals()['bin975_{}'.format(i)] = len( 
        locals()['dfmerge_{}'.format(i)][(locals()['dfmerge_{}'.format(i)].Type == 'Site') &  
                                        (locals()['dfmerge_{}'.format(i)]['Best Probability'] < 0.9)]) 
    locals()['bin99_{}'.format(i)] = len( 
        locals()['dfmerge_{}'.format(i)][(locals()['dfmerge_{}'.format(i)].Type == 'Site') &  
                                        ((locals()['dfmerge_{}'.format(i)]['Best Probability'] >= 0.9) &  
                                         (locals()['dfmerge_{}'.format(i)]['Best Probability'] < 0.99))]) 
    locals()['bin991_{}'.format(i)] = len( 
        locals()['dfmerge_{}'.format(i)][(locals()['dfmerge_{}'.format(i)].Type == 'Site') &  
                                        ((locals()['dfmerge_{}'.format(i)]['Best Probability'] >= 0.99) &  
                                         (locals()['dfmerge_{}'.format(i)]['Best Probability'] < 1))]) 
    locals()['bin1_{}'.format(i)] = len( 
        locals()['dfmerge_{}'.format(i)][(locals()['dfmerge_{}'.format(i)].Type == 'Site') &  
                                         (locals()['dfmerge_{}'.format(i)]['Best Probability'] == 1)]) 
     
for i in list_dfs2: 
    locals()['list_values_{}'.format(i)] = [locals()['regions_{}'.format(i)], locals()['bin975_{}'.format(i)],  
                                            locals()['bin99_{}'.format(i)], locals()['bin991_{}'.format (i)],  
                                            locals()['bin1_{}'.format(i)]] 
 
#make the pie charts 
sns.set_context('poster') 
     
#make a list of labels and colors to use 
list_labels = ['Unlocalized', '<90%', '90-99%', '99-100%', '100%'] 
colors = ["#cbcdcd", "#f39b9f", "#9aacd7", "#be9ec7", "#b3e0a7"] 





p, tx, nums = plt.pie(list_values_601, labels=list_labels, colors=colors, autopct="", startangle=90) 
for i, a in enumerate(nums): 
    a.set_text('{}'.format(list_values_601[i])) 
local_prob_601 = ('Average Localization Probability: ' +  
                  str(round(dfmerge_601[dfmerge_601.Type == 'Site']['Best Probability'].mean()*100, 1)) + '%') 







p, tx, nums = plt.pie(list_values_607, labels=list_labels, colors=colors, autopct="", startangle=90) 
for i, a in enumerate(nums): 
    a.set_text('{}'.format(list_values_607[i])) 
local_prob_607 = ('Average Localization Probability: ' +  
                  str(round(dfmerge_607[dfmerge_607.Type == 'Site']['Best Probability'].mean()*100, 1)) + '%') 








#Preprocess the msms file 
 
#copy the previous df 
dfmq = dfm.copy() 
 
#remove the 601/607 identifier 
dfmq.replace(['GlcNAc601', 'GlcNAc607'], 'GlcNAc', inplace=True) 
 
#remove psms where the number of mods is not equal to the number of mods used for the ratio calculation 
#this will remove all sites without ratios 
dfmqf = dfmq[(dfmq.GlcNAc601 == dfmq['Pyl Count']) | (dfmq.GlcNAc607 == dfmq['Pyl Count'])] 
 
#set new mod name 
MOD_NAME = "GlcNAc" 
pepProbPatt = re.compile(r'[A-Z][(]?\d?[.]?\d*[)]?') 
 
PepInfo = namedtuple("PepInfo",["Protein","StartPos"]) 
peptideInfo = {} 
 
# Get peptide start positions 
pepDF = pd.read_csv("{}peptides.txt".format(sfolder), sep='\t') 
for peptide in pepDF[["id","Leading razor protein","Start position"]].itertuples(): 
    if math.isnan(peptide[3]): 
        peptideInfo[peptide.id] = PepInfo(peptide[2],-1) 
    else: 
        peptideInfo[peptide.id] = PepInfo(peptide[2],int(peptide[3])) 
 
msmsDF = dfmqf 
msmsDF = msmsDF[msmsDF.Modifications.str.contains("GlcNAc")] 
msmsDF["Protein"] = msmsDF["Peptide ID"].apply(lambda x: peptideInfo[x].Protein) 
msmsDF["StartPos"] = msmsDF["Peptide ID"].apply(lambda x: peptideInfo[x].StartPos) 
msmsDF = msmsDF[msmsDF["StartPos"]>=0] 
msmsDF.rename(columns={"Raw file":"RawFile","Scan number":"ScanNumber", "Ratio H/L":"Ratio"}, 
              inplace=True) 
msmsDF['NumMods'] = msmsDF[["GlcNAc601","GlcNAc607"]].sum(axis=1) 
 
#enumerate separately for 601 and 607 (there should be no overlapping sites) 
#convert site prob columns to string 
msmsDF[["GlcNAc601 Probabilities","GlcNAc607 Probabilities"]] = \ 
msmsDF[["GlcNAc601 Probabilities","GlcNAc607 Probabilities"]].astype(str) 
msmsDF.loc[msmsDF.GlcNAc601 > 0, "Probabilities"] = msmsDF.apply( 
    lambda x: ";".join([aa[2:-1] for pp,aa in enumerate(pepProbPatt.findall( 
        x["GlcNAc601 Probabilities"])) if len(aa) > 1]),axis=1) 
msmsDF.loc[msmsDF.GlcNAc607 > 0, "Probabilities"] = msmsDF.apply( 
    lambda x: ";".join([aa[2:-1] for pp,aa in enumerate(pepProbPatt.findall( 
        x["GlcNAc607 Probabilities"])) if len(aa) > 1]),axis=1) 
msmsDF.loc[msmsDF.GlcNAc601 > 0, "Positions"] = msmsDF.apply( 
    lambda x: ";".join([str(pp+x["StartPos"]) for pp,aa in enumerate(pepProbPatt.findall( 
        x["GlcNAc601 Probabilities"])) if len(aa) > 1]),axis=1) 
msmsDF.loc[msmsDF.GlcNAc607 > 0, "Positions"] = msmsDF.apply( 
    lambda x: ";".join([str(pp+x["StartPos"]) for pp,aa in enumerate(pepProbPatt.findall( 
        x["GlcNAc607 Probabilities"])) if len(aa) > 1]),axis=1) 
 
df1_table = msmsDF[["RawFile","Protein","ScanNumber","NumMods","Positions","Probabilities","Ratio"]] 
#Set localization probabilities to equal and export for sites and regions script 
 
#set columns to keep in final df 
cols_to_keep = ["RawFile","Protein","ScanNumber","NumMods","Positions","Probabilities","Ratio"] 
 
#copy the df 
df2_table = df1_table.copy() 
 
#keeping the for loop structure from 20D09 
i = 2 
#count the number of S/Ts 
locals()['df{}_table'.format(i)]['NumSites'] = locals()['df{}_table'.format(i)].Probabilities.str.count(';') + 1 
#calculate the probability at each site based on the number of S/Ts (round to 3 decimals as in MQ) 
locals()['df{}_table'.format(i)]['Prob'] = round(1/locals()['df{}_table'.format(i)].NumSites, 3) 
#define a function to make a repeating list of probability values based on the number of S/Ts 
def repeat(row): 
    return [row.Prob]*row.NumSites 
#apply this function to each df 
locals()['df{}_table'.format(i)]['ProbList'] = locals()['df{}_table'.format(i)].apply(repeat, axis=1) 
#transform the list into a semi-colon separated string for the sites and regions script 
locals()['df{}_table'.format(i)]['ProbListFinal'] = locals()['df{}_table'.format(i)].ProbList.apply( 
    lambda s: ';'.join(map(str, s))) 
#replace all probability values 
locals()['df{}_table'.format(i)]['Probabilities'] = locals()['df{}_table'.format(i)].ProbListFinal 
#remake the original table with the columns required for the sites and regions script 
locals()['df{}_tableF'.format(i)] = locals()['df{}_table'.format(i)][cols_to_keep] 
 
#make a new column to denote the experiment 
 
#set lists for experiment identifiers 
list_mouse = ['A', 'B', 'C', 'D'] 
list_replicate = ['20171218', '20180223'] 
 
#rename the raw files for easier parsing 
df2_tableF.RawFile.replace('Smpl-','', regex=True, inplace=True) 
 




for i in range(4): 
    for j in range(2): 
        df2_tableF.loc[(df2_tableF.RawFile.str.contains('_{}'.format(list_mouse[i])) &  
                        df2_tableF.RawFile.str.contains( 
                            '{}'.format(list_replicate[j]))), 'Experiment'] = '{}_{}'.format(list_mouse[i],j+1) 
 
#export final table to txt file for sites and regions multi-experiment script 
df2_tableF.to_csv('QuantSitesAndRegions_Preprocessed.txt'.format(i), sep='\t', index=False) 
%%capture 
#supresses the output of the cell 
 
#Run the sites and regions script 
%run -i SitesAndRegionsMultiExperiment.py QuantSitesAndRegions_Preprocessed.txt maxparcon_Quant.txt \ 
bestms2_Quant.txt 
#Import the output and as in the 20D09 script 
dfallsitesq = pd.read_csv('bestms2_Quant.txt', sep='\t') 
dfregionsq = pd.read_csv('maxparcon_Quant.txt', sep='\t') 
dfallsitesq = dfallsitesq[~dfallsitesq.Protein.str.contains(';')] 
dfregionsq = dfregionsq[~dfregionsq.Protein.str.contains(';')] 
dfregionsq.loc[dfregionsq['Site ID Constraints'].str.contains('of'), 'Type'] = 'Region' 
dfregionsq.loc[~dfregionsq['Site ID Constraints'].str.contains('of'), 'Type'] = 'Site' 
dfmergeq = dfallsitesq.merge(dfregionsq, how='left', on='Region ID') 
 
#make two new experiment columns for replicate and mouse (facilitates making Venn diagrams) 
 
for i in list_mouse: 
    dfmergeq.loc[dfmergeq.Experiment.str.contains(i), 'Mouse'] = i 
     
for i in range(2): 
    dfmergeq.loc[dfmergeq.Experiment.str.contains(str(i+1)), 'Replicate'] = str(i+1) 
 
#clean up this df 
dfmergeq.rename(columns={'Protein_x': 'Protein'}, inplace=True) 
dfmergeq.drop(columns={'Protein_y'}, inplace=True) 




for i in list_mouse: 
    mouse_dict['Pair {}'.format(i)] = set(dfmergeq[dfmergeq.Mouse == i]['Region ID']) 
 
for i in range(2): 
    locals()['set_{}'.format(i+1)] = set(dfmergeq[dfmergeq.Replicate == str(i+1)]['Region ID']) 
     
plt.figure(figsize=(7,7)) 
venn.venn(mouse_dict, fontsize=18, legend_loc=None) 
plt.title('Biological Replicate Overlap', fontsize=36) 
plt.gcf().text(0.05, 0.5, 'Pair A', fontsize=24, ha='left') 
plt.gcf().text(0.2, 0.7, 'Pair B', fontsize=24, ha='left') 
plt.gcf().text(0.82, 0.7, 'Pair C', fontsize=24, ha='right') 




fig = venn2([set_1, set_2], ('Replicate 1', 'Replicate 2')) 
plt.title('Technical Replicate Overlap', fontsize=36) 
for text in fig.set_labels:  
    text.set_fontsize(32)  
for text in fig.subset_labels: 
    text.set_fontsize(24)  
plt.savefig('ReplicateRegionOverlap_Venn.svg') 
 
#Merge with the preprocssed dataframe to get the ratios 
 
#first normalize the ratios in df_tableF by median sweeping 
 
#copy the df 
dfratios = df2_tableF.copy() 
 
#merge with previous table on raw file, scan number, and protein 
#note that all proteins that don't match will be discarded (decided based on score by the sites and regions script) 
    #these may be real sites, but they will be ignored for the quantification, if there are really 2 peptides matching  
    #to the same precursor, there is no way to quantify them seperately anyway 
dfmergeqf = dfmergeq.rename(columns={'Best Scan Number':'ScanNumber', 'Best Raw File':'RawFile'}) 
dfq = dfmergeqf.merge(dfratios, on=['RawFile', 'ScanNumber', 'Protein', 'Experiment']) 
 
#log 2 transform the ratios 
dfq['LogRatio'] = np.log2(dfq.Ratio) 
 
#subtract the median by experiment 
for i in dfq.Experiment.unique(): 
    dfq.loc[dfq.Experiment == i, 'RatioNorm'] = dfq.loc[dfq.Experiment == i, 'LogRatio'].sub( 
        dfq[dfq.Experiment ==  i]['LogRatio'].median()) 
     
#group the data by mouse (averagign the technical replicates together) and merge with the original regions df 
dfrf = dfregionsq.merge(dfq.groupby(['Region ID', 'Mouse']).RatioNorm.mean().unstack(), on='Region ID', how='left') 
 












#read in the values 
df = read.table('Regions_Limma.csv', sep=',', header=TRUE, row.names=1) #read in the file 
df1 = df[c('A', 'B', 'C', 'D')] #take only relevant columns 
 
#run limma 
f1 = eBayes(lmFit(df1)) 
 
#write the output 
write.table(topTable(f1,n=Inf,confint=.95),'RegionsRatios_limmaOut.csv', sep=',', col.names=NA) 
#Read in the limma output and merge it back with the original df 
 
#read in limma output and concatenate 
dflimma = pd.read_csv('RegionsRatios_limmaOut.csv', index_col=0) 
dfde = pd.concat([dfrf.loc[:,dfrf.columns[0:3]], dflimma], axis=1) 
#Query uniprot to get list of gene names 
 
#define input 
uniprot_input = dfde.Protein 
 
#define variables 
url = 'https://www.uniprot.org/uploadlists/' 
user_agent = 'Mozilla/5.0 (Windows NT 10.0; Win64; x64)' 
 
#make a dictionary for the requests 
params = { 
    "from":"ACC+ID", 
    "to":"ACC", 
    "format":"tab", 
    "columns": "genes(PREFERRED)", 




data = urllib.parse.urlencode(params, doseq=False) 
data = data.encode('ascii') 
headers = {"User-Agent": user_agent} 
request = urllib.request.Request(url, data, headers) 
response = urllib.request.urlopen(request) 
with urllib.request.urlopen(request) as f: 
   response = f.read().decode() 
 
#make a dataframe from the output 
df_res = pd.read_csv(StringIO(response), sep='\t') 
df_res #inspect 
 
#Add the gene names to the ratios table from above based on the uniprot output 
#Then, normalize the ratios based on the protein expression ratios 
 
#copy the df 
dfde1 = dfrf.copy() 
 
dfde1.insert(1, 'Gene', dfde.Protein) 
 
#rename the uniprot output columns 
df_res.rename(columns={df_res.columns[0]: "Gene", df_res.columns[1]: "UniprotID"}, inplace=True) 
 
#set up the dictionary for mapping 
di = df_res.set_index('UniprotID')['Gene'].to_dict() 
 
#replace the gene name column in the ratios df with the gene name based on the above dictionary 
dfde1['Gene'].replace(di, inplace=True) 
 
#import the protein expression output 
dfpe = pd.read_csv('PE_corrections.csv') 
 
#average the fold change for duplicate genes and fill na with 0s  
dfpec = dfpe.groupby('Gene').mean() 
 
#rename the columns 
dfde1.rename(columns={'A':'ASite', 'B':'BSite', 'C':'CSite', 'D':'DSite'}, inplace=True) 
 
#merge the two dataframes (validating that there are not duplicate gene names in the proteins file) 
dfcpe = dfde1.merge(dfpec, on='Gene', how='left', validate='m:1') 
 
#export this to csv 
dfcpe.to_csv('RegionsAndProteins_Ratios.csv') 
 
#copy the df and fill nans in protein ratios with 0s 
dfcpe1 = dfcpe.copy() 
dfcpe1[['A', 'B', 'C', 'D']] = dfcpe1[['A', 'B', 'C', 'D']].fillna(0) 
 
#subtract the protein expression column (taking the ratio of ratios) 
for i in list_mouse: 
    dfcpe1['{}Corrected'.format(i)] = dfcpe1['{}Site'.format(i)] - dfcpe1['{}'.format(i)] 
 
#make a new column to indicate if it was corrected or not (there are no missing values in protein expression df) 
dfcpe1.loc[dfcpe1.A == 0, 'Corrected'] = 'No' 
dfcpe1.loc[dfcpe1.A != 0, 'Corrected'] = 'Yes' 
 












#read in the values 
df = read.table('CorrectedRatios_Limma.csv', sep=',', header=TRUE, row.names=1) #read in the file 
df1 = df[c('ACorrected', 'BCorrected', 'CCorrected', 'DCorrected')] #take only relevant columns 
 
#run limma 
f1 = eBayes(lmFit(df1)) 
 
#write the output 
write.table(topTable(f1,n=Inf,confint=.95),'CorrectedRatios_limmaOut.csv', sep=',', col.names=NA) 
#Import the limma output, clean up, export up and downregulated sites, and export a new df with final ratios 
#Export a df for cytoscape with genes and changing sites for cytoscape 
 
df_limma_c = pd.read_csv('CorrectedRatios_limmaOut.csv', index_col=0) 
df_limma_c.rename(columns={'adj.P.Val':'P-Val_Corrected', 'B':'B_Corrected', 'logFC':'logFC_Corrected'}, inplace=True) 
 
#make a copy of the previous final ratios df and add the protein expression corrected columns in 
dfde_c = dfde.copy() 
dfde_c[['logFC_Corrected', 'P-Val_Corrected', 'B_Corrected']] = df_limma_c[['logFC_Corrected', 'P-Val_Corrected',  
                                                                            'B_Corrected']] 
 
#drop other limma data, rename columns to be consistent, add corrected and gene columns back in, and export 
dfde_c.drop(columns={'CI.R', 'CI.L', 'AveExpr', 't', 'P.Value'}, inplace=True) 
dfde_c.rename(columns={'adj.P.Val':'P-Val'}, inplace=True) 
dfde_c['Corrected for Protein Expression'] = dfcpe1.Corrected 
dfde_cf = dfde_c.copy() 
dfde_cf.insert(1, 'Gene', dfcpe1.Gene) 
dfde_cf.insert(3, 'Site ID Constraints', dfregionsq['Site ID Constraints']) 
dfde_cf.to_csv('CorrectedRatios_Regions.csv', index=False) 
 
#now make a table for importing into cytoscape 
 
#take the relevant columns 
df_ForCytoscape = dfde_cf[['Gene', 'Protein', 'Site ID Constraints', 'logFC_Corrected', 'P-Val_Corrected',  
                           'Corrected for Protein Expression']] 
 
#add an additional column for cytoscape splicing, and combine rows with the same gene 
df_ForCytoscape.loc[dfde_cf['P-Val_Corrected'] < 0.05, 'Significantly Changing Site'] = 1 
 
#concatentate sites/regions together with their position and fold change in a new column 
df_ForCytoscape['Sites_Regions'] = (df_ForCytoscape['Protein'] + '@' +  
                                                df_ForCytoscape['Site ID Constraints'] + ' (FC: ' +  
                                                df_ForCytoscape['logFC_Corrected'].round(2).astype(str) +')') 
 
#import the output of all protein logFC and protein logFC (grouped by gene) to df 
dfpfc = pd.read_csv('Proteins_All.csv') 
dfpfc = dfpfc[['Gene', 'logFC']] 
dfpfc.rename(columns={'logFC':'ProteinLogFC'}, inplace=True) 
dfpfc_g = dfpfc.groupby('Gene').mean() 
df_ForCytoscape1 = df_ForCytoscape.merge(dfpfc_g, on='Gene', how='left') 
 
#calculate the average fold change per gene and save in a separate df 
dfavgFC = df_ForCytoscape1.groupby(['Gene'])['logFC_Corrected'].mean().reset_index() 
dfavgFC.rename(columns={'logFC_Corrected':'AvgLogFC'}, inplace=True) 
 
#store the concatenated sites/regions for each gene as a separate df 
dfsrconcat = df_ForCytoscape1.groupby(['Gene'])['Sites_Regions'].apply('; '.join).reset_index() 
dfsrconcat.rename(columns={'Sites_Regions':'O-GlcNAc Sites and Regions'}, inplace=True) 
 
#store the concatenated significant sites/regions for each gene as a separate df 
dfsigsrconcat = df_ForCytoscape1[df_ForCytoscape1['Significantly Changing Site'] == 1].groupby( 
    ['Gene'])['Sites_Regions'].apply('; '.join).reset_index() 
dfsigsrconcat.rename(columns={'Sites_Regions':'Significant Sites and Regions'}, inplace=True) 
 
#combine everything together in the same df 
df_ForCytoscape1 = df_ForCytoscape1.merge(dfavgFC, how='left', on='Gene') 
df_ForCytoscape1 = df_ForCytoscape1.merge(dfsrconcat, how='left', on='Gene') 
df_ForCytoscape1 = df_ForCytoscape1.merge(dfsigsrconcat, how='left', on='Gene') 
df_ForCytoscape1.Gene = df_ForCytoscape1.Gene.str.upper() 
 
#export for loading into cytoscape 
df_ForCytoscape1[['Gene', 'AvgLogFC', 'ProteinLogFC', 'Corrected for Protein Expression', 'O-GlcNAc Sites and Regions',  
                 'Significant Sites and Regions']].to_csv('RegionsAndProteinExpression_ForCytoscape.csv', index=False) 
#Make a Venn diagram of significant regions before and after protein expression 
 
set_uncorrected = set(dfde[dfde['adj.P.Val'] < 0.05]['Region ID']) 
set_corrected = set(dfde_c[dfde_c['P-Val_Corrected'] < 0.05]['Region ID']) 
 
plt.figure(figsize=(7,7)) 
fig = venn2([set_uncorrected, set_corrected], ('Uncorrected', '')) 
plt.title('Significant Regions Overlap', fontsize=36) 
for text in fig.set_labels:  
    text.set_fontsize(32)  
for text in fig.subset_labels: 
    text.set_fontsize(24)  
plt.gcf().text(0.9, 0.125, 'Corrected for\nProtein Expression', fontsize=32, ha='center') 
plt.savefig('ReplicateRegionOverlap_Venn.svg') 
 





#slice out the signficantly changing genes 
dfup = dfde_cf[(dfde_cf.logFC_Corrected > 0) & (dfde_cf['P-Val_Corrected'] < 0.05)] 
dfdown = dfde_cf[(dfde_cf.logFC_Corrected < 0) & (dfde_cf['P-Val_Corrected'] < 0.05)] 
 
#group by gene 
dfupgene = dfup.groupby('Gene').mean().reset_index()[['Gene', 'logFC_Corrected']] 
dfdowngene = dfdown.groupby('Gene').mean().reset_index()[['Gene', 'logFC_Corrected']] 
 
#rename the columns 
dfupgene.rename({'logFC_Corrected':'logFC'}, axis=1, inplace=True) 
dfdowngene.rename({'logFC_Corrected':'logFC'}, axis=1, inplace=True) 
 
#export gene lists for pathway analysis 
dfupgene[['Gene', 'logFC']].to_csv('Regions_Upregulated.csv', index=False) 
dfdowngene[['Gene', 'logFC']].to_csv('Regions_Downregulated.csv', index=False) 
#Output the number of upregulated and downregulated sites as well as how many were corrected for protein expression 
print('In total, there were {} upregated regions on {} proteins.'.format(len(dfup), len(dfup.Protein.unique()))) 
print('Corrected for protein expression, there were {} upregated regions on {} proteins.'.format( 
    len(dfup[dfup['Corrected for Protein Expression'] == 'Yes']),  
    len(dfup[dfup['Corrected for Protein Expression'] == 'Yes'].Protein.unique()))) 
print('\n') 
print('In total, there were {} downregulated regions on {} proteins.'.format(len(dfdown), len(dfdown.Protein.unique()))) 
print('Corrected for protein expression, there were {} downregulated regions on {} proteins.'.format( 
    len(dfdown[dfdown['Corrected for Protein Expression'] == 'Yes']),  
    len(dfdown[dfdown['Corrected for Protein Expression'] == 'Yes'].Protein.unique()))) 
print('\n') 
print('In total, there were {} sites over {} regions on {} proteins.'.format( 
    dfde['Min Sites'].sum(), len(dfde), len(dfde.Protein.unique()))) 
print('Corrected for protein expression, there were {} sites over {} regions on {} proteins.'.format( 
    dfde_cf[dfde_cf['Corrected for Protein Expression'] == 'Yes']['Min Sites'].sum(), 
    len(dfde_cf[dfde_cf['Corrected for Protein Expression'] == 'Yes']),  
    len(dfde_cf[dfde_cf['Corrected for Protein Expression'] == 'Yes'].Protein.unique()))) 
 
#Make the volcano plot for the regions 
 
#copy the df 
dfvolcano = dfde_cf.copy() 
 




#take tke the -log10 of the p value 
dfvolcano['NegLogP'] = -np.log10(dfvolcano['P-Val_Corrected']) 
 
#plot the figure 
plt.figure(figsize=(7,7)) 
g = sns.scatterplot(x='logFC_Corrected', y='NegLogP',  
                    data=dfvolcano[(dfvolcano['Corrected for Protein Expression'] == 'Yes') &  
                                   (dfvolcano['P-Val_Corrected'] < 0.05) & (dfvolcano['logFC_Corrected'] > 0)],  
                    edgecolor=(1,0,0,1), facecolor=(1,0,0,0.25), marker='o', s=25) 
g = sns.scatterplot(x='logFC_Corrected', y='NegLogP',  
                    data=dfvolcano[(dfvolcano['Corrected for Protein Expression'] == 'No') &  
                                   (dfvolcano['P-Val_Corrected'] < 0.05) & (dfvolcano['logFC_Corrected'] > 0)],  
                    edgecolor=(1,0,0,1), facecolor='none', marker='o', s=25) 
 
g = sns.scatterplot(x='logFC_Corrected', y='NegLogP',  
                    data=dfvolcano[(dfvolcano['Corrected for Protein Expression'] == 'Yes') &  
                                   (dfvolcano['P-Val_Corrected'] < 0.05) & (dfvolcano['logFC_Corrected'] < 0)],  
                    edgecolor=(0,0,1,1), facecolor=(0,0,1,0.25), marker='o', s=25) 
g = sns.scatterplot(x='logFC_Corrected', y='NegLogP',  
                    data=dfvolcano[(dfvolcano['Corrected for Protein Expression'] == 'No') &  
                                   (dfvolcano['P-Val_Corrected'] < 0.05) & (dfvolcano['logFC_Corrected'] < 0)],  
                    edgecolor=(0,0,1,1), facecolor='none', marker='o', s=25) 
 
g = sns.scatterplot(x='logFC_Corrected', y='NegLogP',  
                    data=dfvolcano[(dfvolcano['Corrected for Protein Expression'] == 'Yes') &  
                                   (dfvolcano['P-Val_Corrected'] > 0.05)],  
                    edgecolor=(0.5,0.5,0.5,1), facecolor=(0.5,0.5,0.5,1), marker='o', s=25) 
g = sns.scatterplot(x='logFC_Corrected', y='NegLogP',  
                    data=dfvolcano[(dfvolcano['Corrected for Protein Expression'] == 'No') &  
                                   (dfvolcano['P-Val_Corrected'] > 0.05)],  
                    edgecolor=(0.5,0.5,0.5,1), facecolor='none', marker='o', s=25) 
 
ax1 = g.axes 





#define points to label 
ptup = ['Elovl6', 'Plin2', 'Plin3', 'Plin4', 'Plin5', 'Ugt1a5']  
ptdown = ['Elovl3', 'Creld2', 'Manba', 'Ces3b', 'Ppt2', 'Ctsf'] 
 
for i in ptup: 
    g.text((dfvolcano['logFC_Corrected'][dfvolcano.Gene == i].max() + 0.15),  
            (dfvolcano['NegLogP'][dfvolcano.Gene == i].max() - 0.15),  
            i, color='black', fontsize=14, weight='bold', zorder=1) 
     
g.text((dfvolcano['logFC_Corrected'][dfvolcano.Gene == 'Bhmt'].max() - 1.25),  
        (dfvolcano['NegLogP'][dfvolcano.Gene == 'Bhmt'].max() + 0.05),  
        'Bhmt', color='black', fontsize=14, weight='bold', zorder=1) 
 
for i in ptdown: 




            (dfvolcano['NegLogP'][dfvolcano.Gene == i].max() - 0.2),  
            i, color='black', fontsize=14, weight='bold', zorder=1, ha='right') 
     
g.text((dfvolcano['logFC_Corrected'][dfvolcano.Gene == 'Egfr'].max() - 0),  
    (dfvolcano['NegLogP'][dfvolcano.Gene == 'Egfr'].max() - 0.25),  
    'Egfr', color='black', fontsize=14, weight='bold', zorder=1, ha='center') 
 
#Export a list of all O-GlcNAc substrates for making the network 
#First, get the gene names from uniprot 
 
#make a set of all proteins in sites and regions table 
proteinset = set(pd.concat([dfregions_601.Protein, dfregions_607.Protein])) 
 
#define input 
uniprot_input = proteinset 
 
#define variables 
url = 'https://www.uniprot.org/uploadlists/' 
user_agent = 'Mozilla/5.0 (Windows NT 10.0; Win64; x64)' 
 
#make a dictionary for the requests 
params = { 
    "from":"ACC+ID", 
    "to":"ACC", 
    "format":"tab", 
    "columns": "genes(PREFERRED)", 




data = urllib.parse.urlencode(params, doseq=False) 
data = data.encode('ascii') 
headers = {"User-Agent": user_agent} 
request = urllib.request.Request(url, data, headers) 
response = urllib.request.urlopen(request) 
with urllib.request.urlopen(request) as f: 
   response = f.read().decode() 
 
#make a dataframe from the output 
df_res = pd.read_csv(StringIO(response), sep='\t') 
df_res #inspect 
 
Make a df of substrates and export for cytoscape 
 
#copy the df 
dfde1 = dfrf.copy() 
 
dfde1.insert(1, 'Gene', dfde.Protein) 
 
#rename the uniprot output columns and prepare for export like with previous script for OGT substrates 
df_res.rename(columns={df_res.columns[0]: "Gene", df_res.columns[1]: "UniprotID"}, inplace=True) 






#Count the total number of proteins identified 




#Preprocess the data and output for sites and regions script 
 
#copy the previous df 
dfmover = dfm.copy() 
 
#remove the 601/607 identifier 
dfmoverf = dfmover.replace(['GlcNAc601', 'GlcNAc607'], 'GlcNAc') 
 
#Add an experiment columns based on the GlcNAc601 and GlcNAc607 columns 
dfmoverf.loc[dfmoverf.GlcNAc601 == 1, 'Experiment'] = 'WT' 
dfmoverf.loc[dfmoverf.GlcNAc607 == 1, 'Experiment'] = 'db/db' 
 
#set new mod name 
MOD_NAME = "GlcNAc" 
pepProbPatt = re.compile(r'[A-Z][(]?\d?[.]?\d*[)]?') 
 
PepInfo = namedtuple("PepInfo",["Protein","StartPos"]) 
peptideInfo = {} 
 
# Get peptide start positions 
pepDF = pd.read_csv("{}peptides.txt".format(sfolder), sep='\t') 
for peptide in pepDF[["id","Leading razor protein","Start position"]].itertuples(): 
    if math.isnan(peptide[3]): 
        peptideInfo[peptide.id] = PepInfo(peptide[2],-1) 
    else: 
        peptideInfo[peptide.id] = PepInfo(peptide[2],int(peptide[3])) 
 
msmsDFover = dfmoverf 
msmsDFover = msmsDFover[msmsDFover.Modifications.str.contains("GlcNAc")] 
msmsDFover["Protein"] = msmsDFover["Peptide ID"].apply(lambda x: peptideInfo[x].Protein) 




msmsDFover = msmsDFover[msmsDFover["StartPos"]>=0] 
msmsDFover.rename(columns={"Raw file":"RawFile","Scan number":"ScanNumber", "Ratio H/L":"Ratio"}, 
              inplace=True) 
msmsDFover['NumMods'] = msmsDFover[["GlcNAc601","GlcNAc607"]].sum(axis=1) 
 
#enumerate separately for 601 and 607 (there should be no overlapping sites) 
#convert site prob columns to string 
msmsDFover[["GlcNAc601 Probabilities","GlcNAc607 Probabilities"]] = \ 
msmsDFover[["GlcNAc601 Probabilities","GlcNAc607 Probabilities"]].astype(str) 
msmsDFover.loc[msmsDFover.GlcNAc601 > 0, "Probabilities"] = msmsDFover.apply( 
    lambda x: ";".join([aa[2:-1] for pp,aa in enumerate(pepProbPatt.findall( 
        x["GlcNAc601 Probabilities"])) if len(aa) > 1]),axis=1) 
msmsDFover.loc[msmsDFover.GlcNAc607 > 0, "Probabilities"] = msmsDFover.apply( 
    lambda x: ";".join([aa[2:-1] for pp,aa in enumerate(pepProbPatt.findall( 
        x["GlcNAc607 Probabilities"])) if len(aa) > 1]),axis=1) 
msmsDFover.loc[msmsDFover.GlcNAc601 > 0, "Positions"] = msmsDFover.apply( 
    lambda x: ";".join([str(pp+x["StartPos"]) for pp,aa in enumerate(pepProbPatt.findall( 
        x["GlcNAc601 Probabilities"])) if len(aa) > 1]),axis=1) 
msmsDFover.loc[msmsDFover.GlcNAc607 > 0, "Positions"] = msmsDFover.apply( 
    lambda x: ";".join([str(pp+x["StartPos"]) for pp,aa in enumerate(pepProbPatt.findall( 
        x["GlcNAc607 Probabilities"])) if len(aa) > 1]),axis=1) 
 
df1_tableo = msmsDFover[["RawFile","Protein","ScanNumber","NumMods","Positions","Probabilities","Ratio","Experiment"]] 
df1_tableo.to_csv('RegionOverlap_Preprocessed.txt', sep='\t', index=False) 
%%capture 
#supresses the output of the cell 
 
#Run the sites and regions script 
%run -i SitesAndRegionsMultiExperiment.py RegionOverlap_Preprocessed.txt maxparcon_Overlap.txt \ 
bestms2_Overlap.txt 
#Import the output and as in the 20D09 script 
dfallsitesover = pd.read_csv('bestms2_Overlap.txt', sep='\t') 
dfregionsover = pd.read_csv('maxparcon_Overlap.txt', sep='\t') 
dfallsitesover = dfallsitesover[~dfallsitesover.Protein.str.contains(';')] 
dfregionsover = dfregionsover[~dfregionsover.Protein.str.contains(';')] 
dfregionsover.loc[dfregionsover['Site ID Constraints'].str.contains('of'), 'Type'] = 'Region' 
dfregionsover.loc[~dfregionsover['Site ID Constraints'].str.contains('of'), 'Type'] = 'Site' 
dfmergeover = dfallsitesover.merge(dfregionsover, how='left', on='Region ID') 
 
#clean up this df 
dfmergeover.rename(columns={'Protein_x': 'Protein'}, inplace=True) 
dfmergeover.drop(columns={'Protein_y'}, inplace=True) 
 
#make a new column in the regions df denoting where it was found 
 
#define a function to collapse the data in the merged df 
def experimentO(x): 
    if x.Experiment.eq('WT').all(): 
        return 'WT' 
    elif x.Experiment.eq('db/db').all(): 
        return 'db/db' 
    else: 
        return 'Both' 
 
df_exp = dfmergeover.groupby(['Region ID']).apply(experimentO) 
 
#add this back to the regions df 
dfregionsover['Experiment'] = df_exp 
 
series_sr = dfregionsover.groupby('Experiment')['Min Sites'].sum() 
#Make the Venn diagram 
 
plt.figure(figsize=(7,7)) 
fig = venn2([series_sr[2], series_sr[1], series_sr[0]], ('db/db', 'WT')) 
#plt.title('Technical Replicate Overlap', fontsize=36) 
for text in fig.set_labels:  
    text.set_fontsize(32)  
for text in fig.subset_labels: 




A7.5.4. Interactor Glycosylation Correlation Analysis. 
#Import python packages  
import re 
import sys 
import pandas as pd 
import networkx as nx 
import itertools as it 
from collections import namedtuple 
import numpy as np 
import matplotlib 
import matplotlib.pyplot as plt 
from IPython.display import display 
from functools import reduce 
import seaborn as sns; sns.set() 
from io import StringIO 




from matplotlib_venn import venn2  
import venn 
import pandas as pd 
import numpy as np 
from io import StringIO 
import urllib.request, urllib.parse, urllib.error,urllib.request,urllib.error,urllib.parse 
import math 
import scipy.stats as stats 
 









#magic function to show plots inline 
%matplotlib inline 
 




#Import the relevant data and clean up the dfs  
 
#import data 
dfppi = pd.read_csv('PPINetworkLiverF_ForCytoscape.csv') 
dfpe = pd.read_csv('ProteinFC_ForCytoscape.csv') 
dfgly = pd.read_csv('CorrectedRatios_Regions.csv') 
dfint = pd.read_csv('OGTIntsLiverF_ForCytoscape.csv') 
dfsub = pd.read_csv('OGTSubsLiverF_ForCytoscape.csv') 
 
#take relevant columns and clean up (and remove self interaction from dfppi) 
dfgly2 = dfgly[['Gene', 'logFC_Corrected', 'Corrected for Protein Expression']] 
dfgly2.Gene = dfgly2.Gene.str.upper() 
dfgly2.rename(columns={'Corrected for Protein Expression':'PE_Corr'}, inplace=True) 
dfpe2 = dfpe[['Gene', 'ProteinLogFC']] 
dfppi2 = dfppi[dfppi.Interactor_A != dfppi.Interactor_B] 
dfppi2.rename(columns={'Interactor_A':'Gene'}, inplace=True) 
 
#merge the subs and ints dfs with the ppi df 
dfppi3 = dfppi2.merge(dfint, on='Gene', how='left').merge(dfsub, on='Gene', how='left') 
 
#merge in the protein expression fc for interactor A (rename the column back to interactor a) 
dfppi4 = dfppi3.merge(dfpe2, how='left', on='Gene') 
dfppi4.rename(columns={'Gene':'Interactor_A'}, inplace=True) 
 
#merge in the glycosylation fc for interactor b 
dfppi4.rename(columns={'Interactor_B':'Gene'}, inplace=True) 
dfppi5 = dfppi4.merge(dfgly2, how='right', on='Gene') 
 
#now slice out only the interactors with values for protein expression and that are attached to subs with O-GlcNAc FC 
dfppi6 = dfppi5[dfppi5.OGT_Interactor == 1] 
dfppi6.dropna(subset=['ProteinLogFC', 'logFC_Corrected'], inplace=True) 
#Flip everything around 
 
fdfppi = dfppi.reindex(columns={'Interactor_B', 'Interactor_A'}).rename( 
    columns={'Interactor_B':'Interactor_A', 'Interactor_A':'Interactor_B'}) 
 
#import data 
fdfpe = pd.read_csv('ProteinFC_ForCytoscape.csv') 
fdfgly = pd.read_csv('CorrectedRatios_Regions.csv') 
fdfint = pd.read_csv('OGTIntsLiverF_ForCytoscape.csv') 
fdfsub = pd.read_csv('OGTSubsLiverF_ForCytoscape.csv') 
 
#take relevant columns and clean up (and remove self interaction from fdfppi) 
fdfgly2 = fdfgly[['Gene', 'logFC_Corrected', 'Corrected for Protein Expression']] 
fdfgly2.Gene = fdfgly2.Gene.str.upper() 
fdfgly2.rename(columns={'Corrected for Protein Expression':'PE_Corr'}, inplace=True) 
fdfpe2 = fdfpe[['Gene', 'ProteinLogFC']] 
fdfppi2 = fdfppi[fdfppi.Interactor_A != fdfppi.Interactor_B] 
fdfppi2.rename(columns={'Interactor_A':'Gene'}, inplace=True) 
 
#merge the subs and ints fdfs with the ppi fdf 
fdfppi3 = fdfppi2.merge(fdfint, on='Gene', how='left').merge(fdfsub, on='Gene', how='left') 
 
#merge in the protein expression fc for interactor A (rename the column back to interactor a) 
fdfppi4 = fdfppi3.merge(fdfpe2, how='left', on='Gene') 
fdfppi4.rename(columns={'Gene':'Interactor_A'}, inplace=True) 
 
#merge in the glycosylation fc for interactor b 
fdfppi4.rename(columns={'Interactor_B':'Gene'}, inplace=True) 
fdfppi5 = fdfppi4.merge(fdfgly2, how='right', on='Gene') 
 
#now slice out only the interactors with values for protein expression and that are attached to subs with O-GlcNAc FC 
fdfppi6 = fdfppi5[fdfppi5.OGT_Interactor == 1] 
fdfppi6.dropna(subset=['ProteinLogFC', 'logFC_Corrected'], inplace=True) 
#merge the dfs back together 
dff = pd.concat([dfppi6, fdfppi6]).drop_duplicates(subset=['Interactor_A', 'Gene', 'ProteinLogFC', 'logFC_Corrected']) 










sns.scatterplot(x='ProteinLogFC', y='logFC_Corrected', data=dff, s=15, alpha=0.5, edgecolor='none') 
plt.xlabel('Interactor Log2 F.C.') 









ax = sns.regplot(x='ProteinLogFC', y='logFC_Corrected', data=dff, truncate=False, line_kws={'color':'k'}, 
            scatter_kws={"marker": "D", "s": 15, "color": "b", "alpha":0.25}) 
plt.xlabel('Interactor Log2 F.C.') 
plt.ylabel('O-GlcNAc Region Log2 F.C.') 
sns.despine() 
 
#Calculate Spearman's correlation coefficient 
spearmans = stats.spearmanr(dff.ProteinLogFC, dff.logFC_Corrected) 
spearmans 
 
#Perform the adapter rank script and repeat the above analysis with the top adpator candidates 
#See 20E03 notebook, will keep the for loop structure 
 
df1= dfppi 
dfints1 = dfint.copy() 
dfsubs1 = dfsub.copy() 
 
i=1 
locals()['df{}'.format(i)] = locals()['df{}'.format(i)].merge( 
    locals()['dfints{}'.format(i)], how='left', left_on='Interactor_B', right_on='Gene').drop('Gene', axis=1) 
locals()['df{}'.format(i)] = locals()['df{}'.format(i)].merge( 
    locals()['dfsubs{}'.format(i)], how='left', left_on='Interactor_B', right_on='Gene').drop('Gene', axis=1) 
 
#Interactions with substrates (regardless of if those substrates are also interactors) are given one point 
#Interactors with interactors that are not substrates are given -0.5 points 
def score(df): 
    if df.OGT_Substrate == 1: 
        return 1 
    else: 
        return -0.5 
     
#calculate the score for each df and drop all of the instances of self interactions in the table 
#group the df by interactor a to make an adapter rank df   
locals()['df{}'.format(i)]['Score'] = locals()['df{}'.format(i)].apply(score, axis=1) 
locals()['df{}'.format(i)] = locals()['df{}'.format(i)][locals()[ 
    'df{}'.format(i)].Interactor_A != locals()['df{}'.format(i)].Interactor_B] 
locals()['dfar_{}'.format(i)] = locals()['df{}'.format(i)].groupby( 
    'Interactor_A').Score.sum().reset_index().sort_values(by=['Score'], ascending=False) 
     
#Remove genes that are only substrates to make the final adapter ranking list 
#first merge the df with the interactor list and then drop all nan from the interactor column (and drop added columns) 
locals()['dfarF_{}'.format(i)] = locals()['dfar_{}'.format(i)].merge( 
    locals()['dfints{}'.format(i)], how='left', left_on='Interactor_A', right_on='Gene').dropna( 
    subset=['OGT_Interactor']).drop(['OGT_Interactor', 'Gene'], axis=1) 
#Flip adapter rank and make final list 
 
df2 = dfppi.reindex(columns={'Interactor_B', 'Interactor_A'}).rename( 
    columns={'Interactor_B':'Interactor_A', 'Interactor_A':'Interactor_B'}) 
dfints2 = dfint.copy() 
dfsubs2 = dfsub.copy() 
 
i=2 
locals()['df{}'.format(i)] = locals()['df{}'.format(i)].merge( 
    locals()['dfints{}'.format(i)], how='left', left_on='Interactor_B', right_on='Gene').drop('Gene', axis=1) 
locals()['df{}'.format(i)] = locals()['df{}'.format(i)].merge( 
    locals()['dfsubs{}'.format(i)], how='left', left_on='Interactor_B', right_on='Gene').drop('Gene', axis=1) 
 
#Interactions with substrates (regardless of if those substrates are also interactors) are given one point 
#Interactors with interactors that are not substrates are given -0.5 points 
def score(df): 
    if df.OGT_Substrate == 1: 
        return 1 
    else: 
        return -0.5 
     
#calculate the score for each df and drop all of the instances of self interactions in the table 
#group the df by interactor a to make an adapter rank df   
locals()['df{}'.format(i)]['Score'] = locals()['df{}'.format(i)].apply(score, axis=1) 
locals()['df{}'.format(i)] = locals()['df{}'.format(i)][locals()[ 
    'df{}'.format(i)].Interactor_A != locals()['df{}'.format(i)].Interactor_B] 
locals()['dfar_{}'.format(i)] = locals()['df{}'.format(i)].groupby( 
    'Interactor_A').Score.sum().reset_index().sort_values(by=['Score'], ascending=False) 
     
#Remove genes that are only substrates to make the final adapter ranking list 
#first merge the df with the interactor list and then drop all nan from the interactor column (and drop added columns) 
locals()['dfarF_{}'.format(i)] = locals()['dfar_{}'.format(i)].merge( 
    locals()['dfints{}'.format(i)], how='left', left_on='Interactor_A', right_on='Gene').dropna( 





dfadran = pd.concat([dfarF_1, dfarF_2]).sort_values(by='Score', ascending=False).drop_duplicates(subset='Interactor_A') 
#Export top adaptors 
dfadran.to_csv('AdaptorRanking.csv', index=False) 
topadaptorlist = dfadran[dfadran.Score > 2].Interactor_A.to_list() 
 
#Remake the plots without Egfr 
 




sns.scatterplot(x='ProteinLogFC', y='logFC_Corrected', data=dfppi8, s=15, alpha=0.5, edgecolor='none') 
plt.xlabel('Interactor Log2 F.C.') 









ax = sns.regplot(x='ProteinLogFC', y='logFC_Corrected', data=dfppi8, truncate=False, line_kws={'color':'k'}, 
            scatter_kws={"marker": "D", "s": 15, "color": "b", "alpha":0.25}) 
plt.xlabel('Interactor Log2 F.C.') 
plt.ylabel('O-GlcNAc Region Log2 F.C.') 
sns.despine() 
 
#Calculate Spearman's R 
spearmans = stats.spearmanr(dfppi8.ProteinLogFC, dfppi8.logFC_Corrected) 
spearmans 
 
#Output potential adaptor interactions up/up 
dfadaptup = dff[(dff.ProteinLogFC > 0.5) & (dff.logFC_Corrected > 0.75)] 
dfadaptup = dfadaptup.merge(dfadran, on='Interactor_A', how='left') 
dfadaptup.rename(columns={'Interactor_A':'Adaptor', 'Gene':'Target'}, inplace=True) 
dfadaptup = dfadaptup[dfadaptup.PE_Corr == 'Yes'] 
dfadaptup.drop(columns={'OGT_Interactor', 'OGT_Substrate'}, inplace=True) 
dfadaptup.to_csv('AdaptorInteraction_Up.csv', index=False) 
#Output potential adaptor interactions down/down 
dfadaptdown = dff[(dff.ProteinLogFC < -0.5) & (dff.logFC_Corrected < -0.75)] 
dfadaptdown = dfadaptdown.merge(dfadran, on='Interactor_A', how='left') 
dfadaptdown.rename(columns={'Interactor_A':'Adaptor', 'Gene':'Target'}, inplace=True) 
dfadaptdown = dfadaptdown[dfadaptdown.PE_Corr == 'Yes'] 
dfadaptdown.drop(columns={'OGT_Interactor', 'OGT_Substrate'}, inplace=True) 
dfadaptdown.to_csv('AdaptorInteraction_Down.csv', index=False) 
#Output potential adaptor interactions up/down 
dfadaptupopp = dff[(dff.ProteinLogFC > 0.5) & (dff.logFC_Corrected < -0.75)] 
dfadaptupopp = dfadaptupopp.merge(dfadran, on='Interactor_A', how='left') 
dfadaptupopp.rename(columns={'Interactor_A':'Adaptor', 'Gene':'Target'}, inplace=True) 
dfadaptupopp = dfadaptupopp[dfadaptupopp.PE_Corr == 'Yes'] 
dfadaptupopp.drop(columns={'OGT_Interactor', 'OGT_Substrate'}, inplace=True) 
dfadaptupopp.to_csv('AdaptorInteraction_Up_Opposite.csv', index=False) 
#Output potential adaptor interactions down/up 
dfadaptdownopp = dff[(dff.ProteinLogFC < -0.5) & (dff.logFC_Corrected > 0.75)] 
dfadaptdownopp = dfadaptdownopp.merge(dfadran, on='Interactor_A', how='left') 
dfadaptdownopp.rename(columns={'Interactor_A':'Adaptor', 'Gene':'Target'}, inplace=True) 
dfadaptdownopp = dfadaptdownopp[dfadaptdownopp.PE_Corr == 'Yes'] 
dfadaptdownopp.drop(columns={'OGT_Interactor', 'OGT_Substrate'}, inplace=True) 
dfadaptdownopp.to_csv('AdaptorInteraction_Down_Opposite.csv', index=False) 
 
 
 
 
 
 
 
 
